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ART               Advanced Reproductive Technologies 
ASCO             American Society of Clinical Oncology 
AMP               Adenosine MonoPhasphate 
EHS                Ehler Danlos Syndrome 
ESHRE           European Society of Human Reproduction and Embryology 
FSH                Follicular Stimulating Hormone 
HCG               Human Chorionic Gonadotropin 
HFEA             Human Fertilization and Embryology Authority 
HTA               Human Tissue Authority 
ICM                Inner Cell Mass 
ICSI                Intra-Cytoplasmic Sperm Injection 
IVA                In Vitro Activation 
IVF                 In Vitro Fertilization 
IVM                In Vitro Maturation 
JC-1                 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimi- dazolylcarbocyanine iodide 
LBR                Live Birth Rate 
LH                  Luteinizing Hormone 
LHR               Luteinizing Hormone Receptor 
MEM              Minimal Essential Medium 
 
MtDNA          Mitochondrial Deoxyribonucleic Acid 
OHSS             Ovarian Hyper-Stimulation Syndrome 
OTCP             Ovarian Tissue Cryo-Preservation 
OUFHT          Oxford University Foundation Hospitals Trust 
OXPHOS       Oxidative Phosphorylation 
PCOS             Polycystic Ovarian Syndrome 
PCR               Polymerase Chain Reaction 
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PGD              Preimplantation Genetic Diagnosis 
POI               Premature Ovarian Insufficiency 
P450SCC      Cytochrome P450 Side Chain Cleavage 
PTEN            Phosphatase and Tensin homolog 
RGD              Arginylglycylaspartic acid 
RO                Reaggregated Ovaries 
SCID             Severe combined immunodeficiency 
SF-1               Steroidogenic Factor 1 
SOP               Standard Operating Procedure 
StAR              Steroid Acute Regulator 





Implantation rate- the number of gestational sacs observed at 6 weeks of pregnancy divided by the 
numberof embryos transferred. 
 
Clinical pregnancy rate- the number of cycles with gestational sac/sacs observed at 6 weeks of 
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The dissertation presents my published studies investigating the optimisation of the different fertility 
cryopreservation modalities in females- from In vitro Fertilization to In Vitro Maturation to ovarian 
tissue cryopreservation and in Vitro culturing.  We aim at presenting the advancement of fertility 
preservation options for paediatric, adolescent and reproductive aged female patients. The studies 
include 16 peer reviewed journal articles, two poster abstracts, three book chapters in addition to two 
additional articles in submission. These studies cover my academic career while working in the 
Hebrew University of Jerusalem and Oxford University during the last 20 years.  
The dissertation includes my research on: 
 
1. The basic reproductive physiology and infertility- this will include two book chapters in female 
reproductive endocrinology and pathophysiology and investigations of female infertility and a 
basic science study on poor ovarian responders, done in an attempt to find the 
pathophysiologic basis of this group of patients. We found that granulosa cells from elderly 
poor responders showed normal mitochondrial membrane potential and normal 
endocrinologic function as presented by JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimi- 
dazolylcarbocyanine iodide) mitochondrial stain and the StAR and side chain cleavage enzyme 
levels. We have shown that  low follicular phase oestrogen levels induced by aromatase 
inhibitors do not play a deleterious effect on folliculogenesis and that oestrogen levels per se 
are not critical for folliculogenesis in the mice ovaries. In addition, embryos created and 
cultured showed normal development in culture as shown by satisfactory progression to 
advanced embryonal forms i.e. the morula and blastocyst stages. We then suggested the safety 
of aromatase inhibitors utilised for superovulation in cancer patients. 
2. In Vitro Fertilization (IVF) followed by embryo or eggs freeze as a well-established modality. 
We present several studies done, including the confirmation of random start ovulation 
induction protocol, the safety of egg collections in patients having haemostatic disorders which 
is a common condition in cancer patients, embryonal biomarkers as predictors of implantation 
outcomes and clinical  pregnancy rates and our contribution in the study of the different 
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protocols utilised in frozen embryo replacement cycles, which are the mainstay of the fertility 
treatment after patients recover from their cancer treatment and return for embryo transfer. 
3. The development of In Vitro Maturation (IVM) and its embodiment in the fertility 
preservation programme, as a standalone option and also as a complementary modality, 
together with IVF or ovarian tissue preservation options. I will present my work in this area 
including comparison of IVM and IVF results, using IVM and surrogacy in Ehler Danlos disease 
and utilisation of IVM in under responding or over responding PCOS patients. The adoption of 
IVM is of importance in any fertility preservation programme, as a standalone or a 
complementary modality. 
4. Ovarian Tissue Cryopreservation as a modality in prepubertal girls or adult patients who need 
to proceed urgently to chemotherapy. This work culminated in setting up ovarian tissue 
banking in Oxford including developing protocols, policies and nationwide clinical service. I 
have worked on the establishment of one of the UK's first HTA/HFEA approved ovarian tissue 
cryopreservation programme which offers cancer patients from across the country in a hub and 
spoke model to have ovarian cryopreservation. A chapter in the book will be presented as well 
as a manuscript summarising our experience will be submitted for publication to report the 
first 100 patients referred to this important translational programme. 
5. In vitro culture of ovarian tissue as a future fertility preservation option. We investigated the 
developmental staging of the different follicles in human cryopreserved ovarian tissue from 
patients undergoing fertility preservation. Our findings showed a variation in follicular 
developmental stages and their health in both cultured and non-cultured ovarian tissue. Our 
study reported a new classification system of follicles health in human cryopreserved ovarian 
tissue, based on the presence/absence of pyknosis in granulosa cells, pyknosis in oocytes and 
the presence or absence of shrunken cytoplasm. 
  
 
These publications contributed to the adoption of well-established fertility preservation techniques as 
well as the innovative and experimental technique of ovarian tissue preservation that was adopted 
and offered to patients. My work helped to start basic science and biomedical studies to further the 
development of fertility preservation options in female cancer patients. Future horizons of my work 







Cancer patients are commonly offered chemotherapy and/or radiotherapy treatment schedules 
which are increasingly more effective and providing long disease remission and improving their overall 
survival rates and long term prognosis. Consequently, more cancer survivors are likely to face the late 
sequels of the adverse systemic effects of these anti-cancer treatments on different organs, affecting 
thus patients’ quality of life for a long time after their recovery (Green et al. 2009). In the last decades, 
more attention has therefore been allocated to the effects of anti-cancer treatment on gonadal function 
in cancer survivors (Turan and Oktay, 2014). Gonadal damage might adversely affect their fertility 
prospects as well as their gonadal endocrine function, thus potentially affecting their growth, 
development as well as the long term health and general well-being (Vassilokopoulou et al. 2016). 
The gonadotoxicity extent varies among the different chemotherapeutic agents and the different 
combination protocols and are generally classified as low, intermediate and high risk regimens (Jadoul 
et al. 2010). The incidence of ovarian failure is highly dependent on the agents used, their cumulative 
dose and the reproductive age of the patient (Anderson et al, 2015).   
With the increasingly raised awareness of patients, their guardians and their clinicians to the 
reproductive and endocrine adverse effects of chemotherapies/irradiation therapies, there is an ever 
increasing need and demand to thoroughly discuss these compelling and important issues with patients 
and offer them satisfactory fertility preservation treatments prior to commencing on the 
chemotherapy/radiotherapy regimens of choice (Wallace et al. 2014).  
 
Currently, there are several well established fertility cryopreservation options in females which are 
highly dependent on the physiologic age of the female (Sonmezer and Oktay , 2004); Adult females 
and post menarcheal girls or post-pubertal adolescents can be offered an in vitro fertilization cycle for 
either embryo or oocyte cryopreservation.  These patients commonly undergo ovarian stimulation in 
an IVF cycle and subsequently undergo oocytes retrieval prior to the initiation of chemo/radiotherapy 
(Manuel et al. 2019).  Mature eggs can then be  either fertilized by partner’s sperm if available or by 
donor sperm if patient is a single, to produce embryos to freeze or alternatively, the unfertilized eggs 
can be frozen by rapid vitrification when no partner is available and donor sperm is deemed ethically 
inappropriate or religiously unacceptable. The main advantage of this fertility preservation modality is 
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that it is an established technology and is in routine clinical use in most IVF units throughout the world 
on a daily basis (Tulandi et al. 2008). The major drawback of this option is the need for almost two 
weeks of hormonal stimulation followed by egg collection with all inherent side effects and 
complications that might ensue. In addition, it is a relatively expensive treatment which adds to the 
difficulties these patients endure. Furthermore, only a limited number of embryos/oocytes can be 
created and then stored from a single or a couple of stimulation cycles (Luke et al. 2016).  Secondly, a 
less common modality and relatively further less effective option is in vitro maturation (IVM) followed 
by either embryo freeze or oocyte rapid vitrification (Son et al. 2019).  The main advantage of this 
technique is that patients are saved the ovarian stimulation and the related adverse effects and 
complications, especially OHSS. Thirdly, ovarian suppression attempted by monthly injections of 
GnRH analogues is occasionally prescribed prior to commencement of chemotherapy, nevertheless its 
efficiency in fertility preservation is still of controversial significance and its use should be largely 
offered in well-designed research based experimental protocols (Blumenfeld Z. 2019). Fourthly, 
fixation of ovaries (Oopheropexy) to outside the pelvic radiotherapy field is appropriate in a sub-group 
of patients who would need to undergo pelvic brachytherapy (Moawad et al., 2017).  
 
Ovarian tissue cryopreservation (OTCP) is an emerging fertility preservation technology that 
involves the harvesting of ovarian cortical biopsies, their processing into small slices followed by slow 
freezing or rapid vitrification.  Laparoscopy is usually performed to harvest ovarian tissue either by 
unilateral oophorectomy or ovarian biopsies (Ledanyi et al., 2017). Following patient’s recovery from 
cancer treatment, the ovarian tissue can be thawed out and autotransplanted to the patient. Once blood 
supply to the autograft is successfully re-established usually within days of transplantation, and tissue 
proves viable and functional, folliculogenesis is resumed with possible restoration of natural fertility or 
endocrine ovarian activity (Donnez et al 2010).  The tissue is most often transplanted in the pelvis in 
or near its natural site, such as the cortex of the contralateral ovary or the pelvic sidewall (the so called 
orthotopic transplantation).  This has been shown to offer the potential for spontaneous pregnancy, as 
ovulated eggs are naturally released in their physiologic environment in the proximity of the fallopian 
tubes, obviating thus the need for IVF treatment (Rosendal et al, 2011, Revel et al, 2011, Revel et al, 
2010, Dolmans et al 2013).   Alternatively, the other often used option is undertaking heterotopic 
transplantation which involves autografting of ovarian tissue into non-native ectopic locations such as 
the arm or the abdomen. Heterotopic transplantation has certain advantages (Oktay et al, 2004, 
Demeestere et al 2009) such as being less invasive approach and an easier approach for follicular 
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monitoring and egg retrieval for IVF treatment; however, this clinical approach is less commonly used 
compared with the orthotopic approach.  Orthotopic transplantation has been reported to result in 
more effective revascularization and less follicle loss and consequently is believed to be more effective 
(Demeestere et al 2009). The orthotopic autotransplantation is performed either by laparotomy or 
laparoscopy.  Several ovarian cortical slices are thawed out and then either sutured to the remaining 
ovary or left unsutured into peritoneal windows in the pelvis and more commonly in the mesosalpinx. 
To date more than 100 pregnancies have been reported after autotransplantation of ovarian cortical 
tissue slices mainly after orthotopic but also after heterotopic reimplantation (Donnez et al 2008). The 
published reports of worldwide centres with autografting experience indicate that it has taken 3.5 to 6.5 
months on average after the autografting of the ovarian tissue until signs of endocrinologic activity (a 
rise in estradiol levels and a drop in FSH levels) and folliculogenesis (as observed in ultrasound 
scanning) were detected. Ovarian activity was observed in 93% of patients after autografting. The post-
transplantation pregnancies reported thus far included natural conceptions, ovulation induction cycles 
and IVF cycles (Donnez et al 2008).  The average duration of ovarian function after transplantation is 
4-5 years (Donnez et al 2008, Schmidt et al, 2005) and is mainly dependent on the ovarian reserve 
before the harvesting and the absence of chemotherapy before cryopreservation. These promising 
results strongly suggest that ovarian tissue cryopreservation is a viable fertility preservation option that 
should be part of any oncofertility programmes. 
 As Ovarian Tissue Cryopreservation (OTCP) is the only available fertility preservation approach 
that can possibly be offered to premenarcheal/prepubertal girls and adult women who need to promptly 
and urgently start their chemo/radiotherapy and cannot undergo an IVF cycle (which entails delaying 
their treatment for 3-4 weeks), it is important to set up such a tissue banking service to answer the 
clinical need. OTCP can be performed immediately without any delay, as no hormonal stimulation is 
needed, and potentially thousands of follicles exist in each small cortical slice, conferring thus a 
quantitative advantage (Sonmezer and Oktay, 2004).   
 Several factors should be weighed up when discussing ovarian tissue cryopreservation: patient’s 
age, patient’s oncologic diagnosis, prognosis, obstetric history, fertility plans and the availability and 
affordability of other fertility preservation technologies. In addition, patient should be given the 
accurate and most up-to-date data of success rates reported so far in the pertinent literature and offered 
psycho-social counselling as needed. As the autografted ovarian tissue might be contaminated by 
micrometastases that might result in seeding of cancer cells to the cured patient, carrying thus the risk 
of relapse, it is important to work on in vitro culturing of the ovarian tissue to produce mature eggs for 
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these patients. This would obviate the need for autografting and thus minimizes the risk of relapse. 
This is a newly evolving area of research which would provide the upcoming breakthroughs in the field 



































In my dissertation I intend to present the works that I published in peer reviewed articles that 
contributed to the understanding of basic scientific and clinical biomedical knowledge in the area of 
oncofertility including the following topics: 
1. Introduction to the basic reproductive physiology and infertility- this will include two book chapters in 
female reproductive endocrinology and pathophysiology and investigations of female infertility and a 
basic science study on poor ovarian responders, done in an attempt to find the pathophysiologic basis of 
this group of patients. 
2. IVF followed by embryo or eggs freeze as a well-established modality 
3.  The development of IVM and its embodiment in the fertility preservation programme, as a standalone 
option and  also as a complementary modality, together with IVF or ovarian tissue preservation options 
4. Ovarian tissue cryopreservation as a modality in prepubertal girls or adult patients who should proceed 
urgently to chemotherapy 
5.   In vitro culture of ovarian tissue as a future fertility preservation option. 
6.  Future Horizons  
















           1.     Introduction to the basic reproductive physiology and infertility 
 
         The main challenge that cancer patients face once they finish their anti-cancer treatment, is the risk of 
compromised ovarian reserve which renders them subfertile and in extreme cases might even cause 
infertility (Levine et al., 2015).  The chemotherapeutic agents and irradiation therapy can cause this 
devastating damage by multiple diverse mechanisms (Spears et al., 2019). Proper understanding of the 
reproductive endocrinology and physiology is of critical importance, providing the basis for accurate 
diagnosis and better targeting of the endocrinological and reproductive sequels. In order to better 
understand these underlying mechanisms I started my research studies to look deeper into the 
pathophysiological processes of folliculogenesis, oocyte and embryos development. I wrote two book 
chapters in the Oxford Textbook of Endocrinology and metabolism; The first chapter (Fatum and 
Child, 2016, Appendix 1) discusses the normal physiologic processes and the related reproductive 
anatomy. The second chapter (Fatum and Child, 2016, Appendix 2) pertains to the investigational 
workups that are utilised in order to achieve proper diagnosis of the different aetiologies of infertility, 
which is critical for tailoring the accurate treatment for the patients’ diagnoses. In the first chapter, 
titled the female hormone metabolism: anatomy and physiology, I thoroughly reviewed the pertinent 
literature to understand the physiologic basis of folliculogenesis and the female reproductive 
endocrinology. As discussed in the chapter, the follicle is the basic structural and functional unit within 
the ovary. They are embedded in the loose connective tissue of the ovarian cortex. Only a minority of 
the primordial follicles are recruited for further growth and development. This recruitment induces 
both structural and functional changes in the follicle and especially in the granulosa cell growth and 
maturation. Primordial follicles then grow and develop to primary, secondary, preantral and antral 
follicles stages. Early stages of follicular development are FSH-independent and are mainly controlled 
by local intraovarian factors, i.e. Anti-Mullerian Hormone (AMH). These early stages of the follicular 
growth occur several preceding cycles over a time period of about 85 days prior to achieving 
preovulatory status. Full maturation of the follicles occurs only towards adolescence and adulthood 
when the female reaches her reproductive age with the maturation of the Hypothalamic-Pituitary-
Ovarian axis. The follicles are then either recruited for further development and maturation or undergo 
atresia. Follicles are recruited by an FSH dependent process at the transition time between the 
preceding cycles luteal phase and the early follicular phase of the current follicular phase.  A cohort of 
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2-6 mm antral follicles are usually recruited and start folliculogenesis until the dominant follicle is 
recruited and the other follicles undergo atresia. The basic endocrinologically active structure is 
comprised of theca cells and Granulosa cells where ovarian steroidogenesis in the follicles is regulated 
according to the two-cell, two-gonadotropin theory. According to this theory LH acts on the theca cells 
which is mediated by cyclic AMP, StAR and SF-1 leading to androgens synthesis which then diffuses to 
the granulosa cells. FSH acts on granulosa cells through cyclic AMP, LHR-1 and SF-1 and promotes 
aromatase expression and action with conversion of aromatizable androgens into estrogens. Oestradiol 
is the main and most important oestrogen secreted, its main functions are the development of 
endometrial thickness, the triggering of the midcycle LH surge and subsequent ovulation. In addition, 
the physiologic suppression of FSH secretion by negative oestradiol feedback is key mechanism in 
preventing multi follicular development and the single dominant follicle selection and development. In 
the second chapter, I reviewed the clinical assessment and investigations, including the history and 
physical examination and the biochemical and genetic investigations that are indicated whenever a 
disruption of the normal physiology and female endocrinologic status is suspected (Fatum and Child, 
2016, Appendix 2). 
            The main problem related to anti-cancer treatment is the depletion of the follicular pool in both ovaries 
leading to a spectrum of endocrinologic and/or reproductive ovarian insufficiency. If severe enough, 
such an exposure might lead to Premature Ovarian Insufficiency (POI). These patients may present for 
IVF treatment and as a result of the compromised follicular pool they might present poor ovarian 
response which adversely affects their chances to get pregnant. Low responders (Gonda KJ et al., 2018) 
are commonly defined as women who fulfil two out of three criteria: 1. Positive for low ovarian reserve 
markers 2. Previous low ovarian response with the achievement of less than 6 eggs during ovarian 
stimulation cycle. 3. Age older than 40 years old. In order to study the molecular and cellular 
reproductive mechanism of the resultant poor response, we studied the granulosa cells function in a 
group of older low responder IVF patients and compared them to young normal responder patients 
undergoing IVF cycles (Fatum M et al., 2009, Appendix 3). We selected these two groups as they 
represented the two ends of the reproductive age with the older low responders being the study group 
and the young normal responders the control group.  We aimed to compare the mitochondrial function 
in granulosa cells in both groups. We studied mitochondrial membrane potential by JC-1 (5,5′,6,6′-
tetrachloro-1,1′,3,3′-tetraethylbenzimi- dazolylcarbocyanine iodide) staining as observed by confocal 
microscopy. In addition we performed an assay of the StAR- Steroidogenic acute regulatory protein and 
the cholesterol side chain cleavage cytochrome P450 (P450 scc) in granulosa cells of both groups. We 
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further studied the endocrinologic function within the follicles by testing Oestradiol levels in the 
follicular fluid retrieved during oocyte pick-up in the IVF cycles.  Women in the study group were found 
to have a significantly higher baseline day 3 FSH levels, a lower Oestradiol levels on the day of hCG 
trigger, a lower number of follicles, eggs and embryos achieved. We found that the number of trypan 
blue-negative granulosa cells per follicle to be significantly lower in the study group compared with the 
control group. Western blots of nine women in the study group and four in the control group were 
done. As shown in Figure 1. of the article (Fatum M et al., 2009, Appendix 3) protein  levels of the 
StAR and P450scc were similar, suggesting thus that these two proteins do not play a role in granulosa 
cells function. Figure 2 (Fatum M et al., 2009, Appendix 3) shows similar undisturbed granulosa cells 
mitochondrial membrane potential in both groups. To further validate these results we performed 
propidium iodide to see if there was a difference in apoptosis between both groups. As shown in Figure 
3 (Fatum M et al., 2009, Appendix 3), no significant difference in apoptotic cells percentages in both 
groups.  
           This study of ours was then followed by another study from our centre which aimed at examining the 
effect of ovarian response and age on the oxidation phosphorylation (OXPHOS) by injecting functional 
autologous mitochondrial concentrate from follicular fluid cells into oocytes group (Shufaro Y et al., 
2012). It was found that the OXPHOS function of the respiratory chain in mitochondria is unaffected 
by ovarian response and age. In addition the mtDNA was intact in all samples. These results are in 
keeping with our results concerning the normal functionality in granulosa cells regardless of the ovarian 
reserve and the age. 
           Both studies were done in an attempt to establish the feasibility and safety of using mitochondria from 
granulosa cells to rejuvenate eggs in low responders or elderly patients, by injecting mitochondria from 
granulosa cells of the same patients, thus obviating the need and the potential complications of 
injecting heterologous mitochondria from younger fertile women. The main drawback of our study of 
our study was that it did not study the endocrinologic and mitochondrial functioning of granulosa cells 
in the non-responding follicles which constitutes an important component of follicular population, 
where there may still be a possible defect in the steroidogenesis with resultant hypoestrogenic 
environment. 
 
           In order to simulate this hypoestogenic environment and study the importance of proper secretion of 
estrogen during folliculogenesis, we performed an animal model study, and injected Arimidex 
(Anastrozole), an aromatase inhibitor to C57Black female mice in order to induce low estrogen levels 
 
 20 
(Fatum et al., 2006, Appendix 4). We examined whether hypoestrogenic microenvironment would 
have an impact on the folliculogenesis, the competence and maturation of the eggs and in vivo 
ovulation. In addition we studied the effects of Arimidex administration on the in vitro development of 
embryos into morulae, blastocysts and hatching blastocysts in culture. This study was also done to 
study the safety and the effects of using Anastrozole for ovulation induction in poor responders, as a 
number of publications reported the viability and efficacy of using aromatase inhibitors in ovulation 
induction especially in poor responders and in estrogen-receptor positive breast cancer patients who 
might benefit from reducing the estrogen levels during ovarian stimulation in IVF cycle done to freeze 
eggs or embryos as a fertility preservation option. Our study was unique as it studied the effects of 
Anastrozole on the folliculogenesis and the subsequent development of embryos in culture. We 
confirmed the efficacy of Anastrozole injection into the mice in reducing estradiol levels in the 
circulation. A significant reduction in oestradiol levels was demonstrated in the Arimidex group in 
comparison to the control group. Nevertheless, the two groups did not differ by the total number of 
developing follicles nor by the distribution for antral and pre-antral follicles Table 1. and Figure 1 
(Fatum et al., 2006, Appendix 4). In addition, and despite the low Oestrogen levels, the total numbers 
of embryos resulting from mating these mice were similar in the control and study groups, as well as 
the embryonic development of the embryos into the morula, blastocyst and hatching blastocysts stage. 
This study provided evidence that low follicular phase oestrogen levels do not play a deleterious effect 
on folliculogenesis and that oestrogen levels per se are not critical for folliculogenesis in the mice 
ovaries. In addition, embryos created and cultured showed normal development in culture as shown by 
satisfactory progression to advanced embryonal forms i.e. the morula and blastocyst stages. This study 
showed that aromatase inhibitors could possibly be safely used as part of the ovarian superovulation in 
IVF cycles in general and potentially in hormone-receptor positive cancer patients, where clinicians 
would prefer patients are kept with low oestrogen levels, due to potentially deleterious effects of high 
levels of oestrogen. Several studies and other reports have demonstrated the effective use of aromatase 
inhibitors in ovarian stimulation in IVF patients and in cancer patients (Ben-Haroush et al., 2019, 
Pereira et al., 2016). Nowadays, aromatase inhibitors are widely used in IVF and fertility clinics and 
are considered to be effective adjunct therapies in combination with gonadotropins injections (Balen 
et al., 2016). 
 
            We then did a review of the pertinent literature to assess the safety of using aromatase inhibitors for 
superovulation and study whether congenital malformations rate was increased in these patients. Early 
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small retrospective studies suggested a possible increased congenital cardiac and bone fetal 
malformation rate in patients who were using aromatase inhibitors for ovarian stimulation (Biljan et 
al., 2005). Our review of the literature and analysis of the different studies (for a more detailed 
description of the studies included, see (Fatum et al., 2006, Appendix 5), had shown the relative safety 
of using these agents for ovulation induction. These studies including animal studies and clinical 
human reports indicate that aromatase inhibitors are relatively safe for usage in ovulation induction in 
terms of folliculogenesis, in vitro embryo development and relative safety vis-a-vis teratogenic effects. 
As these medications are used during IVF cycles done for fertility preservation before the 
commencement of chemotherapy and irradiation and in these circumstances embryo transfer is done 
years after ovarian stimulation, there seems to be no safety issues. To the contrary, in the case of 
hormone-receptor positive tumours, the low oestrogen levels in the circulation may be advantageous 
in these patients. Several studies in the literature followed, which validated our results and reinforced 























2. In Vitro Fertilization followed by embryo or eggs freeze as a well-established 
modality. 
 
As IVF followed by embryo or eggs freeze, is the main fertility preservation option, I will present the studies 
done, including the random start ovulation induction protocol, the safety of egg collections in patients 
having haemostatic disorders which is a common condition in cancer patients, embryonal biomarkers as 
predictors of implantation outcomes and clinical  pregnancy rates and our contribution in the study of 
the different protocols utilised in frozen embryo replacement cycles, which are the mainstay of the fertility 
treatment after patients recover from their cancer treatment and return for embryo transfer. 
           Fertility preservation in cancer patients prior to gonadotoxic anti-cancer treatment is a rising clinical 
service and has been an ever-growing discipline, that recently was even granted a specialised 
nomenclature - oncofertility (Jeruss and Woodruff, et al., 2009; Salama et al., 2019). The numbers 
of publications on this risen topic has increased steeply in the last few years due to the new 
breakthroughs in the field and the constantly evolving state-of -the-art practices in the different fertility 
preservation modalities in female oncologic patients (Ataman et al., 2018). Oncologic patients are 
increasingly referred for fertility preservation consultation prior to the commencement of 
chemotherapeutic/irradiation treatment. As the patients’ awareness to the availabilities of the fertility 
preservation options increases and as the general practitioners and oncologic physicians knowledge gap 
of the different oncofertility modalities is being increasingly bridged, fertility preservation service is 
becoming an integral part of the clinical care of cancer patients (Jeruss and Woodruff, et al., 2009). 
Upon their referral, patients are thoroughly assessed to establish the need and the indication for fertility 
preservation. This assessment takes into account the diagnosis, chemotherapeutic agents and the 
irradiation scatter that is planned, their gonadotoxic potential, the urgency with which the fertility 
preservation treatment should be offered, age of the patient and the five years survival of these patients 
(Michaeli, et al., 2012). There are several algorithms for the different cancer diagnoses and the relative 
gonadotoxic potential associated with these cancers and their recommended treatment protocol and 
whether fertility preservation is indicated for these patients. In addition, similar algorithms and 
databases provide estimates of the gonadotoxic effects of different chemotherapeutic agents and 
irradiation protocols to aid clinicians in providing accurate recommendations to cancer patients. ASCO 
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guidelines provide evidence based recommendations for the vast majority of cancers and anti-cancer 
treatment protocols (Oktay, et al., 2018, Knight, et al., 2015). 
             The next step in the decision making tree is to decide on the fertility preservation modality to 
be offered to patients. In adolescents and pubertal patients, an IVF cycle provides the first best option 
in intermediate-high risk patients. This option gives a good reliable fertility preservation in the form of 
egg freezing or embryo freeze. All IVF units can possibly offer these patients a cycle of ovarian 
stimulation and egg collection. This is followed by either fertilisation of these eggs by partner’s or donor 
sperm and embryonal freeze, or by vitrification of eggs if there was no partner or if the use of donor 
sperm is not considered by patient or her guardian. Some patients might opt to do both options with 
half of the patients eggs being vitrified and the remaining half fertilized with sperm followed with 
embryo freeze. In premenarcheal girls  and in pubertal/adolescent patients who must start anti-cancer 
treatment urgently, ovarian tissue preservation is offered. This well be further discussed in chapter 5 
(Fatum and McVeigh, 2013, Appendix 6). 
             Offering IVF cycle for fertility preservation can be accompanied by various challenges that the 
clinician should take into account and would need to thoroughly discuss them with patients before an 
informed consent is given. Patients should be made aware that the treatment cycle might cause 2-4 
weeks delay in the start of chemotherapy or radiotherapy depending on the day of the cycle the patient 
is and whether complications i.e. Ovarian Hyperstimulation Syndrome (OHSS) and its sequels take 
place, imposing further delay. Ideally, the ovarian stimulation should be commenced at the early 
follicular stage so that a higher number of antral follicles could be recruited resulting in a higher harvest 
of eggs. The number of eggs retrieved is critical for fertility preservation, as their number is finite and 
thus conferring a limited extent for fertility preservation. Henceforth, the aim is to safely get the highest 
possible number of eggs retrieved and stored giving a satisfactory fertility preservation potential 
(Mizrachi et al., 2020).  
     
             An IVF cycle for fertility preservation comprises of several components- ovarian stimulation to recruit 
growing follicles followed by oocyte pick up and storage of eggs or embryos, depending on the patient 
marital status and whether she would consider the option using donor sperm to fertilise the eggs 
(Mizrachi, et al., 2020). There are two major possible stimulation protocols that are utilised for ovarian 
stimulation- the short and the long protocols (Manuel, et al, 2019, Lambalk, et al, 2017). The long 
protocol is usually started on day 21 of the cycle for inducing down regulation of the pituitary gland, 
followed by daily injections of gonadotropins for follicular stimulation. This protocol may take 6-8 
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weeks to accomplish, which might prove too long for cancer patients who need to start their ovarian 
stimulation within 2-4 weeks. Due to this prolonged course, the short protocol was offered in cancer 
patients in an attempt to reduce the time scale of ovarian stimulation and allow patients to get their 
anticancer treatment as soon as possible. Short protocol includes the use of GnRH agonists or 
antagonists in the early days of the cycle in parallel to the administration of gonadotropin stimulation. 
Such a cycle may take 3-4 weeks if the patient is lucky to be near the beginning of her menstrual cycle 
(Manuel, et al, 2019, Lambalk, et al, 2017). However, the majority of patients might present in late 
follicular phase or the periovulatory or the luteal phase where they have to wait till the beginning of the 
next menstrual cycle to be able to start the stimulation in the early follicular phase. This might be 
unacceptable to those patients who need to start chemotherapy in a duly time. A third option has been 
suggested in the literature in the context of fertility preservation- the random start protocol (Nayak, 
et al., 2011). In this protocol- regardless of the menstrual cycle phase and especially in the luteal phase, 
patients are started on GnRH antagonists for three days before the administration of gonadotropin 
stimulation. Its main advantage is that no further waiting is required before starting the stimulatory 
protocol (Cakmak, et al., 2015). The classic theory of folliculogenesis and ovarian stimulation 
advocates the early follicular phase stimulation as the ideal timing of stimulation as more follicles are 
possibly recruited in that phase. As the stimulation is delayed to a later stage of the follicular phase, the 
number of follicles recruited drops significantly (Hsueh, et al., 2015). All the more so, luteal phase 
stimulation has been perceived as a counter physiologic regimen. Concerns have arisen concerning the 
number of eggs that are harvested using the random start protocol. For answering this question, we 
have run a retrospective study to compare the outcome of random start protocol to the usual 
stimulatory protocols to assess the efficacy of the random start protocol (Muteshi, et al., 2018 
Appendix 7). The study included 137 cancer patients that were referred for fertility preservation and 
underwent ovarian superovulation for gamete/embryo freeze between February 2003 and June 2016. 
The random start protocol has been offered at any point after the fifth menstrual day. It involved the 
administration of Cetrorelix 250 micrograms (Cetrotide, Serono Pharmaceuticals Ltd, Feltham, UK) for 
a total of three days before ovarian stimulation was commenced on the fourth day. The Cetrorelix was 
continued until the day of the HCG or Buserelin administration. A multivariable logistic regression 
analysis was then performed. 127 patients were treated using the antagonist protocol (103 (81%) in the 
conventional early follicular start group and 24 (19%) in the random start group). As the results show, 
both the study and control groups were similar in their epidemiological parameters as presented in 
table 1 (Muteshi, et al., 2018 Appendix 7). We have found similar outcomes using both antagonist 
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protocols: there was no significant difference in the number of eggs retrieved, eggs fertilised and 
embryos stored between both groups. Consequently, we could conclude that the random start protocol 
is equally effective whilst saving patients unnecessary waiting time to start the treatment with the 
random start protocol. This study is among a limited number of studies in the literature on this topic 
(Nayak, et al., 2011, Ortega, et al., 2018) and was quoted in the 2019 ESHRE guidelines of ovarian 
stimulation ( eshre stimulation guidelines). Nowadays the random start is increasingly becoming 
the treatment of choice in cancer patients requiring IVF treatment for fertility preservation.  
 
             Our aforementioned studies, discussed in the previous chapter, with regards to the utilisation and 
safety of aromatase inhibitors in ovarian stimulation, contributed to the introduction and adoption of 
these medications in ovarian stimulation protocols in cancer patients and in ovulation induction in 
fertility patients (Chapter 2, Fatum, et al., Appendix 2). We have shown the relative safety of using 
the Anastrozole in folliculogenesis, oocyte maturation and the embryonic development in culture in 
mice. In addition, we analysed the different studies on the safety of Letrozole in pregnancy. Henceforth, 
we published an opinion article supporting the usage of aromatase inhibitors in cancer patients having 
estrogen receptors positive tumours (Appendix 5). With time Aromatase inhibitors have become an 
integral part in ovarian stimulation protocols in fertility preservation cycles (Moini, et al., 2019, Azim, 
et al., 2008). 
             
 When discussing the fertility preservation procedure to patients, it is important to keep patients well 
informed of the true fertility preservation potential that the frozen eggs or embryos confer. This is of 
critical importance in their informed consent and reassurance, so that they have realistic expectations 
of the fertility preservation potential. In addition this is crucial also for the clinician to decide whether 
more than one IVF cycle might be needed. We did a study that aimed to examine the different 
morphokinetic characteristics of the blastocysts as predictors of implantation potential and ongoing 
pregnancy rates (Subira, et al., 2016, Appendix 8, Subira, et al., 2014). We designed a retrospective 
cohort study of 1084 fresh elective single blastocyst transfers. We assessed the following grading 
parameters in the different blastocysts transferred: blastocyst expansion, the inner cell mass (ICM) 
grade and the trophectoderm grades, according to Gardner’s blastocyst grading system (Gardner and 
Schoolcraft, 2019). Our primary outcome was the live birth rate (LBR) and the secondary outcomes 
were implantation rates and clinical pregnancy rates and early pregnancy loss rates. Using definitive 
multivariable regression analysis, we found that the ICM and blastocyst expansion were associated with 
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LBR. We found that when the ICM grade dropped from grade A to C the likelihood of LBR was 
significantly reduced by 55%. Similar results were also shown for the clinical pregnancy rates predictors. 
In addition, we found that early pregnancy loss rates in embryos with ICM grade C were more 
significantly increased compared to those with grade A  and grade B (38.0% vs 15.95% vs 17.17%, p = 
0.002). The transfer of a single embryo with a high ICM grade reduces the likelihood of early pregnancy 
loss and increases the likelihood of live birth. Other studies in the literature have shown conflicting 
findings and some reports suggested that the trophectoderm grade is a better predictor (Thompson, 
et al., 2013). As these results may well show the variability of the findings in the different studies, this 
might reflect different laboratories protocols utilised and the different clinical practices being applied 
in each centre. Therefore, we suggest that each fertility preservation programme advise their patients 
of their own results and figures with regard to the programme’s predictors of clinical pregnancy rates 
and LBR, as currently there is no clear consensus as to which predictor is better as an indicator 
(Thompson, et al., 2013). We believe that providing this information is crucial to coordinate patients 
expectations of the embryos stored. 
            Cancer patients, especially those with haematologic diagnoses may present with conditions that 
increase their bleeding predisposition, i.e. thrombocytopenia or prolonged bleeding time either due to 
their oncologic disease ( for instance, leukaemias and lymphomas) or as an adverse effect of the 
chemotherapy they might have been exposed to prior to their referral. One of the main clinical concerns 
in these patients is the possible haemorrhagic complications that might ensue during or after oocyte 
pick up, especially due to the hypervascularity of the overstimulated ovaries. In order to assess the safety 
of performing egg collection procedure in these patients- we did a retrospective cohort study on all 
patients who have had a history of bleeding tendency and who underwent egg collection after 
appropriate preoperative preparation and correction of the haemostatic abnormalities (Fatum, et al., 
2007, Appendix 9). We found eight patients who were found to have a haemostatic disorder including 
thrombocytopenia due to ITP, VW factor deficiency or factor VII or XI deficiencies as described by 
Table 1. (Fatum, et al., 2007, Appendix 9). We had demonstrated the relative safety of oocyte pick up 
in all of these patients, provided the pre-procedure bleeding tendency is timely diagnosed and patients 
are properly prepared preoperatively to restore their haemostatic competence by disorder specific 
treatment. This was an important report and among the first reports in the literature to demonstrate 
the feasibility and relative safety of offering oocyte pick up in patients found to have haemostatic defect 




            Once an oncologic patient has finished her anti-cancer treatment and fully recovered from her disease, 
a debatable waiting period of time, commonly one-two years period of follow up is recommended before 
transferring embryos and attempting pregnancy. This is of importance in order to make sure patients 
have been in long standing remission and further reduce the risk of relapse while being pregnant 
(Lawrenz, et al., 2011). This could be further delayed for longer periods if additional adjuvant 
treatment is needed, i.e. in breast cancer patients where longer treatment with Tamoxifen is commonly 
initiated for several years after the completion of the chemotherapy.  
  
 The treatment that follows includes mainly a hormonal treatment to artificially prepare the endometrial 
lining towards egg/embryo thaw out and embryo transfer. These so called medicated frozen embryo 
replacement protocols are of importance, as these patients may have endured premature ovarian 
insufficiency and might not have menstrual cycles or their natural cycles are not ovulatory. In these 
cases, exogenous hormones should be administered to prepare the lining. The vast majority of women 
would respond well to the administration of oestrogens to thicken the endometrial lining, followed by 
the addition of progesterone pessaries for luteal support. This treatment is continued till the 8th 
gestational week. In the reproductive medical literature, this could be done in either a long protocol 
using GnRH agonists starting in the mid luteal phase or in a short protocol using GnRH antagonist, to 
prevent spontaneous folliculogenesis and premature ovulation whilst being on oral Oestrogen 
medications to stimulate endometrial thickening (Glujovsky, et al., 2010). Other groups have also 
shown the safety and effectiveness of not giving either agonists nor antagonists for the inhibition of 
folliculogenesis and ovulation (Simon, et al., 1998, Ghobara, et al., 2017). 
              
           We performed a prospective randomised controlled study to evaluate a simplified approach of 
artificial endometrial preparation, comparing two doses of oral Oestradiol tablets combined with a 
novel vaginal natural progesterone pessaries (100 mg Endometrin). Twenty-nine patients were recruited 
in the study and divided randomly into two groups. The first group received oral Oestradiol tablets 4 
mg/day from the first day of menstruation and the second group were put on 6 mg/day. Following an 
overall 12 days of oestradiol priming and after with an endometrial thickness of > = 8 mm, Endometrin 
vaginal tablets 100 mg were added twice a day for a total of 10 days. On day 21st an endometrial biopsy 
was taken to evaluate the endometrial secretory changes. We have found appropriate changes in 
estradiol, progesterone and endometrial response (see Figures 1-3, in Appendix 10a , Lewin, et al., 
2002, Appendix 10a). As expected the oestradiol levels were significantly higher in the higher 
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Oestradiol dose, however there was no significant difference in the serum progesterone levels or the 
endometrial thickness in both groups. The histopathological evaluation of the endometrium on day 21, 
revealed adequate secretory endometrium in both groups. These results demonstrated that an 
appropriate endometrial thickness can be achieved using a fixed low dose oral oestradiol (as low as 4 
mg/day) and that adequate late-secretory endometrial transformation can be achieved by the 
administration of low-dose vaginal natural progesterone. This is in line with other reports in the 
literature showing different progesterone medications and different methods of administration to be 
equi-effective in giving adequate secretory transformation and pregnancy support. This study is of 
special importance in cancer patients, where lower doses of hormonal treatment would be preferable 
in patients who are known to have hormone-receptors positive tumours. 
          We then did another retrospective observational cohort case study, in an attempt to study the 
endometrial responsiveness in patients having a history of thin unresponsive endometrium despite the 
administration of oestradiol in usual doses. We retrospectively analysed and studied the different 
artificial endometrial stimulation protocols that were used in an attempt to get the endometrial lining 
to adequately respond and reach an acceptable thickness. Thirteen women were included who 
underwent 99 cycles of artificial endometrium stimulation. This group of women had undergone 
various and diverse empirical treatments with different combinations and doses of Oestradiol In 
combination with Sildenafil and Aspirin. The different treatment modalities and combinations as 
shown in table 2 (Shufaro, et al., 2008, Appendix 10b) had various success rates in achieving adequate 
endometrial response and pregnancy rates. As shown in table 2 (Shufaro, et al., 2008, Appendix 10b), 
no treatment was found to be more beneficial than the other. Out of 99 treatment cycles, in only 22 
cycles an adequate endometrial response was achieved; however the pregnancy rates were low with 
poor reproductive outcomes even if endometrial thickening or implantation was achieved (8 early 
miscarriages, two terminations due to malformations and one live birth). This poor prognosis and the 
failure of the different treatment protocols to improve the reproductive outcome is in accordance with 
other published data (Bu et al., 2016, Mahajan and Sharma, 2016).   
          Therefore, this challenge continues to be a hurdle to these patients who are dependent on responsive 
lining for their frozen embryo replacement treatment. 
             






3. The development of IVM and its embodiment in the fertility preservation 
programme. 
 
 Oxford Fertility Unit is the first unit in the UK to offer in vitro maturation (IVM) treatment, which 
is offered mainly to PCOS patients; however, it is also a viable option to produce eggs for the sake of 
fertility preservation. I will present my work in this area including comparison of IVM and IVF results, 
using IVM and surrogacy in Ehler Danlos disease. The adoption of IVM is of importance in any fertility 
preservation programme, as a standalone option but also as a complementary modality, together with 
IVF or ovarian tissue preservation options. 
 
 IVM is a technology that has been utilised in the last few years as an alternative to In Vitro 
Fertilization (IVF) which reduces the risks of ovarian hyperstimulation syndrome (OHSS)(Yang and 
Chian,  2017). This technique is based on immature oocyte pick up without ovarian stimulation, 
followed by in vitro maturation of the harvested eggs in the lab (Chian, et al., 1999). As a result, 
patients are not exposed to high levels of ovarian stimulatory drugs, unlike the common IVF treatment 
cycles, and consequently the Oestradiol levels remain low and therefore there is no risk for OHSS. This 
technology is mainly offered to patients having polycystic ovaries or those who are at high risk of OHSS. 
In addition, some reproductive medicine centres utilise this technique for women who should be kept 
with low oestradiol levels during their fertility treatment, i.e. patients with estrogen-receptor positive 
tumours. In these patients, keeping the estrogen levels low is perceived as essential to their safety as 
clinicians are increasingly concerned with the possible deleterious effects of the high estradiol levels in 
these estrogen receptor positive tumors (Grynberg, et al., 2016). The IVM programme at the Oxford 
fertility unit was the first and only fertility unit offering this treatment for fertility patients. The 
development and maintenance of the IVM programme in the unit was instrumental in adding this 
modality into the ovarian tissue cryopreservation service that was later introduced in Oxford. This 
enabled the introduction of in vivo and ex-vivo oocyte retrieval for IVM as part of the ovarian tissue 
cryopreservation and as a separate independent modality for patients that need egg collection at short 
notice as they need to proceed with chemotherapy or radiation therapy within days of their diagnosis. 
In order to keep the programme running and available for cancer patients we did several studies to 




 In order to compare the outcome of IVM and routine IVF for women diagnosed with polycystic 
ovaries (PCO), we did a retrospective case control study to compare the live birth rates per cycle and 
the OHSS rates in both groups. The study included ninety-seven patients undergoing IVM treatment 
compared with ninety seven patients undergoing IVF/ICSI, all having ultrasonographic evidence of 
PCO and matched for age. In the IVM cycles hCG was administered 35-40 hours before oocyte retrieval. 
Oocytes were then matured in vitro for 24-48 hours before insemination was done by ICSI. Endometrial 
priming with additional oestradiol and progesterone was commenced after the egg collection and one 
to two good quality embryos were then transferred on days 2-5 of development. For the IVF/ICSI cycles, 
the standard long protocol was used for the control group. As demonstrated in Table 2 in (Gremeau, 
et al., 2012, Appendix 11) we managed to achieve 65% in vitro maturation rate of eggs in the IVM group. 
The implantation rates were significantly higher in the the control IVF group (19.4% vs. 12.9%) and 
similarly the clinical pregnancy rates (50.5% vs. 19.6%) and the live birth rate (44.3% vs. 16.5%) were 
higher in the control group than the IVM. However, the OHSS rate was observed to be significantly 
higher in the IVF/ICSI control group (8.2% vs. 0%). 
 We concluded that in PCO patients who are eligible for IVM treatment, the technique offers 
them a reasonable chance of conceiving while obviating the need of gonadotropins stimulation and 
eliminating the risk of OHSS. IVM has thus been shown to be a safer and simpler alternative to IVF/ICSI 
treatment in PCO patients. This study has shown IVM as a viable option fertility treatment option that 
could possibly be offered with the appropriate clinical set up and indications for fertility preservation. 
This study is in keeping with other studies in the literature showing the success rates of IVM cycles in 
PCO patients to be almost 50% of IVF/ICSI cycles (Child, et al., 2002). 
 
 We then reported the utilisation of IVM in a patient of vascular type Ehler Danlos Syndrome 
(EDS) who experienced postoperative bleeding from aneurysmatic vessel after IVF cycle (Bergeron, et 
al., 2014 Appendix 12). Patients with this disorder are prone to spontaneous arterial and visceral 
ruptures. The occurrence of these life threatening complications is increased in pregnancy. This was 
attributed to the high estrogenic levels associated with ovarian hyperstimulation in the previous IVF 
cycle. The patient in this case report was a 33 years old, suffering from EDS with a history of recurrent 
ruptures of arterial aneurysms and recently she was diagnosed with a ruptured splenic arterial 
aneurysm. The patient had then undergone several natural IVF/ICSI cycles in order to avoid high 
oestrogen levels possibly linked to the previous complications. She then underwent two uncomplicated 
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IVM cycles with PGD in our clinic in an attempt to avoid high Oestrogen levels and increase the number 
of eggs retrieved. The patient underwent embryo transfer of a normal blastocyst; however, the PGD 
cycle was unsuccessful, though the safety of IVM in this vascular-type EDS patient was proven as a 
matter of principle (Bergeron, et al., 2014, Appendix 12). 
 
 We then had a study that offered to widen the range of IVM indications to PCOS patients who 
over respond or under respond to ovarian stimulation during IVF treatment (Fatum, et al., 2020 
Appendix 13, Fatum, et al., 2013, Appendix 14). This was a case series study that included two groups 
of patients- the first group comprised of  PCOS patients undergoing IVF  treatment, who  over 
responded to the ovarian stimulation drugs with high levels of oestradiol and increased risk of OHSS, 
whilst  follicles were still small and medium sized and needed longer stimulation  period to mature. 
However, as further stimulation would be risky, as high estrogen levels would continue to increase and 
thus increasing the risk of OHSS. In these cases, either cycle cancellation or coasting are reasonable 
options, they can possibly compromise the outcome of the cycle. We showed that conversion to a rescue 
IVM cycle with egg collection in these patients followed by treatment of the eggs with IVM media would 
be a safe option as the trigger is given while the oestrogen levels are kept at their initial high levels with 
no further elevation in their levels, reducing thus the associated risk of OHSS. A total of 58 out of 68 
oocytes retrieved were mature or matured in vitro. There were 26 cleaving embryos obtained. Two 
patients had live births and one suffered from a miscarriage.  In the second study group, a rescue IVM 
was offered to PCOS patients who responded poorly to the highest doses of hormonal stimulation. In 
these two patients, a total of 22 out of 26 oocytes retrieved were mature or matured in vitro using IVM 
media. There were 13 cleaving embryos obtained. One patient had a live birth, whilst the other suffered 
a miscarriage. This study was accepted for publication this year and it adds to the diversity of treatment 
options for these patients, see Table 1 and Figure 1 (Fatum, et al., 2020 Appendix 13). We are aware 
of another study that suggested the feasibility of rescue IVM as a viable option (Coskun, et al., 1998, 
Jaroudi, et al., 1999). 
 Introducing the IVM programme and validating the efficacy of in vitro maturation of immature 
oocytes has been instrumental in its translational application in fertility preservation. 
 Upon setting up the ovarian tissue cryopreservation programme in Oxford as will be 
demonstrated in the next chapter,, we could reliably offer this treatment modality as part of the fertility 
preservation repertoire. We then presented our experience that was consequently published in two 
poster abstracts in AAGL 2014 and  ESHRE meeting in 2015, (Fatum, et al., 2014 Appendix 15, Fatum 
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et al., 2015 Appendix 16) . We reported a combined approach in which   ovarian tissue cryopreservation 
is offered to appropriate patients together with either in situ or ex vivo oocyte collection followed by 
IVM. We were among the first fertility preservation programmes that embodied the IVM as a 
complementary option for the ovarian tissue preservation. This experience will be the basis for an either 
independent article or as a subsection of an article that will summarize our experience in introducing 
ovarian tissue cryopreservation clinical service (see next chapter for more details). 
While IVM has been reported as an independent modality of fertility preservation by different other 
groups (Kedem, et al., 2018). However, as we have shown before (Bergeron, et al., 2014 Appendix 
12)- the pregnancy outcomes of IVM embryos is much less (about 50%) than the IVF cycles, and 
henceforth, we believe that in the context of fertility preservation, and whenever time to start 
chemotherapy allows, an IVF cycle with the intention of freezing eggs or embryos, should be the first 
choice procedure. Using IVM as the primary fertility preservation technique, should be kept to patients 
who need to start chemotherapy within days, where further delay would lead to aggravation of the 
patients’ prognosis. Grynberg et al. have offered luteal or even several cycles of IVM with back-to-back 
oocyte pick up to allow pooling of a higher number of immature eggs to increase the efficacy of the IVM 




















4.  Ovarian Tissue Cryopreservation   
 
 In the last few years, I have worked on the establishment of one of the UK's first HTA/HFEA 
approved ovarian tissue cryopreservation programme which offers cancer patients from across the 
country to have ovarian cryopreservation. A chapter in the book will be presented as well as a manuscript 
summarising our experience will be submitted for publication (myself as a first author) to report the first 
100 patients referred to this important translational programme. 
 
 It is estimated that almost two thousand new cancer diagnoses are made each year within the 
UK with almost half of them being in premenarcheal paediatric girls. These patients until recently did 
not have a fertility preservation treatment due to the lack of effective treatment. Ovarian tissue 
preservation was offered as a promising emerging modality although there was no evidence of its 
effectiveness. Therefore, the NICE guidelines continued to recommend ovarian cortical tissue 
cryopreservation as an experimental medicine that should be done only in a well-designed research 
framework (NICE guidelines link). Groups in Edinburgh and Leeds held a research based protocol 
and programme for the cryopreservation of ovarian tissue for these patients (Wallace, et al., 2014). 
However, there was no appropriate HTA and HFEA licences to make clinical use of these stored tissue 
and to permit their autografting back to patients once they were cured and entered their reproductive 
phase of their adult lives. Up till the late nineties, no pregnancies were achieved despite the harvesting 
of ovarian tissue in paediatric oncologic patients for fertility preservation. As a result, we wrote an 
opinion letter and recommended against the routine utilisation of ovarian tissue cryopreservation in 
oncologic patients, as there was no supportive evidence to its efficacy and the benefit /risk ratio 
(Schenker and Fatum, 2004, Appendix 17).  However, after the first pregnancies started to appear 
and to be increasingly reported in the literature, the status of this innovative technology changed from 
research area to experimental medical field. As I worked with one of the pioneering groups in ovarian 
tissue cryopreservation in the world who achieved live births from the transplantation of the stored 
ovarian tissue (Meirow et al., 2005; Revel, et al., 2011), I was then offered a collaborative fellowship 
by Oxford University as a senior research fellow to set up a clinical Oxford Ovarian Tissue 
Cryopreservation Programme for cancer patients. 
 
 34 
 This work commenced in late 2008 and culminated in the achievement of both HFEA and HTA 
licensing of the Oxford ovarian tissue cryopreservation programme in 2013. We achieved both 
authorities licences in order to be able to utilise the ovarian tissue itself which is mainly in the 
regulatory area of the HTA, and the HFEA licence to enable the programme to process oocytes ie IVM 
of immature eggs. This feat included intensive efforts to finalise Laboratory SOPs and modify them as 
necessary, to accommodate for the European Union standards and regulations, then validating the 
protocols on pig ovaries, testing and validating the clean room standards of the surgical theatres at the 
John Radcliffe Hospital and finally getting the institutional permissions from the Oxford University 
Foundation Trust.  
 I published our initial experience in setting up the ovarian biobanking programme in a book 
chapter in reproductive surgery in assisted reproduction which included our modified protocols of 
tissue processing, freezing and thawing out (Fatum and McVeigh, 2015, Appendix 6). To our 
knowledge, our service is among the first if not the first to abide by the new European regulations for 
tissue cryopreservation and by publishing it, we hope to facilitate the licensing of other ovarian tissue 
cryopreservation programmes within the European Union to benefit from these uptodate SOPs. Oxford 
ovarian tissue biobanking programme has offered several unique contributions to the field of ovarian 
tissue cryopreservation: Firstly, The programme introduced a combined fertility preservation option 
including ovarian tissue cryopreservation and in situ and ex vivo oocyte pick up followed by IVM of 
these immature oocytes. The programme has offered the first 20 patients the option of undergoing IVM 
in addition to the normal ovarian tissue harvesting. We have shown as a proof of principle that this 
option is feasible and we have achieved immature eggs from patients as young as two years old with a 
reasonable maturation rate after IVM treatment (see previous chapter and Fatum, et al., 2015  
Appendix 16). Secondly, as this service was pioneering at the national level, with it being the first to 
get HTA and HFEA licensing, we directly built up schemes to offer it for all patients across the UK. We 
have built up two schemes- first one was the referral of patients to OUFHT as a tertiary centre, where 
patients underwent the ovarian tissue harvesting and the processing of the tissue, followed by the slow 
freeze.  The second scheme was through third party contracts where patients were offered to undergo 
the harvesting at their local hospital, followed by transporting the ovarian tissue with ice to the Oxford 
Ovarian tissue biobank. This scheme had the advantage of keeping the patients in their local hospital 
so that they could start their cancer treatment as soon as they recovered from the surgery. 
Thirdly, after the successful introduction of the ovarian tissue cryopreservation, the same laboratory 
infrastructure and facilities were utilised to introduce a testicular tissue cryopreservation programme. 
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Fourthly, establishing the clinical programme has been instrumental in the launching of different 
research studies aiming at improving this innovative technology. This will be further discussed in 
chapter 6, concerning current research projects and future ones. 
 I have written a manuscript that summarises our experience from the first one hundred referrals 
for ovarian tissue preservation. The manuscript will be submitted to a reproductive medicine journal 
with me as the first author. Further details are presented in Appendix 18 and Appendix 6. 
 Being one of the first pioneering units in the UK and in the World, is an opportunity to take 
active part in the discussions of new indications for ovarian tissue preservation. Some of the new 
indications are unique benign or genetic conditions that may be a challenge to the oncofertility 
professionals, as there are no clear guidelines with regard to the fertility preservation indication and 
methods offered. Last year we published an article which reviewed the pertinent literature concerning 
fertility preservation options in girls with Turner syndrome. We discussed the different clinical, 
psychological and ethical dilemmas faced when facing this clinical entity in these young TS girls. We 
then built up a flow chart algorithm to help clinicians in their decision making of the different fertility 
preservation modalities for both pubertal and pre-pubertal girls with Turner syndrome, as appears in 


















5. In vitro culture of ovarian tissue as a future fertility preservation option 
In vitro culture of ovarian tissue is the forefront of fertility preservation studies, in patients having ovarian 
tissue preservation. A first publication from last year is presented together with future implications. 
 
 From the outset, and in parallel to the licensing of the clinical ovarian tissue cryopreservation 
programme, I have worked to get basic science research projects to further develop the technology and 
try to answer the challenges it poses. One of the main challenges in the application of ovarian tissue 
cryopreservation, is the risk of micrometastasis seeding of the primary tumour with the autografting of 
the ovarian tissue slices, once the oncologic patient is interested in fertility. Other than histopathologic, 
immunohistochemical staining, molecular tests ie PCR, to rule out the presence of the tumour cells in 
a sample of the ovarian tissue, there are not currently any viable options to further reduce or even 
eliminate the risk of tumour metastases. This is of special import in haematologic disorders i.e. 
leukaemia as per definition the cancer cells are in the blood vessels everywhere throughout the body 
including the normal ovarian tissue. In order to meet this clinical need and try to eliminate this risk, I 
have set out a research project for in vitro culture of ovarian tissue and follicles. The aim of such 
research is to advance the in vitro folliculogenesis in an effort to get in vitro matured eggs without the 
need of autotransplantation of ovarian tissue and thus preventing the risk of micrometastasis.  
A collaboration was initiated with two labs in the Oxford University - the tissue bioengineering and 
bioprocessing department and the ovarian cryopreservation laboratory. The original ethical approval is 
enclosed in Appendix 20 which includes the collaboration with the department of bioengineering and 
a further modification to include the collaboration with ovarian cryopreservation laboratory was 
applied and appears in Appendix 21 which sheds light on the prospects of research projects planned. 
 We have recently achieved our first publication in this area from last year. In the current study 
(Walker et al, 2019, Appendix 22), we investigated the developmental staging of the different follicles 
in human cryopreserved ovarian tissue from patients undergoing fertility preservation. Our findings 
showed a variation in follicular developmental stages and their health in both cultured and non-
cultured ovarian tissue. Interpatient variation was also documented in the pre-culture samples both in 
the rates of healthy follicles and the different phases of growing follicles. A variation in follicular health 
and growth was also documented after the culturing of the ovarian tissue. We found a variation in the 
health and in the numbers of the transitional, primary and secondary follicles. Of note, we found that 
both cultured and uncultured samples selected by neutral red (NR) - stain for assessment of follicles 
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survival showed higher numbers of healthy follicles. Our study was the first study of this collaboration 
towards optimisation of culture systems for in vitro culture and maturation of ovarian tissue. The 
present study reported a new classification system of follicles health in human cryopreserved ovarian 
tissue, based on the presence/absence of pyknosis in granulosa cells, pyknosis in oocytes and the 
presence or absence of shrunken cytoplasm. Further details and discussion appears in appendix 22 
(Walker et al, 2019, Appendix 22). 
 
We recently submitted another manuscript (Bjarkadottira, et al. 2020, Appendix 23) analysing 
different culturing conditions of human ovarian cortical tissue to maximise the follicle survival. We 
investigated the effect of different culture media and media volumes and dish permeability on health 
and development of cultured follicles. We found that culturing follicles in low volume conditions had 
significantly higher odds of being graded as healthy follicles. The alpha MEM (Minimal 
Essential Medium) medium in a low volume resulted in the highest proportion of healthy follicles and 
higher rates of development into multi-layered follicles, see Figure 5 Appendix 23. 
In view of future studies within this collaboration scheme, there are two directions that I intend to 
further explore- the first is the direction of reconstruction of a bioengineered ovary, based on three 
dimensional culturing of ovarian tissue to support the in vitro culture of ovarian tissue and 
folliculogenesis, towards the development of in vitro matured oocytes. There are indications in the 
literature that three dimensional culture systems that resemble the in vivo three-dimensional structure 
and niche may promote and support follicular growth and development (Xu, et al., 2009, Higuchi, et 
al., 2015). In addition by adding three-dimensional motifs of the extracellular matrix, ie RGD 
(Arginylglycylaspartic acid) components we may mimic the in vivo niche and thus support the 
development of the follicles. I have applied and got the ethical approval for such a study as shown in 
Appendix 20. In addition to further studying the in vitro culturing of follicles, this project  aims also 
to be the basis of a bioengineered ovary intended for autotransplantation, where the ovarian tissue will 
be supported by biofabricated elements including synthetic components to give the tissue a three 
dimensional ecosystem with supportive components and possibly neo angiogenesis factors or bio 
fabricated blood vessels.  
 
Another direction of the current research scheme, is investigating the feasibility of reaggregated ovaries 
of cryopreserved human ovarian cortical tissue, as a mechanism of isolating the somatic supportive cells 
and the germ cells, followed by reaggregating both components that create follicles-like shapes that 
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could reconstitute the ovarian ecosystem and function. Reaggregated ovaries (ROs) were initially 
reported by the Eppig group (Eppig and Wigglesworth, 2000). Eppig described a method for the 
reaggregation of chimeric ovaries by exchanging the germ cells and somatic cells compartments of rat 
and mouse ovaries. The ROs were rafted beneath the renal capsules in ovariectomized SCID mice. They 
then demonstrated development of follicles with the normal morphological characteristics. Species 
specific rat and mouse oocytes developed within follicles composed of somatic cells exclusively of the 
other species. Rat oocytes showed progress into metaphase II when they were removed from follicles and 
cultured in vitro. Mice oocytes progressed to mature eggs and underwent fertilization and in vitro 
development and carried on to term pregnancies. The plan is to adapt this ROs technology to develop 
mature human oocytes in vitro. ROs may possibly develop into functional artificial  ovaries leading to de 
novo development of follicles that can be either cultured in vitro to create mature eggs or autografted 
for  in vivo development of  mature eggs. This is an interesting future direction that I would like to 























6. Future Horizons 
 
Setting up the ovarian tissue cryopreservation programme in Oxford was met with regulatory, ethical, 
clinical and biomedical challenges. We were lucky to get the first UK licence as approved by both HTA 
and HFEA, to set up the ovarian tissue cryopreservation programme and offer the service for all patients 
around the country, together with the more common and classical options of embryo and egg freeze. 
Other groups in the UK were doing this as part of research-based study and later on got the licences for 
clinical application of the technology, i.e. Edinburgh group. Later on, we sought to introduce testicular 
tissue bio-banking as the infrastructure and the licence could be further extended.  
A draft of a manuscript that intends to discuss these aspects is enclosed in Appendix 18. It also 
summarizes the first 100 referrals to the programme. The programme has progressed from earlier stage 
to offer the service not only for the local and regional population, but also to accept referral and even 
offer a spoke and hub model for patients.  
The establishment of the programme has been instrumental in setting up research programmes to 
further study the different challenges and unanswered questions in the field and consequently to 
further develop the technique. The first step was to commence on research projects in the field of in 
vitro culture of follicles and ovarian tissue. I built up a collaboration with the bioengineering laboratory 
at Oxford University to advance the work on 3-D culture systems of follicles and ovarian tissue. In the 
coming years I would like to focus on this area and try to work on bioengineering technologies to 
advance the neoangiogenesis that is important for the autografts reimplantation. Another direction- to 
try and advance the in vitro culture technique in the direction of Reaggregated Ovaries utilisation. In 
this technique, the ovarian tissue is to be cellularized and then separation of somatic and germ cells 
and then reconstitution of the follicular structures towards in vitro maturation or reimplantation of the 
reaggregated follicles in vivo.  
In recent years, a new innovative technique was described by Kawamura for patients suffering from 
premature ovarian insufficiency (POI)( Zhai et, 2016). This technique is called - in Vitro activation and 
it includes the harvesting of ovarian slices and then exposure for PTEN (Phosphatase and 
Tensin homolog) inhibitors before reimplantation in POI patients. Kawamura has described a series of 
pregnancies and live births demonstrating thus its safety in these patients. As preliminary results have 
shown positive outcomes that could possibly be replicated and offered to patients within the UK, I am 
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working on its introduction in the UK, to firstly offer it to the relevant patients and secondly to use it 





































The importance of this work which extends over a long period is the need to address the ever growing 
need to provide cancer patients with fertility cryopreservation options. As has been demonstrated, 
during our work which spread over a decade, we were lucky to achieve the first UK licence to set up the 
first ovarian tissue cryopreservation programme and offer the service for all patients around the 
country, together with the more common and classical options of embryo and egg freeze. The IVM 
programme offers an independent standalone or an adjunct fertility preservation modality in addition 
to other modalities, which could offer unique advantages to a certain group of patients. I presented the 
different contributions that I published during the years that consolidated our knowledge of the 
different modalities. Our work on the basic science of low responders which showed that there was no 
an inherent deficiency in StAR enzyme - a rate limiting factor in steroidogenesis, in addition to the fact 
that the normal mitochondrial function as demonstrated by the JC-1 stain was demonstrated and 
quoted by the pertinent literature. This work was the basis for interventions to transplant autologous 
mitochondria from granulosa cells into oocytes from low responders. We solidified the safety of using 
aromatase inhibitors in IVF patients and it is currently commonly used in different IVF units all over 
the world. We contributed to the literature in the area of morphokinetic markers of the embryos which 
is instrumental in accurately informing the patients of the implantation and clinical pregnancy 
potentials in the future. This is important in order to ensure that significant fertility preservation 
potential has been achieved by way of embryo freeze. We showed the relative safety of performing egg 
collections in patients with haemostatic abnormalities predisposing them to bleeding complications. 
Occasionally, oncologic patients present with bleeding tendency as a result of thrombocytopenia and 
reassuring patients that oocyte reuptake is a safe option is of paramount importance. Our study in the 
random start ovulation induction in cancer patients, has been quoted and embodied in the ESHRE 
guidelines of ovulation induction. Its importance stems from the finding that it offers an equi effective 
ovarian stimulation with a similar egg numbers harvested without the need to waste precious time 
waiting for a specific time in the menstrual cycle. 
Our different works in IVM have richly contributed to the adoption of IVM as an alternative method to 
achieve mature eggs and it was instrumental in offering this modality to patients undergoing ovarian 
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tissue cryopreservation. This utilisation of IVM will be the subject of a separate and independent 
publication in the near future, as there are only a small number of studies in this area. 
The setting up of the ovarian tissue bank was the culmination of a longstanding effort that I led from 
2008 till 2013 and nowadays it provides ovarian tissue preservation to both regional and supraregional 
patients. The infrastructure of the tissue processing and freezing has been utilised to start freezing 
testicular tissue in prepubertal oncologic boys.  
The ovarian tissue biobanking enabled us to expand the scope of research beyond the clinical aspects 
into basic science projects. My main focus is in the field of in vitro culturing follicles and ovarian tissue 
bioengineering. We started with our first publication in this area demonstrating the variation of the 
follicular stages in the frozen thawed ovarian tissue slices.  
In the near future, I intend to develop this research in the direction of optimising the in vitro culture of 
ovarian tissue or follicles, the utilisation of three dimensional culturing and the RO option. As for the 
future, I would like to work to introduce the IVA technology for patients with POI which will enable 
me to study the pathophysiology of folliculogenesis in these patients. I am currently in contact with the 
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gans	 responsible	 for	 the	 periodic	 process	 of	 egg	
maturation	and	ovulation	and	 for	the	production	of	
the	 main	 steroid	 hormones	 oestradiol	 and	 proges-
terone.	 	 Both	 functions	 are	 tightly	 meshed	 with	
feedback	 mechanisms	 to	 the	 hypothalamus	 and	
pituitary	 glands	 in	 the	 hypothalamo-pituitary-
ovarian	(HPO)	axis.	Other	endocrine	organs	such	as	
the	 thyroid	 and	 the	 adrenal	 glands	 are	 equally	 im-
portant	for	normal	reproductive	functions.	This	well	









postero-	 lateral	 pelvic	wall	 and	 are	 attached	 to	 the	
posterior	 leaflet	 of	 the	 broad	 ligaments	 by	 the	
mesovarium.	The	ovary	consists	of	 three	major	dis-
tinct	 portions:	 1.	 The	 outer	 cortex	 containing	 two	
regions:	the	outermost	region	being	the	single	layer	
of	 cuboidal	 epithelium	 referred	 to	 as	 the	 surface	
germinal	epithelium	and	the	inner	region	containing	
the	 follicles	 embedded	 in	 stromal	 tissue	 derived	
from	 mesenchymal	 cells	 which	 have	 the	 ability	 to	
respond	 to	 luteinizing	 hormone	 (LH)	 or	 human	
chorionic	gonadotropin	(HCG).	2.	The	central	medul-
la	consisting	of	stroma	which	is	derived	mainly	from	
mesonephric	 cells.	3.	The	rete	ovarii	 (the	hilum)	 in	
the	area	of	attachment	of	the	ovary	to	the	mesovari-
um.	 It	 contains	 nerves,	 blood	 vessels	 and	 the	 hilar	




The	 follicle	 represents	 the	 basic	 structural	 and	
functional	 complex	 in	 the	 ovary	 with	 respect	 to	
oocyte	 maturation	 and	 steroidogenesis.	 The	 pri-
mordial	 follicles	 start	 to	 form	 at	 18-20	 gestational	
weeks.	 Each	 primordial	 follicle	 contains	 an	 oocyte	
arrested	 at	 the	 prophase	 stage	 of	 the	 first	 meiotic	
division,	enveloped	by	a	single	layer	of	pregranulosa	
cells	 surrounded	 by	 a	 basement	 membrane.	 They	
are	embedded	 in	 the	 loose	connective	 tissue	of	 the	
ovarian	 cortex.	 Only	 a	 minority	 of	 primordial	 folli-
cles	 are	 recruited	 during	 a	 woman’s	 reproductive	
lifetime,	 most	 undergo	 the	 process	 of	 atresia.	 The	
recruitment	 of	 primordial	 follicles	 into	 growing	
follicles	 induces	 changes	 in	 granulosa	 cell	 growth	
and	maturation,	 as	well	 as	 follicular	 structural	 and	
functional	changes.	They	typically	grow	and	develop	
through	primary,	preantral	and	antral	follicle	stages.	
The	 early	 stages	 of	 follicular	 growth	 are	 FSH	 inde-
pendent	 and	 are	 probably	 controlled	 by	 local	 in-
traovarian	 factors	 such	 as	 anti-mullerian	 hormone	
(AMH).	 Full	 maturity,	 as	 expressed	 by	 ovulation,	
typically	occurs	in	the	reproductive	age	only,	as	the	
dominant	 ovulating	 follicle	 is	 selected	 during	 the	
early	 days	 of	 the	 same	 cycle.	 At	 16-20	 gestational	
weeks	there	are	6-7	million	germ	cells.	At	birth,	the	
number	of	oocytes	is	nearly	1	million.	At	the	onset	of	
puberty	 the	 oocyte	 number	 is	 reduced	 to	 about	
500,000	 and	 throughout	 the	 reproductive	 life	 only	
300-500	oocytes	will	be	selected	to	ovulate.	The	vast	







time	 period	 of	 several	 preceeding	 cycles,	 about	 85	




early	 days	 of	 	 the	 current	 cycle’s	 follicular	 phase,	
otherwise,	they	become	arrested	and	undergo	atre-
sia.	 Typically	 a	 cohort	 of	 FSH-dependent	 2-6mm	
antral	follicles	are	recruited	by	the	late	luteal	phase	
due	 to	 the	 FSH	 rise	 of	 the	 preceeding	 cycle.	 The	
average	 time	 for	 the	 development	 of	 the	 selected	







requires	 the	 pulsatile	 secretion	 of	 GnRH	 from	 the	
hypothalamus.	This	pulsatile	rhythmic	release	must	
be	 within	 a	 critical	 range	 of	 frequency	 and	 ampli-
tude	 for	 normal	control	 to	occur.	GnRH	has	a	posi-
tive	 effect	 on	 the	 anterior	 pituitary	 resulting	 in	
increased	 gonadotrophin	 synthesis,	 storage	 and	
pulsatile	 secretion.	 Lower	 GnRH	 pulse	 frequencies	
favour	FSH	secretion	and	higher	frequencies	favour	
LH	secretion.	The	variation	 in	GnRH	pulse	 frequen-




ing	 gonadotrophin	 regulation:	 Oestrogen	 levels:		
low	oestradiol	levels	enhance	FSH	and	LH	synthesis	
and	 storage,	 have	 negative	 effect	 on	 FSH	 secretion	
with	 little	effect	on	LH	secretion.	However,	 it	 is	 the	
high	 oestradiol	 levels	 that	 induce	 the	 LH	 surge	 at	
midcycle.	Progesterone	levels:	Low	levels	enhance	
the	LH	response	to	GnRH	and	are	responsible	for	the	
FSH	 surge	 at	 midcycle.	 The	 increased	 level	 of	 pro-
gesterone	in	the	luteal	phase	inhibit	gonadotrophin	
secretion	 by	 inhibiting	 hypothalamic	 GnRH	 pulses	
and	 inhibiting	 the	pituitary	 response	 to	 GnRH.	 It	 is	
the	raised	progesterone	levels	at	the	end	of	the	lute-
al	 phase	 that	 decrease	 GnRH	 pulsatile	 frequency,	
leading	 to	 preferential	 FSH	 secretion	 in	 the	 late	
luteal	phase	and	 the	 start	of	 the	 next	ovarian	cycle	
with	follicular	cohort	recruitment.	
GnRH	 pulsatility	 is	 also	 modulated	 by	 neuro-
transmitters	 such	 as	 dopamine,	 noradrenaline,	 en-
dorphins,	 kisspeptins	 and	 others.	 The	 half	 life	 of	
GnRH	is	short	(2-4	min)	as	it	is	degraded	rapidly	by	





tion	 of	 LH	 and	 FSH.	 Each	 gonadotrophin	 is	 a	
heterodimer	 and	 is	 made	 of	 two	 peptide	 subunits	
termed	alpha	and	beta.	The	alpha	subunits	are	struc-
turally	 identical	 but	 the	 beta	 subunits	 are	 unique	
and	confer	the	specific	activity.	During	the	late	luteal	
phase	 FSH	 levels	 start	 to	 rise	 and	 reach	 a	 peak	
around	day	3	of	menstruation	in	the	next	cycle.	This	
causes	 FSH-dependent	 antral	 follicular	 recruitment	
and	 growth,	 granulosa	 cell	 proliferation	 and	 differ-
entiation	 and	 aromatase	 action	 and	 oestrogen	 pro-
duction	 and	 inhibin	 B	 secretion.	 The	 last	 two	
hormones	 exert	 negative	 feedback	 at	 the	 hypothal-
amus	 and	 the	 pituitary.	 FSH	 induces	 LH	 receptors	
within	 the	 dominant	 follicle.	 Oestradiol	 levels	 de-
rived	 from	 the	 dominant	 follicle	 increase	 steadily	
and	exert	suppressive	feedback	on	FSH	release	lead-
ing	 to	lack	of	support	and	consequent	atresia	of	the	
non-dominant	 follicles.	 The	 mid-follicular	 rise	 in	
estradiol	leads	to	a	switch	from	negative	to	positive	
feedback	 on	 LH	 release	 resulting	 to	 the	 mid-cycle	
surge.	This	surge	lasts	36-48	hours	and	 is	responsi-
ble	for	the	resumption	of	oocyte	meiotic	maturation,	














sis,	 predominantly	 androstenedione,	 which	 then	
diffuses	to	the	granulosa	cells.	
	
2.	 FSH	 action	 on	 granulosa	 cells	 through	 cyclic	
AMP,	 LRH-1	 and/or	 SF-1	 binding	 activity,	 and	 pro-




	Oestradiol	 is	 the	 most	 important	 oestrogen	 -	 its	
main	 functions	 are	 endometrial	 development	 and	
triggering	 of	 the	mid-cycle	 LH	 surge	 leading	 to	 fol-
licular	 rupture	 and	 ovulation.	 In	 addition,	 the	 sup-
pression	 of	 FSH	 secretion	 by	 negative	 oestradiol	
feedback	is	key	 to	preventing	multi-follicular	devel-
opment	 in	 the	 mid-follicular	 phase	 once	 a	 single	
dominant	follicle	has	been	recruited.	
Oestradiol	levels	rise	rapidly	after	menstruation	to	
reach	 a	 peak	 in	 the	 late	 follicular	 phase	 which	 in-
duces	 the	 mid-cycle	 LH	 surge.	 During	 the	 luteal	
phase	oestradiol	is	produced	by	 the	corpus	luteum;	
in	the	absence	of	an	endogenous	rise	in	hCG	from	an	




The	 granulosa	 lutein	 cells	 have	 high	 levels	 of	 LH	
receptors	and	produce	progesterone,	the	main	luteal	
phase	 hormone.	 Progesterone	 stimulates	 secretory	
changes	 in	 the	 endometrium	 that	 are	 critical	 for	
achieving	 an	 environment	 receptive	 for	 embryo	
implantation.	 Progesterone	 levels	 rise	 following	
ovulation	and	decline	with	the	demise	of	the	corpus	
luteum	 before	 menstruation.	 Peak	 progesterone	
levels	 are	 reached	 in	 the	 mid-luteal	 phase	 and	 a	
blood	 sample	 (taken	 7	 days	 before	 the	 estimated	







tissues	 such	 as	 subcutaneous	 fat	 and	 skin	 fibro-
blasts.	 Peripheral	 tissue	 aromatase	 is	 responsible	
for	 aromatisation	 of	 androstenedione	 resulting	 in	
the	 production	 of	 the	 weaker	 oestrogen,	 oestrone.	
Oestrone	 is	 further	 metabolised	 and	 converted	 to	
the	 more	 biologically	 active	 oestradiol	 in	 target	
tissues	 such	 as	 the	 breast	 and	 endometrium.	 This	










factors	 and	 other	 regulatory	 proteins	 such	 as	 in-
hibin,	 activin	 and	 follistatin	 that	 are	 produced	 by	
granulosa	cells	under	the	control	of	FSH	and	LH	and	
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Female	 reproductive	 hormone	 dysfunction	 is	 of-
ten	 manifested	 by	 disruption	 of	 the	 regular	 cyclic	
menses,	oligo/anovulation,	infertility	or	a	presenta-
tion	 of	 clinical	 hyperandrogenism.	 History	 taking	
and	 physical	 examination	 are	 still	 the	 mainstay	 of	
any	diagnostic	workup.	Based	on	clinical	presenting	
symptoms	 and	 the	 physical	 signs	 obtained,	 further	
investigative	workup	including	biochemical,	hormo-






understanding	 the	 main	 presenting	 complaints	 in-
cluding	 guided	questions	 to	assess	 the	possible	un-
derlying	 hormonal	 disruptions.	 Thorough	
knowledge	of	 the	physiological	effects	of	 the	differ-




should	 be	 thoroughly	 evaluated	 by	 organ-targeted	
questions.	




cal	 and	 surgical	 history,	 intercurrent	 systemic	
illnesses	or	use	of	medications;	primary	versus	sec-
ondary	 amenorrhea;	 galactorrhoea	 and/or	 visual	
disturbances;	 clinical	 presentation	 of	 hyperandro-
genism,	 i.e.	 hirsutism,	 acne	 or	 signs	 of	 virilisation;	
the	gradual	versus	sudden	onset	of	hirsutism;	evalu-
ation	of	reproductive	and	obstetric	histories;	weight	
and	 changes,	 eating	 disorders	 and	 related	 com-
plaints;	physical	activity;	hot	flushes;	fertility	history	






dence	 of	 abnormality	 in	 the	 primary	 endocrine	 or-
gan	 (eg	 the	 thyroid	gland)	and/or	 the	 target	organ	
(eg	the	skin).	Body	mass	index	should	be	calculated	
for	 patients,	 the	 severity	 of	 hirsutism	 and	 acne	 if	
indicated	 assessed,	 and	 signs	 of	 virilisation	 i.e.	 cli-
toromegaly,	voice	deepening	or	hair	loss	looked-for.	
Physical	 examination	 of	 the	 breasts	 and	 Tanner	
staging	 is	 undertaken	 if	 indicated.	Careful	gynaeco-
logical	 examination	 with	 attention	 to	 any	 vulvo-
vaginal,	 cervical,	 uterine	 and	 adnexal	 lesions	 or	
pathologies	is	undertaken.	
			
Based	 on	 careful	 history	 taking	 and	 physical	 ex-
amination,	 a	 tentative	 differential	 diagnosis	 is	 of-
fered.	 The	 final	 diagnosis	 is	 most	 often	 established	
or	 confirmed	 with	 completion	 of	 the	 laboratory	
work-up	including	biochemical	and/or	genetic	tests.	
The	 different	 tests	 that	 are	 routinely	 used	 in	 the	
evaluation	of	female	hormonal	metabolism	dysfunc-
tion	 are	 discussed	below.	A	 structured	detailed	ap-









absent	 or	 very	 irregular	 menses.	 If	 the	 patient	 is	
already	 on	 hormonal	 treatment	 (ie	 the	 COCP)	 then	
blood	 tests	 should	 be	 taken	 on	 the	 7th	 off-pill	 day.	
These	 tests	 will	 commonly	 include:	 FSH,	 LH,	 total	
and	 free	 testosterone,	 prolactin,	 TSH	 and	 free	 T4.	
Based	on	the	clinical	presentation	and	the	results	of	
the	 initial	 workup	 further	 tests	 are	 arranged	 as	
necessary.	 The	 differential	 diagnosis	 and	 the	 step-
wise	 diagnostic	workup	will	 be	 dealt	with	 in	 more	
detail	in	the	relevant	chapters	(chapter	5.1	for	PCOS,	
chapter	3	for	prolactinoma/galactorrhoea,	chapter	3	




entiate	 between	 primary	 and	 secondary	 ovarian	
dysfunction.	 Abnormal	 tests	 should	 be	 repeated	
after	at	least	one	month	to	confirm	the	results.	Table	
6.1	 shows	 a	 classification	 of	 oligo/amenorrhoea,	
common	causes	and	hormonal	profile.		
<Table	6.1	here>	



































Depending	 on	 the	 clinical	 context	 and	 degree	 of	
suspicion	of	Cushing’s	syndrome,	blood	tests	for	free	
cortisol	 or	 the	 over-night	 dexamethasone	 suppres-
sion	testing	are	used.	
	
Prolactin	 is	 measured	 to	 exclude	 hyperprolac-
tinemia	 as	 a	 cause	 of	 galactorrhoea,	 ovulatory	 dys-
function	leading	to	oligo/amenorrhoea	or	infertility.	





dysfunction,	 especially	 if	 either	 hypothyroidism	 or	
hyperthyroidism	is	clinically	suspected.	
	
Progesterone	 challenge	 test:	 progesterone	 with-
drawal	 bleeding	 is	 induced	 using	 10mg	 oral	
medroxyprogesterone	 acetate	 BD	 for	 7	 days.	 If	 a	





Dyslipidaemia	 and	 impaired	 glucose	 tolerance	
screening:	 as	 PCOS	 patients	 are	 at	 higher	 risk	 of	
cardiometabolic	 syndrome	 with	 predisposition	 to	
hypertriglyceridaemia,	 hypercholesterolaemia,	 low	
HDL	 cholesterol	 and	 impaired	 glucose	 tolerance,	
screening	 blood	 tests	 for	 	 blood	 lipids	 and	 fasting	
glucose	are	 indicated	 in	PCOS	 patients,	 especially	 if	
they	have	other	metabolic	risk	factors.	If	the	fasting	

























Levels of steroidogenic acute regulatory protein and
mitochondrial membrane potential in granulosa cells
of older poor-responder women
Muhammad Fatum, M.D.,a Yivgi-Ohana Natalie, Ph.D.,b Shveiky David, M.D.,a Orly Joseph, Ph.D.,b
Alexander Simon, M.D.,a and Neri Laufer, M.D.a
a IVF Unit, Department of Obstetrics and Gynecology, Hadassah Medical Center; and b Department of Biological Chemistry,
The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
Objective: To compare mitochondrial function in granulosa cells obtained from older (>40 y) low-responder IVF
patients with that of young (<35 y) good-responder patients.
Design: Prospective laboratory research.
Setting: In vitro fertilization unit in a university hospital.
Patient(s): Twenty patients undergoing IVF treatment cycles.
Intervention(s): Ultrasound guided oocytes pick-up.
Main Outcome Measure(s): Mitochondrial function examined by using JC-1 stain for the mitochondrial mem-
brane potential in granulosa cells of both groups and Western blots for assaying and quantification of steroidogenic
acute regulatory protein (StAR) and p450scc (side-chain cleavage).
Result(s): The number of granulosa cells per follicle differed between the two groups, with fewer granulosa cells
isolated in the older low-responder women, compared with in the young, normal responders who were the control
women. Trypan blue–negative cells showed similar undisturbed mitochondrial membrane potential, and similar
ratios of apoptotic granulosa cells were observed in the two groups. In addition, there was no difference in
StAR and P450scc protein levels between the two groups.
Conclusion(s): Our results demonstrate a significant decrease in the number of total aspirated granulosa cells per
follicle in older, poor-responder women, which probably explains the reduced hormonal production by those fol-
licles. However, those cells demonstrate normal mitochondrial membrane potential as well as similar levels of
StAR, P450scc, and de novo steroid hormone synthesis in the two groups of patients. Our results do not support
mitochondrial dysfunction as a main mechanism of reproductive aging. (Fertil Steril 2009;91:220–5. 2009
by American Society for Reproductive Medicine.)
Key Words: Granulosa cells, older poor responder, mitochondria, steroidogenesisThe delay in childbearing in most Western societies is an im-
portant societal change, contributing to an increasing incidence
of subfertility. Increasing numbers of women decide at a young
age not to have children, but they change their minds at a later
age. Others deliberately delay childbearing to a period in life
when having children appears to be more compatible with their
chosen lifestyle (1). The progressive increase in reproductive
aging caused by a delay in childbearing contributes signifi-
cantly to the growing incidence of unwanted subfertility.
Therefore, female fertility and its age-related decline is becom-
ing a major problem that still lacks efficient treatment.
In one study, the proportion of infertile women increased
progressively, from 6% in the 15- to 24-year age group to
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220>30% in the 35- to 44-year age group (2). Other studies
have shown that the probability of achieving a pregnancy
within 1 year is significantly decreased in women >35 years
of age (3, 4). A British study based on >35,000 IVF cycles
demonstrated that female age is by far the most important de-
terminant of success (5) and that live-birth rates per embryo
transfer dropped from 24% for women <30 years of age to
8% in women 40–44 years of age and 3.5% in women >45
years of age. The age-related decline of female fertility con-
sists of two components: the first is the decreased monthly
probability of conception, and the second is the increased
probability that a pregnancy will terminate after conception
or implantation (i.e., embryo loss, pregnancy loss, fetal
loss, or spontaneous abortion).
The prevailing concept of human reproductive aging as-
sumes that the age-dependent loss of female fertility is dic-
tated by the decline of both the quantity and quality of the
oocyte and follicle pool. Numbers of follicles decline expo-
nentially, with a marked increase in the rate of disappearance0015-0282/09/$36.00
, Published by Elsevier Inc. doi:10.1016/j.fertnstert.2007.10.027
from age 37–38 years. From the millions present before birth,
only 300,000 follicles are left at the beginning of puberty, and
subsequently, hundreds vanish every month. Below a critical
number of some thousands, reached at an age of 45–46 years,
the menstrual bleeding pattern becomes irregular (6), and
when the menopause is reached at a mean age of 51 years,
the supply is reduced to a %1000 or follicles, which is a num-
ber insufficient to sustain the cyclic hormonal process neces-
sary for menstruation (7). In addition, chromosomal
aneuploidy is considered to be the major cause of the age-re-
lated decline of oocyte quality. The frequency of chromo-
some abnormalities at conception increases rapidly with
increasing maternal age, so that the majority of embryos
are chromosomally abnormal in women approaching 40 years
of age. This has been confirmed by investigations into the
chromosomal status of IVF embryos that have demonstrated
that the majority of embryos derived from women >37 years
of age are chromosomally abnormal and contain all possible
combinations of both monosomies and trisomies (8, 9). Accu-
mulating studies show complex interactions between oocytes
and granulosa cells that are reflected also by changes in the
follicular fluid content (10–12). Age-related changes leading
to an increased probability of meiotic nondisjunction (e.g.,
accumulation of oxidative stress) may well be mediated by
subtle disturbances of granulosa cell function (1).
The free-radical theory is one of the most comprehensive
theories of aging. It suggests that living organisms age be-
cause of accumulation of oxygen radical–induced cellular
damage and that mitochondrial DNA is a possible target of
free-radical attack during the aging process. In recent years,
an increasing number of reports have shown that mitochon-
drial DNA mutations are associated with human aging and
mitochondrial diseases (13). Deleterious mitochondrial
DNA rearrangements cause cellular energy deficiencies and
result in clinical disorders (14). Deficiencies in mitochondrial
adenosine triphosphate production may be associated with
the impairment of oocyte fertilization. It has been suggested
that differences in the amount of adenosine triphosphate gen-
erated by mature human oocytes, during IVF, may be related
to the fertilization potential and developmental competence
of an embryo (15). Another study found that women >38
years of age had granulosa cells that contained a substantial
decrease in the level of normal mitochondria, as compared
with the case of women <34 years of age (16). Women
>38 years of age exhibited an increase in mitochondrial
DNA deletions. These deletions may be a result of exposure
of mitochondrial DNA to oxygen free radicals generated
by several mitochondrial P450 enzymes. In recent years,
increased mitochondrial DNA deletions have been demon-
strated to facilitate the opening of mitochondrial permeabil-
ity transition pores via the mitochondrial release of
cytochrome c and apoptosis-inducing factor, which ulti-
mately leads to the final event of apoptosis (17, 18).
In the present study, we aimed to compare mitochondrial
function in granulosa cells of young women (<35 y) who
had good response to ovulation induction with that of olderFertility and Sterilitywomen (>40 y) with low response. We examined mitochon-
drial membrane potential by assay of the steroidogenic
enzymes steroidogenic acute regulatory (StAR) protein and
cholesterol side-chain cleavage cytochrome P450 (P450scc),
by both their levels and expression in granulosa cells of the
two different groups.
MATERIALS AND METHODS
The trial was approved by the local institutional research
board.
The study included infertile women scheduled for treat-
ment in the IVF unit of the obstetrics and gynecology depart-
ment at Hadassah Hebrew University Hospital. Four young
women (<35) with good response to ovulation induction
and 10 older women (>40 y) with low response were re-
cruited. Low responders were defined as women responding
with three oocytes at most to ovarian hyperstimulation with
exogenous gonadotropins, in the context of IVF treatment.
The number of developed follicles and/or number of oocytes
retrieved after ovarian stimulation protocol are two of the
most important criteria for poor ovarian response. We chose
the definition of low response to include those women with
fewer than three oocytes retrieved after ovarian stimulation
because that is a simple and widely used definition. However,
other, different definitions are present in the literature (19).
All women underwent the same pituitary desensitization
treatment with decapeptyl (Ferring, Malmo, Sweden), followed
by exogenous gonadotropin stimulation with recombinant
FSH (Gonal-F; Serono, Herzlia, Israel) in preparation for IVF.
Granulosa cells were isolated from each woman after
ovum pickup, separated from red blood cells by using Ficoll
separation media, and processed by centrifuge. The follicular
fluid from each woman was pooled and preserved at 20C.
Pooled granulosa cells from each patient were counted by
a hematocytometer, using trypan blue exclusion dye to deter-
mine viability. Granulosa cells were extracted by lysis buffer
(RIPA buffer: 150 mM NaCl; 50 mM Tris-HCl, pH 7.5; 1%
Triton X-100; 0.5% deoxycholate; 0.1% sodium dodecyl
sulfate (SDS); and protease inhibitors cocktail; Sigma;
St. Louis, MO). Samples were put on ice for 30 minutes and
processed by centrifuge for 2 minutes at 14,000  g. The
supernatant was separated, and protein concentration was de-
termined by a modification of the protein assay method of
Bradford (20). Sodium dodecyl sulfate–polyacrylamide
gel electrophoresis sample buffer (31 mM Tris-HCl, pH
6.8; 1% SDS; 0.05 mM ethylenediaminetetraacetic acid;
5% glycerol; and 0.003% bromophenol blue) was added
to the samples, and after heating for 5 minutes at 95C,
samples were stored at 200C until use. Samples (20 mg
per lane) were electrophoresed on a 10% mini gel by standard
SDS–polyacrylamide gel electrophoresis procedures, along
with prestained molecular weight markers (MultiMark; No-
vex, San Diego, CA). Gels were electrophoresed at 30 mA/
mm at 40C by using a running buffer that included 12.5 mM
Tris-base, 96 mM glycine, and 0.01% SDS. The proteins221
were electrophoretically transferred to Optitran BA-S 85 ni-
trocellulose membrane (Schleicher & Schuell, Dassel, Ger-
many) by using a semidry electrotransfer apparatus (E&K
Scientific Products, Saratoga, CA). Protein transfer was con-
ducted for 45 minutes at 3 mA/cm2 in a modified buffer
consisting of 48 mM Tris-base, 39 mM glycine, 0.04%
SDS, and 20% methanol. The membrane was blocked by
a 30-minute incubation in blocking buffer (PBS buffer con-
taining 0.1% Tween 20 and 5% nonfat dry milk), followed
by an overnight incubation with anti-StAR (1:5,000) and
anti P450scc (1:5,000). After three washes for 5 minutes
each with PBS–Tween buffer (similar to the buffer described
in the previous sentence, but without the milk), the membranes
were incubated for 2 hours with peroxidase-conjugated goat
anti-rabbit IgG (1:10,000 dilution). Specific signals were de-
tected by chemiluminescence by using the LumiGlo substrate
(New England BioLabs, Beverly, MA).
Quantitation of chemiluminescence signals on radiograph
films was performed as follows: chemiluminescence pseudo-
autoradiograms were scanned (Astra 4000U; UMAX, Fre-
mont, CA). Quantification of scanned images was performed
according to the user manual of the public-domain NIH Im-
age program (National Institutes of Health, Bethesda, MD).
To investigate the status of mitochondrial membrane po-
tentials in the different age groups, granulosa cells were
stained using the JC-1 stain and examined by confocal mi-
croscopy. For the purpose of JC-1 staining (21), granulosa
cells were seeded onto a glass slide (12-mm diameter) that
was glued onto the outside of a 35-mm tissue culture dish
(Falcon; Becton Dickinson, Plymouth, Devon, United King-
dom) in which a 10-mm hole was drilled at the center. This
custom-made dish allows scanning of live cells with an in-
verted microscope (BioRad 1024 confocal workstation,
BioRad, Richmond, CA). To detect dissipated membrane
potential in aging mitochondria from low-responder granu-
losa cells, we used 5 mM JC-1 (Molecular Probes; Eugene,
OR), which was added for a 15-minute incubation (37C) be-
fore washing and confocal scanning. The cells were scanned
by using a 488-nm wavelength for excitation, and the dual
emissions of JC-1 were collected with a 525  20 filter
(green) and a 585 long-pass filter (red). Loss of membrane po-
tential results in a concomitant loss of red emission, but the
mitochondria remain visible when viewed through the green
filter. Therefore, JC-1–stained cells are shown in red and/or
red-green overlay. Radioimmunoassay of pooled follicular
fluids levels of E2, T, and P of each woman were performed.
Later, we performed a cytospin of granulosa cells of both
groups and stained cells with propidium iodide. We used fluo-
rescent microscopy to study 100 cells of randomly chosen
fields from the cytospin slides for apoptotic features.
RESULTS
Patients
Compared with the control group, women in the older low-
responder group had significantly higher day 3 FSH levels222 Fatum et al. Granulosa cells in older poor-responder(in mIU/mL) (9.6  2.4 vs. 5.8  1.7, n ¼ 10, P¼.02), lower
E2 levels (in pg/mL) on the day of hCG administration (1,856
 1,074 vs. 9,222.5 2,398.2, n¼ 10, P<.01), a lower num-
ber of follicles (3.3  1.2 vs. 12.25  3.3, n ¼ 10, P<.01),
a lower number of oocytes (1.5  0.5 vs. 11.75  2.86, n
¼ 10, P<.01), and a lower number of embryos (1.5  0.8
vs. 10.75  2.6, n ¼ 10, P<.01).
Granulosa-Cell Isolation
The number of trypan blue–negative granulosa cells per fol-
licle differed between the two groups with lesser granulosa
cells isolated in the study group of older low-responder
women, compared with in the control young, normal re-
sponders (121,000  30,888 vs. 475,555  73,333 respec-
tively, n ¼ 10, P<.01).
Levels of StAR in Older Poor Responders and Young,
Normal-Responder Women
Western blots of nine women in the study group and four of
those in the control group are shown in Figure 1. As can be
seen, there is no difference in StAR and P450scc protein
levels between the two groups. This suggests that StAR and
P450scc protein levels do not play a role in granulosa cells’
senescence.
Mitochondrial Membrane Potential in Older Poor
Responders and Young, Normal-Responder Women
Figure 2A shows the JC-1 staining of the group of young,
normal-responder women observed by confocal microscopy.
The mitochondria are stained by red and green colors, an
evidence of normal mitochondrial membrane potential. Fig-
ure 2B shows undisturbed mitochondrial membrane potential
in the older low-responder women group.
FIGURE 1
Western blot of StAR and side-chain cleavage
enzyme (SCC) levels in older low-responder women
compared with young normal-responder women. No
difference was seen in StAR and P450SCC levels in
the two groups.
Fatum. Granulosa cells in older poor-responder women. Fertil Steril 2009.women Vol. 91, No. 1, January 2009
To further validate the results, we performed a cytospin of
granulosa cells of both groups and stained cells with propi-
dium iodide to see whether there was a difference in apoptosis
between the two groups. There was no difference in apopto-
tic-cell percentages in the young good responders, as com-
pared with in the older poor responders (8.6%  3.06% vs.
8%  1.5%, n ¼ 4, P¼.9). As shown in Figure 3A and B,
we noticed that the majority of granulosa cells are normal
and nonapoptotic, with only a minor, and equal, amount
being apoptotic in both groups.
Follicular Fluid Steroid Hormone Levels
In an attempt to see whether other downstream steroidogenic
enzymes are involved in granulosa cell senescence, we exam-
ined the pooled follicular fluids of these women for three tar-
get hormones: E2, T, and P. No significant differences were
seen in the levels of the three hormones: E2 levels (6.2 
105  3.2  105 pM vs. 8.3  105  5.1  105 pM; n ¼ 10,
P¼.3), P levels (9.4  103  4.1  103 nM vs. 6.9  103 
3.6  103 nM; n ¼ 10, P¼.18), and T levels (25.4  7.8 nM
vs. 28  10.2 nM; n ¼ 10, P¼.56) in the young good
responders as compared with in older poor responders. This
FIGURE 2
(A) Staining with JC-1 of sample from young
normal-responder woman as observed by confocal
microscopy. (B) Staining with JC-1 of sample from
poor-responder woman.
Fatum. Granulosa cells in older poor-responder women. Fertil Steril 2009.Fertility and Sterilitysuggested that the steroidogenic hormonal machinery does
not play a central role in the pathophysiology of low response
in older women.
DISCUSSION
The present study was aimed at studying age-related mito-
chondrial function in granulosa cells that were obtained
from IVF patients of two different age groups and with differ-
ent response to stimulation with gonadotropins: older women
(R40 y of age) with low response and young women (<35 y
of age) with good response. Two tests for granulosa cell func-
tion were examined: the JC-1 stain for the mitochondrial
membrane potential and Western blotting technique for
StAR and P450scc measurement. Our hypothesis was that
during the process of reproductive aging, mitochondrial
membrane potential may deteriorate as a result of free-radical
accumulation. In addition, we hypothesized that StAR levels
would be reduced because the follicular pool is depleted and
its endocrinologic steroidogenic machinery is diminished.
Steroidogenic acute regulatory protein was our candidate en-
zyme because its role is to mediate the delivery of cholesterol
substrate to the inner mitochondrial membrane, where the
FIGURE 3
(A) Propidium iodide stain of nuclei of granulosa
cells in young good responder. (B) Propidium iodide
stain of nuclei of granulosa cells in older poor
responders.
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P450scc enzyme complex converts it into pregnenolone, the
first steroid synthesized (22). Contrary to these assumptions,
we did not find any difference in StAR levels or P450scc
levels between the two groups. This observation contradicts
the observation described by other investigators (23). In their
work using similar luteinizing-granulosa cells isolated after
follicular aspiration, Phy et al. (13) found a 17% reduction
in StAR protein in patients with a poor response when com-
pared with those with a normal response. These differences
may stem from the differing definitions for normal re-
sponders and poor responders. Those investigators defined
normal responders as those with a threefold or greater in-
crease in P, whereas patients with an increase of less than
threefold were categorized as poor responders. However,
our definition of low responders is stricter; consequently,
this cannot be the explanation.
Because we did not find any difference concerning StAR
and P450scc levels between the two groups, it may be
assumed that these key enzymes affecting steroid hormone
synthesis cannot be key determinants in reproductive aging
of granulosa cells of older poor-responder women.
In an attempt to examine other candidate enzymes, we
studied the E2, T, and P levels in the pooled follicular fluid
of all follicles punctured at the same oocyte pickup. However,
no difference was shown in follicular levels of these hor-
mones. Hence, other downstream steroidogenic enzymes
cannot be responsible for the different ovarian response in
the two groups.
Similar to these observations, we did not find any differ-
ences in JC-1 staining in the two groups. Both groups showed
normal mitochondrial membrane potential and normal distri-
bution of mitochondria in the cytoplasm. This result is in con-
trast to our assumption that with the accumulation of free
radicals, the mitochondrial membrane potential may be dis-
rupted. Our results show that mitochondrial membrane poten-
tial, as a possible target for free-radical accumulation, does
not appear to play a role in aging granulosa cells. One possible
interpretation of our inability to show a change of membrane
potential is the fact that only the good-quality granulosa cells
survived the overnight incubation in culture and were tested
by confocal microscopy. It is not unlikely that other necrotic
cells degenerated and were washed out. However, the propi-
dium iodide stain consistently has shown similar apoptotic ra-
tios in the two groups. Our results show that apoptotic changes
in granulosa cells isolated from low-responder IVF patients
are similar to those in younger, good-responder patients.
However, in our experiments, we used granulosa cells isolated
from follicles that responded to ovarian hyperstimulation, and
thus there may have been selection bias that led to the unre-
sponding follicles being dropped out of the study. Granulosa
cells from these unresponding follicles may differ from gran-
ulosa cells isolated from the responding follicles and may
have different apoptotic features. According to our results, it
appears that the reduction in the number of granulosa cells
per follicle in the older low-responder women, compared with
young, normal responders, is a result of a non–apoptosis-224 Fatum et al. Granulosa cells in older poor-respondermediated mechanism, leading to direct cellular atresia of
granulosa cells in the older group. This interpretation is in
accordance with that of other studies (24) showing that apo-
ptosis can be the process responsible for atresia of quiescent
(primordial and primary) follicles, whereas secondary folli-
cles may escape the apoptotic process. Because ovarian tissue
biopsies could not be offered for these patients, animal models
may be the next research step.
We believe that further studies to explore the possible
mechanisms of reproductive senescence by using microarray
analyses may be the next step in searching for important
genes that are involved in reproductive senescence.
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Abstract Background: Although high levels of estradiol
are found in the follicular fluid, little is known about its
necessity for adequate follicular growth, oocyte maturation
and embryo development. Arimidex (anastrozole) is a potent
aromatase inhibitor capable to induce an in-vivo milieu de-
prived of estradiol. This study uses a mouse model applying
Arimidex to create an in-vivo system lacking of estradiol,
in order to explore whether this gonadal steroid hormone is
mandatory for folliculogenesis followed by normal fertiliza-
tion and embryo development.
Methods: Experiment 1: Immature C57 Black female
mice, aged 3–4 weeks were superovulated by 5 IU
PMSG given intraperitoneally. A study group (9 mice)
was concomitantly injected with 0.1 mg of Arimidex
intraperitoneally given the morning day before PMSG, the
morning day of PMSG injection and the following two
days. The control group (8 mice) was similarly injected with
normal saline. Estradiol (E2) and progesterone (P) serum
levels were tested 48 hours after PMSG and the ovaries of
each mouse blindly examined by a pathologist to evaluate
follicular development. Experiment 2: 48 h after PMSG
superovulation, hCG (7.5 IU) was injected intraperitoneally,
followed by mating. The study group was treated with
Arimidex 0.1 mg intraperitoneally daily from a day prior to
PMSG injection to the day of sacrifice. The control group
was treated similarly by normal saline. Forty-two hours after
mating blood was withdrawn for E2 and P levels followed by
tubal dissection. Embryos of 2–4 cells were cultured in-vitro
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and the development to the morula, blastocyst and hatching
blastocyst stages were examined 24, 42, and 48 h later.
Results: Experiment 1: A significant reduction of E2 lev-
els was achieved in the Arimidex group in comparison to
control group (126.3 ± 104.8 and 1910 ± 960 pmol/L, re-
spectively; p < 0.0001). Nevertheless, the two groups did
not differ by the mean number of follicles (27 ± 9.5 and
30.4 ± 13.0) or the distribution for antral (65% and 68.4%)
and pre-antral (35% and 31.6%) follicles, respectively. Ex-
periment 2: The reduction of estradiol during follicular phase
did not hamper follicular development, in-vivo fertilization
and in-vitro embryo development. Similar rates of embryo
development to the morula stage (90.6% and 86%), blasto-
cyst stage (86% and 89%) and hatching blastocyst (81% and
78%) were achieved in the Arimidex group and the control
group, respectively.
Conclusions: Adequate folliculogenesis is independent
of estrogen but is conditioned on gonadotropin stimula-
tion. Moreover, depletion of estradiol in the vicinity of the
oocyte did not impair its developmental potential, including
its fertilization and development into morulae, blastocysts
and hatching blastocysts.
Keywords Anastrozole . Arimidex . Aromatase inhibitor .
Embryo . Estradiol . Folliculogenesis . In-vitro
fertilization . Mouse
Introduction
The development and maturation of ovarian follicles as well
as the differentiation of granulosa cells are dependent on
the effect of both gonadotropins, FSH and LH [1]. FSH
receptors are exclusively present in granulosa cells, while
the LH receptors are present in both thecal and granulosa
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cells. According to the “two cell, two gonadotropins theory”
theca interna cells are stimulated by LH to produce aroma-
tizable androgens. The androgens diffuse to granulosa cells
and are converted to estrogens by aromatizing enzymes, the
aromatase complex. Under FSH stimulation, granulosa cells
undergo proliferation and differentiation, acquire LH recep-
tors and aromatizing activity potential. Granulosa cells are
the principal site for estrogen synthesis in the preovulatory
follicle. Estrogens play an important intraovarian role in cre-
ating granulosa cells mitogenesis, the production of intracel-
lular gap junctions, cAMP synthesis and further stimulation
of steroidogenesis and gonadotropins receptors production.
In addition, there are several important extragonadal
effects of the elevated estradiol levels during the follicular
phase, i.e. the build-up of receptive endometrium, an
important process preceding implantation, the production of
the cervical mucus and pituitary priming for the mid-cycle
LH surge.
At the follicle level, there is a growing body of evidence
that estrogens have paracrine and autocrine functions at the
cellular compartments of the developing follicle and the
oocyte.
It is well established that estrogen alpha-receptor is
present in the human oocyte [2]. Recently, with the isolation
of the estrogen beta-receptor and its presence in the human
granulosa cells, the old debate about the local effects and the
importance of estradiol in the growing follicle was reopened.
The expression of both alpha and beta receptors in the
mouse ovary was shown in several studies, revealing a
distinct pattern of distribution of both estrogen receptors. Es-
trogen alpha-receptors are highly expressed in the interstitial/
thecal compartment, whereas estrogen beta receptors expres-
sion is limited to granulosa cells of growing follicles [3, 4].
Although high levels of estradiol are found in the follicular
fluid, little is known about its necessity for adequate follicular
growth, oocyte maturation and embryo development.
Arimidex (Anastrozole) is a potent highly selective aro-
matase inhibitor lacking any other intrinsic hormonal activ-
ity that when used results in a selective decrease in estrogen
synthesis.
In the present study, we apply Arimidex in a mouse model
in order to study the importance of estradiol in folliculoge-
nesis, oocyte maturation and in-vivo ovulation. In addition,
the effects of hypoestrogenic environment on embryo devel-




Immature C57Black female mice aged 3–4 weeks weighing
20–25 gm and mature 6–8 month old C57 Black male mice
of a previously proved fertility were used. The animals were
housed in air-conditioned quarters that were illuminated be-
tween 8:00 am and 10:00 pm and pellet food and water were
always available.
To induce superovulation, 5 IU of pregnant mare’s serum
gonadotropin (PMSG, Gestyl; Organon, Oss, The Nether-
lands) was injected intraperitoneally at 16.00 pm (day 1)
followed by 7.5 IU of human chorionic gonadotropin (hCG,
Sigma Chemical Co., St. Louis Missouri) given 48 hours
later (day 3). After hCG administration, each female mouse
was caged with a single male mouse and left overnight. Mat-
ing was confirmed by the presence of a vaginal plug on the
following morning (day 4).
Medication
Arimidex (Anastrozole) an achiral benzyltriazole derivative
is a potent, highly selective aromatase inhibitor with no in-
trinsic hormonal activities [5]. One tablet of the drug (1 mg)
was crushed and grinded to a powder to be suspended in
2 ml of normal saline. As needed, 0.2 ml of the suspension
(0.1 mg) was injected inraperitoneally to the female mice.
The control groups were similarly injected by normal saline
as appropriate.
Experiment 1: Is estradiol mandatory for normal
folliculogenesis in-vivo?
Immature C57 Black female mice aged 3–4 weeks were
superovulated as previously mentioned. The study group in-
cluded nine mice. This group was concomitantly injected
with 0.1 mg of Arimidex intraperitoneally given in the morn-
ing day (8 am) before PMSG, the morning day of PMSG
injection and for the following two days. The control group
included eight mice and was similarly injected with 0.2 ml
of normal saline.
Six to eight hours after the last Arimidex injec-
tion, the mice were anesthetized with Ketamin (Ketalar;
Parke-Davis, UK) 100 mg/kg and Xylasine 2% veterinary
(Vitamed LTD, Bat Yam, Israel) 5 mg/kg given intraperi-
toneally. Blood samples were withdrawn from the inferior
vena cava for estradiol and progesterone levels. The ovaries
of each mouse were dissected and sent for histological ex-
amination. Ovaries were fixed in formaldehyde solution em-
bedded in paraffin wax and cut serially into 5 µm sections.
These were stained with hematoxylin and eosin and both
ovaries of each mouse were blindly examined by an experi-
enced gynecopathologist to evaluate follicular development
and search for any morphologic changes in its histologic
appearance, if present.
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Experiment 2: Is estrogen deprived microenvironment
in-vivo affect embryo development in-vitro?
Mice were superovulated similarly by 5 IU PMSG given
intraperitoneally.
Forty-eight hours later, 7.5 IU hCG was injected intraperi-
toneally followed by overnight mating. The study group
(15 mice) was treated with Arimidex 0.1 mg injected in-
traperitoneally daily from a day prior to PMSG injection, in
a similar manner to that scheduled in the first experiment, to
the day of sacrifice. The control group (13 mice) was treated
similarly by normal saline. Forty-two hours after mating
(day 5), mice were anesthetized and blood was withdrawn
for E2 and P levels followed by microscopic tubal dissection.
Tubal dissection took place in human tubal fluid medium
(HTF) supplemented with HEPES buffer and enriched with
0.4% bovine serum albumin (BSA, Sigma Chemicals Co.,
St. Louis, MO). Embryos of 2–4 cells were isolated and
transferred for culture in P1 medium ( Irvine Scientific, Santa
Ana, CA, USA). Embryos were incubated at 37◦C under a
5% CO2, 5% O2 and 90% N2 environment and examined for
the development of morulae after 24–26 h of culture. Morulae
were transferred to blastocyst medium (Blastocyst medium,
Ervine scientific, California, USA) and examined for the de-
velopment to the blastocyst stage and hatching blastocyst
after additional 18 and 24 h of incubation, respectively.
Statististics
Data were analyzed using the χ2 test or Student’s t-test as
appropriate and P value of < 0.05 was considered as statis-
tically significant. Statistical analyses were performed using
a standard computer program of Microsoft Excel for Win-




As demonstrated in Table 1, a significant reduction of estra-
diol levels was achieved in the Arimidex group in compari-
son to the control group, 126.3 ± 104.8 pmol/L (mean ± SD)
and 1910 ± 960 pmol/L, respectively (P < 0.0001). This
indicates the efficacy of Arimidex suspension (0.1 mg in-
traperitoneally) used in this experiment to lower the follicular
estradiol levels in the study group. Despite the significant dif-
ference in estradiol levels during the follicular phase, the two
groups did not differ by the mean total number of developing
follicles (27 ± 9.5 and 30.4 ± 13) nor by the distribution for
antral (65% and 68.4%) and preantral (35% and 31.6%) fol-
licles, for the study and control groups respectively (Table 1).
Table 1 Steroids serum levels and follicular distribution in the pre-




(n = 8) P value
Estradiol (pmol/L) 126.3 ± 104.8 1910 ± 960 < 0.0001
Progesterone (nmol/L) 10.2 ± 11.7 44.4 ± 19.4 < 0.0001
Total no. of follicles 27% ± 9.5 30.4 ± 13 NS
Antral (%) 65% 68.4% NS
Preantral (%) 35% 31.6% NS
Figure 1(A) and (B) show the histologic appearance of
ovaries of the study group (A) and the control group (B). As
demonstrated, both ovaries show similar number and distri-
bution of growing follicles. No other morphologic changes,
i.e., atretic or degenerative follicles, were noticed in both
groups. Within the use of PMSG that posses also some
hCG activity, luteinization may took place and explains the
progesterone production during the follicular phase in both
groups (Table 1).
Fig. 1 The effect of Arimidex on ovarian histology. A. An ovary
from Arimidex treated animal. B. An ovary from untreated animal.
No difference in the histologic appearance with similar total number
of follicles and the comparable preantral/antral distribution. Optical
magnification X50
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Table 2 Steroids serum levels during the luteal phase and embryo




(n = 13) P value
Estradiol (pmol/L) 117.0 ± 32.8 200.5 ± 92.3 < 0.01
Progesterone (nmol/L) 207.9 ± 145.0 180.5 ± 110.9 NS
Total no. embryos 2–4
cells
360 335
Morula stage (%) 326 (90.6%) 289 (86%) NS
Blastocyst stage (%) 281 (86%) 256 (89%) NS
Haching blastocyst (%) 228 (81%) 199 (78%) NS
Experiment 2
Table 2 indicates the estradiol and progesterone serum level
in blood withdrawn from the inferior vena cava just before
tubal dissection. The estradiol level in the post-ovulatory
phase is significantly higher in the control group in compar-
ison to that in the Arimidex group. Its level, however, is sig-
nificantly reduced in comparison to that in the pre-ovulatory
phase. This reflects the luteinization that took place after the
exposure to hCG and the shift to progesterone production in
the corpora lutea.
The postovulatory progesterone levels were similarly el-
evated in both groups as compared to the pre-ovulatory lev-
els, once again, indicating that luteinization took place in the
study group despite the exposure to Arimidex.
In spite of the lower levels of estradiol induced by ex-
posure to Arimidex during the follicular phase, ovulation
took place followed by adequate mating and in-vivo em-
bryo production. In addition, when the developmental pote-
nial of these embryos was assessed in-vitro, similar rates
of embryonic development into morulae (90.6% and 86%),
blastocysts (86% and 89%) and hatching blastocysts (81%
and 78%) were achieved in the study and control groups,
respectively (Table 2).
Discussion
This study demonstrates that although a significant reduction
of estradiol levels was achieved with Arimidex treatment dur-
ing the follicular phase, it did not hamper follicular develop-
ment, oocyte fertilization in-vivo and embryo development
in-vitro. These results may indicate that, at least in mice,
intaovarian estradiol plays no role in oocytes maturation or
its developmental potential.
The high levels of estradiol during the follicular and the
preovulatory phases are considered as the hallmark of the
follicular phase. Estrogens are considered to play impor-
tant roles and several pivotal activities at the ovarian follicle
level. These include assisting granulosa cells proliferation
and differentiation, augmentation of gonadotropin action, in-
duction of gap junctions and acceleration of steroidogenesis.
In addition, estrogens have several extragonadal effects: i.e.
endometrial proliferation and cervical mucus biosynthesis.
Despite the high levels of estradiol present in the follicu-
lar fluid during the follicular phase, little is known about its
necessity for adequate follicular growth, oocyte maturation
and subsequent embryo development. During the last years,
several studies have addressed to this important issues in
order to elucidate the role of intraovarian estradiol. Never-
theless, among the different primate and non-primate animal
models no uniform findings were achieved concerning this
matter.
To date, studies addressing to this issue can be divided into
three categories: I. Genetic mutations affecting enzymes par-
ticipating in estradiol biosynthesis. II. Animal models with
knock-out mutations in estrogen receptors. III. Aromatase
inhibitors used in animal models.
Malproduction of estradiol
There have been several case reports showing multiple fol-
licular development with the use of exogenous gonadotropin
administration in women with congenital enzymatic defects
on the estrogen biosynthesis pathway [6–8]. In these women
despite normal development of follicles, ovum pick up and
fertilization, no pregnancy was reported in those patients.
These reports indicated that, in human, folliculogenesis as
well as normal fertilization may take place unrelated to estra-
diol production. Although the number of cycles reported is
low, embryo quality might be the crucial variable associated
with the IVF failure.
In two women with mutations in the aromatase gene that
results in total absence of aromatase activity, large ovarian
cysts resembling the polycystic ovaries syndrome (PCOS)
phenotype had been described indicating that the growth of
antral follicles may occur despite the absence of intraovarian
estrogen biosynthesis [9, 10].
Knock out mutations in estrogen receptors
It was shown [11] that a proportion of estrogen receptor
knock-out (ER KO) mice can have ovarian folliculogenesis
and normal ovulation with the development of what appeared
to be a functional normal corpus luteum.
In addition, in the ovaries of mice lacking estrogen recep-
tor β (ERβ-/-), follicles can be seen at all stages of develop-
ment ranging from primordial to fully developed antral folli-
cles [12]. However, when stimulated by gonadotropins, there
was an increased number of antral follicles but low number
of matured oocytes. Accordingly, fewer corpora lutea were
observed resulting in a reduced fecundity. Taken together,
these works challenged the view that estradiol has a manda-
tory role for folliculogenesis and ovulation in mice.
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Aromatase inhibitors
There were several studies that utilized aromatase inhibitors,
thus blocking the estrogen biosynthesis in animals. The re-
sults reported using different animal models were not con-
sistent making it hard to draw a definite conclusion as to the
effect of aromatase inhibitor on ovarian function. In rats, a
negative correlation was observed between estrogen deficient
environment and normal folliculogenesis leading to oocyte
maturation [13]. Moreover, histological examination of the
rat ovaries indicated a decrease in the number of the healthy
follicles in the aromatase inhibitor treated group compared
to controls.
In rhesus monkeys [14], the administration of aromatase
inhibitor, 1,4,6-androstatrien-3,17-dione ( ATD; Steraloids,
Wilton, NH) during the late follicular phase of gonadotropin
treated cycles resulted in 84% reduction of estradiol levels.
However, there was no alteration in follicular diameters or the
total number of folllicles per animal relative to control values.
Nevertheless, completion of oocyte meiosis to metaphase II
and the in-vitro fertilization of these oocytes were retarded
in the treated group compared to control animals.
In other studies using Fadrozole (CGS 1694A) to block
estrogen synthesis, it was shown that normal cyclical follic-
ular maturation as well as normal hCG/LH induced ovula-
tion were relatively unaffected in all animals studied (ham-
sters, rabbits, monkeys) other than rats [15]. These findings
are in an agreement with our results achieved in a mouse
model. We used Arimidex (anastrozol) suspension in a dose
of 0.1 mg and were able to drastically lower serum estradiol
levels during the preovulatory period. Nevertheless, follic-
ular development, oocyte fertilization in-vivo and embryo
development in-vitro were not affected. In addition, despite
a significant reduction of estradiol levels, the histologic ex-
amination showed no difference in follicular development or
in the distribution of preantral and antral follicles between
the Arimidex treated group and the control group. Our find-
ings corroborate with a recent report by Hu et al. [16] who
utilized Arimidex to investigate the effects of reduced estro-
gen levels on in-vitro culture of preantral mouse follicles.
Their findings indicated that in-vitro mouse follicles can de-
velop normally under very low levels of estrogen and that
a local androgen increase by a factor of 100 is not atreto-
genic. However, significantly less oocyte were fertilized in
the group cultured in the presence of Arimidex, but, once
fertilized, there was no difference in embryo development.
The authors concluded that in mice a pronounced estrogenic
environment is not essential for in-vitro folliculogenesis. In
our study, however, we did not observe any negative correla-
tion between Arimidex administration in-vivo and fertiliza-
tion rates as was manifested by the same mean number of
embryos collected from mice of the two groups.
It should be mentioned that although estradiol levels were
drastically reduced by Arimidex in our study, total reduc-
tion could not be achieved and thus, although low, estradiol
levels might be sufficient enough to support normal follicu-
logenesis, adequate and healthy oocytes resulting in normal
in-vivo fertilization and in-vitro embryo development. This
assumption is supported by the report of Fisher et al. [17]
who described the phenotype of aromatase knock-out mice
to be infertile, with ovaries lacking corpora lutea. Similarly,
Britt et al. [18] observed an age related degenerative changes
in the ovaries of aromatase knock-out mice. Thus, by the age
of one year there were no secondary or antral follicles and all
primary follicles present were atretic. These findings suggest
the possibility that total deprivation of estradiol may indeed
interfere with ovarian function.
In summary, our study suggests that, in mice, adequate fol-
liculogenesis is independent of estrogen but is conditioned on
gonadotropin stimulation. Moreover, depletion of estradiol
in the vicinity of the oocyte did not impair its developmen-
tal potential, including its in-vivo fertilization and in-vitro
development into morulae, blastocysts and hatching blasto-
cysts.
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 SHORT REVIEWS 
 The case for aromatase inhibitors use in Oncofertility patients. 
Should aromatase inhibitors be combined with gonadotropin treatment 
in Breast Cancer patients undergoing ovarian stimulation for fertility 
preservation prior to chemotherapy? A debate 
 MUHAMMAD  FATUM ,  ENDA  MCVEIGH  &  TIM  CHILD 
 Oxford Fertility Unit, Institute of Reproductive Sciences, Nuffield Department of Obstetrics and Gynaecology, 
University of Oxford, Oxford, UK 
 Abstract 
 Breast cancer is one of the hormone-dependent cancers that may be adversely affected by elevated oestrogen or progesterone 
concentrations, particularly the endocrine active (hormone receptor positive) breast cancers. 
 Treatment for breast cancer patients aimed at fertility preservation, includes ovarian hyperstimulation, the harvest of oocytes, 
and subsequent cryopreservation of oocytes or embryos. Classically, gonadotrophins have been used effectively for ovulation 
induction, a treatment often accompanied by high blood oestrogen concentrations produced by the hyperstimulated granulosa 
cells. Despite the uncertainty which surrounds this issue and the lack of clear-cut clinical evidence, it is still of major concern that 
these ensuing high hormone levels might be associated with a high risk of recurrence of the cancer. 
 A growing number of clinical studies have strongly suggested the benefi ts of using aromatase inhibitors in infertility treatment, 
both as single agents or as adjuncts to FSH-containing ovulation induction regimes in reproductive medicine. Combining go-
nadotrophins with aromatase inhibitors would augment the stimulation effect, with a reduced increase in serum concentrations 
of estradiol. We propose to open a debate over the use of aromatase inhibitors in combination with FSH in ovulation induction 
treatment of breast cancer oncofertility patients. 
 As the safety of aromatase inhibitors such as letrozole has recently been demonstrated in several studies, and there is grow-
ing concern over the possible detrimental effects of high estradiol levels on breast cancer cells (at least in mouse models), the 
co-administration of letrozole in these patients would reduce both the high supraphysiologic serum levels of estradiol and the 
intratumoral in situ production of oestrogen. However, since it is unlikely that a well-founded evidence-based justifi cation 
of this treatment will be formulated in the near future, based on well-designed prospective randomised controlled trials, we 
advocate a wider use of aromatase inhibitors in combination with gonadotrophins in breast cancer patients, especially those 
with hormone-receptor-positive tumours. 
 Keywords:  Cancer ,  cryopreservation ,  fertility preservation 
 A growing number of clinical studies have strongly 
suggested the benefi cial use of aromatase inhibitors 
in infertility treatment, both as single agents or as ad-
juncts to ovulation induction regimes using follicular 
stimulating hormone (FSH) in reproductive medicine 
(Mitwally  & Casper, 2001; Mitwally  & Casper, 2005). 
Aromatase inhibitors, mainly the third-generation 
agents, for example, letrozole, offer a seemingly effec-
tive, safe and low-cost option for ovulation induction 
in women with normal or increased levels of oestrogens 
such as in PCOS and in IVF patients who are poor 
responders to gonadotrophin stimulation (Al-Omari 
et  al., 2004; Goswami et  al., 2004). 
 Aromatase enzyme is a member of the Cytochrome 
P450 superfamily that catalyses the synthesis of oestro-
gens by converting C19 androgens to aromatic C18 
oestrogenic steroids. It converts the aromatisable andro-
gens, androstenedione and testosterone to oestrone and 
estradiol, respectively. Its activity can be demonstrated 
in several tissues, including the ovarian granulosa cells, 
adipose tissue, muscle, breast and liver. 
 Aromatase inhibitors have been introduced as an ad-
juvant hormonal treatment in breast cancer postmeno-
pausal women after surgical and chemotherapeutic treat-
ment. Breast cancer is one of the hormone-dependent 
cancers that may be adversely affected by elevated 
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oestrogen or progesterone concentrations, particularly 
the hormone (oestrogen and progesterone)-receptor-
positive breast cancers. 
 With improvement in the diagnosis and treatment of 
early-stage breast cancer, an increased number of young 
women in their child-bearing years survive the disease. 
 Fertility treatment for cancer patients aimed at fertil-
ity preservation primarily includes ovarian hyperstimula-
tion with the intention of superovulation and a high yield 
of oocytes, generally followed by either conventional in 
vitro fertilisation (IVF) or intracytoplasmic sperm injec-
tion (ICSI), leading to gamete/embryo cryopreservation. 
Classically, gonadotrophins have been used effectively 
for ovulation induction. However, the consequential 
endocrinological manifestation of this treatment is the 
accompanying high oestrogen blood concentrations pro-
duced by the granulosa cells. The potential detrimental 
effect of these iatrogenically induced supraphysiologic 
oestrogen concentrations is of major concern for pa-
tients and their oncologists, especially in women with 
hormone-receptor-positive tumours. Despite the un-
certainty and the lack of clear-cut clinical evidence of 
this problem/issue, it is of paramount concern that the 
ensuing high hormone levels may be associated with a 
high risk of recurrence of the disease. On the other hand, 
clinicians might consider the length of time these women 
are likely to have had a cancer of the breast before it 
became clinically detectable. During that period of time, 
it would have been exposed to estradiol concentrations 
of the order of 1000 pmol/l at repeated intervals, and 
thus, one single further exposure might not be expected 
to have a measurable effect on overall prognosis. 
 In IVF cycles for infertile non-cancer patients, estra-
diol is required for the build-up of the endometrial lin-
ing in preparation for the implantation of the embryos. 
By contrast, in IVF cycles for cancer patients, which 
are undertaken for the purpose of obtaining gametes 
or embryos for cryopreservation, the endometrial lin-
ing build-up is unnecessary since the resulting gametes 
or embryos are cryopreserved for transfer long after the 
completion of the cancer therapy. 
 In recent years, the third-generation aromatase in-
hibitors (mainly anastrozole and letrozole) have been 
advocated as new ovulation-induction agents. These 
non-steroidal aromatase inhibitors are selective, highly 
potent, reversible inhibitors with no intrinsic steroidal 
activity. They are orally administered, easy to use, rela-
tively inexpensive, and have minor adverse effects (Kafy 
 & Tulandi, 2007; Al-Fadhli et  al., 2006). 
 Letrozole is the most widely used aromatase inhibi-
tor followed by anastrozole (Requena et  al., 2008; Azim 
et  al., 2007). These agents work by selectively inhibiting 
aromatisation, leading to diminished oestrogen produc-
tion including estradiol, oestrone and oestrone sulphate. 
Consequently, there is release of the hypothalamic –
 pituitary axis from oestrogen-negative feedback. As a 
result, endogenous FSH secretion increases, stimulating 
folliculogenesis in the ovaries. The transient, relatively 
elevated intrafollicular androgens resulting from the 
diminished intraovarian aromatisation activity increase 
follicular sensitivity to FSH stimulation (Holzer et  al., 
2006; Mitwally et  al., 2005). More recently, anastrozole 
has been shown not to suppress E 
2
 levels in women with 
breast cancer undergoing controlled ovarian stimulation 
suffi ciently when compared to letrozole. In a prospec-
tive sequential cohort study investigating the potency of 
anastrozole compared with that of letrozole to suppress 
estradiol concentrations in breast cancer patients under-
going controlled ovarian hyperstimulation (COH), Azim 
et  al. (2007) showed that anastrozole had minimal sup-
pressive effect on rising estradiol concentrations during 
COH, even at fi ve times the comparable dose of letrozo-
le. Thus, breast cancer patients who underwent ovarian 
stimulation with anastrozole had signifi cantly higher ex-
posure to estradiol than those stimulated with letrozole. 
As a result, the study was terminated prematurely. In 
their conclusion, the authors cautioned against routine 
use of anastrozole in fertility preservation cycles. 
 Combining gonadotrophins with aromatase in-
hibitors would augment the stimulation effect of these 
drugs, with a lower increase in serum concentrations 
of estradiol. This decrease in serum concentration is 
hypothesised to be achieved by two mechanisms. First, 
using aromatase inhibitors enables the reduction of go-
nadotrophin dosage leading to reduced stimulation of 
granulosa cells and hence less estradiol production. A 
prospective study comparing the clinical outcomes be-
tween letrozole and clomifene citrate in gonadotropin-
combined intrauterine insemination cycles (Jee et  al., 
2006) found that the concomitant use of Letrozole 
and gonadotrophins was associated with lower serum 
estradiol concentrations; however, the clinical pregnancy 
rate was similar in both groups. 
 Second, aromatase inhibitors cause a reduction in 
estradiol production by virtue of their direct down-
stream inhibitory effect on aromatase enzymes, thus 
inhibiting the aromatisation of target androgens in the 
granulosa cells. 
 We have reviewed the recent relevant literature in 
regard to the use of aromatase inhibitors in ovulation 
induction for cryopreservation in women with breast 
cancers. We propose that there should be a debate over 
the use of aromatase inhibitors in combination with 
FSH in ovulation induction treatment of breast cancer 
oncofertility patients. The safety of aromatase inhibi-
tors has recently been shown in several studies, and 
there is growing concern over the possible detrimental 
effects of high estradiol concentrations in breast can-
cer cells of oncology patients. The co-administration 
of letrozole in these patients would reduce the high 
supraphysiologic serum concentrations of estradiol. 
Consequently, these potentially adverse, untoward ef-
fects would probably be reduced. 
 The importance of low estradiol levels 
 Every oncofertility expert can clearly articulate the 
dilemma in deciding to commence IVF cycles in 
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breast cancer patients because of the presumed risk 
of deleterious effects of elevated oestrogen concentra-
tions on cancer cell proliferation. There have been no 
randomised controlled trials which have examined the 
relative effi cacy, safety and effects (on progression-
free survival rates) of the different ovulation induction 
regimens in breast cancer IVF patients, in particular 
the administration of aromatase inhibitors versus non-
administration. We doubt whether there will be such 
studies in the near future since they may be viewed as 
unethical and of needless risk to the patients. In real-
ity, this situation represents the intricate conundrum 
of taking clinical decisions when no evidence-based 
answers or policies are available. However, in these 
circumstances, lower-order/powered (non-RCT) and 
animal studies may provide indirect clues that help to 
answer this clinical problem, especially when it is clini-
cally implausible and ethically debatable to implement 
such studies. 
 In their early study, Oktay et  al. (2005) reported a 
prospective non-randomised trial aimed at developing 
safe ovarian stimulation protocols in breast cancer IVF 
patients wishing to preserve fertility before chemother-
apy. Twenty-nine patients underwent 33 ovarian stimu-
lation cycles either with tamoxifen 60 mg/day alone or 
in combination with low-dose FSH or letrozole 5 mg in 
combination with FSH. All resultant embryos were cry-
opreserved to preserve fertility. Recurrence rates were 
compared with those of 31 control patients who chose 
not to undergo IVF. The authors found that, compared 
to IVF patients treated with tamoxifen alone, IVF pa-
tients who had been treated with FSH and tamoxifen 
or FSH and letrozole had signifi cantly greater numbers 
of follicles, mature oocytes and embryos. Peak estra-
diol concentrations were lower in patients treated with 
letrozole and FSH and with tamoxifen, compared with 
those in patients treated with tamoxifen and FSH. Re-
currence rates after a mean follow-up of 554    31 days 
was similar between IVF and control patients, and this 
was not affected by cancer stage. Of the three patients 
who had recurrence after IVF, two were in the tamox-
ifen group and one in the FSH group. There was no 
recurrence in the letrozole IVF group. The authors sug-
gested that the letrozole protocol may be preferred be-
cause it resulted in lower peak estradiol concentrations. 
Nevertheless, the short follow-up, non-randomisation 
and low statistical power do not allow any clinically 
meaningful comparisons in survival between IVF and 
control patients to be made. 
 A subsequent retrospective age-matched control 
study of stages I – IIIA breast cancer patients, (Oktay 
et  al., 2006) compared the effi cacy of aromatase inhibi-
tors plus gonadotrophin in breast cancer patients with 
a standard IVF protocol in non-cancer patients. Total 
oocytes, mature oocytes, fertilisation rate, the number of 
embryos and length of stimulation were similar between 
the two groups. Peak estradiol concentrations were 
signifi cantly lower in the letrozole plus FSH group. In 
addition, there was a 44% reduction in gonadotrophin 
requirement in patients treated with letrozole and FSH 
for embryo/oocyte preservation compared with the 
controls. The authors concluded that ovarian stimula-
tion with letrozole and FSH appeared to offer yields 
similar to standard protocols, reducing the amount of 
gonadotrophins required and hence providing a more 
cost-effective alternative for breast cancer patients. 
Considering the high cost of injectable gonadotropins, 
this could lead to signifi cant savings for self-funding 
cancer patients who may already be stretched with costs 
associated with the stressful treatment of their primary 
disease (Oktay et  al., 2006). In a later prospective non-
randomised controlled study (Azim et  al., 2008), a 
total of 215 women with breast cancer were evaluated 
prospectively for fertility preservation before adjuvant 
chemotherapy. The study group comprised 79 of these 
patients, who elected to undergo controlled ovarian 
stimulation using a combination of letrozole with go-
nadotrophins followed by oocyte collection for embryo 
or oocyte cryopreservation. The remaining 136 patients 
who underwent no fertility-preserving procedure served 
as controls. After a median follow-up of 23 months for 
the study group and 33 months for the control group, 
the authors reported no statistically signifi cant survival 
difference between the two groups. Although this study 
is relatively small, non-randomised and the follow-up 
is limited, it does suggest that the use of letrozole and 
gonadotropins for controlled ovarian stimulation before 
embryo or oocyte cryopreservation is unlikely to result 
in a signifi cant increase in recurrence rate at least in 
the short term, compared with those who do not un-
dergo ovarian stimulation. The authors concluded that, 
in the meantime, based on the short-term follow-up of 
these patients, and until further follow-up to assess the 
impact of such therapy on the long-term recurrence or 
survival, the letrozole – FSH protocol is a viable option 
for oocyte or embryo cryopreservation (Azim et  al., 
2008; Partridge  & Farber, 2008). 
 Animal models 
 Mice models of breast cancer have shown deleterious 
effects of high oestrogen concentrations on the cell pro-
liferation rate of cancer cells. Thus, Platet et  al. (2004) 
showed that oestrogens have an obvious role in cancer 
proliferation and invasion. Others (Brodie et  al., 2006) 
used a tumour model with hormone-responsive (ER  ) 
breast cancer cells stably transfected with the human 
aromatase gene. These cells serve as an autocrine source 
of oestrogen that stimulates the cells to form tumours 
when inoculated into ovariectomised, immunosup-
pressed mice. The resulting tumours were used to study 
strategies of treatment with aromatase inhibitors and 
anti-oestrogens. It was found that letrozole alone was 
better in this respect than the anti-oestrogen tamoxifen 
alone or in combination with letrozole. In addition, 
when tamoxifen treatment was no longer effective, tu-
mour growth was signifi cantly reduced in mice switched 
to letrozole treatment. One of the possible explanations 
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for the more benefi cial effect of letrozole could be that 
it is not associated with weak agonist properties and 
therefore exerts a more complete reduction in oestro-
genic effects than tamoxifen. 
 These data are of particular importance since results 
from the mouse model used in this study have been pre-
dictive of clinical outcome. 
 These basic-science studies, together with other stud-
ies on mice (Yue et  al., 1994; Lu et  al., 1998; Yue et  al., 
1999), provide supportive evidence for the relative risk 
to breast cancer cells ’ of exposure to elevated concentra-
tions of estradiol and indirectly confi rm the importance 
of adhering to tighter ovulation-induction regimes, with 
only minimal oestrogen production both systematically 
(by the ovaries) and in situ (intratumoral) production. 
 Human studies 
 Several studies have failed to show any benefi cial ef-
fect of oestrogen exposure in recruiting cancer cells 
and increasing the proliferative fraction, on the chemo-
therapy response. One study (Fabian et  al., 1994) was 
undertaken to test the effect of a high dose of oestrogen 
administered to patients with locally advanced ER-pos-
itive tumours and the subsequent fl are effect on cancer 
cells, prior to chemotherapy. The hypothesis was that 
the oestrogen would increase chemotherapeutic effi cacy 
in breast cancer by increasing the number of tumour 
cells in-cycle through hormonal recruitment prior to 
the initiation of chemotherapy. The high but dose of oe-
strogen administered to these patients reliably increased 
the tumour S-phase fraction and the proliferative index 
within 48 h. However, the response to Adriamycin-
based chemotherapy did not appear to be markedly dif-
ferent from the locally advanced or metastatic disease 
patients. This study and others (Bontenbal et  al., 2000; 
Paridaens et  al., 1993) did not show any signifi cant ef-
fect of administering oestrogen prior to chemotherapy, 
also indicating that deleterious effects from the lower 
oestrogen concentrations that may ensue using the aro-
matase inhibitors are unlikely. 
 Pregnancy rates with aromatase inhibitors 
 A concern has been raised that embryos derived from 
oestrogen defi cient follicles as a result of aromatase 
inhibitor usage may not have the same developmental 
capacity as those obtained after treatment with conven-
tional ovulation induction medications. 
 Indirect reassuring information has been obtained, 
initially from controlled ovarian hyperstimulation cycles 
that showed similar pregnancy rates in aromatase inhibi-
tor and control groups. In a cohort study (Mitwally et  al., 
2005) that examined the early outcome of pregnancies 
achieved after treatment with letrozole compared with a 
control group that included pregnancies achieved spon-
taneously or after other ovarian stimulation protocols, 
treatment with letrozole for ovarian stimulation was 
associated with comparable rates of pregnancy and 
pregnancy loss (biochemical pregnancy and miscar-
riage). This was further confi rmed in other pertinent 
studies (Jee et  al., 2006; Atay et  al., 2006; Aygen et  al., 
2007; Bayar et  al., 2006; Badawy et  al., 2009; Dehbashi 
et  al., 2009; Zeinalzadeh et  al., 2010) which reported 
similar pregnancy rates in the aromatase inhibitor and 
control groups. 
 A small number of non-randomised case-series stud-
ies have been reported on the use of aromatase inhibitors 
for IVF (Verpoest et  al., 2006; Goswami et  al., 2004; 
Garcia-Velasco et  al., 2005; Schoolcraft et  al., 2008), 
none of which found signifi cantly different pregnancy 
rates in the aromatase inhibitor groups compared to the 
control groups. 
 In conclusion, the above-mentioned studies on the 
use of aromatase inhibitors in COH and IVF treatment 
cycles show no adverse impact on embryonic develop-
ment when used as ovulation induction agents. 
 Safety profi le of aromatase inhibitors in 
ovulation induction 
 Concerns have been raised about the safety profi le of 
aromatase inhibitors. A small study presented as an 
Abstract to the American Society for Reproductive 
Medicine meeting in 2005 suggested that Letrozole 
could cause serious foetal anomalies (Biljan et  al., 
2005). The authors reported the outcome of 170 
births, of which 20 were lost to follow-up. One hundred 
and fi fty babies from 130 pregnancies born after the 
use of Letrozole were compared to a control group of 
36,050 infants born from low-risk pregnant women. In 
this study, a malformation rate of 4.7% among the 150 
babies was found comparing with a rate of 1.8% in the 
control group of normal conceptions. The incidence 
of cardiac and musculoskeletal system malformations 
was reported to be signifi cantly higher in the letrozole-
treated group. Several methodological problems of 
this report have been raised; the control group was 
younger (30.5    1.2 years) than the letrozole-treated 
group (35.2    4.7 years); only 110 women in the study 
group gave birth to singleton infants with the rest being 
multiple-foetal pregnancies which are known to be of 
higher risk of congenital malformations. 
 As a result of this report, the marketing company 
(Novartis) issued global warnings to healthcare profes-
sionals that the drug should only be used for its primary 
indication as a treatment for breast cancer therapy for 
postmenopausal women. 
 A large retrospective study (Tulandi et  al., 2006) 
also disputed the results of the above-mentioned Ab-
stract presentation. The authors reported the incidence 
of congenital malformations among 911 newborns 
conceived after infertility treatment with letrozole or 
clomifene citrate. They found 2.4% congenital and 
chromosomal malformations in the letrozole-treated 
group, and 4.8% in the clomifene citrate-treated group. 
The major malformation rate in the letrozole group was 
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1.2% and in the clomifene citrate group was 3%. The 
rate of all congenital cardiac anomalies was signifi cantly 
lower in the letrozole-treated group (0.2%) compared 
to the clomifene citrate-treated group (1.8%). On the 
basis of these data, the concern that letrozole use for 
ovulation induction could be teratogenic is unfounded 
(Tulandi et  al., 2006; Kafy  & Tulandi, 2007; Requena 
et  al., 2008). 
 Hu et  al. (2002) had already shown that when oo-
cytes were exposed to anastrozole there was no increase 
in spindle anomalies and the rate of development to 
blastocysts was similar to that of controls. 
 In another study (Luthra et  al., 2003), aromatase-
overexpressing mice were treated with high doses of 
letrozole for 6 weeks, and mated two weeks after the 
last letrozole dose. There was no difference in litter size, 
birthweight or the number of anomalies in the study 
group when compared with those in the controls. 
 In a study on mice, (Fatum et  al., 2006), the admin-
istration of anastrozole and the consequent depletion of 
estradiol levels had no adverse effects on folliculogenesis 
or the number of oocytes produced after in vivo ovula-
tion induction. When the resultant embryos were grown 
in vitro, there were no signifi cant differences in embryo 
development to day 3 and subsequently to the morula 
and the blastocyst stages. 
 The short half-life of aromatase inhibitors and the 
administration of these drugs during the early follicular 
phase of the cycle leave a suffi cient interval for complete 
washout to occur before fertilisation and implantation 
(Requena et  al., 2008). The half-life of letrozole is 30 –
 60 h, such that it should be cleared from the body by 
implantation (Casper and Mitwally, 2006). 
 Taken as a whole, these studies indicate that aro-
matase inhibitors are safe for usage in terms of folliculo-
genesis, in vitro embryo development and relative safety 
vis- à -vis teratogenic effects. Furthermore, in oncofertil-
ity patients where the resulting embryos are for cryo-
preservation, the teratogenity of aromatase inhibitors 
used in ovarian superovulation is largely irrelevant. 
 Conclusion 
 Despite the lack of well-designed RCT (randomised 
controlled trial) studies, we propose the use of aromatase 
inhibitors in combination with FSH in ovulation induc-
tion treatment of breast cancer oncofertility patients. 
The safety of aromatase inhibitors has been shown in 
several studies whereas there are possible detrimental 
effects of high estradiol concentrations in the breast 
cancer cells of oncology patients. The co-administration 
of letrozole and gonadotrophins in these patients would 
reduce both the high supraphysiologic serum concen-
trations of estradiol and intratumoral in situ oestrogen 
production. Consequently, potentially adverse effects of 
oestrogen production may be avoided. 
 We believe that, in the absence of clear-cut, contrain-
dications (adverse or teratogenic effects) associated with 
the use of aromatase inhibitors, we should advocate a 
wider use of these agents in conjunction with gonado-
trophins in breast cancer patients undergoing ovarian 
stimulation for fertility preservation, especially those 
with known hormone-receptor-positive tumours. 
 This is a classical clinical situation which poses a 
decision-making conundrum, where evidence-based 
medicine cannot be applied because of the lack of 
randomised controlled studies. Moreover, it is unlikely 
that in the near future there will be a well-founded 
evidence-based answer. Clinical judgement can be 
built on plausible biological effects and the acceptable 
safety of such a treatment policy. Clinical insight is in-
tegral to the clinical judgement and decision-making 
in this situation. We propose a policy which embraces 
clinical rationalisation and reasonable fl exibility with 
open discussion with patients wherever there are no 
evidence-based studies or rigorous scientifi c data, the 
case in many areas of daily clinical practice. In other 
words, this discussion of the use of aromatase inhibi-
tors in combination with FSH provides an excellent 
example of common clinical dilemma  – the lack of 
randomised controlled studies. Our view is that this 
should not be considered an absolute contraindication 
that rules out a treatment. 
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Ovarian Tissue Cryopreservation 7 
Muhammad Fatum and Enda McVeigh 
In recent years, cryopreservation of ovarian tissue 
in humans has emerged as a promising technique 
for fertility preservation in premenarchal chil- 
dren and adolescents, as well as an alternative in 
adult women prior to starting gonadotoxic 
chemo/radiotherapy. The prognosis and the sur- 
vival rates of cancer patients have improved tre- 
mendously as a result of recent advances in 
cancer treatment - particularly in childhood can- 
cers - and therefore attention is now being 
directed towards quality of life issues and the 
long-term gonadotoxic side effects of chemother- 
apy or radiotherapy. The incidence of ovarian 
failure is dependent on the agents used, the dose, 
and the age of the patient. 
Currently, there are several modalities for fer- 
tility preservation and these are highly dependent 
on the age of the woman. 
(i) Post-pubertal women requesting fertility 
preservation prior to chemotherapy or radio- 
therapy may be offered controlled ovarian 
stimulation for either oocyte cryopreserva- 
tion or in vitro fertilization (IVF) for embryo 
cryopreservation. With IVF, harvested 
oocytes are fertilized with sperm produced 
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by the husband, partner or donor, or are 
frozen as unfertilized gametes. This technol- 
ogy is in routine clinical use in IVF units 
throughout the world on a daily basis. 
Disadvantages include the need for hor- 
monal stimulation for 2-4 weeks, which 
may defer the anticancer treatment, its rela- 
tively high cost, and the relatively limited 
number of embryos produced and stored 
from a single stimulation cycle. If there is a 
need to undergo immediate anticancer treat- 
ment, this is not a viable option. 
(ii) Another option is obtaining immature 
oocytes (in non-stimulated cycles) for 
in-vitro maturation, subsequent embryo 
freezing or oocyte rapid vitrification. 
(iii) Ovarian suppression prior to chemotherapy 
by GnRH analogues is of controversial sig- 
nificance and its use should be considered in 
well-designed experimental protocols. 
(iv) Oophoropexy prior to radiotherapy (which 
includes an operative procedure, mainly 
laparoscopy, to move ovaries out of the 
pelvic radiotherapy field) is an appropriate 
treatment for only a very few well-defined 
group of patients. 
(v) Ovarian tissue cryopreservation is a fertility 
preservation approach that can usually be 
performed immediately and without hor- 
monal stimulation. It is the only available 
fertility preservation approach that can be 
offered to premenarcheal/prepubertal girls 
and to adult women undergoing aggressive 
M. Metwally, T.-C. Li (eds.), Reproductive Surgery in Assisted Conception, 
DOI I0.1007/978-1-4471-4953-8_7, © Springer-Verlag London 2015 
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chemotherapy/radiotherapy with a high like- 
lihood of gonadotoxicity who cannot defer 
the anticancer treatment to undergoing IVF 
cycle. In this modality, functional ovarian 
cortical tissue is surgically excised from the 
ovary and frozen. Laparoscopy is usually 
performed to harvest ovarian tissue, fol- 
lowed by tissue processing and cryopreser- 
vation. Following recovery from the cancer 
treatment and when the patient is ready to 
proceed with fertility treatment, the ovarian 
tissue is thawed out and autotransplanted. 
Table 7. 1 major paediatric patients groups included in 
the ovarian tissue cryopreservation programme in Oxford 
Whole abdomen and pelvic radiation greater or equal 
to 15 Gy in pre pubertal or 10 Gy in post pubertal girls 
especially in combination with any alkylating agents 
Craniospinal radiation 
Total Body irradiation as part of conditioning for bone 
marrow transplant 
High dose chemotherapy: 
Cyclophosphamide 120-200 mg/kg as conditioning 
forBMT 
Cyclophosphamide >5 g/m2 
Cisplatin 
Ifosfamide >60 mg/m2 
Melphalan 140-210 mg/m2 
Laparoscopic Ovarian Biopsy 
for Cryopreservation 
Indications 
The American Society of Clinical Oncology 
(ASCO) has published clinical practice guide- 
lines [1] to aid in gonadotoxicity estimation and 
define indications of fertility preservation in the 
different cancer diagnoses and treatment proto- 
cols. Similar guidelines have been published by 
International Society of Fertility Preservation 
(ISFP) [2]. These guidelines provide a clear basis 
for good clinical practice. 
Several factors should be taken into consider- 
ation when ovarian tissue cryopreservation is dis- 
cussed with these patients: patient's age, patient's 
oncologic prognosis and quality of life, fertility 
and obstetrical history, availability and afford- 
ability of other fertility preservation technolo- 
gies, explaining and understanding the meaning 
of success as per the most up-to-date data in the 
literature and counselling for the psycho-social 
perspectives. 
Every programme should have its own policy 
and inclusion and exclusion criteria for ovarian 
tissue cryopreservation. In our programme, we 
include females aged not more than 39 years of 
age and no less than 12 months old, with reason- 
able (>50 % ) chance of surviving 5 years and a 
high (>50 % ) risk of having ovarian function 
destroyed by therapy. Another important inclu- 
sion criterion is that the patient should be fit 




enough to undergo general anaesthesia and 
surgery. Table 7 .1 summarizes the paediatric 
groups included in our ovarian tissue cryopreser- 
vation programme. 
As programs progress and more clinical data 
becomes available, we believe that ovarian tissue 
cryopreservation will be increasingly offered to 
non-malignant diseases such as females at risk of 
premature ovarian failure: i.e. Turner syndrome, 
family history of premature ovarian insufficiency, 
benign autoimmune diseases requiring gonado- 
toxic chemotherapy or patients needing bone 
marrow transplantation for benign haematologi- 
cal diseases such as sickle cell anaemia and thal- 
assaemia major. 
Following referral it is mandatory to have a 
thorough pre-treatment consultation by a multi- 
disciplinary team that specializes in fertility 
preservation. This team should include an 
oncologist, a reproductive endocrinologist, a 
surgeon, specialized nurse and a paediatrician 
and social worker as required. The cancer diag- 
nosis, the chemotherapeutic agents and their 
doses, radiotherapy field and scattered radiation 
doses, as well as the patient's age should to be 
taken into consideration before deciding on the 
need and the extent for the ovarian tissue 
cryopreservation. 
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Fig. 7 .1 Shows the different ovarian tissue harvesting 
options: biopsy, partial ovarian cortex resection, unilateral 
oophorectomy. The amount of the ovarian cortical tissue 
Preoperative Workup 
Preoperative workup of the patient is performed 
to exclude ovarian pathology and possible pelvic 
metastases ( e.g. gynecologic ultrasonography, 
CT scans or MRI) [3]. During laparoscopy, a 
meticulous inspection of both ovaries is per- 
formed to look for malignancy [ 4-6]. Ovarian 
activity is measured by either measuring the 
antral follicular count by ultrasound scan or test- 
ing patient's blood for ovarian reserve markers, 
i.e. Anti Mullerian Hormone (AMH) or Follicle 
Stimulating hormone (FSH). 
Ovarian cortical tissue harvesting is commonly 
performed as a laparoscopic procedure under gen- 
eral anaesthesia. Three or four entry puncture 
sites are used: 12 mm intraumbilical trocar , two 
5 mm trocars in the left and right iliac fossae. 
A fourth 12 mm suprapubic trocar can be used if 
oophorectomy is performed to allow atraumatic 
ovarian removal with an endobag. If open surgery 
is planned for the patient, ovarian biopsies should 
be taken at the time of the surgery. Other proce- 
dures requiring a general anaesthetic can be per- 
formed at the same time such insertion of Hickman 
catheter prior to starting chemotherapy. 
Ovarian biopsies are taken either with laparo- 
scopic forceps or scissors. It is important to mini- 
mize as much as possible the use of diathermy so as 
not to damage the ovarian tissue. If bleeding does 
occur, this is best controlled with small, precise 
mirco-bipolar diathermy. Care should also be taken 
to minimize trauma to the ovarian tissue and the 
prompt removal of the tissue to the laboratory team. 
harvested is tailored to the gonadotoxicity degree of the 
anti-cancer treatment and the ovarian size 
The ovarian cortical tissue size harvested or 
number of biopsies taken is dependent on the 
estimated gonadotoxic effects of the planned che- 
motherapy and/or radiotherapy regimen, varying 
from 20 biopsies (10 biopsies from each ovary) 
or 2 cortical strips measuring 15 mm long and 
5 mm wide taken from each ovary. When a high- 
risk chemotherapy or radiotherapy is planned and 
risk of premature ovarian failure is high (60-- 
80 % ), oophorectomy should be considered 
(Fig. 7 .1 ). Ovarian tissue cryopreservation can 
also be combined with intraoperative retrieval of 
immature oocytes from the contralateral ovary in 
cases of oophorectomy or from both ovaries if 
only biopsies are taken. Retrieved oocytes are 
then subjected to in vitro maturation and cryo- 
preservation of either mature oocytes or embryos. 
Processing the Ovarian Tissue 
Preparation of the ovarian tissue, cryopreservation 
and thawing must ensure follicle viability and 
integrity of tissue compartments and cell-to cell 
contacts [7]. Two well-established methods can be 
used: rapid vitrification and slow freezing of finely 
dissected thin slices of ovarian cortex tissue [8-11]. 
Both freezing methods are acceptable with good 
survival rates and comparable tissue viability and 
morphology integrity rates. Several recent reports 
have shown improved outcomes after vitrification 
of ovarian tissue as compared to slow freeze tech- 
nique in preserving granulosa cells and ovarian 
stroma [12, 13]. However, until clinical outcome 
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data show improved outcome of the vitrification 
protocol, we think the slow freeze protocol should 
be adopted. In the upcoming sections the slow 
freeze protocol used in our Unit will be described. 
Ovarian Dissection 
The cooled ovary should be transported from the 
operating theatre to the laboratory within 30 min 
of procurement and then tissue processing is 
immediately commenced within a clean facility 
in the laboratory. Antral follicles are aspirated at 
the beginning and fluid is carefully assessed for 
the presence of oocytes. In addition, the remain- 
ing media left after ovarian tissue dissection is 
ideally given to embryologists at the end of the 
procedure to check for potential immature 
oocytes. If immature oocytes are found then they 
undergo in vitro maturation (IVM) and the resul- 
tant mature eggs are vitrified. The ovary is 
immersed in a petri dish in cooled Leibovitz 15 
medium and is bi-valved using sterile scalpel 
and forceps or tweezers (Fig. 7.2). The inner 
medulla tissue is dissected away leaving the thin 
outer layer of the cortex that contains the 
majority of follicles [9, 14]. Our practice is to 
have two staff working together to minimise 
damage to tissue by reducing the overall pro- 
cessing time and reducing the length of isch- 
aemia before starting the freezing procedure. 
The cortical tissue slices are all trimmed to 
within a standard thickness of 1-2 mm to ensure 
that cryoprotectants adequately diffuse into the 
ovarian tissue during the cryoprotection proce- 
dure prior to freezing. In addition, after auto- 
grafting, thin slice grafts are more likely to 
survive the post transplantation ischemic stage, 
Fig. 7 .2 Ovarian tissue processing in the laboratory as 
demonstrated for whole ovary removal. (a) The ovary is 
bi-valved. (b) The medulla is cut and carefully removed 
and the 1 mm thickness outermost cortex is achieved. 
( c) The ovarian cortex slices before freezing 
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by more efficient simple diffusion before neo- 
vascularisation and perfusion are adequately 
established [10, 15, 16]. The slices are then cut 
in small pieces of 1 mm width and 5 mm length. 
Other groups reported variable sizes of the slices. 
There seems to be no difference in results in the 
different sizes: the most critical factor is the slice 
thinness. Slices are then placed in fresh Leibovitz 
medium until cryoprotection. 
Quality Assessment (After Dissection) 
A standard practice in centres performing ovarian 
tissue cryopreservation is to perform routine tests 
to ensure primordial follicles are present in the 
ovarian tissue slices and that they are morphologi- 
cally normal. At this stage, these tests primarily 
include light microscopy examination to assess 
the percentage of primordial follicles found in 
fresh (or pre-processed) ovarian tissue slices [10, 
17-20). Hence, a specimen should be taken dur- 
ing dissection from the ovarian cortex and sent off 
for histopathological evaluation by light micros- 
copy (x400 magnification) after fixation in 
Bouin's solution and using haematoxylin/eosin 
staining to check for the presence of follicles and 
morphology of the tissue. Samples are also tested 
using standard trypan blue viability staining 
methodology. Another specimen is placed in 4 % 
formaldehyde and sent for pathological evalua- 
tion for the presence of malignant cells, prior to 
cryopreservation. Other samples are also taken 
and stored separately for post-thaw testing before 
reimplantation in the future. All histological tests 
are ideally performed by the same specialised 
consultant pathologist using the same protocols. 
Cryoprotection 
To minimise damage due to normally lethal 
intracellular ice crystal formation and build-up 
of extracellular salt concentration, the tissue is 
quickly transferred after dissection into test 
tubes containing 8 ml of pre-cooled cryoprotec- 
tant medium and labelled. We use a mixture con- 
taining 1.5 M penetrating cryoprotectant medium 
in order to dehydrate cells and increase solute 
concentration around the cells. We use the ethyl- 
ene glycol as an effective cryoprotectant for 
ovarian tissue as was shown in several works 
[10, 11, 15). The non-penetrating sugar, sucrose 
(0.1 M) is also added to the medium since it is 
known to act as an osmotic buffer and is an 
added precaution against excessive osmotic 
swelling during cryoprotectant removal and thus 
minimises freezing injury [21). The tissue is 
incubated on a shaking plate at 2-8 °C for 
exactly one hour. Three to five tissue slices are 
then quickly transferred to cryovials with 1 ml of 
cooled cryoprotectant. The permeation of iso- 
lated cells with cryoprotectants is relatively fast, 
but diffusion through multicellular tissues such 
as ovarian cortical tissue slices is much slower 
i.e. exposure to cryoprotectant is prolonged to 
ensure adequate concentrations in the centre of 
the tissue. However, this has to be balanced with 
the fact that cells on the tissue surface may be at 
risk of excessive toxicity. Cryoprotection time 
periods should therefore be carefully stan- 
dardised and strictly adhered to. 
Freezing 
The freezing protocol of slow freezing has long 
been well established and optimised designs for 
ovarian tissue cryopreservation are very similar 
[3, 10, 14, 15]. As the temperature is cooled, ice 
crystals growth is initiated by ice crystal nucle- 
ation induction (i.e. 'seeding'). As the crystals 
grow the water in the solution is turned to solid 
state, increasing the solute concentration and this 
draws water out of the cells [22). More water can 
be incorporated into ice at lower temperatures but 
the rate at which water can leave a cell also falls as 
temperature is lowered. The effectiveness there- 
fore depends upon equilibrium between the rate at 
which water can leave a cell and the rate at which 
it is converted into ice. The rates used by our pro- 
gramme classically involve an initial cooling rate 
of approximately -2 °C/min down to -9 °C with 
then a hold for 15 min to perform 'seeding'. We 
achieve this by using long handled metal forceps 
dipped in liquid nitrogen and gripping the cryovi- 
als at the meniscus. This is followed by a 5 min 
soaking hold period. Then a slower rate of cooling 
-0.3 °C/min is programmed to reduce tempera- 
ture down to -40 °C. The final stage of the freez- 
ing program is a faster cooling stage of -10 °C/ 
min down to -140 °C. All tissue is frozen in the 
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same programmable Sylab freezer (Ice Cube) 
using the same program. 
Storage 
The cryovials containing the tissue are then sealed 
inside an additional sterile cryogenic bag, which 
is labeled and placed in a protective cardboard 
box and then transferred to liquid nitrogen storage 
into the predetermined quarantine rack position. 
Many establishments then plunge their ovarian 
tissue directly into liquid nitrogen, however, we 
prefer to store tissue in vapour phase nitrogen (at 
approximately -170 °C) rather than in liquid 
nitrogen (at-196 °C) in order to minimise risk of 
cross-contamination of tissue packaging from 
bacteria or viruses surviving in the nitrogen tank 
[23]. This does not affect the quality of tissue stor- 
age, since below -130 °C, the glass transition 
temperature of water, no biological or physical 
changes take place and therefore below this tem- 
perature tissue may be safely stored [22]. 
Thawing Out 
Thawing techniques are a standard amongst the 
different ovarian processing units [10). The rapid 
thawing process is performed within the clean 
room facility in the laboratory whilst the patient is 
in operating theatre in order to minimise ischaemic 
time. The relevant cryovials are removed from the 
nitrogen storage freezer and held in air for 30 s. 
The cryovial is then placed in a water bath at 30 °C 
for 3 min. The cryovial is then transferred to the 
cleanroom microbiological safety cabinet for 
three-stage serial dilution of the ethylene glycol, 
each stage taking 5 min and performed on a shaker 
at room temperature. The ovarian slices then 
remain in a test tube with a final mixture of 1 ml 
sucrose, 1 ml serum substitute supplement and 
8 ml Leibovitz medium. The same protocol is also 
used for all specimens used for testing. 
Post Thawing 
Quality Assessment 
Specimens of the ovarian cortex are thawed out 
approximately 1 month prior to the planned auto- 
transplantation using the same protocol as for tis- 
sue slices for clinical use. They are then sent off 
for the same histopathologic evaluation of the 
presence, viability and morphology of follicles as 
was performed following dissection, involving 
the same histological techniques and trypan blue 
staining [17-20). Published studies consistently 
show there is only minimal difference. between 
results for fresh and for frozen-thawed tissue [10, 
17]. The number of follicles counted, however, 
will depend upon age of donor [17, 22] and 
whether any previous treatment of chemo- or 
radiotherapy has been given prior to procurement 
of ovarian tissue. 
Screening for Micrometastases 
The major concern with ovarian tissue banking is 
the possibility of re-seeding a tumour, harboured 
within the ovarian slices, after auto-grafting the 
frozen thawed tissue slices. Tissue samples are 
therefore carefully screened for the presence of 
malignant cells (micrometastases) by histology 
and specific immunohistochemical or molecular 
tests such as polymerase chain reaction (PCR) 
testing and real-time PCR to detect molecular 
markers that would indicate presence of cancer 
cells [3, 6, 24). The various tumours are catego- 
rised into three groups according to their risk of 
ovarian micro-metastasis [6, 25] and this should 
be taken into account upon the initial consulta- 
tion as part of informed consent. Testing should 
be performed approximately 1 month prior to 
planned transplantation using the up-to-date 
licensed methods available at the time of re- 
implantation, thus taking advantage of the fact 
that diagnostic methods for detecting minimal 
residual disease are likely to be improving with 
time. When tissue shows evidence of malignant 
cells (i.e. any positive test result) , the patient is 
advised against future auto-transplantation of 
ovarian cortical tissue slices. Instead, in the future 
these patients may benefit from later advances 
and possible breakthroughs in the field of In Vitro 
Maturation (IVM) of ovarian tissue, in vitro mat- 
uration of follicles or isolated follicle transplan- 
tation, which probably do not pose any risk to 
transmission of tumour cells [26]. A combined 
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immature oocyte recovery for IVM, in addition to 
the ovarian tissue cryopreservation may be of 
critical importance in these patients. 
Auto-transplantation 
Auto-grafting of the tissue is done when the 
patient is in remission and old enough and ready 
to start a family. The tissue is commonly trans- 
planted in the orthotopic position 
(i.e. into its natural site such as the ovarian hilum 
or medulla or nearby structures such as the broad 
ligament or the pelvic sidewall). This has been 
shown to offer the potential for spontaneous 
pregnancy without the need for primary and 
immediate resort to IVF [10, 15, 27-29]. 
Alternatively, heterotopic transplantation ( e.g. 
non-native ectopic location such as the arm or 
abdomen) has certain advantages [9, 30, 31] such 
as easier follicular monitoring and egg retrieval 
for IVF as well as a closer monitoring for cancer 
recurrence following auto-grafting. Nevertheless, 
orthotopic transplantation has been shown to 
result in less follicle loss and more effective 
revascularisation and is believed to be more 
effective [31]. Orthotopic autotransplantation can 
be performed either by laparotomy or laparos- 
copy. Some advocate [32] performing it in two 
stages: in the first stage laparoscopy is performed 
7 days before the re-implantation procedure, aim- 
ing at creating a peritoneal window at the ovarian 
hilum, broad ligament or the pelvic sidewall. The 
goal of this procedure is to induce neovascular- 
ization and the formation of granulation tissue in 
the area where the ovarian slices are to be re- 
implanted. It is believed that by this neoangio- 
genesis, the ischemic phase after the 
transplantation is shorter. A second stage laparos- 
copy follows after about a week during which the 
ovarian slices are transplanted into the peritoneal 
furrow. The slices can either be sutured to the 
ovarian medulla or left unsutured into the perito- 
neal window. Pregnancies were reported after 
auto-grafting of varying sizes of ovarian slices 
[33] as well as after micro-organ transplantation 
of thinned ovarian slices [15]. 
Outcome of Frozen-Thawed 
Ovarian Tissue Autotransplantation 
To date more than 30 pregnancies have been 
reported after autotransplantation of ovarian cor- 
tical tissue slices mainly after orthotopic but also 
after heterotopic reimplantation [33]. From 
reviewing the accumulative experience as 
reflected in the different case series and case 
reports published so far, it is noted that it takes 
3.5-6.5 months on average after autografting of 
the ovarian tissue until signs of endocrinologic 
activity (a rise in estradiol levels and a drop in 
FSH levels) and folliculogenesis (as observed in 
ultrasound scanning) are detected. Restoration of 
ovarian activity is observed in 93 % of patients 
after autografting. The post-transplantation preg- 
nancies reported thus far included natural con- 
ceptions, ovulation induction cycles and IVF 
cycles [33]. The average duration of ovarian 
function after transplantation is 4-5 years [33, 
34] and is mainly dependent on the ovarian 
reserve before the harvesting and the absence of 
chemotherapy before cryopreservation. These 
promising results strongly suggest that ovarian 
tissue cryopreservation is a viable fertility preser- 
vation option that should be part of any oncofer- 
tility programmes. 
Challenges with Ovarian Tissue 
Preservation 
Restoration of ovarian function with hormone 
production and follicular growth has been 
observed after transplantation of frozen-thawed 
ovarian tissue [30, 35-38], and more pregnancies 
and livebirths are increasingly reported [32-34]. 
However, efforts are still needed to develop and 
optimize harvesting and grafting procedures to 
increase the success rates. A large percentage of 
the grafted follicles are lost as a result of post- 
grafting ischemia before efficient neoangiogene- 
sis networks are established. In addition, 
reperfusion-induced damage might contribute to 
this loss [39-41]. It is estimated that more than 
50 % of primordial follicles are lost following 
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ovarian transplantation due to ischemia. It takes 
4-5 days for neoangiogenesis to result in ade- 
quate perfusion and reoxygenation of the grafts. 
This delay in graft perfusion and reoxygenation 
is believed not only to lead to follicle loss, but 
also to dysregulated communication and asyn- 
chrony between granulosa cells and oocytes [42- 
44]. Basic biomedical research studying 
revascularisation of the grafts may prove impor- 
tant in improving the technique by reducing the 
ischemia period until the reconstitution of effi- 
cient vascularization and perfusion. This can 
possibly be done by delivery of angiogenic fac- 
tors like VEGF or by preparing the vascular bed 
prior to autografting procedure [33, 45-47]. 
A second important issue is the burnout effect, 
in which a relatively large amount of follicles are 
recruited and over activated as a result of reduced 
inhibitory mechanisms, such as those mediated 
by AMH. It has been shown that recovered grafts 
have higher ratios of growing to total follicles 
and higher levels of proliferation staining than 
non-transplanted control tissue [48], and this 
phenomenon was demonstrated to a greater 
degree in thinner grafts. It is hypothesized that 
disruption of the ovarian homeostasis as a result 
of the removal of follicles from their normal 
physiological environment together with the 
absence of larger follicles in the auto-grafted 
ovarian cortical strips result in a decrease in the 
production and secretion of the inhibitory signal- 
ling factor AMH , consequently leading to folli- 
cle activation and burnout [ 48]. More basic 
biomedical studies are needed to thoroughly 
understand the molecular basis and mechanisms 
involved in the burnout phenomenon and its rela- 
tive role in graft function and lifespan. 
Thirdly, some studies have demonstrated a 
risk of possibly transmitting malignant cells pres- 
ent in the cryopreserved tissue back to a patient's 
body [3, 49]. Hence, one of the most important 
concerns of ovarian tissue cryopreservation is the 
re-seeding and relapse of a tumour. The ovarian 
tissue micrometastases risk of the different types 
of cancers and their stages is classified into three 
groups: (a) the low to no risk group - e.g. Non- 
Hodgkin's lymphoma, breast cancer stage I-III, 
Ewing's sarcoma (b) the moderate risk group- 
e.g. Breast cancer stage IV, infiltrative lobular 
colon cancer, upper GI system malignancies, and 
(c) the high risk group- e.g. Leukemia, Burkitt's 
lymphoma and Neuroblastoma. 
The risk that the post-thaw tissue from these 
patients may re-seed malignant cells of the pri- 
mary tumour into the cured patient as a result of 
transplantation, should be ruled out prior to the 
autotransplantation as discussed above. 
The in-vitro culturing and growth of imma- 
ture follicles derived from ovarian slices col- 
lected prior to commencement of cancer 
treatment is an important direction for research 
to avoid the need for autografting in patients at 
high risk of cancer reseeding. The purpose of the 
in-vitro human follicle growth system is to 
mimic the in vivo process by sequentially pro- 
viding follicles with the necessary levels of the 
important growth factors and hormones at the 
right time, which can allow follicular growth and 
oocyte maturation through maintaining the 
essential connections between the two compo- 
nents of the follicle compartment [50, 51]. 
Successful in-vitro culturing and maturation of 
the ovarian tissue or isolated follicles to produce 
mature follicles and competent oocytes that 
could be subsequently fertilized to produce 
embryos would provide a safe fertility preserva- 
tion option. Currently this field is the target of 
intensive research and in the foreseeable future it 
cannot be offered to patients 
Conclusion 
Ovarian tissue cryopreservation is a feasible 
option to preserve ovarian function and future 
fertility in children, premenarchal girls as well 
as young women before they undertake 
gonadotoxic chemotherapy and/or radiother- 
apy. To date more than 30 pregnancies have 
been reported after autotransplantation of 
ovarian cortical tissue slices in young women. 
However, there are still several challenges to 
meet and further intensive research is needed 
to assess the clinical effectiveness of ovarian 
cryopreservation, to optimise the technique 
and increase its safety. 
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Key Practice Points 
1. Ovarian tissue cryopreservation can 
offer an alternative to ovarian stimula- 
tion and oocyte harvesting when cancer 
treatment cannot be delayed. 
2. Recent evidence suggests that vitrifica- 
tion may be superior to slow freezing of 
ovarian tissue. 
3. Thawed ovarian tissue should be tested for 
rnicrometastasis prior to transplantation. 
4. Transplantation of ovarian tissue may 
be orthotopic or heterotopic. 
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A B S T R A C T
Objectives: To determine response to controlled ovarian stimulation in a random start cycle and
utilisation of cryopreserved oocytes and embryos in cancer patients.
Study Design: A retrospective cohort study was carried out in an assisted reproductive treatment centre.
Participants included 137 cancer patients who underwent controlled ovarian stimulation for fertility
preservation between 1 Feb 2003 and 30 June 2016. The primary outcome variable was number of
oocytes retrieved. Multivariable logistic regression analysis was performed, and differences compared
using Chi squared test and student t-test as appropriate. P < 0.05 was considered statistically significant.
Results: Using the antagonist protocol, there was no difference in number of oocytes retrieved between
the early follicular phase or at random start stimulation; 11.9 (95% CI 10.3–13.5) and 12.9 (95% CI 9.6–
16.2), P = 0.602, respectively. Similarly, the number of embryos frozen was comparable between those
starting stimulation in early follicular and random phase, 6.7 (95% CI 5.7–7.7) and 5.1 (95% CI 3.6–6.5), P=
0.1508 respectively. Among patients undergoing fertility preservation, those who returned to attempt a
pregnancy had an ongoing pregnancy rate of 24.3%. Overall, 65% of oocytes and embryos were still in
storage, however, 16 (11.7%) had elected to have their oocytes or embryos disposed of.
Conclusion(s): For women faced with potential gonadotoxic treatment and requiring urgent fertility
preservation, ovarian stimulation with the antagonist protocol can be started at random without
compromising ovarian response. Pregnancy rates following utilisation of frozen-thawed oocytes and
embryos are promising, however, more research is needed to understand reasons underlying disposition
of oocytes and embryos especially when survival following cancer treatment has improved significantly.
© 2018 Elsevier B.V. All rights reserved.
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Over the past few decades developments in cancer treatment
protocols have resulted in improved long-term survival of cancer
patients, however, due to their variable gonadotoxicity these
treatments may leave some survivors with severely compromised
ovarian function [1]. Several studies show that women of
reproductive age would like the opportunity to discuss fertility* Corresponding author at: University of Oxford, Nuffield Department of
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0301-2115/© 2018 Elsevier B.V. All rights reserved.implications of their cancer diagnosis and treatment [2]. Although
an increasing number of oncologists discuss fertility implications
with patients, the overarching urgency to treat cancer implies that
not all patients have the opportunity to explore fertility preserva-
tion [3]. Uniquely for women with hormone receptor positive
breast cancer there is the additional challenge of having to take the
anti-oestrogen tamoxifen for several years during which pregnan-
cy is contraindicated. Since natural fertility declines with age, any
compromise in ovarian function may only become apparent when
trying for a pregnancy years later after completing tamoxifen
therapy [4,5].
Opportunities for fertility preservation prior to gonadotoxic
treatment include: vitrification of oocytes and/ or embryos,
ovarian tissue cryopreservation and concomitant administration
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chemotherapy [6]. Offering a combination of these methods is
recommended as a means of maximizing patients’ chances of
future fertility, rather than choosing one only. Cryopreservation of
oocytes or embryos requires a woman undergoes a cycle of
controlled ovarian stimulation using either of various protocols [7].
The long agonist protocol is less favoured now as it requires a
longer duration of treatment due to initial pituitary down-
regulation and has a higher risk of ovarian hyperstimulation
syndrome (OHSS) [8]. Conversely, the antagonist protocol is devoid
of initial pituitary down regulation and has a lower risk of OHSS,
rendering it the preferred protocol for fertility preservation
programmes [9].
Initiation of ovarian stimulation usually starts in the early
follicular phase of the menstrual cycle based on the long-held view
that recruitment of selectable follicles happens in this phase.
However, observations made in animals as well as humans
challenge this theory by demonstrating a continuous growth of
antral follicles throughout the oestrous/menstrual cycles [10–12].
This was the basis of reports indicating that ovarian stimulation
started in the luteal had a comparable number of mature oocytes
and embryo development to early follicular start [13]. This enabled
development of random start ovarian stimulation protocols for
cancer patients who require urgent treatment [14]. The described
random-start protocols are complex therefore there is a need for a
more simplified approach.
This study aimed to establish whether response to controlled
ovarian stimulation was comparable between random start, early
follicular and luteal phase antagonist cycles in women needing
urgent fertility preservation using a simplified protocol. Secondary
outcomes included adverse events and the outcome of cryopre-
served oocytes and/ or embryos.
Materials and methods
Study population
We undertook a comprehensive analysis of clinical data that is
prospectively entered and stored in a database (Paradox, Borland,
Scott Valley, CA, USA) at Oxford Fertility. All patients recently
diagnosed with cancer and referred for fertility preservation
between Feb 1, 2003 and June 30, 2016 were included in this
retrospective cohort study. Approval was sought from the
University of Oxford Central University Research Ethics Commit-
tee.
Treatment protocol
After a fertility specialist medical consultation, patients attend
nurse treatment planning appointment as soon as possible.
Treatment initiation starts immediately after this planning on
the agreement of the oncologist.
The conventional antagonist protocol at Oxford Fertility during
the period of the study was as follows. On day two to five of the
menstrual cycle, daily ovarian stimulation with gonadotrophin
(recombinant gonadotrophin alpha - Gonal F1, Serono Pharma-
ceuticals Ltd., Feltham, UK; Puregon1, Organon Laboratories Ltd.,
Hoddesdon, UK, or Menopur1, Ferring Pharmaceuticals Ltd., West
Drayton, UK) was commenced. After five days of stimulation,
cetrorilex acetate 250-mcg subcutaneous injection (Cetrotide1,
Serono Pharmaceuticals Ltd, Feltham, UK) was introduced and
continued until human chorionic gonadotrophin or buserelin for
final oocyte maturation was administered. Monitoring follicle
development with transvaginal ultrasound scanning and serum
oestradiol started after the sixth day following the initiation of
stimulation. When at least three follicles measuring 18 mm wereseen on ultrasound scan, human chorionic gonadotropin (hCG)
6500 IU (Ovitrelle1; Serono Pharmaceuticals Ltd., Feltham, UK) or
buserelin 0.5 mg was administered subcutaneously for final oocyte
maturation 37 h prior to oocyte-cumulus complex retrieval. The
practice was to aspirate from all follicles measuring 12 mm.
Oocytes were then stripped clear of the cumulus cells within two
hours of oocyte retrieval for women choosing oocytes vitrification,
whereas those opting to freeze embryos micro-injection of oocytes
with sperm was done after four hours. Fertilisation check followed
16 h from oocyte microinjection.
The random start protocol was used if stimulation started at any
point after menstrual day five. It involved administration of
cetrorilex acetate 250 mcg (Cetrotide1, Serono Pharmaceuticals
Ltd, Feltham, UK) for three days followed by ovarian stimulation
with gonadotrophin from the fourth day. The cetrorilex acetate was
continued together with the gonadotrophin stimulation until
ovarian response was deemed appropriate for HCG or buserelin
administration as described above. Follicle growth monitoring was
as for the conventional antagonist protocol starting after six days of
stimulation.
Gonadotrophin dose determination
The starting dose of gonadotrophins was based on female age,
body mass index (BMI), antral follicle count or anti-Mullerian
hormone (AMH) concentration. Patients were stimulated on a dose
ranging from 150 IU to 375 IU of Gonal-F1 or Menopur1.
Outcome measures
The primary outcome measure was the number of oocytes
retrieved per started cycle. We also analysed the duration from
referral to oocyte retrieval; starting and total dose of gonadotro-
phin; duration of ovarian stimulation; number of follicles
measuring 15 mm and peak oestradiol concentration at the time
of HCG or buserelin trigger; number of fertilised oocytes and
number of oocytes or embryos put in storage. For the oocytes and
embryos cryopreserved, we computed those remaining in storage
at the time of our analysis and determined fate of the rest. We also
assessed immediate complications following oocyte retrieval.
Statistical analysis
For categorical variables, we calculated percentages and
compared differences using the Chi-squared or Fisher's exact test
as appropriate. For the continuous variables, we calculated their
mean and compared differences using the Students t-test. All
statistical analysis was performed in statistical software STATA1




We reviewed 137 records of patients who presented for fertility
preservation prior to starting gonadotoxic treatment between
February 1, 2003 and June 30, 2016. Nine of these had the long
agonist protocol and were excluded from analysis of the main
outcome variables. The remaining 127 women were on the
antagonist protocol (103 in the conventional start group and 24
in the random start group). The baseline characteristics of the
women on the antagonist protocol are shown in Table 1. There
were no statistically significant differences in baseline character-
istics of women in the two treatment groups. The mean age for




N = 103 (95% CI)
Random start protocol
N = 24 (95% CI)
Age (years) 32.6 (31.4–33.6) 30.5 (28.3–32.8)
FSH (IU/L) 6.6 (4.9–8.1) 5.9 (1.2–10.5)
AFC 16.4 (14.5–18.3) 19.3 (14.9–23.6)
AMH (pmol/L) 18.6 (12.0–25.1) 13.0 (4.6–21.4)
BMI (kg/m2) 23.5 (22.7–24.1) 23.6 (21.1–26.1)
Number of children 0.17 0.16
Legend: AFC (antral follicle count); AMH (anti-Mullerian hormone); BMI (body
mass index); FSH (follicle stimulating hormone).
Table 3
Adverse treatment outcomes.
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count and AMH) were comparable between the groups. Fig. 1
shows the proportion of various cancer diagnoses for the complete
cohort of 137 women. Breast cancer was the commonest
underlying referral for fertility preservation.
Main outcome variables
To determine any differences between conventional and random
start cycles using the antagonist protocol, we excluded the long
agonist cycles from the main analysis. A total of 127 antagonist cycles
were included in the outcomes as shown in Table 2.
There was no statistically significant difference between the
conventional and random start cycles in the number of oocytes
retrieved 11.9 (95% CI 10.3–13.5) and 12.9 (95% CI 9.6–16.2); P =
0.602. Additionally, there was no statistically significant difference
for average numbers of embryos frozen per cycle between the two
groups at 6.7 (95% CI 5.7–7.7) and 5.1 (95% 3.6–6.5); P = 0.151,
respectively. It took an average of one month from the date of
oncologist referral to the oocyte retrieval in all the groups. This is
likely due to an over-representation of breast cancer patients who




N = 103 (95% C
Oncology referral -OCR (days) 33.5 (27.9–38
Duration of stimulation (days) 11.5 (11.2–12.
Total dose of FSH (IU) 2543.4 (2328
Number of follicles 15 mm or greater at HCG trigger 9.06 (8.04–10
Oestradiol at HCG trigger (pmol/L) 5426.3 (4682
Number of oocytes 11.9 (10.3–13.
Number fertilised 7.2 (6.1–8.3) 
Number frozen 6.7 (5.7–7.7) 
Legend: FSH (follicle stimulating hormone); HCG (human chorionic gonadotropin); OC
a Denotes reason for admission to hospital, this is not one of the listed complicationdifference between the two groups in other cycle characteristics
during controlled ovarian stimulation as shown in Table 2. For
women who had controlled ovarian stimulation on the antagonist
protocol, 91.3% in the conventional and 83.3% in the random start
groups opted to cryopreserve embryos while the rest vitrified
oocytes (data not shown).
We reviewed the adverse events that occurred during
controlled ovarian stimulation, oocyte retrieval and up to six
weeks following completion of the treatment cycle. These included
cycle cancellation, OHSS, complications of oocyte retrieval (such as
bleeding, infection or perforation of visceral structures) or no
oocytes and/or embryos available to freeze. As these events were
rare, we analysed them according to major cancer diagnostic
categories as the urgency of treatment since diagnosis may be
different. There were four cycles without oocytes or embryos
available for cryopreservation, including one cycle cancelled prior
to oocyte retrieval. Only two cases of moderate OHSS were
recorded while one woman was admitted with leg pain, however, a
diagnosis of deep venous thrombosis was ruled out, Table 3.
We also looked to determine the fate of oocytes and embryos in
cryo-storage for all the treatment cycles as this was independent of
ovarian stimulation protocol. Of the 137 women who underwent
fertility preservation, 89 (65%) patients had oocytes or embryos
still in storage at the time of review. Fifteen patients had returned
to the clinic for oocytes or embryos thaw-transfer in 37 treatment
cycles. This resulted in 29.7% (11 of 37) implantation rate and 24.3%
(9 of 37) ongoing pregnancy rate. Due to a variety of unknown
reasons sixteen women had given consent to discard embryos from
storage while three had their oocytes or embryos transferred
elsewhere. Sadly, eleven women were deceased, representing eight
percent of all patients (data not shown) (Fig. 2).I)
Random start
N = 24 (95% CI)
P valuea
.9) 33.9 (24.8–42.8) N/S
0) 12.2 (10.7–13.7) N/S
.3–2758.5) 2811.9 (2090.8–3533.1) N/S
.1) 10.6 (8.6–12.6) N/S
.9–6169.7) 4423.1 (2866.9–5979.3) N/S
5) 12.9 (9.6–16.2) N/S
5.9 (4.3–7.6) N/S
5.1 (3.6–6.5) N/S











No 71 15 4 36
Yes 1 0 0 0
OHSS
None 71 14 4 34
Mild 0 1 0 1
Moderate 1 0 0 1
Complications (bleeding/infection/other)
No 71 15 4 36
Yes 1a 0 0 0
Nothing to freeze
No 69 15 4 35
Yes 2 0 0 1
a Admitted with leg pain. OHSS (ovarian hyperstimulation syndrome).
Fig. 2. Fate of cryopreserved oocytes/embryos.
C. Muteshi et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 230 (2018) 10–14 13Comment
Controlled ovarian stimulation for oocyte or embryo cryopres-
ervation is an established technique for fertility preservation in
cancer patients [3]. Conventionally, ovarian stimulation is started
in the early follicular phase of the menstrual cycle. Women
diagnosed with cancer and faced with potential gonadotoxic
treatment present for fertility preservation at various times in their
menstrual cycle. Waiting for the follicular phase to start ovarian
stimulation may pose a significant delay in commencing cancer
treatment. Our study demonstrates that ovarian stimulation using
the antagonist protocol in a simplified random start protocol is
comparable to the early follicular phase start.
These findings are similar to those of previous case control
studies in which women underwent ovarian stimulation on the
antagonist protocol starting either in the early follicular phase, late
follicular phase or the luteal phase of the menstrual cycle for
fertility preservation [13,15]. While these authors found that
stimulation started randomly or in the luteal phase took longer
than when started in the early follicular phase, our study showed
no statistically significant difference in the duration of stimulation
and total gonadotrophin dosage used.
Our study confirms the observation that follicular recruitment
can be initiated at any point in the menstrual cycle and further
debunks the long-held view that this is limited to the early
follicular phase [11]. Baerwald et al. demonstrated that follicular
recruitment could be initiated at any point in the menstrual cycle
when they observed multiple waves of follicular activity in both
the luteal and follicular phase of women’s menstrual cycles [12].
For women diagnosed with cancer there is often a necessity to start
and complete controlled ovarian stimulation within tight time
frames and waiting for the early follicular phase may lead to
unwarranted delay or foregoing of the only opportunity available
for fertility preservation.
Previous studies reported on luteal phase stimulation using the
antagonist protocol with results comparable to stimulation started
in the early follicular phase [16–18]. However, women presenting
after the early follicular phase had to wait for the luteal phase to
start ovarian stimulation. This dilemma was overcome as described
by a case series of women with breast cancer where emergency
stimulation starting on days 11, 14 and 17 resulted in an acceptable
number of oocytes and embryos available for cryopreservation
[13]. Subsequently, case controlled studies confirmed that random
start stimulation protocols have comparable outcomes to those of
the conventional follicular or luteal phase stimulation [14,19].
There are complex variations in the methodologies for the luteal
and late follicular start cycles as reported in these studies as well as
the earlier reported luteal phase start cycle. In the Cakmak et al.
study for instance late follicular phase stimulation was started if noleading follicle of greater than 12 mm was present, and the
antagonist introduced when the follicle cohort reached 12 mm. If
there was a larger follicle, ovulation was induced with HCG or
GnRH agonist followed by gonadotrophin stimulation two to three
days later [14]. Whereas Kim et al. started ovarian stimulation on
the day of presentation regardless of the cycle day [19]. In another
study the authors reported that women with a formed corpus
luteum were given the GnRH antagonist to suppress LH activity and
induce luteolysis followed by ovarian stimulation simultaneously
or after three days [15]. These differences between the random and
luteal start protocols are complex, prone to cause confusion among
clinicians and burdensome to patients.
Controlled ovarian stimulation and oocyte retrieval are not
without risk, and cancer patients are in a particularly precarious
position due to time constraints [20,21]. The commonest and
serious complication of these procedures is OHSS which occurs in
around 0.6–5% of cycles and may lead to prolonged hospitalisation
and rarely mortality [22]. Using the antagonist protocol together
with GnRH agonist trigger for final oocyte maturation may reduce
the risk by nearly 80% [23]. There were only two cases of moderate
OHSS in our study representing 1.6% of the cohort of patients.
Whereas the risk of OHSS is significantly reduced with the GnRH-a
trigger for final oocyte maturation, there remains a risk of empty
follicle syndrome and our practice is to give HCG trigger if there are
than fifteen follicles 15 mm and oestradiol level is not higher than
15,000 pmol/L [9,24]. Equally as important is the risk of poor
response resulting in cycle cancellation or no oocytes/ embryos
available for cryopreservation. In a large dataset of 52,676 routine
IVF cycles, 6.7% were cancelled due to poor ovarian response [25].
This is devastating for a woman who has a singular opportunity for
fertility preservation. In our study, four women (3.1%) who
underwent ovarian stimulation had no oocytes or embryos
available to freeze due to poor response to ovarian stimulation.
While fertility preservation with oocyte or creating embryos may
be the golden opportunity for a woman to have biological children,
realistic counselling and informed decision making, including
information about other available methods should be at the centre-
stage of the fertility consultation. Using accurate biomarkers of
ovarian reserve such as antral follicle count or AMH will inform
women of the risk of anticipated poor response, however, this
ought not be grounds to deny treatment [25]. We were unable to
establish the number of women who may have considered other
options such as ovarian tissue cryo-preservation or use of GnRH-
agonist co-treatment as the unit is a standalone referral centre for
assisted reproductive treatment.
Women diagnosed with cancer hope for long-term survival
and consider starting a family in future [26]. This is mainly due to
early diagnosis and improvement in treatment protocols wit-
nessed in recent times [5]. It is reassuring also to note that
pregnancy does not affect the prognosis after cancer treatment
[27,28]. Experience about the use of cryopreserved oocytes or
embryos in women with cancer is limited, however, initial case
reports are reassuring with good outcomes [28]. Generally, the
interval from end of cancer treatment to attempting pregnancy
should be a balance between the end of fetal exposure to
anticancer drugs and the beginning of the lowest risk period for
disease recurrence. Whereas there is reassuring evidence to
suggest women with breast cancer embarking on pregnancy do
not have a worse prognosis, still concerns in breast cancer
survivors exist, with nearly 30% choosing pregnancy termination
[29,30]. Perhaps unsurprisingly, while the majority of women in
our study had breast cancer, only two of the fifteen women who
attempted a pregnancy had this form of the disease. Additionally,
although for various unknown reasons, 12 of the 16 women (75%)
who gave consent to discard their cryopreserved embryos had
previously had breast cancer.
14 C. Muteshi et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 230 (2018) 10–14Our study benefits from a comprehensive database and complete
follow-up of all the cryopreserved gametes or embryos due to the
requirement of the Human Fertilisation and Embryology Authority
that all patients treated in a licensed centre have their treatment and
outcome registered with th authority [31]. Although our study
demonstrated no statistically significant difference in ovarian
stimulation outcomes between the random start and early follicular
phase stimulation in antagonist cycles, the conclusions should be
taken with caution for lack of power calculation and being
retrospective in design. In addition, there may be inherent differ-
ences in response to ovarian stimulation between various cancer
typeswhichwewereunabletodemonstrate.Forexample, ithasbeen
shown that women with lymphoma or BRAC-1 gene mutation have
reduced ovarian reserve [32]. More studies to determine live birth
rate are needed as this is the ultimate outcome for fertility
preservation. It would also be important to explore factors
surrounding decisions to utilised cryopreserved oocytes or embryos.
In conclusion, we have demonstrated that for women faced
with potential gonadotoxic treatment and requiring urgent fertility
preservation, ovarian stimulation using the antagonist protocol
and started randomly has similar ovarian response and outcomes
regardless of the timing in the menstrual cycle. The goal of fertility
preservation is to achieve a live birth outcome; therefore, more
studies are needed urgently to inform the scientific community the
fate of cryopreserved oocytes or embryos and reasons that behind
decisions for use or non-use.
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Grade of the inner cell mass, but not trophectoderm, predicts live birth in
fresh blastocyst single transfers
Jessica Subiraa, Jo Craiga, Karen Turnera, Aysha Bevana, Eric Ohumab, Enda McVeigha, Tim Childa and
Muhammad Fatuma
aNuffield Department Obstetrics and Gynaecology, Oxford Fertility Unit, Institute of Reproductive Sciences, University of Oxford,
Oxford, UK; bNuffield Department Obstetrics and Gynaecology, University of Oxford, Oxford, UK
ABSTRACT
Debate continues over which morphological parameter is most important in selecting blastocysts
for transfer. We aimed to investigate which parameter more accurately predicts the occurrence
of a live birth by designing a retrospective cohort study of 1084 fresh elective single blastocyst
transfers. Primary outcome was live birth rate (LBR) and secondary outcomes were implantation,
clinical pregnancy and early pregnancy loss rates. Blastocyst expansion and inner cell mass (ICM),
but not trophoectoderm, were associated with LBR in the definitive multivariable regression ana-
lysis. When ICM grade dropped from A to C the likelihood of achieving a live birth was reduced
by 55% (OR¼ 0.45, 95% CI 0.26-0.79, p¼ 0.005). These results were similar for clinical pregnancy
rates. Early pregnancy loss rates of embryos with ICM grade C were more than double (38.0%)
compared to those of grades A (15.95%) and B (17.17%, p¼ 0.002). The transfer of an embryo
with an optimal inner cell mass reduces early pregnancy loss and increases the likelihood of a
live birth. We did not find any significant association between trophectoderm and LBR in the
multivariable analysis in contrast with recent studies.
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Blastocyst culture is a worldwide accepted technique
that improves implantation and pregnancy rates by
selecting the most viable embryo (Gardner et al., 1998;
Veeck et al., 2004). In addition, blastocyst transfer is
argued to improve synchronicity between embryo and
endometrium by mimicking what would happen
within a natural conception. Based on these facts, the
possibility of elective single blastocyst transfer became
a reality in the last decade allowing the maintenance
of high pregnancy rates while keeping the risk of mul-
tiple pregnancies to a minimum in selected patients.
Morphological blastocyst grading system proposed
by Gardner and Schoolcraft (1999) has been repeatedly
validated and remains the most accepted and used
morphological method to select the blastocyst(s) with
the higher potential of implantation throughout the
IVF community (Balaban et al., 2000; Gardner, Lane,
Stevens, Schlenker, & Schoolcraft, 2000; Gardner et al.,
2004). This system relies on three morphological fea-
tures within the blastocyst development including the
grade of expansion, the inner cell mass (ICM) and the
trophectoderm (TE). Each blastocyst is graded accord-
ing to this system leading to a number from one to
six (degree of expansion) followed by two letters (A, B
or C) to score ICM and TE, respectively, based on the
size and compactness of its cells (Gardner et al., 1998).
With more uniform consensus about the critical
importance of blastocyst expansion on outcome, sev-
eral studies have tried to identify the individual contri-
bution of each, ICM and TE grades, to the
implantation potential of blastocysts aiming to facili-
tate even more selection of similar grade blastocysts.
However, the conclusions that can be drawn from
these studies remain, to some extent, contradictory,
with a good number of recent studies pointing in the
direction of the TE as the strongest predictor of clinical
pregnancy. Clearly, no consensus has yet been
achieved on this matter. Therefore, there is still a need
for more evidence on this topic, as the question
remains unanswered.
To add evidence to this ongoing debate, we
designed a retrospective cohort study to further inves-
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tigate the correlation between blastocyst morphology
parameters and live birth and clinical pregnancy rates
as well as the individual contribution attributable to
each parameter.
Materials and methods
Study design and patients
The study obtained ethical approval by the
Institutional review board of Oxford University (MSD-
IDREC-C1-2014-055). From January 2009 to June 2012,
1084 single fresh blastocyst transfer cycles were per-
formed at the Oxford Fertility Unit. All patients were
between 20 and 38 years of age, as above this age a
double embryo transfer is routinely recommended to
all patients according to our protocols. We included all
grades of expansion but we did not include blastocyst
transfers on day 6 of development or frozen cycles for
consistency as differential endometrial and embryo-
logical factors could have interfered with the outcome.
There were no other exclusion criteria based upon
clinical characteristics. Thus, in total, 1084 patients
with a single fresh blastocyst transfer were included
for analyses.
Stimulation protocol
A long GnRH agonist protocol was used for all patients
apart from those with a diagnosis of polycystic ovarian
syndrome (PCOS). For these patients, a short GnRH
antagonist protocol was used to reduce the risk of
ovarian hyperstimulation syndrome (OHSS). Briefly,
patients were started on midluteal phase of previous
cycle with nasal nafarelin acetate 800mcg a day
(SynarelVR , Pfizer, Sandwich, UK) or buserelin 500mcg
daily administered subcutaneously (SuprefactVR , Sanofi,
Guildford, UK) which were continued until the day of
human chorionic gonadotropin (HCG) after reduction
to 400mcg or 250mcg a day, respectively, once
down-regulation was achieved. The daily gonadotropin
administered was either human menopausal gonado-
tropin (MenopurVR , Ferring Pharmaceuticals, West
Drayton, UK) or recombinant FSH (Gonal-fVR , Merck
Serono, Feltham, UK). A fixed GnRH Antagonist proto-
col was used with the introduction of Cetrorelix
250mcg a day subcutaneously (CetrotideVR , Merck
Serono, Feltham, UK) on day 4 of controlled ovarian
stimulation (COS).
Serial ultrasound scans to track follicular growth
were performed until at least 3 follicles18mm were
observed, when final oocyte maturation was achieved
with choriogonadotrofin alfa 6500 IU subcutaneously
(OvitrelleVR , Merck Serono, Feltham, UK). The oocyte
retrieval was performed 35 h later transvaginally under
conscious sedation and ultrasound guidance. Oocytes
were either inseminated or microinjected according to
sperm parameters and following standardized proto-
cols. Fertilization checks occurred 15-18 h later.
Embryo culture and blastocyst grading
Embryos were initially cultured in cleavage medium
(Sydney IVF cleavage medium, K-SICM-100, CookVR )
before being moved to blastocyst medium on day 3
(Sydney IVF blastocyst medium, K-SIBM-50, CookVR ).
Embryos were cultured individually in 50ll drops, nor-
mally with 4 embryos per dish and 2 wash drops.
Oxygen and CO2 concentration were 5 and 6%,
respectively.
Embryo development was assessed on day 2 and
again on day 3 after fertilization. Culture to and
embryo transfer on Day 5 required 3 embryos to be
at the 7–8 cell stage, normally with a combined score
for blastomere size and fragmentation of 6 according
to the Cleavage Stage Grading System (Cutting et al.,
2008). The classification of Gardner and Schoolcraft
(1999) was used to classify the blastocysts. All our
embryologists are trained and use this classification on
the daily clinical practice. Briefly, the expansion stage
was assessed as one of the following: (1) an early
blastocyst, blastocoele being less than half volume of
that of the embryo; (2) a blastocyst with a blastocoele
whose volume is half of, or greater than half of that of
the embryo; (3) a full blastocyst with a blastocoele
completely filling the embryo; (4) an expanded blasto-
cyst with a blastocoele volume larger than that of the
full blastocyst, with a thinning zona; (5) a hatching
blastocyst with the TE starting to herniate through the
zona; and (6) a hatched blastocyst, in which the
blastocyst has completely escaped from the zona. For
blastocysts with expansion stage 3 or above, ICM
grade and TE grade were evaluated. The ICM was
assessed as one of the following: (A) tightly packed,
many cells; (B) loosely grouped, several cells; and (C)
very few cells. The TE was assessed as one of the fol-
lowing: (a) many cells forming a cohesive epithelium;
(b) few cells forming a loose epithelium; and (c) very
few, large cells.
Embryos were selected for transfer prioritising
expansion above the other parameters (expansion
grade 3). When multiple expanded blastocysts were
available, a combination of the ICM and TE grades was
used to select the embryo (Aa>Ab> Ba> Bb>… ). If
there were multiple good quality blastocysts with simi-
lar grades then the day 3 grade and the early cleavage
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information was taken into consideration to make the
final decision.
Embryo transfer and pregnancy testing
Ultrasound-guided embryo transfer was performed on
Day 5 of embryo development. Luteal phase support
was started on the day after oocyte retrieval with
400mg/12 h of progesterone administered in the form
of vaginal pessaries (CyclogestVR , Actavis, Barnstaple,
UK) and continued until a urinary pregnancy test was
performed.
The urinary pregnancy test was provided to the
patients who were asked to perform it 11 days after
the embryo transfer and telephone the unit to com-
municate the results. If positive, an ultrasound scan to
evaluate viability was arranged at 6 and 8 weeks of
gestation. For ongoing pregnancies, patients were dis-
charged at 8 weeks of pregnancy after confirming via-
bility with an ultrasound scan and were asked to
contact the unit with the final outcome of the preg-
nancy as required by the Human Fertilisation and
Embryology Authority.
Outcomes
The primary outcome measured was live birth rate,
defined as the birth of a live new-born above 24
weeks of pregnancy. Secondary outcomes included
implantation and clinical pregnancy rates; this latter
defined by the presence of fetal heart activity on ultra-
sound scan at 7 weeks of gestation. Implantation was
defined by a positive pregnancy test (bHCG >25 mIU/L
in urine). Early pregnancy loss was defined as the loss
of the pregnancy before the diagnosis of fetal heart
activity via ultrasound assessment. Clinical and treat-
ment related characteristics were recorded for all
patients including female age, BMI, infertility diagnosis,
type of controlled ovarian stimulation (COS) protocol
used, total dose of gonadotropins, number of eggs
retrieved and fertilization rate.
Statistical analysis
Data were checked for completeness and missing val-
ues and data explorations were performed graphically
using scatter, histograms, and box plots and also by
running frequency checks and descriptive statistics. A
Chi-square test and Fisher’s exact test (when the total
per cell is less than 5) were used where appropriate to
assess associations between any two important varia-
bles. The proportions test was used to evaluate differ-
ences between two categories. Associations between
live birth rate, implantation rate, clinical pregnancy
rate, and early pregnancy loss rate as outcomes and
embryo stage, inner cell mass grade, and trophecto-
derm grade as predictors were performed separately
in a univariable logistic model. Further, for each of the
outcomes, we performed a multivariable logistic
regression analyses adjusting for embryo stage, inner
cell mass grade, trophectoderm grade and maternal
age. All these factors were first considered in a univari-
able logistic model and only variables that were sig-
nificant at the 5% level were further considered and
included in the multivariable logistic model. All statis-
tical significance was assessed at the 5% level of sig-
nificance (p value <0.05). All analyses were analysed
using STATA 12 (StataCorp, College Station, TX).
Results
A total of 1084 patients were included in the analysis
and the median age of the study population was 33.3
years (IQR: 31.0–35.3) and median BMI of 23.0 (IQR:
21.0–25.5). The median number of eggs retrieved was
13 (IQR: 9–17), fertilization rate was 75% (IQR:
63.6–85.7) and median total number of embryos
obtained was 8 (IQR: 6-11). Live birth rate was 45.94%
with only 0.92% of live births related to twin pregnan-
cies and there were no high-order multiple pregnan-
cies. The overall implantation rate for the cohort was
64.02% and the overall clinical pregnancy rate was
51.66% with 15 multiple pregnancies among these
(2.68%). Of those who had a successful implantation,
19.31% experienced an early pregnancy loss. There
were 87 (12.54%) miscarriages after the diagnosis of
clinical pregnancy (fetal cardiac activity), 3 ectopic
pregnancies (0.43%), 2 stillbirths (0.28%) and 7 termi-
nations related to fetal pathology (1%).
Table 1 compares the baseline and treatment char-
acteristics of patients who achieved a live birth and
patients who did not. There were no significant differ-
ences among them. Figure 1 shows the number of
embryo transfers performed according to blastocyst
degree of expansion. There were no embryo transfers
of hatched blastocysts (grade 6) as we did not include
embryo transfers performed on day 6 of development.
A live birth was 3.4 (OR¼ 3.48, 95% CI 1.15–10.50,
p¼ 0.027) and 2.5 (OR¼ 2.58, 95% CI 1.24–5.35,
p¼ 0.011) times more likely to occur for hatching
embryos and fully expanded blastocysts, respectively,
when compared to early blastocysts in a univariable
logistic regression. Regarding ICM, grade C resulted in
a 60% less likelihood of a live birth when compared to
grade A (OR 0.39, 95% CI: 0.23–0.66, p¼ 0.001). The
reduction in the ICM from A to B appears not to affect
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the live birth in a significant manner according to our
study (OR 0.78, 95% CI 0.58-1.04, p¼ 0.099). This is sig-
nificant though when a more important drop in the
quality of the ICM occurs (from A to C). For TE, the
association with LBR was significant for TE grade c
(OR 0.53, 95% CI: 0.33–0.84, p¼ 0.007) when compared
to grade a. Similar results were observed for CPR
(Table 2).
We performed a multivariable logistic regression to
confirm these preliminary results in two separate
models. On the first one and after adjusting by age,
LBR according to blastocyst expansion was analyzed
(Table 2). The association remained significant for all
grades of expansion, except for cavitating or grade 1
embryos, probably because the number of cases
included was comparatively small (n¼ 12) compared
to the other groups of expansion. We then designed a
second model to investigate ICM and TE after adjust-
ing by age. For LBR, the only predictor that remained
significant was ICM grade C (OR¼ 0.45, 95% CI:
0.26–0.79, p¼ 0.005). Thus, the inner cell mass grade C
was the only one that showed a statistically significant
association with LBR and CPR when compared to
grade A, by reducing the likelihood of a live birth
occurring by 55%. There were no significant associa-
tions between TE and LBR or CPR (Table 2). Of note,
because of multicollinearity, derived from the intrinsic
association between blastocyst expansion and ICM
and TE grades, it was not possible to introduce all
three parameters on the same multivariable regression
model.
Replicating the interesting analysis performed by
Hill et al. (2013) we created different categories of
combinations of grades between ICM and TE. The
most prevalent combination was Bb accounting for
529 transfers (51.36% of all the transfers with grade 3
or higher). Preliminary analysis did suggest an associ-
ation between combinations of grades between ICM
and TE (Aa, Ab, Ba… ) with LBR (Chi-square p¼ 0.011).
There was no statistical difference with a drop in the
TE grade from a to b when the ICM remained
unchanged (p¼ 0.710). A drop in the ICM grade from
A to B with the TE remaining unchanged also showed
no effect (p¼ 0.644) on the LBR. The results were simi-
lar for CPR and IR.
Early pregnancy loss rates were found to be signifi-
cantly correlated with embryo stage (p value¼ 0.001)
and ICM grade (p value¼ 0.002) but not with TE grade
(p value¼ 0.668). Early pregnancy loss rates of
embryos with grade C ICM were more than double
(38.00%) compared to those of grades A (15.95%) and
B (17.17%, p¼ 0.002).
Discussion
Our study confirms an association between blastocyst
expansion and live birth rates in the multivariable ana-
lysis, which has been repeatedly corroborated on all
the studies published about the topic (Gardner et al.,
2000; Shapiro, Harris, & Richter, 2000; Thompson,
Onwubalili, Brown, Jindal, & McGovern, 2013; Van den
Abbeel et al., 2013; Yoon, Yoon, Son, Im, & Lim, 2001).
In contrast with the most recent published studies
Figure 1. Distribution of embryo transfers performed accord-
ing to embryo stage.
Table 1. Summary of baseline and treatment characteristics in






Patient and cycle characteristicsa
Age (years) 32.99 32.75 0.21
BMI (kg/m2) 23.57 23.59 0.92
Total number of gonadotropins units used 1915.26 2028.14 0.59
Total number of eggs collected 13.56 13.86 0.43
Type of protocol usedb
Antagonist protocol 32 18
Long agonist protocol 554 480 0.15
Infertility diagnosisb
Combined male/female infertility 107 96
Endometriosis 23 27
Previous failed donor insemination 2 1
Male factor 141 120
Female infertility: multiple diagnosis 47 45 0.95
PCOS 72 58
Tubal pathology 54 40





3 15 12 0.89
4 4 2
TOTAL N¼ 586 N¼ 498





(Ahlstrom, Westin, Reismer, Wikland, & Hardarson,
2011; Hill et al., 2013; Honnma et al., 2012; Thompson
et al., 2013), which did not find the ICM to be signifi-
cant and focused on the TE as main predictor of out-
come, we found a strong association between LBR and
ICM in the multivariable analysis and none between TE
and measured outcomes.
Some authors have published that the degree of
expansion is the most predictive factor of implantation
(Dokras, Sargent, & Barlow, 1993; Shapiro et al., 2000;
Yoon et al., 2001). Others though advocate the quality
of the inner cell mass as the most important factor
related to implantation potential (Balaban et al., 2000;
Richter, Harris, Daneshmand, & Shapiro, 2001; Shapiro,
Richter, Harris, & Daneshmand, 2001). In our study, we
found a significant association between LBR and ICM
in the multivariable analyses.
Recently, three studies have reported similar conclu-
sions identifying an association between the TE
morphology and implantation rates (Ahlstrom et al.,
2011; Hill et al., 2013; Honnma et al., 2012; Thompson
et al., 2013). However, methodological differences
among these studies can be argued since the one
from Honnma et al. (2012) was performed in frozen
blastocysts, hence non-controlled endometrial factors
could have played an important role. Other authors
have grouped good quality blastocysts under new cre-
ated categories making the results not comparable
with previous studies (Goto et al., 2011).
One of the most recent papers from Hill et al.
(2013) analyzing almost 700 single blastocyst transfers
concluded that the TE was the strongest predictor of
live birth with no apparent contribution of the ICM to
the outcomes. Our study, which includes a higher
number of cases, did not confirm this association in
the multivariable analysis. They also created different
categories according to the possible combinations
between TE and ICM grade and confirmed the import-
ance of the TE by finding a significant reduction in IR
and live birth rate when the TE dropped from a to b.
Analogously, we replicated the analysis of these differ-
ent combinations and did not confirm this reduction
in LBR when the TE dropped from a to b.
Thompson et al. (2013) recently published data of
more than 3000 cycles retrieved from the Society for
Assisted Reproductive Technologies registry showing
that blastocyst expansion stage, TE grade and age pre-
dict clinical pregnancy and live birth. For Van den
Abbeel et al. (2013) in their recent study including
over 600 single fresh blastocyst transfers all three
parameters correlated with live birth rate in the simple
logistic regression analysis. Interestingly in the multi-
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expansion remained a significant predictor. In our
study, once multivariable regression was applied only
blastocyst expansion and ICM grade showed a signifi-
cant correlation with live birth, which was especially
important for ICM grade C.
We found a significant association between blasto-
cyst expansion and poor ICM grade with early preg-
nancy loss. In the latter study from Van den Abbeel
et al. (2013), they report an association between ICM
and early pregnancy loss. This is in keeping with our
findings and implies a strong association between a
robust ICM and viable pregnancy beyond the initial
positive pregnancy test.
The importance of the quality of the ICM is con-
firmed in this study as one of the most important pre-
dictors when it comes to select single blastocysts for
transfer among those with similar grades of expansion.
Deselecting an embryo with a poor quality ICM (grade
C) over TE grade will increase the likelihood of achiev-
ing a live birth considerably. This has a plausible bio-
logical explanation given that this particular parameter
is a reflection of embryo competence and it could be
associated with higher rate of aneuploidies, which will
result in turn into a higher miscarriage rate (Alfarawati
et al., 2011). However, this correlation is not absolute
with some aneuploid embryos managing to reach the
blastocyst stage (Fragouli et al., 2013). Interestingly
and in contrast with the most recent body of litera-
ture, TE failed to demonstrate this association in the
multivariable analysis, in line with the results from Van
den Abbeel et al. (2013). Various arguments could pos-
sibly explain this difference. Firstly, blastocyst grading,
despite using a standardized score system, is subject
to variability to some extent. This means that same
embryos may have been given different grades on dif-
ferent studies and even on the same study by different
observers making the results not comparable. This
highlights the importance of standardization of intra
and inter-observer variability and the need for strict
internal quality control within centres to promote con-
tinuous training thus reducing the impact of subjectiv-
ity on treatment and research. Secondly, the study size
may have affected the power of this study to detect
the difference. We have included more cases than Hill
et al. (2013) but fewer than Thompson et al. (2013)
and it is not possible to exclude the effect of this on
the results.
We acknowledge certain limitations to our study,
which should encourage caution on the interpretation
of the results. Firstly, the current study is retrospective
in nature and so is the case of most of the studies
published on this topic. We accept this as a weakness
to our study but nevertheless we think that it still
provides a good insight as to which blastocyst param-
eter should be prioritized above others. A second limi-
tation is the small number of non-fully expanded or
hatching transfers included (n¼ 54, 5.0%), not provid-
ing a complete homogenous group for comparison in
reference to blastocyst expansion as a parameter. This
is explained by the fact that a good proportion of
patients with non-fully expanded blastocysts will not
opt for a single transfer approach aware of the known
reduction on implantation rates. This could represent a
source for selection bias, as cycles with lower quality
embryos in which double transfers are performed have
not been included. Yet, this proportion is similar to
the one reported in other studies and it does not
affect the ICM and TE parameters as these are only
graded on fully expanded blastocysts, which represent
more than 90% of all the transfers. There is no adjust-
ment in the multivariable analysis for BMI or other
potential confounders such as number of previous
cycles or number of units of gonadotropins used.
However, the mean BMI of the cohort was 23.0 and
therefore we think it unlikely to have affected the
results in any manner. Moreover, there were no signifi-
cant differences on the BMI or other baseline or treat-
ment characteristics of patients achieving a live birth
compared to patients who did not as presented in
Table 1. Based on the wide inclusion criteria inherent
to the design of our study, patients who had more
than one single blastocyst transfer in the period
studied were included more than once. Because it is
well known that the number of cycles performed can
have an impact on success rates, a comparison
between patients who achieved a live birth and
patients who did not depending on cycle number was
performed and it is shown in Table 1. No differences
were found attending to cycle number.
As valuable strengths of our study we could under-
score the high number of cycles included and the
exclusion of frozen cycles and double transfers. The
exclusion of frozen cycles relates to the differential
endometrial factors that could have impacted on the
analyzed outcomes should we have included fresh and
frozen cycles. We acknowledge that there is an
increasing body of evidence suggesting that the
replacement of embryos in frozen cycles appears to be
more physiological than the replacement in the con-
text of high oestrogen levels achieved after controlled
ovarian stimulation in fresh cycles (Roque et al., 2013).
Nevertheless, fresh transfers are still widely used in the
majority of IVF centres as the standard approach, espe-
cially for first cycles, and consequently it is clinically
relevant to analyze the outcomes in this type of
cycles.
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We conclude that blastocyst expansion and ICM
correlate with the chances of achieving a live birth as
reported in previous studies. Blastocyst expansion
appears to be an unquestionable predictor of outcome
as discussed above. Inner cell mass (when a drop to
Grade C occurs) stands out clearly among the rest as a
deselecting tool of a blastocyst that is unlikely to
result in a live birth among those with similar grades
of expansion. Therefore, an optimal ICM may reduce
the risk of early pregnancy loss and increase the likeli-
hood of a live birth occurring. We think it is too early
to assume a benefit of the TE grade above the ICM as
a predictor of outcome based on previous studies and
we did not find a significant association on this
respect. Randomized controlled studies are needed in
order to determine which parameter among these
should be prioritized in the selection of the single
blastocyst for transfer.
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Gynecology and Reproductive Biology 137 (2008) 247–261 259Unusual presentation of metastatic Crohn’s diseaseDear Editor,
We wish to report a very unusual case of Crohn’s disease,
which manifested in the form of a vulval polyp. A 50-year-
old lady presented to the gynaecology outpatients clinic with
a history of sudden onset swelling of 2–3 months’ duration in
the right labium minor. There was not much increase in the
size of the swelling after the onset and no history of any pain
or abnormal discharge.
She had a past medical history of severe Crohn’s disease
for the last 15 years. Medical treatment with azathioprine
and steroids was unsuccessful at controlling her symptoms.
The patient had initially undergone a hemicolectomy and
ileo-rectal anastomosis followed by a pancolectomy and
ileostomy. She later developed a perianal abscess, which was
drained. She had recurrence of the ileitis in the ileostomy
stoma leading to an entero-cutaneous fistula for which she
had a revision ileostomy. She was then started on
Sandostatin injections (20 mg every 3 weeks) and she
remains symptom-free until now as far as her bowels are
concerned.
On examination, she was systemically well. Abdominal
examination revealed a functioning ileostomy. On the right
labium minor there was a pedunculated mass of 3–4 cm.
No other ulcer or fissure was noted. The patient had an
excision biopsy under general anaesthesia. The excision
site was closed with Vicryl Rapide and healed with no
problems.
Histological examination revealed a fibro-epithelial
polyp with an oedematous fibro-vascular core in which
there were many non-caseating epithelial granulomata,
features representing cutaneous metastatic Crohn’s disease
(Fig. 1). Review after 6 months revealed a normal looking
vulva with no signs of recurrence.
Medical management has been the mainstay of treatment
of vulval Crohn’s disease as the usual presentation is either
vulval ulcer or vulval oedema and the diagnosis is made or at
Letters to the Editor / European Journal of Obstetrics &Fig. 1. Histological picture of the polyp showing granuloma in the fibro-
vascular core in the centre of the field.least suspected before histological confirmation of the
condition [1]. Oral metronidazole, augmentin, azathioprine
and topical steroid creams have all been used with some
success to control vulval symptoms.
In our case, the diagnosis was not suspected as the
patient’s intestinal symptoms were well controlled at the
time of presentation and it is extremely rare for metastatic
Crohn’s to be in the form of a polyp. Although the extra-
intestinal manifestations run parallel to the intestinal
symptoms, metastatic disease can still be present in the
absence of any intestinal symptoms. This case showed that
diagnosis of Crohn’s disease should be considered in cases
of vulval polyps. Conservative surgical treatment may be
the right way to treat solid lesions [2], although concerns
about poor healing and recurrence remain. In our case the
wound healing was very good and there is no sign of
recurrence so far, although long-term follow-up may prove
different.References
[1] Aviles-Izquierdo JA, Suarez-Fernandez R, Lazaro-Ochaita P, Longo-
Imedio I. Metastatic Crohn’s disease mimicking genital pyoderma gang-
renosum in an HIV patient. Acta Derm Venereol 2005;85(1): 60–2.
[2] Mould TA, Rodgers ME, Burnham WR, Weekes ARl. Metastatic
Crohn’s disease causing a vulval mass and involving the cervix. Int
J STD AIDS 1997;8(7):461–3.
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The safety of ultrasound-guided oocyte pick-up in IVF
patients with haemostatic disorders
Dear Editor,
As we know, the preoperative assessment of an in vitro
fertilization (IVF) patient’s haemostatic status and the
approach towards those patients having haemostatic defects
remains unstudied. To the best of our knowledge, there are
no publications in the gynaecologic professional literature
dealing with this important topic and its practical applica-
tions with IVF patients.
The puncture of the hypervascularized overstimulated
ovaries poses a particularly great challenge to haemostatic
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Table 1
Patients’ characteristics, preparations for OPU and clinical outcomes
Age Cause of infertility Total
cycles









1 28 Male factor NOA 5 141 9.7 F VII deficiency FFP*3 before OPU Long 11,044 17 2 NVD*2
2 29 Unexplained 4 43 2.8 VW type B2 F VIII during OPU Long 3377 8.3 1 NVD
3 32 Unexplained 3 58 3.4 F XI deficiency FFP*2 before OPU Long 9960 6.3 3 NVD*2
4 36 Male factor OTA 1 73.4 7.1 FVII deficiency FFP*2 before OPU Short 5384 7 1 NVD twins
5 25 Male factor OTA 5 95 3.9 ITP <50,000 plt IVIG + steroids Long 6469 12 1 miscarriage
6 40 Male factor OTA 2 10.5 4.3 FVII deficiency FFP*2 before OPU Antagonist 3839 6.5 2 NVD*1
miscarriage*1
7 33 Mechanical factor 2 71 4.4 F XI deficiency FFP*4 before OPU Long 6991 12 1 O.P.
8 24 Unexplained 1 133 5.9 F XI deficiency FFP*2 before OPU 12,200 16 1 O.P.
NOA, non-obstructive azospermia; OTA, oligoteratoastenospermia; E2, estradiol pmol/L; FSH, follicle stimulating hormone IU/L; COH, controlled ovarian
hyperstimulation; FFP, fresh frozen plasma; IVIG, intravenous immunoglobulin; NVD, normal vaginal delivery; OP, ongoing pregnancy.competence. Thus, the safety of ovum pick-up in patients
with haemostatic disorders is of crucial importance.
During the last 6 years, we reviewed 1800 IVF patient
files undergoing IVF-ET of whom 8 (undergoing 23 cycles
of oocyte retrieval) were found to have a bleeding tendency
disorder. The preoperative haemostatic evaluation, the
preparation of the patients before ovum pick-up (OPU),
and the clinical course of ovum retrieval and the post-
operative course were evaluated. Further evaluation,
preparation and medication before OPU of patients with
abnormal results were performed as needed by consultant
haematologist. Patient’s characteristics are shown in Table 1.
In two patients, haemostatic tendency was known before
admission to IVF program due to their bleeding histories. In
six cases the bleeding tendency was revealed by routine
blood tests and none of these patients had a suggestive
history. All women were treated preoperatively and some
also immediately postoperatively by transfusion of fresh
frozen plasma (FFP), concentrated preparations of the
deficient clotting factor, intravenous immunoglobulins
(IVIG) and steroids (Table 1). All patients were discharged
after overnight observation without related complications. In
addition, there was no significant influence in regard to IVF
outcome.
Transvaginal ultrasound guided ovum pick-up is the
method of choice for OPU among most IVF units. The
procedure, which involves puncture, then aspiration of
ovarian follicles via vaginal route, unavoidably results in
damage to the finevascular haemostasis on the ovarian surface
and theca interna layer. Dessole et al., found that the estimated
blood loss 24 h after OPU was 230 mL [1]. Severe life-
threatening bleeding complications may rarely occur [2].
The mainstay for recognition of a clinically significant
bleeding state is still the clinical, personal and familial
histories and the physical examination. Several levels of
probability for the existence of a bleeding disorder were
outlined by Rapaport offering some preoperative laboratory
tests for the confirmation of such a clinical suspicion [3].
Although these broad guidelines did not attain widespread
clinical use, they add to other publications showing theimportance of a detailed history in the presurgical
assessment of potential haemostatic problems. In fact, the
value of routine preoperative haemostatic screening tests for
asymptomatic patients has not been shown [4].
In our study, six of eight patients had negative personal or
familial bleeding history and were discovered only by
routine preoperative tests. Preoperative evaluation of
haemostatic defects should be performed in patients coming
from a high-risk background even if there is a negative
history of bleeding tendency (i.e. Ashkenazi Jews in our
study) [5].
Ovum pick-up should be considered as one posing a
particularly great challenge to haemostatic competence and
consequently of great risk to undiagnosed patients.
From this observational study, we can infer that with
proper preparation aiming at restoration of the haemostatic
competence by specific treatment, this group of patients with
haemostatic defects could be offered ovum pick-up with
good margins of safety.
We propose that this workup should include routine
complete blood count (CBC) and PT/PTT tests for high-risk
populations with known common inherited bleeding
problems. A thorough evaluation of this important topic
needs to be further studied before clear-cut and general
guidelines can be formed.References
[1] Dessole S, Rubattu G, Ambrosini G, Miele M, Nardelli GB, Cherchi PL.
Blood loss following noncomplicated transvaginal oocyte retrieval for
in vitro fertilization. Fertil Steril 2001;76:205–6.
[2] Dicker D, Ashkenazi J, Feldberg D, Levy T, Dekel A, Ben-Rafael Z.
Severe abdominal complications after transvaginal ultrasonographi-
cally guided retrieval of oocytes for in vitro fertilization and embryo
transfer. Fertil Steril 1993;59:1313–5.
[3] Rapaport SI. Preoperative hemostatic evaluation: which tests, if any?
Blood 1983;61:229–31.
[4] Houry S, Georgeac C, Hay JM, Fingerhut A, Boudet MJ. A prospective
multicenter evaluation of preoperative hemostatic screening tests. The
French Associations for Surgical Research. Am J Surg 1995;170:
19–23.
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ABSTRACT
There are various successful protocols for artificial
endometrial preparation, comprising induction of endo-
metrial proliferation with estrogens and secretory trans-
formation with progestins. The aim of this prospective
randomized study was to evaluate a simplified approach
for endometrial preparation, comparing two constant doses
of oral estradiol combined with a novel low-dose vaginal
natural progesterone preparation (100 mg EndometrinÒ
tablets). Twenty-nine patients were enrolled in the study
and divided randomly into two groups. Both groups
received oral estradiol tablets from the beginning of
menstruation, group A (15 patients) receiving 4 mg/day
divided into two doses of 2 mg each, and group B (14
patients) receiving 6 mg/day divided into three doses.
Serum estradiol and progesterone and sonographic thick-
ness of the endometrium were measured on the 1st day of
menstruation and on the 6th, 11th, 16th and 21st days
of the artificial cycle. Following the first 12 days of
estradiol priming, with an endometrial thickness of
³ 8 mm, Endometrin vaginal tablets 100 mg were
added twice a day for 10 days. On the 21st cycle day, an
endometrial biopsy was taken from all patients using
PipelleÒ.
In all 29 patients, appropriate changes in estradiol,
progesterone and endometrial thickness were observed.
Estradiol levels were significantly higher in the 6 mg/day
group on days 6 and 11, but no significant difference
was noted in serum progesterone level and endometrial
thickness between groups. Histological evaluation of
endometrial biopsies, on the 21st day, revealed adequate
late-secretory endometrium in 14/15 (93.3%) patients
of group A and in 13/14 (92.9%) patients of group B.
In conclusion, our results demonstrate that an appropriate
endometrial secretory transformation may be induced
using an economical regimen of fixed low-dose oral
estradiol (4 mg/day) and low-dose vaginal progesterone
tablets (Endometrin 100 mg twice daily).
INTRODUCTION
Since the first successful attempts to establish
normal endometrial development and maintain
pregnancies in patients with absent or non-
functioning ovaries1,2, it has been well docu-
mented that exogenous administration of estrogens
and progestogens may induce an artificial
Gynecol Endocrinol 2002;16:131–136
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endometrial preparation for embryo transfer, both
in ovarian failure patients and in normally ovulat-
ing patients scheduled for the transfer of frozen–
thawed embryos. Various protocols for artificial
endometrial preparation have been studied,
including the use of a variable estradiol protocol
combined with a fixed intramuscular progestin
dose; the use of a fixed oral estradiol dose with a
fixed intramuscular progestin dose; the use of
different oral estradiol doses and a fixed dose of oral
progestins; estradiol implants and intramuscular
progestins; and oral estradiol and different pro-
gestin preparations. Also, the efficacy of trans-
dermal estradiol and vaginal progestogen gel, and
of combining gonadotropin-releasing hormone
analogs (GnRHa) in artificial cycles of recipients
with functioning ovaries prepared for oocyte
donation or of frozen–thawed embryos, and the
role of spontaneous and induced cycles have been
assessed2–11. Clearly, some protocols are less con-
venient than others, with regard to the use of artifi-
cial agonadism with GnRHa for priming the
artificial cycle, the use of variable estradiol doses or
elevated amounts of estradiol during the pro-
liferative phase, and the use of an intramuscular
progestin or multiple vaginal progestogen applica-
tions. The aim of this prospective randomized
study, therefore, was to evaluate a simplified proto-
col, comparing the effect of two fixed doses of
oral estradiol combined with a new low-dose
vaginal natural progesterone preparation (100 mg
EndometrinÒ tablets) on serum estradiol and pro-




Twenty-nine patients expecting frozen–thawed
embryo transfer in the in vitro fertilization (IVF)
program of the Hadassah University Hospital,
Ein-Kerem, were enrolled in this study. The insti-
tutional Helsinki committee approved the study,
and informed consent was obtained from each
patient. Patients were divided prospectively and
randomly into two groups. Both groups received
oral EstrofemÒ 2 mg tablets (Novo, Denmark)
from the beginning of menstruation, group A
(15 patients) receiving 4 mg/day divided into two
doses of 2 mg each, and group B (14 patients)
receiving 6 mg/day divided into three doses. The
mean age of patients was similar in both groups
(32.5 ± 5.8 years in group A and 32.1 ± 6.3 years in
group B). On the 11th day of estradiol priming,
with an endometrial thickness of ³ 8 mm,
Endometrin 100 mg vaginal tablets (Florish, Israel)
were added twice daily.
Hormonal and endometrial monitoring
Blood samples for immunoassay of serum estradiol
levels (measured in pmol/l) and serum progester-
one levels (measured in nmol/l) were collected,
and endometrial thickness was sonographically
measured starting on the 1st day of menstruation
and then on the 6th, 11th, 16th and 21st days of
the artificial cycle. All ultrasound examinations
in this study were carried out by a gynecologist
experienced in transvaginal ultrasonography
(A.L.). Endometrial measurements were per-
formed using a transvaginal sagittal view, from
outer to outer edges at the maximal thickness point
of the uterine cavity. The ovaries were screened
during each examination for the purpose of
monitoring any spontaneous follicular growth.
Serum collections took place at 08.00, some 8 h
following the last hormone administration.
Endometrial biopsy
On the 21st cycle day, following the later 10 days of
combined estradiol plus progesterone administra-
tion, an endometrial biopsy was taken from all
patients. The endometrial biopsies were performed
immediately after a transvaginal sonography,
carried out to exclude pelvic pathology and to
determine the uterine position and depth. This
was followed by speculum insertion and cervical
cleaning with chlorhexidine gluconate 0.4% solu-
tion. The endometrial sampling was obtained with
a PipelleÒ (Prodimed, Neuilly-En-Thelle, France),
introduced transcervically, and a single continuous
sampling was performed from all aspects of the
uterine body. Following fixation and staining,
morphological study of the endometrial samples
was based on the dating criteria of Noyes and
colleagues12. A senior pathologist, blinded to the
clinical status of the patient, performed the histo-
logical evaluation.
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RESULTS
In all 29 patients who completed the study, appro-
priate cyclic changes in serum estradiol and
progesterone levels and in endometrial thickness
were observed. Serum estradiol levels on cycle
days 1, 6, 11, 16 and 21 are presented in Figure 1,
being significantly higher in group B on days 5 and
10. Adequate luteal phase progesterone levels were
achieved with the Endometrin tablets, and no
significant difference was noted in serum proges-
terone levels between groups on the same cycle
days (Figure 2). A similar endometrial thickness
was noted between groups (Figure 3). Histological
evaluation of endometrial biopsies revealed
adequate late-secretory endometrium, showing
intraluminal secretion, tortuous glandular outline,
prominent stromal edema, spiral arteries in
stroma, and periarterial pseudo-decidual changes
(Figure 4) in 14/15 (93.3%) patients in group A
(mean day 24.2 ± 2.2) and in 13/14 (92.9%)
patients in group B (mean day 23.0 ± 2.8). Only in
one patient in each group (1/15 (6.6%) in group A,
and 1/14 (7%) in group B) was an earlier-secretory
endometrium of days 18–19 noted, although they
did not differ in terms of their groups’ mean
hormonal and endometrial measurements. No
side-effects were noted following the hormonal
treatment. Spontaneous follicular growth and
ovulation were sonographically ruled out in all
patients.





























Figure 1 Mean serum estradiol levels during the artificial cycle in the 4 mg/day group (group A, ) and in the
6 mg/day group (group B, ). *p < 0.05 compared with the 4 mg/day group
























Figure 2 Mean serum progesterone levels during the artificial cycle in the 4 mg/day group (group A, ) and in
the 6 mg/day group (group B, )
DISCUSSION
In this prospective randomized study, we found
that a simplified sequential protocol of a fixed low
dose of 4 mg/day of oral estradiol, combined
sequentially with low-dose natural progesterone in
vaginal tablets (Endometrin 100 mg, twice daily),
allowed the attainment of adequate cyclic
hormonal levels, and may induce appropriate
endometrial development for embryo transfer.
Adequate estradiol and progesterone priming is
required for normal endometrial growth, and may
be achieved with various regimens. The efficacy of
three protocols of endometrial preparation using
spontaneous cycles, artificial preparation and
ovarian stimulation, for cryopreserved–thawed
human embryo transfer (CT–ET), was studied by
Tanos and colleagues10. No statistically significant
difference was found in implantation and clinical
pregnancy rates between the endometrial prepara-
tion protocols used. The authors concluded that
the specific method of endometrial preparation for
CT–ET had no significant impact upon the
implantation rate. In fact, in most centers, artificial
endometrial preparation is considered to be a con-
venient approach used often. Progesterone treat-
ment for endometrial secretory transformation in
artificial cycles may be administered via the oral,
intramuscular or vaginal route. The oral adminis-
tration of progesterone presents problems arising
from its hepatic metabolism, and the resulting
elevated levels of progesterone metabolites, along
with too low plasma progesterone concentra-
tions13. The use of intramuscular progesterone has
for a long time been the gold standard of proges-
terone administration. It delivers higher serum
progesterone levels than other routes of adminis-
tration, but is associated with low patient compli-
ance owing to marked pain at the injection site,
and its prolonged use often results in gluteal
abscesses14. Vaginal progesterone administration,
although providing lower serum concentrations
than intramuscular injections, was found to result,
via direct local absorption, in higher tissue levels in
the gynecological tract, especially the endo-
metrium14,15. The vaginal route has been described
as a targeted drug delivery system with uterine
first-pass effect16, and is therefore considered the
best route for natural progesterone treatment. The
efficacy and safety of this approach for
Artificial endometrial preparation with estradiol and vaginal progesterone Lewin et al.
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Figure 3 Mean endometrial thickness during the artificial cycle in the 4 mg/day group (group A, ) and in the
6 mg/day group (group B, )
Figure 4 Late secretory endometrium (patient YR),
showing intraluminal secretion, tortuous glandular
outline, prominent stromal edema, spiral arteries in
stroma, and periarterial pseudo-decidual changes
progesterone delivery, in luteal-phase support of
fertility and IVF treatments, including artificial
cycles for oocyte donation and for the transfer of
frozen–thawed embryos, has previously been
demonstrated17. Until recently, only micronized
progesterone tablets at a daily dose of 900 mg
(300 mg every 8 h) were available for vaginal
application, described as an effective treatment for
CT–ET7. The main drawback is the need for three
daily applications of three small round tablets each
time, making it very inconvenient for working
patients. Gibbons and colleagues8 compared the
efficacy of a recently introduced vaginal progester-
one gel with that of intramuscular progesterone
within a donor-egg program. Both groups under-
went EstradermÒ patch–progesterone treatment in
a mock cycle, finishing with an endometrial biopsy
on day 26. Women with residual ovarian function
received a GnRH agonist. In the intramuscu-
lar-treatment group, 100 mg progesterone was
administered from cycle days 15 to 27. In the vagi-
nal-treatment group, CrinoneÒ 8%, a
polycarbophil-based gel preparation containing
90 mg of micronized progesterone, was adminis-
tered twice daily from the evening of day 14. Mean
serum progesterone levels were found to be signifi-
cantly lower in the Crinone group, compared with
the intramuscular-progesterone group. Neverthe-
less, endometrial histology was ‘in phase’ for all
subjects in both groups.
It is clear that some protocols are less convenient
than others, especially with regard to the use of
artificial agonadism with GnRHa for priming the
artificial cycle9. This was recently shown to be
unnecessary for endometrial preparation, as estra-
diol priming was sufficient to prevent a luteinizing
hormone (LH) surge11. The above corroborates
our finding that none of the studied patients
showed sonographic signs of spontaneous
ovulation. There are also disadvantages in the use
of intramuscular progesterone14 in multiple vaginal
progesterone applications7, and in possible allergic
skin reactions described with estradiol patches18.
With regard to progesterone gel, it must be taken
into account that an important clinical parameter,
the serum progesterone level, found to be signifi-
cantly lower in the above Crinone-treated
patients, cannot serve for monitoring a patient’s
response to treatment, as the endometrial appear-
ance and thickness do not necessarily correlate
with histological ‘in phase’ dating, as was observed
in our study.
We therefore chose to compare the administra-
tion of two fixed doses of estradiol combined with
a new, low-dose, vaginal natural progesterone
preparation (100 mg Endometrin tablets), as these
simple estradiol regimens, as well as being better
handled by most patients, were previously demon-
strated to allow an appropriate endometrial
proliferative growth. We have previously shown,
in a program of oocyte donation in patients with-
out ovarian function, that a high pregnancy rate
was achieved using the 4-mg/day dose for a
particular length of artificial follicular phase3. The
4-mg/day fixed dose was also studied, by compar-
ing four different estrogen doses: variable, fixed
1 mg/day, fixed 2 mg/day and fixed 4 mg/day4.
Similar endometrial responses were shown in those
treated with the fixed 4-mg dosage and those
treated with the variable regimen, as previously
described by our group2.
Finally, one must consider the cost of treat-
ment, which is expected to be lower for the oral
use of a fixed low dose of 4 mg of estradiol
compared with estradiol patches or even some oral
variable regimens, and also lower for vaginal pro-
gesterone tablets compared with vaginal proges-
terone gel or multiple tablets application.
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Abstract
Purpose Endometrial thickness is important for implanta-
tion. Little data addresses the etiology of persistently thin
endometrium. We present a patient cohort in order to define
common features and draw conclusions.
Methods Thirteen out of 1,405 IVF patients repeatedly had
thin unresponsive endometrium (<7 mm). Age, history,
uterine cavity status, treatment type and outcome were
examined.
Results Patient age was 35.9±5.7 years. Ten patients had a
curettage performed previously. Nine patients had normal
cavity and endometrium, and in four adhesions were
diagnosed and removed. Out of 99 cycles performed
afterwards, endometrial thickness increased in 22. ETs
were performed in 49 cycles resulting in 11 pregnancies.
Their outcome was eight miscarriages, two terminations
due to malformations, and one live birth.
Conclusions Thin unresponsive endometrium was associ-
ated with curettage, not necessarily with intrauterine
adhesions. Even if adequate thickening eventually occurred,
the reproductive outcome was still very poor. Therefore
other alternatives should be sought for these patients.
Keywords ART. Curettage . Thin and unresponsive
endometrium
Introduction
The importance of endometrial thickness, as measured by
ultrasonographic examination, to successful in vitro fertil-
ization (IVF) outcome is still under debate. While some
studies have shown that this parameter is important for
predicting the outcome of In Vitro Fertilization (IVF) cycles
[1–8], other studies have failed to show such a positive
relationship [9–14]. In a third category of studies the
endometrial thickness was related to the IVF outcome, but
only in correlation with other parameters [15, 16]. Different
thresholds of endometrial thickness were suggested as
essential for successful implantation and most demonstrated
that no pregnancy was established when the thickness of
the pre-ovulatory endometrium was <6 mm [17]. Never-
theless, Sundstrom [18] have reported a successful outcome
of an IVF cycle in a patient with an endometrial thickness
of no more than 4 mm.
This retrospective cohort study examines the clinical
characteristics and background of such unique patients
treated in our IVF unit, in an attempt to shed some light on
the etiology and response of the endometrium to different
treatment modalities.
Methods
One thousand four hundred five patients underwent IVF
treatment cycles in our unit between 2004–2007. Of these
we identified 13 patients who repeatedly had a thin and
unresponsive endometrium during various types of treat-
ment cycles. The ultrasonographic definition was a maxi-
mal endometrial thickness of no more than 7 mm, as
measured by trans-vaginal ultrasound scans prior to
ovulation or to the administration of human chorionic
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Capsule Thin unresponsive endometrium without adhesions is
associated with past surgical curettage procedures and results in a very
poor reproductive outcome.
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gonadotropin (hCG) or progesterone, despite adequate
ovarian response and serum estradiol (E2) level. None of
them had a uterine malformation or was exposed to DES in
utero. All patients had a diagnostic hysteroscopy performed
and intrauterine adhesions were surgically removed if
found. ETs were performed on day 3 under US guidance
or according to previous uterine length measurements from
the same cycle. The patients' records were studied for
general medical and gynecologic history, and for the
different protocols which were utilized for ovulation
induction and endometrial preparation. The major outcomes
that were recorded from the post hysteroscopy cycles were:
endometrial responsiveness to the different protocols used,
serum estradiol level, the performance or cancellation of
embryo transfer (ET), the number and quality of embryos
transferred, clinical pregnancies and outcome.
Results
We identified 13 patients who repeatedly had thin and
unresponsive endometrium, as defined by our criteria, in
their past and present treatment cycles. Their characteristics
are summarized in Table 1.
Four patients had tubal occlusion, four had a male factor
problem, four had unexplained infertility and one patient
had combined mechanical and male factor infertility.
Diagnostic hysteroscopies revealed a normal appearing
uterine cavity in nine women, and in four a few thin mild
and scarce intra-uterine adhesions were diagnosed and
removed. None of these patients had a history acute pelvic
inflammatory disease (PID) or of intrauterine device (IUD)
insertion. Two patients had a history of prior pelvic surgery
(one patient had underwent salpingectomy and the other
reconstructive tuboplasty). In one of these patients a later
diagnostic laparoscopy was performed and some mild
peritoneal adhesions were found. Ten out of the 13 patients
had at least one surgical curettage performed in their
history, and six of them had more than one. All the
curettage procedures were performed in order to terminate
past undesired pregnancies or following a diagnosis of
missed abortion (IVF and spontaneous pregnancies). These
patients were treated with different protocols of hormonal
supplements in an attempt to adequately build-up and
prepare the endometrium for embryo transfer. The different
types of treatment were categorized into six main groups:
(i) artificial cycles with exogenous estrogens administered
(frozen–thawed embryos only), (ii) induced cycles with
exogenous gonadotropins (fresh and frozen–thawed embry-
os), (iii) induced cycles with exogenous gonadotropins
supplemented with exogenous estrogen, (iv) induced cycles
with exogenous gonadotropins and low dose (100 mg/d)
aspirin (administered during the entire treatment not just
after ET), (v) induced cycles combined with sildenafil
(Viagra™, Pfizer) and (vi) spontaneous cycles. In the cycles
with exogenous estrogens, estradiol was administered
mainly orally in incremental doses, and vaginal estradiol
was added in some of the cycles. The maximal oral
estradiol dose administered was 4 mg qid, and the maximal
vaginal dose was 3 mg tid. Transdermal estrogen was added
only in two cycles without any benefit. The ETs were
performed on day 3 and were not difficult or complicated.
The total number of cycles using each protocol, peak serum
estradiol level, the number of cycles in which there was an
adequate endometrial response, cycles with ET, the number
of transferred embryos, embryo quality (according to
Rijnders and Jansen [19]) and pregnancies are summarized
in Table 2.
Out of 99 additional treatment cycles performed follow-
ing hysteroscopy, in only 22 cycles an adequate endome-
trial response was achieved reaching an endometrial
thickness of at least 7 mm. Eventually transfer of either of
fresh or frozen thawed embryos was performed in only
49 cycles (all 13 patients had one or more ET eventually).
Eleven clinical pregnancies were achieved of which eight
were in the subgroup patient who had endometrial thickness
of 7 mm or more. The overall pregnancy rate per transfer
was 22% and much lower when calculated for the initial
intent to treat cycles (11%). The pregnancy rate per ET was
reasonable in the sub-group in which the endometrial
response was adequate (8/22, 36.4%), and low in those
who had an ET despite a thin endometrium (3/27, 11.1%).
The lowest endometrial thickness in which a successful
pregnancy was obtained was 6.8 mm, and this was the only
pregnancy that ended in a live birth. The outcome of these
pregnancies was poor; they ended in one live birth, two
mid-trimester terminations due to malformations, and eight
miscarriages.
Discussion
Endometrial receptivity is essential for successful implan-
tation and establishment of pregnancies in both natural and






Infertility type (primary/secondary) 5/8
Infertility duration (years) 5.3 ±1.7 (3–9)
Previous IVF cycles 2.3±1 (1–4)
D&C procedures performed 1.9±2.5 (0–10)
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ART cycles [20]. There are still no accepted criteria for
evaluating endometrial receptivity in IVF patients. Howev-
er, in an attempt to assess the endometrial receptivity and
define uterine predictors of implantation and pregnancy,
various ultrasonographic endometrial features like thick-
ness, echogenicity and pattern were studied. Despite the
existence of quite a few published studies, the prognostic
value of ultrasonographic endometrial thickness measure-
ments (and other parameters) in predicting implantation and
pregnancy rates remains controversial. Some investigators
have demonstrated a positive correlation between endome-
trial thickness and pregnancy rates [1–8, 11] while others
have not found such an association [9, 10, 12–14], or only
in association with other parameters [15, 16]. However,
these differences may be in part attributed to different
patient populations, stimulation protocols used or measure-
ment timing. The incidence of thin endometrium in natural
cycles has been reported to be 5% in women <40 years of
age and 25% in 41 to 45 years old women [6]. The etiology
of unresponsive endometrium and its impact on ART
outcome have not been well characterized.
This retrospective observational cohort study includes 13
women who repeatedly had a thin and unresponsive
endometrium in various types of treatment cycles (echoge-
nicity and pattern data are not available). Their age was
35.9±5.7 and had they had a poor outcome of assisted
reproduction treatments, despite their quite good embryo
quality. One important observation which may shed some
light on a possible mechanism is that ten out of 13 patients
had a dilatation and curettage performed prior to the onset
of their problem, and six of them had more than one
curettage performed. All the curettage procedures were
performed for the management of induced abortion or
miscarriage. Although an association between endometrial
curettage and thin unresponsive endometrium seems plau-
sible, post curettage infertility and implantation failure was
mainly attributed to the formation of intra-uterine adhe-
sions. This small uncontrolled patient cohort does not allow
us to conclude that the curettage procedures without
synechiae were the cause of the injury to the endometrium.
However, in this group only four out of 13 patients had
intra-uterine adhesions and they were quite mild. A possible
explanation to this observation might be the existence of a
spectrum of post curettage endometrial injuries ranging
from a thin and unresponsive (but otherwise normal)
endometrium at one end, to Asherman's syndrome on the
other. It is impossible to estimate the occurrence rate of
such complications based on this small study. However,
these post curettage sequelae are devastating to the
reproductive future and should be cautiously taken into
consideration when intra-uterine procedures are planned.
Alternatives to the traditional dilatation and curettage
procedure should be considered in women of child
bearing age seeking further fertility. Pharmaceutical
management of abnormal uterine bleeding, early missed
and induced abortions, should be encouraged in young
women. Directed hysteroscopic resection of polyps should
be preferred upon undirected global curettage. Such
measures might prevent the type of endometrial damage
reported here.
This unfortunate group of women had undergone various
empirical treatments with combinations of steroid hormones
Table 2 Different treatment protocols, endometrial response, peak blood estradiol, ETs performed and number of achieved pregnancies in 13

















Artificial cyclea 28 12 4,044±3,363 14 3.07±0.92 1.74±0.54 3 (3)
Induced cycleb 28 6 8,093±3,420 14 3.29±0.73 1.89±0.6 4 (3)
Induced cycle +
aspirinc
7 3 8,577±4,218 4 3.5±0.58 1.93±0.62 1(1)
Induced cycle +
estrogenc
18 1 8,745±4,336 9 3.3±1.0 1.97±0.61 2(1)
Induced cycle +
Viagra™c
4 0 5,308±4,555 2 3.5±0.7 1.86±0.69 0
Spontaneous
cyclesc
14 0 642±274 6 3.17±1.17 2.0±0.58 1(0)
Total 99 22 49 11 (8)
a Frozen thawed embryos
b 22 fresh embryos+5 frozen–thawed embryos
c Fresh embryos
d According to Rijnders and Jansen [19], grade 1—no fragmentation; grade 2—<20% fragmentation; grade 3—20–50% fragmentation; grade 4>
50% fragments
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with Silfendanil and Aspirin in an effort to improve the
endometrial response as measured by its ultrasonographic
thickness. These different modalities, categorized in
Table 2, had various success rates in terms of adequate
endometrial response (defined as an ultrasonographic
thickness ≥7 mm) and pregnancy rates. The treatment plans
in all cycles were tailored individually and the data was
collected retrospectively. Therefore no treatment was found
to be better than the other, adequate endometrial thickening
was achieved in only a minority of the patients, and embryo
transfers were performed in only half of the cycles. The
pregnancy rate was low despite the adequate number of
embryos that were transferred. The thinnest endometrium
which was associated with a successful pregnancy was
6.8 mm thick, quite close to the established cutoff and in
conformity to published data [17]. The outcome of these 11
pregnancies (eight miscarriages, two late terminations due
to malformations and one live birth) demonstrated that
these patients had a poor reproductive prognosis even if
some endometrial thickening or implantation did occur. The
failure of the different treatment modalities to improve the
poor reproductive outcome in these patients is unfortunately
in accordance to published data [20]. The high pregnancy
loss rate might be the consequence of an endometrial
cellular or molecular defect which is presently beyond
our recognition. Further studies involving direct exami-
nation of the endometrium are required in order to
establish the mechanism of such an endometrial injury.
Stimulation of the endometrium by local injury using an
endometrial biopsy catheter was reported to be beneficial
to patients with normal endometrial measurements who
had otherwise unexplained repeated implantation failures
[21, 22]. However the patient population in this study
differs significantly by having a functionally abnormal
endometrium. The effectiveness of endometrial biopsy in
patients with thin unresponsive endometrium is yet to be
determined.
Once the insult occurred and the endometrium is
constantly thin and unresponsive, proper counseling re-
garding the very low live birth rate achieved by IVF and
alternatives such as surrogacy and adoption should be
discussed with these patients.
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In vitro maturation or in vitro
fertilization for women with
polycystic ovaries? A case–control
study of 194 treatment cycles
Anne-Sophie Gremeau, M.D., Natasha Andreadis, M.D., Muhammad Fatum, M.D., Jo Craig, M.D.,
Karen Turner, M.D., Enda Mcveigh, M.D., and Tim Child, M.D.
Oxford Fertility Unit, Institute of Reproductive Sciences, Oxford, United KingdomObjective: To compare the outcome of unstimulated in vitro maturation (IVM) and routine IVF/intracytoplasmic sperm injection (ICSI)
for women with polycystic ovaries (PCO).
Design: Retrospective case–control study.
Setting: Fertility unit.
Patient(s): Ninety-seven patients undergoing IVM were compared with 97 patients undergoing IVF. All had PCO and matched for age,
infertility diagnosis, and ovulatory status.
Intervention(s): In vitro maturation cycles were unstimulated and hCG was administered 35–40 hours before oocyte retrieval. Oocytes
were matured in vitro for 24–48 hours before insemination by ICSI. Endometrial priming with E2 and P was commenced from the day of
egg retrieval and one to two embryos were transferred on days 2–5 of development. Standard long protocol IVF/ICSI was used in the
control group.
Main Outcome Measure(s): Live birth rate per cycle and ovarian hyperstimulation syndrome (OHSS) rate.
Result(s): Overall, 65% of IVM eggs matured in vitro in the IVM group. Implantation rates were significantly higher in the IVF group
(19.4% vs. 12.9%) as clinical pregnancy rates (50.5% vs. 19.6%) and live birth rates (44.3% vs. 16.5%) than in the IVM group. The OHSS
rate was significantly higher in the IVF group (8.2% vs. 0%).
Conclusion(s): In vitro maturation is a safer and simpler alternative to conventional IVF for women with PCO. It avoids difficulties ofUse your smartphonegonadotropin stimulation and the risk of OHSS but has a significantly lower live birth rate. Cur-
rent research projects aim to close the success gap between IVM and IVF. (Fertil Steril 2012;98:
355–60. 2012 by American Society for Reproductive Medicine.)
Key Words: In vitro maturation (IVM), in vitro fertilization (IVF), polycystic ovaries (PCO),
ovarian hyperstimulation syndrome (OHSS)
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ovaries, with an increased risk of the
iatrogenic, and potentially fatal, com-
plication of ovarian hyperstimulation
syndrome (OHSS) (1, 2).
The in vitro maturation (IVM) of
oocytes retrieved from unstimulated
ovaries is an evolving form of fertility
treatment. The aim of IVM is to simplify
assisted conception along with reduc-
ing both costs and treatment complica-
tions. This is achieved through the
collection of immature oocytes from
unstimulated ovaries followed by their
in vitro maturation for up to 48 hours
and, once mature, insemination and355
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONfertilization. Embryo culture and transfer then occurs as per
routine IVF. The first birth after IVM specifically in patients
with polycystic ovaries was published by Trounson in 1994
(3). Initial IVM success rates were relatively low and only spo-
radic pregnancies were reported (4, 5), though more recent
studies have demonstrated success rates of 21.5% (6), 22.5%
(7), and 38.5% (8).
To our knowledge, no randomized controlled trials com-
paring IVM and IVF have been reported, and only a single
case–control study from 2002 (6). That study, from McGill
University, Montreal, Canada, demonstrated that for women
with ovaries of polycystic morphology, the success rates
achieved with IVMwere approximately half of that using rou-
tine IVF. The study was undertaken 10 years ago and both
IVM and IVF techniques have developed over time. The aim
of this study is to compare the live birth rate of IVM and
IVF treatment in the Oxford Fertility Unit for women with ul-
trasonographic evidence of polycystic ovaries.
MATERIALS AND METHODS
Eligible Patients
In vitro maturation and IVF treatment cycles undertaken for
women with polycystic ovaries at the Oxford Fertility Unit be-
tween January 2007 andMarch 2010 were identified from the
prospectively collated unit database. The study was a retro-
spective case–control analysis of routinely collected data dur-
ing standard patient treatments. Consequently, institutional
review board approval was not sought. Patients gave written
consent, before treatment, to the use of their data for analysis.
No power analysis was performed. Cases were defined as all
IVM cycles performed in women with ovulatory PCO or an-
ovulatory polycystic ovary syndrome (PCOS). An ovary was
considered as polycystic (PCO) if at least 12 follicles between
2 and 9 mmwere visualized on transvaginal ultrasonographic
scan. Women with PCO on scan and regular ovulatory men-TABLE 1





(n [ 97) P value
Age 32.40  3.6 32.38  3.8 NS
BMI 24.19  4.5 24.20  4.6 NS
FSH 5.1  1.8 5.5  1.4 NS
Ovulatory PCO, % (n) 46.4 (45) 46.4 (45)
Anovulatory PCOS, % (n) 53.6 (52) 53.6 (52)
Hyperandrogenism, % (n) 16.5 (16) 20.6 (20) NS
Etiology
Duration 3.77  2.5 4.20  2.4 NS
Primary infertility 69.1 (67) 56.7 (55) NS
Secondary infertility 30.9 (30) 43.3 (42) NS
Mixed infertilitya 38.1 (37) 36.1 (35) NS
Multiple female factor
infertilityb
19.6 (19) 17.5 (17) NS
PCO-PCOS ovulatory only 15.5 (15) 16.5 (16) NS
PCOS anovulatory only 26.8 (26) 29.9 (29) NS
Note: Values are presented as mean  SD, percent, or percent (n). BMI ¼ body mass index;
NS ¼ not significant.
a Mixed infertility (male and female factor).
b Multiple female factors include at least two of the following factors: dysovulation, tubal
infertility, and uterine infertility.
Gremeau. IVM or IVF for women with PCO. Fertil Steril 2012.
356strual cycles were considered to have ovulatory PCO. Women
with PCO on scan and menstruations 6 weeks or more apart
were considered to have anovulatory PCOS. Ninety-seven
women underwent 97 first IVM cycles; these were the cases.
The control for each IVM cycle was an IVF cycle performed
in the same period matched for female age, infertility diagno-
sis, and ovulatory status (see Table 1). All patients' files were
manually checked to confirm the diagnosis of ovulatory PCO
or PCOS and to assess for cycle cancellations, cryopreserva-
tion of all embryos, and complications such as OHSS. Women
with amenorrhea received oral P tablets (Provera 5 mg three
times per day during 5–7 days) to induce a withdrawal bleed.In Vitro Fertilization Cycle
For IVF treatment, a long GnRH agonist protocol was used: pi-
tuitary suppression was commenced on day 21 of the men-
strual cycle using intranasal nafarelin (Syneral; Pharmacia
Ltd.) 400 mg twice daily. Pituitary suppression was confirmed
after 3 weeks of nafarelin by a withdrawal bleed and serum
E2 < 150 pmol/L. Once patients were down-regulated, FSH
treatment using Gonal-F (Serono Pharmaceuticals Ltd.), Pure-
gon (Organon Laboratories Ltd.), or Menopur (Ferring Phar-
maceuticals Ltd.) was started at a maximum daily SC dose
of 150 IU. Response to treatment wasmonitored with serial ul-
trasonographic scans and serum E2 levels starting from day 7
of gonadotropin stimulation. Subcutaneous hCG (Ovitrelle,
Serono Pharmaceuticals Ltd.) was given as a trigger 35 hours
before oocyte retrieval for which the patient was sedated with
IV propofol, fentanyl, and midazolam. Conventional IVF or
ICSI was used for oocyte insemination dependent on semen
quality. A maximum of two embryos were replaced into the
uterus trans-cervically on day 2, 3, or 5 of embryonic devel-
opment. The luteal phase was supported using 400 mg daily
vaginal P pessaries (Cyclogest; Shire Pharmaceuticals Ltd.)
from oocyte retrieval until the pregnancy test, and then
stopped regardless of the result. A urine hCG pregnancy test
was performed 16 days after oocyte retrieval. Pregnancy scans
were undertaken at 6 and 8 weeks' gestation.IVM Treatment
Patients had a baseline transvaginal ultrasound scan between
days 2 and 7 of menstrual bleeding, whether spontaneous or
induced, to confirm the antral follicle count (AFC), ovarian
accessibility for oocyte retrieval, and the absence of ovarian
cysts. Gonadotropin ovarian stimulation was not used. A sec-
ond scan was performed as necessary between days 6 and 10
of the cycle in ovulatory women to exclude the development
of a dominant follicle (>14 mm), which is associated with
poorer IVM outcome. In anovulatory women, oocyte retrieval
was undertaken between days 8 and 16 of the cycle. For ovu-
latory PCO women, oocyte retrieval was performed before
a dominant follicle of>14 mm in diameter was present. Prim-
ing with 10,000 IU hCG (Ovitrelle; Serono Pharmaceuticals
Ltd.) was given SC 35 or 40 hours before oocyte retrieval.
Transvaginal ultrasonography-guided oocyte collection was
performed using a 17-gauge single-lumen needle (K-OSN-
1735-A-60; Cook) with an aspiration pressure of 85 mmHg.VOL. 98 NO. 2 / AUGUST 2012
Fertility and Sterility®All patients received a paracervical block of 10 mL 1% lido-
caine in addition to routine oocyte retrieval IV sedation. A
multiple-puncture technique was used with the needle pass-
ing through the vagina into the ovary, and aspirating a num-
ber of antral follicles, before being withdrawn and flush
aspirated from a test tube to prevent lumen blockage from
the ovarian stromal tissue and blood. The needle was then re-
introduced into the vagina and ovary until all small follicles
were aspirated, without follicular flushing.
The follicular aspirates were collected in culture tubes
containing Cook Flush Buffer (K-SIFB-100, Cook Europe)
with 2.5 IU/mL heparin. Following their identification,
oocytes were initially placed in Oocyte Washing Medium
(SAGE). Oocyte maturity was assessed after the oocyte collec-
tion, as follows: oocytes were considered as immature if
either a germinal vesicle was visualized in the cytoplasm or
if no polar body was present (metaphase I oocyte). They
were considered as mature if extrusion of the first polar
body (metaphase II) had occurred. Oocyte maturation was
evaluated with cumulus cells by trained embryologists on
days 0, 1, and 2 after the oocyte retrieval. The oocytes are
stripped just before ICSI (Fig. 1). All oocyte-handling proce-
dures were conducted on warm stages and plates at 37C.
Mature and immature oocytes were then transferred into
Oocyte Maturation Medium (SAGE) supplemented with 75
IU/L FSH and 75 IU/L LH (Menopur, Ferring) and cultured
at 37C in an atmosphere of 6% CO2, 5% O2, and 89% N2
with high humidity for a maximum of 48 hours. Intracyto-
plasmic sperm injection (ICSI) was performed on all mature
oocytes identified on either day 0 (day of oocyte collection),
day 1 (24 hours after collection), or day 2 (48 hours after
collection). Mature oocytes were denuded of cumulus cells,
using standard procedures, prior to the ICSI procedure. Intra-
cytoplasmic sperm injection was not performed beyond the
afternoon of the second day of oocyte culture. Fertilization
was assessed 16–18 hours after ICSI for the appearance of
two distinct pronuclei. The embryos were cultured for 2, 3,
or 5 days, depending on numbers and quality. Estradiol
valerate 4 mg orally twice daily from oocyte retrieval and
400 mg daily vaginal P pessaries from the day after oocyteFIGURE 1
Different stages of oocytes maturity after denudation. (A) Germinal vesicle (
polar body extrusion (immature); and (C) metaphase II oocytes, extrusion o
Gremeau. IVM or IVF for women with PCO. Fertil Steril 2012.
VOL. 98 NO. 2 / AUGUST 2012retrieval were used for endometrial preparation. Both drugs
were continued until the pregnancy test and then on until
10 weeks' gestation if pregnant.Results and Statistical Analysis
Mains results were biochemical pregnancy rate (bHCG
positive), clinical pregnancy rate (defined by an ultrasono-
graphic scan heart activity at 8 weeks' gestation), and live
birth rate. All rates were defined per oocyte collection. We
have only taken into account fresh-embryo transfer.
The data were analyzed using Instat3 software and the
Student's t-test or c2 test as appropriate. All P values quoted
are two sided, and values below .05 were considered statisti-
cally significant. The primary outcome measure was live
birth. Secondary outcome measures included rates of oocyte
maturation (number of mature oocytes obtained per number
of oocytes retrieved), clinical pregnancy (fetal heart rate
activity at 8 weeks' gestation), and complications (including
OHSS, coasting, and freeze-all embryo cycles).
RESULTS
Ninety-seven IVM and 97 IVF cycles were identified as cases
and controls, respectively. Cycles were matched for female
age and ovulatory status (45 ovulatory PCO and 52 anovula-
tory PCOS cycles in each group) (Table 1). There were no dif-
ferences in terms of age, body mass index, FSH level, and
cause and duration of infertility. No dominant ovulatory cy-
cles were found in our 97 IVM patients.
Fewer follicles were aspirated during oocyte retrieval in
the IVF than IVM group (22.2  9.0 vs. 35.3  18.6;
P¼ .0005) though the oocyte retrieval rate per aspirated follicle
rate was significantly higher (75.7% vs. 48.8%; P< .0001)
(Table 2). The oocyte IVM rate by 48 hours of culture was
65.01% in the IVM group. Oocyte maturity was assessed in
all IVM cycles, but in the IVF group it was assessed only if
ICSI was being used (38 cycles). The mean (SD) number of
mature oocytes was similar in the 38 IVF-ICSI cycles
(12.3  6.2) and 97 IVM cycles (11.2  7.0; P¼NS). Note
that in the IVM group, after first examination: 68.2% of theimmature); (B) metaphase I oocytes, absence of germinal vesicle but no
f the first polar body (mature).
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TABLE 2




(n [ 97) P value
Cycle
Follicles retrieved 22.2  9.0 35.3  18.6 < .0001
Eggs retrieved 17.2  9.9 15.8  7.2 NS
Oocytes/follicle 75.7 48.8 < .0001
Maturation rate – 65.01 –
Mature oocytes
obtaineda
12.3  6.2 11.2  7.0 NS
Fertilization rate 61.5 62.9 NS
Cleaving embryos 9.6  5.8 6.4  4.8 < .0001
Embryos transferred 1.7  0.6 1.9  0.4 .0043
Day 2 8 13 NS
Day 3 58 80 .0008
Day 5 24 0 < .0001
No transfer 7c 4d NS
Embryos frozen 2.6  3.2 1.4  2.7 .0058
Outcome
Biochemical pregnancy 63.9 (62) 28.9 (28) < .0001
Clinical pregnancyb 50.5 (49) 19.6 (19) < .0001
Miscarriage 12.2 (6) 15.8 (3) NS
Live birth rate 44.3 (43) 16.5 (16) < .0001
Implantation rate 39.4 12.9 < .0001
Twins 25.6 (11) 25 (4) NS
Note: Values are presented as mean  SD, percent, or percent (n). NS ¼ not significant.
a Oocyte maturation is not assessed on IVF, so we compared 38 ICSI cycles (metaphase
II ¼ 469) with 97 IVM cycles (metaphase II ¼ 1,087).
b Clinical pregnancy ¼ fetal heart activity at ultrasonographic scan 8 weeks' gestation.
c FIV ¼ 4 freeze-all embryo for risk of OHSS þ 3 failed fertilization.
d MIV ¼ 3 failed fertilization þ 1 freeze-all embryo for significant bleeding after oocyte
retrieval.
Gremeau. IVM or IVF for women with PCO. Fertil Steril 2012.
TABLE 3
Complications of IVF cycles versus IVM cycles.
IVF group IVM group P value
OHSS moderate or severe
(Golan)
8a (8.2) 0 .0067
Coasting 9 (9.3) 0 .0032
Freeze-all embryo 3 (3.1) 1b (1.0) NS
Note: Values are presented as n (percent) or percent. NS ¼ not significant.
a Eight OHSS (five were coasted and one patient had all the embryos frozen).
b One freeze-all embryo for massive bleeding after oocyte retrieval.
Gremeau. IVM or IVF for women with PCO. Fertil Steril 2012.
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only 3.6% were metaphase II. Fertilization rates were similar
between the groups. More cleaving embryos were produced
in the IVF group but more were transferred in the IVM group
(IVF 1.7  0.6 vs. IVM 1.9  0.4; P¼ .0043). A maximum of
two embryos were transferred per cycle in both groups. The
majority of ETs were performed on day 3 after insemination
in both groups, though significantly more day 5 blastocyst
transfers were undertaken in the IVF compared to IVM group.
In total, 11 cycles did not reach ET, 7 in the IVF group (5 freeze-
all embryos because of a severe risk of OHSS, and 3 because of
failed fertilization) and 4 in the IVM group (3 for failed fertil-
ization and 1 for significant bleeding after oocyte retrieval).
The rates of live birth, pregnancy, and clinical pregnancy
per cycle and the implantation rates were significantly higher
in the IVF compared with the IVM group. The miscarriage and
multiple pregnancy rates were similar between the groups
(Table 2).
There were eight cases (8.2%) of moderate or severe OHSS
requiring hospitalization in the IVF group compared to none
(as expected) in the IVM group (Table 3). Among these OHSS
admission cycles, five were coasted (withdrawal of gonado-
tropin stimulation for 1 or more days) and one had all the
embryos frozen without transfer. In total, in the IVF group,
nine cycles underwent coasting (i.e., four of these cycles did
not end in OHSS requiring admission) and three had all their
embryos frozen in order to prevent OHSS. The only complica-
tion in the IVM group was one case of needing to freeze all
embryos without transfer because of excessive bleeding at358oocyte retrieval. Interestingly, we noted that 27% of the
IVM cycles were performed for women who had previously
undergone IVF treatment complicated by OHSS or cancelled
because of risk of developing OHSS.DISCUSSION
Our case–control study confirms that IVM is a treatment
alternative to IVF for women with PCO. IVM is, however,
significantly less successful than IVF. Our IVM pregnancy
rates are in agreement with previous studies by Child, le Du,
and Cha (6–8), with rates of 22%–27% per cycle.
Ovarian hyperstimulation syndrome is an iatrogenic con-
dition secondary to gonadotropin ovarian stimulation. Fluid
shifts from the intravascular to the third space result in vol-
ume depletion, hemoconcentration, and possible severe com-
plications such as thromboembolism, renal impairment,
respiratory distress, and rarely, death (9). Preventive strategies
during IVF include withholding the hCG trigger (2), coasting
(10), albumin administration at the time of oocyte retrieval
(11), freezing all embryos without transfer, and in women
with PCOS, cotreatment with metformin (12) or use of
GnRH antagonist protocols (13). However, OHSS can occur
despite the use of these strategies. The only way to absolutely
avoid OHSS is to avoid ovarian stimulation, as in IVM. This is
particularly true for women with risk factors for OHSS such as
PCO on scan (regardless of whether ovulatory or anovulatory
cycles) and younger age. Swanton et al. (1) recently reported
OHSS rates in 285 first IVF cycles for younger women. Of
women with anovulatory PCOS, 15.5% developed OHSS,
which was statistically similar to the 12.6% rate in ovulatory
PCO patients, but both were significantly higher than the
2.7% rate for women with normal ovaries. In our study, no
OHSS occurred in the IVM group (as expected) compared to
a rate of 8.2% in the IVF group.
Our results confirm that the IVM live birth rate is signifi-
cantly lower than that for IVF for women with polycystic ova-
rieswhen controlling for patient age and other fertility factors.
A previous study from 10 years ago for a similar patient group
from McGill University in Montreal had similar findings (6).
The live birth rate per IVM cycle was 15.9% and for IVF
26.2% though the difference did not reach statistical signifi-
cance. The numbers of embryos replaced in Montreal was
much higher than in the current study (in the United Kingdom,
the HFEA guidance is for amaximumof two embryos replaced
per cycle). In the 2002 study, the implantation rate of IVMVOL. 98 NO. 2 / AUGUST 2012
Fertility and Sterility®embryos was 9.5% compared to 12.9% in the current study
and for IVF embryos 17.1% then and 39.4% now. Therefore,
it appears that the success rate of IVF has improved over the
past decade to a greater extent than the success rate of IVM.
The continued lower success rate of IVM could
be explained by suboptimal oocyte maturation and/or
impaired endometrial receptivity. An IVM oocyte retrieval is
ideally performed before the development of a dominant
follicle >14 mm diameter in ovulatory women (14), whereas
no dominant follicle develops at all in anovulatory patients.
Hence, the endometrium is exposed to lower levels of endog-
enous E2 than with conventional IVF. In IVM, endometrial
priming with oral estrogen is commenced from the day of oo-
cyte collection. Consequently, the endometrium is exposed to
estrogen for only a few days before ET. Russell et al. (15) re-
ported that initiation of E2 before IVM oocyte retrieval is as-
sociated with reduced oocyte potential and lower success
rates. This unphysiological truncated E2 endometrial priming
regime currently used may explain in part the lower rate of
implantation, particularly because data show that the endo-
metrial thickness at the time of IVM ET is related to the preg-
nancy rate (16).
The lower implantation rate may be also due to subopti-
mal oocyte maturation. We can confirm nuclear maturation,
with extrusion of the first polar body, but are unable to reli-
ably assess cytoplasmic maturation, which depends on a com-
plex cascade of events. Suboptimal and asynchronized
nuclear and cytoplasmic maturation has been postulated as
a cause of IVM implantation failure (17). This also explained
the lower embryo quality and the lower frozen rate in IVM.
To improve IVM results, many authors had proposed a so-
lution such as FSH priming, prolonged hCG interval, or freez-
ing all the oocytes of embryos after IVM to proceed in
a delayed transfer in a subsequent and prepared cycle (18). Re-
garding hCG priming, it has been reported as being of benefit
in women with normal ovaries and ovulatory cycles. All of
our patients had polycystic ovaries, so we did not consider
such adjuvant treatment. Regarding the delay between hCH
and oocyte collection, we have undertaken an internal study,
after the Son paper suggested an advantage of prolonged hCG
interval (19). In our unit, we did not find any difference when
HCG was given 35 or 40 hours before egg collection. These
data are being prepared for submission. At least, in IVM, em-
bryo quality is poorer than IVF (suboptimal oocyte matura-
tion). It is also known that the results of frozen-embryo
transfer are poorer than after fresh cycles. For these two rea-
sons, freeze-all during IVM is unlikely to increase the preg-
nancy rate, even with a better endometrial preparation.
Despite the lower success rate, IVM treatment has many
advantages over standard IVF. It simplifies assisted concep-
tion treatment by using the natural cycle, with no pituitary
suppression or ovarian stimulation, and no need for frequent
ultrasound and blood test monitoring. During an IVM treat-
ment cycle, patients require only one or twomonitoring scans
(with no blood tests), followed by oocyte retrieval and ET. This
simple, unstimulated regime is well accepted by patients.
However, no studies have been reported assessing the cost-
effectiveness of IVM compared with IVF though the lack of
need of expensive gonadotropins is a clear advantage.VOL. 98 NO. 2 / AUGUST 2012More than 1300 babies have been born using IVM (20).
Perinatal and obstetric outcomes of IVM pregnancies are
reassuring according to the small number of studies reported.
Cha et al. (21) reported similar outcomes between IVM and
IVF pregnancies for women with PCOS in terms of gestational
age at delivery, birthweight, and obstetric complications.
No neurodevelopmental concerns during infancy and early
childhood were found (22). Most studies have reported gesta-
tional age at birth and birthweight that is comparable with the
general population. However, the report by Buckett et al. (23)
of higher birthweights in IVM singletons compared to SC
singletons highlights the need for larger studies and empha-
sizes the importance of future studies investigating potential
epigenetic differences in IVM children.
Our study only includes patients with ovaries of polycys-
tic morphology (regardless of whether ovulatory or anovula-
tory cycles). The IVM success rate is related to the number of
immature oocytes retrieved, which is predicted by the antral
follicle count (24). Women with high antral follicle counts
(i.e., PCO) therefore have a higher IVM success rate than do
women with normal ovaries (25). Furthermore, the risk of
OHSS during standard IVF is significantly higher in women
with PCO (1), making these patients ideal candidates for
IVM. The IVM success rate, for women with ovaries of poly-
cystic morphology, is not affected by their ovulatory status
(26). All IVM oocytes were fertilized using ICSI. The reason
for poor fertilization rates after standard insemination has
been thought to depend on altered characteristics of zona
pellucida as a result of the longer culture time before insem-
ination (26). By using ICSI, the fertilization rate of human
IVM oocytes has been reported to be 70%–80% (25, 27).
However, the developmental potential of the fertilized egg
was similar irrespective of the insemination method. A more
recent study (28) reported a higher fertilization rate with
ICSI compared with IVF but higher pregnancy and
implantation rates with IVF compared with ICSI. Therefore,
it is not clear whether ICSI is definitely beneficial or
absolutely necessary to effectively inseminate IVM oocytes
in the absence of impaired sperm parameters.
We conclude that IVM is a safer and simpler, though less
successful, alternative to conventional IVF for women with
ovulatory PCO or PCOS. Many patients, having developed
OHSSwith standard IVF, are unwilling to risk the same compli-
cation again and IVM is a good treatment option. Other patients
approaching assisted conception for thefirst time are very keen
to avoid ovarian stimulation, either because of the hormonal
side effects, the costs of gonadotropins, or the potential risk
of OHSS. Current research projects aim to close the gap between
IVM and IVF. In vitro maturation may never supersede IVF as
the gold standard assisted conception treatment, but is avail-
able as an option to those requiring an alternative.REFERENCES
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 ORIGINAL ARTICLE 
 In vitro maturation and surrogacy in patients with vascular-type 
Ehlers – Danlos syndrome  – A safe assisted reproductive technology approach 
 MARIE-EVE  BERGERON 1,2 ,  TIM CHILD 1  &   MUHAMMAD  FATUM 1 
 1 Nuffield Department of Obstetrics and Gynaecology, Oxford Fertility Unit, Institute of Reproductive Sciences, University of Oxford, 
Oxford, UK and  2 Department of Obstetrics and Gynaecology, Faculty of Medicine, Centre Hospitalier Universitaire de Qu é bec, 
Universit é Laval, Qu é bec, QC, Canada 
 Abstract 
 Ehlers – Danlos syndrome (EDS) is an autosomal dominant connective tissue disorder with one of the highest maternal mortality 
rates of any condition. Patients with the vascular type of EDS are prone to spontaneous arterial and visceral ruptures. The occur-
rence of these severe and life-threatening complications is increased in pregnancy. Moreover, these patients carry a 50% risk of 
having an affected child. However, little is known about the risks of assisted conception treatments on these patients. We present 
the case of a 33-year-old woman suffering from EDS with a history of repeated ruptures of arterial aneurysms and a recently 
ruptured aneurysm of the splenic artery during her fi rst intracytoplasmic sperm injection (ICSI) cycle who was then advised to 
undergo only unstimulated cycles. After a few natural ICSI cycles, the patient safely underwent two in vitro maturation cycles with 
pre-implantation genetic diagnosis in our unit. An unaffected blastocyst was transferred into a surrogate host. To our knowledge, 
this is the fi rst case of EDS in assisted reproduction technologies including pre-implantation genetic diagnosis to be reported in 
the medical literature. This case has shown that unstimulated in vitro maturation and pre-implantation genetic diagnosis can safely 
be offered for vascular-type Ehlers – Danlos patients. 
 Keywords:  Oocyte maturation ,  preimplantation genetic diagnosis ,  surrogacy 
 Introduction 
 Ehlers – Danlos syndrome (EDS) type IV, also known as 
the vascular type of EDS, is an uncommon autosomal 
dominant disorder affecting connective tissue (Pepin 
et  al., 2000; Germain, 2007). It results from abnormali-
ties in the synthesis and structure of collagen (Pepin 
et  al., 2000). Affected patients are at risk of arterial and 
visceral ruptures, such as intestinal and uterine ruptures 
(Pepin et  al., 2000). The diagnosis is often made only 
after a catastrophic complication or at post-mortem 
examination (Pepin et  al., 2000). Women suffering from 
EDS type IV have an increased risk of vascular com-
plications in pregnancy as well as a 50 per cent risk of 
having an affected child (Pepin et  al., 2000). Moreover, 
it is believed that pregnancy increases the likelihood of 
vascular and uterine ruptures (Germain, 2007). EDS 
type IV has one of the highest mortality rates for preg-
nant women of any condition, with signifi cant morbid-
ity if the mother survives (Hammond  & Oligbo, 2012). 
Many reports have been published regarding EDS and 
pregnancy (Pope  & Nicholls, 1983; Jaleel  & Olah, 2007; 
Kundu et  al., 2006) and its catastrophic complications 
(Kundu et  al., 2006; Combeer  & Combeer, 2008; 
Gdynia  & Huber, 2008; Bj ö rck et  al., 2007; Tassart 
et  al., 2006). The complications of EDS in pregnancy 
have been described in several case reports and case 
series, and are now better understood. However, little 
is known of the impact of fertility treatments on this 
disorder and on the reproductive strategies that are most 
suitable for affected patients. Furthermore, the safety 
of assisted reproductive technologies (ARTs) in these 
complex and challenging patients is poorly studied. 
We report a case of an EDS type IV patient who has 
safely undergone several IVM cycles, after experiencing 
a life-threatening abdominal bleed in a previous IVF 
cycle. The patient has given written informed consent 
for the publication of her medical history. 
 Case 
 A 33-year-old woman was diagnosed with EDS type IV 
(vascular type) 6 years previously. She suffered from a 
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number of vascular complications including a coronary 
artery dissection, a right iliac artery aneurysm, a left 
popliteal aneurysm, and a spontaneous subcapsular 
liver haematoma. In order to avoid all the vascular and 
obstetrical complications of EDS in pregnancy as well 
as the genetic risk to offspring, this patient decided to 
undergo in vitro fertilization (IVF) plus intracytoplas-
mic sperm injection (ICSI) with pre-gestational diag-
nosis (PGD) and surrogacy. The patient went through 
her fi rst fresh IVF cycle in 2010 in another unit and 
had a ruptured splenic artery aneurysm the day before 
her oocyte retrieval was planned. This life-threatening 
complication was successfully treated with emergency 
coil embolization. It was hypothesized that the supra-
physiological female steroid hormonal levels (mainly 
oestradiol) contributed to the aneurysm rupture. 
For this reason, the patient was advised by her consul-
tant vascular surgeon not to contemplate any further 
stimulated IVF treatment, although unstimulated ART 
treatment was not contraindicated. 
 The patient then underwent her fi rst unstimulated 
natural IVF cycle, during which one oocyte was collect-
ed and fertilized normally. The embryo was screened for 
EDS and was found to be unaffected. The test is defi ned 
to identify the variant c.2492G   A in the COL3A1 
gene which is responsible for the patient ’ s EDS type IV. 
Polymerase chain reaction (PCR) was employed to am-
plify it to a detectable level a fragment of DNA contain-
ing the variant that is associated with the disease. The 
presence or absence of the variant is then determined 
using the minisequencing technique. Then, one mic-
rosatellite polymorphism, situated in close proximity 
to the defective gene, is amplifi ed and analysed using 
capillary electrophoresis. The analysis of the mutation 
site revealed the normal copy of the COL3A1 gene. The 
embryo was then transferred into a surrogate host, but 
failed to implant. Subsequently, the patient had four 
unstimulated natural IVF cycles with oocyte retrievals. 
In total, 5 oocytes were retrieved and fertilized nor-
mally with ICSI. All embryos were vitrifi ed on day 1 of 
development. On thawing, only one embryo reached 
the 5-cell stage on day 3 and was biopsied. However, 
this embryo did not continue to divide after the biopsy 
and the cycle was abandoned. 
 After these failed unstimulated IVF cycles, this 
patient was referred to our Unit to discuss the option 
of in vitro maturation (IVM) plus ICSI, PGD and sur-
rogacy. The process of an unstimulated IVM cycle in 
our unit has been described recently (Gremeau et  al., 
2012). Having obtained the patient ’ s informed consent, 
it was planned to undergo a number of unstimulated 
IVM cycles and to freeze all fertilized eggs on day 1 of 
zygote development. The plan was to achieve a satisfac-
tory number of embryos in storage, thaw them all and 
culture them to day 3 for the PGD biopsy with the hope 
of fi nding some unaffected embryos to replace on day 5 
into the surrogate recipient. 
 The patient had regular menstrual cycles lasting 26 –
 28 days. A baseline scan was done before starting the 
treatment and her antral follicle count (AFC) was 11. The 
patient then underwent a fi rst unstimulated IVM cycle. 
After ultrasound scan follow-up, the patient was given an 
injection of 10 000 IU of rHCG on day 6 of her natural 
cycle. The oocyte retrieval was performed 35 h after the 
trigger. On the day of the oocyte retrieval, the leading fol-
licle measured 12 mm and there were 9 follicles. During 
the oocyte retrieval, extra attention was paid to the known 
right iliac artery aneurysm. All follicles were punctured, 
but only one oocyte was collected. Unfortunately, the egg 
was atretic and ICSI could not be performed. 
 One month later, the patient underwent another un-
stimulated IVM cycle. rHCG was prescribed on day 6 
of her natural cycle with a leading follicle of 14.5 mm. 
The oocyte retrieval was performed 35 h later, and the 
leading follicle was then 16 mm with an AFC of 7. Three 
oocytes were collected and matured in vitro. They all 
fertilized normally with ICSI. According to the plan, all 
fertilized oocytes were frozen on day 1. 
 A third unstimulated IVM cycle was booked, and 
it was planned that all embryos would be thawed and 
biopsied during this cycle. However, the patient was 
diagnosed with a 25-mm simple ovarian cyst on day 7, 
and the IVM cycle had to be cancelled. However, the 
patient decided to go ahead with the planned frozen 
embryo replacement (FER) cycle into the surrogate 
using the embryos from previous cycles. The surrogate 
underwent a natural FER cycle. All three embryos 
were thawed and 2 embryos survived. These were both 
biopsied at the cleavage stage on day 3. The fi rst embryo 
had 7 cells, one cell was taken for PGD, but failed to 
yield a diagnosis and did not continue to divide. The 
second embryo also had 7 cells when biopsied. One cell 
was taken and found to be unaffected with EDS. This 
unaffected embryo then progressed to the early blasto-
cyst stage. This blastocyst was transferred on day 5 of 
embryo development into the surrogate host, but 7 days 
after the surrogate ’ s natural LH surge. Unfortunately, 
the embryo did not implant. 
 Discussion 
 The vascular type of EDS is a rare connective tissue 
disorder caused by abnormal synthesis of type III procol-
lagen due to COL3A1 gene mutation on chromosome 
2 (Oderich et  al., 2005). The resultant tissue fragility 
and weakness can lead to multiple complications such 
as visceral rupture and spontaneous arterial rupture. 
The mean life expectancy is 48 years, and premature 
death is usually caused by vascular complications 
(Pepin et  al., 2000; Oderich et  al., 2005). The inheri-
tance is autosomal dominant: affected individuals have 
a 50% chance of transmitting the disease to each child. 
In about half of the patients, a  de novo mutation is found 
(Nanayakkara et  al., 2006), so they do not have any 
familial history of EDS. 
 In EDS patients, catastrophic vascular ruptures tend 
to occur more frequently during pregnancy and post-
partum (Germain, 2007). Knowing that the mortality 
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rate among pregnant women affected by this disorder 
is estimated to be between 12% (Pepin et  al., 2000; 
Germain, 2007; Hammond  & Oligbo, 2012) and 25% 
(Pope  & Nicholls, 1983), women are often advised to 
avoid pregnancy and to consider adoption (Germain, 
2007). Surrogacy represents a good medical alterna-
tive to adoption in affected women who wish to have 
a biological child and to avoid any severe obstetrical 
complications. Therefore, IVF and surrogacy could be 
the reasonable options. 
 In our current patient, who previously experienced 
severe life-threatening vascular complications, the 
latest being during her fi rst stimulated IVF cycle, and 
knowing that pregnancy increases the likelihood of vas-
cular and other organ ruptures, it was agreed upon to 
proceed with unstimulated IVM treatment followed by 
PGD and embryo transfer into a surrogate host. It was 
clinically hypothesized that the relatively high supraphysi-
ological levels of oestradiol, similar to the high oestrogen 
levels in pregnancy, might be the underlying mechanism 
for the increased vascular fragility especially in the locus 
minoris resistentiae  – the thinning aneurysmatic wall. It 
is well known that these severe complications happen 
more frequently during the third trimester and during 
the immediate post-partum period (Germain, 2007). 
The increasing serum oestradiol concentration together 
with the associated increased vascularity throughout 
pregnancy might therefore explain the increased risk of 
vascular rupture in pregnant women, especially during 
the third trimester and immediate post-partum period 
(Germain, 2007). For these reasons, it might be advis-
able to avoid ovarian stimulation in these patients and 
to use unstimulated natural IVF or IVM treatment. 
Natural IVF cycles remain a good option for these pa-
tients, but sequential IVM cycles should probably be 
considered as an alternative, in that they may achieve 
more oocytes per cycle, thus decreasing the number 
of egg retrievals and potentially increasing the number 
of embryos available for PGD with the prospect of an 
increased success rate. Although no specifi c treatments 
can prevent complications in EDS patients, knowl-
edge of the diagnosis can infl uence the reproductive 
counselling and prevent catastrophic complications. 
 PGD can be performed on cell(s) biopsied from 
the polar body of an oocyte or from a pre-implantation 
embryo with the aim of establishing a pregnancy that is 
unaffected by a specifi c genetic anomaly. In this case, 
biopsies were performed at the cleavage stage to avoid 
any risk of loss of embryos during their in vitro culture 
since serial IVM frozen embryos were used. PGD could 
have also been performed following polar body biopsy 
since the mutation which needed to be detected was 
maternal, or at the blastocyst stage. Blastocyst biopsy 
seems to be least disruptive to subsequent development 
while providing the most DNA for testing (Ly et  al., 
2011). However, in the absence of scientifi c evidence in 
the fi eld of PGD on IVM oocytes and embryos, it was 
thought that the safest option was to biopsy all embryos 
at the cleavage stage and culture them to the blastocyst 
stage while awaiting the PGD result. 
 Conclusion 
 To our knowledge, this is the fi rst case of EDS type IV 
in IVF – ICSI and IVM – ICSI with PGD and surrogacy 
to be reported in the literature. Many reports have been 
published regarding EDS in pregnancy (Hammond 
& Oligbo, 2012; Pope  & Nicholls, 1983; Jaleel  & 
Olah, 2007) and its catastrophic complications (Jaleel 
 & Olah, 2007; Combeer  & Combeer, 2008; Gdynia  & 
Huber, 2008; Bj ö rck et  al., 2007; Tassart et  al., 2006). 
Clinicians ’ awareness and accumulated knowledge of 
this rare, high-risk syndrome in pregnancy have recently 
improved, and new obstetrical strategies are emerging 
to help these women (Jamard et  al., 2012; Palmquist 
et  al., 2009). In fact, new protocols for managing these 
patients in pregnancy could encourage more affected 
women to consider pregnancy. Thus, an increasing 
number of women may contemplate assisted repro-
duction techniques using PGD to eliminate the risk 
of transmission of their disease to their offspring. How-
ever, the risks of fertility treatments in this syndrome 
are unknown and, as often is the case with rare genetic 
disorders, unfamiliarity with the disease could compro-
mise care (Pepin et  al., 2000). In conclusion, this case 
has shown that IVM – ICSI and PGD can be done safely. 
Moreover, during this treatment, the blastocyst stage 
was reached, which is an important step forward for this 
patient. It also adds to the medical literature for PGD 
and gives additional reproductive choices for couples 
who carry the EDS mutations. 
 Declaration of interest: The authors report no 
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Background: This study intends to present the role of rescue in vitro maturation (IVM) 
in polycystic ovarian syndrome (PCOS) patients undergoing in vitro fertilization (IVF) 
treatment who have inappropriate responses to ovarian stimulation. 
 
Materials and Methods: This was a retrospective case series study of five PCOS 
patients undergoing IVF treatment considered for cycle cancellation due to increased 
risk of ovarian hyperstimulation syndrome (OHSS) as group A or poor response to 
ovarian stimulation as group B. Patients in group A had high oestradiol levels and 
recruitment of high numbers of small/intermediate sized follicles that did not meet the 
criteria for human chorionic gonadotropin (hCG) triggering. Patients in group B 
responded inadequately to hormonal stimulation despite high gonadotropin dosage. 
Treatment was changed to rescue IVM cycles after the patients provided consent.  
 
Results: In group A, three IVF patients deemed to have high chances of developing 
OHSS as evidenced by high oestradiol levels were converted to IVM. A total of the 
58/68 oocytes retrieved were mature or matured in vitro. There were 26 cleaving 
embryos obtained. Two patients had live births and one patient suffered a miscarriage. 
In group B, rescue IVM was implemented in two patients due to poor ovarian response 
(POR). A total of 22/26 oocytes retrieved were mature or matured in vitro. There were 
13 cleaving embryos obtained. One patient had a live birth, whilst the other suffered a 
miscarriage. 
 
Conclusion: Rescue IVM could be a viable option in PCOS patients undergoing IVF 
treatment who are unable to safely meet the criteria for hCG triggering due to 
overresponse to ovarian stimulation or ovarian resistance to high doses of stimulation. 
Conversion to IVM can still result in reasonable oocyte retrieval and lead to clinical 
pregnancy and live births without the risks of OHSS. 
 





Ovarian superovulation with gonadotropin stimulation is still the mainstay of in vitro 
fertilization (IVF) (1). The aim of ovarian stimulation is to induce multifollicular 
recruitment with as much synchronized cytoplasmic and nuclear maturation as possible, 
and to safely obtain a higher number of mature eggs at the time of egg collection (2). 
Side effects of ovarian stimulation can include breast tenderness, abdominal bloating, 
nausea and vomiting (3). More importantly, it can lead to ovarian hyperstimulation 
syndrome (OHSS), particularly in women with polycystic ovarian syndrome (PCOS) 
(4, 5). 
 
PCOS is probably the most frequently encountered endocrinopathy in women of 
reproductive age (6). It is characterized by irregular menses, hyperandrogenism, and 
polycystic ovaries (PCO) on ultrasound findings. The prevalence of PCOS may be as 
high as 15-20% (7). It is believed that harvesting more eggs would compensate for 
subfertility in these patients. However, ovarian responses to the same stimulation 
protocols may vary considerably among different PCOS patients and even among 
different cycles in the same patient (8).  
 
In some cycles, patients may be overstimulated, resulting in a very high number of 
growing follicles and increased levels of oestradiol. This group of patients is at higher 
risk of developing OHSS (9-11). In addition, a large cohort of antral and preantral 
follicles are recruited in these overstimulated cycles, which are asynchronous and 
heterogeneous in their growth and development (1). Consequently, immature and 
mature eggs are retrieved in these cycles. In some cases, this may prove to be a complex 
conundrum that needs much consideration, particularly when the patient is at high risk 
of OHSS, as demonstrated by high hormone levels, and there is an insufficient number 
of large-sized follicles. In these cases, cancellation could be the only option. Coasting 
may not be effective or plausible, as oestradiol production may increase further (12). 
 
On the other end of the spectrum, management of PCOS women with poor ovarian 
response (POR) can be an equally frustrating challenge. Despite the high number of 
small follicles per ovary (2-3 times that of normal) (13), there is poor follicular growth 
and development in response to gonadotropin stimulation. This adversely affects 
mature oocyte retrieval and, more importantly, pregnancy success. Like patients at high 
risk of developing OHSS, these women also face the prospect of cycle cancellation. 
We report a cohort of overstimulated IVF patients, as indicated by their rapidly 
increasing oestradiol levels and the large number of follicles, and a cohort of poor 
responders to ovarian stimulation who converted to rescue in vitro maturation (IVM) 
treatment. The aim of this study is to examine the rate of immature oocyte recovery and 
their potential for IVM from cancelled IVF cycles due to an abnormal response to 
gonadotropin stimulation. 
 
Materials and Methods 
Eligible patients 
Unplanned IVM rescue cycles were undertaken for five PCOS patients who had 
abnormal responses to gonadotropin stimulation as part of their IVF treatment between 
2007 and 2010 at the Oxford Fertility Clinic.  
PCOS was defined according to the modified Rotterdam criteria (14) . Women who 
were considered to have overresponded had either high levels of oestradiol and/or a 
high number of growing follicles (>20 at an early stage). Conversely, women who were 
considered as resistant to gonadotropin stimulation either responded poorly 
biochemically with low oestradiol levels or had poor follicular growth as evidenced by 
scans. Women aged over 40 and who had more than three previous failed IVF cycles 
were excluded from the study. In accordance with Oxford University Ethics Committee, 
the study was not registered and Ethical approval was not required as data were 
anonymised, not identifiable by researchers and were collected before the study was 
formulated.  
 
In vitro fertilization and in vitro maturation  
Our standard protocol for IVF and IVM treatments were described previously (15). 
Statistical analysis  
This was a case series study produced as part of an IVM programme at Oxford Fertility 
Unit, UK. Statistical analysis was carried out by a biostatistician at Oxford University. 
Statistical analyses were done using Microsoft Excel (Microsoft Office 365). Tables 
were produced using Microsoft Excel (Microsoft Office 365). Graphs were produced 
using GraphPad Prism 8.0.0 on Mac OSX (????, ???). The case series was reported 
using the case report (CASE) guidelines checklist (16). 
 
Results 
We present five cases of PCOS patients (see criteria above) aged between 31 and 39 
years who each underwent an unplanned rescue IVM cycle due to an abnormal ovarian 
response to gonadotropin stimulation at Oxford Fertility Clinic between 2007 and 2010. 
They agreed to undergo immature oocyte maturation retrieval with subsequent IVM of 
oocytes to rescue their IVF treatment. Prior to the treatment, they all had normal ovarian 
reserves according to their early follicular phase follicle stimulating hormone (FSH) 
and antral follicle counts (AFC). The main results examined were biochemical 
pregnancy [beta human chorionic gonadotropin (βhCG) positive], clinical pregnancy 
rate (defined as heart activity at 8 weeks on an ultrasonography scan) and live birth rate. 
Three patients (group A) were offered the option of converting to IVM rather than 
cancelling their IVF cycles as they were deemed to be at risk of developing severe 
OHSS. Average oestradiol on the day of cancellation was 11 078 ± 5141.9 pmol/L 
(Fig.1). Nevertheless, none of these patients actually developed OHSS. Oocyte retrieval 
rate per aspirated follicle was 35%. A total of 68 oocytes were retrieved between the 
three patients in each group, and 58 of the 68 oocytes reached metaphase I (MI) or 
metaphase II (MII, Fig.2). Twenty-six cleaving embryos were obtained in group A 
(Table 1). 
In group B, two patients were offered the option of rescue IVM cycle because they had 
POR to gonadotropin stimulation. Average oestradiol level of the day of cycle 
cancelation was 2141.5 ± 482.9 pmol/L (Fig.1). Despite their disappointing response to 
ovarian stimulation, 13 oocytes were retrieved from each patient. In fact, oocytes could 
be obtained in 33% of all follicles identified and aspirated.  Eleven oocytes were mature 
or matured in vitro for each patient (Fig.2). A total of 13 cleaving embryos were 
obtained in this group. 
 
Table 1: Baseline characteristics and outcomes for each patient. Table showing baseline 
characteristics of each patient, oestradiol levels on the day of cancellation of IVF treatment, as 





Patients 1-3 represent group A. Patients 3-4 represent group B. Pt; Patient, no; Number, MI; 
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1 32 23 6065 22 22 (100) 22 17 (77) 12 2 + Live birth 
2 31 21 16 340 34 28 (82) 28 15 (54) 12 2 + Miscarriage 
21 weeks 
3 34 23 10 830 12 8 (67) 8 4 (50) 4 2 + Live birth 
4 32 23 1800 13 11 (85) 11 6 (55)  5 2 + Live birth 
5 39 24 2483 13 11 (85) 11 8 (73) 8 2 + Biochemica
l pregnancy 
 
In both groups, all patients had two fresh cleavage embryos transferred on day 3 of 
development and all (100%) had positive pregnancy tests two weeks later. Three of the 
five patients (60%) gave birth to healthy singletons at term (38 and 40 weeks) or near 
term (35 weeks). Unfortunately, one patient in group A had a late second trimester 
miscarriage and one patient in group B had an early first trimester miscarriage (Fig.1). 
Moreover, three patients had the opportunity to store their embryos. Two patients 






Fig.2: Numbers of oocyte retrieved and matured. Bar chart shows the numbers of oocytes retrieved and 







Our case series study shows that rescue IVM could be a viable option in PCOS patients 
undergoing IVF treatment but failing to safely meet the criteria for hCG triggering 
because of either ovarian overresponse or underresponse to hormonal stimulation. 
 
In our study, we did not use the conventional definition of POR as defined by the 
European Society of Reproduction and Embryology (ESHRE) (17). Instead, POR in 
our study referred specifically to PCOS patients with normal ovarian reserve and high 
antral follicular count (AFC), yet showed poor hormonal and follicular response despite 
controlled ovarian hyperstimulation (COH). It leads to reduced oocyte production, 
cycle cancellation and, most importantly, a reduced probability of pregnancy. It is 
unclear why women with PCOS can have such contrasting responses to gonadotropin 
stimulation, although it has been suggested that certain PCOS phenotypes may be 
correlated with adverse assisted reproductive outcomes (8). There is no test that can 
reliably predict outcome of ovarian stimulation in women with PCOS. However, anti-
Müllerian hormone (AMH) on day 3 of the IVF stimulation cycle may positively predict 
ovarian response to gonadotropin stimulation. Oestradiol levels on the day of hCG 
administration and oocyte retrieval rate positively correlate with increasing AMH levels 
during IVF cycles in PCOS patients (18). As there is no way to reliably predict poor 
responders to gonadotropin stimulation, we cannot identify these women for IVM 
straightway. However, rescue IVM after failed IVF may provide these women with a 
chance of pregnancy within the same cycle of treatment. 
 
There have been efforts to identify an algorithm based on the woman’s age and markers 
of ovarian reserve to optimise the FSH starting dose in assisted reproductive techniques 
(ARTs). A recent study suggested that the application of a nomogram could lead to a 
more tailored approach, increasing the cost-effectiveness of infertility treatment. In 
general, the starting dose of FSH as calculated by the nomogram was lower than the 
actual prescribed dose, which might reduce the risk of OHSS. However, the authors 
also suggested the inadequacy of the nomogram in PCOS patients, especially in those 
with high AMH levels (19). Further studies are required to assess the utility and 
generalisability of such nomograms. The risk of OHSS may also be reduced by the 
administration of adjuvant medication. Administration of D-chiro-inositol (DCI) in 
PCOS patients resulted in a higher ovulation rate compared to placebo (20, 21). Myo-
inositol and DCI may improve many of the metabolic and hormonal dysregulations 
characteristic of PCOS (22), and myo-inositol seems to be able to increase oocyte 
quality, decrease the days of FSH stimulation before hCG administration and, hence, 
the risk for OHSS (23, 24). 
 
OHSS is an iatrogenic, systemic condition secondary to gonadotropin stimulation that 
occurs either during the luteal phase or during pregnancy. The most common form 
happens a few days after the induction of follicular rupture via injection of hCG when 
follicular growth has been medically induced (25). Fundamentally, in OHSS, an 
increase in vascular permeability results in third-space fluid loss, leading to 
intravascular volume depletion and haemoconcentration (9). Thromboembolism is a 
potentially serious consequence of OHSS, and can sometimes be fatal despite treatment 
(26). Additionally, OHSS been reported to be linked to hepatic and renal dysfunction 
(27, 28), but the link between COH and renal/liver dysfunction are still debated. A study 
by Romito et al. (????) examined 426 patients undergoing IVF treatment and found that 
COH did not significantly alter renal and hepatic functions. In contrast, Giugliano et al. 
(29) reported a case of hepatic failure after four cycles of COH in a patient that 
developed severe haemolysis, elevated liver enzymes and low platelets (HELLP) 
syndrome. Various preventative strategies of OHSS during IVF have been suggested, 
such as coasting (30), co-treatment with cabergoline (31) or metformin (32), 
cryopreservation of embryos (33), or the administration of gonadotropin releasing 
hormone agonists (GnRH-agonist) instead of hCG in women treated in antagonist 
protocols (34). However, the only absolute way of preventing OHSS is to avoid ovarian 
stimulation, as in IVM. Given the evidence between COH and renal/liver dysfunction 
is still debated, avoiding ovarian stimulation by using IVM may have the added 
advantage of preventing such complications, especially when many women have 
already gone through multiple cycles of IVF and may be at higher inherent risk for 
developing renal/hepatic dysfunction. 
 
Despite the advances in ARTs, one of the main challenges is the management of 
patients who have POR. To this end, luteal phase ovarian stimulation and 
dehydroepiandrosterone (DHEA) supplementation have shown promising results in 
improving outcomes in PORs. Preliminary results from a single centre pilot study by 
Lin et al. have demonstrated that luteal phase ovarian stimulation significantly 
improved oocyte retrieval and quality when compared to follicular phase ovarian 
stimulation in patients undergoing IVF (35). In a similar finding, Chern et al. (36), in 
their retrospective study, reported a potential benefit of DHEA supplementation pre-
IVF cycle in PORs by showing improved oocyte retrieval rate, quality of embryos and 
live birth rate compared to the control group.  
 
The success rate with IVM is associated with the number of immature oocytes obtained, 
which is predicted by the AFC. Women with PCOs have higher AFCs (13) and, 
therefore, have a comparatively increased rate of success than those with normal 
ovaries. Women with PCO are at significantly higher risk of developing OHSS (4, 5). 
In our previous study, we have reported that IVM is a simpler, safer, although less 
successful alternative, for women with PCO or PCOS (15). Balancing the higher 
success rate of IVF in PCO/PCOS women with the risk of potentially developing OHSS 
can be a complex dilemma. With the possibility of initial IVF treatment, and then rescue 
IVM if they are at significant risk of developing OHSS, we may be able to make a 
compromise between success rate and safety that neither IVF nor IVM alone can 
achieve in PCOS patients. 
 
One of the strengths of our study is the corroboration of previous findings, not only 
from our own group but that of others. The concept of rescue IVM began approximately 
two decades ago. Coskun et al. (37) have demonstrated that immature oocytes can be 
recovered from cancelled human gonadotropin cycles and these oocytes can be matured 
in vitro. Later, in a related publication, Jaroudi et al. (38) reported on 18 patients who 
underwent IVF but were then deemed to be at significant risk of developing OHSS. 
These women had cycle cancellation and underwent immature oocyte retrieval with 
subsequent IVM. On average, 8.1 immature oocytes were retrieved from each patient 
and 44 embryos were transferred in 17 cycles. There were two live births; however, one 
baby was delivered preterm and died shortly after. The study suggested that oocytes 
matured in vitro from incomplete IVF cycles could be fertilised by intracytoplasmic 
sperm injection (ICSI) and the those embryos could result in pregnancies. However, at 
time, the low success rate could not justify recommendation of more widespread use 
without further research. In our study, the average number of oocytes retrieved per 
patient in both groups was higher than reported by Jaroudi et al. (38). There are a 
number of potential explanations for this. First, the study by Jaroudi et al. (38) included 
not only PCOS patients, but also those with other types of infertility, such as 
anovulatory and unexplained cases. It is known that PCOS patients have higher 
numbers of follicles from which immature oocytes may be retrieved. It is also plausible 
that the improvements in both the IVF and IVM protocols have contributed to the higher 
numbers of immature oocytes picked up in our study.  The live birth rate (60% overall) 
in our study was also higher. Again, improvements in techniques and protocols may 
have contributed to results; however, we are aware that our cohort is very small. In our 
study, the maturation rate (reaching MII) in group B (27%) was lower than that in group 
A (58%), which was comparable with our previous study (65%) (39). Whilst this seems 
to be a significant difference, it is noteworthy that the cohort size in our previous study 
was 94, which is considerably larger than that of our current study. It is possible that 
there a genuine difference exists in the ability of oocytes to mature between poor 
responders and overresponders, which may share the same aetiology as ovarian 
resistance to hormonal stimulation. The fertilization rate for both groups is similar to 
that reported in our previous study, which is promising as it suggests that oocytes in 
rescue IVM are not adversely affected by their previous exposure to gonadotropin 
stimulation, regardless of the ovarian response. 
  
The main limitation of our study is the sample size - the high clinical pregnancy rate 
and live birth rate reported in this study are arguably influenced by the small cohort 
size and interpretation of these results requires caution. Whilst a biostatistician carried 
out the data analysis, we did not calculate the sample size required before the start of 
the study. This was due to logistical reasons of finding cases of cancelled IVF with 
subsequent agreement of undergoing IVM. Arguably this affects the generalisability of 
our study and the ability to draw definitive conclusions based on the findings of this 
mini case series. However, our aim is to highlight the possibility of IVM success in a 
proportion of PCOS patients who fail IVF treatment in a field that has the scope for 
further study and research. 
 
IVM has an inherent advantage over conventional IVF by utilising the natural menstrual 
cycle, and bypassing the need for ovarian stimulation and pituitary suppression, albeit 
at the cost for reduced chances of success. Conventionally, IVM has been considered 
an alternative to IVF in women at risk of OHSS or in those who may have a POR to 
gonadotropin stimulation. Here, we present IVM as a potential add-on treatment, which 
is not considered as an alternative to IVF, but rather alongside it as a rescue strategy. 
The advantage is that potentially recoverable immature oocytes in cancelled cycles are 
not wasted and the emotional stress associated with facing a potentially cancelled cycle 
is reduced. Additionally, it may help prevent these patients from undergoing another 
costly, lengthy stimulation protocol.  
Conclusion 
We conclude that rescue IVM could be a viable option in PCOS patients undergoing 
IVF treatments who fail to safely meet the criteria for hCG triggering, either due to 
overresponse to ovarian stimulation or ovarian resistance to high doses of stimulation. 
Conversion to IVM can still result in reasonable oocyte retrieval and lead to clinical 
pregnancy and live births without the risks of OHSS. Further research is needed to 
determine the aetiology of POR and OHSS, and identify markers that will allow us to 
reliably predict which patients for whom IVF is less appropriate than IVM. Larger 
studies are needed to determine whether rescue IVM is a widely applicable strategy for 
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CONCLUSION: This study represents the first vibrational approach to
evaluate the macromolecular changes associated with oocyte ageing. So,
FPAFT-IR imaging could be considered a powerful technique to provide
a biochemical fingerprint. This novel approach may represent a synergic sup-
port to evaluate oocyte quality.
Supported by: University of Ancona founding 2010 to O. Carnevali and E.
Giorgini.P-449 Wednesday, October 19, 2011
IMPAIRED DNA REPAIR AS THE ROOT CAUSE OF OOCYTE AG-
ING. K. Oktay, E. Heytens, R. Soleimani, V. Baltaci, S. Goswami. Institute
for Fertility Preservation, Obstetrics & Gynecology, New York Medical Col-
lege, Valhalla, NY; Cell Biology & Anatomy, New York Medical College,
New York, NY; Department of Human Genetics, Istanbul Bilim University,
Istanbul, TR, Turkey; Department of Biology, Yeshiva University, New
York, NY.
OBJECTIVE: The molecular mechanisms behind age-related decline in
oocyte quantity and quality are unknown. Recent work indicated that women
with BRCA mutations may have lower egg reserve and experience meno-
pause earlier. Because BRCA is a key double strand DNA break (DSB) repair
gene, we hypothesized that impaired DSB repair and resulting accumulation
of DSBs is responsible for oocyte aging.
DESIGN: Experimental.
MATERIALS AND METHODS: Given the age-related decline in oocyte
yield after ovarian stimulation (41 15 at 4 wks to 11 5 at 9-mo), we used
‘‘young’’ (4-wk-old) and ‘‘old’’ (9-mo-old) female FVB mice (n¼ 24). Either
primordial follicles (PDF) were assessed for DSBs by gH2AX immunostain-
ing in ovarian sections, or GVoocytes by confocal microscopic quantification
ofgH2AX foci. The expression of ATM-mediated DSB repair pathway genes
were analyzed by QRT-PCR in PDF captured by laser dissection (LD) as well
as GVoocytes. The same was also analyzed in single human oocytes (n¼ 20)
by QRT-PCR from young (age<27) and old (age>37) subjects.
RESULTS: gH2AX-positive PDF increased significantly in old mice com-
pared to young (16  3 vs. 10 2; P¼0.002). Mean number of gH2AX foci
was also significantly higher in GVoocytes of old vs. young (1,279 594 vs.
373  258; P¼0.01). By QRT-PCR from mouse GVoocytes, the expression
of MRE11, a gene involved in sensing DSBs and activating repair via the
ATM- pathway, was downregulated by 50-99% with age. In PDF from old
mice, the expression of BRCA1 was downregulated by 77-89%. Consistent
with findings in rodent oocytes, QRT-PCR of single human oocytes showed
that the key genes in the DSB repair pathway was down-regulated with age.
CONCLUSION: These rodent and human data support our novel hypoth-
esis that oocyte aging is associated with accumulation of potentially lethal
and mutagenic DSBs due to the impairment of DSB repair in the aging oo-
cyte. Active and efficient DNA repair appears to be vital for oocyte health.
These findings can be paradigm-shifting in understanding oocyte aging.
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ROLEOFMELATONIN IN PREVENTINGHYPOCHLOROUSACID
INDUCED ALTERATIONS IN MICROTUBULE AND CHROMO-
SOMAL STRUCTURE IN METAPHASE-II MOUSE OOCYTES IN
VITRO. J. Banerjee, D. Maitra, F. Shaeib, G. M. Saed, M. P. Diamond,
H. Abu-Soud. Obstetrics and Gynecology, Division of Reproductive Endo-
crinology and Infertility, Wayne State University, Detroit, MI.
OBJECTIVE: Recently, we have shown that melatonin, a pineal gland hor-
mone, can prevent hypochlorous acid (HOCl) mediated protein aggregation
and hemeprotein destruction. We have demonstrated that HOCl may alter
metaphase-II oocyte microtubule and chromosomal alignment. The objective
of the study was to test whether melatonin prevents the impairment of oocyte
quality induced by HOCl in vitro.
DESIGN: Dose response study.
MATERIALS AND METHODS: Metaphase–II mouse oocytes, obtained
commercially, were incubated in HTF for 60 minutes. Oocytes were grouped
as: control, melatonin (150, 200 nmol/mL), HOCl (10, 20, 50, 100 nmol/mL)
and HOCl (50 nmol/mL) pretreated with 150 and 200 nmol/mL of melatonin.
Microtubule and chromosomal alignment was studied on fixed and stained
oocytes and then scored by two observers based on a previously published
scoring system (Fert Stert 1222,Vol 88,Suppl 2, October 2007). PearsonFERTILITY & STERILITYChi-square test, Fisher’s Exact test were used compare outcomes between
controls and treated groups and also amongst each group.
RESULTS: Poor scores for the spindle and chromosomes increased signif-
icantly at 50 nmol/mL of HOCl (P<0.001). Oocytes treated with melatonin
only at 150 and 200 nmol/mL showed no changes; significant differences
(P<0.001) were observed when oocytes exposed to 50 nmol/mL of HOCl
were compared to oocytes pretreated with melatonin 200 nmol/mL.Fifty per-
cent of the oocytes demonstrated good scores both in microtubule and chro-
mosomal alterations when pretreated with melatonin at 150 nmol/mL
compared to 0% in the only HOCl group.
CONCLUSION: HOCl alters the metaphase-II mouse oocyte spindle and
chromosomal alignment in a dose dependant manner, a potential cause of
poor oocyte quality in patients with endometriosis. Melatonin prevented
the HOCl-mediated spindle and chromosomal damage. Melatonin supple-
mentation could be an attractive therapeutic option to prevent oocyte damage
in endometriosis or inflammatory diseases to improve fertility and reproduc-
tive outcome.
Supported by: Wayne State University.
OOCYTE MATURATION
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IVM FORWOMEN WITH POLYCYSTIC OVARIES? A CASE-CON-
TROL STUDY. T. J. Child, J. Craig, K. Turner, E. McVeigh, M. Fatum, A.-
S. Gremeau. Oxford Fertility Unit, Oxford, Oxfordshire, United Kingdom.
OBJECTIVE: The in-vitro maturation (IVM) of immature oocytes re-
trieved from unstimulated ovaries is a promising treatment, particularly for
women with polycystic ovaries (PCO). IVM is safer, simpler and cheaper
than IVF. There are no published RCTs comparing IVM and IVF and only
one case-control study from 2002. The aim of this study is to compare the
outcome of unstimulated IVM and routine IVF/ICSI for women with ultraso-
nographic PCO undergoing treatment at the Oxford Fertility Unit.
DESIGN: Case-control study.
MATERIALS AND METHODS: The study included 250 women with
PCO undergoing their first IVM (n ¼ 125) or IVF (n ¼ 125) cycle, matched
for age, infertility diagnosis and ovulatory status (ovulatory PCO or anovu-
latory PCOS). The primary outcome measure was live birth rate per cycle.
IVM cycles were unstimulated and hCG was administered 35-40h before
trans-vaginal immature oocyte retrieval. Oocytes were matured in-vitro for
24-48h before insemination by ICSI. Endometrial priming with estradiol
and progesterone was commenced following oocyte retrieval and 1-2 em-
bryos transferred on day 2-5 of embryo development. Standard long protocol
IVF/ICSI was used in the control group.
RESULTS: The mean age was 32.8 years in both groups. A mean (SD) of
17.4 (9.6) and 15.3 (7.4) eggs were retrieved in the IVM and IVF groups, re-
spectively (P<0.05). 66% of IVM eggs matured in-vitro. The live birth rate
per retrieval was significantly lower for IVM compared to IVF (18.4% v
42.4%; P<0.001), as were the implantation (14.2% v 37.2%; P<0.001)
and clinical pregnancy rates (21.6% vs. 52.0%, P<0.001). The OHSS rate
was significantly higher in the IVF group (8.8%) compared to none in the
IVM group.
CONCLUSION: IVM is a safer and simpler alternative to conventional
IVF for women with PCO or PCOS. IVM avoids the cost of gonadotropin
stimulation and the risk of OHSS, but has a significantly lower live birth
rate than IVF.P-452 Wednesday, October 19, 2011
EFFECTS OF ANDROGEN SUBSTRATE ON BOVINE CUMULUS-
OOCYTE COMPLEXES STEROIDOGENESIS DURING IN VITRO
MATURATION. A. C. J. S. Rosa-e-Silva, D. L. Bulgarelli, A. A. Vireque,
C. P. Pitangui, M. P. Bernuci, M. F. Silva-de-Sa. Gynecology and Obstetrics,
Faculty of Medicine of Ribeir~ao Preto - University of S~ao Paulo, Ribeir~ao
Preto, S~ao Paulo, Brazil.
OBJECTIVE: Ovarian steroids are known as important factors on the route
of oocytes development. Since serum-supplemented in vitro maturation
(IVM) media decreases estradiol secretion by bovine cumulus-oocyte com-
plexes (COCs), the aim of this study was to assess whether this effect is
caused by deficiency of substrate or by low cumulus cells aromatase activity.
DESIGN: Prospective experimental study with bovine oocytes.S239
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FCV1- Interstitial Pregnancy: ANovel Technique UsingMisoprostol,
Modified Dillon's Method and Operative Laparoscopy to Minimise
Blood Loss
Kuhan Dharmarajah1*, Stewart Disu1, Raphael Laiyemo2
1London North West Healthcare NHS Trust, London, UK; 2Sherwood
Forest Hospitals NHS Foundation Trust, Nottingham, UK
Introduction:
Interstitial pregnancy is rare with an incidence of 1:2500-5000 live births.
It has a mortality rate that is 7 times higher compared to tubal pregnancies
and is associated with excessive blood loss.
Case Report:
A 26 year old lady presented at 7 weeks of pregnancy with vaginal
spotting. She previously had a 10 week miscarriage. A trans-vaginal
ultrasound revealed a right sided interstitial pregnancy based on the
Timor Tritsch et al criteria. There was a 3.5 x 4.4cm highly vascular
cornual mass containing a gestation sac and yolk sac. Her β-HCG
level was 85,874 IU/L. She was offered emergency laparoscopic
surgery. Per rectal Misoprostol 400mcg was administered at induc-
tion of anaesthesia to increase myometrial contractility and
vasoconstrict the arcuate and spiral arteries. An Endoloop was
placed around the base of the pregnancy to occlude the Sampson
artery. A modified Dillon's method where 20IU of Pitressin diluted
with 200ml of normal saline was used to minimise cardiovascular
compromise. Dillon first described dilution with 100ml of normal
saline in 1958. 60mls was injected beneath the Endoloop with
blanching effect. The Harmonic Ace Scalpel was used to perform
a cornuostomy and right salpingectomy. Closure was in two contin-
uous layers using Stratafix Spiral Poly Dioxanone (PDO) sutures.
PerClot (hydrophilic polysaccharide) was applied for haemostasis
and Hyalobarrier gel to reduce adhesion formation. The intra-
operative blood loss was 300ml.
Conclusion:
This is a novel combination of modified Dillon's method with medical
and surgical techniques to treat an interstitial pregnancy with minimal
blood loss.
FCV2- En-bloc resection of “the butterfly area” for deep infiltrating
endometriosis
Suruchi Pandey1*, Shaheen Khazali1
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK., Chertsey, UK
Complete removal of deep infiltrating endometriosis is crucial to the reso-
lution of symptoms in women suffering with severe endometriosis. We
describe the technique of en-bloc resection of “the butterfly area” for deep
infiltrating endometriosis. Removal of this area en-bloc ensures complete
removal of the disease. Resection of “the butterfly area” includes peritone-
um along with the endometriotic deposits covering bilateral pelvic side-
walls, bilateral uterosacral complexes along with the rectovaginal nodule.
Steps include:
1. Thorough pre-operative work up including transvaginal scan by a
gynaecologist to diagnose recto-vaginal disease. IVP and MRI are per-
formed if deemed necessary. Ureteric stenting is performed if extensive
disease is located adjacent to ureters.
2. A pelvic survey is performed followed by adhesiolysis. Uterine and
ovarian suspension is performed to optimise access.
3. Bilateral ureterolysis and subsequently resection of lateral pelvic side-
walls is performed.
4. A rectal manipulator is inserted to clearly define the rectal margins.
5. This is followed by hypogastric nerve sparing resection of deep infiltrat-
ing endometriosis and all the peritoneum over bilateral pararectal spaces.
6. Resection of peritoneum over the rectovaginal septum and resection of
any nodules in this region is performed.
7. At the end of the procedure, bowel integrity test is performed using air
and methylene blue.
FCV3- Fluorescent Indocyanine Sentinel Node Dissection
for Endometrial Cancer
Thomas Ind1*, Michelle Harris1, Marielle Nobbenhuis1
1Royal Marsden Hospital, London, UK
Abstracts of Oral, Poster and Video Presentations
British Society for Gynaecological Endoscopy
Silver Jubilee Meeting
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Central Hall Westminster, London
4th & 5th June 2015
Gynecol Surg (2015) 12:213–265
DOI 10.1007/s10397-015-0903-7
Wewill present the first indocyanide green sentinel node dissection in the
UK for endometrial cancer as part of the Royal Marsden Hospital FRIE
NDS study. Flourescent Robotic Indocyanine Endoscopic Node
Dissection Survey (FRIENDS).
FCV4- The 8 Steps of Excising Deep Infiltrating Endometriosis
George Goumalatsos1*, Charlotte Smith1, Olivier Chappatte1
1Maidstone & Tunbridge Wells NHS Trust, Pembury, Kent, UK
GB is a 26 year-old nulliparous woman who presented with
subfertility, dysmenorrheoa, cyclical rectal bleeding, dyspareunia
and intermittent pelvic pain. A first stage laparoscopy performed by
a fertility specialist revealed stage IV endometriosis. She was subse-
quently discharged on GnRH analogues and referred to us. Pelvic
MRI confirmed rectovaginal endometriosis involving the full anterior
rectal wall thickness. A sigmoidoscopy revealed petechial patches in
the anterior rectum suggestive of endometriosis. She understood that
clearance of her endometriosis may improve her chances of concep-
tion and her pain. She was also informed that she will require bowel
resection with the possibility of a colostomy. Bowel preparation was
prescribed preoperatively.
Laparoscopy revealed severe endometriosis in both uterosacral ligaments,
a large rectovaginal nodule eroding through the posterior fornix and a
stenosing lesion in the mid rectum, affecting 2/3 of the bowel thickness.
After ureteric stenting, we resected all the rectovaginal endometriosis and
repaired the vagina with interrupted Monocryl sutures. The rectum was
then mobilised and the colorectal team using a 33mm EEA gun, under
antibiotic cover, completed an anterior resection. The ovaries were nor-
mal and the tubes patent. She had an uncomplicated recovery and was
discharged home 72 hours later.
The footage of her operation has been edited using a variety of tech-
niques, to depict the 8 basic steps of excising Deep Infiltrating
Endometriosis.
FCV5- 12-week size Ectopic Pregnancy in a non-communicating
uterine horn - VIDEO
Alison Montgomery1*, Shaheen Khazali1
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK
Case Presentation
A 20 year old female presented to A&E with abdominal pain and chest
pain. A CTPA was organised for investigation of the chest pain. The
patient was subsequently found to have a positive pregnancy test, how-
ever, she consented to proceed with the investigation. This was negative
for pulmonary embolus but demonstrated fluid around the spleen. HCG
was 45,000 with progesterone of 41. ATV USS consequently showed a
12 week size live ectopic pregnancy with free fluid.
Laparoscopy revealed a unicornuate uterus on the left hand side with a non-
communicating rudimentary horn on the right with an ectopic pregnancy
within the horn and fallopian tube, attached onto the pelvic side wall. There
was blood filling the pelvis. Right ureterolysis was performed and the
pelvic side wall dissected to allow removal of the ectopic pregnancy and
the uterine horn.
Discussion
Ectopic pregnancy is a common presentation with 1-2% of pregnancies
affected. However, ectopic pregnancy within rudimentary uterine horn
occurs in only 1:76,000 to 1:140,000[i]. These pregnancies have in-
creased and there should be a high index of suspicion as the consequences
are high with maternal mortality. Rapid management by laparoscopy is
crucial to reduce the morbidity and mortality.
[i] Iran J Reprod Med. 2015 Jan;13(1):49-52. Unruptured rudimentary
horn pregnancy presenting with acute haemoperitoneum with combined
intrauterine pregnancy: A case report. Lallar M, Nandal R, Sharma D.
FCV6- Single sheet laparoscopic ventral mesh rectopexy
and hysteropexy for complete uterine prolapse and full thickness
rectal prolapse
Abdalla Fayyad1*, Ivlina Pandeva1, Shanks Gurjar1
1Luton and Dunstable University Hospital, Luton, UK
Aim: To evaluate the efficacy and safety of single sheet laparoscopic
ventral mesh rectopexy and hysteropexy for full thickness rectal prolapse
and complete uterine prolapse. A video of the procedure will be
presented.
Methods: Over a 5 year period, 12 women presented with full thick-
ness rectal prolapse and complete uterine prolapse to at least 3 cam
below the introitus. The procedure involved dissection of the
rectovaginal septum to the level of the pelvic floor and attaching a
single sheet mesh to the ventral surface of the rectum and then to the
posterior aspect of the cervix. Women were evaluated pre and post
operatively with the Prolapse Quality of Life Questionnaire, and Pel-
vic Organ Prolapse Quantification System and Patient global Impres-
sion of improvement.
Results: All procedures were successfully completed with no complica-
tions. Complete anatomical cure of rectal prolapse was achieved in all
cases and all patients reported feeling either much better or very much
better on PGII. Obstructive defecation symptoms particularly incomplete
evacuation persisted in 2 cases despite anatomical cure of rectal prolapse
Conclusion: Single sheet ventral mesh rectopexy can be combined with
hysteropexy in women withmultiple compartments prolapse of the pelvic
floor.
FCV7- Ultrasonic excision of endometriosis: what you see is what you
burn, or perhaps not?
Shaheen Khazali1, Christina Stylianou1*, Alexandros Derpapas1
1CEMIG, London, UK
High-frequency ultrasonic technology has less lateral thermal
spread than most electrosurgery modalities. These devices, how-
ever, ultimately work by generating heat and therefore can easily
cause burns to adjacent organs.
In this video, we present a case of a 42-year old woman who sustained a
superficial burn to the small bowel by a Harmonic scalpel during a total
laparoscopic hysterectomy. In an otherwise straightforward procedure, a
small bowel burn occurred when the surgeon accidentally touched a loop
of ileum with the non-active blade of the ultrasonic device, seconds after
ligation of the uterine artery. A 2-3 cm longitudinal white-coloured ther-
mal line was immediately recognised on the bowel serosa, but no further
damage was revealed after careful inspection of the proximal and distal
bowel. Colorectal surgeon's opinion was sought who advised conserva-
tive management without over sewing the burn line. The patient was
closely observed as outpatient and was asked to attend for further blood
test a few days later. She made an uneventful recovery with no sequelae.
Thermal bowel injury is the most serious type of bowel injury as it is less
likely to be recognised intraoperatively and peritonitis may occur up to 14
days later. Ultrasonic devices can get very hot. The jaws of these instru-
ments, therefore, should be kept in view at all time and the device should
not be used to manipulate or grasp tissue when recently activated. Intra-
operative recognition of such injuries can be life saving.
FCV8- Video case presentation of laparoscopic bilateral
salpingectomy for chronic pain developed after Essure hysteroscopic
sterilization showing migration of the wires via the serosa of both
tubes
Claire Stewart1*, George Botros1
1Liverpool Women’s hospital Liverpool UK
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Title: Laparoscopic Bilateral Salpingectomy for Chronic Pelvic Pain De-
veloped After Essure Hysteroscopic Sterilization Showing Migration of
the Wires Via the Serosa of Both Tubes.
A 34years old lady developed chronic pelvic pain after outpatient
Essure hysteroscopic sterilization for almost a year. The hystero-
scopic procedure was uneventful. Three months check by HSG
confirmed wires in place and bilateral tubal blockage. Since the
procedure the patient developed chronic persistent bilateral iliac
fossa pain for more than 9 months. A diagnostic laparoscopy
showed migration of the middle part of both wires outside the
tubes. The proximal ends of the wires were seen in the uterine
ostia and the distal ends of the wires in the tubal lumen. The
patient agreed to proceed with removal of both tubes and the wires.
The following edited video shows the above described findings and
the technique of removal of the tubes and the wires by laparoscopic
approach.
FCV9- Transvaginal ultrasound diagnosis and laparoscopic excision
of bladder endometriosis
Tom Holland1*, Ertan Saridogan1, Alfred Cutner1
1UCLH London UK
Bladder endometriosis affects up to 4% of patients with endometriosis.
The symptoms include cyclic cystitis with menstruation and occasionally
cyclic haematuria. The ultrasound features of thickening of the bladder
wall, adjacent and adherent to the uterus are typical and facilitate an
accurate diagnosis in the majority of cases.
In this video we show a case of bladder endometriosis with a videos of the
pre-operative ultrasound findings, the cystoscopy findings, bilateral in-
sertion of ureteric Pollock catheters, laparoscopic excision of the diseased
area and laparoscopic interrupted suturing of the bladder at University
College London Hospital.
FCV10-The role of illuminated ureteric stents in laparoscopic
excision of severe endometriosis
Ilias Nikolopoulos1*, Graham Phillips1
1James Cook University Hospital Middlesbrough UK
Introduction: The incidence of ureteric injury is reported to be between
0.08% and 8% depending on the complexity of laparoscopic surgery.
Laparoscopic excision of infiltrating endometriosis can be challenging
and poses an increased risk for ureteric injury. We have used illuminated
stents for 17 years for selected cases to prevent ureteric injury.
Objective: To describe our experience from the use of illuminated ureteric
stents Rocket UriglowR during laparoscopic treatment of severe
endometriosis.
Methods: Out of the 45 cases submitted to the BSGE database we iden-
tified 26 cases of treatment of severe endometriosis from January 2014 to
January 2015 where UriglowR ureteric stents were used intra-operatively.
We reviewed the intra-operative findings and the intra-operative and post-
operative complication rates.
Results: The insertion of illuminated ureteric stents takes less than
10 min and it can reduce the need and extend of ureteric dissection
and the associated morbidity. We had no ureteric injuries during this
case series. All our patients experienced transient post-operative
haematuria that did not affect their recovery. Two patients developed
urinary tract infection at 2 and 4 weeks post-operatively (7.7%). It is
difficult assess whether the infections were secondary to the insertion
of the stents or the cystoscopy.
Discussion: The insertion of illuminated ureteric stents is a safe procedure
that ensures easy identification of the ureters and prevents ureteric injury.
It is a skill that it is easily learnt and should be considered in complex
laparoscopic pelvic surgery where ureterolysis and pelvic side wall dis-
section proves to be difficult or risky.
Oral Presentations
FC1- Haemorrhage reduction techniques used in myomectomy
surgery: a survey of UK practice
Paul Simpson1*, Monica Mittal2, Haitham Hamoda2, Edward Morris1
1Department of Obstetrics & Gynaecology Norfolk and Norwich Univer-
sity Hospital Norwich UK; 2Department of Obstetrics & Gynaecology
Kings College London UK
Uterine myomas (fibroids) are benign tumours of the uterus but in 20-
50% of women the symptoms they cause warrant treatment. Myomecto-
my surgery carries with it significant risks including haemorrhage, need
for blood transfusion and emergency hysterectomy. These negatively
impact on the aims of the surgery, patient's fertility wishes and length of
hospital stay.
A Cochrane review, in 2011, reviewed ‘Interventions to reduce haemor-
rhage during myomectomy for fibroids'. Unfortunately, this review was
unable to conclude that any one approach to reducing blood loss was
superior. Currently, there is significant heterogeneity in the techniques
and approaches used by gynaecological surgeons.
An on-line survey was designed to collect information on surgical expe-
rience, techniques used to minimise blood loss and preferences. In par-
ticular, we gathered data on the use of Vasopressin and frequency of
complications. This survey was distributed to members of the British
Society of Gynaecological Endoscopy (BSGE) as a representative group
of UK gynaecologists.
Wewill present data from 108 clinicians, whichwere initially presented at
the RCOGWorld Congress in Brisbane. This will include a breakdown of
the techniques used and the preferences expressed by users. In particular
we will present the data related to the use of intra-operative Vasopressin-
the average number of units, the use of diluent, the administration tech-
nique and the complications experienced.
Although limited by recall bias, this survey gives a good guide to UK
practice. It helps to highlight the potential advrse reactions clinicians
should be aware of when using Vasopressin to reduce intra-operative
blood loss.
FC2- Taking it one step further to tariffs: Better Care, Better Value
Miriam O’Kane1*, Rasiah Bharathan1, Apryll Chase1, Elias Kovoor1
1Maidstone and Tunbridge Wells Hospital NHS Trust Tunbridge Wells
UK
Introduction
Hysteroscopy is the gold standard in the investigation of abnormal uterine
bleeding. Outpatient hysteroscopy (OPH) is a safe and effective tech-
nique. Despite this, most hysteroscopies are still performed under general
anaesthesia (GA). It is pertinent that clinicians demonstrate an under-
standing of healthcare rationalization. The concept of Best Practice Tariffs
(BPTs), introduced by the Department of Health (DoH) in April 2010,
aims to promote clinical excellence and cost effectiveness. The DoH
anticipates 80% of women to receive OPH.
Methods
A prospective audit of the OPH service was carried out in order to assess
current practice, success rates and overall patient satisfaction. Information
on national tariffs and local costs were also sought to identify opportuni-
ties for improvement.
Results
Indication for OPH included postmenopausal bleeding, abnormal uterine
bleeding and polypectomy. The overall success rate of the procedure was
98%. 23% of patients required hysteroscopy under GA. The average pain
score during the procedure was 4.3 out of10 (4.2/10 for vaginoscopy, 5.3/
10 with traditional hysteroscopy technique). Overall patient satisfaction
score was 9.7 out of 10. A significant correlation between intra-
Gynecol Surg (2015) 12:213–265 215
procedural pain and satisfaction exists (P<0.05). BPT for OPH is higher
(£472) than those under GA (£268).
Conclusion
Vaginoscopic OPH is a well-tolerated procedure with minimal pain and
high levels of patient satisfaction. Such positive results should encourage
migration to OPH. We need to explore additional strategies for
minimising discomfort. Given the financial constraints of the NHS, the
leverage of financial incentives combined with clinical quality will spur
an expansion of OPH service.
FC3- Development of a Core Outcome Set for Heavy Menstrual
Bleeding
Natalie Cooper1,2*, Khalid Khan1
1Blizard Institute Queen Mary University London UK; 2Royal London
Hospital London UK
Core outcome sets (COS) are an agreed, standardised set of trial outcomes
that clinicians and patients consider critical or important in the manage-
ment of a condition. COS are disease specific and should form the min-
imum data sets to be collected and reported in clinical trials of that con-
dition. The aim of COS is to prevent selective reporting, improve data
synthesis.
Heavy menstrual bleeding (HMB) is an important health issue which
affects 1 in 5 women of reproductive age. Currently there is no COS for
HMB. Developing a COS for HMB will ensure that future trials report
useful outcomes that benefit women, clinicians and healthcare service
providers alike.
COS development will follow methodology recommended by COMET
(Core Outcome Measures in effectiveness Trials) and will include all
relevant stakeholders. Reported outcomes are identified by literature
searches, and patient workshops are held to identify outcomes that are
most important to them. The outcomes are combined into a long list
and a three round Delphi survey is conducted asking participants (pa-
tients and their families, clinicians, nurses) to rate the importance of
each outcome to move towards consensus. A consensus meeting is held
to finalise the COS. Dissemination of the HMB COS will be via pub-
lication in CROWN (Core Outcomes in Women's Health) initiative
journals.
We will present results of the first stages of development of a COS for
HMB and discuss the heterogeneity that exists across studies. We will
also promote our HMBDelphi survey and encourage interested clinicians
to register their interest.
FC4- Outpatient Endometrial Ablation: The Benefits
and Advantages of Conscious Sedation
Cecilia McKee1*, Camilla Lyon-Dean1, David Pachter1, Will Wight1,
Tony Chalhoub1
1Royal Victoria Infirmary Newcastle Upon Tyne UK
Background:
Outpatient endometrial ablation has revolutionized the management of
heavy menstrual bleeding. The optimal treatment, currently advocated
to be under local anaesthetic (LA) has significant limitations, which could
be overcome with the use of Conscious Sedation (CS).
Aim:
To demonstrate the benefits of CS over LA for outpatient endometrial
ablation, based on observational data from a large teaching hospital where
Endometrial ablation under CS is standard.
Method:
LA endometrial ablation was initially introduced in this unit, but due to
high patient pain scores, CS was later introduced. Data was collected
prospectively (at time of procedure and before discharge) from 2007 until
2013, but retrospectively analysed. The anaesthetic protocol involves
Midazolam and a variable infusion of Remifentanil
Results:
66 patients underwent Endometrial Ablation under LA (Group A), and
122 under CS (Group B). Using a Likert-type 5 point scale, (0=no pain,
1=mild pain, 2=acceptable pain, 3= very painful, 4=worst pain) 50% of
patients in group B reported scores of 0, with 94% reporting acceptable
pain, or less. In Group A, the majority reported scores of 3 or 4. In Group
A, 14% had procedure abandoned, with no abandoned procedures in
group B, and no complications related to sedation. Patient satisfaction
post CS was 87%.
Conclusion:
Our data demonstrate that CS provides a safe and effective means to carry
out almost all endometrial ablations in the outpatient setting. This im-
proves patient experience, and in the longer term, with the consideration
of nurse-led sedation, would prove more cost effective
FC5- Treatment decision-making and support needs in heterosexual
couples living with endometriosis
Helene Mitchell1*, Nicky Hudson1, Lorraine Culley1, Caroline Law1,
Elaine Denny2, Nick Raine-Fenning3
1De Montfort University Leicester UK; 2Birmingham City University
Birmingham UK; 3University of Nottingham Nottingham UK
Endometriosis impacts upon a range of domains including intimate rela-
tionships. However, previous research has focused on the woman at the
expense of her partner who may also be negatively affected by the con-
dition and its treatment.
Couples were interviewed to provide in-depth data on living with endome-
triosis, either as patient or partner. This paper focuses on decision-making
regarding management, and couples’ information and support needs.
Twenty-two heterosexual couples, together for at least 12 months, and
where the woman had laparoscopically-diagnosed endometriosis, were
recruited via NHS clinics, support groups and snowball sampling. Sepa-
rate, in-depth, face-to-face interviews (n=44) were conducted and tran-
scribed verbatim. Data were analysed thematically and dyadically.
Treatment decisions had implications for both partners. The majority of
couples reported discussing surgical and medical options together, with
men being described as ‘largely supportive’. However, whilst women
reflected on living with and managing the condition in the longer term,
men reported a desire for a cure and, for some partners, hysterectomy was
perceived as a way to “fix” endometriosis.
Healthcare professionals need to consider the role of partners in treatment
decision-making and be aware that within the couple unit patients and part-
ners may have differing views about how endometriosis should be treated.
Signposting to support groups and relevant information, along with
couple-focused information that highlights the effect of endometriosis
on relationships, would be welcomed by patients and their partners. In
addition, men highlighted the need for advice on how best to support their
partner and cope with living with endometriosis themselves.
FC6- New Laparoscopic Peritoneal Pull-Through Vaginoplasty
Technique
Pravin Mhatre1,2*, Jyoti Mhatre2
1G S Medical college, N Wadia hospital Mumbai Maharashtra India;
2Kedar hospital Mumbai Maharashtra India
Background: Many reconstructive surgical procedures have been de-
scribed for vaginal agenesis. Almost all of them are surgically challeng-
ing, multi-staged, time consuming or leave permanent scars on abdomen
or skin retrieval sites.
Aim:A new simple technique using laparoscopic peritoneal pull-through
in creation of neo vagina has been described.
MaterialMethods:Total of forty five patients with congenital absence of
vagina (MRKH syndrome) were treated with laparoscopic peritoneal pull
through technique between 2003 till 2014. The author has described 3
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different techniques using, thin peritoneal graft, thick peritoneal graft with
substratum, and combined use of peritoneum with amnion grafts (in pa-
tients with pelvic kidney peritoneum retrieval is difficult)
Results: This technique has given excellent results over a period of one to
seven years of follow-up. Using the principle of Mullerionosis the peri-
toneum is transformed in normal multi-layer vaginal epithelium. The
peritoneal lining changes to stratified squamous epithelium resembling
normal vagina and having acidic Ph. Vaginal biopsies were done at var-
ious stages of follow-up, from one month to one year.
Conclusion: In conclusion the new laparoscopic peritoneal pull-through
vaginoplasty offers a relatively easy surgical procedure with excellent
results on long term follow up. This procedure is practically devoid of
morbidity associated with other techniques. Peritoneal lining undergoes
metaplasia and transforms itself in to stratified squamous epithelium re-
sembling normal vagina. This transformation has been documented in 9
patients.
As the ovary became accessible per vaginum 3 patients underwent ovum
retrieval and pregnancy using surrogate mother making this a fertility
enhancing procedure.
FC7-Laparoscopic hysterectomy. Does minimal access surgery alone
maximise recovery?
Joan Melendez2,1, Zwe Magama1, Funmilayo Odejinmi1*
1Whipps Cross University Hospital, Barts Health NHS Trust London UK;
2Royal Free London NHS Trust London UK
Introduction
Laparoscopic surgery has been credited with multiple benefits when com-
pared to open surgery. One of them is amore rapid return to work and normal
activities. The Department for Work and Pensions is seeking to develop
evidence based guidance on periods of incapacity for work following com-
mon procedures. Current recommendation for return to full activity after
laparoscopic and laparoscopic assisted vaginal hysterectomy is 3 weeks. 7
weeks for abdominal hysterectomy. We wanted to find out if that is realistic.
Methods
Patients who underwent laparoscopic hysterectomy for benign condition
at Whipps Cross University Hospital between 2011 and 2013 were
contacted by phone. Data was collected through a questionnaire designed
and validated by the authors and later analysed.
Results
33 patients were included in the study and 21 (63%) of those worked, and
of those, 18 (54%) of them took 8 weeks or more to return to work. 16
(48%) described her job intensity as moderate and 4 as heavy. Overall
there was no relationship to the intensity of work, the number of hours
worked or job satisfaction. 12 patients did not work, 11 (33%) of them
took 8 weeks or more to return to normal activities.
Conclusion
Recovery from hysterectomy can be longer than expected. Laparoscopic
surgery alone without good postoperative support may not be enough.
The authors feel that Enhanced Recovery programs could help maximise
the benefits of laparoscopic surgery.
FC8- Validation of a new Endometriosis Surgical Scoring system
(Visual Numeric Endometriosis Scoring System-VNESS) using
Videotaped Laparoscopic Procedures
Abdelmonim Abdalla1*, Shaheen Khazali2
1Frimley Park Hospital Surrey UK; 2Ashford and St Peters Hospital
Chertsey UK
Background: VNESS has been developed to facilitate clear and easy
communication of intraoperative findings for endometriosis. It consists
of 8 numbers, each corresponding to an area of the pelvis starting clock-
wise from the left adnexa, Each compartment is given a score of 0-4
depending on the severity of the disease.
Objective: This project aims to examine the inter-rater and intra-rater
validity of VNESS. This is phase 2 of a bigger project. Phase 1 was
development, conceptualisation and consultation, which has concluded.
Materials and methods: 63 edited videos of endometriosis laparoscopic
procedures were scored by three scorers, twice using VNESS, producing
378 sets of VNESS scores. Theese were then examined for inter-rater and
intra-rater agreement.
Results: VNESS showed excellent intra-rater and inter-rater agreements.
The mean percentage agreement in all the 8 areas for the two rounds of
scoring was between 83.9% and 87.7%. For all the scorers the mean
percentage agreement in all the 8 areas for the two rounds of scoring
was 85.7% (range 73.2% - 95.8%). The level of perfect agreement (the
percentage of the 63 video pairs on which all scorers scored exactly the
same) was strong (>90%) for adnexa, pelvic sidewall and uterovesical
fold, but noticeably weaker (< 75%) for both Uterosacral Ligaments and
Pouch of Douglas.
Conclusion:VNESS is a simple, intuitive and reliable system for scoring
of endometriosis and may have application for audit and research. Some
adjustments may be needed to optimise the system to make it more de-
scriptive and discriminative.
FC9- Enhanced recovery pathway for laparoscopic hysterectomy,
a model to follow in major gynaecological surgery. Study of a pilot
protocol to assess feasibility and demonstarte measurable outcomes
Oudai Ali1*
1West Cumberland hospital Whitehaven UK
Introduction
Creating Enhanced recovery pathway in gynaecology will apply the best
evidence to stream up practice in a very standardised steps which can be
audited. The enhanced recovery will require a central investment in a
team that will involve many facets of the care.
Methods
This is a study of the effectiveness of applying a pilot protocol in laparo-
scopic hysterectomy. In 20 cases the elements of the pathway were well
applied and these included preoperative patient education and pre assess-
ment. All cases were admitted on the same day of the operation and were
given gabapentin 300mg BD and laxatives BD for 7 days postoperatively.
Local anaesthetic was used at the wounds at the start of the procedure and
some was left in the pelvis at the end.
Results
There was reluctance to give preoperative energy drinks in all of the 20
cases. Only 4/20 cases reported mild pain in recovery and the rest report-
ed no pain. 2/20 were discharged on the same day and the rest were
discharged on next day with no pain. 18/20 cases had no catheter on
discharge from theatre and no one needed recatheterisation. 4/20 had
postoperative nausea the rest were given oral fluids in recovery. There
was 2/20 cases with minor complications on follow up.
Conclusion
Enhanced recovery requires leadership and change of culture on the part
of surgeons, anaesthetists, and nursing staff. It is not only important to do
the procedure with best of technical skills but to ensure early return to
function with maximum patient satisfaction. Laparoscopic hysterectomy
offers a model of care to apply to other gynaecologic procedures.
FC10- Taking the red pill or the blue pill - How to turbo charge our
laparoscopic skills using neurofeedback
Zahid Khan1*
1Birmingham Women’s Hospital Birmingham West Midlands UK
Objectives
Since the EWTD was fully implemented in 2009, it has become apparent
that the experiential model of learning has to change dramatically, if the
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NHS is to continue to produce safe and well-trained surgeons in this
changing environment.
Attention, concentration, focus and emotional balance are key to peak
performance in all areas, including laparoscopic surgery. Neurofeedback
is direct quantification and training of brain function, it is brainwave
biofeedback, allowing you to learn how to maintain brainwave activity
associated with optimal brain function.
We present the application and promising results of brainwave training on
enhanced performance of basic laparoscopic skills, consolidated by
neuroplasticity.
Material
Our proposed system utilises a state-of-the-art Bluetooth EEG biosensor
headset, the NeuroSky MindSet. A high-end laptop is required for data
capture and data processing. Sophisticated software is used to detect the
full range of brainwave activity and analyse this data using complex
algorithms.
Method
6 trainee doctors with varying levels of laparoscopic experience were
randomized into either receiving neurofeedback therapy prior to basic
laparoscopic skills training or just receiving skills training. The test group
took part in a daily session of brainwave training, for three days. The
completion of simple tasks on a box trainer was timed on day four, to
compare, if the application of neurofeedback sessions improved perfor-
mance in the test group.
Results
The test group showed up to 12% improvement in performance of simple,
directed tasks.
Conclusion
Neurofeedback therapy can play a vital role in achieving peak perfor-
mance levels during laparoscopic skills training.
FC11- Virtual Reality Laparoscopic Simulator: Face Validity
of Essential Gynaecological Procedures
Rasiah Bharathan1*, James McLaren1, Thomas Ind1
1Department of Obstetrics and Gynaecology St.George Hospital London
UK
Introduction
Simulation-based skills training in laparoscopic surgery leads to
enhanced quality of performance, reduced errors, shorter operative
time and superior patient safety profile. The aim of this study was to
determine trainers and trainees assessment of face validity of the
Simbionix LAP MentorTM III in three essential gynaecological
procedures.
Methods
27 gynaecologists (5 Consultants, 3 Senior Registrars, 13 Registrars, 6
Senior House Officers) were orientated to the training modules. Subse-
quently, at their convenience they performed bilateral tubal ligation, bi-
lateral salpingo-oopherectomy and right salpingectomy, for tubal ectopic
pregnancy. Following completion, a ten-point Likert-scale questionnaire
was completed evaluating each task based on appearance of instruments
and pelvic tissue, manoeuvring and function of instruments, response to
tissue manipulation, depth perception, ergonomics of the simulator and
overall utility as a training tool.
Results
The median Likert-scale scores for the appearance of instruments, hand-
eye coordination and utility as a training device tasks were scored 9. The
instrument manoeuvring & function of instruments, appearance of tissue
and response to manipulation, depth perception, bimanual handing and
simulator's ergonomics were rated a median score of 8.
Conclusion
Instrumentation, tissue depiction and response to manipulation appear to
have a high face validity. The Simbionix LAP MentorTM III was
regarded as a valid training tool. In our next steps, construct and predic-
tive validity assessments will enable construction of a proficiency based
curriculum. We believe the simulation based training can translate to
clinical benefit in gynaecology.
FC12- Laparoscopic Myomectomy versus Open Myomectomy- A
meta analysis of Randomised Controlled Trials
Thafar Al-Safar1, Hasib Ahmed2,1*
1Canterbury Christ Church University Medway Kent UK; 2Medway
Maritime Hospital Gillingham Kent UK
Background: Leiomyomata are the commonest benign tumours of the
female genital tract and are associated with a number of symptoms in-
cluding difficulty to conceive. Leiomyomata can be surgically removed
with preservation of the uterus in women with symtomatic fibroids who
wish to retain their fertility. The procedure, myomectomy can be achieved
via laparotomy, laparoscopically or hysteroscopically depending on the
site, size and type of myoma. There is paucity of data with regards to
which approach is associated with the best outcomes in terms of subse-
quent pregnancies.
Method:A systematic review to assess pregnancy rates after laparoscop-
ic myomectomy compared with pregnancy rates follwing open myomec-
tomy is presented. The following data bases were searched: PubMed
Central, Medline, BioMed Central, CINAHL (EBSCO), ScienceDirect,
Cochrane library ,Google search in general and Google scholarly. Studies
which met the inclusion criteria were selected and analysed.
Results: Evidence from andMeta-analysis of the two randomised control
trials which met the review criteria show no significant difference be-
tween laparoscopic and open myomectomy for large myomas with
regards to subsequent fecundity, in women from the reproductive age
group. The laparoscopic approach, if it is practicable, is associated with
a number of patient advantages including less post operative pain, less
fever, reduced blood loss, shorter length of hospital stay and faster return
to normal activity.
Conclusions: The surgical approach to myomectomy does not appear to
influence the subsequent pregnancy rate or outcomes. Interpretation is
guarded because of the small number of studies eligible for analysis.
Further large studies are required to validate the findings. The laparoscop-
ic approach is, however, associated with a number of patient advantages
including faster recovery and should be the method of choice.
FC13- Introduction of a novel approach to maintaining
Pneumoperitoneum at Total Laparoscopic Hysterectomy (TLH)
Lorna Hutchinson1, Sirkhar Sircar1, David McMurray1, Karina Datsun1*,
Mohammed Allam1
1NHS Lanarkshire Wishaw UK
During TLH diathermy is used to circumferentially cut around the uterine
manipulator. At this stage in the procedure CO2 can be lost.
We have developed a fluid filled "donut" which can be placed inside the
vagina. This maintains pneumoperitoneum at the time of removing the
uterus from the vagina. Once the specimen has been removed the "donut"
can then seal the lower vagina while suturing takes place in order to avoid
ongoing loss of CO2.
The following equipment is required:
• condom
• silastic foley catheter 14
• 60ml syringe
• suture material for tying (silk)
• Sterile water
1. The catheter is inserted inside the condom (3-4 cm of the catheter tip
should be placed inside the condom)
2. Silk is used to tie a knot about 1cm from the end of the condom so it is
fixed to the catheter
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3. The tip of the condom should be then be placed alongside the above knot.
4. The tip of the condom is tied in place using the suture material forming
a donut
5. The integrity of the donut is checked by filling it with 60ml of sterile
water via the catheter.
6. Following insertion of the uterine manipulator the donut is threaded
over the handle of the manipulator and pushed up the vagina close to the
cup.
7. Prior to excising the cervix the donut is inflated with sterile water.
8. Following removal of the specimen the donut is replaced in the lower
vagina to ensure ongoing pneumoperitoneum.
FC14- Opportunistic Laparoscopic Salpingectomy (OLS):
An Opportunity for Training
Rasiah Bharathan1*, Jody Taylor1, James McLaren2 Iranthi Meththananda3,
Rachel Read4, Mallika Azizia3, Sujeewa Fernando4, Shreelatha Datta3,
Elias Kovoor1
1Maidstone and Tunbridge Wells Hospitals NHS Trust Tunbridge Wells
UK; 2Croydon University Hospital NHS Trust Croydon UK; 3Kings
College Hospital NHS Trust London UK; 4Wrexham Maelor Hospital
Wales UK
Introduction
OLS offers potential benefits to the patients including ovarian cancer risk
reduction, reduced infective morbidity following hysterectomy and con-
traception. The concept of OLS offers an opportunity for training in an
essential gynaecological procedure in an 'in vivo' setting. It would be vital
to garner consensus prior to this significant step. This study explores the
attitude of professionals toward OLS.
Methods
A survey was undertaken at five hospitals, recruiting trainees & consul-
tants, theatre personnel and pathologists. The questionnaire permitted free
text commenting.
Results
The response rate was 100% amongst 150 participants. Majority
of the consultants (90%) and theatre personnel (100%) support the
concept of OLS for training. Trainees reported, OLS would offer
additional training benefit (Median score of 8/10). 46% of partic-
ipants felt OLS for training may have adverse effect on the pa-
tients. 70% of participants felt further ethical exploration amongst
patients would be warranted. 92% felt trainees should undertake
prior simulation-based training. 91% of trainees had used a sim-
ulator with 37% having performed a simulated salpingectomy; the
stage of training did not significantly influence the latter. 44% of
theatre staff expressed OLS may impact on theatre work flow.
100% of consultants and pathologists recommend histological as-
sessment of the surgical specimen.
Discussion
The clinic-pathological argument for OLS is compelling. OLS offers a
unique training opportunity. The concept of OLS training could be en-
hanced through simulation based training. This would introduce the ‘pre-
trained' novice to the 'in vivo' training using OLS. This may resolve any
ethical and safety concerns of OLS.
FC15- Laparoscopic Myomectomy for Large Myomas
Danai Balfoussia1*, Lindsay Kindinger1, Hua Zen Ling1, Tom Setchell1,
Tariq Miskry1
1St Mary’s Hospital, Imperial College Healthcare NHS Trust London UK
Introduction
Laparoscopic myomectomy has established itself as an alternative to open
myomectomy. Its role in the setting of larger fibroids has been controver-
sial due to technical challenges. We present a case series of laparoscopic
resection of fibroids ≥8cm in our institution
Methods
This was a single-centre retrospective review of patients undergoing lap-
aroscopic myomectomy for large fibroids (≥8cm) between September
2005 and December 2014. Outcomes included operative time, complica-
tions, blood loss and rate of conversion to laparotomy.
Results
One hundred and forty nine patients aged 25-64 years (median: 38)
underwent laparoscopic surgery. The commonest symptoms were men-
orrhagia (29%) and pressure effects (28%). One hundred and fifty
leiomyomas were removed, ranging between 8-20cm (median: 10cm)
and weighing between 76-1600g (median: 450g). Operative time ranged
from 55 to 300 minutes (median: 120 minutes) and 56 patients (38%) had
a concurrent procedure. Blood loss was 20-2000mls (median: 150mls).
Two patients underwent laparotomy for specimen retrieval. Five patients
required blood transfusion. One patient had a pulmonary embolism. A
single patient required laparoscopy for small bowel obstruction four
weeks post surgery. Finally, one patient developed a collection and one
an ileus. Both were managed conservatively.
Conclusion
This is the largest UK case series examining laparoscopic myomecto-
my for large myomas (≥8cm). Our findings demonstrate that in expe-
rienced hands a laparoscopic approach should not be limited by fi-
broid size per se.
FC16- Awarm-up strategy is effective in reducing mental load
during laparoscopic prophylactic bilateral salpingo-oophorectomy:
A Randomised Controlled Trial
Rasiah Bharathan1,2* James McLaren1, Thomas Ind1
1St.Georges Hospital London UK; 2Maidstone and Tunbridge Wells
Hospitals NHS Trust Tunbridge Wells UK
Introduction
Laparoscopic prophylactic bilateral salpingo-oophorectomy (LapBSO) is
performed as a risk reduction intervention for ovarian cancer. Pre-task
warm-up is proven to enhance performance. This is the first trial to ex-
plore mental load during surgery.
Method
This is a cross-over randomised trial. Participants were stratified prior to
computer generated allocation. Eighteen participants were first trained to
proficiency bench. Training and assessments were completed on LAP
Mentor virtual reality simulator. Each participant performed a ‘control’
LapBSO and a warm-up task followed by LapBSO. The warm-up task
was ‘circle cutting’ which is FLS validated; this is time-limited to five
minutes. During the LapBSO the participants were required to simulta-
neously perform a validated visuo-cognitive secondary task. After the
LapBSO tasks, participants completed two validated questionnaires -
NASA-TLX and subjective mental effort questionnaire (SMEQ).
Results
Warm-up intervention lead to significant reduction in SMEQ scores
(P=0.02). In n four of the six dimensions of NASA-TLX, warm-up inter-
vention resulted in significant improvement in workload measures [men-
tal demand (P=0.04), temporal demand (P=0.015), performance
(P=0.007) and frustration (P=0.003). The ratings approached statistical
significance for physical demand (P=0.051) and effort (P=0.06).
The visuo-cognitive secondary task measure of mental load, revealed a
significant reduction in mental load: the overall detection rate (P=0.003)
and correct detection rates (P<0.05) were significantly higher in the in-
terventional arm.
The correlation coefficient between mental load and SMEQ is significant
for the control group (0.801) and interventional group (0.72); this
strengthens our findings.
Conclusion
Pre-task warm-up is an effective technique in reducingmental load during
LapBSO.
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FC17- The effect of co-morbidity on the cost of laparoscopic surgery
for endometrial cancer
Selina Chiu2,1*, Michelle Harris1, Marielle Nobbenhuis1, Thomas Ind1
1Royal Marsden Hospital London UK; 2Aberdeen University Aberdeen
UK
AIMS
To determine the effects of co-morbidities such as obesity, diabetes, hy-
pertension and age on the in-patient costs of laparoscopic endometrial
cancer (EC) surgery.
METHODS
Seventy seven patients with EC treated by laparoscopic surgery were
assessed. Clinical data were obtained from the trusts electronic patient
record (EPR). The costs of each in-patient episode were calculated inde-
pendently by the trust’s finance department and included the costs of staff,
ward, theatres, drugs, intensive care, rehabilitation, pathology, imaging
and blood products.
RESULTS
Diabetes was associated with an increased median cost of £2426.83
(P = 0.0385). Hypertension, age over 65, and a Body Mass Index
(BMI) of over 30 were associated with median increased costs of
£2070.66 (P = 0.0044), £1842.40 (P = 0.0084) and £1699.59
(P=0.0225) respectively. No statistical difference was demonstrated in
median costs for women who had had a previous laparotomy.
CONCLUSION
Diabetes, obesity, hypertension and increased age are associated with a
significant increased cost of surgery for EC. This should be reflected
FC18- Evolution in the surgical management of endometrial cancer
(2007-2014) at the DELTA centre - Royal Derby Hospital
Natalie Grant1*, Graham Geary1, Rahamatulla Latheef1, Summi Abdul1,
Royal Derby1
1Hospital Derby UK; 2DELTA Centre Derby UK
Aims: Assess the changing management of endometrial cancer 2007-
2014.
Methods: Patient records attained from cancer database. Data collected
retrospectively from electronic records.
Results: 618 patients assessed. Age-mean=66 (28-92). Pre-operative in-
vestigations: endometrial thickness-mean=14.95mm (1-85mm), uterus
AP diameter-mean=39.4mm for TLH (13-73mm), 44.6mm for TAH
(20-96mm). Pre-op hysteroscopy 65.2% cases. Histology-88.1%
endometrioid, serous 3.81%, carcinosarcoma 6.68%, other 1.41%. Man-
agement in 2008: TLH 15.9%, TAH 62.3%, LAVH 18.8%. In 2014: TLH
74.7%, TAH 22.1%, LAVH 1.1%. 40 laparoscopic cases combined with
PLND. Operating time-mean: TLH 97.99 minutes(36-213), TAH 108.13
minutes(44-250), (P=0.0071). Estimated blood loss-mean:TLH 212ml,
TAH 469ml (P<0.0001). Length of stay-mean: TLH 2 days, TAH 5 days
(P<0.0001). Rate of conversion (TLH to TAH): 5.44%(overall) - declined
17.5% 2008 to 3.76% 2013-2014. Reasons for conversion: bleeding,
adhesions, failed entry, uterus too big and other. Complication rate:
TLH 8.9%, TAH 16%. Serious complications <1%. Rate of readmission:
TLH 7.96% (commonly vault haematoma), TAH 6.54% (commonly
wound dehiscence/infection).
Conclusions: In our large 8-year case series there has been a significant
change in surgical management from open to laparoscopic surgery,
resulting in significantly shorter operating times, hospital stays, and lower
morbidity. TLH can increase bed capacity allowing more cases to be
done. Increased morbidity with TAH may be due to the more complex
cases over TLH (bigger uterus, higher stage disease). All centres should
offer TLH as a gold standard for all hysterectomies. The DELTA centre
has developed a Training Programme for consultants and senior trainees
to facilitate a transition in practice in other centres.
FC19- ‘Laparoscopic Hysterectomies in the obese: not so dangerous
after all’
Amy Hawarden1*, Jeremy Hawe1, Michael James McCormack1
1Countess Of Chester Hospital Chester UK
Rising BMI is a growing problem, with the current UK average BMI for
women being 27. Initially, morbid obesity was considered a contraindi-
cation to laparoscopic hysterectomy, however in advanced laparoscopic
units it is now considered an indication for, rather than a contra-indication
to the laparoscopic approach.
417 cases of laparoscopic hysterectomies were performed between 2010
and 2015 at the Countess of Chester Hospital. The average BMI was 29.
Of these patients, 40 were identified as having a BMI of 40 and above.
These patients had a higher incidence of co-morbidities such as diabetes,
hypertension and mobility issues and were more likely to have a pre-
cancerous or cancerous indication for surgery (50% vs 29%). BMI ranged
from 40-68, operation times (knife to skin) were longer (122mins vs
103mins), with a longer length of hospital stay (43 hours vs 40 hours),
higher rates of intra-op (2.5% vs 1.3%), post op (7.5% vs 2.6%) compli-
cations, and a higher rates of re-admissions (2.5% vs 2.1%). Major com-
plications included a thermal bowel injury requiring laparoscopic minor
bowel resection, and a patient on anti-coagulant therapy requiring a blood
transfusion after re-admission following vaginal bleeding.
Laparoscopic hysterectomy in women with a BMI > 40 is technically
possible, with no intra-operative conversions to open, but is associated
with an increase in morbidity compared to women with a lower BMI.
However, most patients still benefit from the laparoscopic approach as
opposed to an open procedure. Laparoscopy should be considered the
preferred route for surgery in this group of women.
FC20- Day Case Laparoscopic Burch for Genuine Stress
Incontinence
Alison Micallef Fava1, Daliso Chetcuti1*, Joy Got1, Sarah Sultana
Grixti1, Igor Knyazev1, John Mamo1
1Department of obstetrics and gynaecologyMaterDei hospitalMsidaMalta
Introduction: Surgical management is available for those select patients
with genuine stress incontinence, when conservative measures are
unsuccessful.
Aim: Comparison of results in patients undergoing open and laparoscopic
Burch colposuspension, as well as mid urethral tension free mesh for the
surgical management options of genuine stress incontinence.
Method: Patients who presented with stress incontinence underwent
Urodynamics studies prior to undergoing a surgical intervention. Laparo-
scopic Burch colposuspension, open Burch procedures as well as mid-
urethral tape procedure between 1st Jan 2013 and 31st Dec 2014 were
included in the study. The length of stay following the respective surgical
intervention as well as the readmission rate were assessed.
Results: Fourteen patients underwent laparoscopic Burch procedure (age
range between 37 to 72years) while fifteen patients underwent open
Burch procedure (age ranged between 40 to 62years). Mid-urethral tape
procedures was carried out on twenty patients. (age ranged from 37 to
71years). The average length of stay was 2.57days (ranging from 1-
3days), 6.22 days (ranging from 4-9days) and 2.95 days (ranging from
1-9days) for laparoscopic Burch colposuspension, open Burch
colposuspension and mid-urethral tape procedure respectively. There
were no readmissions after laparoscopic Burch colposuspension while
there were two readmissions after open Burch colposuspension and two
readmissions after mid-urethral tape procedures.
Conclusions: Patients undergoing laparoscopic Burch procedure had a
shorter hospital stay, quicker recovery and earlier return to work; as well
as requiring no readmissions. It is envisaged that we achieve day case
laparoscopic burch colposuspension for the management of genuine
stress incontinence.
220 Gynecol Surg (2015) 12:213–265
FC21- Feasibility of A Randomised Controlled Trial (RCT)
to compare Recovery, Pelvic Floor and Sexual Function following
Laparoscopic Total Hysterectomy with that following Laparoscopic
Sub-Total (Supracervical Hysterectomy): The LaHoST study
Hasib Ahmed1,2*, Hany Wisa1,2, Jeremy Wright3
1Medway Maritime Hospital Kent UK; 2Canterbury Christ Church
University Kent UK; 3University of Surrey Surrey UK
Background: Patient benefit following cervical conservation at abdominal
hysterectomy remains unproven (Lethaby 2012). Numerous observational
studies suggest an advantage of Laparoscopic Supracervical Hysterectomy
(LSH) over Laparoscopic Total Hysterectomy (LTH). The only randomised
comparison showed no difference (Morrelli 2007) but assessments may
have been too infrequent to demonstrate a difference.
Aim:To assess the feasibility of an RCTcomparing recovery, pelvic floor
and sexual function following LSH with that following LTH.
Method: Premenopausal women with a benign indication for hysterec-
tomy, uterine size of less than 16 weeks gestation and less than 2nd degree
uterine descent were randomised to LSH or LTH. Participants were
followed up weekly using validated recovery questionnaires until 12
weeks. In addition they were asked to complete validated pelvic floor
and sexual function questionnaires at baseline, 6 weeks and 6 months.
Results: 50 of 70 eligible women agreed to randomisation. Data collec-
tion was complete at 24 months. 100%, 88% and 60% of recovery ques-
tionnaires were captured at baseline, 6 weeks and 12 weeks respectively.
Recovery data between 7 and 12 weeks did not appear discriminatory.
98%, 90% and 76% of pelvic floor and sexual function questionnaires
were captured at baseline, 6 weeks and 6 months respectively. Recovery
to normal activity occurred at 4-5 weeks in the LSH group compared to 7-
8 weeks in the LTH group.
Conclusions: An RCT to compare outcomes following LSH and LTH
appears feasible. Those undergoing LSH appear to be back to normal 2
weeks prior to those undergoing LTH.No effect was observed on bladder,
bowel or sexual function. We propose a larger multicentre study to inves-
tigate this important issue.
FC22- Outcome of reproductive surgery in sub fertile women
with tubal disease
Nihal Abdu1*, Shamma Al-inizi1
1South Tyneside NHS Foundation Trust South Tyneside UK
Tubal disease accounts for at least 25% of female factor subfertility with
more than half of the cases due to Chlamydia salpingitis. We have
reviewed our reproductive surgical outcome in a group of 89 sub fertile
women who underwent laparoscopic tubal surgery having had tubal co
morbidities such as previous Chlamydia infection (75%) or endometriosis
(25%). Tubal disease was graded laparoscopically.
The commonest surgical interventions undertaken were division of
adhesions/ tubal surgery and HELICA coagulation of endometriosis. Oc-
casionally, division of large hydrosalpinx, proximal tubal cannulation or
total salpingectomy to prepare for IVF were performed. After the surgery,
51% of the patients who had Chlamydia induced tubal disease were
referred for IVF indicating the significant damage this organism might
cause to the fallopian tubes; and only 31% of those with negative Chla-
mydia serology needed IVF referral. The rest of the patients received
either ovulation induction or had conceived naturally. Pregnancy rate
was 40% in women who had Chlamydia induced tubal disease (3 had
ectopic pregnancy) and 38% in those with negative Chlamydia serology.
Although the recommendation for tubal disease favours assisted repro-
ductive technique (ART), still tubal microsurgery has the advantage of
long-standing restoration of fertility. The NICE Guideline favours lapa-
roscopic tubal surgery for mild tubal disease and salpingectomy for
hydrosalpinx before ART. Adequate counselling regarding the risks of
surgery and ectopic pregnancy is paramount.
Proper laparoscopic grading of tubal disease with adequate counselling
following consideration of clinical picture and patient`s preferences can
result in a good success rate.
FC23- Combined laparosciopic ovarian tissue cryopreservation
and retrieval of immature oocytes followed by in vitro maturation
and vitrification: Results from the Oxford Ovarian Tissue
Cryopreservation (OTCP) Programme
Christian Becker1,2*, Enda McVeigh1, Tim Child1,3, Karen Turner4,3,
Kokila Lakhoo5, Muhammad Fatum1,3
1NDOG, Oxford University Oxford UK; 2Oxford Fertility Unit Oxford
UK; 3Institute of Reproductive sciences Oxford UK; 4Oxford Heart Valve
Bank Oxford UK; 5Oxford Children’s Hospital Oxford UK
Introduction: Combining ovarian tissue cryopreservation with retrieval
of unstimulated immature oocytes followed by IVM and vitrification may
potentially increase the prospects of fertility preservation in oncologic
patients. No clear consensus is established whether a combined strategy
should be utilized.
Aims: To study the feasibility of intraoperative egg retrieval in oncologic
patients undergoing ovarian tissue preservation. The different surgical
techniques utilized to be described.
Materials and Methods: A retrospective study of the first clinical ovar-
ian tissue cryopreservation(OTCP) service in England. Oncology patients
undergoing OTCP before high-risk gonadotoxic chemo-radiotherapy,
were all offered immature egg retrieval, IVM and vitrification. Egg re-
trieval was done either by ex situ puncturing the ovary after excision or by
percutaneous video-assisted oocyte pick-up in patients undergoing ovar-
ian cortical strips resection, in addition to the fluid collection after tissue
processing.
Results: The results of the first two years of activity at Oxford University
OTCP Programme will be presented. . So far, 20 patients aged 2-31 years
were recruited and undergone laparoscopic ovarian tissue harvesting and
ex situ or in situ video-assisted egg retrieval. In 14/20 patients immature
eggs were retrieved. The youngest patient with viable oocytes found, was
9 years old. Maturation rates and correlations will be presented. Nomajor
adverse events were experienced.
Conclusions: Oocytes can be retrieved by ex-situ puncturing of the ex-
cised ovary, in situ percutaneous video assisted egg retrieval during lap-
aroscopy or from the processing fluid, then matured in vitro, and cryo-
preserved by vitrification. This fertility preservation modality could be
combined with ovarian tissue preservation.
FC24- How to interpret presenting symptoms of ectopic pregnancy?
The triad associated with major haemorrhage
E Mullins1, D Chandrashekar1, N Agarwal1, F Odejinmi1
1NorthWest LondonHospitals NHS Trust LondonUK; 1Barts Healthcare
NHS Trust London UK
Introduction
Ectopic pregnancy (EP) occurs in up to 2% of pregnancies and can be life
threatening (Barnhart 2009). The association between presenting symp-
toms and quantity of intra-peritoneal bleeding has not been assessed.
Methods
Prospective audit of all women requiring surgery for EP over a 5-year
period atWhipps Cross Hospital. Secondary analysis of presenting symp-
toms and blood loss documented on the operation note was performed.
We analysed the association of presenting symptoms with blood loss at
surgery. Statistics were calculated with SPSS v.20, Mann-Whitey U-test
was used to compare groups, significance at p<0.05.
Results
318 women underwent surgery for EP during the 5 year study period,
Table. 1.
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Statistical comparison of group of patients with the stated symptom to
those without it
EBL= estimated blood loss
Table. 1. Characteristics and blood loss at surgery in women with the
stated symptom at presentation
The triad of vomiting, shoulder-tip pain and syncopewere associated with
significantly increased blood loss at surgery (Fig. 1), none was associated
with increased blood loss when independent of the other two. Shoulder
tip pain and syncope combined (median EBL 1520mls (0-2800),
p<0.0001) and the triad combined (median EBL 2562mls (500-4000),
p<0.001) were associated with significantly increased blood loss.
Conclusion- Vomiting and syncope are signs of hypotension, shoulder-
tip pain signals diaphragmatic stimulation, in EP likely due to intra-
peritoneal haemorrhage. Their association with greatly increased blood
loss may not be appreciated by clinicians. Those managing women with
EP and shared CEPOD lists must understand the necessity of urgent
surgery and blood products for women with suspected or confirmed ec-
topic pregnancy with vomiting, shoulder-tip pain or syncope.
Figure 1. Summary Venn infographic
FC25- A Proposed Inexpensive Uterine Hysteroscopy Model
for simulation-based Education
Somaia Elsayed1* Wei Zian Szetho1, Ray O’sullivan1, Naveen Usman1
1St. Luke’s General Hospital Kilkenny Ireland
BACKGROUND: In obstetrics and gynaecology practice, hyster-
oscopy is the standard procedure for diagnostic evaluation of the
uterine cavity and for operative treatment of uterine abnormali-
ties.1,2 Diagnostic and operative hysteroscopy can be challenging
and requires significant skill set and good hand-eye coordination.
Simulation can benefit the trainee, educator and patient. Simula-
tion allows for practice, real-time feedback, and learning in a safe
environment.3 A growing body of data supports the effectiveness
of formal, objective teaching of surgical skills and the effective-
ness of surgical simulation in training.4 Additionally, for some
clinical tasks, simulation training can be effective when inexpen-
sive but realistic models are used.5 However there is a relative
paucity of simulation-based education in obstetrics and gynaecol-
ogy training programmes. Besides, the existing simulators are ex-
pensive and trainees have limited access to them due to lack of
resources.
OBJECTIVE: We propose an effective, inexpensive and reproducible
model for developing the skills and hand-eye coordination for diagnostic
and operative hysteroscopy.
METHOD: Advanced surgical skills can be practiced and improved
using simple clay, play-doh uterine models. Four different clay,
play-doh uterine models were developed, demonstrating techniques
of diagnostic and operative skills including removal of mirena coil,
resection and biopsy of endometrial polyp and cannulation of
fallopian tubes. A rigid hysteroscope is simulated Using flexible
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CONCLUSION: The described play-doh uterine models are a cost ef-
fective way to improve hand-eye coordination in the use of diagnostic and
operative hysteroscopy.
Video Poster Presentations
FCVP1- ‘Pockets and Pouches': Dangerous, Deceptive
Endometriosis:
Rajiv Sreekumar1*, Dominic Byrne1
1Royal Cornwall Hospitals Truro Cornwall UK
Severe endometriosis can sometimes be very discrete and easily missed
without a systematic thorough laparoscopic pelvic survey. Lesions can be
hidden from view in a peritoneal pocket, or the pocket itself can be hidden
behind other structures. This can lead to false negative laparoscopy or
incomplete excision of disease.
Endometriosis can also cause subtle distortion of pelvic anatomy which
on initial inspection can be unrecognised. Failure to recognise subtle
bowel adherence creating a pouch can lead to major surgical complica-
tions. We present videos of 2 cases showing these pockets and pouches.
The first video demonstrates a significant endometriotic nodule situated
deep within a peritoneal pocket in the recto-vaginal septum hidden from
view behind the uterosacral ligaments. The video shows resection of the
nodule by inverting the pocket to ensure complete excision of the disease.
The second case was referred for excision of "mild" endometriosis. There
is subtle but significant tethering of the rectum creating a pouch up to the
back of the uterus, which was previously missed at the first laparoscopy.
The video shows release of the rectal tethering and the techniques
employed to carefully resect the disease off the rectum. These two exam-
ples clearly demonstrate the misleading appearance of endometriosis and
the traps that await both diagnostic and therapeutic laparoscopic surgery.
Valuable lessons for us all.
FCVP3- VIDEO - Our first attempt at in-bag power morcellation
Thomas Ind1,2, Owen Heath1, Tim Hookway1
1St Georges Hospital London UK; 2Royal Marsden Hospital London UK
Power morcellation has received a bad press recently due to the perceived
risk of dissemination of inadvertant leiomyosarcomas.
A number of authors have advocated 'in-bag' morcellation.
This video demonstrates our first attempt to achieve in-bag morcellation
of an ovarian fibroma. Particular attention is made on the methodology
and difficulties encountered.
Overall, the procedure prolonged the operation by half an hour but we did
not encounter many technical difficulties.
FCVP4- Teaching an old dog new tricks - A surgeon's first docking
of the new Da Vinci Xi
Thomas Ind1*, Ilyas Arshad1, Marielle Nobbenhuis1
1Royal Marsden Hospital London UK
This is an unedited 10 minute video with sound. When a new Da Vinci
Xi was purchased in our institution, one robotic surgeon had formal
teaching in docking while another was taught in-house by the trained
surgeon.
This video demonstrates how the Xi is docked in a real surgical setting
and is an insight for those unfamiliar with robotic surgery. The video also
shows the process of an established robotic surgeon being taught the new
process.
It is clear from this video that even in a teaching setting, the process adds
only ten minutes to the operation.
FCVP5- Extra-peritoneal laparoscopic colposuspension (EP-LC)
for women with Stress Urinary Incontinence
Shaimaa Ibrahim1*, Inna Sokolova1, Robert Hawthorn2, Wael Agur1
1University hospital Crosshouse Kilmarnock/Ayrshire UK; 2Southern
general hospital Glasgow UK
Introduction
Laparoscopic colposuspension has been shown to be equivalent to the
open procedure in Cochrane reviews (1), however, it did not catch mo-
mentum due to the technical demand of the procedure the emergence of
tension-free vaginal tapes (2).
Objective:
We present short-term follow up of the first 16 procedures performed by a
simplified extraperitoneal approach.
Method:
Veress needle is introduced above the symphysis to insufflate 1L of CO2
into the retropubic space (RS). Umbilical trocar introduced and rectus
sheath is pierced midway between the umbilicus and the symphysis pubis.
Recti are separated and the ‘cob-web’ of gas will guide the scope to RS.
Two 5-mm trocars are introduced 2 cm above and 1 cm lateral to pubic
tubercle. Using the usual perineo-abdominal approach, the vagina at the
level of the bladder neck is dissected and attached to Cooper's ligaments
with 2 non-absorbable sutures on each side. Straight needles with integrated
knot-pusher are used. Data were extracted from BSUG national database.
Results:
16 procedures were performed over 18 months. 11/16 had pure and 5/16
had mixed incontinence. Mean BMI: 30.5 and mean age: 45.5. One
patient required repair of bladder injury via laparotomy with no
consequences.
3-month postoperatively, 15 patients were dry and 1 had persistent SUI.
One patient developed de novo urgency and one required rectocele repair.
Conclusion:
EP-LC procedure appears to be a valid minimally-invasive alternative for
women with SUI.
References:
1- Cochrane review. July 2006.
2- BJOG.2006; 113; 985-987.
FCVP6- A case of Ligasure failure to seal ovarian vessels in a patient
with a history of ovarian vein emobilization during performing
hysterectomy
Osama Eskandar1*, Afaf Diyaf1
1North Devon Hospital Barnstaple UK
Case report
A 48 year old lady had a total laparoscopic hysterectomy for heavy and
painful periods.
During the operation a Ligasure was used as an energy source to perform
the hysterectomy. The infundibulopelvic ligament was cut successfully
however; down near the anastomosis of the ovarian vessels with the
uterine artery, the Ligasure repeatedly failed to initiate energy. It was
thought that the Ligasure was faulty as the generator indicator kept illu-
minating indicating that the tissue has not been sealed. A closer look at the
ovarian blood vessels, a spiral metal wire was found near the left pelvic
side wall which was coming from the ovarian vein. The wire was re-
moved laparoscopically and the rest of the operation was performed
successfully.
From the history, this patient had had peripheral vascular disease. She had
pelvic venography and left ovarian vein embolisation. As a part of the
procedure, segment of titanium spiral wire is placed and left within the
blood vessel.
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Discussion
The Ligasure fails to seal vessels when the tissue impedance is out of
range, the seal cycle was interrupted before the cycle was complete,
insufficient amount of tissue inside the jaws of the ligasure or grasping
metal objects; such as staples, wire, spiral, or clips; in the jaws of the
instrument.
Conclusion
The clinicians should be aware that one of the reasons of the ligasure
failure is a presence ofmetal object such as titaniumwire between its jaws
which can be hiden inside a blood vessel as in this case.
FCVP7- Introduction of a novel approach to maintaining
Pneumoperitoneum at Total Laparoscopic Hysterectomy (TLH)
Lorna Hutchinson1, Sirkhar Sircar1, David McMurray1, Karina Datsun1*,
Mohammed Allam1
1NHS Lanarkshire Wishaw UK
During TLH diathermy is used to circumferentially cut around the uterine
manipulator. At this stage CO2 can be lost.
We have developed a fluid filled "donut" which can be placed inside the
vagina. This maintains pneumoperitoneum at the time of removing the
uterus from the vagina. Once the specimen has been removed the "donut"
can then seal the lower vagina while suturing takes place in order to avoid
loss of CO2.
The following equipment is required:
• condom
• silastic foley catheter N14
• 60ml syringe
• suture material for tying - silk 0/2
• Sterile water
1. The catheter is inserted inside the condom (3-4 cm of the catheter tip
should be placed just inside the condom)
2. Silk is used to tie a knot about 1cm from the end of the condom so it is
fixed to the catheter
3. The tip of the condom should be then be placed alongside the above knot.
4. The tip of the condom is tied in place using the suture material forming
a donut
5. The integrity of the donut is checked by filling it with 60ml of sterile
water via the catheter.
6. Following insertion of the uterine manipulator the donut isthreaded
over the handle of the manipulator and pushed up the vagina close to
the cup.
7. Prior to excising the cervix the assistant inflates the donut with sterile
water.
8. Following removal of the specimen the donut is replaced in the lower
vagina to ensure ongoing pneumoperitoneum.
https://vimeo.com/122824001
FCVP8- Hysterectomy for Filshie clip Migration
Rebecca Hardcastle1,2*, Chris Guyer2
1Ethicon London UK; 2University Of Surrey Guildford UK
Objective
To examine an example of rare Filshie clip migration.
Setting
The Filshie clip has become the most popular sterilisation device in the
UK since its introduction in the 1980’s2. There have been a number of
case reports published describing migrated clips3,4,5 and it has been sug-
gested that migration can occur in over 20% of cases6.
Case:
Following an uneventful laparoscopic Filshie sterilisation a 36 year old
P3 was seen in clinic (by multiple different consultants) complaining of
pelvic pain. Investigations including a diagnostic laparoscopy gave a high
suspicion of an embedded Filshie clip between the vagina and bladder.
Follow up appointments were missed. Re-referrals lead to multiple clini-
cians’ involvement. There was no note of the surgical findings and em-
phasis on pelvic pain occurred. She eventually had a TAH BSO.
She was re-referred, seeing a different consultant, with swelling in the
vagina and a suggested foreign body between the vault and bladder on
MRI/USS. Cystogram confirmed no communication to the bladder.
The patient had a n excisional laparoscopy, which identified a nodule
containing an old abscess and a Filshie clip was retrieved from within.
Discussion
There was discontinuity of the patient care that has become common
practice since the NHS plan7. This has led to the abandoning of named
consultants and instead the use of clinician pools. The result is loss of
clinical information and incorrect diagnostic pathways taken. It seems
likely that, had the patient returned to the consultant performing the initial
laparoscopy, perhaps hysterectomy would have been avoided.
FCVP9- Prophylactic skeletonisation of infundibulopelvic vessels
and temporary clipping of bilateral uterine arteries
during myomectomy for large sub mucous fibroid
Suruchi Pandey1*, Shaheen Khazali1
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK, Chertsey, UK
Introduction
Randomized trials have demonstrated that laparoscopic myomectomy is
associated with decreased morbidity and quicker recovery. However, it can
be associated with considerable blood loss. Temporary clipping of bilateral
uterine arteries is shown to decrease blood loss during myomectomy with-
out affecting uterine perfusion. In addition, prophylactically skeletonising
infundibulopelvic vessels and placing a loose knot around them can pro-
vide extra security to enable quick bleeding control if required.
Video Presentation
In our video presentation of a laparoscopic myomectomy for a large
fibroid uterus, we demonstrate lateral pelvic sidewall dissection,
ureterolysis, temporary clipping of bilateral uterine arteries, prophylactic
skeletonisation of infundibulo pelvic vessels andmyomectomy for a large
fibroid uterus.
Following steps were undertaken:
1. Trocar placement was individualized to ensure easy manipulation
2. Pelvic survey was performed and bilateral ureters were identified
3. Right infundibulo pelvic vessels were skeletonised as these were par-
ticularly large. A loose knot was placed around the IP ligament prophy-
lactically to be tightened in case of significant bleeding.
4. Peritoneum covering bilateral lateral pelvic sidewalls was opened and
bilateral ureterolysis was performed
5. Uterine arteries were identified
6. Vascular clips were placed loosely over bilateral uterine arteries
7. Vasopressin was infiltrated over the myometrium covering the fibroids
8. Myomectomy and multiple layers of suturing were performed.
9. At the end of the myomectomy, bilateral vessel clips and temporary tie
were removed
10. Haemostasis was reconfirmed after removing clips
Blood loss during surgery was minimal and the patient was discharged
the next day.
FCVP10-Management of a large torted dermoid with a viable ovary:
de-torsion with orchidopexy and interval cystectomy or de-torsion
and cystectomy?
Suruchi Pandey1*, Saikat Banerjee1
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK, Chertsey, UK
224 Gynecol Surg (2015) 12:213–265
Introduction
Follow up of women of reproductive age who underwent de-torsion of
torted ovaries has revealed resumption of ovarian function and successful
pregnancies. Where there is a torted viable ovary with a large ovarian
cyst, the choice is either to de-tort, perform orchidopexy and perform
interval ovarian cystectomy or to de-tort and perform cystectomy to re-
duce the risk of re-torsion and repeat surgery.
Video Presentation
We present the case of a 30 year old with a known 12cm right dermoid.
While awaiting elective surgery, she presented with classical signs of
torsion. Prompt laparoscopy revealed that the cyst had torted 4 times
around the utero- ovarian ligament. The ovary had a bluish hue but
regained colour immediately after de-torsion. There was no obvious oe-
dema. An uncomplicated ovarian cystectomy was performed but the cyst
ruptured during the process. A thorough lavage was performed.
3months after the procedure, the patient underwent a repeat laparoscopy for
pelvic pain, which revealed a frozen pelvis, bilateral hydrosalphinges and
an ovarian mass on the right side. Adhesiolysis, partial right oophorectomy
and pelvic lavage were performed. Our differential diagnosis was: chemical
peritonitis, pelvic infection post surgery and severe PID. The patient needed
another pelvic lavage following which she recovered completely.
We present pictures and videos from the laparoscopic procedures and also
discuss in detail the management of large torted ovarian cysts in women
of the reproductive age group.
FCVP11- Video presentation of 2 different approaches for complex
salpingo-oophorectomy
Victoria Asfour1*, Saikat Banerjee1
1St Peter’s Hospital, London, UK
Salpingo-oophorectomy is a common gynaecological operation. Increas-
ing ovarian preservation at the time of hysterectomy, leads to more com-
plex surgery to be required later in the woman’s life. We present 2 differ-
ent approaches to manage intraoperative access difficulties.
Case1: Frozen pelvis due to severe endometriosis. Unilateral salpingo-
oophorectomy was performed for a large endometrioma in a patient with
severe pelvic pain wishing for fertility. Ureteric stents inserted to facilitate
identification at ureterolysis. Severe adhesions and fibrosis necessitated an
unusual approach. Starting medially at the ovarian ligament and fallopian
tube, ligating laterally. The ovary was stuck to sigmoid colon. The POD
was obscured. The round ligament was divided, the ovary was medialised,
the ureter identified and lateralised. The IP pedicle was divided last.
Case 2: Dense adhesions on entry were obscuring the pelvis due to pre-
vious hysterectomy.This patient was fully anticoagulated for cerebral vein
thrombosis. We show a systematic adhesiolysis normalising the pelvis.
Then, anatomical salpingo-oophorectomy is shown starting from the IP
ligament. Once the pelvis was visualised, the ureter identified
transperitonially. Meticulous haemostasis was achieved. Adhesiolysis
and raw surfaces for dissection kept to a minimum. In this case ureter
lateralised and IP ligament divided.
Conclusion: Laparoscopic surgeons need to build have a wide armamen-
tarium of techniques to adapt to the challenges encountered intra-
operatively safely.
FCVP12- Incidental finding of well differentiated papillary
mesothelioma of the fallopian tube: a rare differential diagnosis
of endometriosis at laparoscopy
Kenneth Ma1*, Kingshuk Majumder1, Rick Clayton1
1St Mary’s Hospital, Manchester, UK
Well differentiated papillarymesothelioma (WDPM) is amesothelial tumour
that occurs in the peritoneum but rarely on the fallopian tube. A 36 year old
nulliparous patient presented to gynaecology out-patients clinic with a 3
month history of lower abdominal pain, dysmenorrhoea and menorrhagia.
Ultrasound scan found a complex ovarian cyst of the left ovary measuring
7cm in diameter.Magnetic resonance imaging suggest a 7cm endometrioma,
adenomyosis and rectovaginal endometriosis. A plan for laparoscopic ovar-
ian cystectomy and staging of endometriosis was arranged.
At laparoscopy the left fallopian tube had an unusal appearance, was swol-
len with mutiple psedocysts attached that was suggestive of endometriosis.
A left salpingectomy, left ovarian cystectomy and excision of pelvic endo-
metriosis was performed. Histology of the left fallopian tube showed well
differentiated papillary mesothelioma while ovarian cyst wall and pelvic
peritoneal biospy showed endometriosis. Our patient made an uneventful
recovery and will now be followed-up with a interval diagnostic laparos-
copy and perinteal biopsy to exclude multifocal disease.
WDPM is generally considered a tumour of low malignant potential, al-
though little is known regarding its natural history and there are no con-
sensus for its management. This case highlights its appearance at laparos-
copy and the importance for histological diagnosis of endometriosis.
FCVP13- Unusual presentation of ovarian cyst, successful
laparoscopic excision
Anita Nargund1*, Anthony Griffiths1
1UHW, Cardiff, UK
We are here with presenting a successful laparoscopic excision of an
unusually presenting dermoid cyst as a video presentation.
A 25 yrs old lady presented to Emergency unit with left side lower ab-
dominal pain. She underwent extensive investigations, CT scan revealed
large 14+12+19 cm cystic lesion in the upper quadrant, suggestive of
dermoid cyst. Tumour markers were normal.
Ovarian cyst present in upper abdomen, mimicking mesenteric/splenic
cyst.
As she was symptomatic, was offered laparoscopic excision of ovarian
cyst with or without oophorectomy.
She underwent laparoscopy, cyst was removed without spillage into peri-
toneal cavity. Procedure was uneventful. Histology confirmed mature
cystic teratoma.
FCVP14- Practical and anatomical advantages of uterine suspension
for access optimisation in resection of deep infiltrative
and rectovaginal endometriosis (video and animation)
Alexandros Derpapas1*, Shaheen Khazali1
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK
Radical surgical excision of deep infiltrative endometriosis (DIE) is the
current mainstay of treatment. Optimal surgical access is crucial for
achieving good results. In our experience temporary suspension of the
uterus, in addition to that of the adnexa, provides superior exposure than
conventional uterine manipulation. We demonstrate the advantages of
this technique via a short video and an animation that outlines the relevant
anatomical relations.
The technique involves the passing of a 2-0 prolene suture on a straight
needle through the skin suprapubically into the pelvis under direct vision.
The needle is then passed through the uterine fundus in a dorsal to ventral
direction and subsequently taken out through the anterior abdominal wall
right by the original entry point. The suture is either tied extracorporeally
over a Raytec gauze or clipped on a heamostatic clamp, so as adjustment
of the degree of anteversion during the procedure is readily achievable.
The same result can be achieved by a modified version of the technique,
whereby a large curved needle is passed through the uterine fundus and
the suture is retrieved through the skin by use of a rectus sheath closure
device.
Temporary uterine suspension results in a better-exposed and still operat-
ing field due to avoiding excessive manoeuvres from the second assistant,
especially when concomitant rectal manipulation is warranted. It is a
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rather easy and quick method of enhanced exposure of the surgical field;
hence we advocate its routine use where resection of endometriosis from
the cul-de-sac and uterosacral ligaments is required.
FCVP15- Laparoscopic ventrosuspension as treatment
for dyspareunia and dysmenorrhea: Another nice operation that
doesn’t work?
Alexandros Derpapas1*, Shaheen Khazali1
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK
Mobile uterine retroversion has long thought to be the cause of pelvic
pain symptoms. Various reports stemming mainly from uncontrolled co-
hort studies over the last 20 years have shown inconsistent results of
surgical correction of acute uterine retroversion. More recent data from
medium and long-term observational studies, however, suggest that de-
spite some decline in the overall effect of surgical ventrosuspension with
time, symptom improvement is durable in about 50% of cases.
Amid ongoing debate amongst laparoscopic gynaecologists about the
efficacy of this method, we present two cases in which we performed
laparoscopic ventrosuspension, hoping to reproduce the promising results
reported in the literature. Both cases regarded premenopausal women
presenting with severe persistent pelvic pain and no other intraoperative
findings apart from an acutely retroverted uterus and elongated round
ligaments.
A non-absorbable suture was placed at the most lateral aspect of each
round ligament, at the point of its entry into the internal inguinal canal and
tied laparoscopically. A running suture was continued medially, using
several bites around the round ligament and tied to the short end of the
initial lateral knot, resulting in shortening of both round ligaments and an
axially positioned uterus.
No symptom improvement was evident at 3 months postoperatively in
either of the cases. Although failure of this method in a small case series
can not question the results in much larger cohorts, we remain uncon-
vinced that correcting a finding that is present in around 15% of asymp-
tomatic women can be an effective treatment for pelvic pain.
FCVP16- A failure of the Novasure Cavity Integrity Assessment
(CIA) due to tubal patency: a video presentation. DrMonikaOktaba,
Mr Andrew Baxter, The Royal Hallamshire Hospital, Sheffield, UK
Andrew Baxter1, Monika Oktaba1*
1Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Avideo will be presented demonstrating a failure of the Novasure Cavity
Integrity Assessment (CIA) due to gas flow down a Fallopian tube. The
ablation was being performed as part of a combined procedure and when
the CIA would not pass it was noted laparoscopically that CO2 was
flowing from the fimbrial end of one of the tubes. When this tube was
clamped proximally the flow ceased and the CIA passed. A video dem-
onstrating the sequence of events clearly will be presented and discussed.
This potential problem is not mentioned in device literature. If this phe-
nomenon is more than an isolated event it could lead to:
& trauma to the cervix in attempts to seal an 'incompetent' cervix
& unnecessary hysteroscopic checks of the cavity
& wasted devices
& if no other technique available, patients potentially having an unnec-
essary GAwithout an ablation being performed
It would be interesting to know the incidence of 'failed' Novasure procedures
and whether this tubal cause of a failed CIA is a major contributing factor.
FCVP17- TITLE: A Junior Trainee: Laparoscopic salpingectomy
for ectopic pregnancy
Elisabeth Bean1*
1University College London Hospital, London, UK
Developing skills for laparoscopy is an essential part of our training
curriculum in Gynaecology. As an ST3 in Obstetrics & Gynaecology,
with an interest in laparoscopy, I have been developing skills under senior
supervision. Having achieved competence in diagnostic laparoscopy, I
am now gaining confidence in simple minimal access procedures. I am
in a privileged position training in a unit with regular laparoscopic lists,
where consultants and senior registrars alike are highly experienced and
confident in supervising juniors.
The most common laparoscopic procedure that trainees will be expected to
do and should be competent to carry out independently by ST6 is a
laparoscopic salpingectomy. It is a valuable skill if you are the senior
presence out of hours, in order to treat the acute admission of an ectopic
pregnancy, when your consultant may be delayed in attending.
I show two videos comparing two techniques, both useful in their own
right.
1. Bipolar and cold scissors: Achieves full excision of the fallopian
tube, without leaving a tubal stump. A favourite of reproductive
medicine specialists, who fear stump ectopics in the event of an
incompletely excised tube. However, often time consuming, with
the need for frequent swapping of instruments and a potentially
dangerous tool near neighbouring bowel.
2. Loop excision: a more simple but effective method. Enables quick
haemostasis in the event of rupture or active bleeding and usually
prevents the need for diathermy. An efficient method to allow the
ever pressured registrar to return quickly to their duties on labour
ward.
FCVP18- A video illustration of a proposed cost effective uterine
hysteroscopy simulator
Somaia Elsayed1*, Wei Zian Szetho1, Ray O’Sullivan1
1St Luke’s General Hospital, Kilkenny, Ireland
BACKGROUND: In obstetrics and gynaecology practice, hysteroscopy
is the standard procedure for diagnostic evaluation of the uterine cavity
and for operative treatment of uterine abnormalities.1,2 Diagnostic and
operative hysteroscopy can be challenging and requires significant skill
set and good hand-eye coordination. Simulation can benefit the trainee,
educator and patient. Simulation allows for practice, real-time feedback,
and learning in a safe environment. 3 A growing body of data supports the
effectiveness of formal, objective teaching of surgical skills and the ef-
fectiveness of surgical simulation in training.4 Additionally, for some
clinical tasks, simulation training can be effective when inexpensive but
realistic models are used.5 , however there is a relative paucity of
simulation-based education in obstetrics and gynaecology training
programmes. Besides, the existing simulators are expensive and trainees
have limited access to them due to lack of resources.
OBJECTIVE: We propose an effective, inexpensive and reproducible
model for developing the skills and hand-eye coordination for diagnostic
and operative hysteroscopy.
METHOD: Advanced surgical skills can be practiced and improved
using simple clay, play-doh uterine models. This video describes Four
different clay, play-doh uterine models, demonstrating techniques of di-
agnostic and operative skills including removal of mirena coil, resection
and biopsy of endometrial polyp and cannulation of fallopian tubes. A
rigid hystroscope is simulated Using flexible snake scope camera,while a
pipette was used to simulate a channel for operative hysteroscopy.
226 Gynecol Surg (2015) 12:213–265
CONCLUSION: The described play-doh uterine models are inexpen-
sive, effective, reproducible and can be used to improve hand-eye coor-
dination in the use of diagnostic and operative hysteroscopy.
FCVP19- Efficacy and safety of laparoscopic sacrocolpopexy for post
hysterectomy recurrent vaginal prolapse
Abdalla Fayyad1*, Damola Onifade1, Ivlina Pandeva1
1Luton and Dunstable University Hospital, Luton, UK
Aim: To prospectively evaluate the efficacy and safety of laparoscopic
sacrocolpopexy for the management of post hysterectomy recurrent vag-
inal prolapse
Methods: 160 consecutive women who underwent laparoscopic
sacrocolpioopexy for recurrent post hysterectomy vaginal prolpase were
prospectively evaluated over a 5-year period. Sacrocolpopexy was per-
formed with a Y shaped mesh after dissection of the vagina from the
rectum and the bladder. Patients were assessed at 3, 12 and 24 months
using the Prolapse Quality of Life (P-QOL) questionnaire; Patient Global
Impression of Improvement (PGII) and were examined using the Pelvic
Organ Prolapse Quantification system (POP-Q).
Results: 88% of patients reported complete cure of vaginal bulge symp-
toms. 92% reported feeling “much better” or “very much better” on PGII.
15% had recurrent anatomical prolapse defined as point Ba ≥ -1, which
were asymptomatic apart from eight patients (5%) that underwent further
surgery. Postoperatively, vault support (point C) was at stage 0 in all
patients. Two patient developed vaginal mesh extrusion that needed sur-
gical revision.
Conclusion: Laparoscopic sacrcolpopexy with Y shaped mesh placement
is safe and effective treatment for recurrent vaginal wall prolapse up to 2
years follow up. The procedure had minimum complications and should
be considered the gold standard in recurrent prolapse.
FCVP20- Resection of large endometriotic nodule from bladder
with full thickness bladder wall resection
Lidia Ewa Kwasnicka, MRCOG MSc1*, Richard Penketh, BSc MD
FRCOG1, Shibs Datta, FRCS1, Elizabeth Bruen, RGN1
1University Hospital of Wales, Cardiff, UK
A 27 year old underwent laparotomy by a gynaecologist and urologist
elsewhere. Her bladder nodule was not tackled as it was felt by both
surgeons to be too large to safely remove without diminishing bladder
capacity.
At the age of 30 she was referred to the University Hospital of Wales,
Cardiff, Endometriosis Centre for further management. She complained
of severe dysmenorrhea, constant pelvic pain, menstrual haematuria, and
cystitis like symptoms during and after her period. On cystoscopy she was
found to have visible endometrioma sub mucosally above the right ure-
teric orifice and protruding into the lumen of the bladder.
Operative Laparoscopy
Following cystoscopy and bilateral ureteric stenting under X-ray guid-
ance she underwent laparoscopic excision of bladder endometriosis.
The bladder dome was welded to the anterior uterine wall by a large
endometriotic nodule occupying the utero-vesical fold. The extensive
disease in her posterior compartment was not addressed on this occasion
The nodule was bisected transversely using a monopolar hook. The blad-
der was then separated from the lower uterus. The remaining
endometriotic tissue was shaved off the uterus, and bladder to leave
healthy bladder tissue. The bladder was repaired with continuous 3/0
Vicryl suture. The patient was discharged the next day with an indwelling
catheter which was removed 10 days later after a normal cystogram.
Ureteric stents were left in situ and will be removed following the second
stage of her operation when her recto vaginal and pelvic endometriosis
will be addressed.
FCVP21- Laparoscopic excision of rudimentary uterine horn
with a failed pregnancy at nine weeks gestation
Kenneth Ma1*, Jennifer Hemers1, Roberta Morris1 ,Kingshuk
Majumder1, Edmond Edi-Osagie1
1St. Marys Hospital, Manchester, UK
Rudimentary horn pregnancies are rare and have an estimated incidence
of 1 in 76 000 to 150 000 pregnancies. We present a case of a failed
rudimentary horn pregnancy at 9 weeks gestation managed by interval
laparoscopic excision and morcellation.
A 34 year old Para 1 lady initially presented with a delayed miscarriage
diagnosed on ultrasound scan outside of NHS services. Images on repeat
ultrasound scan were suggestive of an ectopic pregnancy but at laparos-
copy a rudimentary uterine horn pregnancy was diagnosed. A single dose
of methotrexate was given in this case to reduce vascularity of the rudi-
mentary horn before an interval procedure four weeks later to complete
excision. Magnetic Resonance Imaging(MRI) was used to assess pelvic
anatomy and demonstrated communication between both uterine horns.
At surgery an advanced energy source was used for tissue dissection and
intra-corporeal suture ligation was used to achieve haemostasis. The ex-
cised rudimentary horn was removed by morcellation and the fetus was
retrieved separately intact.
This case highlights the need for a high index of suspicion for uterine
anomalies at ultrasound scan and also demonstrates techniques common
to other laparoscopic procedures. Our literature search found that al-
though most rudimentary horn pregnancies have been managed by lapa-
rotomy in the past there is an increasing number of cases managed
laparoscopically and this appears to be as safe and effective.
FCVP22- Demonstrating the advantages of 3D laparoscopy,
the precision of operating in small spaces; case of severe
endometriosis with complex adhesions due to previous midline
laparotomy and caesarean section
Oudai Ali1
1West Cumberland hospital, Whitehaven, UK
Objective
3D laparoscopy needs to be appraised outside research laboratories. Its
value in enhanced detailed visual navigation in narrow spaces is demon-
strated in multiple adhesions and endometriosis.
Case
A 35y female with previous caesarean and longmidline laparotomywhile
young to correct pyloric stenosis had long standing pelvic pain,
dyspareunia and dysmenorrhea despite mirena inserted 3y ago. Examina-
tion indicated BMI of 32 and scarred abdomen from previous operations.
Pelvic examination indicated tender bulky immobile retroverted uterus
with scarred Douglas Pouch. Ultrasound and CT indicated Left complex
10x12cm adnexal mass towards the benign end of the spectrum with
raised series of Ca125 but values less 200.Patient agreed for laparoscopic
adnexectomy.
Methods and Results
Palmers point was used to introduce 10mm 3D Einstein vision technolo-
gy scope. Findings indicated extensive adhesions creating difficult access
to the pelvis which was scarred from endometriosis and previous caesar-
ean and filled by left sided big endometrioma. Extensive adhesiolysis was
performed with great accuracy and the added depth appreciation helped
operating in confined spaces. The added feature of autonomous scope
warming kept the view steady and avoided the interruptions to defog
scope lenses. No difficultywas experienced by surgeons and staff in using
the system and left salpingo-oophrectomy was achieved. Patient made
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full recovery and discharged home after 24h and the follow up reported
improved symptoms and return to normal function
Conclusion
In advanced laparoscopic gynaecology surgeons should consider 3D lap-
aroscopy and adopt its benefits of improved vision and depth perception
particularly in complex cases.
FCVP23- Laparoscopic Management of Residual Interstitial
Pregnancy
Julia Kopeika1*, Judith Hamilton1, Kumar Kunde1
1Guys and St Thomas NHS Hospital, London, UK
Interstitial ectopic is reported in 2 to 4% of all ectopic pregnancies. The
management can be challenging even where diagnosis is made in a timely
manner, before potentially life-threatening rupture has occurred. Surgical
management carries an increased risk of bleeding due to a high vascular-
ity of interstitial part of the uterus. We encountered a case where repeat
laparoscopy was required 4 weeks after incomplete removal of an inter-
stitial ectopic pregnancy.
Methods: We demonstrate the laparoscopic management of an incom-
pletely removed interstitial ectopic pregnancy.
Results: A patient presented with suboptimal rise of βHCG. Following an
ultrasound diagnosis of tubal ectopic pregnancy, laparoscopic
salpingectomy was performed. However, βHCG continued to rise with a
maximum level of 12500iu/l following surgery. A repeat ultrasound scan
showed presence of residual interstitial ectopic pregnancy. Patient declined
medical treatment and opted to have a surgery. During the repeat laparos-
copy, adhesions and postoperative inflammatory changes were found, mak-
ing tissue more vascular and friable. However laparoscopic removal of
residual trophoblastic tissue with intra-corporeal suturing of the uterus
was successfully performed. The patient recovered uneventfully.
Conclusion: Laparoscopic removal of residual interstitial ectopic preg-
nancy is feasible and should be attempted. This video will demonstrate
the steps that were undertaken to do this successfully.
FCVP24- Laparoscopic management of a ruptured interstitial
pregnancy associated with massive haemoperitoneum and history
of ipsilateral salpingectomy
Vasileios Minas1*, Khadija Ahsraf1
1Wirral University Teaching Hospital, Upton, Wirral, UK
Interstitial pregnancy is an ectopic pregnancy which is implanted in
the interstitial part of the fallopian tube, the part that transverses the
myometrium. It accounts for 2-4 % of all tubal gestations. Mortality
rates are reported as being between 2-2.5 %. The commonest risk
factor is history of ipsilateral salpingectomy. Traditional treatment,
particularly in cases of haemodynamically unstable patients, has
been by laparotomy. Literature review reveals that a few such cases
have been managed by laparoscopy and either cornual resection and
suturing or suturing alone.
Our patient presented with low abdominal pain at 7 weeks gestation. She
was para 1 with one previous caesarean section and a right laparoscopic
salpingectomy for previous ectopic pregnancy. Her beta-hCG was ap-
proximately 6000 mIU/ml and her haemoglobin 13.5 g/dL. Ultrasound
examination showed a left adnexal mass and small amount of free fluid
raising the suspicion of a left-sided ectopic. She was scheduled for a
laparoscopy. Over the following hours she became tachycardic and hy-
potensive, her haemoglobin dropped to 9.5 g/dL and the procedure was
expedited. At laparoscopy massive haemoperitoneum was seen, the left
adnexae appeared normal and a ruptured right interstitial pregnancy was
diagnosed. The pregnancy tissues were removed and the uterine wound
repaired with intracorporeal suturing. The estimated blood loss was 2.5 lt.
Post-operative recovery was uneventful and the beta-hCG levels dropped
rapidly.
In conclusion, ruptured interstitial pregnancy with massive
haemoperitoneum may be managed safely by laparoscopy, provided the
required skills and the option to quickly convert to a laparotomy are in place.
FCVP25- Diagnostic and Intra-operative Challenges for Ovarian
Ectopic Pregnancy, Including Ovarian Conservation
Elisabeth Bean1*, Kostas Doufekas1, Ghada Salman1, Alfred Cutner1,
Davor Jurkovic1
1University College London Hospital, London, UK
Up to three percent of ectopic pregnancies develop in the ovary, thought
to be subsequent to fertilisation prior to ovulation, implantation on the
ovarian surface or presence of endometriosis. They can be technically
difficult to diagnose on ultrasound scan and may well be an unexpected
finding at laparoscopy. There is some suggestion that the presence of an
IUCD may be a pre-disposing factor and that they may be more likely
when conception follows IVF treatment.
We show two cases of ovarian ectopic pregnancy, both diagnosed by pre-
operatively on ultrasound and managed with conservation of ovarian
tissue at University College London Hospital.
FCVP26- Laparoscopic CESA (CErvical SAcropexy) guided
by retroperitoneal tunnelling: an anatomic reconstruction
Rasiah Bharathan1*, Rahul Gore1, Rowan Connell1, Elias Kovoor1
1Maidstone and Tunbridge Wells Hospitals NHS Trust, Maidstone, UK
Case summary
A 56 year old woman presented with symptomatic stage 3 utero-vaginal
prolapse.
Procedure
A laparoscopic subtotal hysterectomy was performed. Then a one
centimetre peritoneal window was created over the S2 vertebral body
on either side. A PVDF mesh is sutured onto the cervical stump using
ethibond. A tunnelling device was inserted through one of the windows
and advanced toward the cervical stump. The proximal end of one arm of
the mesh is grasped by the tunnelling device and retracted through the
retroperitoneal tunnel. This manoeuvre is performed on the contralateral
side. These 8 cm arms form the neo-uterosacral ligaments. Then the
proximal ends of the mesh is secured to the S2 body with ethibond.
The peritoneal windows are closed.
Patient was discharged on day two. Post-operative follow up at 8 week
revealed excellent anatomical support and functional results.
Discussion
We describe a laparoscopicmodification of the traditional open sacropexy
with the added advantage of a near normal anatomical support. The arms
of the mesh comprise of non-absorbable sutures; not mesh. There are
three mesh segments – a distal cervical segment and the two sacral
components.
In view of the much small volume of mesh and a more anatomical
support, we feel that this technique is safer than the traditional
procedure.
A limitation of this technique is that it does not addressing the anterior or
posterior compartment defects. In our experience, correction of the apical
compartment obviates the need for further repair. Long term results are
awaited.
FCVP27- A video illustration for morcelation in a bag Laparoscopic
Supracervical Hysterectomy (LASH):
Manhal Najdy1, K Elsapagh1
1Wishaw General Hospital, Glasgow, UK
Majority of hysterectomies are performed for benign conditions
(Einarsson JI, et al, 2009).
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Objective:
To assess the safety, reproducibility and cost efficacy of LASH.We com-
pared the cost effectiveness of LASH and open subtotal hysterectomy and
intruduced morcellation in bags towards the end of the audit.
Methods:
Data was collected retrospectively from 143 of women who underwent LASH
from August 2008 - November 2014 for various benign indications with
normal cervical smears and endometrium. Patients towards the end of the
study had morcellation in bag in a way to comply with the recent FDA safety
advice and it seems that operating time is getting better with learning curve.
Results:
3.4% hadwound infection howeveronly one pelvic haematoma, one ureteric
oedema, one uterovaginal fistula, one hernia from lateral port site and
one had scar pain at morcellator porte. No conversion to laparotomy, no
blood transfusion, no DVT and no return to theatre. Average theatre
time was 70 minutes for open subtotal hysterectomy and (90 min
for LASH 15 min. for bag morcellation). The average cost per min-
ute is £3.08.
Instruments for LASH costs £1156 plus cost of bag variable versus £200
for open. The average stay for LASH was 1.7 nights versus 3.7 nights for
open. Average cost per night was £486. Overall cost of LASH was
£2259.2 versus £2213.8 for open.
Conclusion:
LASH is safe, reproducible, cost effective and quicker recovery and less
complication rates and can comply with FDA uterine morcellation advise.
FCVP28- A combined cystoscopic and laparoscopic approach
to resect a full-thickness deep endometriotic nodule
from the bladder
Kirana Arambage1*, Horace Roman2, Geoffroy Pasquier2, Benoit
Resch2, Emmanuel Huet2
1John Radcliffe Hospital, Oxford, UK; 2Rouen University Hospital,
Rouen, France
Setting: A French university hospital.
A 34-year-old nulliparous woman with a large (35-mm) endometriosis
nodule infiltrating the bladder and deep endometriotic lesions of the rec-
tum and sigmoid colon.
Intervention: The urological surgeon has performed cystoscopy to iden-
tify the limits of mucosal involvement, and incised the muscular layer up
to the subcutaneous tissue surrounding the bladder. The gynecological
surgeon identified and followed the circular incision, and completed full-
thickness resection of the bladder wall to isolate large nodule. Surgical
technique reports in anonymous patients are exempt from ethical approv-
al by the institutional review board.
Measurements and Main Results: The patient’s functional outcome was
better. The laparoscopic resection of large endometriotic nodules of the
bladder per se may lead to inadvertent removal of healthy bladder muscle.
Thus, it increases the risk of postoperative complications and symptoms
due to small bladder volume. Conversely, if resection of the nodule is
performed only cystoscopically, it probably would not be completely
removed. The combined approach enables to complete resection of the
endometriotic nodule. It not only averts the risk of excessive removal of
healthy bladder muscle but also leaves no disease behind.
Conclusions: On the basis of our experience, we propose the combined
cystoscopic and laparoscopic approach in managing large endometriotic
nodules with full-thickness infiltration of the bladder.
FCVP29- Very big cervical broad ligament fibroid, an intraoperative
surprise during laparoscopic hysterectomy; a demonstration to deal
with the unexpected finding, a strategy to manage retroperitoneal
masses
Oudai Ali1*
1West Cumberland Hospital, Whitehaven, UK
Objective
It is recommended to exercise the best pathways in preoperative assess-
ment to reduce intraoperative uncertainty before committing theatre re-
sources and time. An unexpected big retroperitoneal mass was managed
laparoscopically and retrieved vaginally.
Case
45y para 4 female presented with pain, pelvic mass and normal Ca125.
Scans indicated 9cm right adnexal mass suggesting a big dermoid. On
examination there was palpable mass at the right iliac fossa which was
mobile and filled the Douglas Pouch. She opted for pelvic clearance given
other symptoms of dysmenorrhea and dyspareunia.
Methods
Laparoscopy indicated rather a very big mobile retroperitoneal mass oc-
cupying the whole right broad ligament and consistent with cervical fi-
broid pushing the uterus to the left of the pelvis. The Vcare manipulator
was actually in the fibroid rather than the uterus. Pelvis sidewall dissec-
tion was meticulous and achieved full mobilisation down to the origin of
the fibroid. Hysterectomy was concluded laparoscopically and the spec-
imen was retrieved vaginally after morcellation. Alexis retractor were
used to protect vaginal walls. Total operative time was 315mins with
30min break in the middle. The estimated blood loss was 200ml and
cystoscopy at the end of the procedure was reassuring. The specimen
weighed 730gms.
Results
She made full recovery and discharged home after 48 hours. Follow up at
6 weeks indicted no complication and normal return to function and
patient satisfaction. Histology confirmed benign fibroid.
Conclusion
Operative time cannot always be accurately predicted. It is better to have
the resilience and skill to deal with unexpected intraoperative findings
laparoscopically when possible.
FCVP30- Case report: An interesting case of complex pelvic
pathology associated with subfertility – demonstration
of investigative work up and operative management
Donna Ghosh1*, Tom Aust1
1Wirral University Teaching Hospital, Mersey, UK
Case Report
A 38 year-old nulliparous woman presented to the fertility clinic with a
history of recurrent first trimester miscarriage. She had a regular menstru-
al cycle associated with dysmenorrhoea and previously treated chlamyd-
ial infection but no other relevant medical or surgical history. Blood tests
suggested normal ovulation, thrombophilia and endocrine screen was
negative and both patient and partner karyotypewas normal. Transvaginal
ultrasound demonstrated a bulky uterus with a 5cm sub-serous fibroid, a
right ovarian dermoid cyst and a possible left ovarian endometrioma.MRI
further identified a bi-cornuate uterus and showed the 76mm sub-serosal
fibroid arising from the posterior myometrium and projecting posteriorly
to the left pelvic side-wall. The right kidney was seen within the pelvis,
abutting the right ovary, which contained the dermoid cyst.
Management options were fully discussed and the patient counselled with
regard to potential impact on fertility and future pregnancies if surgery
was undertaken along with explanation of the risk of oophorectomy and
hysterectomy. A CT IVU was performed pre-operatively to delineate the
urinary tract in relation to the pelvic structures and help plan surgical
approach.
Laparoscopy confirmed the pelvic imaging findings as well as
rectovaginal endometriosis and bilateral endometriomas. Hysteroscopy
identified a uterine septum. The patient underwent laparoscopic myomec-
tomy, with extensive adhesiolysis, right ovarian cystectomy and hystero-
scopic septoplasty.
Discussion
We present the full review of this case of subfertility along with relevant
USS, MRI and CT imaging for discussion. The video presentation
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contains demonstration of anatomical variation and pathology and the
surgical techniques for management.
FCVP31- Stretching laparoscopic instruments to their limits, a case
of of total laparoscopic hysterectomy of big fibroid uterus
weighed>1000gm
Oudai Oudai1*
1West Cumberland Hospital, Whitehaven, UK
Introduction
There are case reports and series of laparoscopic hysterectomies with very
large weights. There are not well defined limitations to laparoscopic ap-
proach. Intraoperative assessment is important to checkmobility and access
to the sidewall of the pelvis to allow progression with laparoscopic route.
Case
49y female with previous two vaginal deliveries presented to the surgical
team with pyrexia, with acute abdominal pain and pyrexia with pelvis
mass up to the umbilicus. She was also anaemic from menorrhagia for
more than 6 months required antibiotics and blood transfusion and imag-
ing indicated 14x12x13 uterine complex mass causing right
hydronephrosis. She improved on conservative measures with Esmya
and booked for hysterectomy with the intention of intraoperative assess-
ment for laparoscopic hysterectomy.
Methods
Using 10mm scopewith 30 degree angle at Palmers point it was possible to
easily access the left side of the pelvis with bladder reflection. Mobilising
the right side was difficult as the whole uterus was rotated and pressing on
the sidewall but ultimately achieved. G2 Enseal articulating sealing device
was particularly useful. Retrieval was done vaginally with the help of
Alexis ring retractor to protect vaginal walls and vault was closed vaginally.
Part of a laparoscopic grasper was missing intraoperatively.
Results
This was retrieved separately at a later procedure within 24h and ultimate-
ly patient made full recovery. The specimen weighed 1100gm and histol-
ogy indicated necrotic infected fibroid.
Conclusion
Achieving laparoscopic hysterectomy is still the least traumatic route with
the best enhanced recovery if safely achievable. However, the weight and
mobility of the uterus can put significant strains on laparoscopic
instruments
Poster Presentations
P1-A case of incarcerated and calcified GyneFix intra-uterine device
successfully and safely removed endoscopically
Osama Eskandar1*
1North Devon Hospital, Barnstaple, UK
Introduction
A case of intrauterine incarcerated and impacted GyneFix IUCD is de-
scribed. It was removed successfully hysteroscopically.
Case report
A 55 year old woman was referred to the Gynaecology outpatient
clinic. Her GP had attempted to remove the Gynaefix however, it
was found to be firmly fixed and traction on the strings caused
considerable pain to the patient. The patient underwent hysterosco-
py and D&C and removal of incarcerated GyneFix. The GyneFix
was found calcified and incarcerated at the fundus of the uterus and
was removed hysteroscopically.
Discussion
The GyneFix is a "frameless" IUCD, consists of six copper sleeves, each
5 mm long and 2.2 mm in diameter.(1) It is inserted by a needle through
knot, at a depth of 1 cm, into the fundal myometrium. Due to its frameless
design, flexibility, and minimal presence in the uterine cavity, the
GyneFix is associated with few expulsions and dysmenorrhea than the
IUCDs.
An incorrect technique may increase the risk of perforation.(2) The fact
that the GyneFix was found calcified, suggests that it had been partially
perforating the myometrium. However, the patient did not manage to
conceive after the insertion of the coil. A frameless device anchored in
the myometrium might erode through more easily than a framed
device.(5)
Conclusion
Although it is rare, the possibility of incarceration, migration and late
perforation highlights the importance of the routine regular post insertion
check up. Incarcerated or partially perforating GyneFix can be safely
removed hysteroscopically.
P2- A close shave in the management of rectovaginal endometriosis
Naomi Bullen1*, Matthew Browning1, Mark Coleman1, Jonathan
Frappell1
1Derriford Hospital, Plymouth, Devon, UK
Introduction: Endometriosis affects bowel in 3-37% of all cases. There is
ongoing debate regarding the necessity of either segmental resection or full-
thickness disc rectal excision. This study aimed to review the use of the
laparoscopic rectal shave technique to assess outcomes and patient satisfaction.
Methods: A retrospective database was established for patients requiring
operative management of rectovaginal endometriosis between 2009 and
2014. Both electronic records and case notes were reviewed and data was
collected on pre-operative symptoms, surgical procedure, length of stay,
complication and re-admission rates and post-operative symptom recur-
rence. In addition patients answered a telephone satisfaction questionnaire.
Results: 52 patients underwent surgery during the study period with 69.2%
carried out by a combined colorectal and gynaecological surgical team.
Average age was 33.9 (21-43). Out of 52 patients 90% underwent rectal
wall shave, 8% had segmental resection and 2% hysterectomy in combina-
tionwith rectal shave. Surgery was performed laparoscopically in 96%with
a 0% conversion rate. Average length of stay was 1.5 days with a re-
admission rate of 5.8%. Major complications occurred in 2% with no pa-
tients requiring re-operation within the early postoperative period. Overall
17.3%went on to have further surgery for their endometriosis although only
3.8% required bowel resection. Patient satisfaction levels were high with a
high proportion of patients having symptom improvement post surgery.
Conclusion: The laparoscopic rectal shave is a successful technique for
the management of rectovaginal endometriosis with low complication
rates and high patient satisfaction. Outcomes are improved by using com-
bined colorectal and gynaecological surgical teams.
P3- A Decade of Fibroid Morcellation at UCLH
Elisabeth Bean1*, Thomas Holland1, Alfred Cutner1, Ertan Saridogan1
1University College London Hospital, London, UK
Introduction:
Following recent concerns regarding laparoscopic myomectomy, we in-
vestigated the outcomes of patients who had undergone laparoscopic
myomectomy at UCLH.
Methods:
A retrospective review of all women who had laparoscopic myomectomy
from January 2004 to June 2014 at UCLH.
Results:
250 patients underwent laparoscopic myomectomy. Average number and
size of fibroids removed was 1.89 (1-10) and 71.2mm (10-150mm) re-
spectively. Breach of the uterine cavity occurred in 9.6%. Themorcellator
was used in 240/250 of cases. Average blood loss was 215ml (minimal-
1500ml) and 6 cases had blood loss >1000ml. Average post-operative
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admission was two nights (0-7). Post-operative complications included
one wound haematoma, one readmission due to urinary retention and one
case of small bowel obstruction. No procedures were converted to lapa-
rotomy after attempting laparoscopic myomectomy.
One additional planned laparoscopic myomectomy was converted to lap-
arotomy due to sustaining a bowel injury during initial entry (previous
history of bowel surgery during endometriosis treatment). Another patient
had a uterine mass inconsistent with a benign fibroid at laparoscopy. The
procedure was terminated after biopsy, which later showed a malignant
leiomyosarcoma. All morcellated fibroids had benign histology.
Discussion:
In this subject group, morcellation was successful and safe, with no cases
of morcellation of malignant tissues.
Conclusion:
In experienced hands, laparoscopic myomectomy appears to be safe and
effective. When a fibroid appears suspicious, a biopsy should be taken
and histology awaited prior to proceeding. Patient selection should be
dependent on co-morbidities, in addition to site, size, number and location
of fibroids.
P4- A multi-disciplinary approach to diagnosis & management-
Caecal endometriosis versus a Gastrointestinal Stromal Tumour
(GIST)
Paul Simpson1*, James Hernon2, Edward Morris1
1Department of Obstetrics & Gynaecology, Norfolk and Norwich
University Hospital, Norwich, UK; 2Department of Colorectal Surgery,
Norfolk and Norwich University Hospital, Norwich, UK
Endometriosis has an estimated prevalence of 2-10% but this increases to
between 10-25% in those presenting with gynaecological symptoms.
About 12% of confirmed endometriosis cases are associated with extra-
pelvic disease, involving structures such as the lower gastrointestinal
tract- the most common site being the sigmoid, followed by the rectum,
the ileocaecal valve and the appendix.
A 42 year old patient with known endometriosis wasmanaging her symp-
toms of dysmenorrhoea and non-menstrual pelvic pain with a Gonado-
trophin Releasing Hormone (GnRH) agonist and add-back hormone re-
placement in the form of Tibolone. This had been effective for a duration
of three years but a decision was taken for definitive surgery and a lapa-
roscopic bilateral salpingo-oophorectomy was booked.
Concurrently she was under investigation for chronic anaemia and low
ferritin. A colonoscopy was undertaken, which demonstrated a 10-12mm
smooth sub mucosal lesion arising from the opening of the appendix. The
clinical impression was of a possible Gastrointestinal Stromal Tumour
(GIST) or carcinoid. The patient was offered a choice between surveil-
lance and surgical excision.
Histological examination of the tissues confirmed endometriosis within
the ovarian tissue and the polyp arising from the appendix base. These
findings suggest the ‘exuberent pedunculate polyp of 0.9cm' may have
developed as a result of endometriosis.
Changes in the appearance of the serosal and mucosal surfaces of the
large bowel in response to deposits of endometriosis are unpredictable.
Therefore, any suspicious gastro-intestinal lesion in patients with endo-
metriosis requires a multi-disciplinary approach to investigation andman-
agement to ensure appropriate management.
P5- A new regional anaesthetic block technique for laparoscopic
surgery providing enhanced recovery
Malcolm John Dickson1*
1Rochdale Infirmary, Lancashire, UK
Post operative pain control is an important element of promoting rapid
recovery and hospital discharge following day case laparascopic surgery.
Yet only 60% of patients are satisfied with their analgesia.
Ultrasound guided TAP blocks provides very effective pain relief follow-
ing laparoscopy. And allow patients to be fit for hospital discharge 25%
faster. However, the procedure is highly operator dependant, requires
expensive equipment and takes time - So any benefit it offers is negated
by getting through fewer patients on an operating list. These drawbacks
may explain why its use has never become popular.
A novel technique is described where local anaesthetic agent is placed
into the transversus abdominus plane (TAP). This is done under direct
vision, when the laparoscope is being introduced with a direct cut down
technique. Results of its use show that women having gynaecology lap-
aroscopy as a day case are fit for transfer from theatre recovery to the
discharge ward 24% faster (28 mins vs 37 mins. p value 0.03) It is
planned to run a randomised trial
It is hoped that as pain is better controlled in the immediate post op phase,
this effect will persist and provide more rapid hospital discharge and
reduced analgesic demand
There are in excess of 250,000 laparoscopic procedures carried out per
annum in the USA. Whilst not all of these are day cases, if this technique
allowed patients to be fit for discharge even 20 minutes earlier, there are
substantial financial benefits to be made.
P6- A pathway for the management of patients with PMB, once
endometrial cancer is excluded
Zenat Nazzal1*, Aarti Mohindra2, Mary Connor1
1Sheffield Teaching Hospitals NHS FT, Sheffield, UK; 2University of
Sheffield Medical School, Sheffield, UK
There are clear management pathways for investigating women who
present with postmenopausal bleeding (PMB). The first task is to exclude
endometrial and other cancers. However, once this has been accom-
plished there are no pathways for subsequently managing women. For
example, it is not clear at what endometrial thickness women should be
offered hysteroscopic examination, and which endometrial polyps, once
identified, should be removed. It can be expected that 10 - 20% of women
presenting with PMB will have endometrial polyps; others will have
recognisable atrophic vaginitis or, by a diagnosis of exclusion supported
by features in their history, a resurgence of ovarian activity.
We performed a retrospective review of a cohort of patients who attended
with PMBduring the first sixmonths of 2014. After excludingwomenwith
endometrial and other cancers we collected the following information:
endometrial thickness found on (transvaginal) ultrasound scan; findings at
hysteroscopy if performed, including the presence of endometrial polyp(s);
the histology results of any removed polyps. We developed models to see
howmany women would be offered hysteroscopy for three given endome-
trial thicknesses: 5, 7 and 10 mm and for each of these thicknesses how
many women would have polyps identified (or missed) and if any unsus-
pected malignancies were subsequently identified (or potentially missed).
This information will help us define what endometrial thickness in our
PMB patients should trigger subsequent hysteroscopic investigation, and
so enable us to plan our outpatient hysteroscopy sessions and further
develop our ‘See & Treat’ for endometrial polypectomy.
P7- A patient information leaflet for hysteroscopic examination:
a proposed generic leaflet
Alex Sutcliffe1*, Katharine Tylko2, Elaine Falkner2, Mary Connor1
1Sheffield Teaching Hospital, NHS FT, Sheffield, UK; 2Macmillan,
CancerVOICE, London, UK
There is good evidence that patients who receive written information about
a procedure prior to attending a hospital appointment experience less anx-
iety. However, the content of the leaflet is important, as well as how the
information is presented, and considerable effort is required when writing
such leaflets to ensure that they are comprehensive and can be understood.
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Our outpatient hysteroscopy leaflet was due for revision and a new ver-
sion was produced. However, following last year’s BSGE meeting it was
apparent from a patient representative that our new leaflet might still not
be adequate. For example, it was still insufficiently clear that patients
have a choice between outpatient and inpatient examination and investi-
gation, and some of details about the stages in the outpatient investigation
were lacking clarity.
We therefore asked for comments from a group of patient representatives
about another version of the leaflet and compared ours with those from
other units to see if we could develop one that would be more patient-
friendly and available to all units providing a hysteroscopy service. The
new patient-friendly leaflet will be presented.
P8- A proposal to introduce Cognitive Apprenticeship
in Gynaecological Endoscopy Training
Suruchi Pandey1*
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK., Chertsey, UK
Traditional teaching, especially in technical fields, used the apprentice-
ship model. Collins et al. in 1991 described the instructional teaching
model of Cognitive Apprenticeship (CA), which is a situated teaching
model where the expert is required not just to demonstrate the technical
(or clinical) procedure, but also to vocalize their thinking, so that the
students can learn from their thought process and the various points ex-
perience that informed the teacher’s decision-making. Thus, CA can be an
extremely effective means of training in Gynaecological endoscopy.
CA encompasses 6 key teaching methods:
1. Modelling: the expert shows the students how the task is done, while
vocalizing their thought process
2. Coaching: the students perform the task under expert supervision
3. Scaffolding: the expert “fades” as per student needs
4. Articulation: the students articulate their thoughts during performing
the task
5. Reflection: the students reflect on the tasks they performed and com-
pare their performance to expert performance
6. Exploration: the students perform tasks independently
A study undertaken by Stalmejer et al has demonstrated that CA is not
being used to its full potential in clinical medicine due to shortage of time
available to clinical teachers, short placements of students, clinicians
while modelling not describing why they were doing what they were
doing, clinicians being unaware of the exact stage of student’s learning
and more emphasis on assessment than feedback. Also, reflection and
exploration, though deemed as the 2 most useful components of cognitive
apprenticeship, remained largely unused.
P9- A prospective cohort study to investigate the effectiveness
of a simulation based structured stepwise approach to diagnostic
laparoscopy in gynaecological trainees
Kirana Arambage1*, Dilip Visvanathan1
1John Radcliffe Hospital, Oxford, UK; 2Whipps Cross University
Hospital, London, UK
Background: The outcome of the RCOG trainees’ survey in 2010 has
showed that laparoscopic surgery is one of the top areas of deficiency
among gynaecological trainees in the UK. Thus, this 10 step structural
stepwise training module was proposed to fulfil training needs in novice
trainees in gynaecology.
Aim: To investigate the effectiveness of a simulation based structured
stepwise training module on diagnostic laparoscopy in gynaecological
trainees in The North East Thames region using box trainers.
Method: This prospective cohort study was proposed to investigate
whether the simulation based structural stepwise training module
(SSTM) would improve knowledge, skills and perception in
gynaecological trainees in the North-East London denary. The im-
pact of SSTM on the trainees were determined using pre and post
test score differences between knowledge (MCQs, SEQ), skills
(objective and subjective assessments) and perception (reaction
evaluation form).
Results: The results demonstrated that the proposed SSTM significantly
improved the knowledge and skills in novice gynaecology trainees from
ST1-ST3 (p=0.000). The maximum % improvement observed in an in-
dividual for of MCQ SEQ, objective and subjective assessment were
45%, 50%, 60.5% and 57.5% respectively. Furthermore, a significant
relationship between previous experience in laparoscopic surgery and
pre-test scores for skills (p=0.03 for objective pre-test, p=.0.01 for sub-
jective pre-tests) were observed in the trainee cohort. The% improvement
of knowledge or skills after simulationwere not related to the demograph-
ic factors (P>0.05).
Conclusion: Based on above results, this study concluded that
proposed SSTM is an effective tool for laparoscopic simulation
in novice trainees.
P10- A rare and unusual necrotising fasciitis with E.Coli
as complication of laparoscopy
Ramawadhsingh Motolall1*, Sean Watermeyer1
1Royal Glamorgan Hospital, Llantrisant, UK
Necrotising fasciitis is a rare and potentially fatal infection characterised
by rapid and progressive involvement of the fascia and subcutaneous
tissue. Early diagnosis and appropriate debridement of the infected tis-
sues, with aggressive antibiotics therapy, remains the mainstay of the
treatment. This is the case of a 22 year old lady who underwent a straight
forward diagnostic laparoscopy for chronic pelvic pain, during which, no
cause for her pain was identified. It was an uneventful procedure but this
was shortly followed by an overwhelming necrotising fasciitis of the
anterior abdominal wall from the suprapubic port insertion. A subsequent
CSU culture indicated that she probably had an asymptomatic coliform
UTI at that time. Intraoperatively, there was a ‘through and through’
injury to the bladder, presumably by the Veress needle insertion, which
extravasated infected urine around the subcutaneous tissue of the anterior
abdominal wall, bladder and peritoneal cavity. Her condition was ex-
tremely poor but she was managed appropriately by surgical debridement
and antibiotics and thus escaped a catastrophic event.
P11- A rare case of acute non-puerperal uterine inversion managed
by laparoscopically-assisted vaginal hysterectomy
Kinza Younas1*, Ben Chisholm1, Joshy Neelankavil1, Euan Kevelighan1
1Singleton Hospital, Swansea, UK
Aim
To highlight a rare cause of severe abdominal pain and vaginal bleeding,
and describe a laparoscopic approach to managing non-puerperal uterine
inversion.
Case Report:
A 47-year-old nulliparous female presented to the emergency department
with sudden onset, severe abdominal pain and vaginal bleeding. Her
history included menorrhagia and 2cm fundal fibroid. She was pale and
vomiting with severe pain despite 20mg of intravenous morphine. On
examination, her abdomen was firm and her uterus impalpable. A round,
broad-based mass lay within the introitus, acting as bung to profuse vag-
inal bleeding. An expelled Mirena coil lay posteriorly. An extruded fi-
broid polyp or uterine inversion was suspected.
In theatre, vaginal examination revealed almost complete inversion of the
uterus with a fundal fibroid attached. On laparoscopic entry, the uterus
was found to have formed a funnel into which the fundus, corpus,
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fallopian tubes and round ligaments had retracted. After a successful
laparoscopically-assisted vaginal hysterectomy, the patient was
discharged well the following day.
Conclusion
Acute non-puerperal uterine inversion is rare with fewer than 150 cases
reported until 2006. It should be suspected in women with sudden onset
pain and bleeding, an impalpable uterus and a vaginal mass. We have
found only one other report of non-puerperal uterine inversion managed
by laparoscopically-assisted vaginal hysterectomy1. The procedure is
complicated by the distortion of the pelvic anatomy resulting from uterine
inversion, with the ureters being brought into close proximity of the
ovarian and uterine vessels by traction on the vascular pedicles.
P12- A retrospective descriptive comparison study of transvaginal
ultrasound scan findings with hysteroscopy and histology findings
on postmenopausal women who underwent hysteroscopy
for postmenopausal bleeding
Chellappah Gnanachandran1,2*, Paul woollett1, Peter Kimani1, Kumaran
Mylvaganam1, Amit Patel2, Feras Izzat1
1University hospital coventry and Warwickshire, Coventry, UK;
2University hospital Bristol NHS foundation Trust, Bristol, UK
Objective:
To define an endometrial thickness, that helps to identify postmenopausal
women with a high risk of having an endometrial polyp.
To bring clinical effectiveness in investigation for postmenopausal
bleeding
Design: Retrospective descriptive study. Outcomes were compared with
histology outcomes.
Population: postmenopausal women who underwent a transvaginal scan
followed by hysteroscopy within 28 days of the scan over a two year
period (390 cases)
Results: 143 (37%) women had ultrasound findings suggestive of an
endometrial polyp and 140 (36%) had a thickened endometrium but no
evidence of an endometrial polyp on USS. The remaining 107 cases
(27%) had inconclusive USS findings, and an endometrial polyp could
not be excluded.
When a scan was suggestive of an endometrial polyp in postmenopausal
women, the positive predictive value of a polyp in histology was 82%.
When a scan was not suggestive of an endometrial polyp (140), 41% ( 57/
140) had no polyps but 59% (83/140) had polyps on histology.
Mantel-Haenszel common odds ratio estimate shows that the statistical
significance of the risk of having an endometrial polyp is higher when the
endometrial thickness is 9mm and above compared to if the endometrial
thickness is 8 mm or below.
Conclusion: Difference in detection rate of endometrial abnormality and
polyps in patients with postmenopausal bleeding shown ineffectiveness
in present clinical pathways.
For a protocol to decide the need of operative hysteroscopy or hysteros-
copy under general anaesthesia, for postmenopausal women, an endome-
trial thickness of 8 mm cut off can be used.
P13- A story of a patient and her ovarian monsters
Gabriella Yongue1*, Tariq Miskry2
1Luton and Dunstable University Hospital, Luton, UK; 2St. Mary’s
Hospital, London, UK
Background: Mature ovarian teratomas account for 10-20% of all ovarian
tumours and are most common in women aged 20-40 years. It is reported
that 8-15% occur bilaterally and recur in just 4.2% of cases following
surgical excision.
Case Presentation: We report a case of a 39 year old nulliparous female
who has had six operations over the last 17 years to excise a total of 19
ovarian dermoid cysts that recurred bilaterally. Her first two initial ovarian
cystectomies were performed by laparotomy whilst the last four proce-
dures were laparoscopic. During all laparoscopic procedures, there was
no spillage of cyst contents into the abdomen or pelvis and the dermoids
were all removed using an endocatch bag. There were no residual cysts
left behind at the end of each operation.
Discussion: There is little in the literature about why ovarian ter-
atomas recur after surgical excision and what steps can be taken to
prevent this. It has been suggested that recurrence of ovarian tera-
tomas are more frequent following laparoscopy as opposed to lap-
arotomy. However, this case demonstrates that dermoid cysts can
recur after laparotomy and perhaps with the advantages of mini-
mally invasive procedures, such as swifter post operative recovery,
laparoscopy should prevail as the gold standard.
P14-Acceptability of Out-patient Hysteroscopy procedures
Sreebha Rajesh1*, Rebecca Hardcastle2, Chris Guyer1
1Queen Alexandra Hospital, Portsmouth, UK; 2Royal Hampshire County
Hospital, Winchester, UK
Aim: To assess patient tolerance to hysteroscopic procedures at the am-
bulatory Gynaecology clinic at Queen Alexandra Hospital, Portsmouth.
Materials and Methods: Data was collected prospectively over a two year
period from January 2013 to December 2014. Primary outcome was pain
score on a 10-point visual analogue score at the beginning, mid proceure,
on completion and in recovery. We also looked at the additional analgesia
requirements post procedure and complication rate. The data was
analysed using SPSS.
Results: A total of 61 procedures were performed. Essure sterilisation
(26.2%), Myosure polypectomy (23%) and Endometrial ablation pro-
cedures - Novasure (21.3%); Minitouch ablation (16.4%) and Hydro-
thermal ablation (13.1%). Median Visual analogue score mid proce-
dure was highest for Novasure(7). (whisker plot attached). However,
in recover the Median visual analogue score dropped down to 2 for
all procedure except HTA with a VAS of 1. Only 4 (6.5%) patients
required additional analgesia in recovery and 2 (3.2%) patients had a
vasovagal episode.
Conclusion: Essure, Myosure and endometrial ablation procedures are
well tolerated by patients in the Out patient settings with low procedure
related complications. Novasure has the hightest mid procedure visual
analogue score but in recovery all patients reported a low pain score.
P15- An audit of the adherence to the 2 week wait referral pathway
for patients with Post-Menopausal Bleeding
Thirumagal Bavananthan1,2*, Hannah Lowden1, Pratibha Arya1,
Mamta Pathak2
1Worcestershire Acute Hospitals NHS Trust, Redditch, UK;
2Worcestershire Acute Hospitals NHS Trust, Worcester, UK
Aim To assess referrals of patients with postmenopausal bleeding are
compliant with National cancer care pathway guidelines and to improve
compliance with standards, as well as improve clinical efficiency and
patient experience.
MethodologyRetrospective audit on patients identified from 2week wait
referrals made to the Ultrasound department between July 2013 and April
2014. 138 patients were identified and data obtained.
Results Women with endometrial thickness <4mm were appropriately
discharged in 80% of the cases. Of the 96 patients seen in Gynae out-
patient department 19% were not examined. The pipelle biopsy was suc-
cessfully obtained in 61% with most common cause of failed procedure
being cervical stenosis. Endometrial carcinoma was identified in 6
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patients accounting for 10% of those who underwent hysteroscopy. The
target of 14 days was met in 58% of patients.
DiscussionDedicated ultrasound supported PMB clinics will be useful as
80% of the cases were appropriately discharged reducing the work load to
the GOPD.
One-stop PMB clinics where USS, examination and biopsy can all be per-
formed in succession, improves patient experience and reduces waiting time.
It is reasonable to suggest that biopsy should be attempted in all patients
in GOPD unless the patient opts out. Women with cervical stenosis
should be referred to OPH to have the option for the procedure under
local anaesthesia. Patients unable to tolerate speculum examination could
be referred to out-patient hysteroscopy for vaginoscopy to avoid general
anaesthesia where possible.
Implementation of a guideline with a flowchart followed by re-audit
would be valuable.
P16- An investigation into laparoscopic entry technique preference
amongst UK Surgeons and Gynaecologists - Assessment of the best
practice and future training
Raj (Prithwiraj) Saha1*, Pratyasha Saha2
1Heart of England NHS Foundation Trust, Birmingham, UK; 23rd Yr
Medic, Cambridge University, Cambridge, UK
Although laparoscopic surgery is now practiced commonly as a first
choice over open surgery, its major complications have not changed in
the last 25 years. At least 50% of its major complications happen during
access, and therefore worryingly even before commencement of the
intended procedure. We carried out a comprehensive survey of over
150 UK Surgeons and Gynaecologists with the aim of investigating in-
fluences in the practice of different entry techniques. This included train-
ing, attitude to change and willingness to address any training issues. Our
results highlight interesting trends in practice. Perhaps this is the first
studywhere Surgeons and Gynaecologists are questioned simultaneously.
78% of our respondents were Consultants, 70% of them practicing over 10
years and 40% over 20 years clinical situation, over 50% had not changed
their practice from what they were trained in. justify the views of this study
from established doctors. Most of the gynaecologists indicated a preference
for closed entry surgery whilst majority of our 38 general surgical respon-
dents preferred open entry technique. This variance was mostly due to the
way these senior practitioners were trained. Although 85% believe that
methods of entry should be changed according to the patient's Despite a
heartening 94%were in agreement that different methods of training should
be made available, our study also indicates that an opposition to change is
present in laparoscopy and should be addressed. We suggest that the cur-
riculum of training in both these surgical specialties should be broadened to
include wider training opportunities.
P17- An unusual cause of chronic pelvic pain: Pseudomyxoma
Peritonei
Gemma Nightingale1*, Renee Behrens1
1Royal Hampshire County Hospital, Winchester, UK
A 35 year old, para two, presented to the gynaecology department with a
two year history of increasing suprapubic pain. It intensified mid-cycle
and five days prior to her period. She complained of significant menor-
rhagia, dysmenorrhoea, deep dyspareunia and dyschezia.
At laparoscopy copious amounts of mucoid exudate was seen occupying
the uterovesical fossa and surrounding both ovaries. Her uterus, fallopian
tubes and ovaries appeared normal and there was no evidence of endo-
metriosis. An inflammatory exudate was seen along peritoneal surfaces of
the anterior abdominal wall with obvious adhesions on both lobes of the
liver. The appendix appeared normal. A sample of the mucoid fluid was
sent for microscopy and culture and the patient was treated for presumed
pelvic inflammatory disease.
The infection screen was negative and the fluid showed pus cells with no
bacterial growth. Her symptoms did not improve and she was therefore
referred to a national specialist centre with a possible diagnosis of
pseudomyxoma peritonei. Further investigations including CT scan, co-
lonoscopy and repeat laparoscopy, confirmed the diagnosis of a perforat-
ed mucinous appendiceal tumour. She underwent complete cytoreduction
with pelvic clearance, appendicectomy, splenectomy, cholecystectomy
and omentectomy. All peritoneal surfaces were stripped including the
diaphragms and liver capsule followed by heated intraperitoneal chemo-
therapy (HIPEC).
Although pseudomyxoma peritonei is a rare condition affecting one per-
son per million per year, any surgeon operating within the abdomen may
occasionally encounter this borderline malignant, slowly progressing tu-
mour which has poor long-term survival rates of 10-30% over 10 years if
untreated.
P18- Application of the principles of higher education to laparoscopic
training
Suruchi Pandey1*
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK., Chertsey, UK
As we enter the golden era of gynaecological endoscopy, training future
generations to provide high quality patient centred care gains paramount
importance. In my review, I discuss how the theories of learning in higher
education can be applied to laparoscopic training.
Firstly, I discuss, the need to develop an outcome-based spiral curriculum
(in accordance with Biggs) for gynaecological endoscopy (GE), which is
constructively aligned with the teaching delivered and the assessments
used with an aim to facilitate the development of a holistically trained
laparoscopic surgeon.
I elaborate on my proposal under the following subheadings:
1. Intended learning outcomes including development of specialist
knowledge, organizational skills, intellectual skills and personal
attributes.
2. Learning in GE: to promote a deeper approach to learning – to ensure
that the students Remember, Understand and Apply well (as per Ander-
son et al.’s update to Bloom’s taxonomy) and also spend considerable
time Analyzing, Evaluating and Creating.
3. Teaching in GE to include cognitive apprenticeship, integrated longitu-
dinal clerkship, peer controlled teaching, collaborative exercises and self-
reflection.
4. Assessment of learning outcomes: Based on the work of Rust, I propose
a wide variety of assessments spread throughout the year with emphasis
on formative assessment and timely constructive feedback.
5. Evaluation of training provided: Trainees be encouraged to provide
confidential training feedback to the BSGE on the adequacy of the cur-
riculum, training methods and the assessments
These measures would hopefully enhance higher order thinking with ap-
preciation of the principles of caring and the human dimension.
P19- Are we counseling patients correctly prior to Endometrial
Ablations?
Rebecca Hardcastle1,2*, Chris Guyer1
1University of Surrey, Guildford, UK; 2Ethicon, London, UK
Background:
Despite following NICE guidance2007 promoting Mirena/Ablation for
heavy periods we noted that our hysterectomy rates had not decreased.
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Objectives:
To investigate further intervention rates post second generation endome-
trial ablation.
Design:
We undertook a retrospective study looking at patients undergoing endo-
metrial ablation procedures and their satisfaction/further intervention
rates
A surgical coding report was produced containing patients undergoing an
ablation procedure between January 2008 and December 2012 (5 years)
All 682 patients were contact via mail and asked to complete a survey,
287 responded.
Results:
64% of patients were satisfied with the outcome of procedure (i.e. symp-
tom relief)
of this group 12% still required further treatment.
Of ALL patients 39.5% required further treatments
52% of Patients who failed to be satisfied with ablation and had previ-
ously failed with a mirena coil went on to require further treatment, much
higher than the 22% of the group previously successful treatment with a
mirena .
It is interesting that in the previous failure with Mirena group 34% went
on to have a hysterectomy compared to none of those previous successful
with a mirena..
Discussion:
Ablations are now inwidespread use and perhapswe are using it above its
limitations - meaning a higher failure with more difficult cases
Patients who have previously failed to be successfully treated with a
mirena coil are at a higher chance of having a failed ablation procedure
More specifically a higher risk of Hysterectomy
If these patients were told of their increased further intervention risks they
choose an ablation?
P20- Asherman syndrome
Victoria Asfour1*, Georgina Fraser1, Saikat Banerjee1
1St Peters hospital, London, UK
The outcomes of Asherman’s syndrome after surgical correction
have a wide variation in reported outcomes in terms of menses,
conception and complications in pregnancy. The challenges and
possible variables affecting the outcomes of hysteroscopic
adhesiolysis is discussed in the context of 2 cases that went on
to achieve ongoing pregnancy. In the first case, pregnancy was
achieved after 4 months. Pregnancy was complicated by abruption
requiring emergency caesarean section at 34 weeks and severe
haemorrhage.The second patient is 31 weeks in an ongoing
pregnancy.
In both cases the endometrial cavity was obliterated by adhesions.
Neither tubal ostia were reached. Hysteroscopic location the
adhesiolysis was confirmed by concurrent trans-abdominal ultra-
sound guidance. First case: The cavity was essentially normalised
though the endometrium appeared denuded. Second case: 3D ultra-
sound gave the appearance of a subseptated uterus reaching down to
the cervix. At hysteroscopy the septum had the hallmark appearance
of fibrotic scar. Both tubal ostia were identified through a narrowed
passage from the cervix to each tubal ostium on each side. The
adhesions between the two were divided using a twizzle via a 0
degree angulated 4mm versascope (Gynaecare). In both cases a
copper IUS was placed for 6 weeks. Both patients received 28 days
of ethyl-oestradiol.
We propose an audit tool for Asherman’s syndrome that could be used by
clinicians to audit their outcomes, and if endorsed by the society could
provide a reflection of the UK experience of the incidence, severity,
management and outcome of this condition.
P21- Atypical polypoid adenomyomas
Anita Nargund1*, Anthony Griffiths1
1UHW, Cardiff, Wales, Cardiff, UK
Atypical polypoid adenomyomas (APA) are rare tumours of uterine cor-
pus, usually occurs in premenopausal group, presents with abnormal
uterine bleeding. APAs are classified as benign mixed epithelial and mes-
enchymal tumour, was first described by Mazur in 1981.
The histology features are very similar to well differentiated endometrial
carcinoma, in some cases it is difficult to distinguish between APA and
endometrial cancer.
Even thoughAPA is categorised as a benign lesion, recurrence or residual
primary lesion has been reported to occur in 30.1% of cases that were
managed conservatively. Moreover, endometrial carcinoma is detected in
8.8% of APA cases.
There have been cases reported with coexisting carcinoma or cases,
which have progressed to carcinoma. Thus follow up is crucial in man-
agement of these cases.
We present a case of atypical polypoid adenomyoma, which was diag-
nosed after hysteroscopy and polypectomy prior to IVF treatment.
P22- Audit of 23 women diagnosed with miscarriage who attended
University Hospital South Manchester Early Pregnancy Unit
over a 3 month period
Sandra Sasson1*
1University Hospital South Manchester, Manchester, UK
Approximately 20% of clinical pregnancies end in miscarriage. The aim
of this audit was to compare current practice with National Guidelines.
Women attended the Early Pregnancy Unit between October and Decem-
ber 2014. Their ages ranged between 22 to 41 years of age. Parity ranged
between Para 0 to Para 5. 22%(5/23) had a previous miscarriage and
13%(3/23) had a previous termination. 42%(8/23) were referred by their
General Practitioner and 32%(6/23) from the Accident and Emergency
Department. 43%(10/23) presented with abdominal pain and vaginal
bleeding, 39%(9/23) with vaginal bleeding alone. Themajority of women
required 2 ultrasound scans for their diagnosis. 57%(13/23) were diag-
nosed with missed miscarriage and 43%(10/23) with incomplete miscar-
riage. Bloods were taken in 100%(23/23) of cases. 4%(1/23) required
emergency admission for heavy vaginal bleeding. In women who chose
expectant management, 75%(6/8) were successful. 25%(2/8) proceeded
to medical management with 100%(2/2) success rate. In women who
chose medical management, 67%(4/6) were successful. 33%(2/6)
proceeded to surgical management with 100%(2/2) success rate. Their
length of admission ranged from 22 to 62 hours. In women who chose
surgical management, 100%(6/6) were successful. Their length of admis-
sion ranged from 6 to 9 hours. All women had consent forms completed
and Anti-D administered if appropriate. Patient choice is paramount and
psychological sequelae common, thus patients should have access to
support and counselling. Alternative methods are becoming more widely
available which help reduce length of hospital admission and improve
patient quality of life. These include outpatient medical management and
manual vacuum aspiration.
P23- Bowel Herniation into Pre-peritoneal Space in a 5mm port site
James Dilley1*, Jenny Lo1
1West Sussex Healthcare Trust, Sussex, UK
A 45 year old G3 P3 with BMI 25 underwent a total laparoscopic hys-
terectomy with bilateral salpingo-oophorectomy for fibroid uterus and
menorrhagia.
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The procedure used 4 non-dilating ports (10, 5,5,5mm), a 20 French
Robinson drain was inserted into left lateral 5mm port at closure. Other
port sites were closed with Prolene.
The following day, the patient complained of localized lower abdominal
pain 4 hours after drain was removed and a mass developed gradually at
the port site. A presumed diagnosis of port side bowel herniation was
confirmed by CT imaging showed a small bowel hernia associated with
bowel obstruction.
Laparoscopy revealed mid-small bowel incarcerated hernia within the pre
peritoneal space which was reduced laparoscopically. The patient made
an uneventful recovery.
This case highlights the rare but known risk of herniation through a 5mm
port after removal of drain1. Current RCOG guidelines suggest all lateral
ports of less than 10mm do not need closure. The musculature of the
abdominal wall that underlies the fascia and the fascia elasticity will
normal prevent herniation2
A systematic review has found that slowly absorbable and non-
absorbable sutures reduce risk.3There is evidence to suggest that a non
traumatic, bladeless trochars in reducing risk of hernia.4
Diabetes, smoking, excessive manipulation of trocar and lower quadrant
ports due to absence of posterior sheath may increase the risk. 5Elderly
patients and thin patients also have a reduced strength and elasticity of
fascia so may be more prone to hernia2.
P24- Carboprost: A Useful Adjunct in the Laparoscopic Resection
of a Cornual Ectopic Pregancy
Rebecca Mallick1*, Tosin Ajala1, Tony Kelly1
1Royal Sussex County Hospital, Brighton, UK
Introduction
Cornual ectopic pregnancies are a rare, but very challenging form of
ectopic to manage. Laparoscopic resection can be a successful fertility
preserving treatment option, but there is always a high risk of haemor-
rhage/hysterectomy. We present the first case of its kind where
intramyometrial carboprost injection was used successfully, prior to lap-
aroscopic resection, to help delineate the ectopic, improve visualisation,
aid resection and reduce potential blood loss in a challenging case.
Case Report
A 38-year-old woman presented to the EPU at 6-weeks pregnant with
abdominal discomfort. A right cornual ectopic was diagnosed on scan and
subsequently managed surgically. In theatre, the findings were a diffuse
enlargement of the cornua with no discrete ectopic visible making
attempted resection technically difficult and potentially hazardous.
500mcg carboprost was injected laparoscopically directly into the
myometrium surrounding the ectopic. This resulted in localised
myometrial contractions, pushing the trophoblastic tissue closer to the
uterine surface and demarcating it more clearly for resection. Monopolar
diathermy was used to make an incision over the ectopic and suction used
to remove the POC. The incision was sutured laparoscopically and blood
loss was <50mls. She was discharged home the following day and
completely discharged 2 weeks later with a negative βHCG.
Conclusion
Cornual ectopic pregnancies remain a challenging clinical dilemma. Lapa-
roscopic resection is a safe treatment option and the use of intramyometrial
carboprost injection prior to resection appears to improve visualisation and
delineation of the ectopic pregnancy, resulting in a technically more
straightforward resection with significantly reduced blood loss.
P25- Case Report - Laparoscopic management of a 20cm ovarian
cyst in the third trimester of pregnancy using direct optical entry
as an alternative approach
Donna Ghosh1*, David Rowlands1
1Wirral University Teaching Hospital, Mersey, UK
Introduction
The prevalence of ovarian cysts in pregnancy is reported as between 1-
2%. The decision to operate in pregnancy is difficult with views on
optimal management and timing of surgery being controversial.
Case Report
A 20-year-old primiparous woman presented with a 16x11x20cm multi-
septated right adnexal cyst, identified at first trimester ultrasound. She had
a past medical history polycystic ovarian syndrome and a BMI of 44.
Tumour markers were normal. Conservative management with regular
monitoring was agreed.
Following an acute admission with abdominal pain the patient underwent
ultrasound-guided aspiration of the cyst at 23/40. Cytology showed no
malignant cells. The patient had recurrent admissions with acute pain
from 27-30 weeks gestation, managed conservatively due to risk of mid-
line laparotomy, preterm labour and prematurity. USS confirmed re-
accumulation of the cyst. The aim was for caesarean delivery by 32-34
weeks with right ovarian cystectomy/oophorectomy. At 30+4
weeks-gestation the decision was made for surgery in view of
non-resolving symptoms and suspicion of torsion. The patient
underwent laparoscopy via direct optical entry to the right-side of
the abdomen with planned insertion into the ovarian cyst capsule.
The ovarian vessels were identified, demonstrating evidence of mul-
tiple torsion. The patient underwent right salpingo-oophorectomy. A
small grid-iron incision was made to remove the enlarged complex
cyst. Histology confirmed ischaemic necrosis.
Discussion
We present this case report with contemporary review of the literature.We
describe our laparoscopic approach as a safe alternative in the manage-
ment of large ovarian cysts in advanced pregnancy.
1. Zanetta et al. BJOG 2003; 110:578-583.
P26- Case Series of DifferentManagement of Caesarean Section Scar
Pregnancy
Radwan Faraj1*, Gemma Govinden1, Hannah Yeeles1
1Rotherham Hospital, Rotherham, UK
Case1:
1st case was in her third pregnancy diagnosed at 7 weeks gestation when
she presented with vaginal bleeding. Gestational sac was seen implanted
at CS scar away from uterine cavity.
She was counselled o have systemic and local MTX. Dose calculation at
1mg/m2 and also next day she was given transvaginal ultrasound guided
using double lumen egg collection needle. Initially sac content was aspi-
rated then 1 ml KCLwas injected till cessation of fetal heart activity. Then
40mg MTX was injected into the sac.
HCG follow up showed gradual decline till negative in 6 weeks.
Case 2:
The second case was 33 years old previous 1 CS. In this case we gave
her systemic MTX only at 1mg/m2. Her initial response was good
with decline of HCG by 60% over one week but plateau in the second
week at 600 IU and 55IU. The sac was getting bigger, more vascular
on Doppler.
Decision was to proceed with surgery in view of the size of the
mass and plateuing HCG. We decided on vaginal approach with
ultrasound guided surgical/suction evacuation. The procedure was
started with a Shirodkar suture that acted as a tamponade to
control any operative bleeding. The procedure continued by suc-
tion evacuation under ultrasound guidance. She stayed inpatient
and suture was removed in 48 hours. Her HCG decline was
steeper and became negative in 3 weeks.
Case 3:
This patient was managed by Ultrasound guided suction evacuation with-
out the use of Methotrexate. Her HCG decline was satisfactory.
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P27- Comparing laparoscopic and open surgical management of all
endometrial cancer patients in the North West Thames
Gynaecological Cancer Network
Rebecca Pugh1*, Alan Farthing1
1Queen Charlottes and Chelsea Hospital, London, UK
BACKGROUND: Endometrial cancer is the fourth most common ma-
lignancy in women in the UK. NICE guidelines state that there is suffi-
cient data on safety and efficacy to support the use of laparascopic total
hysterectomy and laparoscopic assisted vaginal hysterectomy for the
treatment of endometrial cancer.
METHOD: A retrospective audit was compiled looking at all women
treated for endometrial cancer in the North West Thames Gynaecological
Cancer Network from 1st April 2012 to 30th September 2012.
RESULTS: 62 women were identified as having had surgical treatment
for endometrial cancer. 76% of cases were managed in a tertiary cancer
unit and 71% of cases were completed laparoscopically. Many of the
patients were obese (average BMI 32) and 66% of cases had stage 1A
disease. Patients having a laparoscopic procedure stayed in hospital for a
significantly shorter time than those who had an open procedure. Two
laparoscopic procedures were converted to an open operation but there
were a greater number of post-operative complications in those having
open surgery. 45% of patients did not require any adjunctive treatment.
CONCLUSION: Despite the growing problem of obesity, the majority
of patients still present with early stage disease. Most patients were op-
erated on by a laparoscopic approach. These patients had fewer compli-
cations rates and were able to be discharged more quickly. Confirming
that laparoscopic procedures are a safe and affective way of treating
endometrial cancer.
P28- Comparing MRI and laparoscopic results of patients in an
endometriosis MDT
Danielle Nimmons1, Lakshmi Sandu Aana1*, Peter Byrne1,
Sonali Limdi1, Gaity Ahmad1
1Pennine Acute Hospitals NHS Trust, Greater Manchester, UK
Background and Aim
MRI has been shown to be an accurate and a cost-effective tool for
the preoperative staging of deeply infiltrating endometriosis (DIE).
Pennine Acute Hospitals NHS Trust is a recognised endometriosis
centre. An MDT was established in March 2014 to aid management
of the condition. This MDT includes gynaecologists, radiologists,
urologists, and colorectal surgeons. The severity of disease can be
assessed on diagnostic laparoscopy. However MRI is a non-invasive
tool that can help women in making a choice of different treatment
options. The aim of our retrospective quality improvement project
was to compare preoperative MRI findings and diagnostic laparo-
scopic results.
Methodology
Fourty-five patients were included in an endometriosis MDT be-
tween 07/04/14 and 03/01/15. Thirty-six patients who had DIE on
MRI were included in the study. MRI findings, MDT results, his-
tology results and laparoscopic findings were collected for these
patients. These were tabulated and analysed using Microsoft Excel.
Results
Twenty-five out of the 36 patients had surgery, 6 chose medical
treatment and 5 are awaiting surgery. Furthermore, due to the
MDT a patient was identified as having diverticular disease and
not endometriosis. Overall, approximately 80% of MRI findings
correlated with laparoscopic findings. Specifically, this was 92%
for bladder endometriosis, 76% for recto-vaginal, 64% for rectal,
80% each for left and right endometrioma; and 83% for bilateral
endometriomas.
Discussion and Conclusions
MRI is beneficial for localising and mapping DIE. It helps plan MDT
approaches to surgical management and helps women tomake an informed
choice.
P29- Complications and Length of Hospital Stay following Total
Laparoscopic Hysterectomy: Support for Daycase Laparoscopic
Hysterectomy
Islam Abdelrahman Ramadan1*, Sophie Elaine Slater Bennett1
1West Wales General Hospital, Carmarthen, UK
Background:
Laparoscopic hysterectomy has proved a cost saving and viable alternative
to a total abdominal hysterectomy or a vaginal hysterectomy. Day case total
laparoscopic hysterectomies are already being performed and these could
lead to even further cost reduction due to the decreased hospital stay.
However this needs to be evaluated carefully to ensure that patient's risk
of post operative complications are not increased. Here we look at a small
cohort of womenwho have undergone a total laparoscopic hysterectomy as
an inpatient to evaluate whether this supports day case hysterectomies.
Aim:
To evaluate the complications, length of hospital stay and patient satis-
faction after total laparoscopic hysterectomy in a district general hospital
in order to provide support to the possibility of outpatient (day case)
laparoscopic hysterectomy
Methods:
A retrospective analysis of 64 women who had undergone a total laparo-
scopic hysterectomy in a district general hospital.
Results:
Of the 64 women booked for total laparoscopic hysterectomy, there were
no major intra-operative or immediate post-operative complications. The
average haemoglobin drop was 1.75 g/dL. The median hospital stay was
2.5 days (one of these being pre-admission) and the median period of
recovery to normal activity was 3.5 weeks.
Conclusion:
The low rates of complications, minimal blood loss coupled with the already
short hospital stays (the average length of stay post procedure was 1.5 days)
suggest that total laparoscopic hysterectomy as a day case is a safe, viable
and potentially cost saving procedure for a large number of patients.
P30- Correlation of MRI findings with findings at laparoscopic
surgery
Ronnie Rahman1, Emmanuel Ofuasia1*
1Croydon University Hospital, London, UK
Our study going back 5 years looks at how MRI reports have correlated
with actual findings at laparoscopic surgery. We discuss when differences
have occured, its impact on patient management.
P31- Documentation of Laparoscopic procedures. How good are we
at completing operative notes and discharge summaries?
Dana Touqmatchi1*, Jennifer Davies1, Sonal Dave1, Ian Chilcott1,
Nick Nicholas1
1Hillingdon Hospital, London, UK
Accurate and legible documentation are prerequisites for delivering high-
quality care.
Almost 250,000 woman undergo Laparosopic surgery yearly. Articles on
safety entry techniques and operating are established, therefore every effort
should bemade to include these techniques on operation notes. In addition to
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this, most laparoscopic day cases are discharged back to GPs, and with NHS
England stating that 33% of hand written and 26% of electronic discharge
summaries fell short of NICEs minimum standards for clinical communica-
tion, it is vital to ensure discharge summaries are clear and accurate.
Given this, an audit was performed to determine how well we documented
our operative procedures and how accurate our discharge summaries were.
A prospective audit was completed which include 50 sets of notes.
Results: 90% of primary operating surgeon completed notes. 50% of
attempts of veress entry were documented. Palmers test documented in
10%. Starting intraabdominal pressure documented in 72%. Reduction of
pressure after trocar insertion documented in 34% of cases. 86% of op-
eration notes were clearly documented. Suture material used for skin
documented in 94%. Of those discharged back to GP, 80% had clear
discharge summaries.
Results showed areas that can be improved on in terms of documentation, and
we have devised a sticker that can used on operating notes to help document
key steps. Other recommendations include computerised documentation.
The discharge summary can be improved by ensuring a registrar or con-
sultant reviews this, as this is usually left up to the most junior member of
the team to complete.
P32- Does the addition of bilateral salpingectomy (BS)
at laparoscopic hysterectomy increase morbidity?
Obi Ojukwu1*, Alice Hurrell1, Funlayo Odejinmi1
1Whipps Cross University Hospital, London, UK
Background: Recent evidence suggests the fallopian tubes may be the
origin of certain serous ovarian cancers. Post-hysterectomy the fallopian
tubes are redundant and can cause hydrosalpinx, pelvic pain and ectopic
pregnancy. Increasingly more women are undergoing prophylactic BS
and studies demonstrate that BS does not affect ovarian function. How-
ever, does it affect short-term morbidity?
Objective: To assess whether BS at total laparoscopic hysterectomy
(TLH) or laparoscopic subtotal hysterectomy (LASH) influenced surgical
time, blood loss or length of hospital stay.
Method: A retrospective case-control study. The cohort consisted of 306
consecutive single surgeon laparoscopic hysterectomies in a London hos-
pital. BS or bilateral salpingo-oophorectomy (BSO) was used selectively.
Results were analysed using the Student t-test and Mann-Whitney test.
Significance was a p-value of <0.05.
Results: 57 out of 112 (51%) had a TLH, 21 (19%) had a TLH-BS and 34
(30%) had a TLH-BSO.
117 out of 194 (60%) had a LASH, 50 (26%) had a LASH-BS and 27
(14%) had a LASH-BSO.
LASH-BS was significantly associated with lower blood loss and shorter
length of hospital stay compared to LASH alone or LASH-BSO. TLH-BS
was significantly associated with lower blood loss compared to TLH
alone or TLH-BSO, and significantly shorter surgical time compared to
TLH-BSO.
Conclusion:We conclude that the addition of BS at laparoscopic hyster-
ectomy is not associated with short-term morbidity. Lower blood loss
may reflect the surgeon learning curve. This bolsters evidence that wom-
en should consider BS at laparoscopic hysterectomy and this information
can be used during informed consent.
P33- Encephalitis associated with dermoid cyst - case report
and review of literature
Monika Oktaba1*, Lucy May1, Andrew Baxter1, David Paling2, Basil
Sharrack2, Julia Palmer1
1Sheffield Teaching Hospital; Department of Obstetrics and
Gynaecology, Sheffield, UK; 2Sheffield Teaching Hospital; Department
of Neurology, Sheffield, UK
Case presentation:
A 29 year-old office worker presented to hospital with history of head-
ache, pyrexia, aggressive behaviour and hallucinations.
Her past history included depression treated with Sertraline, which was
discontinued one week prior to admission.
Gradually she became obtunded with dystonic attacks and developed
seizures.
Her condition deteriorated further requiring ICU care and intubation.
After several investigations she was diagnosed with autoimmune
encephalitis.
CT pelvis showed 14 mm ovarian dermoid cyst.
Anti-NMDA encephalitis was suspected and decision was made for
oophorectomy.
NMDA receptor antibody was negative in serum but positive in cerebro-
spinal fluid.
She has been making gradual clinical recovery.
Discussion:
The N-methyl-D-aspartate receptor (NMDA) is involved in normal phys-
iological and pathological states in the brain.
Anti-NMDA encephalitis is characterized by memory deficits, seizures,
confusion, and psychological disturbances in males and females of all
ages. This type of encephalitis is often associated with ovarian teratoma
in young women.
Treatment includes immunotherapy e.g. high-dose intravenous cortico-
steroids, immunoglobulins, plasma exchange, cyclophosphamide, azathi-
oprine, mycophenolate mofetil, tacrolimus, methotrexate, and monoclo-
nal antibodies (e.g., rituximab) in sequence or in combination. Some
patients may recover to their normal state with supportive care alone.
Most of the patients required further treatments such as tumor resection
and immunotherapy. It has been proposed that the tumour should be
removed when present.
Recovery may take 2 years or longer, and the patient may not always
return to their former levels of motor function and cognition. Prognosis is
better after tumor resection and immunotherapy.
P34- Endometrial ablation using radiofrequency in women
with previous Caesarean Section: is this a safe procedure?
Gudrun C. Rieck1*
1Betsi Cadwaladr Health Board, Bangor, Gwynedd, UK
Introduction:
The device used radiofrequency for endometrial ablation (NovaSure®).
The machine switches itself off when the impediance is too high.
Aim:
Does the device perform safely in cases with previous Caesarean Sections
if the thickness of the scar is unknown?
Method:
Prospective safety audit between March 2011 and August 2014. Most
women had an ultrasound but the caesarean section scar was only men-
tioned once. All women undergone a hysteroscopy before insertion of the
device.
Results:
94 patients were listed for endometrial ablation. In eleven cases endome-
trial ablationwas not attempted as there were unexpected clinical findings
at the time of the diagnostic hysteroscopy.
83 cases undergone endometrial ablation.
In four cases (5%) endometrial ablation device was introduced but
the procedure was abandoned by the machine: one case had large
fibroid, one case cavity was probably too wide, one case a possible
instrument failure. One case had a very thin lower segment as docu-
mented on pre-op scan (one case out of the 20 cases with previous
caesarean section 5%).
79 patients had endometrial ablation performed. Out of those 19 cases had
previous LSCS: 6 cases had one previous LSCS, 3 cases had two previous
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LSCS, 8 cases had three previous LSCS, one case had four previous
LSCS. One case had a history of uterine perforation.
There was no acute complication.
P35- Endometriosis care pathway and the role of an Endometriosis
Specialist Nurse
Michelle Davies1*, Suruchi Pandey1, Saikat Banerjee1, Shaheen Khazali1
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK., Chertsey, UK
The role of an Endometriosis specialist nurse (ESN) varies from centre to
centre andwithin each centre, the role will evolve over timewith experience.
In this poster, we share our experience in setting up a post for a newESN and
the effects this has had on our service provision. We explore various duties
and responsibilities of the ESN and also share our integrated endometriosis
care pathway for the benefit of other developing centres.
Our ESN started in the year 2014. Her job was initially funded by the
innovation fund and later her salary was paid by the income generated by
her clinics.
Following duties are performed by our ESN:
Triage and co-ordinatation of care between teams and with GPs
Educating junior doctors and nurses
Collating and entering data into the BSGE database
Running patient support groups and follow-up clinics
Managing and updating the website, patient information leaflets and care
pathways
Telephone follow-up
Providing direct telephone access for patients
Counselling and supporting patients throughout their treatment journey
Supporting ward nurses in caring for patients who had complex surgeries
Contributing to audit and research
The ESN has proven to be an invaluable asset to our centre
P36- Essure hysteroscopic sterilisation : Compliance with NICE
guidance, our experience
Anita Nargund1*, Caryl Thomas1, Richard Penketh1
1UHW, Cardiff, Cardiff, UK
Essure hysteroscopic sterilisation is minimally invasive outpatient meth-
od of female sterilisation.
This method has many advantages including no incision, high successful
bilateral placement rates, non-mandatory use of anesthesia, out patient
procedure, Low level of pain, and low risk surgery. Therefore it is highly
recommended than traditional laparoscopic sterilisation, which has more
serious complications.
This type of sterilisation is particularly useful in patients with high BMI,
with multiple previous abdominal surgeries.
The Essure system consists of two microinserts comprising a dynamic
outer coil and an inner flexible coil, which are placed hysteroscopically
into the fallopian tubes under direct vision.
Essure hysteroscopic sterilisation was performed in Outpatient procedure
clinic, University hospital of Wales.
We present successful placement rates, pain scores during the procedure
and outcomes at 3 month follow up.
It is a safe, quick, effective and irreversible method of sterilisation.
P37- A new regional anaesthetic block technique for laparoscopic
surgery providing enhanced recovery
Malcolm John Dickson1*
1Rochdale Infirmary, Lancashire, UK
Post operative pain control is an important element of promoting rapid
recovery and hospital discharge following day case laparascopic surgery.
Yet only 60% of patients are satisfied with their analgesia.
Ultrasound guided TAP blocks provides very effective pain relief follow-
ing laparoscopy. And allow patients to be fit for hospital discharge 25%
faster. However, the procedure is highly operator dependant, requires
expensive equipment and takes time - So any benefit it offers is negated
by getting through fewer patients on an operating list. These drawbacks
may explain why its use has never become popular.
A novel technique is described where local anaesthetic agent is placed
into the transversus abdominus plane (TAP). This is done under direct
vision, when the laparoscope is being introduced with a direct cut down
technique. Results of its use show that women having gynaecology lap-
aroscopy as a day case are fit for transfer from theatre recovery to the
discharge ward 24% faster (28 mins vs 37 mins. p value 0.03) It is
planned to run a randomised trial
It is hoped that as pain is better controlled in the immediate post op phase,
this effect will persist and provide more rapid hospital discharge and
reduced analgesic demand
There are in excess of 250,000 laparoscopic procedures carried out per
annum in the USA. Whilst not all of these are day cases, if this technique
allowed patients to be fit for discharge even 20 minutes earlier, there are
substantial financial benefits to be made.
P38- Evaluation of the 2-week referral system for urgent
investigation of postmenopausal bleeding in a District General
Hospital setting Maria Boland MBBS BSc , Mark Broadbent BSc
MFFP FRCOG
Maria Boland1*, Mark Broadbent1,2
1University College London, London, UK; 2Barnet General Hospital,
London, UK
Aim: To investigate the incidence of endometrial carcinoma in patients
screened according to theNHS 2-week target for postmenopausal bleeding.
Methods: Cross-sectional study undertaken at one NHS District General
Hospital. Retrospective analysis of all patients presenting to our Gynae-
cology department under the 2-week referral pathway over one year.
Hysteroscopy was offered to patients with endometrial thickness of great-
er than 5mm on TVUSS. Ultrasound findings, hysteroscopy findings, and
histology results were correlated with clinical history to determine the
incidence of endometrial carcinoma. Inclusion criterion was postmeno-
pausal bleeding. Multips and primips were included.Women on hormon-
al treatment were excluded from the study.
Results: 107 referrals were received during this period. The mean age was
72 (range=50 – 86). 51 women (48%) underwent biopsy. Of these, 6 cases
of endometrial cancer were detected, equating to 5.6% of all referrals.
Conclusions: The incidence of endometrial carcinoma in patients pre-
senting with postmenopausal bleeding is 5.6%. Less than half of all re-
ferrals during this timemet the criteria for hysteroscopy and biopsy. NICE
guidelines (2012) infer that the pick up rate is expected to be 10%. These
findings suggest that the two week wait results in over referral for inva-
sive and costly investigations for women who do not have a diagnosis of
endometrial carcinoma.
P39- Factors Affecting Surgeons' Decisions about the type
of Hysterectomy they perform: A Qualitative Study
Sujata Gupta1,2*
1University of Surrey, Surrey, UK; 2LTHTR NHS trust, Preston, UK
Summary-Majority of hysterectomies in the UK are performed through
an abdominal approach. This is despite robust evidence in favour of
vaginal and laparoscopic approach.This study aimed to find out what
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factors influence decision regarding the mode of hysterectomy offered.
Although this question has been addressed in various studies in the past,
no UK study has explored this.
Aim -Themain aim of this studywas to explore the gynaecologists' views
and factors that influence surgical decision making on the type of
hysterectom offered.
Methodology-This is a qualitative study for which NHS consultants
practising benign gynaecology in the northwest of England were
interviewed. A total of 22 participants were interviewed.
Results-Key factors influencing surgical decision-making were surgeons'
perceptions of an increase in clinical indications of hysterectomy for which
an abdominal route was more appropriate. Abdominal route was also often
preferred due to familiarity. They felt that there was a lack of training in
vaginal and laparoscopic hysterectomy. Due to this, many surgeons
expressed concerns about higher complications with minimal access routes
in their hands. Low case load, time pressures and lack of organisational
support were other influencing factors which favoured abdominal route.
ConclusionsMost surgeons prefer abdominal hysterectomy as this is the
route they feel most comfortable with. Lack of training and experience are
the main contributing factors limiting the use ofminimal access approach.
Most surgeons want to develop their laparoscopic skills but similar desire
is lacking towards vaginal hysterectomy.
P40- Findings of a quality improvement survey
Suruchi Pandey1*, Alex Robinson1, Michelle Davies1, Saikat Banerjee1,
Shaheen Khazali1
1Centre for Endometriosis and Minimally Invasive Gynaecology-
CEMIG, Ashford & St. Peter’s Hospital, Chertsey, UK., Chertsey, UK
In order to improve the quality of care we offer to our patients, we are
undertaking a telephonic survey of patients who had treatment of endome-
triosis in our unit. It is an on-going survey and the results are interesting.
The information below is based on the data available as of now. On an
average the patients suffered for 5 years with pelvic pain before seeing the
GP. 6 patients saw the GP more than 10 times before being referred to a
specialist clinic. The gap between GP referral and appointment with the
endometriosis team ranged from 2weeks-4months. The satisfaction
scores with initial consultation, explanation of the disease condition, abil-
ity to directly access an endometriosis specialist nurse were high being
9.3, 8.7 and 9.5 out of 10 respectively. The patients felt that their views
were respected with the average score being 9.1. However, not all were
happy with the explanation of surgery preoperatively with the average
score being 8.3. The likelihood of recommending the unit to a friend or
family was 9.8.
The key areas where the patients wished to see improvement were – GP
education regarding endometriosis symptoms, waiting times for surgery,
operation cancellation, inability to see consultant post op due to split site
working, inability to see consultant on follow up and being discharged too
soon after surgery.
Even when there were complications, patients commented on the care
being excellent emphasizing the importance of candour, good communi-
cation and teamwork.
P41- Grading quality of preoperative endometrial biopsy
in endometrial cancer
Rasiah Bharathan1*, Lim Teo1, Mena Farag1, Desmond Barton1,
Paul Bulmer1
1St. Georges Hospital, London, UK
INTRODUCTION
When women present with postmenopausal bleeding, following an
ultrasound or hysteroscopic assessment, an endometrial biopsy may
be performed. This biopsy informs the clinician regarding the histo-
logical subtype and the grade of differentiation of the cancer. Accurate
preoperative grading is important in determining the place of care,
counselling the patient about the extent of recommended surgery
and forewarning the patient regarding potential adjuvant chemother-
apy. This retrospective study examines the grading quality of preop-
erative biopsy.
METHOD
Patients who were diagnosed with endometrial cancer between 2008 and
2013were identified through the histopathology database. The sensitivity,
specificity, positive and negative predictive values and grading accuracy
of preoperative biopsy was determined using final histology.
RESULTS
During the six year period, 158 women had surgical treatment for endo-
metrial cancer. 46 patients were excluded because of lack of complete
dataset or because of sarcomatous diagnosis. Complete set of data was
available for 112 women. The sensitivity of preoperative grade 1, 2 and 3
are 61.5%, 61.5% and 81%, respectively. The specificity of grade 1, 2 and
3 diagnoses are 91.7%, 73.3% and 84%, respectively. PPVof G1, G2 and
G3 are 80%, 41% and 71.4%, respectively. NPVof G1, G2 and G3 are
81.5%, 86.3% and 90%, respectively. The overall accuracy of G1, G2 and
G3 are 80.4%, 70.5% and 83%.
CONCLUSION
Preoperative biopsy grading performance is moderate in quality.
Randomised comparative trials of sampling techniques are required to
define performance benchmarks. Accurate preoperative grading has po-
tential implications for patient counselling, logistics, outcomes and
resourcing.
P42- Gynaecological day case surgery: A snap shot view to improve
cost-effectiveness
Lakshmi Sandu-Aana1*, Rizwana Yakub1, Uzma Ahmed1, Sarah Carter1,
Gaity Ahmad1
1Royal Oldham Hospital, Oldham, Manchester, UK
BACKGROUND: The current NICE recommendation is for 75% of
elective surgery to eventually be performed as day-case. Effective day-
case surgery minimises hospitalisation whilst optimising efficient patient
care and cost-effectiveness.
AIMS: Our service set-up for gynaecological surgery comprises of
two sites specifically for day-case and one for inpatient procedures.
Day-case procedures are routinely being done in the operating list at
the inpatient site and this significantly increases ‘bed pressure'. The
aim of doing this study is to assess the efficiency of operative care
and timely discharge of the day case procedures being done at the
inpatient site.
SUBJECTS AND METHODS: We prospectively reviewed 100 day
case patients at the inpatient site. We obtained the following information
(1) Type of the procedure (2) Intra-operative/Post-operative complica-
tions (3) Reason for delayed discharge
RESULTS: 20% of the patients were not discharged on the same day.
9 % of patients had medical reasons for delayed discharge. The com-
mon reasons for extended stay included delayed medical review,
consultant choice and afternoon surgery. There were no intra-
operative complications. 6% of patients developed postoperative
complications such as pyrexia, high drain output and anaesthetic
complications.
CONCLUSION: Our study has highlighted the lack of local protocol
and areas for improvement to avoid unnecessary inpatient stay at
hospital. We aim to develop robust local protocols which stipulate;
a clear pathway and co-ordinated nurse-led discharge under clinical
leadership to make this service cost-effective in the current NHS
climate.
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P43- Gynaecological review in the ED. A trainees perspective
James Rowland1*, Andrew Watson1,2
1NW Deanery, Manchester, UK; 2Tameside General Hospital, Gtr.
Manchester, UK
Introduction:
To evaluate the views of O&G trainees regarding gynaecological assess-
ment in emergency departments in the Northwest England.
Methods:
An anonymous internet survey tool was used to gather data.
Results:
Of the 156 surveys, sixty two (62) responses were received. Fifty-six
(55.7%) of those responded. Most trainees are working in units with
greater than 4500 deliveries per annum. Fifteen percent (14.7%) and
eighty six (86.3%) of the examinations are done by ED doctors and
O&G doctors respectively. Ninety one percent (90.9%) have an
agreed protocol for referral to emergency pregnancy assessment unit
(EPAU). Fifty five (54.8%) stated that there is no direct access to
emergency gynaecology outpatients at their hospitals and only forty
eight percent (47.9%) have a referral protocol in A&E to the clinic.
Forty four percent (43.9%) confirmed a lack of rooms with adequate
patient privacy. Approximately a third (32.5%) reported that specu-
lum examinations are not performed due to lack of privacy in A&E.
Two thirds (66.7%) of the trainees state that they have encountered
delayed referrals by A&E staff. Nearly half (46.3%) of the trainees
state that patients aren't reviewed by medical staff in A&E before
being transferred to a O&G ward setting.
Conclusion:
The majority of gynaecological examinations in emergency departments
appear to be being performed by gynaecological staff. There appears to be
strong evidence of suboptimal conditions for reviewing gynaecological
patients. Clear protocols can improve patient satisfaction and reduce the
burden on already overstretched departments
P44- Harmonic instrumentation significantly reduces the mental
load compared with diathermy during simulated laparoscopic
salpingectomy: A Randomised Cross-over Trial
Rasiah Bharathan1*, Elias Kovoor1
1Maidstone and Tunbridge Wells Hospitals NHS Trust, Maidstone, UK
Introduction
Laparoscopic salpingectomy (LS) is an essential gynaecological proce-
dure, which may be performed for tubal ectopic pregnancy or ovarian
cancer risk reduction. Harmonic devices are purported to offer superior
ergonomics. This study examines the impact of instrumentation on sur-
geons’ mental load.
Method
Nine participants were stratified at recruitment to this cross-over
randomisd comparative study, using computer generated allocation. Par-
ticipants were first trained to proficiency in salpingectomy. All the per-
formances were completed on LAP Mentor virtual reality simulator
which captured the dexterity metrics and simultaneously recorded videos
of the procedures. Each participant performed a salpingectomy using
harmonic and diathermy (bipolar/monopolar) techniques during sep-
arate sessions. During the salpingectomy participants were required
to perform simultaneously, a validated visuo-cognitive secondary
task. After the procedures, participants completed two validated
questionnaires - NASA-TLX and subjective mental effort question-
naire (SMEQ).
Results
In all six dimensions of NASA-TLX, harmonics resulted in significant
improvement in workload measures [mental demand (P=0.02), physical
demand (P=0.008), temporal demand (P=0.004), performance (P=0.007),
effort (P=0.02) and frustration (P=0.003). SMEQ measure also reflected
significant reduction in mental load associated with harmonic instrument
(P=0.037).
The visuo-cognitive secondary task measures of mental load, re-
vealed a significant reduction associated with harmonics: the overall
detection rate (P=0.0004) and correct detection rates (P=0.0004)
were significant.
Pearson correlation coefficient between mental load (NASA-TLX) and
SMEQ was 0.74 for diathermy group and 0.76 for the harmonics group,
thus demonstrating a moderately strong concurrent validity of outcome
measures. This fortifies our findings.
Conclusion
Harmonic instrument significantly reduces mental load during simulated
laparoscopic salpingectomy.
P45- Homemade Simulation Training - Does It Work?
Emily Gelson1*, Helen Bolton1, Ashish Pradhan1
1Hinchingbrroke Hospital, Huntington, UK
Aims/Objectives: To determine if a low cost task-based simulation train-
ing course, using household and DIY items, can improve laparoscopic
surgical skills
Background: The surgical competencies required to perform lapa-
roscopic surgery are challenging and require a period of intensive
learning. The validity and benefits of simulation in gynaecological
surgical training are being increasingly recognized. Indeed, the re-
cent RCOG document ‘Becoming Tomorrow’s Specialist’ recom-
mends simulation training not only for trainees but also for contin-
uous professional development throughout a career as a
gynaecologist. Despite this, the availability of simulation training
is patchy and costly.
Methods: Using household and DIY items twenty tasks were de-
vised for individual use in a laparoscopic ‘box trainer’. Sixteen
gynaecology trainees spent six hours practicing these tasks. Each
trainee was timed at completing four tasks before and after prac-
tice. Eight laparoscopically naive medical students were also timed
at these four tasks.
Results: Compared to the medical students, the trainees did not perform
the four test tasks significantly faster at baseline. However, after practice,
the trainees showed a significant improvement in the median time taken
to complete three of the four test tasks. On direct questioning all the
trainees felt their laparoscopic skills had improved significantly as a result
of practice.
Discussion: Time needed to complete a set task is a marker of hand-eye
co-ordination and dexterity, an essential part of laparoscopic surgery. The
overall improvement in the trainee’s timings suggests practice improved
these modalities.
Conclusions: A low cost, task-based simulation-training course can im-
prove laparoscopic skills for gynaecology trainees.
P46- How do we best prepare our patients for their outpatient
services appointment?
Fani Gkrozou1*, Eve Gaughan1, Richard Pyper1, Bronwyn Middleton2,
Natasha Waters1
1Southlands Hospital, West Sussex, UK; 2St Richard’s Hospital, West
Sussex, UK
Introduction: This study aims to assess the value of our patient informa-
tion leaflet with regard to improving their out-patient hysteroscopy
experience.
Material and Methods:We analyzed data from a questionnaire given to
74 women after outpatient hysteroscopy.
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Results: 84% of women had received our information leaflet prior
to their appointment. Of these women who received the leaflet in
advance, 20% reported a pain score of 5 or less whereas only 8%
of women who did not receive the leaflet reported pain scores of 5
or less.
Also, only 12% of those who had received our leaflet reported pain scores
of 8 or more but 25% of the women who did not receive a leaflet reported
such scores.
Only 14% of women took oral analgesia before the procedure.
85% of women were satisfied with the information leaflet they received
before having hysteroscopy .
73% of women rated their experience as 10 (scale 0 - 10 ).100% were
satisfied with the staff.
Women with no analgesia gave higher pain scores compared to those who
took oral analgesic pre- procedure. There was no significant difference in
pain scores between women taking only oral analgesics compared with
those who had local analgesia.
Discussion: This study highlights the importance of a high quality patient
information leaflet as reflected by the lower pain scores reported by the
women who received information before the procedure compared to
those who did not.
P47- How does histopathology correlate with the indication
for hysterectomy?
Ilias Nikolopoulos1*, Pinky Khatri1
1James Cook University Hospital, Middlesbrough, UK
Hysterectomy is one of the most common gynaecological proce-
dures and provides a definitive cure for many benign diseases, but
is sometimes associated with significant morbidity. Alternatively
there are effective conservative treatment options available for
such conditions.
Objective:
To correlate the indication for hysterectomy with the histopathology.
Design:
In this retrospective study, 189 hysterectomies performed at a University
teaching hospital during a one year period were analyzed. The indications
for surgery and the histopathological findings were correlated.
Results:
The majority of the procedures were done laparoscopically (54.5%) and
vaginal hysterectomy was done in 35.5% of the cases.
The commonest indication for hysterectomy was genital prolapse in 58
cases (31%) followed by menstrual disorders in 56 cases (30%) and
chronic pelvic pain/endometriosis in 51 cases (27%).
Sixty one percent of specimens from cases of chronic pelvic
pain/endometriosis showed abnormal histology. Analyzingmenstrual dis-
orders further, when the indication for hysterectomy was DUB (without
endometrial ablation), abnormal histology was found in 30% cases only.
Whereas if it was done for post ablation pain or bleeding, abnormal
histology was found in 73% of the cases.
Discussion:
Histopathology from cases of chronic pelvic pain/endometriosis and post
ablative problems showed abnormal pathology in majority of the cases
vindicating the need for surgery. However, when the indication was DUB
(without offering ablation), only one third cases showed abnormal pathol-
ogy. Hence it is prudent for each unit to conduct regular audit of hyster-
ectomies correlating indication and diagnosis, in order to justify the need
for major operative intervention.
P48- Hysteroscopic sterilisation : An advancing alternative
to laparoscopic surgery?
D Tannous1*, SJ Bonner1, JE Davies1
1Blackpool Victoria Hospital, Blackpool, UK
Hysteroscopic sterilisation by tubal cannulation and placement of intra-
fallopian implants has been approved by NICE since 2009 and current
literature suggests it is an effective, safe and well tolerated alternative to
laparoscopic sterilisation.
The Essure insert system was introduced early, locally within the North
West and as there are no clear national auditable standards we performed
a retrospective case series of patients who have had hysteroscopic
sterilisation performed from 2011 to 2015 (n= 60).
Through excel, data has been analysed to confirm adherence to
NICE and FSRH guidance looking at consent, patient information,
safety and procedure performance. Particular interest locally is to
improve patient compliance with follow up in confirming bilateral
tubal occlusion and to look at complications to maintain high pro-
cedural success rates and patient satisfaction, comparable to nation-
al data. Local guidance will be produced from this data to provide
auditable standards.
At present we are yet to fully analyse the data however provisional results
show hysteroscopic sterilisation is a safe, cost effective and well tolerated
procedure with high rates of patient satisfaction. To date, both short and
longer term complications are low and suggest to be less prevalent than
with laparoscopic procedures.
P49- Indication and Outcome of Repeat Hysteroscopy
Under General Anaesthesia Following Outpatient Hysteroscopy
James McLaren1*, Abi Oladipo1, AshleyMehmi1
1Croydon University Hospital, London, UK
Aim: To determine the indication and outcome of patients referred for
hysteroscopy under general anaesthesia following outpatient hysterosco-
py at Croydon University Hospital.
Method: Retrospective audit of hysteroscopies performed under general
anaesthesia following outpatient hysteroscopy over a 3 month period at
Croydon University Hospital. Indication for referral, correlation of oper-
ative findings, and outcome were reviewed
Results: 89 hysteroscopies performed under general anaesthesia, 30
(22 for PMB, abnormal PVB >45yo, 1 HMB <45yo, 5 incidental
findings of thickened endometrium) of these were referred following
an outpatient hysteroscopy appointment. 14 were referred due to
unsuccessful hysteroscopy - 12 unable to enter (2 of these remained
unsuccessful under GA), 2 withdrew consent. 9 were referred due to
diagnosis of polyps during the outpatient procedure - 2 of these had
an attempt at polypectomy (1 unable to tolerate, 1 unsuccessful
21mm), 7 had no attempt at polypectomy (1 had no polyp on repeat
hysteroscopy, 3 had polyps <15mm, 3 had polyps 20-40mm). 6 were
referred due to insufficient sample (4 of these had normal hystero-
scopic findings). 1 was referred due to persistent PMB (atrophic
endometrium and insufficient sample during outpatient procedure).
14/16 successful diagnostic outpatient hysteroscopies correlated with
the intraoperative findings under GA. No malignancies were diag-
nosed in this small group of repeat hysteroscopies.
Conclusion: Insufficient histological sample with normal outpatient hys-
teroscopy should not be an indication for repeat hysteroscopy under GA.
Review of local skill and training in outpatient hysteroscopy and resection.
P50- Intergration of fast track and outpatient hysteroscopy services.
Questions and answers to help to create a successful outpatient
hysteroscopy service
Fani Gkrozou1*, Eve Gaughan1, Richard Pyper1, Bronwyn Middleton1,
Natasha Waters1
1WSHT, Worthing, UK
Introduction:The leading role of hysteroscopy in the investigation of
endometrial pathology is well known. With the development of new
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technology and the expanding role of outpatient hysteroscopy it is very
important to understand the benefits and safety of outpatient hysterosco-
py. We combined outpatient hysteroscopy service and Fast Track service
to investigate postmenopausal bleeding and created a pathway to stream-
line the patient's journey. Material and Methods: We performed a 6
month retrospective study of 165 post menopausal women, referred from
Fast Track to outpatient Hysteroscopy Clinic and seen within two weeks
of referral. The indications were post menopausal bleeding and increased
focal endometrial thickness (> 5 mm), suspicion of polyp on ultrasound,
inability to obtain sample in Fast Track clinic and non-diagnostic sample.
Rigid or flexi hysteroscopes were used. All women had endometrial
biopsy. Results:Most of patients were able to be seen and complete in-
vestigation and treatment in One Stop Outpatient Hysteroscopy clinic.
10% declined outpatient hysteroscopy or had referral cancelled due to
finding of endometrial carcinoma on Fast Track biopsy. Hysteroscopy
in postmenopausal group revealed 29% normal endometrium, 44.24%
endometrial polyps, 7.27% fibroids, 0.6% with endometrial cancer. No
perforations were seen. 15% of patients needed cervical dilatation.
Discussion:It is very important to take these results, showing a high rate
of abnormal findings, into consideration and to create a pathway that can
achieve better integration of these two services to investigate symptoms
in women with high risk of cancer.
P51- Is Endometriosis a risk factor for ectopic pregnancy?
Michael Magro1*, Alexandra Saetta2, Funnmilayo Odejinmi1
1Whipps Cross University Hospital, Barts Health NHS Trust, London,
UK; 2QueenMary University of London - Barts and the London School
of Medicine and Dentistry, London, UK
IntroductionThere are multiple risk factors for ectopic pregnancy. Tubal
pathology, caused by previous surgery, pelvic infections or endometri-
osis1,2 is known to be a strong risk factor. Endometriosis alone may
double the risk3, however some authors have disputed this4-7. We sought
to investigate if endometriosis truly is a risk factor for ectopic pregnancy.
MethodsRetrospective review of 698 patients with an ectopic pregnancy
who underwent laparoscopic surgery between 2004-2014 at a multiethnic
district general hospital in London. The presence or absence of endome-
triosis was identified and known risk factors compared between the 2
groups.
Results 36 (5.2%) had endometriosis and 662 (94.8%) had no evidence
of endometriosis. 34 (94%) had grade 1-2 disease, 2 (6%) stage 3 disease
and 0 stage 4 disease. Mean age was 31 in both groups. No significant
difference between tubal or extra-tubal ectopic location (p0.33) was iden-
tified. Significantly, 75% with endometriosis were nulliparous and 0%
had a previous ectopic pregnancy, whilst it was 46% and 11% respective-
ly in those without endometriosis (p0.0008 and p0.03). 11% with endo-
metriosis conceived using Artificial Reproduction Techniques (ART) and
4% without endometriosis (p0.04).
Discussion We believe that endometriosis per se is not a risk
factor for ectopic pregnancy, at any site, as the prevalence in those
with ectopic pregnancy over the last 10 years is equivalent to that
of the general population; 2-10%8,9. However, those with endome-
triosis had a statistically higher chance of being nulliparous and
needing ART, which does independently increase the odds of ec-
topic pregnancy.
P52- Is robotic sacrocolpopexy really necessary?
Heleni Mastoroudes1*, Alexander Slack1
1Maidstone and Tunbridge Wells NHS Trust, Kent, UK
Objective: The use of robotic surgery is increasing rapidly. Proponents
for robotic sacrocolpopexy(RS) advocate similar operating times, out-
comes and a faster learning curve compared to laparoscopic
sacrocolpopexy(LS). This is at the expense of high setup and procedural
costs.
The aim of our study was to compare our unit's LS operating times to the
published RS operating time data and the impact that this would have on a
busy unit if RS were to become the 'standard'.
Method: We used an electronic theatre management system to iden-
tify LS performed between July 2011-March 2015 by a single,sub-
specialist urogynaecologist in a busy DGH. Demographic data in-
cluded age,BMI,and parity. Perioperative data included,operating
time,estimated blood loss,complications and length of stay.Six week
follow-up looking at prolapse grade was used to calculate success
rate.
Results: Seventy-three patients were identified, 21 were excluded due to
concomitant procedures. Of the 53 patients that were included, the aver-
age age was 57.9 years, parity 2.3 and BMI 19-36. The mean operating
time was 89.5 minutes compared to 230.5 minutes for RS. The average
blood loss was less than 100 millilitres. There were no documented com-
plications and the length of stay was 1 night. Both subjective and objec-
tive outcomes were good.
Conclusions: Most reports claim an equivalence between standard lapa-
roscopic surgery and robotics in all but cost. In a unit with a high volume
of LS, operating times are significantly shorter by a factor of almost 3.
Combined with increased costs this wouldmakeRS entirely unfeasable in
standard practice.
P53- Laparoscopic ability is an invaluable skill in unexpected cases
Lewis Nancarrow1*, Tarun Ghosh1
1Nobles Hospital, Isle of Man, Isle of Man
A 39 year old was referred to Gynaecology clinic with recurrent
dyspareunia and vaginal discharge 1 year after abdominal hysterectomy
for menorrhagia.
Speculum examination showed granulation tissue in the vault and the
plan was for removal of granulation tissue under anaesthesia.
On attempting to remove the tissue, further tissue prolapsed and it was
thought to be fallopian tube in origin. This diagnosis was queried initially
and the patient had been consented for laparoscopy. Having not seen a case
like this before it was decided a laparoscopic approach would give us the
conclusive diagnosis and on investigation it was a fallopian tube prolapse
(FTP). Having the ability to perform laparoscopically allowed for quick de-
finitive diagnosis and the patient had a laparoscopic bilateral salpingectomy
and subsequent repair of vault defect vaginally under laparoscopic vision.
Systematic review by Ouldamer et al. found 51 cases of FTP following
hysterectomy. This review looked at multiple management options,
which ranged from silver nitrate application, resection of prolapsed tissue
and then laparoscopic management. This review determined that laparos-
copy was the most effective management with these cases with reduced
recurrence and better symptom relief.
Having laparoscopic abilities at your disposal is invaluable in unexpected
situations such as these and can greatly benefit patient management. The
presentation of vault granuloma following hysterectomy needs to be
reviewed as a potential FTP until proven otherwise. This is a rare com-
plication following hysterectomy that can lead to potentially serious com-
plications (peritonitis) and is a risk for clinicians to be aware of.
P54- Laparoscopic Bowel Injuries: The importance of early
recognition and treatment
Alexa Lilley1*, Jonathan Chamberlain1
1City Hospitals Sunderland, Sunderland, UK
Introduction
Complex gynaecological procedures are increasingly performed
laparoscopically exploiting the benefits of shorter hospital stay and rapid
recovery. Complications may be more subtle and not recognised
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immediately with delayed treatment contributing to seriousmorbidity and
mortality. The incidence of intestinal injuries is 0.06%-0.5% for diagnos-
tic laparoscopy rising to 0.3%-0.5% for operative laparoscopy1, relating
mainly to entry complications, electro-surgery and port-site herniation.
Case Series
Patient outcomes following eight cases of bowel injury relating to lapa-
roscopic adhesiolysis, excision of endometriosis, oophorectomy and hys-
terectomy are discussed. 37.5%of injuries were detected intra-operatively
and better outcomes followed with no need for bowel resection, blood
transfusion, additional surgery or readmission, with an average length-of-
stay in this group of 2 days (range 1-3). Bowel injuries not recognised
immediately had their diagnosis delayed by an average of 4.8 days (range
1-12) and 100% required stoma formation with an average of 1.8 addi-
tional surgeries (range 1-3) and 3.4 hospital readmissions (range 1-7).
These patients stayed an additional 34.5 days in hospital (range 11-90).
Intervention was delayed further if the patient was discharged before the
injury was diagnosed (6.3 days) compared to those diagnosed postoper-
atively during the primary admission (2.5 days). Early warning scores and
biochemical markers were not discriminatory, but symptoms of abdomi-
nal pain, anorexia and reluctance to mobilise were common features.
Summary
These cases highlight the significance of failing to promptly recognise
bowel injury or post-operative deterioration. Gynaecologists should be
vigilant through thorough patient selection, careful operative technique,
assessments of bowel integrity and post-operative management.
P55- Laparoscopic Entry Technique – review
Monika Oktaba1*, Andrew Baxter1
1Sheffield Teaching Hospital, Department of Obstetrics and
Gynaecology, Sheffield, UK
Techniques used in laparoscopic entry depend on experience and prefer-
ence of surgeon and complexity of operations undertaken.
At least 50% of laparoscopic complications occur prior to commence-
ment of intended procedures.
Studies suggest that 30-50% of bowel injuries and 13-50% of vascular
injuries are undiagnosed at the time of surgery.
To minimize entry-related injuries several techniques, instruments, and
approaches have been introduced.
Closed entry – Veress needle
Most popular between gynaecologist.
Pre-peritoneal insufflation: 2.7%, 15%, 44.4% and 100% of cases at one,
two, three, and more than three attempts respectively.
Umbilical infection: 1%.
Bowel injury: 0.04% - 0.2%
Vascular injury: 0.03% - 0.2%
Carbon dioxide embolism: 0.001%
Open entry – Hasson technique
Prevention of gas embolism and pre-peritoneal insufflation.
Longest laparoscopic entry, gas leak.
Umbilical infection: 0.4%.
Bowel injury rate: 0.05% - 0.5%,
Vascular injury: 0% - 0.005%
Direct trocar entry
Avoidance of failed pneumoperitoneum, pre-peritoneal insufflation, car-
bon dioxide embolism.
Fastest abdominal entry.
More than three attempts to enter the abdomen in 2.7%.
Failed technique: 0.4% - 1.4%
Bowel injury: 0.05% - 0.1%
Vascular injuries: 0%
Perforation of omentum: 4.8%
Optical trocars (Visula entry system)
Permits visually guided trocar entry without insufflation and easy recog-
nition of injuries at the time of entry.
Quicker than Veress and Hassan
Bowel injury: 0% - 2%
Mesenteric injury: 0.1%
Vascular injury: 0.04%
Complication rate related to laparoscopic entry remained the same during
the last 25 years. There is no clear evidence as to the optimal form of
laparoscopic entry in the low-risk patients.
P56- Laparoscopic entry techniques - 2014 Cochrane Review update
David Gent1*, Daniel Henderson1, Kevin Phillips2, Andrew Watson3,
Gaity Ahmad1
1Pennine Acute NHS Trust, Manchester, UK; 2Castle Hill Hospital,
Cottingham, UK; 3Tameside Hospital NHS Foundation Trust, Ashton-
Under-Lyne, UK
Background
Complications from laparoscopy are often related to the initial entry into
the abdomen and range from life-threatening (e.g. visceral injury) to mi-
nor (e.g. extraperitoneal insufflation). There is no clear consensus as to
the optimal method of entry. We present the second update to the 2008
Cochrane review on laparoscopic entry techniques.
Methods
The review used the search strategy developed by the Cochrane Menstru-
al Disorders and Subfertility Group. MEDLINE, EMBASE, CENTRAL
and PsycINFO were searched up-to August 2014.
Results
46 randomised controlled trials with 7,844 individuals that underwent 13
different laparoscopic entry techniques were included. No advantage was
identified of using any technique to prevent major vascular or visceral
complications. Significant reduction in the incidence of failed entry,
extraperitoneal insufflation, and omental injury for open-entry compared
to a Veress Needle technique; and in vascular injury in the direct-trocar
group compared to the Veress needle entry group were identified.
A reduction in trocar site bleedingwas associated with radially expanding
access system (STEP) trocar entry compared to standard trocar entry; and
an advantage of not lifting the abdominal wall before Veress Needle
insertion for failed entry.
Conclusions
There is a significant reduction in failed entry, but no difference in the inci-
dence of visceral or vascular injury for open versus closed-entry techniques.
Low rate of complications are associated with laparoscopic entry however
small participants numbers within these studies may account for lack of
significant difference in associated major complications between entry
techniques.
P57- Laparoscopic Hysterectomy for Endometrial Cancer - Surgical
Outcomes in a District General Hospital Cancer Unit
He l e n B o l t o n 1 * , H ema No s i b 1 , Ta r a n g Ma jmu d a r 1 ,
Hisham Abdel-Rahmen1
1Hinchingbrooke Hospital, Huntingdon, UK
Background: Endometrial cancer is the most common gynaecological
malignancy in the UK. Most women present with early stage disease
when surgery alone may be adequate to achieve cure. NICE Guidance
[IPG356] states that the current evidence on the safety and efficacy of
laparoscopic hysterectomy for endometrial cancer is adequate to support
its use. Laparoscopic hysterectomy is the offered route of choice offered
in our Gynaecology Cancer Unit.
Aim: To investigate peri-operative outcomes for women undergoing sur-
gery for endometrial cancer.
Methods: Retrospective case review audit comprising 2 years of patients
undergoing hysterectomy for endometrial cancer within our unit.
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Results: We identified 34 cases. Of these 31 (91%) had a laparoscopic
procedure. Two open procedures were carried out due to pre-existing co-
morbidities, and there was one conversion due to the presence of dense
adhesions. There were no intra-operative complications. 32 had an esti-
mated blood loss of less than 500ml (94%) and none required transfusion.
There were no major post-operative complications. Six women experi-
enced minor complications (18%) with just one requiring readmission.
Our average hospital stay for laparoscopic hysterectomy was 1.5 days.
Conclusions: This audit has confirmed that we safely offer a laparoscopic
approach to women requiring hysterectomy for early endometrial cancer
within our Unit. Our rates of complications are comparable to reported
rates in the literature despite our unit achieving one of the highest lapa-
roscopic surgery rates in our region.
P58- Laparoscopic Hysterectomy for endometrial cancer: Analysis
of eighty-seven cases from a cancer unit, Greater London
Rowena Sharma1*, Panos Sarhanis1
1Northwick Park Hospital, London, UK
Background.
Endometrial cancer is the most common gynaecology cancer in the UK
and often presents with postmenopausal bleeding. Stage 1 disease is
treated surgically by total hysterectomy with bilateral salpingo-
oophorectomy (BSO). Previously an open approach was mainstay, how-
ever use of total laparoscopic hysterectomy (TLH) with BSO is now
supported as a surgical modality for endometrial cancer.
Materials and Methods.
Women proposed for surgery following multidisciplinary review for
suspected gynaecology malignancy were included. All cases for TLH
and BSO were included between 21/11/2011 and 27/02/2015. Informa-
tion regarding patient age, surgery, length of stay, histology and compli-
cations was recorded onto an excel database. Information was analysed
and compared to current NICE guidance.
Results.
Eighty-seven cases were included, the median age of the patient was
58yrs. Five cases underwent TLH only and the remaining underwent
TLH and BSO. Results of histology demonstrated 39.4% were benign,
4.6% simple hyperplasia, 10.8% complex hyperplasia, 8.04% complex
hyperplasia with atypia, 34.5% endometrial carcinoma, 2.3% metastatic
endometrial carcinoma, 4.6%CIN, 1.15%GCIN, 1.15% borderline ovar-
ian tumour 1C and 2.3% Lynch syndrome. The complication rate was
10.3%. The conversion rate to TAH was 3.45% (n=3). One case resulted
in a laparotomy due to bowel perforation, there was one wound infection
and four bladder injuries (4.59%). The median length of stay was 2
nights.
Conclusions.
Analysis of the cases performed in our unit is comparable to those report-
ed in the literature supporting this method. As illustrated in this study it
offers a number of advantages compared with open approaches.
P59- Laparoscopic hysterectomy training for endometrial cancer
surgery: Validation of a virtual reality simulator
Rasiah Bharathan1*, James McLaren1, Thomas Ind1
1Department of Obstetrics and Gynaecology, St.Georges Hospital,
London, UK
Introduction
Laparoscopy is the preferred route for hysterectomy. Surgical errors are
more prevalent during the learning curve. High quality evidence supports
simulation based training over standard training. Prior to adopting a sim-
ulator, the device must be tested for face and content validity. We present
the first study of a hysterectomy simulator.
Methods
Twelve consultant and five subspecialty traineeswho are certified to perform
TLH for endometrial cancer, were recruited. The Simbionix virtual reality
simulator offers a hysterectomy module and suturing tasks. The participants
performed TLH +BSO and vault closure before completing the assessment.
Participants rated the ten features of face validity and the seven features of
content validity using a ten point Likert scale: a score of one equals mini-
mum and ten indicates maximum. Qualitative feedback was captured.
Results
The face validity assessment scores were high, with median scores rang-
ing 7-9: instruments' appearance (9), instrument manoeuvring (8), instru-
ment functionality (8), tissue appearance (8), response to manipulation
(7), depth perception (7), hand-eye coordination training (8), bimanual
coordination training (8), value as a training device (8) ergonomics (7).
The scores for content validation are uterinemanipulation (9), IP ligament
(8), bladder dissection (7), UA (8), colpotomy (7), identification of ureter
(7) and vault closure (4).
Discussion
The study demonstrates face and content validity of theVR-LH simulator.
The vault closure task on this VR simulator was not highly rated. We
believe this simulator will enhance the learning of LH. The next steps
would be assessments of construct validity and learning curves.
P60- Laparoscopic hysterectomy: Experience of a British district
general hospital
Osama Eskandar1*, Ibrahim Erfan1
1North Devon Hospital, Barnstaple - Devon, UK
Introduction Hysterectomy is the most frequently performed major
gynaecological operation. In the UK the rate of hysterectomy is 42/100,
000 population, with higher-rates in the United States (143/100,000) and
236/100,000 in Germany. It is interesting to note that while the trends
showed a decline from the 1990’s to early 2000, from 2002 till date the
rates show a plateau.
Method This is a retrospective study of hysterectomies performed in
North Devon District Hospital (NDDH) in UK over a period of one year
(2014). Types of hysterectomies were analysed in light of the NICE
guidelines standards November 2010 – interventional procedure guid-
ance 356 and the Hospital Episode Statistics (HES).
Results 165 hysterectomies were performed during the period of the
study. The rate of vaginal, abdominal and laparoscopic hysterectomy at
the NDDH was 58.7%, 7.8%, 28.5%, compared to 35%, 66% and 3% of
the national rate respectively.
The mean length of hospital stay after laparoscopic hysterectomy was 2
days compared to 4.6 days for abdominal hysterectomy. The mean oper-
ative time was 120 minutes compared to the national reported time in
NICE guidelines of 111 – 168 min.
The rate of conversion was 5.4% compared to the reported 7% in the
NIIC guidelines. The rate of intra-operative and post-operative complica-
tions was 2.8% and 5.6% compared to national rates of 10% and 17%
respectively with a re-admission rate of 1.8%.
Conclusion This retrospective study reflects the current practice regard-
ing one of the commonest gynaecological operations in one of the district
hospital in the UK.
P61- Laparoscopic Location of sentinel lymph node in cervical
carcinoma and factors affecting bilateral detection
Milica Perovic1*, Rekha Wuntakai1, Andreas Papadopoulos1, Stephen
Attard Montalto1, Samar Geris1, Luma Saad1, Omer Devaja1
1West Kent Cancer Centre, Maidstone and Tunbridge Wells NHS Trust,
Maidstone, Kent, UK
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Retrospectively analysed data for the laparoscopic detection of the senti-
nel lymph nodes (SLN's) in early cervical cancer patients: FIGO Stage
1a1 (with LVSI) - 1b1. We looked at the anatomical location of the SLN
and factors associated with unilateral detection, utilising intraoperative
gamma probe and blue dye. All patients were consecutively treated be-
tween January 2005 and January 2015 at the Wet Kent Gynaecological
Oncology Centre, Maidstone Hospital, Maidstone, UK.
The aim of the study was to document locality of SLNs in cervical carci-
noma and examine factors affecting unilateral detection during laparo-
scopic surgical procedures.
A total of 84 women were investigate with a combined intra-operative
approach. The 70% (N=59) of the patients presented in FIGO Ib1, 17%
(N= 14) in Ia2 and 13%( N=11) in Ia1 stadium. In total 24 patients
(28.6%) had lymph vascular space invasion (LVSI).
The most common SLN locationwas the external iliac region in 38.5% of
the patients, 23.8% was in the internal iliac, with a percentage being
identified in less common sites (obturator area, common iliac, para-
aortic and pre-sacral areas).
SLN were detected unilaterally in 15 patients (17.9%), bilaterally in 66
patients (78.6%) and no sentinel node was found in 3 patients (3.5%).
Of all factors analysed only older age and higher BMI were associated
with unilateral detection of the SLN.
P62- Laparoscopic management of a rudimentary horn pregnancy
using EnSeal
Eve Rawlinson1*, Swapna Ramasubramanian1, Zul Anjum1, Olubusola
Amu1
1Royal Oldham Hospital, Manchester, UK
Background
Rudimentary horn pregnancy is a rare form of ectopic pregnancy with an
incidence ranging from 1:76,000 to 1:140,0001. It carries a high risk of
rupture, in the late first or mid-second trimester, with potentially life
threatening intra-abdominal haemorrhage. Laparoscopic management is
reported in only 9 cases. This is the first case of laparoscopicmanagement
using EnSeal.
Case
A 31 year old, G3P1, presented at 11 weeks gestation with lower abdom-
inal pain. Ultrasound suggested an ectopic pregnancy within a non- com-
municating horn of the uterus. It was confirmed byMRI. The rudimentary
horn and products of conception were removed laparoscopically using
EnSeal. The patient recovered well and was discharged next day.
The rudimentary horn was dissected and ligated with EnSeal, it was cut
into slices with EnSeal, allowing removal through the laparoscopic port.
Discussion
We present successful management of an 11 week gestation rudimentary
horn pregnancy. EnSeal enabled bloodless dissection of the vascular ped-
icle and small sample size enabling easy laparoscopic retrieval. It further
widens the scope of EnSeal in laparoscopic surgery.
Reference
1. [1] Nahum GG (2002) Rudimentary uterine horn pregnancy: the 20th-
century worldwide experience of 588 cases. J Reprod Med 47:151-163
P63- Laparoscopic management of giant ovarian masses: case report
of a 44-litre cyst
Victoria White1*, Viviene Lee1, Summi Abdul1
1Royal Derby Hospital, Derby, UK
The RCOG/BSGE guidance and Cochrane review state that laparoscopic
management of ovarian cysts is preferable due to reduction in adverse intra-
operative events, pain and length of hospital stay. However, there is insuffi-
cient evidence to guide our management of large or ‘giant' ovarian cysts.
We aim to demonstrate that laparoscopicmanagement of giant ovarian cysts
is possible and may indeed be preferable in carefully pre-selected patients.
We report the case of a 44 year old lady whose CT scan revealed a
massive pelvic mass 43x40cm, most likely ovarian in origin. Insufflation
of the abdomen was not possible prior to deflation of the cyst and so 44
litres of serous fluid were drained through the umbilical port, after the
trocar was inserted directly into the cyst. Once the sac was deflated it was
removed through the lateral port after being bought to the surface in an
endobag. The cyst wall was then extracted with Kocher's forceps. Histol-
ogy confirmed a large benign paraovarian serous cyst.
Spillage of potentially malignant cyst contents should be avoided but
according to the RCOG/BSGE, in pre-menopausal women, the incidence
of ovarian cysts being malignant is only 1 in 1000. Therefore, after indi-
vidual risk stratification and frank discussion with the patient laparoscop-
ic cystectomy may be the most appropriate management. Management of
giant ovarian cysts laparoscopically remains a controversial issue, how-
ever we demonstrate that with careful patient selection, avoidance of the
pit-falls of open surgery is possible, even in the largest of cysts.
P64- Laparoscopic management of post myomectomy sequelae
Suku George1*, Anita Thomas2, Richard Hale1
1Stockport NHS Foundation Trust, Stockport, UK; 2St Helens &
Knowsley NHS Trust, Whiston, UK
A 37 year old Gravida 2 Para 0 lady was seen 10 months following a
difficult myomectomy which was converted to a laparotomy from planned
laproscopy. Presenting symptoms were ongoing discomfort and pain in the
suprapubic region with an ultrasound showing a calcified 4 cm fibroid.
An MRI scan excluded a myoma but raised the possibility of a resolving
collection in the myoma bed. With the histology of the fibroid while
benign had features of a mitotically active myoma, a recurrence with
degeneration was also suspected.
Follow up ultrasound scans failed to show resolution and a repeat lapa-
roscopy was undertaken.
At laparoscopy a firm mass of 3 cm in the right lateral aspect of the lower
uterus underneath the bladder reflectionwas notedwhich corresponded to
the area of tenderness and imaging. Once the bladder was reflected below
this are a 1.5 cm defect was apparent in the anterior myometrial wall with
a well defined cavity containing a dark brown fibrous degenerated mate-
rial. The cavity was evacuated and a thorough lavage carried out followed
by a two layered closure with intracorporeal sutures.
Histological examination confirmed the material to be consistent with
documented appearance for oxidized cellulose. On reviewing the original
operative notes it was apparent for haemostasis , multiple sheets of sur-
gical were used to pack the myoma bed and extra peritonised thus
delaying reabsorption.
Post operative ultrasound 8 weeks late showed normal uterine contour
with complete resolution of symptoms.
P65- Laparoscopic management of ruptured ectopic pregnancy
with major intra-abdominal haemorrhage (Over 1.5 L): Case series
and demonstration of operative technique
Mohamed Shahin1, Sobha Ramakoti1*
1Royal Stoke University Hospital, Stoke on Trent, UK
Ruptured ectopic pregnancy with significant intra-abdominal haemor-
rhage is an indication for emergency surgical management. The choice
between laparotomy and laparoscopy have been always subject to debate,
with more growing reports supporting the feasibility and safety of lapa-
roscopic treatment in such cases.
Traditionally, laparotomy was the preferred choice for those cases, espe-
cially with haemodynamically unstable patients, due to perception that
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laparotomy is quicker and easier to achieve haemostasis in such cases.
Factors affecting choice included: surgeon's, anaesthetist and theatre team
laparoscopic experience, availability of laparoscopic instruments, patient
observations and estimated intra-abdominal loss.
Our work represents case series of three cases of acutely ruptured ectopic
pregnancies, with massive intra-abdominal haemorrhage (Range= 1500 -
3500 ml). All the 3 cases were managed laparoscopically, with
haemostasis achieved within 5 minutes of the start of the procedure.
The technique demonstrated could not have been achieved with a knowl-
edgeable supportive theatre team, involving anaesthetists, nursing staff
and surgeons. The readily available laparoscopic instrumentation facili-
tated quick procedure and prompt haemostasis.
The technique included: Rapid perioperative resuscitation, +/- bedside
US scan. No uterine instrumentation, 10 mm Zero degree scope,
10 mm supra-pubic and 5 mm lateral ports. Quick and efficient suction
of blood using a powerful 10 mm suction system. Haemostasis quickly
achieved using Endoloop or Ligasure. Non-use of irrigation. Alternating
patient position between trendleberg and ante-trendleberg.
In conclusion: Laparoscopic surgery is safe and effective for managing
ruptured ectopic pregnancy with significant bleeding. The volume of
intra-abdominal bleed should not be a limiting factor in experienced hands.
P66- Laparoscopic Myomectomy - A ten year learning curve
Ravnee t S i rha1 , 2 * , Reeba Ol ive r2 , 1 , Ni lesh Agarwal1 , 2 ,
Funlayo Odejinmi2,1
1Northwick Park Hospital, London, UK; 2Whipps Cross University
Hospital, London, UK
Aim: Laparoscopic myomectomy (LM) is an organ preserving technique
not only lending itself to enhanced recovery pathways, it has been de-
scribed as the gold standard for certain fibroids and cases.
To review LM over a ten year learning curve, including peri-operative
outcomes and resolution of symptoms/patients satisfaction.
Methods: Retrospective cohort study of 217 consecutive single surgeon
LM performed at a London teaching hospital over a ten year period. A
comparison was made between those cases performed in the first half of
the data collection (first 5 years) with those performed in the second half.
Results: The demographics of the two cohorts of patients did not differ
significantly. On clinical examination the size of fibroids selected were sig-
nificantly larger in the second half of the study(13.26 vs 14.73, p=0.0089).
There was no significant difference in the duration of surgery, number of
fibroids removed and estimated blood loss over the ten years. There was an
increase in the number of drains left in situ(0.44 vs 0.70, p<0.0001) and a
significant decline in the number of complications ( 0.09 vs 0.02 p= 0.0156).
In patient stay was reduced over time (2.40 vs 1.67, p<0.0001) whilst the
resolution of patients symptoms improved (0.99 vs0.99, p=0.0014).
Conclusions: Our data shows that surgical performance of laparoscopic
myomectomy improves over time and this is evidenced by a decline in
complications and length of hospital stay. It also shows as surgical expe-
rience is gained the complexity of case selection increases, as does patient
experience of symptoms resolution.
P67- Laparoscopic myomectomy - an appropriate option
for peri-menopausal women?
Ravneet Sirha1 , 2* , Reeba Oliver2 , 1 , Ni lesh Agarwal1 , 2 ,
Funlayo Odejinmi2,1
1Northwick Park Hospital, London, UK; 2Whipps Cross University
Hospital, London, UK
Aims: The decision to undertake a surgical approach in the management
of uterine fibroids in peri-menopausal women can be controversial.
To compare peri-operative outcomes and symptom resolution of laparoscop-
ic myomectomy(LM) in peri-menopausal and non menopausal women.
Methods: Retrospective cohort study of 217 LM performed between
2005 and 2013 for the management of uterine fibroids.
Results: The estimated blood loss(233.3 vs 305.1, p=0.2382) and drop in
haemoglobin(1.13 vs 1.76, p=0.4512) was lower in the peri-menopausal
group compared to non menopausal women, although this did not reach
clinical significance. There was no difference in the use of surgical drains
or length of hospital stay in both groups. The resolution of symptoms was
comparable between patient cohorts, however the post operative patient
satisfaction was greater in the non menopausal compared with the peri-
menopausal women(0.91 vs 0.50, p=0.0128).
Conclusions: These findings suggest the surgical technique of LM is
similar in both cohorts of women and not complicated by age. There
was a slight reduction in estimated blood loss and drop in haemoglobin
in the peri-menopausal group which could reflect the reduction in vas-
cularity of fibroids at this age. Interestingly, whilst there was no differ-
ence in the resolution of symptoms between the groups, patient satis-
faction was significantly less in the peri-menopausal women leading us
to question whether surgical management is the most appropriate choice
of management for them. This warrants further investigation into sur-
gical recovery in peri-menopausal women and patient satisfaction with
alternative forms of fibroid management to optimise treatment in this
group of women.
P68- Laparoscopic port site Incision Hernia: A case report
and review of literature
Meera Adishesh1*, Tim Kundodyiwa1
1Whiston Hospital, St Helens and Knowsley NHS Trust, Prescot,
Merseyside, UK
Introduction:
Port site hernia following laparoscopic surgery is less common compared
to incisional hernia following open surgery. It is important to increase
awareness among laparoscopic surgeons of the possibility of intrafascial
incisional hernia as clinical findingsmay be subtle and early CT diagnosis
is necessary for timely surgical intervention.
Case Report:
We report a case of port site hernia in a 67 yr. old woman who underwent
laparoscopic bilateral salpingo-oophorectomy for a 16 cm right ovarian
cyst with low risk of malignancy. Our practice is to close the fascial layer
for any port sites more than or equal to 10 mm laparoscopically under
direct view. She was readmitted with nausea, vomiting on post operative
day 4. Conservative management was unsuccessful hence an urgent CT
scan was performed, which showed small bowel obstruction due to her-
niation at the left port site (extended for specimen retrieval). She
underwent laparoscopic release of port site hernia and the peritoneal de-
fect was closed with GraNee's needle under direct vision.
Discussion:
Trocar/ port diameter and access technique can affect the rate of hernia
formation. Port site hernias appear to be related to large diameter ports
used for specimen extraction, older age group , high BMI, increased
operative times and excess tissue manipulation leading to fascial weak-
ening. However, in spite of primary fascial closure of ports, hernia is still
reported.
We recommendmeticulous closure of fascia and peritoneum for port sites
above 7 mm, with GraNee's needle or laparoscopic suture passer closure
system under direct vision.
P69- Laparoscopic subtotal hysterectomy with power morcellation.
A single centre experience
Dimitr ios Miligkos1*, Ioannis Douridas1 , Adam Moors1 ,
Aderemi Kola-Adejumo1, Sameer Umranikar1
1SouthamptonUniversity Hospital NHS Foundation Trust, Princess Anne
Hospital, Southampton, UK
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Introduction:
Recent reports about the safety of powermorcellation during laparoscopic
subtotal hysterectomy (LSTH) have raised concerns because of the risk of
intra-abdominal spread of unsuspected uterine malignancy. The AAGL
and BSGE have released good practice guidelines for clinicians under-
taking these procedures.
The aim of our study was to evaluate our practice of risk assessment,
preoperative investigations and unexpected histology results in women
undergoing LSTH.
Methods:
This was a retrospective single centre study from a tertiary university
hospital. Consecutive patients that underwent planned LSTH from Janu-
ary 2010 until February 2015 were included. Medical records were
reviewed for patient characteristics and outcomes.
Results:
One hundred and seven patients were identified. The median age was 46
years (range, 31-59). Preoperative endometrial sampling was obtained in
75 patients (70%). Nineteen patients (18%) had their last cervical smear
more than 30 months before surgery. In the only postmenopausal patient
of our cohort, the uterus was removedwith an extension of the suprapubic
skin incision without morcellation. Final histology demonstrated Smooth
muscle Tumour of Unknown Malignant Potential (STUMP) in 2 cases
and simple endometrial hyperplasia in 1 patient. All 3 patients have had
no problems at follow up.
Conclusion:
Even though our cohort was small, there were however 2 unexpected
histology results; although none of these patients had any adverse out-
comes. Women undergoing LSTH with power morcellation should be
appropriately selected and have adequate counselling about the proce-
dure. Our preoperative work up can be improved and should adhere to
guidelines in order to maintain safety.
P70- Laparoscopic Supracervical Hysterectomy (LASH): Are we
looking for trouble?
Manhal Najdy1*, Sikhar Sircar1, Makarand Oak1, Khalid Elsabagh1,
Mohamed Allam1
1Wishaw general hospital, Wishaw, UK
Objective:
To assess the safety, reproducibility and cost efficacy of LASH.
Methods:
Data was collected retrospectively, 143 women had LASH between Au-
gust 2008 - November 2014 for benign indications with normal cervical
smears and endometrial samples.
Initially one consultant performed the procedure and trained others. 4
consultants are now independently performing LASH.
2 patients towards the end of the study had morecellation in bag to com-
ply with the recent FDA safety advice.
Results:
78% of LASH were performed for AUB, 88.3% had failed treatment.
17% were performed for chronic pelvic pain. The mean operating time
was 90 min and mean blood loss was 136 ml.
3.4% had wound infection after LASH however only one pelvic
haematoma, one ureteric oedema, one uterovaginal fistula, one hernia
from lateral port site and one had scar pain at morcellator porte. No
conversion to laparotomy, no blood transfusion, no DVT and no return
to theatre.
Average theatre time was 70 minutes for open subtotal hystrectomy and
90 min for LASH. The average running theatre per minute is £3.08,
giving £60 more for the LASH.
Instruments for LASH costs £1156 versus £200 for open. The average
hospital stay for LASHwas 1.7 nights versus 3.7 nights for open. Average
cost for one night stay in hospital is £486. Overall cost of LASH was
£2259.2 versus £2213.8 for open which obviously comparable with quick
recovery and better patient satisfaction for LASH.
Conclusion:
LASH is safe, reproducible, cost effective and quicker recovery and less
complication rates.
P71- Laparoscopic surgical approach in premenopausal ovarian
cysts
Sudipta Banerjee1*, Gourab Misra1
1University hospital of North Midlands, Staffordshire, UK
Introduction
As per RCOG guideline, 1 in 10 women have some surgery for ovarian
cyst in premenopausal age group.
If surgery is needed, laparoscopic approach is the preferred way
We are reporting an outcome of how benign ovarian cysts were surgically
managed in a tertiary care unit.
Methods
30 cases of premenopausal benign ovarian cysts were followed from first
clinic appointment till surgery.
Each case was reviewed from history, clinical examination to biochemical
and ultrasound markers to detect their suitability for surgical management.
Outcome of surgery and follow up with histology report completed the
procedure.
Results
• 27 out of 30 patients had laparoscopic surgery
• 16 of them had laparoscopic cystectomies and 11 had oophorectomy
• All the laparoscopic procedure had an in-patient stay of around 24 hrs
• 3 procedures that had laparotomy started as a laparoscopy
• One had bleeding from pedicle
Twowere too large to be removed through ports and both turned out to be
dermoid cysts
Conclusion
Laparoscopic approach is the preferred way for surgery of benign ovarian
cysts
Preoperative assessment including RMI can determine the success of
laparoscopic surgery
Bigger and solid complex cysts, suggestive of dermoid, has a less success
of being removed laparoscopically
All women should be informed about a small but important risk of
oophorectomy
These factors should be added in when counselling patients
preoperatively
Continued training in laparoscopic surgery amongst junior trainees will
improve the outcome in laparoscopic benign ovarian cyst surgery.
P72- Laparoscopic treatment of uterine fibroids: A comparison
of peri-operative outcomes of single verses multiple myomectomy
Ravnee t S i rha1 , 2 * , Reeba Ol ive r2 , 1 , Ni lesh Agarwal1 , 2 ,
Funlayo Odejinmi2,1
1Northwick Park Hospital, London, UK; 2Whipps Cross University
Hospital, London, UK
Aims: To compare peri-operative outcomes of laparoscopic myomecto-
my (LM) for the management of single vs. multiple uterine fibroids.
Methods: Retrospective cohort study of 217 LM performed between
2005 and 2013 at a London teaching hospital.
Results: Length of surgery was significantly greater with multiple myo-
mectomy compared to single myomectomy ( 128.6 vs 80.5, p<0.0001).
Multiple myomectomy was associated with increased weight of fibroids
(224.1 vs 184.6 p= 0.0261), a greater estimated blood loss (333.3 vs
222.8, p <0.0001) and an increased use of surgical drains (0.65 vs 0.41,
p = 0.0006). There was no statistical difference between the rate of sur-
gical complications, drop in haemoglobin, length of hospital stay, resolu-
tion of symptoms or patient satisfaction.
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Conclusion: Laparoscopic myomectomy for multiple fibroids can be
complex and technically difficult surgery. Despite an increase in length
of surgery, estimated blood loss and requirement of intraoperative drains,
the overall cost effectiveness of a laparoscopic procedure is maintained
with no significant increase in hospital stay, requirement of blood trans-
fusions or intraoperative complications. The patient satisfaction and res-
olution of symptoms is comparable in both groups, suggesting that by an
suitably trained surgeon - laparoscopic myomectomy is an appropriate
option of management for multiple uterine fibroids.
P73- Learning from Lanarkshire - Informed Consent in Outpatient
Hysteroscopy
Katharine Tylko1*
1Macmillan CancerVOICE; Cochrane Gynae Cancer Group Consumer
Reviewer; James Lind Womb Cancer Alliance member, London, UK
The Supreme Court in Montgomery v Lanarkshire Health Board
(March 2015) ruled that a pregnant diabetic patient should have been
informed of a serious risk of shoulder dystocia and been made aware of
her right to choose caesarean section, which would have spared her son
from cerebral palsy.
The Lanarkshire judgment updates the law regarding informed consent.
Doctors are now obliged to inform patients of serious risks and common
less serious complications. The judgment quotes the GMC's 'Good
Medical Practice': "Work in partnership with patients. Listen to,
and respond to their concerns and preferences."
The presentation will analyse the implications for informed consent re-
garding the risk of severe pain during specific stages of outpatient diag-
nostic and/or operative hysteroscopy: cervical dilation, LA injection,
electro-surgery, morcellation.
Using data from the Outpatient versus inpatient uterine polyp treat-
ment for abnormal uterine bleeding: randomised controlled non-
inferiority study, 2015, the presentation will argue that polypectomy
patients should be informed of a) the % risk of severe pain and failure
during an outpatient procedure and b) the % risk of uterine perforation
during inpatient investigation. It is up to each individual patient to assess
the risks and benefits and determine her preferred treatment modality.
This is consistent with the NHS Choices Hysteroscopy advice.
Numerous patients' responses to the Daily Mail's 2015 article 'NHS doc-
tors who inflict intimate and agonising surgery on women with NO
anaesthetic' will illustrate how the denial of sufficient pain relief could
post-Lanarkshire amount to negligence.
P74- Life threatening anaemia secondary to intracardiac metastatic
leiomyomatosis
Ilyas Arshad1*, Rahul Nath1, Conal Austin1
1Guy’s and St Thomas’ Hospital, London, UK
Introduction
49 year old Jehovah's witness with a PE on clexane, presented with
dyspnoea, per vaginal bleeding and a pelvic mass on examination. She
previously had two myomectomies for fibroids. Her haemoglobin was 3
and platelets 25.Our initial impression included that this could be a sar-
coma with metastases to the lungs?
Resuscitation was complex without the use of blood and required a mul-
tidisciplinary team involving Gynaecology, Haematology and Anaes-
thetics. Management included: IV immunoglobulins, Methylpredniso-
lone, Romiplostin, Ferrinject, EPO, ferrous sulphate, B12, folic acid
and Zoladex. Whilst also being on clexane for her PE.
We diagnosed this mass to be a leiomyomatosis that had metastasised to
the heart, it was extending from the IVC to the RA involving the Tricus-
pid valve.
Definitive surgery was carried out with the gynaecology team carrying
out a hysterectomy and the cardiothoracic surgeons removing the intra-
cardiac lesion and repairing the tricuspid valve.
Discussion
This case could be a common scenario that every gynaecology on call doctor
may encounter, it illustrates the medical management to treat both severe
anaemia and thrombocytopaenia in a Jehovahs’ witness, of which there are
Leiomyomatosis was first described in 1896 by Birch-Hirschfeld, only
182 cases have been described until 2013. Key factors for suspicion
include a lady in her fifth decade of life with a history of having fibroids,
even if she has had a hysterectomy or myomectomy as in our case.
P75- Local Anaesthetic for Laparoscopic surgery: Are we doing it
right?
Mohamed Shahin1, Sobha Ramakoti1*
1Royal Stoke University Hospital, Stoke on Trent, UK
Laparoscopic surgical procedures are established to have quicker recov-
ery, less need for analgesia and better patient experience.
As laparoscopic procedures are getting more popular, various techniques
and adjuvant methods have been adopted to enhance experience and
recovery of the patient from the procedure.
Injection of local anaesthetic is currently widely practiced technique to
supplement postoperative analgesia of patients following laparoscopic
surgery, however the technique, timing, dosage and choice of agents vary
significantly among different laparoscopy teams.
Also, there is rarely a written local guidance or agreement for the best way
of providing local anaesthetic. This is usually given to the local preference
agreed between the anesthetist and the surgeon.
The aim of the current study is to provide an evidence-based guidance for
the best practice of providing local anaesthetic for laparoscopic surgery. A
survey is undertaking place to enquire about views, preferences and tech-
niques for local anaesthetic administration. This included: technique,
timing, agent, procedure, counseling and appraisal of evidence. This
was very useful to gain insight to the variations of practice and willing-
ness for an evidence based guidance.
A comprehensive literature review was done for clinical studies, system-
atic reviews and basic science reviews, covering different agents and
techniques.
There is a need for an evidence-based guidance to be agreed nationally
and internationally for the use of local anaesthetic in laparoscopy. We
hope that our study will be a helpful starting frame for any further guide-
line.
P76- Long term self-reported bladder voiding function following
surgery for severe endometriosis
Alice Beardmore-Gray1*, Tom Holland1, Arvind Vashisht1,
Ertan Saridogan1, Alfred Cutner1
1University College London Hospitals, London, UK
Aims
Urinary voiding has been noted to be adversely affected in the immediate
postoperative period for women undergoing surgery for severe endome-
triosis. This study aimed to assess the effect of laparoscopic surgery for
severe endometriosis on long term self-reported bladder voiding function.
Methods
We retrospectively selected patients with deep endometriosis requiring
pararectal dissection who completed both a pre-operative and post-
operative (either 6 month, 1 year or 2 year follow-up) BSGE Pelvic Pain
Questionnaire. We used patient reported scores from this questionnaire to
evaluate urinary voiding following surgery and assess any significant
differences by type of surgery.
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Results
37/203(18%) patients in our study reported a worsening in score of uri-
nary voiding post-operatively. Of these, 24/37(64%) had a rectovaginal
nodule excised, 16/37(43%) underwent bilateral uterosacral ligament ex-
cision and 21/37(57%) underwent bilateral ureterolysis. The remaining
patients reported either an improvement 28/203(14%) or no overall
change 138/203(68%) in voiding function. There was no significant dif-
ference noted by type of surgery.
Conclusion
These findings suggest approximately 1/5 women report a worsening in
long term bladder voiding function following severe endometriosis sur-
gery. There does not appear to be a correlation between the type of sur-
gery performed and long term self-reported voiding difficulties. However
due to the inherent heterogeneity of surgery in these cases, greater num-
bers of patients may be required to corroborate this. We plan to assess
objective urinary voiding tests to further evaluate these important subjec-
tive findings.
P77- Measures of success: local experience of an outpatient
hysteroscopy service
Helen Nicks1*, Faizah Mukri1, George Richter1, Cinzia Voltolina1,
Shalini Srivastava1
1Surrey and Sussex NHS Trust, Surrey, UK
Nicks, H., Mukri, F., Richter, G., Voltolina, C., Srivastava, S.,
Surrey and Sussex NHS Trust, Canada Avenue, Redhill, RH1 5RH
Introduction
Outpatient hysteroscopy is an effective and safe procedure which pre-
vents the risks of general anaesthesia and minimises the impact of this
investigation on a woman’s life.
Primary aim
The success rates of outpatient hysteroscopy.
Secondary aims
The percentage of women where a vaginoscopic approach was used. The
percentage of women who had an operative procedure successfully. The
reason for any failures. The rates of complications.
Method
This was a retrospective six month audit from September 2014 until the
end of February 2015 of women attending the outpatient hysteroscopy
clinic at Crawley Hospital. The clinic notes and operative diaries used in
the outpatient hysteroscopy clinic were analysed. SPSS was used to input
and analyse the data.
Results
96% of women successfully underwent the procedure. 98% of women
underwent the procedure vaginoscopically. The commonest reason for
failing were cervical stenosis and pain. 2% of women went on to require
a hysteroscopic procedure under general anaesthetic. There were no uter-
ine perforations and the rate of complications was low.
Conclusion
The results of this audit are very promising that we are delivering a
successful service. However further work on the development of opera-
tive procedures such as ablation is needed to reduce the number ofwomen
needing day case surgery under general anaesthetic.
P78- Measuring outcome of Laparoscopic hysterectomy
in a university hospital
Sudipta Banerjee1*, Gourab Misra1
1University hospital of North Midlands, Staffordshire, UK
Introduction
NICE guidance 2007 suggests that safety and efficacy of laparoscopic
techniques for hysterectomy appears adequate to support their use,
provided that arrangements are in place for consent, audit and clinical
governance.
As a teaching university hospital we are moving towards laparoscopic
hysterectomy than conventional open surgery.
We are reporting the outcome of laparoscopic hysterectomy in our
department.
Methods
34 cases of laparoscopic hysterectomy were reviewed.
Cases were studied from consenting for the procedure to a follow up of 6
weeks postoperative period.
The main outcomes were
• Indication
• Preoperative counselling
• Level of surgeon
• Length of inpatient stay
• Rate of conversion and reason
• Complications (blood loss, visceral injury)
• Return to normal activity at 6 weeks follow up
Result
There were 23 total laparoscopic, 8 laparoscopic assisted vaginal, 1 sub-
total laparoscopic and 2 open hysterectomies (converted from TLH)
Main indications were endometriosis and endometrial hyperplasia, fi-
broids and pelvic pain
Three different consultant teams were reviewed
Two third of procedures were performed by consultants and one third by
senior trainees.
Our departmental conversion rate was 2/34, which is 5.9%
There has been no bowel, visceral or major vascular injuries
Rate of bladder and ureteric injury were high (around 3%)
Conclusion
• Proper preoperative counselling regarding urinary tract injuries, rate of
conversion, haemorrhage and visceral and vascular injuries are essential
• Early and delayed complications need diagnosis and management ag-
gressively to prevent adverse outcome
•Adequate training is key to the success rate and prevention of complications
P79- Missed opportunities for total laparoscopic hysterectomy
Jane Borley1,2*, Robert Richardson1
1Chelsea & Westminster NHS Foundation Trust, London, UK; 2Imperial
College, London, UK
Introduction
Total laparoscopic hysterectomy (TLH) is associated with less pain,
shorter hospital stay and quicker recovery. It is widely advocated to be
the preferred method over total abdominal hysterectomy (TAH) when
possible, but despite this there are still some women who are not offered
the laparoscopic approach.
Aim
To determine the number of women who underwent TAH where TLH
may have been possible.
Methods
A retrospective audit on women undergoing TAH from 1st January 2014
to 31st December 2014 for benign disease. Women with suspected/
confirmed malignancy or large ovarian masses were excluded.
Results
60 patients were identified who underwent TAH in 2014. Indications for
hysterectomy were menorrhagia or pressure symptoms caused by uterine
fibroids - 41 patients (68.3%), dysfunctional uterine bleeding - 15 (25%),
adenomyosis/pain - 2 (3.3%), recurrent CIN - 1 (1.7%), postmenopausal
bleeding - 1 (1.7%).
In 41 patients undergoing TAH for fibroids, 33 cases (80.5%) had a
uterine volume of ≥12/40, with a median of 17/40. Of those <12/40 size
(n=8), only 2 had known contraindications for TLH (extensive pelvic
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adhesions with planned colorectal surgical involvement and uterus too
large at laparoscopy).
19 patients had TAH without fibroids, all of these were <12/40
size. 14/19 cases (73.7%) did not have an obvious contraindication
for laparoscopy. Contraindications were extensive pelvic and bowel
adhesions in 3 cases and patient request for abdominal approach in
2 cases.
Conclusion
20 patients (33.3%) who underwent TAH for benign disease may have
been suitable for a laparoscopic approach, this approach should always
discussed and considered preoperatively.
P80-Modified Palmer's Point (MPP) : ANewAlternative Laparoscopic
Initial Entry Point
Raphael Laiyemo1*, Stewart Disu2
1Kings Mill Hospital, Nottinghamshire, UK; 2NorthWick Park Hospital,
London, UK
Introduction
Intra-umbilical entry is the traditional laparoscopic initial entry point to
establish pneumo-peritoneum used by most gynaecologists.
Laparoscopic surgeon should have an alternative entry point in patients
with previous abdominal surgery involving paramedian, midline or
paraumbilical incisions. The risk of bowel and omental adhesions to the
umbilical region is significantly higher in this group of patients.
Furthermore, after 2 or more failed intra-umbilical entry attempts, very high
or low BMI patients, an alternative entry point like Palmer's point or Lee-
Huang point should be considered. This minimises complications such as
pre-peritoneal insufflation and injury to intra-peritoneal structures.
Palmer's point, an entry point at the mid-clavicular line 3cm below the left
subcostal margin, was first described by Raoul Palmer. However,
Palmer's point as originally described falls within the anatomical zone
of the superior epigastric artery as shown by Saber et al in 2004.
Technique
Start by measuring 8cms laterally from the midline just above the level of
the umbilicus (Point A). A second line is drawn vertically from ‘Point A'
to 3cm short of the left subcostal margin (Point B). ‘Point B' is the
Modified Palmer's Point (MPP).Entry at this point avoids any potential
injury to the superior epigastric artery. MPP entry has an equal
puncture:pneumo-peritoneum (P:P) ratio as Palmer's Point.
If significant caudal displacement of umbilicus due to morbid obesity is
present, Pelosi re-alignment technique should be done before using MPP.
Conclusion
MPP is a new safe alternative entry point which avoids the superior
epigastric artery. It is reliable, accurate and easily reproducible.
P81- Morbidity at Laparoscopic Surgery
Deepa Balachandran Nair1*, Ganashelvi Premkumar1, Franz Majoko1,
Adnan Bunkheila1
1Singleton Hospital, Swansea, Wales, UK
Introduction
The reported incidence of complications of laparoscopic surgery varies
between 1-12.5/1000 and is dependent on complexity of the procedure
and experience of the operator. We conducted this audit to examine entry
techniques, indications & complication rates of laparoscopic surgery in
our department.
Methods
This was a retrospective audit conducted at Singleton Hospital, Swansea.
Ninety women who had laparoscopic surgery were selected from the
hospital database. Case notes were reviewed when additional information
was required. Standards for comparison were derived from the BSGE
guideline and a recent Cochrane review.
Results
Twenty one percent of women (19/90) had a previous surgery. Veress
entry was used in 90% of cases (81/90). In women with previous surgery,
the Veress entry was still preferred in 74% of cases (14/19). Pelvic pain
was the most common indication. 79% (71/90) were elective procedures.
There were 3 cases of haemorrhage from the secondary port site. There
were no major complications.
Discussion
It was recognised that the hospital database lacked a means of capturing
intra-operative complications. Recommendations were made to capture
this information electronically. A new theatre database system was intro-
duced, that records risk factors and complications allowing prospective
monitoring of laparoscopic surgical morbidity.
There was a distinct tendency to use the Veress entry. Recommendations
were made to make use of other methods of entry. Training to enable
surgeons to gain experience in different forms of entry was started.
P82- Mutidisciplinary Meeting for Endometriosis- An approach
to optimise Patient outcomes
Suku George1*, Joanne Dzyra1, Sajal Rai1, Andrew Pickersgill1, Maryna
LLewinsky1
1Stockport Endometriosis Center, Stockport, UK
Methods
Stockport Endometriosis Centre was accredited by the BSGE in 2013. From
its inception a multidisciplinary meeting was set up to have a formal con-
sensus over management and to make individualised patient plans. This was
modelled on the Gynaecological OncologyMDTmeeting and takes place in
a video conferencing roomwith ability to link various hospitals in the region.
Monthly meetings are held with Radiologist, Gynaecological surgeons,
Colorectal surgeon and Endometriosis nurse with outcome and discussion
documented on a dedicated proforma and communicated to GP and pa-
tient. Level of Colorectal/ Urology involvement, Postoperative follow up
and imaging are agreed at MDT.
Clearly defined referral criteria such as
Clinical or radiological suspicion of Rectovaginal disease
MRI showing visceral involvement
Lateral disease with distal ureteric involvement
Post hysterectomy disease
Recurrent disease after complex surgery
Post operative discussion to close MDT loop
MDT makes consensus recommendations for treatment modality, further
investigations and level of multidisciplinary involvement. Colorectal sup-
port is decided as either assistance or joint procedure.
When joint procedure is planned with high probability of bowel resection,
preoperative meeting with stoma nurses is arranged and patients are ad-
mitted day before surgery in the surgical ward with bowel prep and
enhanced recovery pathway.
Results
135 cases discussed over past two years and 54 were categorized as
severe endometriosis. With 5 patients currently awaiting surgery 46 pa-
tients (94%) were correctly identified with pre operative MRI imaging . 2
cases (4%) were under called on MRI and one patient (2%) had disease
volume over diagnosed.
P83- New outpatient hysteroscopy services set up: lessons learned
Eve Gaughan1*, Fani Gkrozou1, Bronwyn Middleton2, Richard Pyper1,
Natasha Waters1
1Southlands Hospital, West Susssex, UK; 2St Richard’s Hospital, West
Sussex, UK
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Introduction: Our out-patient hysteroscopy clinic is a new service for
our trust andwe reflect on lessons learnt after the first year of its existence.
Material and Methods: All staff were interviewed regarding lessons
learnt over the course of the year with a view to providing a safe and
efficient service associated with the highest possible patient satisfaction
scores. We performed a 6 month audit of our service and analysed data
from a questionnaire given to 74 women after outpatient hysteroscopy.
Results: Clinic protocols for patient assessment, procedure performance
and management of potential complications are necessary to ensure an
efficient and safe service.
The collection of patient feedback is invaluable in helping to inform and
improve the service
Patient leaflets given before attending were beneficial in terms of improv-
ing pain and patient satisfaction scores. Reminding patients in their ap-
pointment letter of the importance of to reading the leaflet and taking
analgesia was found to be helpful.
Patients waiting over 30 minutes pre-procedure increased anxiety levels
and increased pain scores. Appropriate timing and duration of appoint-
ments improved patient satisfaction rates-
Uniform pregnancy testing in all premenopausal women and deferring
procedures in the luteal phase in those without appropriate contraception
should be the policy
Strategy for difficult entry cases with extra equipment readily available
Vaginoscopic technique is default approach.
Importance of the same team of nurses familiar with equipment and
procedures who can trouble shoot and ensure efficient set up to which
help to reduce patient anxiety
P84- Obesity and subfertility: identifying the challenges faced
by the subfertility specialist and reproductive surgeon
Sophie Elizabeth Mayhew1*, Shamma Al-Inizi1
1South Tyneside District Hospital, South Tyneside, UK
Background: Obesity is a well documented risk factor for subfertility;
impacting ovulation, eqq quality, implantation and miscarriage rate. Ad-
ditionally, treatment of this subgroup of patients may pose further chal-
lenges in the form of technically difficult procedures, treatment resistance
and poor patient engagement.
Methods: we retrospectively evaluated the management of 100 women
with a body mass index (BMI) >30kg/m2 attending subfertility clinic,
analysing procedure failure and laparoscopic complication rate, ovulation
induction and drilling rate, successful weight-loss and pregnancies
achieved.
Results: BMI ranged from 30-60kg/m2. Weight loss was achieved in 35
(35%) of patients. 39 (39%) became pregnant and 17 (43%) of those had
lost weight. 10 (10%) fell pregnant following advice alone. 67 (67%) of
women were anovulatory and 17 (25.4%) of those were resistant to Clomi-
phene Citrate. 12 (16.4%) required ovarian drilling. 8 (11.9%) of anovula-
tory women were too overweight to safely commence Clomiphene Citrate.
For 6 (6%) women, the cervix could not be visualised and/or cannulised at
hysterosalpingogram leading to laparoscopy. 3 (10%) of laparoscopies con-
verted to open laparoscopy using Hassan's method due to difficult entry. 35
(35%) of women were lost to follow up without achieving pregnancy.
Conclusions: Obesity can present many challenges to subfertility treat-
ment including treatment resistance and procedure failure. However, ap-
propriate counselling and support alone may often lead to successful
weight loss and pregnancy.
P85- Observational Study of Outpatient Hysteroscopy Outcomes
Amongst Postmenopausal Women in a UK District General Hospital
David Ankers1*, Lynda Coughlin1, Ajay Swaminathan1
1Mid Cheshire Hospitals NHS Foundation Trust, Crewe, UK
Ankers D, Coughlin L, Swaminathan A
Mid Cheshire Hospitals NHS Foundation Trust
Introduction
Outpatient hysteroscopy is a well established technique for the investiga-
tion of postmenopausal bleeding. The appropriate use of miniature sized
hysteroscopes can allow good visualisation of the endometrial cavity,
facilitate image guided biopsy, polypectomy and also avoid the risks of
general anaesthesia (1,2).
Methods
Retrospective case note review over an 18 month period. Cases identified
via hospital information services department.
Results
89/90 patients who had undergone hysteroscopy had postmenopaus-
al bleeding. 81/90 patients had an endometrial thickness above 3mm
not on hormone replacement therapy. There was a 97.5% success
rate of outpatient hysteroscopy during the sample period. The rate of
malignancy identified on histology was 14/90 (15.5%), with 5/14
(35%) highlighting endometrial adenocarcinoma. There was also
one case of carcinosarcoma and papillary serous carcinoma during
this timeframe.
Conclusions
Our results indicate that most patients had an appropriate endometrial
thickness for hysteroscopic assessment. We also found that our rate of
malignancies identified from endometrial sampling is comparable with
other research. Further investigation is required to study prevalence of
rarer malignancies such as carcinosarcoma.
References
& 1. Royal College of Obstetricians and Gynaecologists.Green Top
Guideline No.59: Best Practice in Outpatient Hysteroscopy.
London:RCOG; 2011
& 2. Marsh F,Kremer C,Duffy S.Delivering an effective outpatient ser-
vice in gynaecology.A randomised controlled trial analysing the cost
of outpatient versus daycase hysteroscopy.BJOG 2004;111:243-8.
P86- 'One Stop' Hysteroscopy Clinic: A Patient Survey
Caroline Smith1*
1NHS Greater Glasgow and Clyde, West of Scotland, UK
Objectives:
Identify the percentage of women receiving written information prior to
appointment.
Evaluate patient experience and pain scores for scan, hysteroscopy and
endometrial biopsy.
Data collection:
Survey given to patients following their visit to the one-stop clinic at
Clinic F, Stobhill ACH from June to September 2014. 77 surveys were
returned.
Results:
The majority of patients received an information leaflet in advance, found
it easy to understand, and felt it made their visit easier.
Patients who underwent hysteroscopy had a mean pain score of 3.1,
whereas those who had a biopsy scored 4.3.
Almost all those surveyed (97%) would recommend the service to a
friend.
Discussion:
The clinical and economic benefits of a ‘One Stop' clinic for the
management of abnormal uterine bleeding are well recognised and
in general the procedures involved are well tolerated1. However it is
important that all efforts are made to reduce patient anxiety as this
can decrease the likelihood of successfully completing all relevant
procedures2. Patient information leaflets should therefore be provid-
ed to help prepare patients.
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The most striking finding of this survey was the overwhelmingly positive
impact of the clinic staff on the patient experience.
In conclusion, the vast majority of patients attending the One Stop Clinic
at Stobhill have a positive experience and tolerate all necessary proce-
dures well. The support of the dedicated staff is invaluable and signifi-
cantly contributes to the overall perception of the service.
1. RCOG Green Top Guideline No.59
2. Surg Endosc. 2004 Jul;18(7):1099-104. Epub 2004 May 12
P87- One-stop out-patient hysteroscopy service reduces time
to definitive investigation in women referred with Post-menopausal
bleeding
Christopher Brewer1*, Carole Wilson1, Claire Oxby1
1York Teaching Hospital NHS Foundation Trust, York, Yorkshire, UK
Introduction.
Post-menopausal bleeding (PMB) may signify the presence of endometrial
cancer, 10%with PMB under 60 years will have endometrial cancer; rising
to 13% over 60 years. The Cancer Reform Strategy (2007) recommends
that patients with a suspected cancer should be referred urgently to second-
ary care and 1st hospital assessment should take place within two weeks.
We sought to determinewhether the introduction of a one-stop out-patient
hysteroscopy clinic for women with PMB and increased endometrial
thickness (ET>4mm) reduced referral to attendance interval.
Methods.
A retrospective audit comparing of a two month period in 2011 following
the historical “PMB clinic”model (November 2011-December 2011) and
a two month period in 2012 following the “Out-patient hysteroscopy
clinic” model (August 2012-September 2012).
Data regarding referral times, scan and clinic visits, and outcomes were
drawn from the hospital clinical database.
Results.
In the study period, 89 women attended the “PMB clinic” and 111 in the
“Out-patient hysteroscopy clinic” model.
The “PMB Clinic”model had an average referral to assessment interval of
11 days (95% CI 9.75-12.25d). However, patients with increased ET then
went on to receive urgent hysteroscopy, as such mean time from referral to
definitive investigation was 48.2 days. The “OP hysteroscopy clinic”mod-
el had an average referral to assessment interval of 15.4 days (95% CI 11-
19.78d), 13.41 days (95% CI 11.58-15.24d) with the exclusion of a 127d
outlier.
Conclusion.
The one-stop out-patient hysteroscopy model was associated with a re-
duced interval from referral to definitive investigation in women PMB.
P88- Opportunistic Bilateral Salpingectomy (OBS) for prevention
of ovarian cancer: support for a clinical trial or routine care amongst
UK clinicians
Ranjit Manchanda1,2, Dhivya Chandrasekaran3*, Ertan Saridogan4,
Robin Crawford5, Eleanor Brockbank1, Jatinder Kalsi2, Davor Jurkovic4,
Usha Menon2
1Department of Gynaecological Oncology, St Bartholomew’s Hospital,
London, UK; 2Department of Women’s Cancer, EGA Institute for
Women’s Health, University College London, London, UK; 3Department
of Obstetrics and Gynaecology, Northampton General Hospital, North-
ampton, UK; 4Department of Gynaecology, University College London
Hospital, London, UK; 5Department of Gynaecological Oncology,
Addenbrookes Hospital, Cambridge, UK
Background
Opportunistic Bilateral Salpingectomy (OBS) is being advocated as an
ovarian cancer (OC) prevention strategy at the time of benign
gynaecological surgery/tubal ligation for premenopausal women who
have completed their family. We report on the prevalence of OBS in
current practice and its acceptance amongst UK clinicians.
Methods
An anonymised web-based survey was sent via the RCOGmonthly e-news-
letter. Baseline characteristics were described using descriptive statistics.
Chi-square test was used to compare categorical, Kendal-tau-b test for ordi-
nal and Mann-Whitney test for continuous variables between two groups.
Results
Of the 395/4000(9.9%) respondents, 81% were general obstetricians &
gynaecologists and 17% subspecialists. 61% agreed with the tubal hy-
pothesis, 33% performed OBS ‘always/most of the time’ and 50% sup-
ported its introduction. However, 53% thought OBS should ‘only’ be
offered within a clinical trial with 89% willing to support such a study.
Lack of data on OC risk reduction(78%), RCT evidence of benefit(76%),
and impact on ovarian function(65%) were the leading factors limiting its
introduction into routine clinical practice. Maximum support for OBS
was at the time of hysterectomy (92%) and tubal ligation (65%). Training
implications for self/trainees were highlighted by 21%/49% respectively.
Conclusion
There is broad support in the UK for the principle of OBSwith equivalent
support for introduction ‘only’ within a trial/ within clinical practice. The
need for prospective evidence to validate its efficacy was highlightedwith
89% willing to support a clinical trial. A randomised trial powered on
menopause outcomes may be a way forward.
P89- Outpatient hysteroscopy versus ultrasound in abnormal uterine
bleeding - should we scope everyone?
Emma Abery1*, Lois Delchar1
1Barking Havering and Redbridge NHS Trust, London, UK
Background : Hysteroscopy is considered the gold standard in diagnosing
intrauterine pathology in women presenting with abnormal uterine bleed-
ing (AUB) and post menopausal bleeding (PMB) suggestive of endome-
trial pathology. Routine practice in our unit is to carry out ultrasound (US)
in all women with AUB, only proceeding to hysteroscopy for recurrent
episodes, if US suggests pathology or there is high clinical suspicion.
Method : We carried out a prospective audit to compare US, outpatient
hysteroscopy findings and final histopathology results in women referred
with abnormal uterine bleeding.
Results : 98 patients, aged 36-91 were seen for outpatient hysteroscopy.
75 had PMB, 5 were perimenopausal, 3 had incidental endometrial thick-
ening and 15 had other AUB. 5 had serious pathology detected (3 endo-
metrial hyperplasia; 2 endometrial cancer).
Hysteroscopy revealed intrauterine pathology in 62% of cases, with 1
false negative where the cavity appeared atrophic in the presence of
simple hyperplasia on biopsy. USwas normal in only 5 women, of whom
2 had benign pathology found at hysteroscopy. The sensitivity of US to
detect pathology was 96% but it had only 11% specificity. We found the
ultrasound reports had heterogenous descriptions, making it difficult to
identify whether serious pathology may or may not be present.
Conclusion : If US is to be considered a useful tool for investigating
AUB, stricter guidance should be used for reporting findings, otherwise
with a specificity of only 11% it has been proposed that we save the cost
of an ultrasound and offer a hysteroscopy to everyone.
P90- Patient feedback on outpatient hysteroscopy in a busy district
general hospital – The importance of improving patient care
in ambulatory gynaecology
Fiona Cowan1*, Vidya Shirol1, Annabelle Burnham1
1Frimley Health NHS Trust, Surrey, UK
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The RCOG guideline ‘Best Practise in Outpatient Hysteroscopy’ states
that ‘all gynaecology units should provide a dedicated outpatient hyster-
oscopy service to aid management of women with abnormal uterine
bleeding’. Recommendations include the use of appropriate facilities out-
side a formal operating theatre setting, written patient information and
consent taking prior to the procedure and ways to decrease pain scores
including the use of miniature hysteroscopes, vaginoscopy and encour-
aging NSAIDs one hour prior to the procedure.
Objectives: To assess patient satisfaction and whether further improve-
ments were required to the service provided in our unit.
Methods: 100 patient satisfaction questionnaires were completed between
June 2014 and November 2014.
Results: 100% of patients believed the clinic was easily accessible, staff
professional and privacy and dignity maintained. All patients surveyed
believed they were given suitable information prior to the procedure with
adequate aftercare. 87% received information leaflets prior to the proce-
dure. 84% of patients were waiting for their procedure for less than 30
minutes with 93% finding self -check in kiosks beneficial. 76% had only
mild to moderate discomfort. 93% would have outpatient hysteroscopy
again, 89% recommending the procedure.
Conclusion: with excellent patient satisfaction, outpatient hysteroscopy
should be encouraged in suitable candidates. Further improvements to
clinic set up and facilities should be ensured and audited across all units.
Information evenings could be arranged for General Practitioners and
better dissemination of patient information leaflets prior to outpatient
procedures should be encouraged to further improve care and satisfaction.
F91- Patients’ perspective of the outpatient hysteroscopy service:
a patient satisfaction survey
Faizah Mukri1*, Helen Nicks1, George Richter1, Shalini Srivastava1,
Cinzia Voltolina1
1Surrey and Sussex NHS Trust, Surrey, UK
Introduction
With a move towards outpatient hysteroscopy as a first line for women it
is important to ensure the best experience during this procedure.
Primary aim
The percentage of women who were satisfied with the service and would
recommend it to a friend.
Secondary aims
The percentage of women who received information pre procedure. The
percentage of women who were satisfied with the reception, staff, and
after care. The experience of women during their visit to clinic.
Method
This was a prospective patient survey, given to all patients attending the
clinic between December 2013 and February 2014. Qualitative and quan-
titative data was analysed.
Results
The response rate was 53%. 100% were satisfied with the experience and
would recommend to a friend. 100% felt they were treated with dignity
and respect. However, only 78% were given pre-procedure information.
8% were not satisfied with the reception area and staff.
Conclusion
The results of this audit are very promising that we are delivering a
successful service which is well received by our patients. However it
has highlighted areas for continued improvement including pre-
procedure information and the welcoming area.
P92- Post Menopausal Endometriosis, A Rare Case Report
Chandrakala Sathish1*, Matteo De Martino1, Stanley Okolo1
1North Middlesex University Hospital, London, UK
Introduction: Endometriosis is one of the most common gynaecological
disorders that affects women in reproductive age and postmenopausal
age. It is defined as the abnormal implantation of the glandular epithelium
or the endometrial stroma at extrauterine sites. Endometriosis can be
misdiagnosed and thus pose a diagnostic predicament. Diagnosis is gen-
erally made after Laparoscopy and histological examination.
Case presentation: We present a case of postmenopausal endometriosis
in a 41-year-old woman with history of recurrent endometriosis despite
undergoing hysterectomy and bilateral salpingoophrectomy (BSO). Post-
menopausal endometriosis is uncommon, since after the cessation of
menstruation, production of ovarian oestrogen ceases. Although a num-
ber of such cases have sporadically been reported the present state of the
data is insufficient to permit any appraisal of this and the mechanisms
fundamental to the entity have not been thoroughly explained.
Here we discuss about pathophysiology associated with recurrent
endometriosis in postmenopausal status, especially the activity of
Aromatase P450 enzyme, which is present in the endometriotic tis-
sue itself producing estrogen and hence a positive feedback causing
endometriosis in postmenopausal women without any need for ex-
ternal estrogen.
Laparoscopic excision has been recommended for such cases because it
reduces the risk of possible malignant transformation in such cases. Ad-
ministration of aromatase inhibitors has also shown success in suppress-
ing local and exogenous oestrogen, but there is still a need of further
research to validate its clinical uses.
Conclusion: Although the reported situation is uncommon, it is vital to
be aware of post-menopausal endometriosis because it confers a threat of
malignant transformation (0.7-1%).
P93-Prognostic factors that predict success in office endometrial
ablation: a cohort study
Paul Smith1*, Shilpaja Karpate1, Justin Clark1
1Birmingham Women’s Hospital, Birmingham, UK
The objective of the cohort study was to identify clinical factors that influ-
ence the rate of further surgical intervention in women who had endome-
trial ablation. Prospectively held electronic databases and patient records
were scrutinised to obtain historical, examination, investigative and proce-
dural data considered to be potentially predictive of the need for further
surgical intervention after endometrial ablation in the office setting. A total
of 391 consecutive women were identified who received endometrial ab-
lation in the office setting between July 2005 and December 2012, with an
average follow-up of 4.3 years. Univariable and multivariable logistic re-
gression were used to estimate the influence of these variables on progno-
sis. Factors predictive of further surgical treatment were dysmenorrhea
(aOR 4.01; 95% CI 1.63 to 9.91) and a uterine cavity length >9cm OR
(aOR 2.65; 95% CI 1.33 to 5.27). In conclusion, dysmenorrhoea before
treatment or a uterine cavity length >9cm are associated with the need for
further surgical interventions after office endometrial ablation. These find-
ings should help inform clinician and patient decision making when con-
sidering treatment options for heavy menstrual bleeding.
P94- Rate of laparoscopic skill acquisition in novice students
Dominic Harrison1, Jessica Stephen1*, Jamie Burrell2, Emma Chang2,
Edward Christopher2, Ellie Couser2, Shivali Dawda2, Sasha Gold2,
Iain Hettle2, Rory Thompson2, Kathryn Young2, Tony Yu2, PaulMills1
1St John’s Hospital, Livingston, UK; 2University of Edinburgh, Edin-
burgh, UK
This study aims to investigate the rate of laparoscopic skill acquisition on
a simulator to gain insight into the inherency of these skills and potential
for their improvement.
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Ten first year medical students with laparoscopic experience were timed
at five-minute intervals over an hour as they completed a task on a simple
laparoscopic simulator. Their initial times were compared with those of
obstetrics and gynaecology registrars (ST3+) with no experience of the
task, but laparoscopic experience.
The mean recorded initial time of trained registrars (n=9) (191 sec-
onds (range 90-332s)) was significantly shorter than novice students
(n=10) (452 seconds, (range 208-787s). The mean time taken for
novices to complete the simulated task decreased with time; mean
completion time had decreased by 42.18% after 5 minutes of practice,
62.0% after 10 minutes, 74.2% after 25 minutes, and 80.6% after 65
minutes.
The results suggest an overlap between the skills developed through
laparoscopic surgery and those required to complete the simulated task
as registrars and students were differentiated by skill level. Themean time
that novices took to complete the simulated task decreased over time, as a
result of increased familiarity with the task’s skill requirements such as
depth perception and dexterity, and tended towards a plateau. Further
work will be needed to see if increased access to these inexpensive sim-
ulators for registrars may improve their rate of skill acquisition and if this
is transferable to their performance in theatre.
P95- Relation between bodymass index and patient outcomes in total
laparoscopic hysterectomy: a retrospective observational study
in benign and cancer cases
Vasileios Minas1*, Claudia Ventii1, Nicola Murray2, Thomas Aust1,
Nahid Gul1, David Rowlands1
1Department of Obstetrics & Gynaecology, Wirral University Teaching
Hospital, Upton, Wirral, UK; 2School of Medicine, University of
Liverpool, Liverpool, UK
Increasing numbers of gynaecologists are offering the benefits of lapa-
roscopy to obese patients. Obesity is a risk factor for peri-operative mor-
bidity across surgical specialties. Limited research has been conducted on
the effect of obesity on outcomes of major laparoscopic pelvic surgery.
Some authors report worsening outcomes in obese women having lapa-
roscopic hysterectomies. Others suggest that complication rates do not
increase, but operating times are longer.
Herewe report our experience from 252 total laparoscopic hysterectomies
performed for both benign conditions and gynaecological cancers, andwe
compare outcomes among normal, overweight, obese andmorbidly obese
patients. We used a composite score index calculated on the basis of
operating and theatre times, estimated blood loss, length of stay, and
number and severity of complications.
The mean BMI of our patients was 30.8 and mean age was 52.9 years.
The highest mean composite score was observed in morbidly obese pa-
tients. In these patients operating and theatre times were longer. Over-
weight and obese patients' mean scores were lower than normal weight
patients, but statistical analysis failed to show significant differences with
the exception of morbid obesity. Regression analysis showed no relation-
ship between the two variables.
Our study has a number of limitations including the inherent bias of a
retrospective observational study and a relatively low number of cases. Still,
it suggests that meticulous, consistent surgical technique may produce sim-
ilar outcomes in normal and obese patients having total laparoscopic hyster-
ectomy, with longer operating/theatre times noted only at BMI levels >40.
P96- Review of 6 months data of outpatient hysteroscopy episodes
at West Cumberland Hospital; setting up the standards of Care,
philosophy of the service and defining outcome measures
Oudai Ali1*, Haissam Moukarram1
1West Cumberland Hospital, Whitehaven, UK
Introduction
Outpatient hysteroscopy is very valuable, particularly in managing post-
menopausal bleeding. A failed episode will happen in case of the
following;
& inability to proceed with the procedure after premedication
& failure to access the cavity after proceeding
& inability to remove pathology after accessing the cavity
& causing severe pain with unsatisfactory experience
Methods
74 actualised hysteroscopies out of 85 referrals for a newly set
outpatient hysteroscopy service were analysed. The practice was
supported by a thorough recording of many parameters and out-
come measures through prospective audit together with patient
satisfaction survey including pain scores. The local anaesthesiolo-
gy pathway included, if tolerated, patients taking paracetamol and
ibuprofen with a light meal before coming to their appointments.
The majority on arrival will be given, tramadol, buscupan, ranit-
idine and cyclizin.The cervix is infiltrated with 4-6 injections of
lignospan and instillagel is used for lubrication. If there is pathol-
ogy then the cervix is dilated to deal with it.
Results
The pick up rate of significant pathology was about 47/74 and the pickup
rate of focal pathology was 31/74.There were 7 cancers diagnosed and 6
pre cancers of the endometrium. The cavity was accessed in 100% of
cases but there were three failures to remove pathology. Complications
were limited; one cervical trauma and 4 cases vagal reaction. Only two
cases reported unsatisfactory experience. The procedure's average dura-
tion was less than 15min in 85% of the cases
Conclusion
Outpatient hysteroscopy service is feasible, safe with high satisfaction
rate and proved valuable in picking up significant pathology. It is essential
to define the philosophy of service and reflect its performance through
prospective audit.
P97- Review of outcome following hysteroscopic division
of intrauterine adhesions or uterine septum
Dona Edirisinghe1*, Ephia Yasmin1
1University College Hospital, London, UK
Background: Hysteroscopic procedures are well tolerated by the patients
and effective in treating intrauterine pathology. Systemic reviews did not
find any significant difference in reproductive outcome following resec-
tion of intrauterine septum and adhesions. However, small observational
studies have found beneficial effects.
Method: An observational study of women, who has undergone either
resection of intrauterine septum or intrauterine adhesions during the pe-
riod of 3 years from 2011 till 2014 at University College Hospital,
London.
Results: Eleven women were identified for the study. Seven wom-
en had intrauterine adhesions following either previous delivery or
surgical evacuation of miscarriage. Four women had uterine sep-
tum, while two of them had recurrent miscarriages. Following
resection of septum and division of adhesion three women needed
repeat procedure. Two women had successful pregnancies with
IVF treatment and spontaneous conception. Three women had
early pregnancy losses and one had failed IVF. Three women
who needed repeat procedure are awaited for formation of normal
endometrium prior to assisted conception.
Conclusion: There is no significant improvement in fertility outcome
following the procedure. This may related to other contributing factor
such as age and premature ovarian failure.
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P98- Safe entry Techniques; Patient selection and Risk Factors
Assessment in Tailoring Individual Patient-Based Laparoscopic
approaches
Karim Abdallah1*
1Royal United Hospital NHS Foundation Trust, Bath, UK
Minimal access surgery is one of the hall marks of this day and age of
gynaecological surgery. Laparoscopy is progressively taking over most of
the procedures. Different access techniques have been discussed in more
than several occasions. Assessing the individual risk factors of each patient
is an absolute necessity in the decision-making process on the best way of
gaining safe entry into the abdominal cavity. We aim at reviewing different
entry techniques described in the literature and highlighting different indi-
vidual risk factors that should be taken into consideration when choosing
the entry technique. We aim at providing a simple guidance to help safe
decision -making on the choice of entry technique to be used. The evidence
will be drawn fromEnglish-language articles published over the last decade
on Medline, Pubmed and the Cochrane data base.
P99- "See & Treat" Satisfaction - Procedural Outpatient
Hysteroscopy @ St Richard's Hospital Chichester
Gina Michel1*, Bronwyn Middleton1
1St Richard’s Hospital, Chichester, UK
All patients attending the See & Treat outpatient hysteroscopy clinic are
asked to complete an anonymous patient satisfaction survey following
their appointment to support service improvement and development. All
patients are given an information leaflet prior to their appointment about
what to expect, pre-procedural analgesia, after care and alternative treat-
ment options including general anaesthetic. Each clinic has a dedicated
team with a list of 6-8 patients, each with a half hour slot. Diagnostic and
procedural hysteroscopies are performed.
Data from surveys collected from 150 women over 6 months regarding
demographics, patient information leaflets, appointment waiting times,
pain scores, and experience and satisfaction rates were put onto a spread-
sheet and analysed.
93% of women received a patient information leaflet prior to their ap-
pointment, of which 98% found this to be ‘very informative' or ‘informa-
tive'. 84% of women reported that the information leaflet relieved their
anxieties partially or completely prior to the procedure.
A third of women did not experience any adverse symptoms after the
procedure. The most common symptom after the procedure was abdom-
inal cramps, which 47% of women reported. A minority of others expe-
rienced shoulder tip pain, nausea and feeling faint.
Overall there was a 99% satisfaction rate with 51% of women reporting
their experience was better than expected and 40% as expected. 91%
rated their care as excellent.
Analysing patient feedback is imperative to service development and im-
provement and forms an integral part of our Trust's Patient First initiative.
P100- Size of submucous fibroid and success of TCRF
Rubab Ali1*, Dimitrios Mavrelos1, Ertan Saridogan1
1Reproductive Medicine Unit, University College London Hospital,
London, UK
Introduction:
Submucous fibroids are associated with menorrhagia and adverse repro-
ductive outcome. Transcervical resection (TCRF) is an effective opera-
tion to remove these tumours. We have shown that women with a
submucous fibroid >38mm diameter are more likely to require a repeat
TCRF. This study aimed to audit our practice and validate this cut off.
Methods:
A retrospective 5-year observational study. Primary outcome measure
was complete fibroid resection. Secondary outcome measures were oper-
ative fluid deficit, symptom resolution and complication rate.
Results:
During the study period 91 patients underwent TCRF. On ultrasound 74/
91 (81%) women had a single fibroid and the median diameter of the
largest fibroid was 25mm (15mm IQR). On hysteroscopy 38/78 (49%)
fibroids were Type 2, 15/78 (19%) fibroids Type 1 and 25/78 (32%)
fibroids Type 0. 50/78 (64%) fibroids were completely resected at a single
operation. Median fluid deficit was 275 ml (range 0 – 3000), 3/78 (4%)
women received diuretics for suspected fluid overload and 1/78 (1%)
required an intrauterine Foley catheter. 63/80 (79%) women had symp-
tom resolution.
37/48 (77%) fibroids <38mm diameter were completely resected at a
single operation vs. 3/8 (38%) fibroids ≥38mm (p=0.022). Those that
had incomplete resection 7/16 (44%) had a repeat TCRF. 9/16 (56%)
had sufficient improvement in symptoms.
Conclusion:
TCRF is an effective and safe procedure that improves symptom. A cut
off of 38mm for the preoperative diameter of the largest fibroid can
predict need for a repeat TCRF.
P101- Spinal abscess as a complication of ultrasound guided
per-vaginal drainage of hydrosalpinx in a patient with a background
of Marfan Syndrome
Tim Hookway1*, Sophie Kay1
1St George’s Hospital, Tooting, London, UK
Introduction
We present an unusual case of spinal abscess as a complication of ultra-
sound guided per-vaginal drainage of hydrosalpinx.
Case Report
A 56 year old woman with a background of Marfan’s syndrome and
metallic aortic heart valve underwent an elective repeat transvaginal ul-
trasound guided drainage of left hydrosalpinx under local anaesthetic.
Following the procedure she became pyrexial with worsening pelvic and
back pain and cycling tachycardia. Intravenous antibiotics were initiated
for probable pelvic infection. Inflammatory markers were raised with
negative blood cultures.
CT scanning identified inflammatory changes within the left greater sci-
atic foramen, involving the piriformis and gluteus medius muscles, along
with a thickened ectatic dural sac extending into the spinal canal sugges-
tive of meningeal inflammation. Subsequent MRI revealed a large
intraspinal cystic structure.
Intravenous antibiotic therapy was instigated and an image-guided aspi-
ration performed. Frank pus was drained and E. Coli cultured. Appropri-
ate antibiotics were continued and her symptoms resolved.
Conclusion
Dural ectasia is a common structural feature ofMarfan syndrome and under
ultrasound visualisation would be indistinguishable from hydrosalpinx.
In reflection of this case our team felt that in cases of connective tissue
disease or possible skeletal abnormalities that further imaging must take
place prior to ultrasound guided gynaecological procedures to eliminate
structural differences.
Inadvertent piercing of dural ectasia is a rare cause of spinal abscess.
P102- Spontaneous resolution of paediatric hydrosalpinx: a case
for conservative management
Zainab Kazmi1,2*, Sujata Gupta2, Mike Dobson2
1University of Manchester, Manchester, UK; 2Lancashire Teaching
Hospitals Trust, Preston, Lancashire, UK
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Background
Hydrosalpinx is a rare cause of abdominal pain in non-sexually active pae-
diatric and adolescent patients, although there are cases documented in the
literature. Diagnosis of this presentation can made via ultrasound scan.
Case
A 12-year-old non-sexually active girl presented to the surgical admis-
sions unit with left-sided acute abdominal pain that settled within 24
hours of admission. An ultrasound scan performed by a sonographer
suggested the presence of a hydrosalpinx.
A post-discharge follow-up appointment with a consultant paediatric and
adolescent gynaecologist demonstrated no symptomology but a repeated
ultrasound scan by a second sonographer more clearly revealed continued
presence of hydrosalpinx, which had now grown larger.
A decision to operate was made on the principle of risk minimization. The
risk of future ovarian torsion is increased in hydrosalpinx, so a decision to
operate was made to preserve fertility even in the absence of any trouble-
some physical symptoms.
Prior to the operation, an MRI was performed to confirm the site of the
hydrosalpinx. However, the MRI revealed no tubal masses, suggesting
spontaneously resolved hydrosalpinx. A consultant-administered ultra-
sound scan confirmed no present tubal abnormalities.
Conclusion
This case demonstrates the possibility of spontaneous resolution of pae-
diatric hydrosalpinx demonstrated by repeat imaging, which has not been
previously reported. Our recommendation now, based on the same prin-
ciple of risk minimization mentioned above, is for conservative manage-
ment of asymptomatic paediatric hydrosalpinx shown on ultrasound,
alongside education of the patient and parent/guardian of the presentation
of tubal torsion, for which emergency admission and surgery would then
be indicated.
P103- Subfertility and Severe Endometriosis: Is endoscopic surgical
intervention now the way forward?
Rizwana Yakub1*, Sandu-Aana Lakshmi1, Sara Nasser1, Gaity Ahmad1,
Peter Byrne1, Zul Anjum1
1Royal Oldham Hospital, Oldham, Manchester, UK
Endometriosis is a leading cause of pelvic pain and subfertility, with a 20-
30% incidence in infertile patients. The presence of severe endometriosis
(stage III/IV) is widely accepted as negatively impacting fecundity; with
rates of conception being reported at almost 0. Whilst gynaecologists are
fully aware of this, the decision of how to primarily manage subfertility in
this scenario is highly debatable especially in the absence of any other
endometriosis related symptoms. There remains a divide with assisted
reproduction specialists championing IVF/ICSI as the primary treatment
of choice and laparoscopic gynaecologists supporting excision of endo-
metriosis +/- subsequently combining it with an assisted reproductive
approach.
In this review we aim to evaluate the conflicting literary evidence, to
provide a summary which can help clinicians when counselling pa-
tients of the best primary approach for severe endometriosis related
sub fertility. Currently there are no published, large, well designed,
randomised control trials or meta-analyses comparing the efficacy of
all three approaches.
The majority of evidence recognises assisted reproduction as an
effective treatment modality which has favourable clinical pregnan-
cy rates, ranging from 32% - 60%. Studies reviewing endoscopic
surgery though limited suggest pregnancy rates of 54%. Further-
more when subsequently combined with IVF/ICSI achieving cumu-
lative clinical pregnancy rates of 56%-75%, consistently higher than
that achieved by surgery alone or IVF alone in these studies. With
evidence also suggesting that the optimal time to conceive is <2
years after surgery by IVF/ICSI and will achieve 2.65 times the
pregnancy rate that IVF alone will achieve.
P104- Successful Novasure endometrial ablation following
laparoscopic suturing of uterine perforation
Susan Tracey1*, Olorunfunmi Odusoga1, Andrew Pickersgill1, Ciaran
Clarke2
1Stepping Hill Hospital, Stockport, UK; 2University of Manchester,
Manchester, UK
We present a 26 year old para 2 patient with a two year history of dys-
functional uterine bleeding. Management with tranexamic acid,
norethisterone and Mirena IUS had failed. Ultrasonography and bloods
were normal. After counselling about further management, as she had
completed her family she opted to have Novasure ablation for her dys-
functional bleeding and laparoscopic bilateral salpingectomy for perma-
nent contraception.
Following dilatation of the cervix at surgery and insertion of the Novasure
device, the device opened to 3.5cm cavity width with no suggestion of
perforation; however the cavity integrity assessment failed twice. The
procedure was abandoned; we then proceeded with laparoscopy where
a small perforation to the uterine fundus was noted. The perforation was
closed laparoscopically with two interrupted sutures and bilateral
salpingectomy was performed.
A subsequent cavity integrity assessment was successful and Novasure
ablation was performed under direct vision.
Conclusion
The Novasure system uses carbon dioxide to verify cavity integrity prior
to performing the procedure. Failure of this cavity integrity assessment
should raise suspicion of uterine perforation.
As the Novasure is an expensive single use device, our case highlights the
options available in conserving resources in cases where uterine perfora-
tion occurs and allows the patient to still benefit from an effective day
case procedure. This case brings to the fore the value of laparoscopic
suturing in gynaecological surgery.
Opting for laparoscopic salpingectomies meant our patient could
potentially reduce her risk of ovarian cancer in future, prevent
post ablation sterilisation syndrome and achieve permanent con-
traception.
P105- Surgical Approach for the Benign Ovarian cysts at York
Teaching hospital NHS Foundation Trust
Georgios Grigoriadis1*, Charilaos Charalampidis1, Fawzia Sanaullah1
1York Teaching Hospital NHS Foundation Trust, York, UK
Laparoscopic management of ovarian cyst is well established offering
distinct advantages of quick postoperative recovery and reduced cost.
Operative laparoscopy should be our primary surgical approach to treat
majority of benign ovarian cysts.
Objective:
To assess the surgical approach for the management of benign ovarian




All consecutive womenwhowere operated for ovarian cyst not suspected
to be malignant from Sept 2013 to Sept 2014. Total 61 women were
identified from the theatre computer record and pathology department.
The data was collected from the hospital computer.
Results:
Laparoscopic approach was used in 43 (71%) and 18 (29%) had
laparotomy. The mean operation time in the laparoscopy group
was 100 minutes (range 40 to 237min) compared to 96 minutes
(range 51 to 270 minutes) in the laparotomy group. Mean cyst
diameter was 10cm (2 to 31cm) with one 26cm cyst managed
laparoscopically. 31 (51%) were managed by cystectomy and 30
(49%) had oophorectomy preferably in women over 45years. In
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the laparoscopy group, 43 women were discharged on the same day
or following day compared to average 3.5 days in laparotomy
group. Two women required second operation by oncologist to com-
plete the operation as the histology suggested borderline and ade-
nocarcinoma. There were no major complications in both groups.
Conclusion:
Laparoscopy should replace laparotomy in the management of benign
ovarian cyst.
Further audit is needed in the department to assess the factors affecting the
surgical approach.
P106- SURGICAL MANAGEMENT OF OVARIAN CYST IN
PREMENOPAUSALWOMEN
Subashini Sivalingam1*, Hannah Wigginton1, Zeiad El-Gizawy1
1Royal Stoke Hospital, Stoke-On-Trent, UK
Aim: To assess our surgical management of premenopausal women with
Ovarian cysts.
Method: All Women who underwent surgery for ovarian cyst were iden-
tified from the surgical database in a 12 month period (August 2013 to
July 2014). A total of 100 women were audited. BSGE/RCOG guidance
was used as the auditable standard.
Results: Cysts were managed by laparoscopic surgery in 86% and lapa-
rotomy in 14% (4 at caesarean section). Method of surgery was ovarian
cystectomy in 52% (45 laparoscopic and 7 open), aspiration in 10%,
oophorectomy in 36% and oophorectomy with hysterectomy in 2%.With
laparoscopic approach the cyst was removed intact 63%, spill of cystic
contents were noted in 37%. However in all the cases the specimen was
removed in a contained bag. During open surgery this was 57% and 43%
respectively. 50% of the women had midline and lower transverse lapa-
rotomies each. There were no significant complications noted. In this
cohort 4%women had borderlinemalignant tumours. Among the 10 open
surgery for ovarian cyst/mass 7 benign and 4 were malignant tumours.
The size of the cyst at the time of booking for surgery was <5cm in 36%,
5-7cm in 29% and >7cm in 31%. In 7% this was not available. In our
study group only 8 women (13%) <40 years had all the recommended
tumour markers 32 women (52%) had atleast 1 other tumour marker.
Recommendation: Aspiration of ovarian cysts should be avoided as this
increases recurrence. Women with cyst <5cm should be offered conser-
vative management.
P107- Survey on Laparoscopic Specimen Retrieval
among Consultant Gynaecologists in UK
Sridevi Sankaran1*, Funlayo Odejinmi2
1Frimley Health NHS Foundation Trust Frimley UK; 2Whipps Cross
University Hospital Leytonstone UK
As laparoscopic surgery involves major surgery through small incisions
specimen retrieval can present a challenge, for cosmesis, ease of specimen
delivery, pain and potential complications.We thus conducted a survey of
consultant laparoscopic surgeon members of the BSGE to determine
practices of retrieval of specimen after laparoscopic surgery and the rea-
sons behind the choice of ports sites for retrieval for common laparoscop-
ic procedures
Results
Of the 460 registered consultants 187 (40%) responded to the
SurveyMonkeyÔ questionnaire. The most commonly used port for spec-
imen retrieval was umbilical 10mm ports for ectopic pregnancy, ovarian
cysts and endometriomas 49%,43% and 43% respectively with no extra
port used or existing port extended just for retrieval of specimen.
The second commonest port was suprapubic 10mm ports 35% for ectopic
pregnancy,34% for ovarian cysts and 36% for endometriomas.
During the retrieval of specimenmost consultants routinely use a retrieval
bag.
For laparoscopic myomectomy 84 % of those who performed the proce-
dure would retrieve the specimen by power morcellation, as opposed to a
minilaparotomy or posterior colpotomy, 5% of them would perform
morcellation in a bag. For laparoscopic subtotal hysterectomy the figure
was 93%.
Conclusion
Umbilical port is the most commonly used port for specimen retrieval
among UK gynaecologists, most would not insert an extra port just for
specimen retrieval. For more complicated procedures despite the recent
scare most will still use power morcellation for laparoscopic myomecto-
my and subtotal hysterectomy.
P108- Temporary psychogenic lower limb paralysis (conversion
disorder) following diagnostic laparoscopy for investigation of pelvic
pain
Sami Shawer1*, Atul Nalawade1, Asokan Krishnan1, NicholasMatthews1,
Ajay Asokan1
1North Tees and Hartlepool Foundation Trust Stockton-On-Tees UK
Background:
Functional (psychogenic) loss or weakness of motor functions following
hospital admission or surgery is a known conversion disorder. Formerly
known as "hysteria", conversion disorder is a rare complication after
gynaecological laparoscopies. Patients with conversion disorder tend to
regain their sensorimotor functions spontaneously. This is the second case
reported with similar complication post-laparoscopy and the first case
reported after diagnostic laparoscopy.
Case:
A 25 years old female patient underwent a day case diagnostic laparos-
copy under general anaesthesia to investigate pelvic pain. No intra-
operative complicationswere noted. Patient was otherwise fit and healthy.
During immediate recovery period, she developed unexplained bilateral
lower extremity paralysis. MDT approach was adopted and patient was
reviewed by neurology and orthopaedics teams. Diagnostic tests includ-
ing MRI to exclude any organic aetiology, were all normal. After exclu-
sion of possible organic causes, diagnosis of conversion disorder was
made. Patient spontaneously regained full sensorimotor functions around
36 hours after the surgery. Patient was discharged 48 hours post-operative
without neurological complication.
Conclusion:
Conversion disorder causes patients to suffer from neurological symp-
toms, such as numbness, blindness, paralysis, or fits without organic
cause. It is thought that symptoms arise in response to stressful situations
affecting patient's mental health. The loss of sensorimotor functions as
part of conversion syndrome is rare, but still a possible post-operative
complication which may be encountered with gynaecological laparosco-
pies. MDT approach and exclusion of other organic lesions is crucial to
establish this diagnosis.
Reference(s):
1.Berhane L, Kurman R, Smith S. Lower extremity paralysis after oper-
ative laparoscopy from conversion disorder.A case report.J
Reprod.Med1998;43:831-5.(and other references).
P109- The birth of an endoscopic audit tool in a developing country
Raj Dodia1*, Timona Obura2
1University of Oxford Oxford UK; 2Aga Khan University Hospital Nai-
robi Kenya
PURPOSE: Clinical audit determines gaps between what is andwhat should
be done, revising any ‘lacks' in patient care processes, and is a vital step in
quality improvement strategies including accreditation processes.
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DESIGNANDMETHOD: Laparoscopy and hysteroscopy procedures
done at the Aga Khan University Hospital Nairobi in 2013 were
audited against a newly designed endoscopic audit tool. Laparosco-
py procedures were coded as diagnostic, for ectopic pregnancies,
myomectomies, endometriosis, cystectomies, hysterectomies, and
other (specify). Hysteroscopies were coded as diagnostic, polyp re-
section, myoma resection, adhesiolysis, ablation, and other (speci-
fy). Possible complications included injury to intraperitoneal and
retroperitoneal organs, herniae, pneumoperitoneum related, nerve
injury, venous thromboembolism, death, wound infections, and
functional compromise after surgery. Electrosurgical sources
(monopolar, bipolar, ultrasound) utilized and procedure duration
was noted. Hysteroscopic distention fluid was identified and the
end deficit recorded.
RESULTS: In 2013, there were 192 laparoscopies and 193 hysterosco-
pies. Of 286 patient records, 78.3% did not have complete data as per the
designed form (except complications). Only 51.6% of the complete data
records were by departmental faculty.
LIMITATIONS: Errors in data transcription; incomplete recording of
procedure notes.
CONCLUSION AND COMMENTS: The inclusion of this data tool as a
necessary and compulsory part of the operation notes for every endoscop-
ic procedure may assist in improving procedure documentation and can
provide (e.g. six monthly, or yearly) a valuable resource for audit, which
would ultimately lead to higher quality of patient care once the clinical
audit cycle is followed through, including feedback to groups as well as
individuals.
P110- The impact of 3D Einstein vision laparoscopic technology
on Theatre efficiency with surgeons and theatre staff perspective
Oudai ALI1*
1West Cumberland Hospital Whitehaven UK
Objective
The benefit of the 3D vision in minimal access surgery is well recognised
through incorporation in the DaVinci system. However the 3D concept in
standard laparoscopy needs to be evaluated and its value demonstrated in
the actual theatre environment.
Methods
The 3D system was tried over 4 weeks in laparoscopic gynaecology
procedures. Surgeons and theatre staff feedback was collected. Operating
time was observed for TLH. The time to close the vault laparoscopically
was considered a function of the improved vision and video clips of
suturing with 2D and 3D were compared.
Results
There was positive feedback supporting many aspects particularly supe-
rior image quality,feasibility and enhanced surgical experience with
shorter operating times.For one surgeon's standard technique in
performing TLHwith intracorporeal suturing the vaginal cuff, the average
operative time dropped to 74.17(SD;13.75)mins from 127mins(SD;+/-
14.4) and the vault closure to 11.21min(SD;+/-1.85) from 20.82(SD;+/-
3.16)min. The unique feature of autonomous warming of the scope was
noted to keep the view stable avoiding the frequent interruptions to defog.
The sterile sleeve over the scope concept was safe and easy to use and
kept the scope ready for the next cases.
Conclusion
The introduction of approved innovations to theatre systems should be
tried in a controlled structure where safety, acceptability and impact on
productivity are tested and feedback is analysed. Minimal access surgery
adopted many developments across its history however the best invest-
ment will always be the continuous improvements in optics. 3D vision
improved the surgical performance and the increased precision translates
into better efficiency.
P111- The Impact of the Presence of a Colorectal Surgeon
on the Management and Outcomes of Surgery for Rectal
Endometriosis
Jonathan Clarke1,2*, Neda Taghinejadi2, Charles Craddock2, Thomas
Holland2, Richard Cohen2, Ertan Saridogan2, Alfred Cutner2
1Imperial College London LondonUK; 2University College LondonHos-
pitals NHS Foundation Trust London UK
For women with extensive endometriosis involving the bowel, multidis-
ciplinarymanagement including a colorectal surgical opinion has become
the standard of care. This study examines how the presence of a colorectal
surgeon influences the surgical management and post-operative colorec-
tal symptomatology of rectal endometriosis.
The BSGE Endometriosis Centre Database was examined for pa-
tients with rectal endometriosis. The presence or absence of a co-
lorectal surgeon upon intraoperative techniques used and patient
self-assessment of symptoms, quality of life and effect on daily
activities following surgery was examined. Fisher's Exact Test
was used to compare treatments and symptomatology with and
without a colorectal surgeon present.
426 patients were present in the database, of which 106 (24.9%) had
rectal involvement. Teams involving a colorectal surgeon were signif-
icantly more likely to perform surgery to the bowel (97.5% vs. 83.3%,
p<0.05). Scissors were significantly more likely to be used in the
presence of a colorectal surgeon (52.4% vs. 21.2%, p<0.05) while
bipolar diathermy was significantly less likely to be used (4.8% vs.
19.4%, p<0.05). There is no significant difference in the patients'
symptoms or quality of life between groups following treatment.
The presence of a colorectal surgeon in rectal endometriosis surgery sig-
nificantly alters surgical treatment, however the ultimate impact of these
differences on a patient's overall outcomes remains unclear. It is probable
that colorectal surgical involvement is reserved for more extensive cases
of rectal endometriosis, and the use of scissors may reflect a need to avoid
administration of electrosurgical energy in proximity to the bowel.
P112- The learning curve: do the first few laparoscopic
hysterectomies carry a higher risk of complications?
Annabel Grossmith1*, Aarti Shetty1, Jemma Mistry1, Fariha Rahim1,
Sujata Gupta1
1Lancashire Teaching Hospitals NHS Foundation Trust Preston UK
The increasing trend towards choice of laparoscopic route for hysterectomy
in our unit, has led to an expansion in personnel competent in benign
gynaecological endoscopy. We conducted an audit of practice at a large
teaching hospital to investigate our results for laparoscopic hysterectomies.
All patients coded as having had a hysterectomy performed over a three
year period between 1/6/11 and 31/5/14 were identified retrospectively
from prospectively recorded computerised theatre data. For each case, the
indication for hysterectomy, surgical approach, duration of surgery, estimat-
ed intra-operative blood loss, duration of stay, complications, need for
conversion to open approach, BMI, and previous abdominal surgery were
ascertained from computerised casenotes and theatre logs. 1056 patients
were identified. Of these, 253 had laparoscopic hysterectomies. The level
of experience of the surgeon was noted, and the above data was compared
for each successive year during the period of investigation to assess the
learning curve within the department. The findings and conclusions will be
discussed together with our suggestions for future local policy.
P113- The outcome of laparoscopic assisted vaginal hysterectomy
in a district hospital
Neelam Agrawal1*, Shamma Al-Inizi1
1South Tyneside hospital South Shield UK
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Vaginal route is the recommended route for benign indications of hyster-
ectomy. Though laparoscopic assisted vaginal hysterectomy could re-
place abdominal route where early stage 1 endometrial carcinoma, en-
larged uterus, advanced endometriosis and no uterine descent.
We reviewed case-notes for 38 patients who underwent this procedure at
STH over 2 year period to check conversion rate, intra-operative and
postoperative complication rates, hospital stay, readmission and reopera-
tion rates. About 85% procedures were completed by laparoscopy and
conversion rate was 15.7%. Among them 5 patients (11.3%) has had
previous abdominal surgery. Half of them (44.7%) underwent peritoneal
washing in addition to LAVH+BSO for endometrial carcinoma. Intra-
operatively 5 patients (11.3%) bled > 900 ml. The major intra-operative
and postoperative complication rate was 2.6% each. None of them has
had trauma to bladder, bowel or ureters. No significant differences were
seen in intra-operative and postoperative complication rates of patients
who were morbidly obese (BMI>35), enlarged uterus (14 weeks) or who
underwent additional procedures (bilateral salpingo-oophorectomy,
adhesiolysis or prolapse surgery). Majority of them (40%) went home
day 2 and only 3 patients (7.9%) needed to stay more than 3 days. None
of them was readmitted secondary to surgery complications and reoper-
ation rate was 2.6%. None of the variables studied: age, medical problem,
morbidly obesity, enlarged uterus, additional procedures were found to
have any association with readmission or reoperation. Conclusion: Lap-
aroscopic assisted vaginal hysterectomy can be performed successfully in
most patients with benign indications and early stage of endometrial
carcinoma with low complication rate and short hospital stay.
P114- The relationship between pelvic vein incompetence
and chronic pelvic pain in women: an evidence synthesis
Jane Daniels1*, Rita Champaneria1, Laila Shah1, Janesh Gupta1, Jon
Moss2, Judy Birch3, Lee Middleton1
1University of Birmingham Birmingham UK; 2North GlasgowUniversity
Hospital Glasgow UK; 3Pelvic Pain Support Network Poole UK
Background
Pelvic congestion syndrome (PCS) is described as chronic pelvic pain
(CPP) arising from dilated and refluxing pelvic veins, although the causal
relationship between pelvic vein incompetence (PVI) and CPP is not
established. Percutaneous embolisation is the principal treatment for
PCS, with high success rates often cited.
Objectives
To systematically review the association between PVI and CPP and the
effectiveness of embolisation for PVI.
Methods
A comprehensive search strategy encompassing various terms for
pelvic congestion, pain and embolisation was deployed in 17 biblio-
graphic databases. There was no restriction on study design. Meth-
odological quality was assessed using appropriate tools. The quality
and heterogeneity generally precluded meta-analysis so results were
described narratively.
Results
We identified six association studies and 21 case series and one poor
quality randomised trial of embolisation.
We found the associations between CPP and PVI were generally fairly
similar, with three of five studies with sufficient data showing statistically
significant associations (odds ratios between 31 and 117). The prevalence
of PVI rangedwidely, although themajority of womenwith PVI had CPP.
Early substantial relief from pain symptoms was observed in approxi-
mately 75% of women undergoing embolisation, which generally in-
creased over time and was sustained.
Conclusions
The quality of data supporting the treatment of PCS is limited and of
variable methodological quality. There is some evidence to tentatively
support a causative association, but it cannot be categorically stated that
PVI is the cause of CPP in women with no other pathology. Embolisation
appears to provide symptomatic relief in the majority of women and is
safe.
P115- To morcelate or not to morcelate : a case series of ‘abnormal’
fibroids
John Wahba1,2*, Tom Setchell3, James Richard Smith2, Tariq Miskry3,
Alan Farthing1,2
1Imperial College London London UK; 2Queen Charlotte’s & Chelsea
Hospital, Imperial College Healthcare NHS Trust London UK; 3St.
Mary’s Hospital, Imperial College Healthcare NHS Trust London UK
The issues surrounding the use of power morcellation during laparo-
scopic myomectomy for symptomatic fibroids have caused wide-
spread controversy amongst gynaecologists. Such issues include the
risk of severe trauma and seeding of morcellated tissue in the abdom-
inal cavity. One of the most serious concerns is the risk of dissemi-
nating occult malignancy such as an inadvertent leiomyosarcoma
(LMS); a risk which the FDA has quoted as 1:350 cases. However,
the number may be as low as 1:7400 according to research. The
incidence of finding ‘unexpected' pathology is 1.2% according to
one study. Evidently, not all ‘unexpected' pathologies will carry a
serious prognosis, but distant spread would clearly negatively affect
those with LMS.
We present a case series of pre-menopausal women who presented with
symptomatic fibroids for which they underwent a myomectomy or a total
abdominal hysterectomy. Histological and radiological examination later
revealed unexpected pathologies such as LMS and widespread endome-
trial sarcoma. In two cases, laparoscopic myomectomy was converted to
open surgery due to the intra-operative findings and abnormal dissection
planes). In both cases power morcellation was not utilised due to open
conversion. Following subsequent hysterectomy one patient was shown
histologically to have had complete tumour excision the original open
myomectomy. The other patient was unfortunately found to have dissem-
inated extra-uterine pelvic spread.
It is unclear whether the risk of dissemination of inadvertent LMS differs
with power morcellation versus myomectomy without morcellation (e.g.
open myomectomy). Understandably, any disruption of malignant tissue
intra-operatively may have significantly poor consequences in those with
a sarcoma.
P116- Torted Haematosalpinx: A pain beyond compare
Lewis Nancarrow1*, Tarun Ghosh1
1Nobles Hospital Isle of Man Isle of Man
Torted haematosalpinx is a rare condition with the majority of cases
associated with an ovarian torsion; however an isolated torted fallopian
tube is very rare with only a few cases being reported in the literature.
We present a case of a 41 year old nulliparous women who attended with
severe left iliac fossa pain that had been getting progressively worse over
a 2 week period. On examination abdomen was soft with minimal ten-
derness in left iliac fossa with no rebound or guarding. Bloods and in-
flammatory markers were normal. She was known to have hydrosalpinx
previously but on admission ultrasound there was a haemorrhagic left
ovarian cyst.
Patient was taken for Laparoscopy and findings showed a grossly en-
larged torted left haemosalpinx. The left fallopian tube had twisted 4
times on itself. The right tube showed hydrosalpinx and otherwise the
pelvic anatomy was grossly normal. The patient underwent bilateral
salpingectomy and on histology both tubes showed evidence of chronic
salpingitis and the left tube showed haemorrhagic infarction. Vaginal
swabs were negative and no cause was evident for the salpingitis. Post-
operatively the patient had near complete resolution of her pain.
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This is a rare cause of sudden onset abdominal pain but should be con-
sidered as a potential differential. On review of the literature and from our
own scans, imaging for tube torsion has a low sensitivity therefore early
laparoscopy would seem to be the most appropriate method of diagnosis
in patients presenting with these symptoms and no definitive diagnosis.
P117- Total Laparoscopic hysterectomy (TLH): a Holly Grail
or a Harbinger of Trouble?
Karina Datsun1*, Khaled Elsapagh1, Mohammed Allam1
1NHS Lanarkshire Wishaw UK
Objective. The aim is to analyze indications, outcomes, preoperative and
postoperative histopathology results, compare the intraoperative and
short-term postoperative complications of laparoscopic hysterectomy
and total abdominal hysterectomy and to analyze the shift towards lapa-
roscopic approach in a district general hospital (NHS Lanarkshire).
Methods. Retrospective analysis of 250 cases: 166 cases of total abdom-
inal and 84 cases of total laparoscopic hysterectomies.
Results. Over a period of 16 months we performed 250 total
hysterectomies.
2/3 of them (n=166, 66.4%) were TAH and remaining 1/3 (n=84, 33.6%)
TLH.
To compare, only 21 TLH were performed over a period of 12 months
after introduction of total laparoscopic hysterectomy in our department in
2012.
There were total 3 cases of bowel injury: 1 case during TLH, which
required conversion to laparotomy and 2 cases during TAH.
There were 2 cases of bladder injury in patients who underwent TAH;
none of the TLH was complicated by bladder or ureteric injury.
There was only 1 re-admission to the hospital after TLH versus 19 re-
admissions post TAH.
Majority of the pre-operative histopathology reports were confirmed
postoperatively. However, there were nine cases of undiagnosed cancer.
Conclusion. Laparoscopic hysterectomy can be safely done with a low
and reasonable complication rate, and a shorter hospital stay.
As experience is gained the operation time, complication rate and hospital
stay are decreased.
It is possible to change a practice within settings of a district general
hospital. The skills of preforming TLH are reproducible and most
gynaecologists can adapt the technique for laparoscopic hysterectomy.
P118- Total Laparoscopic Hysterectomy: incorporating the findings
of a retrospective audit for designing an Enhanced Recovery Care
Pathway at a tertiary London teaching Hospital
Tina Kapoor1*, Kim Lawson1, Amer Raza1
1Chelsea and Westminster Hospital NHS Foundation Trust London UK
Objective: The primary objective of the study was to obtain updated sur-
veillance statistics for laparoscopic hysterectomy procedures in order to lay
a foundation for designing an enhanced recovery care pathway in our unit.
Methodology: A Retrospective case notes review was taken of all women
who underwent Laparoscopic Hysterectomy between May 2012 and
May 2014. Demographic data was collected and entered onto MS Excel
spreadsheet. Details of surgical procedure including indication, type of
surgery, duration of procedure, any intra-operative and/ or post-operative
complications and duration of hospital stay were entered electronically
for ease of analysis. Any adverse events including unplanned admissions
following discharge were recorded.
Results: A total of 38 hysterectomies were performed over these 2 years of
which 56 % were performed for benign indications. 84% were completed
laparoscopically thus giving a conversion rate of 12.5%. Mean operating
time was 199 minutes. 32% of patients were discharged within 48 hours
with a mean in-patient stay of 63 hours. Main reasons delaying discharge
were postoperative nausea, vomiting, pain, and urinary retention. There
were no readmissions following the surgery during this period.
Conclusion: This analysis was crucial to devise a Care Pathway that
would ensure patient safety while delivering a high standard of care. With
appropriate multi-disciplinary team input and a robust enhanced recovery
programme, advanced laparoscopic surgery can be safely performed with
improved patient turnover within 36-48 hours, while keeping complica-
tions rates at the minimum.
A comprehensive literature review has been undertaken and is presented
along with.
P119- Training new hysteroscopists in the setting of a new out-patient
hysteroscopy service
Fani Gkrozou1*, Eve Gaughan1, Bronwyn Middleton2, Richard Pyper1,
Natasha Waters1
1Southlands Hospital West Sussex UK; 2St Richard’s Hospital West Sus-
sex UK
Introduction: The development of ambulatory hysteroscopy requires out-
patient procedures to be performed by an experienced clinician. The
service requires the clinician not only be able to perform a range of
diagnostic and operative procedures but also to perform appropriate risk
assessment for each individual patient and modify these technique for
difficult cases on a patient who is awake. It is important to establish safe
protocols for teaching new hysteroscopists in this setting.
Results: Our 6/12 audit of the out-patient hysteroscopy service showed that
hysteroscopy and biopsy could be performed in 90% of women referred
with a history of unsuccessful or inadequate pipelle endometrial biopsy.
No perforations in over 1200 OPH procedures performed in our trust. In
40% of cases vaginoscopic approach was used. It took trainees about 48
procedures to learn all techniques including vaginoscopy with both flex-
ible and rigid hysteroscopes. 7% required cervical dilatation and 1%
required dilatation under direct vision with micro-hysteroscopy using
graspers and scissors. 4% of patient felt sick and 1% had vaso-vagal
episodes. 5% of procedures could not be completed.
Conclusion: Although it is possible to shorten pre-clinical training by
attending hands on courses, the attainment of skills for outpatient hyster-
oscopy is individual and competence based. A simple check list would
help to guide a new hysteroscopist and will ensure patient safety, while
being directly supervised by an experienced clinician
P120-Treating symptomatic uterine fibroids with myomectomy:
Current views and practices of consultants
Fusun Sirkeci,1,2* Isaac Manyonda1,2
1St George´s University of London London UK; 2St George´s Healthcare
NHS Foundation Trust London UK
With women increasingly postponing childbirth into their late thirties and
early forties, when fibroids are more numerous and more symptomatic, the
number of women seeking uterus-sparing treatments is increasing. With
rising education and empowerment, women now demand a wider range of
treatments that not only meet their individual needs, but also have an
evidence base. Since myomectomy arguably remains the most commonly
used treatment, we sought to establish current views and practices
concerning myomectomy among consultant gynaecologists in the UK.
Methods: We constructed a 25-stem questionnaire that addressed issues
such as the pre-myomectomy use of GnRh analogues (GnRHa) and
ulipristal acetate, routine cross-matching of blood, use of cell salvage,
any limitations on number of fibroids to be removed at open, laparoscopic
and hysteroscopic myomectomy, intraoperative approaches to reduce
blood loss etc. This was then emailed to xxx consultant gynaecologists.
Gynecol Surg (2015) 12:213–265 261
Results: To date responses have been obtained from 280 consultants, a
response rate of 13%. Open myomectomy is the most common route,
with 80% surgeons using GnRHa despite 60% believing that GnRHa
destroy tissue planes. Vasopressin is the most common intervention to
reduce intraoperative blood loss. The majority of respondents (62%) were
not influenced by the size of the fibroids.
Conclusions:We acknowledge the low response rate and therefore inter-
pret our findings with caution. There does not appear to be any major
changes in gynaecologists’ views and practices regarding myomectomy
in recent years, including with regard to the use of GnRHa.
P121- Treatment of caesarean scar ectopic pregnancy at the Royal
London Hospital- a series of 19 cases and a literature review
Natalie Cooper1,2*, Mary Gbegbaje2, Elizabeth Ball2, Emeka Okaro2
1Blizard Institute, Queen Mary University London UK; 2Royal London
Hospital London UK
Caesarean scar pregnancy is rare which means that the treatment options
are difficult to evaluate. We present a series of 19 cases of caesarean scar
pregnancy, treated at the Royal London Hospital between September 2007
and October 2014. During this time frame our treatment evolved so that the
current management combines the use of methotrexate, suction curettage
and cervical cerclage. None of the cases experienced any complications.
We also present the results of a literature review examining the reported
methods for treating scar pregnancy, including surgical and medical
methods and uterine artery embolization.
P122- Ultrasound, Intra-operative and Histological correlation
of ovarian cysts in pre-menopausal women
Ilias Nikolopoulos1*, Pinky Khatri1, Graham Phillips1
1James Cook University Hospital Middlesbrough UK
Preoperative differentiation between the benign and the malignant ovar-
ian cysts is useful in planning their management. Pelvic ultrasound is the
most effective way to assess these cysts. The standard treatment for be-
nign cysts is laparoscopic ovarian cystectomy.
Objective:
To evaluate pre operative accuracy of ultrasound assessment of ovarian
cysts with laparoscopic findings and histological confirmation.
Methods:
Retrospective analysis of 29 cases of laparoscopic ovarian cystectomies was
done. Ultrasound scan, laparoscopic and histological results were compared.
Results:
Preoperative assessment of all the cysts indicated a benign nature
resulting in laparoscopic management. Laparoscopic findings correlated
with USS in 25/29 (86%) cases resulting in cystectomies. In the remain-
ing 4 cases, intraoperative findings suggested complex nature necessitat-
ing oopherectomy and peritoneal cytology.
Histological examination proved that all the cysts were benign. The his-
tology included serous/mucinous cystadenoma, dermoid, endometrioma,
luteinised corpus luteal cysts and simple cyst. This showed 100% corre-
lation with USS findings.
P123- Uterine Adhesions: An Iatrogenic Cause of Chronic Pelvic
Pain
Rebecca Mallick1*, James English1
1Royal Sussex County Hospital Brighton UK
Over the past 10 years there has been increasing debate over the closure
versus non-closure of peritoneal layers at the time of caesarean section
(CS). Historically closure of both layers was advised as this was thought
to correctly restore anatomy and reduce the risk of adhesion formation.
Current NICE guidance advises against the closure of the peritoneal
layers and this now appears to be common practice amongst obstetricians
nationwide.
Uterine to abdominal wall adhesions are not a well documented long term
complication associated with CS, however with this change in practice,
we have increasingly encountered extensive uterine adhesions at the time
of laparoscopy in women presenting with pelvic pain with approximately
20 cases in the past 10 years. Although these adhesions cannot definitely
be linked to surgical practice it seems credible that the practice of not
closing the peritoneum at CS may be a significant contributing factor.
We present one of these cases, resulting in chronic pelvic pain, where
extensive uterine to abdominal wall adhesions were found at the time of
laparoscopy and adhesiolysis was performed using a harmonic scalpel
prior to a total laparoscopic hysterectomy. We also review the literature
regarding closure versus non-closure of the peritoneal layers and explore
possible long-term surgical implications.
P124- Uterine Artery Embolisation for symptomatic fibroid uterus
Sreebha Rajesh1*, David Shaw2, Chris Kremer2
1QA Hospital Portsmouth UK; 1Midyorks Hospital NHS Wakefield UK
Aim: Determine outcome for women with symptomatic fibroids treated
with Uterine Artery Embolisation. Audit the adherance to NICE guide-
lines: UAE for fibroids.
Materials and methods: A retrospective audit of 54 patients who
underwent UAE from 2007-2013.
Results: Steady increase in patients accepting UAE for fibroids over the
years with highest number of 42%(23/45) in 2013. The age group was 28-
52 years. Out of the 8 nulliparous women, one had a successful pregnancy
after a year and another ended with emergency hysterectomy for sepsis..
The commonest presenting symptoms were menorrhagia (63%) and pres-
sure symptoms (14%). More than 75% of patients had UAE within 6
months of referral by a gynaecologist. Day case UAE was offered to
patients from December 2011 and so far 80% had successful bilateral
UAE as day case. The complication rates were immediate-3.8%, early-
1.9% and late-9.6%. 3 patients underwent repeat UAE and 4 ended up
with a hysterectomy. Out of the 73% of patients who attended GOPD
follow up post procedure; 80% were satisfied with results and 91% had
MRI evidence of shrinkage in fibroid size.
Conclusion: UAE is widely accepted treatment for symptomatic fibroids.
More and more UAE’s have been performed as day case since 2012 with
a low re-admission rate (11.5%). Re-intervention rate was comparable to
literature.
Recommendation: Ensure UAE leaflets are offered to patients and copy
of discharge letter post-UAE are sent to the gynaecologist so that patients
are followed up in the GOPD post procedure.
P125- Variables which Influence the Duration of Laparoscopic
Hysterectomy
Sarah Manohar1*, Sujata Gupta1
1Royal Preston Hospital Preston Lancashire UK
INTRODUCTION: There are many factors which affect the Duration of
laparoscopic Hysterectomies but it is not known which of these factors
influence the duration of surgery. The purpose of this study is to analyse
the effect of the size of the uterus, previous surgeries and Body mass
Index on the duration of 69 laparoscopic hysterectomies performed by
one consultant over a period of 2012-2015.
RESULTS: There was a statistically significant overall reduction in the
duration of surgery performed by the consultant over the 3.5yr study (p=
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0.00642). Factors such as BMI and uterine size also increased the length
of surgery although this was not found to be statistically significant. There
was only one significant complication in this case series.
CONCLUSION: Laparoscopic hysterectomy is an effective way of
performing hysterectomy with minimal complications. There is a positive
correlation between the duration of surgery and the uterine size. But
perhaps the most important factor is surgeon's experience on its own.
Certainly, this is what our case series reflects.
P126- Visual Numeric Endometriosis Scoring system, VNESS. A new
endometriosis scoring system aimed to facilitate communication
and documentation of disease severity and surgical findings
Shaheen Khazali1,2*
1CEMIG-Centre for Endometriosis and Minimally Invasive Gynaecology
Chertsey UK; 2Ashford and St. Peter’s Hospitals NHS Foundation Trust
Chertsey UK
Since 1918, at least 17 systems have been proposed for staging, catego-
rization or description of endometriosis. Despite multiple attempts, an
easy to use, reproducible, clinically useful and properly validated system
is yet to be developed.
The Visual Numeric Endometriosis Scoring System (VNESS) is an at-
tempt to address the shortcomings of previously proposed systems.
VNESS consists of 8 numbers, each between 0-4, representing the sever-
ity of endometriosis in each anatomical location in the pelvis, starting
from left adnexa, going down to pelvic sidewall, then to the uterosacral
complex, then to the uterovesical fold and pouch of Douglas and back up
the right side. The intention is that one can easily picture how severe the
disease was in different compartments. Examples are provided within the
scoring sheet to assist with scoring and a comment box is provided to
describe disease outside the pelvis or to provide further description. For
example: 313/04/302 – small nodule on terminal ileum.
This presentation reports on the first phase of this project: conceptualiza-
tion and consultation with experts. Phase two includes two separate stud-
ies to assess the inter-rater and intra-rater validity using videotaped pro-
cedures. One of these studies has now concluded, showing excellent
validity (reported separately) and another is ongoing.
VNESS is a promising system for description of endometriosis severity
and can potentially be useful for audit and research purposes by providing
a reproducible system that allows benchmarking. It also can be an easy-
to-use tool for communication between healthcare professionals and sur-
gical documentation.
P127- Establishing a one-stop ambulatory hysteroscopy service using
vaginoscopy at a large Acute Trust - outcomes, learning curve
and patient acceptability
Richard Keedwell1*, Jonathan Lord1, Edward Keedwell2
1Royal Cornwall Hospital Truro Cornwall UK; 2University of Exeter
Exeter UK
Ambulatory hysteroscopy has been shown to be an efficient, cost-
effective and acceptable method of gynaecological diagnostics and ther-
apeutics. Barriers to the implementation of this service may include lack
of training and skills, and concerns about patient acceptability. In this
presentation we report establishing a successful ambulatory hysteroscopy
service using a vaginoscopic approach in a large acute trust.
Data was collected over a 4 year period using a standardised database.
Analysis was performed on over 1000 cases. Although the hysteroscopists
had not previously had experience of outpatient hysteroscopy or
vaginoscopy, success rates were satisfactory from the outset (87%) rising
to 98%. Mean pain scores overall were almost identical for diagnostic and
operative procedures with no learning curve effect. The pain scores for
individual procedures are discussed and evaluated statistically. Also, explo-
ration of the data using data mining techniques is performed.
Feedback taken from patients directly after their procedure showed 89%
would elect to have an outpatient procedure again (3% not), with no
difference in the first 6 months. A brief discussion of the economic situ-
ation surrounding the service will be included.
These data show that establishing a one-stop hysteroscopy service in a
large acute trust can be achieved successfully even where clinicians have
not previously had experience of vaginoscopy. We recommend the estab-
lishment of a similar service in other trusts, such that the economic and
patient benefits may become more widespread.
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TITLE 
Combined laparascopic ovarian tissue cryopreservation and immature oocyte retrieval followed by 
in vitro maturation  and vitrification for fertility preservation: Uk pilot study results 
STUDY QUESTION 
To study the feasibility of oocyte retrieval and in vitro maturation (IVM) in oncology patients 
undergoing ovarian tissue cryopreservation (OTCP) for fertility preservation  
Summary Answer 
The pilot study revealed that IVM of immature oocytes followed by vitrification could be successfully 
achieved in some oncology patients undergoing OTCP 
What is known already 
Previous studies, outside the UK, have already shown that the combination of ovarian tissue 
cryopreservation and immature oocyte retrieval followed by vitrification is a feasible option, 
irrespective of the phase of menstrual cycle or age of the patient. This is the first time this approach 
has been attempted in the Uk in both paediatric and adult patients to try to maximise fertility 
preservation.  
Study design,size,duration 
Prospective pilot study of 23 oncology patients (both paediatric and adult, age range 2-31)  from 
2013-2015. Laparascopic immature oocyte retrieval and removal of ovarian tissue for 
cryopreservation was scheduled at the time of insertion of the Hickman line, to avoid the patient 
undergoing multiple procedures. 
Participants/materials, settings,method 
All patients undergoing laparascopic ovarian tissue harvesting before cancer therapy were offered 
immature oocyte retrieval. Oocytes were retrieved by three methods: - in situ percutaneous video-
assisted oocyte retrieval for those patients undergoing ovarian cortical strip resection (rather than 
oophorectomy), ex-situ puncturing of the excised ovary and removal of the fluid remnants post 
dissection and tissue processing of the ovarian tissue. Oocytes were then matured in vitro using 
standard IVM methodologies and any resultant mature oocytes vitrified. 
Main results and role of chance 
Of the 23 patients who participated in the pilot study, 15/23 (65%) were paediatric (age 2-17) and 
8/23(35%) adults (age 22-31). Successful immature oocyte retrieval was achieved in 78% of the 
patients, 80% in the paediatric v 75% in the adult group, with the majority of the oocytes being 
isolated from the dissection remnants (61%).  A total of 140 oocytes were collected, of which 
57(41%) were degenerate and therefore non-viable. Of the remaining 83 oocytes, 40 reached 
metaphase (MII), giving a maturation rate of 48% following 24-48 hours in IVM culture. The 
remaining 43 (52%) arrested at germinal vesicle (GV) stage. All metaphase II oocytes were 
subsequently vitrified. Vitrification of mature oocytes was achieved in 60 %( 9/15) of the paediatric 
patients (range 1-5), the youngest of which was aged 2 (1 frozen), in comparison to 38 % (3/ 8) in the 
adult group.  
Limitations, reasons  for caution 
None of the oocytes vitrified in this study have been thawed and therefore their viability is at 
present unknown. Also, due to restrictions in both the timings and collection methods of the oocytes 
the quality of the oocytes may be compromised as the main priority was OTCP. 
Wider implications of the findings 
This pilot study showed that immature oocytes can be successfully harvested /matured and vitrified 
from both antral follicles and excised tissue in both paediatric and adult patients undergoing OTCP. 
This is in accordance with other published studies .However, this study has also demonstrated 
freezing for the youngest patient to date. 
Study funding/competing interest 
Part NHS/charity funded patient participation. 
No competing interests 
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Piece of Mind
Should Ovarian Tissue Cryopreservation
Be Recommended for Cancer Patients?1
Joseph G. Schenker2,3 and Mohammad Fatum2
The emergence of ovarian tissue cryopreservation
(OTCP) for fertility conservation has led to a new
worldwide trend of ovarian tissue banking for re-
productive cancer patients, scheduled to undergo
chemotherapy or radiotherapy (1). Since the survival
of young women and children who undergo such cura-
tive anti-cancer treatment is increasing, it is impera-
tive for the consulting clinician to have an updated
and accurate understanding of the proven benefits
and the limitations of this new and hitherto evolving
technique. OTCP was shown to be successful in sev-
eral animal models during the last decades. In 1960,
Parrott reported successful pregnancies in mice af-
ter implantation of frozen-thawed ovarian grafts (2).
Other studies reproduced the similar results in mice
(3) and in sheep (4). Despite these promising prelim-
inary animal outcome, the efficiency of ovarian tissue
autografting whether orthotopic (the autotransplan-
tation to the ovarian pedicle) or heterotopic (the au-
totransplantation to a different site) has not yet been
clearly demonstrated in humans (5,6).
Since the primordial and primary follicles can sur-
vive the freezing–thawing procedures, it was hoped
that in vitro maturation would be an important source
for harvesting mature oocytes (7,8). However, the in
vitro maturation of both animal and human follicles
was no less disappointing than autografting. There
still are no reports of harvesting mature oocytes from
in vitro culturing and maturation of primordial and
primary follicles. Hence, there is increasing interest
in improving the cryopreservation, autografting, and
the in vitro culturing and maturation techniques, ne-
1As of the date this paper was submitted, Donnez et al. (Lancet,
Oct. 2004) reported a live birth after orthoptic transplantation of
cryopreserved ovarian tissue.
2Department of Obstetrics and Gynecology, Hadassah, Hebrew
University Hospital, Ein kerem, Jerusalem, Israel.
3To whom correspondence should be addressed at The Department
of Obstetrics and Gynecology, Hadassah University Hospital,
Ein Kerem, P.O. box 12000, Jerusalem 91120, Israel; e-mail:
schenker@cc.huji.ac.il.
cessitating further intensive research to increase their
efficiency and to test their safety (9). To our knowl-
edge, no pregnancy or embryo transfer was reported
in humans as a result of utilizing cryopreserved ovar-
ian tissue.
From the aforementioned data, it seems that the
use of ovarian tissue banking as a method to preserve
fertility in cancer-treated-female patients is still in its
early stages. We believe that at this stage of experience
and outcome, OTCP should not be proposed to these
patients. These relatively debilitated cancer patients
are a priori in a suboptimal health state and hence,
the risk of invasive surgical procedures for retrieving
ovarian tissue is not justified.
Women should be informed of the current state
of data concerning the success rates in order to
prevent developing false expectations and further
disappointments.
Furthermore, ovarian transplantation might be un-
safe in some malignancies (e.g. acute leukemia) be-
cause of the risk of ovarian involvement and the pos-
sible receding of malignant cells through the implant
(10,11). On the other hand, studies have shown that
ovarian tissue harvested before high dose chemother-
apy for lymphomas may not carry a risk of disease
transmission by autotransplantation (12,13). How-
ever, even in these low risk cases, transmission of
the malignant cells is difficult to exclude completely.
Thus, if autografting is considered, testing for malig-
nant cells in the tissue must be performed using ade-
quate techniques. This subject needs further extensive
research.
Animal models show that ovarian slices can convey
short time function only. Assuming that these stud-
ies apply to human ovarian tissue, the potential of
achieving pregnancy is limited. For this reason it is
recommended to transplant the auto-graft only when
immediate fertility is desired (11).
Studies on organ cryopreservation, ovarian freez-
ing, and transplantation are in its first steps of research
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and thus it is not an applicable modality and cannot
be recommended as a fertility-conserving measure
in the near future. Since OTCP is yet to be yielding
and in the absence of other more promising modal-
ities, we believe that in order to preserve poten-
tial fertility in cancer patients, they should be ad-
vised to undergo one cycle of ovarian super-ovulation
with subsequent IVF before chemotherapy or irradi-
ation in order to obtain embryos for cryopreserva-
tion. This strategy can be suggested to stable couples,
since fertilization can be performed with the partner’s
sperm.
These frozen zygotes have an acceptable rate of
viability and so far are the only proven modal-
ity ensuring delayed pregnancy. To our experience
one cycle of ovarian super-ovulation knowledge, is
adequately safe and is equally acceptable by these
patients and their consulting oncologists in most ma-
lignancies without any significant deleterious influ-
ence of the delay in chemotherapy/radiotherapy on
patients’ prognosis.
In single adolescent women, donor sperm can be
used for oocyte fertilization. In accordance with their
desires, both couples and single women will always
have embryo transfer as an option. According to the
present state, embryos can be cryopreserved for 5
years and in some countries according to legislation or
regulation, even to 10 years, then women can decide
whether they are interested in the sustained cryop-
reservation and transfer of these embryos.
With patients refusing to use donor sperm due to
ethical or religious attitudes, oocyte harvesting and
freezing might be offered despite present low fertil-
ization and pregnancy rates. This modality is still in
its early experimental stages and only few cases of
pregnancies were achieved, however it is still more
promising than OTCP in which no cases of pregnan-
cies were reported.
Until large-scale human transplantation studies to
test and improve the efficacy and the safety of OTCP
procedure are undertaken, this procedure should not
be recommended as a routine therapeutic approach.
The current experience with no documented preg-
nancy in humans from OTCP, does not justify ex-
posing these patients to the risks of anesthesia and
invasive surgical procedure before the definitive anti-
cancer treatment. This is of utmost importance in or-
der to avoid creating false expectations and disap-
pointments in these patients. Therefore, these women
should be recommended to undergo one cycle of
ovarian super-ovulation with subsequent IVF with
partners sperm in coupled women and donor sperm
in single women in order to achieve embryos for
cryopreservation.
However, only in prepubertal girls in whom ovu-
lation induction can not be performed and mature
oocytes can not be achieved, OTCP is at present the
only option. These patients and parents ought to be
informed that this clinical approach is still in its early
stages of experimentation and their chance to pre-
serve fertility can not be guaranteed.
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Introducing a centralised tertiary programme for ovarian tissue cryopreservation in female 
cancer patients. Biomedical, ethical, regulatory and funding challenges. 
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Introducing a nationwide ovarian tissue cryopreservation programme (OTCP) for 
female cancer patients, an innovative technology based upon largely experimental technology 
developed elsewhere in the world, is a challenging task with a number of scientific, ethical, 
regulatory and funding implications1,2. We report these challenges when introducing a new 
scheme for ovarian tissue cryopreservation, achieved through collaboration between Oxford 
University, Oxford University Hospitals NHS Foundation Trust and the private sector. 
Across the world, more than 300,000 children under the age of 19 are diagnosed with 
cancer each year3.  Overall survival for children and young adults following cancer treatment 
in high-income countries now exceeds 80%4. However, the treatments required to achieve these 
very encouraging survival figures are associated with significant morbidity: for example 1 in 
10 women who survive cancer face premature ovarian insufficiency (POI) and sterility at a 
very early age before they have had children5,6. With the increasing awareness of patients, 
guardians and clinicians on the reproductive and endocrine disrupting effects of 
chemotherapies, there is an increasing need and demand to thoroughly discuss these issues with 
patients and offer them satisfactory fertility preserving treatments prior to commencing the 
chemotherapy/radiotherapy7.  
Currently, there are several well established fertility preservation options in females which are 
highly dependent on the physiologic age of the female8,9. Firstly, post-menarchial girls or post-
pubertal adults can be offered in vitro fertilization (IVF) for either embryo or oocyte 
cryopreservation.  The main advantage of this fertility preservation modality is that it is an 
established technology and is in routine clinical use in IVF units throughout the world on a 
daily basis. The major drawback of this option is the need for almost two weeks of hormonal 
stimulation followed by egg collection with their inherent side effects and complications. In 
addition, it is a relatively expensive treatment and not routinely NHS funded  which adds to 
the difficulties these patients endure. Furthermore, only a limited numbers of embryos/oocytes 
can be stored from a single or couple of stimulation cycles.  Secondly, a less common modality 
and less effective option is in vitro maturation (IVM) followed by embryo or oocyte 
vitrification10.  The main advantage of this technique is that patients do not need ovarian 
stimulation and its related adverse effects and complications, especially ovarian 
hyperstimulation syndrome OHSS. Thirdly, ovarian suppression by monthly injections of 
GnRH analogues is occasionally prescribed prior to commencement of chemotherapy. Its 
efficiency in fertility preservation is still controversial and its use should be offered only in 
well-designed research-based experimental protocols11. Fourthly, fixation of ovaries 
(Oophoropexy) outside the pelvic radiotherapy field may be appropriate in a small   subgroup 
of patients who need to undergo pelvic brachytherapy or radiotherapy where it is possible to 
mobilise the ovary and move it  without compromise to ovarian blood supply. Success of 
oophoropexy is very variable12. 
 
Ovarian tissue cryopreservation is an emerging fertility preservation technology that 
involves the procurement of ovarian tissue either as ovarian cortical biopsies or unilateral 
oophorectomy, followed by processing of this tissue into  small slices and cryogenic freezing 
in a controlled freezing programme.  Laparoscopy is usually performed to procure ovarian 
tissue either by unilateral oophorectomy or ovarian biopsies. Following the patient’s recovery 
from cancer treatment and when they are ready to start a family, if they have developed POI 
(Premature Ovarian Insufficiency), the ovarian tissue can be thawed out and autotransplanted 
to the patient. Once blood supply is reestablished and tissue proves viable, folliculogenesis is 
resumed with restoration of natural fertility and endocrine ovarian activity.  The tissue is 
commonly transplanted in or near its natural site, such as the ovarian hilum, ovarian medulla, 
broad ligament or the pelvic sidewall (orthotopic transplantation).  This has been shown to 
offer the potential for spontaneous pregnancy as eggs are left in their physiologic environment, 
in the proximity of the fallopian tubes, thus obviating the need for IVF treatment2,11,13-14. 
Alternatively, heterotopic transplantation which involves auto-transplantation of ovarian tissue 
into non-native ectopic locations such as the arm or abdomen has also been attempted15,16. 
Heterotopic transplantation has certain advantages such as an easier approach for follicular 
monitoring and egg retrieval for IVF, but, this approach is less commonly utilized.  Orthotopic 
transplantation has been reported to result in more effective revascularization and less follicle 
loss and consequently is believed to be more effective17,18. Orthotopic autotransplantation is 
performed either by laparotomy or laparoscopy.  Several ovarian cortical slices are thawed out 
and then either sutured to the remaining ovary or left unsutured placed into a peritoneal 
window. To date, more than 100 pregnancies  have been reported after autotransplantation of 
ovarian cortical tissue slices mainly after orthotopic approach17,18. Published reports indicate a 
time interval of 3.5 to 6.5 months after the autografting before endocrine function is restored 
(ie decreasing FSH levels) or folliculogenesis are detected. Ovarian endocrine activity was 
observed in over 95% of patients after autografting19.  The post-transplantation pregnancies 
reported thus far included natural conceptions, ovulation induction cycles and IVF cycles.   
Ovarian tissue grafts have been reported to maintain endocrine function for up to 10 years20 
and is mainly dependent on the ovarian reserve before the harvesting, the absence of 
chemotherapy before cryopreservation and the degree of ischemia after re-implantation21. 
These promising results strongly suggest that Ovarian Tissue Cryopreservation (OTCP) is a 
viable fertility preservation option that should be part of any oncofertility programme. 
 OTCP is the only available fertility preservation approach for 
premenarchial/prepubertal girls and for adults who need to promptly start their 
chemo/radiotherapy and who cannot undergo an IVF cycle and delay their cancer treatment for 
3-4 weeks. OTCP can be performed immediately without any delay, as no hormonal 
stimulation is needed, and in children and young adults potentially thousands of follicles exist 
in each small cortical slice, thus conferring a quantitative advantage. In this report we present 
our collaborative results and discuss the diverse challenges encountered during the 
establishment of the first OTCP service in England including the medical, scientific, 
legal/regulatory and financial ramifications. 
 




Following approval from the Human Tissue Authority (HTA), the Human Fertilization 
and Embryology Authority (HFEA) and the new Technologies Advisory Group at Oxford 
University Hospitals NHS Foundation Trust (OUHFT), we commenced recruitment of suitable 
patients. Patients were largely referred by their treating oncologists and acceptance for ovarian 
tissue cryopreservation, was accessed on clinical information and by reference to the service 
eligibility criteria as  listed in the PPD (Preparation Process Dossier) which was submitted to 
the HTA. Once the indication for OTCP was established, informed consent was obtained.  For 
minors under the age of 18 years, parents or guardians were required to sign a written consent 
form. Patients are routinely screened for mandatory viral serologic screening tests including 






Our ovarian tissue cryopreservation programme eligibility criteria were:  
1. Female patients aged between 12 months – 40 years who are unable to have egg/embryo 
storage and who are at significant/high risk of POI. Later, the age range was redefined 
to 0-35 years, as no live births have been reported in tissue collected from women over 
35 years. 
2. Prognosis – curative treatment intent and OTCP procedure possible without an 
unacceptable delay to definitive treatment i.e. within 7 days of referral. 
3. Patients unable to store eggs/embryos 
4. Patient fit enough to undergo general anaesthetic and surgery. 
 The lead consultant for OTCP reviewed all referrals. Complex referrals or cases that fell 
outside the referral criteria are discussed at the monthly OTCP (MDT) board meeting which 
was held on a regular basis or virtually when an urgent response was needed. The MDT was 
comprised of a paediatric oncology consultant, paediatric and reproductive surgeons, an IVF 
specialist, consultant ethicist when needed, the Person Responsible for the HTA and 
Designated Individual for the HFEA license for the service and University researchers. The 
MDT , oversees the scientific, clinical, financial and research management of the programme.  
The referred patients’ chemotherapeutic protocols and irradiation programmes were carefully 
studied in order to estimate the gonadotoxicity of the planned treatment. This risk 
quantification was based on the best evidence as reflected in the most up to date pertinent 
literature. In addition, a subgroup of females who had non-malignant conditions that put them 
at risk of  POI, i.e. a family history of POI or autoimmune diseases requiring high dose 
cytotoxic treatment or patients requiring Bone Marrow Transplantation for benign 
haematological diseases such as thalassemia major, were added to the indications as the 
programme developed. This board was set up as part of the detailed HTA license extension and 
the Preparation Process Dossier (PPD) submission. 
Following each patient referral, a mandatory thorough pre-treatment consultation by at least 
one OTCP consultant was performed.  
 
Tissue Collection, processing and storage: 
 
Ovarian tissue harvesting: 
Ovarian cortical tissue procurement was done after the consenting process. In preference, it 
was performed as a laparoscopic procedure under general anaesthesia. If open surgery was 
planned for the patient, ovarian biopsies or oophorectomy were performed at the time of the 
planned surgery. In order to save the patient to needlessly undergo an additional general 
anaesthesic, the ovarian harvesting procedure was combined where possible with other elective 
procedures: e.g. the insertion of Hickman catheter prior to starting chemotherapy. Unilateral 
oophorectomy was commonly performed in order to ensure an adequate amount of tissue was 
taken and to reduce the risk of post-operative bleeding. Alternatively, ovarian biopsies were 
taken with laparoscopic scissors. The surgeon decided whether to perform a unilateral 
oophorectomy or less commonly resect several 15mm long and 5mm wide cortical strips from 
each ovary. Any resultant bleeding was best controlled with small, precise bipolar diathermy. 
As excessive use of diathermy might cause thermal damage to the ovarian tissue, it was 
important to minimize the use of diathermy in the proximity of the ovary. In addition, the 
surgeon must gently handle the tissue and refrain from any untoward trauma to the ovarian 
tissue and to promptly extract the tissue and aseptically transfer directly into sterile cooled 
transport fluid in a labelled container held by the Oxford Cell and Tissue Bank’s (OCTB) 
technician attending.  
 
Tissue Processing and storage: 
 
After procurement, packaging and labeling the ovary or biopsies were transported from the 
operating theatre to the OCTB licensed cleanroom facility by the OCTB attending technician 
in cooled transport media. For tertiary sites the tissue was transferred within 6 hours to the 
OCTB. The laboratory protocols for the processing and storage of ovarian tissue are essentially 
as has been described elsewhere in detail22,13.  In keeping with the requirements of the HTA 
Licence the tissue was processed in the grade A processing suite according to the protocol 
detailed in the PPD22. A slow freeze protocol was adopted to satisfy the HTA regulations  and 
because most live births have been reported in programmes using this technique13. 
 
Supraregional referrals and third party contracts: 
 
In the first phase of the programme referrals were from patients within the Oxford and 
Thames Valley cancer networks. As the programme matured, increasing number of cases were 
referred from outside the local catchment area. Initially all cases had surgery in Oxford but 
more latterly we developed a ‘hub and spoke’ model whereby patients could have surgery at 
their local hospital with samples being couriered to Oxford for processing and storage. This 
arrangement required HTA approval and the development of third party agreements  with each 
‘spoke.   A “Third Party Agreement” (TPA) confirming roles and responsibilities for each party 
involved is mandatory to ensure that the statutory and regulatory requirements for procurement 
of ovarian tissue are met, and was put in place.  
 
Database development 
A digital database was developed onto which  all patients  were registered upon 
acceptance of referral. It included epidemiological, clinical, surgical information obtained 
from referring consultants, medical and surgical records. The tissue procurement, processing 
and testing details were also recorded. This also allowed capturing and recording of all 





Our goal from the current report is to prove the feasibility of introducing OTCP as a 
fertility preservation modality in a well-defined range of indications. Prior to the launch of 
the Oxford Service, ovarian tissue cryopreservation was only available in the UK as part of a 
research programme running in Scotland. However, with the increasing evidence concerning 
its efficacy, including ever growing numbers of livebirths worldwide, we believe this 
technology should be made available as an experimental medicine, clinical service for 
patients at high risk of infertility who were unable to store eggs and embryos. In the present 





During the first three years of patients enrolment to the programme, 100 patients were 
referred for ovarian tissue cryopreservation. At the time of processing the data from the first 
100 patients , five patients were not offered tissue collection as they did not fulfill eligibility 
criteria, 5 patients or their families declined tissue collection after the initial consultation and 
4 patients were still awaiting surgery. The results from the 86 patients undergoing tissue 
collection in the first 3 years of the programme are included in this paper.  
The majority of patients (n=82) were operated in OUHFT either by a gynaecologic surgeon at 
the Women’s Centre at the John Radcliffe Hospital (n=24) or by a Paediatric surgeon, Oxford 
Children Hospital (n=57), with one patient operated by gynae-oncologist at Churchill 
Hospital in Oxford. Four patients, were operated in other supraregional hospitals and the 
tissue was transferred to OCTB within 6 hours, with three of them operated by gynae-
oncologist and one operated by a general surgeon. 
The majority of the operations were done laparoscopically (n=81) and the rest (n=5) where 
done in an open approach whilst patients were having open procedures to treat their primary 
disease.   
 
Ages: 
The majority of the recruited patients were paediatric and adolescents patients (up to but not 
including 19th birthday) (n= 60, 69.8%) and  26 patients (n=26, 30.2%) were adult 









The majority of the patients who had their ovarian tissue cryopreserved were 
oncological patients (n=74, 86%) and the rest (n=12, 12%) underwent the procedure as they 
were having bone marrow transplant and therefore high dose conditioning treatment to cure 
their underlying  benign disease. All patients were at high risk of POI due to chemotherapy or 
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Malignant diseases: 
Of the first 100 referred patients, the vast majority were patients diagnosed with 
malignancies, while the rest were referred due to benign diagnosis before the commencement 
of cytotoxic treatment.  
In the current series, 74 patients underwent ovarian tissue cryopreservation for malignant 
disease that posed the at high risk of POI, (see Fig. 2). Haematologic malignancies  
constituted the main indication (47.3%, n=35) and included: relapsed/resistant Leukemias , 
high risk Hodgkin’s Lymphomas and non-Hodgkin Lymphoma. The second main indication 
was Sarcomas ( 32.4%, n=24). Other indications included CNS tumors (5.4%, n=4), 
Borderline ovarian tumor (BOT)and early stage ovarian cancer (5.4%, n=4), Breast 
carcinoma (n=1, 1.4%), Colorectal carcinoma (1.4%, n=1), Peritoneal papillary serous 
adenocarcinoma (1.4%, n=1), Nasopharengeal carcinoma (1.4%, n=1), Wilm’s tumor (1.4%, 
n=1), mixed ovarian teratoma (1.4%, n=1), Synovial carcinoma (1%, n=1). 
 
Figure 2. Pie chart showing the different underlying diagnoses of participant patients and 




Ovarian tissue cryopreservation prior to BMT for benign disease was undertaken in 12 
patients and constituted 14% of all patients. The diagnostic categories were sickle cell anemia 
before bone marrow transplantation (41.8%, n=5). Other indications included: Beta 
Thalassemia major prior to bone marrow transplantation (25%, n=3), Autosomal recessive 
chronic granulomatous disease prior to bone marrow transplantation (8.3%, n=1), NMDA 
receptor encephalitis (8.3%, n=1), Blepharophimosis, ptosis, and epicanthus inversus 

















Malignant Disease n = 74
 
Figure 3. Patients who underwent ovarian cryopreservation for benign indications 





Laparoscopy was the main and preferred operative approach applied to harvest ovarian tissue 
(n=81) whilst the rest (n=5) had open surgery performed for the planned definitive surgery 
for the cancer treatment. All procedures were uneventful. In one patient a surgical wound 






We report on the establishment of the first children and young adult fertility 
preservation programme in England and the outcomes of the first three years since its advent 
and development. Up to the launch of the service at Oxford University Hospitals NHS 
Foundation Trust and offering this as a clinical application, OTCP was only available as part 
of a research programme in Edinburgh23. Following the worldwide reporting of successful 
outcomes of ovarian tissue autografting24, we designed a stepwise scheme that included 
initially a regional and then a countrywide service that could be applied within a clinical setting, 
in addition to starting different research programmes to advance the technology and address 




  We report our series of 86 patients undergoing OTCP who fulfilled the strict inclusion 
criteria. Initially the majority of patients were regional referrals. As the programme became 
more established, we developed a countrywide framework to respond to the growing interest 
and need from extra-regional trusts.  
The indication for ovarian tissue cryopreservation was restricted to patients at high risk 
for POI. Initially the hematological indications constituted the main group (47.3%, n=35), 
whereby relapsed and resistant Leukemias were the  most common, followed by high risk 
Hodgkin’s Lymphomas and non-Hodgkin Lymphomas. The second main indication was 
Sarcomas (32.4%, n=24). These indications and the other less common indications are 
presented in the pie chart in fig 2, and are a direct reflection of the common cancers in the 
paediatric, adolescent and young adults. This population of patients enrolled in the current 
report may change in future as patients awareness of the service increases and as oncologists 
and other care providers allocate more time and resources to fertility preservation for young 
patients. Other series showed a similar spectrum of indications with haematological indications 
being one of the main indications25. Similarly sarcomas were also common as an indication of 
ovarian tissue preservation26. Sarcoma patients are at high risk of early infertility due to the 
gonadatoxic chemotherapy they receive , as with any children and young adult patients even if 
they are old enough to store eggs they cannot delay start of treatment for several weeks. 
Of note, only one of our patients had breast cancer, in contrast to several other studies 
who reported varying numbers of breast cancer patients undergoing ovarian tissue 
cryopreservation26. This could be partially explained by different fertility preservation 
approaches in different countries for patients with breast cancer. Concern on the safety of 
ovarian stimulation in the context of IVF treatment for fertility preservation, especially in the 
presence of hormone receptor positive breast tumors remains. Consequently, while some 
fertility preservation programmes prefer OTCP for such patients, others, including our fertility 
preservation programme in Oxford, believe that there is insufficient evidence to suggest 
prognosis-aggravation of a single IVF cycle for fertility preservation. As breast carcinoma is 
primarily  an adulthood tumor, these patients are offered an IVF as their first best option. 
As the programme progressed, more patients with benign indications were offered 
OTCP including benign haematological conditions prior to BMT and autoimmune conditions 
that require high doses of gonadotoxic chemotherapies. We anticipate this section of 
indications to increase in the future. One patient with BPES syndrome, a genetic condition 
associated with high risk of POI, was offered to undergo the procedure in an anticipation of 
looming future gonadal failure. This genuinely opens up a new horizon of fertility preservation 
for a wide range of genetic and chromosomal conditions known to predispose to early ovarian 
failure. 
 
The success in setting up OTCP service in Oxford University Hospitals Trust, despite 
the lack of central governmental funding, sets a fascinating example of the ability of the 
medical community backed by charities and the private sector to initiate a change in health 
care. This is of critical importance especially as the main population is the paediatric and 
adolescent population, who are essentially dependent on their guardians, families and 
professional health carers. With the advancement of the programme locally, the service was 
opened to referrals from all over the UK, as will be discussed in more details below.  
The emergence of this ever evolving fertility preservation technology, has necessarily 
met medical, financial and regulatory challenges that needed to be settled in order to run the 
programme. 
 
Establishing a tissue bank: 
 
One of the first challenges was to find a facility to bank ovarian tissue fulfilling for all 
licensable activity’s regulations associated with human tissue cryopreservation. The HTA is 
the competent authority in the UK to monitor compliance of tissue banks with the Quality 
and Safety (Q and S) regulations transposing the European Union Tissue and Cells Directives 
(EUTCD’s). A clean room, filtered and pressurized with high-efficiency particulate air 
(HEPA), is required, which must be continuously monitored to meeting environmental 
requirements as set out in Q & S regulations, and detailed in the Rules and guidance for 
pharmaceutical manufacturers and distributors. One option was to house the bank at the 
Oxford Fertility Unit but environmental monitoring requirements for processing of gametes 
in the UK do not stipulate use of cleanroom facility. IVF units therefore do not meet 
requirements set out in Q&S regulations. The second option was to request an HTA licensed 
tissue bank processing tissue for human transplantation within OUHFT to complete all 
required processes in order to submit an application to extend their licence to include ovarian 
tissue banking. We were fortunate that the Oxford Heart Valve Bank (OVHB) was already 
operating within OUHFT with experienced scientific and technical staff and they had all the 
necessary equipment, clean rooms and storage facilities and agreed to apply to take on this 
additional tissue cryopreservation service. Later on, the tissue bank also submitted an 
application to further extend the OVHB licence to include immature testicular tissue 
cryopreservation.     
 
                         
HTA and HFEA  
Understanding the current legal and regulatory status of ovarian tissue banking was of 
most importance at the early stages of service building. The regulatory complexity of OTCP 
stems from the fact that it consists of  tissue preservation with the ultimate purpose  to create 
gametes in the future. Henceforth, regulation of OTCP fell within the scope of both authorities, 
HTA and HFEA and tissue banks preserving ovarian tissue initially required licenses by both 
authorities. However, HFEA and HTA later published a joint statement confirming HTA 
license was sufficient for preserving ovarian tissue27. A tissue bank must first submit a dossier 
to the HTA before it can apply for a licence to store a new tissue type. A review of all published 
methods for ovarian tissue preservation was thoroughly done, together with direct collaboration 
with successful existing ovarian tissue programmes13,23. The Standard operating policies and 
procedures for tissue processing and cryopreservation were validated using porcine ovaries. A 
slow freeze protocol was adopted for freezing, as most programmes reporting live births have 
used this technique. Post-thaw tissue morphology demonstrated preservation of ovarian 
follicles. OCTB also repeated post thaw assessment following cryopreservation for the first 
three human ovarian tissue samples. After meticulous validation of our protocols,  
demonstration of  full compliance with UK requirements for ovarian tissue licensable activities, 
compliance with the requirements for gametes, and on-site inspection we were awarded an 
HFEA Licence in July 2013, followed by the initial conditional authorization to extend HTA 
licence for OTCP. 
 
TAG approval for experimental medicine procedure: 
Approval also had to be sought from the OUHFT Technologies Advisory Group 
(TAG), a committee responsible for conducting an independent appraisal of all proposed new 
technologies or procedures introduced into routine clinical practice or within an experimental 
medicine programme with the exception of drugs, which are addressed in a separate forum.  In 
the context of the TAG committee, the term experimental medicine refers to any new 
technology/procedure be introduced to ‘demonstrate proof-of-concept evidence for the validity 
and importance of new discoveries or treatments’.  TAG, which reports to the OUHFT Clinical 
Governance Committee, evaluates proposals in terms of patient safety, clinical effectiveness, 
staff training and competency, service improvement and the impact on other clinical areas. It 
does not consider the cost of new technologies/procedures, nor how they are funded. 
 
Service Funding: 
Despite 2007 NICE guidelines indicating the need of developing ovarian tissue 
cryopreservation (OTCP) for paediatric and premenarcheal females, albeit in a research based 
framework, this recommendation was not adopted by the NHS and no public funding was 
available to start the service28. The fact that at the time of launching the service,  OTCP was 
not included in the NICE  Fertility guidelines , was a major hurdle as Clinical Commissioning 
Groups had no requirement to fund the service and money was not available to fund set up. 
Supported by the increasing evidence of the efficacy of the technology, we decided to resort to 
charities to fund the introduction of the OTCP service in Oxford University Hospitals, where 
all needed biomedical disciplines coexisted, and started a well orchestrated multidisciplinary 
collaboration. The presence of an existing  tissue bank facility with equipment and staff able 
to take on this extension of service was instrumental to reduce the costs and enable its launch.  
The current report is the culmination of a comprehensive collaboration between the University 
of Oxford, Nuffield Department of Obstetrics and Gynaecology, the Oxford University 
Hospitals NHS Foundation Trust, the Oxford Fertility Unit, the Oxford Cell and Tissue 
Biobank; the Department of bioprocessing and tissue bioengineering, Oxford University; the 
Department of Pathology, the Paediatric surgery and haemato-oncology departments at Oxford 
Children Hospital. As the programme expanded to patients from outside Oxford , those external 
referrals were done in a third party scheme at their local hospitals. 
 
 
Patients pathways and criteria: 
 We decided to recruit patients with  high (>80%) risk for POI undertaking 
chemotherapeutic protocols and irradiation regimens, based on the most uptodate pertinent 
literature. The inclusion criteria for oncologic patients are summarized in the methods section. 
As the programme develops and clinical data become available, we believe that ovarian tissue 
cryopreservation will be increasingly offered to patients with non-malignant diseases such as 
females at risk of POI: i.e. Turner syndrome, family history of premature ovarian insufficiency, 
benign autoimmune diseases requiring gonadotoxic chemotherapy or patients needing bone 
marrow transplantation for benign haematological diseases such as sickle cell anemia and 
thalassemia major.  
 
Third party agreements: 
In order to accommodate supraregional referrals we offered two options. The first 
option is to arrange for the patients to travel to OUH for their tissue procurement. The consent 
interview for tissue storage is then performed by the OUH OTCP lead consultants, the surgery 
by OUH trained surgeons and the tissue collected and transported and processed by the OCTB 
technical staff. The alternative service that we offer is to extend the OCTB HTA license to 
enable procurement at the patients local hospital. This involves OCTB working closely with 
HTA to address the technical challenges and to secure collaboration with the hospitals 
operating theatres and with surgeons who will procure the tissue. Consent is taken by the OUH 
OTCP consultant, one of the OCTB technical staff attends the procurement, packages and 
transports the tissue back to OUH for processing. This also involved   basic training of the 
procurement surgeons. The tissue processing is done  at OCTB  within 6 hours of procurement, 
although there is evidence from other international programmes that tissue may be successfully 
cryopreserved up to 24 hours afterwards . With these schemes, we are able to provide a service 
for patient referrals from all areas of England . These supraregional referrals are assisted either 
by the charitable funds which cover the processing and storage of the tissue or are privately 
funded as a last resort. Following the relative success of applying this technique at OUHFT, 
together with the heightened awareness of patients, their families, oncologists and health care 
providers and trusts, we hope to be able to secure funds to continue this service. 
 
Centralizing service and data 
As the programme aims at addressing and providing for the clinical need of OTCP 
services for oncological patients across England a website has been launched to aid patients, 
guardians and professionals in their pursuit to access our ovarian tissue preservation 
programme. Up to date information concerning the fertility preservation programme is 
provided for patients, together with clear referral system for healthcare professionals. With the 
increasing rate of referrals and procurement procedures done, it will probably be inevitably 
important to produce a centralized database of all ovarian tissue preservation procedures and 
autografting done throughout the UK.   
 
In summary, in the current report we have shown the feasibility of building up a countrywide 
scheme throughout England, Wales and Northern Ireland for ovarian tissue cryopreservation 
for cancer patients and other non-cancer patients who are at high POI risk. The introduction of 
this innovative fertility preservation technology, presented a wide range of scientific, medical, 
regulatory and financial challenges. Our scheme comprises of either direct referrals to OUHFT 
or by third party agreements with other regional hospitals, builds the foundations for offering 
this technology to all patients requiring the service from all over England, Wales and Northern 
Ireland. Future translational research projects will have pivotal importance to continue the 
development of this technique and answer the hitherto unsolved challenges. With the 
successful establishment and the growth of the clinical OTCP programme in Oxford, we hope 
to envisage and implement complementary basic and translational research projects to continue 




Strengths and Limitations of this study 
• We have demonstrated the feasibility of building up an ovarian tissue bank for cancer 
patients. 
• Our suggested model of either extra regional referral of patients to a tertiary center 
or by third party contracts with regional hospitals, offers flexibility to patients and 
health care providers. 
• Our ‘hub and spoke’  model whereby patients could have surgery at their local 
hospital with samples being couriered to Oxford for processing and storage, can offer 
ovarian tissue cryopreservation to patients from all over the country. 
• The study pertains to the early years of set up and indications and scope of work is 
dynamically changing, as patients and health care professionals awareness of the 
service increases and more time and resources are allocated for fertility preservation 
for young patients. 
• Ovarian tissue cryopreservation is a novel technology and the use of frozen tissue is 






Background: In the recent years, cryopreservation of ovarian tissue has emerged as a 
promising technique for fertility preservation in premenarchal children and adolescents, as well 
as an alternative in adult women prior to starting gonadotoxic chemo/radiotherapy.  The 
prognosis and the survival rates of cancer patients have improved tremendously as a result of 
recent advances in cancer treatment - particularly in childhood cancers - and therefore attention 
is now being directed towards long-term gonadotoxic side effects of chemotherapy or 
radiotherapy. In the current report we aim at exploring the feasibility of establishing ovarian 
tissue banking in a tertiary hospital at John Radcliffe Hospital, Oxford University Hospitals 
trust.  
 
Study population: Ovarian tissue cryopreservation has been offered to premenarchal, 
adolescent and adult females with cancer or benign conditions who were scheduled to get a 
high risk gonadotoxic treatment. The study was performed between August 2013 and July 
2016. 
Methods: In the first phase of the programme referrals were from patients within the Oxford 
and Thames Valley cancer networks. As the programme matured increasing number of cases 
were referred from outside the local catchment area. Initially all cases had surgery in Oxford 
but more latterly we developed a ‘hub and spoke’  model whereby patients could have surgery 
at their local hospital with samples being couriered to Oxford for processing and storage.  In 
this study we present our scheme, methods, results and challenges of establishment of a new 
ovarian tissue bank including medical, scientific and financial ramifications. 
Findings: We report the  series of 86 patients undergoing ovarian tissue preservation 
treatment who fulfilled the strict inclusion criteria. The majority of patients were initially 
regional referrals coming within the Thames Valley Trusts, then as the programme became 
more established, we developed a centralised referral framework to answer growing interest 
and need from extra-regional trusts. Seventy four patients underwent ovarian tissue 
cryopreservation for malignant disease. Haematologic malignancies constituted the main 
indication (47.3%, n=35) and included: Leukemias , Hodgkin’s Lymphomas and non-
Hodgkin Lymphoma. The second main indication was Sarcomas ( 32.4%, n=24). Other 
indications included CNS tumors (5.4%, n=4), Borderline ovarian tumor and early stage 
ovarian cancer (5.4%, n=4), Breast carcinoma (1.4%, n=1), Colorectal carcinoma (1.4%, 
n=1), Peritoneal papillary serous adenocarcinoma (1.4%, n=1), Nasopharengeal carcinoma 
(1.4%, n=1), Wilm’s tumor (1.4%, n=1), mixed ovarian teratoma (1.4%, n=1), Synovial 
carcinoma (1.4%, n=1). Ovarian tissue cryopreservation due to benign diseases was done in 
12 patients and constituted 14% of all patients. The main indication was sickle cell anemia 
patients before bone marrow transplantation prior (41.6%, n=5). Other indications included: 
Beta Thalassemia major prior to bone marrow transplantation (25%, n=3), autosomal 
recessive chronic granulomatous disease (8.3%, n=1), NMDA receptor encephalitis (8.3%, 
n=1), Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) (8.3%, n=1). 
 
Interpretation: In the current report we have shown the feasibility of building up an ovarian 
tissue cryopreservation bank for cancer patients. Our suggested scheme of either extra regional 
referrals to our ovarian tissue bank at John Radcliffe Hospital or by third party contracts with  
regional hospitals, build the foundations for offering this technology to all patients requiring 
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ABSTRACT: Turner’s syndrome (TS) is the most common sex chromosome abnormality in women. In addition to short stature and gonadal
dysgenesis, it is associated with cardiac and renal anomalies. Due to rapid follicular atresia, the majority of women with TS suffer from primary
ovarian insufficiency around puberty. Thus far, donor oocyte conception has been the key fertility option for these women. With advancing
technology, ovarian tissue cryopreservation (OTCP) has emerged as a clinically justifiable option especially for pre-pubertal girls with cancer.
Recently published results following the use of cryopreserved ovarian tissue are reassuring. It would be prudent to consider the extension of
these technological and scientific advances to other conditions, such as TS, where accelerated follicular atresia is suspected. It is possible to
obtain competent oocytes from cryopreserved ovaries of girls with TS provided the ovaries were preserved before ovarian failure. However,
it is a complex decision whether and when to offer OTCP as a fertility preservation (FP) option for girls with TS. The rate of decline in fertility
is variable in girls with TS and can be more complex in cases with mosaicism. On the other hand, OTCP has shown some promising results
in patients with cancer, which can potentially be replicated in TS and other benign indications of patients at risk of premature ovarian failure.
There are proven psychological and clinical benefits of FP. Thus, an argument could be made for offering OTCP to these patients to endow
these girls with the option of having biological fertility using this innovative technology. Ethical, clinical and psychological dilemmas should be
considered, discussed and addressed before considering such a novel approach. We believe that the time has come to start this discussion and
open this avenue of FP for girls with TS.
Key words: Turner’s syndrome / ovarian tissue cryopreservation / IVF / fertility preservation / premature ovarian failure
Introduction
Turner’s syndrome (TS) is the most common sex chromosome abnor-
mality of human females with an incidence of approximately 1 in 2000
female live births (Gravholt et al., 2017). Short stature and gonadal dys-
genesis are two of the characteristic clinical features of the syndrome,
together with a broad range of other phenotypic characteristics, which
include an increased risk for heart and renal defects (Ford et al., 1959).
The range of morbidities associated with the syndrome can have a
profound effect on quality of life. Infertility and short stature are major
concerns for women diagnosed with TS, influencing their psychosocial
development (Sylven et al., 1991). Growth hormone treatment at a




































all height, as compared to untreated girls (Baxter et al., 2007). Conse-
quently, oestrogen replacement and fertility treatment are currently
the mainstay of their endocrine management. A spontaneous puberty
occurs in 5–10% of girls with TS, but only 2–5% reaches menarche
with the possibility of achieving pregnancy (Hovatta, 1999). A recent
study showed an overall 5.6% (27/480) prevalence of spontaneous
pregnancies in women with TS. Most of these pregnancies occurred
in women with mosaic TS and only 0.4% (2/480) spontaneous preg-
nancies were reported in women with a non-mosaic (X0) karyotype
(Bernard et al., 2016). Due to the accelerated follicular atresia seen
in TS patients, the majority of adolescent girls undergo ovarian failure
prior to or around the time of puberty (Modi et al., 2003). Traditionally,
donor oocyte conception has been the predominant fertility option
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for such patients. Donor oocyte conception has its own limitations
including various pregnancy complications (Jeve et al., 2016), difficulty
in obtaining a suitable donor and psychological issues associated with
the process (Bracewell-Milnes et al., 2016). Although technologically
acquired parenthood may add a highly-desired dimension to their social
identities, a sense of loss could persist in most of the women’s personal
identities (Hallebone, 1991). With recent technological advancements,
fertility preservation (FP) may be successfully achieved using oocyte
cryopreservation for pubertal girls and ovarian tissue cryopreservation
(OTCP) for pre-pubertal girls (Grynberg et al., 2016). Although the
exponential development of technology in the past few decades has
led to promising results in the field of FP with OTCP, there are many
unanswered questions about the clinical use of OTCP in TS patients.
The purpose of this article is to examine the current and likely future
status of OTCP for girls with TS.
Biological mechanism of follicular atresia
In TS ovaries, the premature ovarian failure is believed to be the
result of follicular depletion. The mechanism and onset of follicular
depletion has been widely studied in literature. Follicular atresia is a
highly orchestrated and periodic process that results in destruction
and elimination of follicles and oocytes from the ovary. Apoptosis is
recognized as a key factor in atresia of antral follicles (Tilly et al., 1991)
and is carried out by several molecular pathways, including mainly the
B-cell lymphoma (Bcl-2) family, tumour necrosis factor (TNF), cas-
pases and transforming growth factor beta-β proteins (Hussein, 2005).
Apoptosis is regulated by genes such as Bcl-2 (pro-survival), Bax (pro-
apoptotic) and cellular myelocytomatosis (c-Myc), which are expressed
in granulosa cells of both foetal and adult ovaries, suggesting their
possible role in atresia (Nandedkar and Dharma, 2001). The ovarian
microenvironment and the interplay between pro-apoptotic and anti-
apoptotic molecules play a significant role in folliculogenesis. Apoptosis
was studied by terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labelling (TUNEL) in human foetal ovaries (Modi et al., 2003).
TUNEL analysis of the TS (45X) ovaries revealed massive apoptosis
of the oocytes. It was concluded that chromosomal defects, by some
means, accelerates apoptosis that probably leads to gonadal dysgenesis
later in life.
The unique chromosomal mark-up in TS is the presence of only
one copy of the X chromosome. However, in 46 XX females, one
copy of the X chromosomes is inactivated to achieve a balanced gene
expression dosage between males (XY) and females (XX) (Berletch et
al., 2011). Therefore, logically, the absence of one sex chromosome
would not be predicted to have any deleterious effect. Nevertheless,
this X inactivation is incomplete in persons with a normal karyotype;
15% of the genes on the silenced X chromosome escape inactivation
and are expressed from both chromosomes (Berletch et al., 2011).
Abnormalities associated with TS are thought to be caused by hap-
loinsufficiency of genes that are normally expressed by both X chro-
mosomes. Haploinsufficiency of multiple genes on both arms of the
X chromosome (both X chromosomes remain active in germ cells), in
addition to pairing failure during meiosis, leads to gonadal dysgenesis in
TS (Davenport, 2010). X-linked inhibitor of apoptosis protein is one of
the key intracellular pro-survival proteins and an intracellular modulator
of the TNF-alpha death signalling pathway in granulosa cells (Xiao et al.,































































































































bone morphogenetic protein 15 (BMP15) as a critical signal promoting
the growth and differentiation of ovarian follicles, and its action is
intrinsically linked to oocyte-derived growth and differentiation factor
9 (GDF9). Alternations in the BMP15 and GDF9 genes are associated
with different ovarian phenotypic abnormalities (Rossetti et al., 2014).
The process of accelerated apoptosis in the aneuploid gonad starts
already in foetal life (Modi et al., 2003) and continues throughout
childhood; therefore, most of the girls with TS fail to achieve the
spontaneous puberty. The overall incidence of spontaneous puberty in
TS is reported to be 5–10% (Pasquino et al., 1997). Therefore, it would
be sensible to discuss options of FP before accelerated apoptosis leaves
no follicles in the ovaries.
Current status of FP through OTCP
The first case of FP using OTCP, in a young woman with mosaic TS,
was reported in 2008 (Huang et al., 2008). It was proposed more
than 10 years ago that the combination of ovarian tissue cryobanking
and immature oocyte collection from the tissue followed by IVM
and vitrification of matured oocytes represents a promising approach
of FP for young women with mosaic TS. OTCP protocols and the
evidence supporting its use are derived mainly from patients with
cancer. OTCP involves laparoscopic removal of ovarian tissue. To
obtain the best results for cryopreservation, it is beneficial to remove
the ovarian cortex from the medulla, which helps extreme penetration
of cryoprotectants into the cortical tissue (Fathi et al., 2011). As
ovarian reserve is already low in girls with TS, the recommendation is
to remove as much tissue as possible, typically an entire ovary (Oktay
et al., 2016). This is followed by making small strips of ovarian tissue to
allow the cryoprotectants to penetrate the tissue. Slow freezing in liquid
nitrogen has been the main procedure for preserving the ovarian tissue
(Silber, 2012). The standard protocol for ovarian cryopreservation
is slow programmed freezing, using human serum albumin-containing
medium and propanediol, dimethylsulphoxide or ethylene glycol as a
cryoprotectant, combined with sucrose (Hovatta, 2005). When the
woman is ready to attempt pregnancy, autotransplantation of the
thawed pieces of ovarian tissues is performed. Autotransplantation
of the ovarian tissue can be performed in the ovarian fossae beneath
the pelvic peritoneum (Oktay and Karlikaya, 2000; Pacheco and Oktay,
2017). The first live birth after orthotopic autotransplantation of cry-
opreserved ovarian tissue was reported in 2004 (Donnez et al., 2004).
In a recent meta analysis, 85.2% of women had restored endocrine
function, a 57.5% (69 of 120) clinical pregnancy rate and a 37.7%
(65 of 172) live birth rate and ongoing pregnancy rate were reported
(Pacheco and Oktay, 2017). This suggests approximately one in three
women attempting the ovarian tissue transplant being able to have
at least one child. This data is mainly derived from OTCP for cancer
patients in different age groups. A recently published retrospective
case-control study of 15 girls and young women aged 5–22 years with
TS showed evidence of follicles in 60% of the biopsies; however, a high
rate of abnormal follicle morphology was noted. The author suggested
that the benefits of OTCP may be limited to a highly selected group of
TS mosaic patients (Mamsen et al., 2019). Cryopreservation of oocytes
or ovarian tissue has been performed experimentally in more than 150
girls and adolescents with TS over the past 16 years (Schleedoorn et
al., 2019). The efficacy is still unknown for this subgroup of patients
due to the lack of follow-up data.
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Figure 1 Fertility preservation (FP) options for girls with Turner’s syndrome (TS). OTCP, ovarian tissue cryopreservation.
OTCP for girls with TS
Age to offer OTCP
The full biological development of ovaries is believed to be complete
during the third trimester of pregnancy; therefore, it is biologically
plausible that the ovarian tissue will be functional regardless of the
age of the child that the tissue was cryopreserved. A confirmation
of this notion was found by the report of the first live birth after an
autograft of ovarian tissue that was cryopreserved before menarche,
which was reported in 2015 (Demeestere et al., 2015). Recently,
84 children and eight ongoing pregnancies were reported following
cryopreserved autologous ovarian tissue transplantation (Pacheco and
Oktay, 2017), which includes adult and paediatric tissues. Chromo-
some abnormalities, such as TS, and trisomy 18 or 21, modify normal
ovarian development by reducing the pool of available follicles and
inhibiting follicular growth (Peters et al., 1978). Unless ovarian tissue








































girls with TS, especially 45X karyotype, may be thus predictably limited
as a result of the accelerated follicular pool depletion. The chance of
restoring fertility is related to the number and quality of follicles existing
within the transplanted cortical tissue (Dolmans et al., 2009). It has
been reported that primordial follicles can be found in ovarian tissue
collected from girls (n = 57) with mosaic and non-mosaic TS up to the
age of 17 years (Borgstrom et al., 2009). OTCP might be the only
option for the paediatric and the pre-adolescent patients. Pre-pubertal
girls with TS who are not timely assessed and considered for OTCP,
could be missing the window of an opportunity for FP using OTCP,
which could result in a TS generation without the real benefit of this
technology. Figure 1 shows our suggested empirical approach for FP
in girls with TS. Clinical decision making for FP is relatively clearer for
pubertal girls with TS as it mainly comprises ovarian stimulation fol-
lowed by oocyte or embryo vitrification. Patients with mosaic or non-
mosaic TS with good ovarian reserve have the opportunity to undergo
or not undergo FP depending on their ovarian reserve markers. There
is a lack of conclusive data on ovarian reserve markers, such as antral
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follicle count or anti-Müullerian hormone (AMH), for young pubertal
girls (Lie Fong et al., 2012). The study evaluating serum AMH as a
marker for ovarian reserve in young girls and adolescents reported that,
as a screening test of premature ovarian failure in TS, the sensitivity and
specificity of AMH <8 pmol/l was 96 and 86%, respectively (Hagen
et al., 2010). Fifty-seven girls with TS aged 8–19.8 years were studied
(Borgstrom et al., 2009). The author concluded that spontaneous
puberty, mosaicism and normal hormone concentrations were signif-
icant but not exclusive prognostic factors for finding follicles in TS
ovaries (Borgstrom et al., 2009). Therefore, the decision should be
based on considerations of the complete clinical picture, desire of the
individual and opinion of the team involved. It is prudent to discuss FP
as soon as possible in both mosaic and non-mosaic TS. The patients
or their parents or guardians should be made aware of all the related
risks, benefits and future chances of fertility before making any decision
for FP, in the best interest of the child. A provision should be made
for supportive counselling for both patients and parents, to aid in
decision making, and multidisciplinary team agreement before a child is
subjected to laparoscopy and oophorectomy for OTCP.
Amount of tissue for OTCP
The amount of tissue to be taken for OTCP is another debatable issue
open for discussion. Currently, there is no consensus on a standard
operative technique for surgical ovarian cortical tissue removal in
adult females, and there are limited published reports of the surgical
approach and outcomes in the paediatric population (Corkum et
al., 2017). Ovaries are often small in girls with TS, and therefore
unilateral oophorectomy would be advantageous to only having several
ovarian strips sampled and would render more tissue for preservation.
In addition, unilateral oophorectomy carries a relatively low risk of
bleeding. Laparoscopic unilateral oophorectomy for OTCP can be
performed safely and as a day case procedure in children (Rowell et al.,
2019). On the other hand, partial ovarian biopsy, with some ovarian
tissue left remaining, offers a potential site for future implantation of
cryopreserved tissue. The evidence evaluated from various age groups
showed that at least 1/2 to
2/3 of the ovary should be taken from
the anti-mesenteric surface of the ovary (Beckmann et al., 2016). It
was found that premenopausal unilateral oophorectomy significantly
reduces the age of menopause by 1.8 years, and patients or their
guardians should be counselled accordingly (Rosendahl et al., 2017).
Partial ovarian cortical biopsy or unilateral oophorectomy could be
planned after careful counselling and an agreed strategy for the OTCP
programme.
Clinical dilemma
Three prominent clinical concerns are debated while offering OTCP for
girls with TS: insufficient evidence for the efficacy of this technology for
TS, safety of women with TS carrying a pregnancy and risk of chro-
mosomal anomalies in children. The current literature has reported
promising results following OTCP and subsequent transplantation of
preserved tissue as a new option of FP. More than 130 births have
been reported worldwide following orthotopic transplantation of cry-
opreserved ovarian tissue (Beckmann et al., 2019). These results are
mainly derived from FP before cancer treatment and largely from adult
patients who had their ovarian tissue cryopreserved during adulthood.





























































































































of 545 patients who had OTCP (mean age ± SD of 22.3 ± 8.8 years)
reported 33% (7 out of 21) live births (Jadoul et al., 2017). A single-
centre study reported on OTCP for 418 girls and adolescents aged
younger than 15 years. Three hundred and thirteen patients had
malignant diseases, and 105 had benign conditions. Recently three
patients had auto-transplantation but no pregnancy has been reported
yet (Poirot et al., 2019). A systematic review evaluating FP options
in women with TS included 67 studies. The efficacy of different FP
options is still unknown due to the lack of follow-up data (Schleedoorn
et al., 2019). Another review reported on 1019 patients undergoing
OTCP with ages ranging from 0.4 to 20.4 years, with 298 aged younger
than 13 years. Eighteen patients underwent auto-transplantation of
thawed ovarian cortical tissue that was cryopreserved before the age
of 21 years, resulting in 10 live births (Corkum et al., 2019). An
update paper on worldwide OTCP activity and on the Danish cohort
reported a total of 93 children born, and 51% pregnancies were
achieved by natural conception. The age range of patients at the time of
OTCP who succeeded in having a live birth or ongoing pregnancy was
9–38 years (Gellert et al., 2018). Fertility outcome including successful
natural or assisted conception for girls with TS who were pre-pubertal
at the time of FP remains limited. This could be due to the fact that
OTCP is a relatively new technology, and the pre-pubertal girls who
had cryopreserved ovarian tissue are not yet ready to start fertility
treatment. Ovarian tissue of girls with TS could be biologically different
from that of girls with cancer, and therefore the success with OTCP
may be different. It may be possible that despite OTCP women with
TS will still have accelerated atresia after implantation of ovarian
tissue. This is especially important for women who are planning natural
conception. There could be a better chance if assisted conception
is planned shortly after autologous implantation, but there is lack of
evidence to support this opinion.
Regardless of whether conception is natural or assisted, using their
own eggs or donated eggs, pregnancies in women with TS carry
higher risks than the general population, mainly due to coexistent
medical morbidities. Potential pregnancy complications are related to
cardiac, renal and other medical conditions. In women with TS, the
risk for aortic dissection or rupture during pregnancy may be 2% or
higher (Practice comittee 2005). Maternal mortality in women with
TS has been reported to be as high as 1–2%, which is 100 times
greater than general population (Grynberg et al., 2016). Therefore,
appropriate pre-pregnancy counselling and screening is recommended
before pregnancies are planned by women with TS. Such a pregnancy
should be managed as a high-risk pregnancy by a multidisciplinary team
(Grynberg et al., 2016). It would be important to put a comprehensive
pregnancy plan in place before embarking on any fertility treatment for
women with TS. These obstetric risks are present irrespective of the
origin of the gametes. Therefore, similar concerns could be debated
for cryopreservation of the patients’ oocytes or for donor eggs. If it is
deemed relatively safe and clinically acceptable to use donor oocytes
for conception for girls with TS, then the option of OTCP does not add
any further risk for pregnancy. Additional increased obstetric risks are
due to the donor origin of the oocytes. Donor oocyte pregnancy acts
as an independent risk factor for pregnancy complications, including
hypertensive disorders (odds ratio (OR), 3.92), small for gestational
age (OR, 1.81) and preterm delivery (OR, 1.31), and these risks could
possibly be eliminated by using autologous oocytes (Jeve et al., 2016).
FP provides an opportunity for future fertility using a patient’s own
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gametes, should it be safe to carry a pregnancy in the future. For
women who are at high risk of carrying a pregnancy because of cardiac
or renal conditions, gestational surrogacy with preserved oocytes
or ovarian tissue could be an option to have their own biological
offspring. There is no conclusive data on the incidence of chromosomal
abnormalities in biological children of women with TS. There is a
possibility of meiotic non-disjunction in the oocytes of women with TS
and chromosomal aberrations have been shown to be more common
in children born after naturally conceived pregnancies (King et al.,
1978; Swapp et al., 1989). It has been suggested that women with TS
should be offered PGD, chorionic villous sampling or amniocentesis if
fertilization of their own oocytes is successful (Karnis et al., 2003). The
clinical dilemma becomes even more multifaceted if future research
potential, such as oogonial stem cells (OSC), in-vitro activation (IVA)
and oocyte–granulosa cell complexes are taken into consideration
(Ghazal, 2013). However, these approaches are presently in their initial
stages. OSC, identified in human ovaries (Kawashima and Kawamura,
2017), have been suggested to have the potential to develop into
oocytes. The TS ovary contains a population of OSCs, but the ovarian
stroma in TS does not support follicle formation. The IVA modality is
based on fragmentation of ovarian tissue to disrupt Hippo signalling,
with or without drug treatment to stimulate Akt signalling and resulting
in IVA of folliculogenesis before autotransplantation (Kawashima and
Kawamura, 2017).
Any clinical dilemma is often balanced on risk versus benefit ratio.
OTCP has been demonstrated as a clinically viable and acceptable
option of FP for children with cancer. We argue to extend its
benefits to benign conditions, such as TS, as an option for future
fertility.
Psychological dilemma
The psychological impact following the diagnosis of genetic condi-
tions such as TS is under-reported. A significant psychological impact
including social, behavioural and educational components is associated
with TS (Saenger et al., 2001). Delayed initiation of sexual activities
and an impaired sense of self-esteem in women with TS has been
reported (McCauley et al., 1986a). Furthermore, it is thought that
women with TS suffer from limited emotional arousal, high tolerance
for adversity, unassertiveness and over compliance (McCauley et al.,
1986b). This is compounded by the reports showing that premature
menopause can impair sexual identity and sexual function along with a
woman’s well-being and achievement of life goals (Graziottin, 2007).
However, it is not clear whether these psychological issues are due
to some underlying genetic or hormonal influence on behaviour or
due to the issues of short stature, physical anomalies and infertility
(Saenger et al., 2001). A study has shown that infertility is the most
frequently cited concern followed closely by short stature, regardless
of age (Sutton et al., 2005). Infertility alone is associated with significant
psychological distress (Lukse and Vacc, 1999). Even for persons who
may have not planned to have children, the threat of infertility can
result in a deep sense of loss and anger. With wider acceptance
of growth hormone treatment, short stature is being successfully
treated. Psychological wellbeing of the girls with TS deserves further
attention beyond hormone treatment. Given the complexity of a TS
diagnosis and the psychosocial impact of the condition, counselling on





























































































































and future adult life needs to be integrated into standard paediatric
endocrinologist care (Culen et al., 2017).
The inability to bear biological children was reported as the most
prevalent and painful challenge endured by most of the adult women
with TS (Sutton et al., 2005). Although the use of donor oocytes has
been a widely used fertility option, evidence is limited on the psycho-
logical issues surrounding donor gamete conception (Bracewell-Milnes
et al., 2016). Child-free living may be a reasonable choice for some
women, but it would be helpful for girls and their parents to hear all
life-plan and family-building options presented in a balanced manner.
Girls in the peri-pubertal age group begin to realize the implication of
TS, including reduced fertility potential. A clear guideline is required
on how, when or what to discuss regarding fertility and potential FP
options; and how to support them to accept their differences and
empower them (Colindres et al., 2016).
The studies on the psychological and emotive effects of FP tech-
niques are still scarce (Laganà et al., 2017). It can be argued that the
primary benefit of OTCP is to promote autonomy by giving them the
hope of having genetically concordant children in the future.
Ethical dilemma
Ethical dilemmas should be tested on the principle pillars of autonomy,
beneficence, justice, non-maleficence and, additionally, confidentiality
and honesty (Das and Sil, 2017). One of the top choices an individual
makes in life is the opportunity to have one’s own children. An
individual’s autonomy of choice, which is an essential foundation of
a free society, should be respected (Carvalho et al., 2017). Unique
ethical issues arise in the paediatric and adolescent population while
applying these ethical principles. The moral and legal recognition of
autonomy is achieved normally with informed consent. However, it
would be difficult to establish autonomy in children in certain age
groups especially when discussing future fertility and childbearing. It is
commonly an easy decision when the child, parents and caring team
agree on the best interest of the child but it would be difficult if
there is a disagreement. The ESHRE Task Force on Ethics and Law
recommended that the child’s decision should be respected if the
child is mature and understands the issues at stake. When the child is
immature, the decision to cryopreserve (or not) may be taken by the
parents or the guardians, unless it poses grave prejudice to the well-
being/welfare of the child. The child’s or adolescent’s opinion should
be sought when they are able to understand the circumstances (de
Carvalho et al., 2017). The importance of preserving the possibility of
having genetically related offspring in the future is generally recognized,
and the parents will have to decide whether this benefit outweighs the
current risk of intervention for their child (ESHRE Task Force on Ethics
and Law, 2004). The decision of FP is complex enough for an adult
deciding for themselves, but parents face additional decisional conflict
and regret when making the decision for their child (Li et al., 2017).
On the principle of beneficence and non-maleficence, meaning risk and
benefit analysis, it is recommended that discussion should include the
potential risks emanating from application of the technique weighed
against the proposed but as yet unproven benefits. It is important to
note that the promising data published so far is derived from the cancer
population and various age groups at the time of cryopreservation. FP
could be justified on medical indications, social grounds and on the
prevention of the biopsychosocial impact of a procreating disability
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(Carvalho et al., 2017). At the same time, the powerful desires for
a biological child should be weighed against the risks of pregnancy
in TS. Such desires may have biological roots, but it is reinforced by
powerful social and cultural expectations about motherhood; these
expectations should be satisfactorily questioned rather than uncritically
accepted. The tissue storage period should be until the age at which it is
considered acceptable for the tissue to be used for the achievement of
a pregnancy, taking into account the welfare of the child and the risks
to the pregnant mother (Carvalho et al., 2017). Further, consensus
on posthumous reproduction is still required. A task force recom-
mended that the parents do not have the right to decide about the
(reproductive) use of the genetic material of their child after his/her
death (ESHRE Task Force on Ethics and Law, 2004). All specialties
present in the caring team (oncologists, paediatricians, reproductive
specialists, psychologists/counsellors) should be heard during decision-
making about the best procedure. Another important ethical aspect
is the question of legal ownership and rights applying to the banked
ovarian tissue. The legislation may vary in different countries or may
be lacking in some countries. Parental consent should not be static
and should be reviewed regularly with increasing involvement of the
child where possible, especially as children become legally competent.
These regulatory issues need to be addressed based on local and
national guidance. Where appropriate, guidance could be requested
from the local medical ethical committee. Although the ESHRE task
force guidance provides a good ethical framework for cryopreserved
ovarian tissue (ESHRE Task Force on Ethics and Law, 2004), there is
a crucial role for a multidisciplinary Ethics Committee to guide clinical
practice in individual circumstances (Voultsos et al., 2016).
Conclusions
Recent evidence has supported OTCP as one of the promising options
for FP. Although there is no convincing evidence on fertility outcome
for girls with TS, further studies are urged to evaluate the efficacy of
OTCP in girls with TS. While waiting for the evidence to accumulate
we feel that it is still important to discuss this option with children and
their family. Current and future rapid development in the pertinent
technologies would allow OTCP to be a successful and widely accepted
method. However, young girls diagnosed with TS are faced with rapidly
reducing fertility potential due to increased follicular depletion and
atresia. Further delay in offering them OTCP may obviate their chances
of FP. It could be argued that OTCP was offered to cancer patients a
while ago despite lack of enough evidence at the time, which now is
shown to be one of the successful methods. Therefore, the discussion
on FP using OTCP for these girls should be started as soon as the
diagnosis is established. When it comes to FP, all treatment options
should be discussed along with their efficacy. Our duty is to fully inform
patients about the various options, including OTCP, and enable them
and their families to make an informed decision based on available
evidence. At some point in their life, this may be their only option to
preserve their fertility. In the present review, we have argued the case
for offering OTCP to girls with TS after a well-informed discussion and
counselling by the relevant multidisciplinary team. A multidisciplinary
team should be actively involved in the decision-making, addressing
all clinical, psychological, legal and ethical aspects while keeping the
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1. SYNOPSIS 
 
Study Title In Vitro Culture and Maturation of Ovarian Tissue and 
Follicles: Follicle Microenvironment Engineering as a tool 
to study folliculogenesis and provide fertility preservation 
Short title Methods of ovarian tissue culturing for fertility preservation  
 
Study Design Bench research using donated human tissue samples 
Study Participants Females aged 6-43 having clinically indicated ovarian tissue 
cryopreservation 
Women aged 18-43 having planned ovarian surgery or sterilisation  
Planned Sample Size Up to 50 
Planned Study Period 5 years 
 Objectives Endpoints 
Primary 
 
To determine a successful in vitro 
culturing system of early stage human 
follicles. 
Number of follicles that survive in 





To identify follicular development and 
maturation using this system. 
To further identify factors involved in 
the in vitro maturation of follicles. 
 
Proteomic, metabolomic and 
genomic studies to determine the 
success of the in vitro culture – 
measured by: 
• The increase in size of the 
follicles 
• Variations in the 
morphology of the follicles 
• Measuring numbers of 
follicles which form an 
antrum and time taken for 
antrum to develop 
• The concentration of 
hormones secreted by the 




CI Chief Investigator 
CRF Case Report Form 
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CTRG Clinical Trials & Research Governance, University of Oxford 
GCP Good Clinical Practice 
GP General Practitioner 
ICF Informed Consent Form 
ICH International Conference of Harmonisation 
IVF In Vitro Fertilisation 
IVM In Vitro Maturation 
NHS National Health Service 
NRES National Research Ethics Service 
OCTE Oxford Centre for Tissue Engineering and Bioprocessing,  Department of Engineering Science, Oxford University 
PI Principal Investigator 
PIL Participant/ Patient Information Leaflet 
R&D NHS Trust R&D Department 
REC Research Ethics Committee 
RGD Three dimensional (3D) scaffold and adhesion motif 
SOP Standard Operating Procedure 
 
3. BACKGROUND AND RATIONALE 
3.1. Overview 
 
For female adolescents and young adults, the increasing probability of surviving a cancer diagnosis 
combined with the expectation and desire for reproductive options following cancer remission has 
fuelled a growing need for fertility sparing techniques.  
Currently there are several methods available to women hoping to preserve their fertility before cancer 
therapy. As it has been used most often, traditional hormone stimulation and in vitro fertilization (IVF) 
followed by embryo cryopreservation is the most successful approach to preserve fertility. More recently 
live births have also been achieved with cryopreserved oocytes harvested before cancer treatment. Both 
methods require a delay in cancer treatment and use hormonal stimulation that might be deleterious in 
some patients. Ovarian tissue cryopreservation followed by autotransplantion is a promising fertility 
preservation approach that can usually be performed immediately without hormonal stimulation. 
Worldwide, a dozen live births have been reported thus far as a result of auto-transplanting 
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frozen/thawed ovarian tissues(Donnez, Silber et al. 2011). Despite these promising findings, 
transplantation of cryopreserved tissue carries the risk of re-introducing cancer cells into the patient. 
Thus, the in vitro maturation (IVM) of immature follicles derived from ovaries collected prior to 
commencement of cancer treatment is an important direction for new fertility preservation approach as 
it avoids the need for auto grafting and prevents the possibility of cancer cells reseeding.  
In this proposal we aim to study and improve the existing early-stage follicle culture protocol by the use 
of three dimensional (3D) scaffold and adhesion motif (RGD). These 3D culture systems can preserve the 
follicle architecture and maintain the cell-cell and cell-matrix signalling lost in two-dimensional attached 
follicle culture systems. Maintaining the follicular structure while monitoring and manipulating the 
hormonal and biochemical environment through the perfusion system will allow the development of 
controllable systems to investigate and improve the biological and molecular processes underlying 
follicle growth and maturation. Advances in our understanding of in vitro culturing and maturation of 
follicles may also be applied to provide a fertility preservation option for women at risk of premature 
ovarian insufficiency as well as facilitating research in folliculogenesis. 
3.2. Fertility Preservation in Cancer Patients 
 
In recent years cryopreservation of human ovarian tissues has emerged as a promising alternative for 
fertility preservation in pre-menarchal and adolescent females, as well as for adult women prior to 
chemo/radiotherapy.  The prognosis and survival rates of cancer patients have improved tremendously 
as a result of recent advances in cancer treatment, particularly in childhood cancers, and attention is 
now being directed towards quality of life and the long-term gonadotoxic side effects of chemotherapy 
or radiotherapy. Given that 1 in 46 females between birth and age 39 are diagnosed with 
cancer(American Cancer Society 2012) many women are potentially affected. The incidence of ovarian 
failure is dependent on the type and dose of chemotherapy agents, and the age of the patient. Currently, 
there are several modalities for fertility preservation for different age groups: 
Post-pubertal women 
Post pubertal women requesting fertility preservation prior to chemotherapy or radiotherapy may be 
offered any of the following options: 
3.2.1. Embryo cryopreservation  
This is currently the only widely accepted and well-established option to preserve fertility, during which 
patients undergo a stimulated IVF cycle with subsequent retrieval of mature oocytes prior to the 
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initiation of chemo/radiotherapy. Harvested oocytes are then fertilized with sperm produced by 
husband, partner or donor, and the resulting embryos are cryopreserved. This technology is in routine 
clinical use in IVF units throughout the world on a daily basis. An evolving newer strategy is obtaining 
immature oocytes in non-stimulated cycle for in vitro maturation of oocytes and subsequent fertilization, 
and embryo freezing.  
The advantages of embryo cryopreservation modality are its worldwide availability and its proven and 
established pregnancy success rates. Disadvantages include the need for hormonal stimulation of 2-4 
weeks (which may defer and delay the anticancer treatment), its costs (£4000-5000), the need for a 
partner/husband or the decision of using donor sperm, and the relatively limited number of embryos 
produced and stored from a single stimulation cycle. It is not a viable option for pre-menarchal or 
adolescent girls, single women unable/unwilling to use donor sperm and women who are unable to 
undergo an in vitro fertilization cycle due to the need to undergo immediate anticancer treatment. In 
addition, the IVF procedure, especially hormonal stimulation, causes discomfort and increases the risk 
for OHSS, ovarian, breast and endometrium cancer, and stroke (Gilchrist et al., 2011). Additionally, there 
are ethical issues regarding embryo storage and usage.  
3.2.2. Oocyte cryopreservation 
 
In this modality, the patient undergoes a stimulated IVF cycle and subsequently the harvested oocytes 
are cryopreserved for later thawing out and fertilization. This technology can be an option for single 
female patients who are not in a stable relationship and not willing to opt for sperm donation. Because 
of the large size and more complex and fragile nature of the oocyte, oocyte freezing has been technically 
difficult with limited proven success rates. The introduction of rapid vitrification is promising, as it has 
been shown to have much elevated oocyte survival rates.  However, the issues with the hormonal 
stimulation described above remain. 
A newer strategy of oocyte preserving involves obtaining immature oocytes from unstimulated ovaries. 
These immature oocytes, which are smaller-sized, less complicated structurally and metabolically less 
active than mature oocytes, are either subsequently frozen or cultured in an in vitro system and 
cryopreserved as mature oocytes. The merits of this option include the sparing of the ovulation induction 
process; as a result, it can be performed immediately, avoiding the delay of chemo/radiotherapy and has 
lower risks related to exposure of high oestradiol levels. In addition, it requires less patient monitoring 
and reduces the associated costs.  The challenge is the in vitro maturation process.  
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3.2.3. Ovarian tissue cryopreservation 
 
In this approach an operative procedure (usually laparoscopy, rarely laparotomy) is performed, prior to 
commencement of anticancer treatment, to harvest ovarian tissue. This is cryopreserved and is followed 
by auto-transplantation later in life i.e. following recovery from the cancer treatment and when patient 
is ready to proceed with fertility treatment. The so called autografting of the cryopreserved tissue 
involves transplanting the ovarian tissue back into the patient immediately after thawing, either to the 
ovarian fossa (orthotopic graft) or to a different site (heterotopic graft). With autografting, immature 
follicles and oocytes would mature in vivo (thus obviating the need for exogenous gonadotropin 
stimulation) or ovulation induction treatment or IVF cycle may be needed. This treatment is still 
considered experimental, albeit a promising one for fertility preservation. An increasing number of 
pregnancies are being reported and thus far approximately 13 live births have been reported using this 
technology (Donnez, Silber et al. 2011).  
As with immature oocyte cryopreservation, this approach can be performed immediately, often without 
hormonal stimulation. It may be offered to women undergoing aggressive chemotherapy/radiotherapy 
with a high likelihood of gonadotoxicity. This modality may be suggested as well for fertility preservation 
in young women to allow future childbearing through assisted conception without the risk of age related 
loss of fertility, the so called- social indication.  There are several points to be taken into account when 
considering this approach and to tailor treatment to the individual concerned: the reproductive age, the 
chance of survival and the relative risk of subfertility related to the chemotherapy versus the possibility 
of the re-introduction of cancer cells and other clinical considerations. 
3.2.4. Other options for fertility preservation 
Ovarian suppression prior to chemotherapy  
The use of GnRH analogues for ovarian suppression is controversial, and with no hitherto established or 
well-proven value. Its use should be considered in well-designed experimental protocols. 
Oophoropexy prior to radiotherapy: 
This modality includes an operative procedure, mainly laparoscopy, to move ovaries out of the pelvic 
radiotherapy field. It would be appropriate for only a very few well-defined patients. 
Pre-pubertal children: 
Ovarian tissue cryopreservation, though still considered as an experimental approach, is the only 
available fertility preservation approach that can be offered for premenarcheal/ pre-pubertal girls. 
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Currently, this technique is available in only a limited number of fertility centres in several countries. It 
has been used in children as young as 2.7 years of age.  
In summary, ovarian tissue preservation is a feasible option to preserve ovarian function and possibly 
fertility in children and young women before gonadotoxic chemotherapy and/or radiotherapy. However, 
further research is needed to assess the clinical effectiveness of ovarian cryopreservation, to optimise 
the technique and to define clear indications. 
3.3. Challenges with Ovarian Tissue Preservation 
Restoration of ovarian function with hormone production and follicular growth has been observed after 
transplantation of frozen–thawed ovarian tissue (Oktay, Newton et al. 2000; Radford, Lieberman et al. 
2001; Oktay, Buyuk et al. 2004; Tryde Schmidt, Yding Andersen et al. 2004; Schmidt, Andersen et al. 
2005; Rosendahl, Loft et al. 2006; Donnez, Squifflet et al. 2008), and more than a dozen of pregnancies 
(Donnez, Dolmans et al. 2004; Meirow, Levron et al. 2005; Demeestere, Simon et al. 2006; Demeestere, 
Simon et al. 2007; Meirow, Levron et al. 2007; Andersen, Rosendahl et al. 2008) have been reported to 
date. 
Nevertheless research efforts are still needed to develop and optimize grafting procedures; a large 
percentage of grafted follicles are lost as a result of post grafting ischemia and reperfusion-induced 
damage (Newton et al., 1996; Aubard et al., 1999; Donnez et al., 2006b). In addition, some studies have 
demonstrated the risk of possibly transmitting malignant cells present in the cryopreserved tissue back 
to patient’s body (Shaw et al., 1996; Meirow et al., 1998, 2008). Thus, an important direction for 
research is into ways to avoid the need for autografting, such as the in vitro maturation of immature 
follicles derived from ovaries collected prior to commencement of cancer treatment. So far, most cases 
utilising in vitro maturation (IVM) have been from patients with polycystic ovaries (PCO) (Tan and Child 
2002; Gremeau, Andreadis et al. 2012). This is mainly because of the greater number of small follicles in 
PCO ovaries. This technology may similarly be suggested for patients with a high number of antral 
follicles. A successful in vitro culture system for ovarian tissue would then enable the growth and 
maturation of follicles and oocytes which could be subsequently fertilized to produce viable embryos. 
3.4. In vitro culture and maturation of follicles  
In order to avoid the risk of transmitting cancer cells as well as other technical challenges of grafting 
including long term biocompatibility, matrix degradation vascularization, and integration with existing 
tissue (Kim and Mooney 1998; West, Xu et al. 2007), isolated follicles could be grown in vitro to achieve 
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in vitro maturation of oocytes followed by fertilization and embryo transfer. The IVM procedure would 
also allow the assessment of follicular quality after cryopreservation by the direct monitoring of follicles 
during the culture period (Abir, Roizman et al. 1999), which could also help to assess the factors involved 
in the folliculogenesis in humans. 
The first human oocyte IVM was performed by Edwards in 1965 (Edwards 1965). The purpose of the in 
vitro human follicle growth (IVFG) system is to mimic the in vivo process by providing follicles with 
appropriate growth factors and hormones, in the correct amount and at the right time, to enable growth 
of the follicle and oocyte whilst maintaining the essential connections between somatic cells and the 
oocyte (called transzonal projections (TZPs)). (Anderson and Albertini 1976; Albertini and Barrett 2003; 
Xu, Barrett et al. 2009). At the moment IVM is regarded as an adjunct procedure to IVF but successful in 
vitro culturing and maturation of the ovarian tissue or isolated follicles to produce mature follicles and 
oocytes, would provide a safe fertility preservation option.  
Currently there are two standard clinical protocols for IVM (Gilchrist, Smitz et al. 2011). First, the 
cumulus-oocyte complex is removed when the woman’s endometrium thickness is at least 5 mm. The 
complex removed from the meiotically inhibiting environment is spontaneously matured to the 
metaphase II stage in 36 hours. The other method involves a large bolus of Human Chorionic 
Gonadotrophin (HCG) administration, to initiate meiotic resumption, 36 hours prior to oocyte retrieval. 
In this case IVM time is significantly reduced to 24 hours. The In vitro culture systems can also be 
categorized into two approaches. In the first approach isolated follicles are placed on two-dimensional 
surface and permitted to attach and spread on the surface. The second one is the three dimensional 
intact follicle approach in which follicles do not adhere to a surface but maintain their architecture and 
the cell-cell and cell-matrix interactions which are critical regulators of follicle development (West et al., 
2007). 
These current clinical IVM methods only support late stage pre-ovulatory follicles. However, as the 
procedures depend on the hormonal regulation and the availability of antral follicles, they are not yet an 
option for pre-pubertal children and cancer patients who require urgent treatment. The ability to culture 
immature follicles will be invaluable for fertility preserving technologies. Primordial follicles are the most 
abundant follicle stage in the ovary and present at all ages.  They are also less susceptible to cryogenic 
and cancer therapy damage.  
Therefore, IVM for pre-antral follicles should be developed, although to date the culture of early stage 
(primordial or primary) follicles to the antral stage has yet to be fully elucidated (Galdones, Shea et al. 
2011) and only a few studies have been performed and published (Roy and Treacy 1993; Oktay, Nugent 
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et al. 1997; Abir, Roizman et al. 1999; Abir, Fisch et al. 2001). However, although the in vitro culture of 
isolated small pre-antral follicles (30–50 µm) from human ovaries has not yet yielded satisfactory results, 
samples from fresh and frozen–thawed ovarian tissue have been shown to survive in vitro for up to 24 
hours (Abir, Roizman et al. 1999; Abir, Fisch et al. 2001) in collagen gel.  
At the moment, two step approaches seem to be promising in the development of a method for the 
culture of primary follicles. Because of the different requirements of the primary and secondary follicles, 
two separate systems were developed to support each development stage. First, primary follicles in ex 
vivo ovarian tissue were cultured to secondary follicles. Then the secondary follicles were collected and 
cultured in an encapsulated system.  Murine fetal ovaries and cryopreserved ovaries have been cultured 
successfully using this two-step method.  
 
Unfortunately, another challenge of in vitro human follicle culture is that most IVM studies have 
previously been done in rodents where the terminal follicle size is smaller and the culture period is 
shorter. The increased volume means the follicles are more susceptible to sheer and diffusion limitation. 
The human ovary also contains more fibrous stroma which makes follicle collection difficult. Telfer and 
colleagues tried to culture human preantral follicles using the two step culture system, but the follicles 
could maintain their structure only up to 4 days (Telfer, McLaughlin et al. 2008). However, human 
secondary follicles could be cultured to the antral stage in the presence of activin.  
Animal studies have shown that the major problem in early stage IVM is how to maintain the oocyte 
development competence in the artificial environment. Despite all attempts to manipulate the culture 
conditions, the differences between cellular environment in standard 2D cell culture system and the real 
physiological environment usually exist  and are significant, which results in the deviated cellular 
behaviour. For example, more abnormal chromosome configurations and disturbed methylation pattern 
on the gene H19 are observed in IVM oocyte compared to oocyte matured in vivo under ovarian 
stimulation (Borghol, Lornage et al. 2006; Li, Feng et al. 2006). As a result, these oocytes are likely to fail 
to mature and result in high miscarriage rate of IVM derived embryos.  
Most IVM researchers have tried to improve IVM conditions by optimizing culture medium formula. Pre-
IVM treatment with cyclic adenosine monophosphate (cAMP) modulating agents and addition of, for 
example, FF-MAS, oocyte secreting factors, protein kinase c activator, have shown to enhance the 
embryo yield and the fetal survival significantly see Gilchrist for reviews (Gilchrist, Smitz et al. 2011). 
Nevertheless, Abir et al. reported that isolated follicles could only grow in a supporting matrix i.e. a  3D 
system(Abir, Nitke et al. 2006), possibly  due to the preservation of intercellular interactions between 
granulosa cells (GCs) and the oocyte in this system and the provision of optimal support for the fragile 
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isolated follicles, similar to the ovary itself. 
3.4.1. 3D scaffold 
In the ovary, primordial and primary follicles are localized to the rigid part of the ovary and migrate to 
the less rigid part while growing. The presence of 3D scaffold and its rigidity are sensed through cellular 
contact that subsequently triggers various signalling cascades for cell survival and differentiation. 
Subsequently, cells survival period and tissue integrity are enhanced. 
Two-dimensional cultures have been revealed as insufficient for sophisticated cell culture. Over time the 
structure of the spherical follicle is disrupted as it flattens and the loss of follicular structure releases 
denuded oocytes. The degree of disruption increases with the terminal size of the follicles. 2D follicle 
tissue culture also leads to granulosa cell proliferation, migration from the oocyte, and subsequent 
flattening of the oocyte (Pangas, Saudye et al. 2003).   
Morphophysiological observations suggest that the suitable conditions for in vitro oocyte maturation 
maintain its cellular environment and well defined extracellular matrix structure in 3D organization 
(Torre, Faustini et al. 2007). Many aspects of oocyte growth and development are believed to be 
regulated by interactions with adjacent GCs (Murray, Gosden et al. 1998; Reynaud, Cortvrindt et al. 
2000) and this is probably why most studies are performed with pre-antral follicles enclosed in ovarian 
tissue (Hovatta, Silye et al. 1997; Hovatta, Wright et al. 1999; Carlsson, Scott et al. 2006). 
Cell encapsulation is the technique whereby a pool of live cells is entrapped within a semi permeable 
membrane. Since the first publication by Chang et al in 1964 (Chang 1964), bioencapsulation has gained 
interest from researchers. The first application of cell encapsulation in reproduction was made by Nebel 
et al. who devised a technique for bovine sperm encapsulation in calcium alginate and polyamines 
(Nebel, Bame et al. 1985). Later, Pangas et al. developed an alginate beads 3D culture system designed 
for cumulus/oocyte complexes (Pangas, Saudye et al. 2003); such technology yielded good results in 
terms of structural development and meiosis resumption for murine ovary. 3D culture scaffold will slow 
the structural deterioration of the spherical follicle by giving mechanical support (Smitz and Cortvrindt 
1998).   
3.4.2. Alginate Hydrogel 
Bioactive material such as collagen and Matrigel would appear to be excellent scaffold for in vitro follicle 
culture however, since the matrices are bioactive, some degree of cell migration from the follicle and 
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enzyme activity can lead to changes in the follicle structure and follicular damage. Inert 3D matrix such 
as alginate or polyethylene glycol (PEG) has proven to be a well characterized and customizable tool for 
in vitro culture.  
Alginate is a nontoxic polysaccharide composed of repeating units of mannuronic (M)  and glucuronic 
acids (G) that may be reversibly linked by exposure to divalent cations such as calcium (Ca2+)(Pangas, 
Saudye et al. 2003; Torre, Faustini et al. 2007).  It is permeable to small molecules such as glucose and 
oxygen and its permeability can be easily tailored to suit different applications. The alginate 
encapsulation procedure does not damage the ovarian cells or cellular junctions. It results in a 
surrounding alginate matrix that maintains the positions of the granulosa cells within the oocyte; hence 
preserving the granulosa cell–oocyte interactions in the presence of appropriate growth and 
differentiation factors (Pangas, Saudye et al. 2003).  Also, oocytes grown in vitro can be readily retrieved 
from the matrix for further uses by the addition of a chelating agent such as EDTA or sodium citrate. 
Further uses could include in vitro fertilisation. According to the properties described above, alginate 
hydrogel should be suitable for in vitro culture of isolated follicles. Its porous structure allows diffusion of 
hormones and other proteins that are essential for follicular development. Indeed, alginate is one of the 
most widely used biomaterials for microencapsulation because of its biocompatibility, high affinity to 
water and ability to form hydrogels under very mild conditions (Smidsrod and Skjak-Braek 1990; Draget, 
Skjak-Braek et al. 1997; Amsden and Turner 1999; West, Xu et al. 2007). 
Moreover, alginate scaffold can be functionalised for specific use. Small proteins and functional groups 
can be attached to the alginate scaffold by chemical modification. The rigidity and mechanical properties 
of the alginate can be altered by the ratio of G:M monomer and calcium concentration in the linking 
solution. The dynamic characteristics of alginate scaffold make it a suitable material for robust dynamic 
in vitro follicle culture.  
A fluid core alginate capsule can support human oocyte maturation well with 90.3% success rate after 48 
hr. Recently, another 3D alginate hydrogels system has been successfully applied to in vitro culture of 
isolated mouse (Pangas, Saudye et al. 2003; Kreeger, Fernandes et al. 2005; Kreeger, Deck et al. 2006; 
Xu, Kreeger et al. 2006; Xu, West et al. 2006; West, Xu et al. 2007) and rat (Heise, Koepsel et al. 2005) 
follicles. Mouse follicle encapsulated in alginate beads culture in 100 uL growth medium (a-MEM-0.3% 
BSA, fetuin 1 mg/mL) for 10 days grew as intact spheres of cells within the alginate bead. At this stage, 
the oocytes showed no signs of degeneration, had cortical granules around the periphery, and contained 
an intact zona pellucida with numerous microvilli projecting from the oocyte. The granulosa cells 
surrounding the oocyte were organized, spherical and had few vacuoles. No morphological evidence of 
cellular apoptosis was noted (Pangas, Saudye et al. 2003). Follicles cultured in alginate produced 
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fertilizable oocytes and live mice have been born from these (Pangas, Saudye et al. 2003; Xu, Kreeger et 
al. 2006). However, alginate exhibits minimal cellular interactions with mammalian cells, and thus likely 
provides only mechanical support.  
3.4.3. Adhesion motif RGD 
Along with the signalling molecules between cells in the follicle, the interaction between follicle cells and 
the surrounding extracellular matrix (ECM) also appear to contribute to follicle fate (Irving-Rodges et al, 
2009).Most of the inert scaffolds lack interaction with the cells. They are coated with cell surface 
adhesive proteins such as collagen, laminin and fibronectin to enhance cell attachment. However, these 
proteins are usually derived from animals so they may be contaminated with pathogen or trigger the 
immune response. Also, since they are susceptible to denaturation and degradation, they need to be 
replenished constantly.  What is more the binding of large protein molecules onto scaffold backbone 
molecules such as alginate is not easy technically. To overcome these drawbacks, immobilized peptides 
are presented as the cell recognition motifs instead. ECM usually contains several protein motives to 
interact with specific receptors. The smaller peptide motif is more stable and can be packed at higher 
density. 
RGD peptide is a cell recognition motif that consists of Arginine (R), Glycine (G), Aspartic acid (D). It is 
recognized by cell surface receptors of the integrin family. Integrins are the major receptors mediating 
adhesion to the extracellular matrix. Following ligand binding, conformational changes of integrins 
induce the recruitment of multiple signalling and scaffolding proteins that connect integrin tails to the 
actin cytoskeleton and permit activation of signalling pathways regulating cell proliferation, apoptosis, 
differentiation, and migration. In the ovary, extracellular matrix components present in the follicular 
basement membrane, around follicular cells, and in the follicular fluid and the role of integrins in the 
regulation of follicular development is strongly suggested (Monniaux, Huet-Calderwood et al. 2006). 
Smitz et al. reported that the presence of an extracellular matrix enhances follicle survival, especially 
after 10 days in mouse follicle culture and 14 days in sheep follicle culture (Smitz and Cortvrindt 1998), 
but there is no significant difference in follicle diameters with ECM culture compared to non-ECM 
culture. 
Kreeger et al showed that encapsulation and culture of follicles with RGD-modified alginate significantly 
increased growth of secondary follicles and improved meiotic competency rates of oocytes compared 
with follicles cultured in alginate alone (Kreeger, Deck et al. 2006). 
3.4.4. Perfused system 
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Follicles at different stages require different culture conditions. Consequently, well defined and well 
controlled culture environment will be the key to the success of in vitro follicle culture and this can only 
be achieved in a dynamic perfused culture system. In the conventional static culture environment all 
parameters in the culture medium change with time depending on metabolic rate and local conditions.  
Perfused technology, where culture media is pumped and flows through the culture at a pre-set manner, 
not only allows the better transportation (i.e. overcome diffusional control) and temporal regulation of 
nutrients and supplements but can also accommodate the growth of follicles by altering the calcium 
concentration in order to regulate properties of the alginate scaffold. The dynamic customizable system 
will provide an excellent tool for the in vitro culture of human follicles. 
In addition, the profuse system will facilitate the monitoring of nutrition uptake and secretion of 
signalling molecules from the culture. On line monitoring of key biomarkers can be performed in real 
time.  This information will be crucial to understand the biological and molecular process of follicles 
tissue maturation in vitro. 
The success of the in vitro culture will be monitored by the number of follicles that survive during a 
certain period of time, the increase in sizes of the follicles and the morphology of the follicles. We will 
examine the ability of these follicles to form an antrum (the first sign that a follicle has reached the next 
stage of maturation) and secrete hormones, so to support oocyte development.  
Advances in our understanding of in vitro culturing and maturation of follicles may be applied to provide 
a fertility preservation option for women at risk of premature ovarian insufficiency as well as facilitating 
research in folliculogenesis. 
4. OBJECTIVES AND OUTCOME MEASURES/ENDPOINTS 
Objectives Outcome Measures/Endpoints  
Primary Objective 
To determine a successful in vitro culturing 
system of early stage human follicles.  
• Number of follicles that survive in vitro 
during a certain period of time 
Secondary Objectives 
To identify follicular development and 
maturation using this system. 
To further identify factors involved in the in vitro 
maturation of follicles. 
 
Secondary endpoint/outcome measures –  
Proteomic, metabolomic and genomic studies to 
determine the success of the in vitro culture – 
measured by: 
• The increase in size of the follicles 
• Variations in the morphology of the 
follicles 
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• Measuring numbers of follicles which 
form an antrum and time taken for 
antrum to develop 
• The concentration of hormones secreted 




5. STUDY DESIGN 
The study design is experimental bench research, using donated human tissue samples. 
 Patient participation is limited to consenting to the study for the purposes of donating samples 
only.  
In this study donated ovarian tissue will be requested from three patient populations: 
1. Female patients having ovarian tissue cryopreservation, from age 6 years onwards, if 
clinically indicated. 
2. Adult women having planned gynaecological surgery: 
• Surgery which already involves the removal of their ovaries (Oophorectomy) or 
ovarian cysts (Cystectomy). This requires no additional interventions. 
• Surgery to provide sterilisation (i.e. family completed) – surgeons will take a 
small slice of ovarian tissue (less than 5% total ovary) at the time of surgery from 
women who agree. This will not affect the endocrine functioning of her ovaries 
since 10-20% is needed for this. 
3. Adult women having elective caesarean section with sterilisation – surgeons will take a 
small slice of ovarian tissue at the time of surgery from women who agree.  
6. PARTICIPANT IDENTIFICATION 
6.1. Study Participants 
 
Participants will be female patients who are able to donate ovarian tissue samples to the study. 
6.2. Inclusion Criteria 
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• Participant (or parent/guardian if child unable to consent for themselves) is willing and able to give 
informed consent for participation in the study. 
• Female aged ≥6 and ≤ 43 years having clinically indicated ovarian tissue cryopreservation OR 
Female aged ≥ 18 and ≤ 43 years and having planned ovarian surgery (Oophorectomy or 
cystectomy) or sterilisation. 
6.3. Exclusion Criteria 
• Patients donating new tissue samples (i.e. not samples ‘left over’ from Oophorectomy or 
cystectomy) with only one ovary. 
7. STUDY PROCEDURES 
 
See Appendix A Study Flow Chart for overview of procedures 
7.1. Recruitment 
 
All potential study patients (and parent/guardian as appropriate) will have a consultation with a Doctor 
at a hospital clinic prior to their gynaecological surgery or ovarian tissue preservation surgery. It is at this 
consultation that the clinic Doctor will present the Patient Information Sheet to suitable patients. 
 The patient will take the information sheet home and be able to consider the contents. Along with the 
information sheet we will include a (pre-paid) reply slip which patients will be asked to return if they are 
interested in taking part in the study. 
A research nurse will contact any patient who returns the slip to discuss the study further and, if they 
wish to take part, will arrange to obtain informed consent at the time when the patients return to the 
hospital for their surgical procedure. 
7.2. Informed Consent 
 
The participant (or parent/guardian if the patient is a child) must personally sign and date the latest 
approved version of the Informed Consent form before any study specific procedures are performed. 
Written and verbal versions of the Participant Information and Informed Consent will be presented to 
the participants (or parent/guardian) detailing no less than: the exact nature of the study; what it will 
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involve for the participant; the implications and constraints of the protocol; the known side effects and 
any risks involved in taking part. It will be clearly stated that the participant is free to withdraw from the 
study at any time for any reason without prejudice to future care, and with no obligation to give the 
reason for withdrawal. 
The participant will be allowed as much time as wished to consider the information, and the opportunity 
to question the Investigator, their GP or other independent parties to decide whether they will 
participate in the study. Written Informed Consent will then be obtained by means of participant (or 
parent/guardian) dated signature and dated signature of the person who presented and obtained the 
Informed Consent. The person who obtained the consent must be suitably qualified and experienced, 
and have been authorised to do so by the Chief/Principal Investigator. A copy of the signed Informed 
Consent will be given to the participant (or parent/guardian). The original signed form will be retained at 
the study site. 
7.3. Discontinuation/Withdrawal of Participants from Study 
 
Each participant has the right to withdraw from the study at any time.  In addition, the Investigator may 
discontinue a participant from the study at any time if the Investigator considers it necessary for any 
reason such as Ineligibility (either arising during the study or retrospectively having been overlooked at 
screening) or withdrawal of consent. 
However, in this study patient participation involves the donation of tissue samples only and so their 
involvement is for a short duration (from consent to removal of tissue). The donated tissue samples are 
anonymous to the research team (not linked to individuals) and once tissue samples have been given to 
the researchers they will continue to use the samples even if consent is withdrawn. 
7.4. Tissue samples 
 
Surgeons will collect the tissue samples from the study participants and place them in a study labelled 
container. This will be handed to the research team. The experimental analysis will be carried out 
immediately in a University laboratory at OCTE. No identifying details are stored. 
7.5. Definition of End of Study 
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The end of the study is the date when the last sample from the last participant has been analysed, and 
any remaining tissue destroyed. 
8. SAFETY REPORTING  
 
We believe it very unlikely our study will be associated with any serious adverse events.  
However, the following considerations regarding safety are relevant to this study. 
Participants, including children aged 6 and older, are already having planned surgical procedures which 
require hospitalisation. Study participants are only those patients who are appropriate to donate 
samples to us and these are: 
 a) Women already having planned surgery to remove ovarian tissue (whole ovaries in oophorectomy or 
ovarian cysts in cystectomy). In both these cases the research sample can be taken from the tissue which 
is already being removed (by the surgeon doing operation) and is therefore ‘left over’ after the surgery. 
Nothing extra will happen to these women. 
b) Women having planned surgery, including caesarean section, to provide sterilisation (i.e. family 
completed) – the same surgeon will take a small slice of ovarian tissue (less than 5% total ovary) at the 
time of surgery from women who agree. This will not affect the endocrine functioning of the ovaries 
since 10-20% is needed for this. 
 c) Women and children storing their own ovarian tissue for storage for their own fertility preservation. 
We will ask this group of patients for their consent to donate a small extra sample for the research study. 
The surgeon is already doing operation. The extra amount will not affect the procedure they are already 
having. We are including children is this study as they are most likely to be the population having this 
procedure and, potentially may be the beneficiaries of this research. 
The study interventions will increase their surgery time by 10 minutes only. There are extremely unlikely 
to be increased surgical risks above that of the planned surgical procedure. 
The surgeons are not part of the research team. 
Definitions of and reporting of any Serious Adverse Events are described below.  
8.1. Definition of Serious Adverse Events 
A serious adverse event is any untoward medical occurrence that: 
• results in death 
• is life-threatening 
• requires inpatient hospitalisation or prolongation of existing hospitalisation 
• results in persistent or significant disability/incapacity 
• consists of a congenital anomaly or birth defect. 
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Other ‘important medical events’ may also be considered serious if they jeopardise the participant or 
require an intervention to prevent one of the above consequences. 
NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the 
participant was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe. 
8.2. Reporting Procedures for Serious Adverse Events 
A serious adverse event (SAE) occurring to a participant should be reported to the REC that gave a 
favourable opinion of the study where in the opinion of the Chief Investigator the event was ‘related’ 
(resulted from administration of any of the research procedures) and ‘unexpected’ in relation to those 
procedures.  
Reports of related and unexpected SAEs will be submitted within 15 working days of the Chief 
Investigator becoming aware of the event, using the NRES report of serious adverse event form  to the 
REC/NHS R&D and reported to the sponsor immediately (within 24 hours). 
9. STATISTICS AND ANALYSIS 
9.1. Description of Statistical Methods 
For this study, samples will be analysed using proteomic, metabolomic and genomic methods and 
the data generated will take the form of experimental measurements to study the factors involved 
in the in vitro maturation of follicles obtained from human ovarian tissue samples.  
9.2. Number of Participants 
The number of participants is likely to small but we estimate it to be up to 50 in total.  
9.3. Analysis of Endpoints  
The samples of ovarian tissue will be collected during the patients’ surgery. Samples are put in a labeled 
container for immediate analysis. No identifying patient data e.g. name, will be retained. Samples are 
then analysed as follows: 
9.3.1. Ovarian follicles isolation 
The protocol previously described by Dolmans et al. (Dolmans, Michaux et al. 2006) will be used to 
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isolate small pre-antral follicles. Briefly, the cortical portion of the ovary was placed in a tissue chopper, 
adjusted to 0.5 mm. Ovarian fragments obtained are transferred to 50 ml conical flasks containing 10 ml 
of Dulbecco’s phosphate-buffered saline (D-PBS; BioWhittaker, Verviers, Belgium) supplemented with 1 
mg/ml collagenase type IA (Sigma), and incubated in a water bath at 37 °C for 60 min with gentle 
agitation. The ovarian digest is periodically (every 15 min) shaken with a pipette to mechanically disrupt 
the digested tissue. Digestion is completed by the addition of an equal volume of D-PBS at 4 °C 
supplemented with 10 % fetal bovine serum (FBS; Gibco). Thereafter, the resulting suspension is 
centrifuged at 50 g for 10 min at 4 °C. The supernatant is discarded and the pellet is transferred to Petri 
dishes and investigated for follicles under a stereomicroscope (Leica, Van Hopplynus Instruments, 
Brussels, Belgium). The follicles are picked up using a 135-mm-diameter stripper tip (Mid-Atlantic 
Diagnostics, Inc., Mount Laurel, NJ, USA) and washed three times in D-PBS supplemented with 10% FBS 
at 4 °C in order to avoid introduction of stromal cells into the alginate matrix.  
Follicles are then incubated for several days in this media and during this time the follicle diameter is 
measured from the basement membrane using an ocular micrometer scale. Two to five follicles from 
each sample are subsequently processed for live/dead assays in order to evaluate follicular viability after 
isolation. The remaining follicles are embedded in an alginate matrix (4–8 follicles/group). 
9.3.2. Follicle and oocyte measurement 
To measure the increase in sizes of the follicles  
Photographs of each follicle (during the culture period) are captured using a Leica light microscope. 
Follicle diameters are later measured using ImageJ software (National Institutes of Health, USA). Oocyte 
diameters are measured without zona pellucida. 
Sectioning and staining 
To study the morphology of the follicles 
Follicles will be fixed in 4% PFA for 30 min at 37 °C and then overnight at 4 °C. Fixed follicles are 
dehydrated in increasing concentrations of ethanol (10–100%) and embedded in paraffin using an 
automated tissue processor (Leica, Manheim, Germany). Serial 5 µm sections are cut and stained with 
hematoxylin and eosin (Xu, Barrett et al. 2009). 
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9.3.3. 3D confocal staining and imaging  
To confirm whether follicles have formed a antrum 
Follicles for confocal microscopy studies are fixed in 4 % PFA at 37 °C for 1 hr, followed by 1 hr in wash 
buffer (Barrett and Albertini 2007). They are then stained overnight at 4 °C on a shaker with Rhodamine-
Phalloidin (1:50 Molecular Probes, Invitrogen, Eugene, Oregon) that labels F-actin in TZPs, rabbit anti-
connexin 43 (1:100 Zymed) that labels gap junctions or affinity purified polyclonal rabbit antisera that 
recognize the inhibin βA-subunit (1:100) or the inhibin βB-subunit (1:100). The inhibin subunit antisera is 
a gift from Dr W. Vale (The Salk Institute, La Jolla, CA, USA). The primary antibodies is  followed by 
incubation with 1:800 goat anti-rabbit Alexa 568 for inhibin βA and connexin 43, 1:800 goat anti-rabbit 
Alexa 488 for inhibin βB (Molecular Probes) and 1 µg/ml Hoechst 33342 (Molecular Probes) for 
chromatin/DNA. Follicles are mounted in 5–10 µl of a 50 % glycerol/PBS solution containing 25 µg/ml 
sodium azide. The coverglass is placed on glass shards, to prevent the compression of the follicle. 
Follicles are then imaged on a Zeiss LSM 510 confocal microscope using a Neoflaur 40× oil objective. 
Overlapping 1–3 µm sections are taken throughout each follicle imaged (Xu, Barrett et al. 2009). 
9.3.4.  Hormone assays 
To measure the ability of follicles to secrete hormones 
17β-estradiol (E2) and Progesterone (P4) concentrations in culture media were measured by specific 
electrochemiluminescent assay using a Roche Elecsys 2010 Analyzer (Roche, Indianapolis, IN, USA). 
Inhibin A, inhibin B and anti-Müllerian hormone (AMH) were measured using ELISA kits (DSL-10-28100, 
DSL-10-84100 and DSL-10-14400, Diagnostic Systems Laboratories, Webster, TX, USA) following 
manufacturer instructions (Xu, Barrett et al. 2009). 
10. DATA MANAGEMENT 
10.1. Access to Data 
Direct access will be granted to authorised representatives from the Sponsor or host institution for 
monitoring and/or audit of the study to ensure compliance with regulations. 
10.2. Data Recording and Record Keeping 
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Copies of consent forms will be kept securely with other study documentation. Samples will be labelled 
with a Study ID only (anonymous). Data from experiments will be recorded by researchers in laboratory 
books which are stored securely in a locked building. Data will be transcribed onto Excel spread sheets 
for analysis. All data is kept on secure University computers and only encrypted data sticks id used. No 
personal data is available to researchers about the participants. 
11. QUALITY ASSURANCE PROCEDURES 
The study may be monitored, or audited in accordance with the current approved protocol, ICH GCP, 
relevant regulations and standard operating procedures. 
12. ETHICAL AND REGULATORY CONSIDERATIONS 
12.1. Declaration of Helsinki 
The Investigator will ensure that this study is conducted in accordance with the principles of the 
Declaration of Helsinki.  
12.2. ICH Guidelines for Good Clinical Practice 
The Investigator will ensure that this study is conducted in full conformity with relevant regulations and 
with the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996. 
12.3. Approvals 
The protocol, informed consent form, participant information sheet and any proposed advertising 
material will be submitted to an appropriate Research Ethics Committee (REC), and host institution(s) for 
written approval. 
The Investigator will submit and, where necessary, obtain approval from the above parties for all 
substantial amendments to the original approved documents. 
12.4. Reporting 
The CI shall submit once a year throughout the study, or on request, an Annual Progress report to the 
REC Committee, host organisation and Sponsor.  In addition, an End of Study notification and final report 
will be submitted to the same parties. 
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12.5. Participant Confidentiality 
The study staff will ensure that the participants’ anonymity is maintained.  The participants will be 
identified only by initials and a participants ID number on the CRF and any electronic database.  All 
documents will be stored securely and only accessible by study staff and authorised personnel. The study 
will comply with the Data Protection Act, which requires data to be anonymised as soon as it is practical 
to do so. 
12.6. Expenses and Benefits 
There is no requirement for participants to attend additional visits as part of the study, but if this is the 
case then we will reimburse reasonable travel expenses on production of receipts, or a mileage allowance 
provided as appropriate. 
 
13. FINANCE AND INSURANCE 
13.1. Funding 
Funding is provided by  two grants from BBSRC : Engineering human neural network, (BB/H008608), 
£3,282,711, June 10 – May 15 and Development of a high-throughput perfused three dimensional cell 
culture platform for stem cell study and drug testing, Taiwan Partnering Award,  (BB/L003961/1), 
£24,991, 1 Sept 13-31 Aug 15. 
13.2. Insurance 
The University has a specialist insurance policy in place which would operate in the event of any 
participant suffering harm as a result of their involvement in the research (Newline Underwriting 
Management Ltd, at Lloyd’s of London). NHS indemnity operates in respect of the clinical treatment 
which is provided. 
14. PUBLICATION POLICY 
The investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and 
any other publications arising from the study. Authors will acknowledge that the study was funded by 
the BBSRC. Authorship will be determined in accordance with the ICMJE guidelines and other 
contributors will be acknowledged. 
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16. APPENDIX A:  STUDY FLOW CHART 
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1. SYNOPSIS 
 
Study Title In Vitro Culture and Maturation of Ovarian Tissue and 
Follicles: Follicle Microenvironment Engineering as a tool 
to study follicle development and provide fertility 
preservation 
Short title Methods of ovarian tissue culturing for fertility preservation  
 
Study Design Bench research using donated human tissue samples 
Study Participants Females aged 6-43 having clinically indicated ovarian tissue 
cryopreservation 
Women aged 18-43 having planned ovarian surgery or sterilisation  
Planned Sample Size Up to 50 
Planned Study Period 5 years 
 Objectives Endpoints 
Primary 
 
To determine a successful in vitro 
culturing system of early stage human 
follicles. 
Number of follicles that survive in 





To analyse follicular development and 
maturation using this system. 
To further identify factors involved in 
the in vitro maturation of follicles. 
 
Proteomic, metabolomic and 
genomic studies to determine the 
success of the in vitro culture – 
measured by: 
• The increase in size of the 
follicles 
• Variations in the 
morphology of the follicles 
• Measuring numbers of 
follicles which form an 
antrum and time taken for 
antrum to develop 
• The concentration of 
hormones secreted by the 




CI Chief Investigator 
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CRF Case Report Form 
CTRG Clinical Trials & Research Governance, University of Oxford 
GCP Good Clinical Practice 
GP General Practitioner 
ICF Informed Consent Form 
ICH International Conference of Harmonisation 
IVF In Vitro Fertilisation 
IVM In Vitro Maturation 
NHS National Health Service 
NRES National Research Ethics Service 
OCTE Oxford Centre for Tissue Engineering and Bioprocessing,  Department of Engineering Science, Oxford University 
PI Principal Investigator 
PIL Participant/ Patient Information Leaflet 
R&D NHS Trust R&D Department 
REC Research Ethics Committee 
RGD Three dimensional (3D) scaffold and adhesion motif 
SOP Standard Operating Procedure 
 
3. BACKGROUND AND RATIONALE 
3.1. Overview 
 
For female adolescents and young adults, the increasing probability of surviving a cancer diagnosis 
combined with the expectation and desire for reproductive options following cancer remission has 
fuelled a growing need for fertility sparing techniques.  
Currently there are several methods available to women hoping to preserve their fertility before cancer 
therapy. As it has been used most often, traditional hormone stimulation and in vitro fertilization (IVF) 
followed by embryo cryopreservation is the most successful approach to preserve fertility. More recently 
live births have also been achieved with cryopreserved oocytes harvested before cancer treatment. Both 
methods require a delay in cancer treatment and use hormonal stimulation that might be deleterious in 
some patients. Ovarian tissue cryopreservation followed by autotransplantion is a promising fertility 
preservation approach that can usually be performed immediately without hormonal stimulation. 
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Worldwide, a dozen live births have been reported thus far as a result of auto-transplanting 
frozen/thawed ovarian tissues (Donnez, Silber et al. 2011). Despite these promising findings, 
transplantation of cryopreserved tissue carries the risk of re-introducing cancer cells into the patient. 
Thus, the in vitro maturation (IVM) of immature follicles derived from ovaries collected prior to 
commencement of cancer treatment is an important direction for new fertility preservation approach as 
it avoids the need for auto grafting and prevents the possibility of cancer cells reseeding.  
In this proposal we aim to establish follicle culture using tissue from human ovarian biopsies and also 
improve them by exploring the use of three dimensional (3D) scaffold and adhesion motif (RGD). These 
3D culture systems can potentially improve follicle growth and development via enhances structural 
support. Furthermore, maintaining the follicular structure while monitoring and manipulating the 
hormonal and biochemical environment through the perfusion system will allow us to explore the 
development of controllable systems to investigate and improve the biological and molecular processes 
underlying follicle growth and maturation. Advances in our understanding of in vitro culturing and 
maturation of follicles may also be applied to provide a fertility preservation option for women at risk of 
premature ovarian insufficiency as well as facilitating research in follicle development.  
3.2. Fertility Preservation in Cancer Patients 
 
In recent years cryopreservation of human ovarian tissues has emerged as a promising alternative for 
fertility preservation in pre-menarchal and adolescent females, as well as for adult women prior to 
chemo/radiotherapy.  The prognosis and survival rates of cancer patients have improved tremendously 
as a result of recent advances in cancer treatment, particularly in childhood cancers, and attention is 
now being directed towards quality of life and the long-term gonadotoxic side effects of chemotherapy 
or radiotherapy. Given that 1 in 46 females between birth and age 39 are diagnosed with 
cancer(American Cancer Society 2012) many women are potentially affected. The incidence of ovarian 
failure is dependent on the type and dose of chemotherapy agents, and the age of the patient. Currently, 
there are several modalities for fertility preservation for different age groups: 
Post-pubertal women 
Post pubertal women requesting fertility preservation prior to chemotherapy or radiotherapy may be 
offered any of the following options: 
3.2.1. Embryo cryopreservation  
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This is currently the only widely accepted and well-established option to preserve fertility, during which 
patients undergo a stimulated IVF cycle with subsequent retrieval of mature oocytes prior to the 
initiation of chemo/radiotherapy. Harvested oocytes are then fertilized with sperm produced by 
husband, partner or donor, and the resulting embryos are cryopreserved. This technology is in routine 
clinical use in IVF units throughout the world on a daily basis. An evolving newer strategy is obtaining 
immature oocytes in non-stimulated cycle for in vitro maturation of oocytes and subsequent fertilization, 
and embryo freezing.  
The advantages of embryo cryopreservation modality are its worldwide availability and its proven and 
established pregnancy success rates. Disadvantages include the need for hormonal stimulation of 2-4 
weeks (which may defer and delay the anticancer treatment), its costs (£4000-5000), the need for a 
partner/husband or the decision of using donor sperm, and the relatively limited number of embryos 
produced and stored from a single stimulation cycle. It is not a viable option for pre-menarchal or 
adolescent girls, single women unable/unwilling to use donor sperm and women who are unable to 
undergo an in vitro fertilization cycle due to the need to undergo immediate anticancer treatment. In 
addition, the IVF procedure, especially hormonal stimulation, causes discomfort and increases the risk 
for OHSS, ovarian, breast and endometrium cancer, and stroke (Gilchrist et al., 2011). Additionally, there 
are ethical issues regarding embryo storage and usage.  
3.2.2. Oocyte cryopreservation 
 
In this modality, the patient undergoes a stimulated IVF cycle and subsequently the harvested oocytes 
are cryopreserved for later thawing out and fertilization. This technology can be an option for single 
female patients who are not in a stable relationship and not willing to opt for sperm donation. Because 
of the large size and more complex and fragile nature of the oocyte, oocyte freezing has been technically 
difficult with limited proven success rates. The introduction of rapid vitrification is promising, as it has 
been shown to have much elevated oocyte survival rates.  However, the issues with the hormonal 
stimulation described above remain. 
A newer strategy of oocyte preserving involves obtaining immature oocytes from unstimulated ovaries. 
These immature oocytes, which are smaller-sized, less complicated structurally and metabolically less 
active than mature oocytes, are either subsequently frozen or cultured in an in vitro system and 
cryopreserved as mature oocytes. The merits of this option include the sparing of the ovulation induction 
process; as a result, it can be performed immediately, avoiding the delay of chemo/radiotherapy and has 
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lower risks related to exposure of high oestradiol levels. In addition, it requires less patient monitoring 
and reduces the associated costs.  The challenge is the in vitro maturation process.  
3.2.3. Ovarian tissue cryopreservation 
 
In this approach an operative procedure (usually laparoscopy, rarely laparotomy) is performed, prior to 
commencement of anticancer treatment, to harvest ovarian tissue. This is cryopreserved and is followed 
by auto-transplantation later in life i.e. following recovery from the cancer treatment and when patient 
is ready to proceed with fertility treatment. The so called autografting of the cryopreserved tissue 
involves transplanting the ovarian tissue back into the patient immediately after thawing, either to the 
ovarian fossa (orthotopic graft) or to a different site (heterotopic graft). With autografting, immature 
follicles and oocytes would mature in vivo (thus obviating the need for exogenous gonadotropin 
stimulation) or ovulation induction treatment or IVF cycle may be needed. This treatment is still 
considered experimental, albeit a promising one for fertility preservation. An increasing number of 
pregnancies are being reported and thus far approximately 13 live births have been reported using this 
technology (Donnez, Silber et al. 2011).  
As with immature oocyte cryopreservation, this approach can be performed immediately, often without 
hormonal stimulation. It may be offered to women undergoing aggressive chemotherapy/radiotherapy 
with a high likelihood of gonadotoxicity. This modality may be suggested as well for fertility preservation 
in young women to allow future childbearing through assisted conception without the risk of age related 
loss of fertility, the so called- social indication.  There are several points to be taken into account when 
considering this approach and to tailor treatment to the individual concerned: the reproductive age, the 
chance of survival and the relative risk of subfertility related to the chemotherapy versus the possibility 
of the re-introduction of cancer cells and other clinical considerations. 
3.2.4. Other options for fertility preservation 
Ovarian suppression prior to chemotherapy  
The use of GnRH analogues for ovarian suppression is controversial, and with no hitherto established or 
well-proven value. Its use should be considered in well-designed experimental protocols. 
Oophoropexy prior to radiotherapy: 
This modality includes an operative procedure, mainly laparoscopy, to move ovaries out of the pelvic 
radiotherapy field. It would be appropriate for only a very few well-defined patients. 
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Pre-pubertal children: 
Ovarian tissue cryopreservation, though still considered as an experimental approach, is the only 
available fertility preservation approach that can be offered for premenarcheal/ pre-pubertal girls. 
Currently, this technique is available in only a limited number of fertility centres in several countries. It 
has been used in children as young as 2.7 years of age.  
In summary, ovarian tissue preservation is a feasible option to preserve ovarian function and possibly 
fertility in children and young women before gonadotoxic chemotherapy and/or radiotherapy. However, 
further research is needed to assess the clinical effectiveness of ovarian cryopreservation, to optimise 
the technique and to define clear indications. 
3.3. Challenges with Ovarian Tissue Preservation 
Restoration of ovarian function with hormone production and follicular growth has been observed after 
transplantation of frozen–thawed ovarian tissue (Oktay, Newton et al. 2000, Radford, Lieberman et al. 
2001, Oktay, Buyuk et al. 2004, Tryde Schmidt, Yding Andersen et al. 2004, Schmidt, Andersen et al. 
2005, Rosendahl, Loft et al. 2006, Donnez, Squifflet et al. 2008), and more than a dozen of pregnancies 
(Donnez, Dolmans et al. 2004, Meirow, Levron et al. 2005, Demeestere, Simon et al. 2006, Demeestere, 
Simon et al. 2007, Meirow, Levron et al. 2007, Andersen, Rosendahl et al. 2008) have been reported to 
date. 
Nevertheless research efforts are still needed to develop and optimize grafting procedures; a large 
percentage of grafted follicles are lost as a result of post grafting ischemia and reperfusion-induced 
damage (Newton et al., 1996; Aubard et al., 1999; Donnez et al., 2006b). In addition, some studies have 
demonstrated the risk of possibly transmitting malignant cells present in the cryopreserved tissue back 
to patient’s body (Shaw et al., 1996; Meirow et al., 1998, 2008). Thus, an important direction for 
research is into ways to avoid the need for autografting, such as the in vitro development of immature 
follicles derived from ovaries collected prior to commencement of cancer treatment. A successful in vitro 
culture system for ovarian tissue would then enable the growth and maturation of follicles and oocytes 
which could be subsequently fertilized to produce viable embryos. 
3.4. In vitro culture and maturation of follicles  
In order to avoid the risk of transmitting cancer cells as well as other technical challenges of grafting 
including long term biocompatibility, matrix degradation vascularization, and integration with existing 
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tissue (Kim and Mooney 1998, West, Xu et al. 2007), isolated follicles could be grown in vitro and then 
oocytes isolated for in vitro maturation (IVM) followed by fertilization and embryo transfer. The follicle 
culture procedure would also allow the assessment of follicle quality after cryopreservation by direct 
monitoring of follicles during the culture period (Abir, Roizman et al. 1999), which could also help to 
assess the factors involved in the follicle development in humans. 
The first human oocyte IVM was performed by Edwards in 1965 (Edwards 1965). The purpose of in vitro 
human follicle growth is to mimic the in vivo process by providing follicles with appropriate growth 
factors and hormones, in the correct amount and at the right time, to enable growth of the follicle and 
oocyte whilst maintaining the essential connections between somatic cells and the oocyte (called 
transzonal projections (TZPs)) (Anderson and Albertini 1976, Albertini and Barrett 2003, Xu, Barrett et al. 
2009). At the moment IVM is regarded as an adjunct procedure to IVF but successful in vitro culturing 
and maturation of the ovarian tissue or isolated follicles to produce mature follicles and oocytes, would 
provide a safe fertility preservation option.  
Currently there are two standard clinical protocols for IVM (Gilchrist, Smitz et al. 2011). First, the 
cumulus-oocyte complex is removed when the woman’s endometrium thickness is at least 5 mm. The 
complex removed from the meiotically inhibiting environment is spontaneously matured to the 
metaphase II stage in 36 hours. The other method involves a large bolus of Human Chorionic 
Gonadotrophin (HCG) administration, to initiate meiotic resumption, 36 hours prior to oocyte retrieval. 
In this case IVM time is significantly reduced to 24 hours. The in vitro culture systems can also be 
categorized into two approaches. In the first approach isolated follicles are placed on two-dimensional 
surface and permitted to attach and spread on the surface. The second one is the three dimensional 
intact follicle approach in which follicles do not adhere to a surface but maintain their architecture and 
the cell-cell and cell-matrix interactions which are critical regulators of follicle development (West et al., 
2007). 
These current clinical IVM methods only support late stage pre-ovulatory follicles. However, as the 
procedures depend on the hormonal regulation and the availability of antral follicles, they are not yet an 
option for pre-pubertal children and cancer patients who require urgent treatment. The ability to culture 
immature follicles will be invaluable for fertility preserving technologies. Primordial follicles are the most 
abundant follicle stage in the ovary and present at all ages.  They are also less susceptible to cryogenic 
and cancer therapy damage.  
Therefore, culture techniques for pre-antral follicles should be developed, although to date the culture 
of early stage (primordial or primary) follicles to the antral stage has yet to be fully elucidated (Galdones, 
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Shea et al. 2011) and only a few studies have been performed and published (Roy and Treacy 1993, 
Oktay, Nugent et al. 1997, Abir, Roizman et al. 1999, Abir, Fisch et al. 2001). However, although the in 
vitro culture of isolated small pre-antral follicles (30–50 µm) from human ovaries has not yet yielded 
satisfactory results, samples from fresh and frozen–thawed ovarian tissue have been shown to survive in 
vitro for up to 24 hours (Abir, Roizman et al. 1999, Abir, Fisch et al. 2001) in collagen gel.  
At the moment, two step approaches seem to be promising in the development of a method for the 
culture of primary follicles. Because of the different requirements of the primary and secondary follicles, 
two separate systems were developed to support each development stage. First, primary follicles in ex 
vivo ovarian tissue were cultured to secondary follicles. Then the secondary follicles were collected and 
cultured in an encapsulated system.  Murine fetal ovaries and cryopreserved ovaries have been cultured 
successfully using this two-step method.  
 
Unfortunately, another challenge of in vitro human follicle culture is that most follicle culture studies 
have previously been done in rodents where the terminal follicle size is smaller and the culture period is 
shorter. The increased volume means the follicles are more susceptible to sheer and diffusion limitation. 
The human ovary also contains more fibrous stroma which makes follicle collection difficult. Telfer and 
colleagues tried to culture human preantral follicles using the two step culture system, but the follicles 
could maintain their structure only up to 4 days (Telfer, McLaughlin et al. 2008). However, human 
secondary follicles could be cultured to the antral stage in the presence of activin.  
Animal studies have shown that the major problem in early stage follicle culture is how to maintain the 
oocyte development competence in the artificial environment. Despite all attempts to manipulate the 
culture conditions, the differences between cellular environment in standard 2D cell culture system and 
the real physiological environment usually exist and are significant, which results in the deviated cellular 
behaviour. For example, more abnormal chromosome configurations and disturbed methylation pattern 
on the gene H19 are observed in IVM oocyte compared to oocyte matured in vivo under ovarian 
stimulation (Borghol, Lornage et al. 2006, Li, Feng et al. 2006). As a result, these oocytes are likely to fail 
to mature and result in high miscarriage rate of IVM derived embryos.  
Most IVM researchers have tried to improve IVM conditions by optimizing culture medium formula. Pre-
IVM treatment with cyclic adenosine monophosphate (cAMP) modulating agents and addition of, for 
example, FF-MAS, oocyte secreting factors, protein kinase c activator, have shown to enhance the 
embryo yield and the fetal survival significantly see Gilchrist for reviews (Gilchrist, Smitz et al. 2011). 
Nevertheless, Abir et al. reported that isolated follicles could only grow in a supporting matrix i.e. a  3D 
system (Abir, Nitke et al. 2006), possibly  due to the preservation of intercellular interactions between 
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granulosa cells (GCs) and the oocyte in this system and the provision of optimal support for the fragile 
isolated follicles, similar to the ovary itself. 
3.4.1. 3D scaffold 
In the ovary, primordial and primary follicles are localized to the rigid part of the ovary and migrate to 
the less rigid part while growing. The presence of 3D scaffold and its rigidity are sensed through cellular 
contact that subsequently triggers various signalling cascades for cell survival and differentiation. 
Subsequently, cells survival period and tissue integrity are enhanced. 
Two-dimensional cultures have been revealed as insufficient for sophisticated cell culture. Over time the 
structure of the spherical follicle is disrupted as it flattens and the loss of follicular structure releases 
denuded oocytes. The degree of disruption increases with the terminal size of the follicles. 2D follicle 
tissue culture also leads to granulosa cell proliferation, migration from the oocyte, and subsequent 
flattening of the oocyte (Pangas, Saudye et al. 2003).   
Morphophysiological observations suggest that the suitable conditions for in vitro oocyte maturation 
maintain its cellular environment and well defined extracellular matrix structure in 3D organization 
(Torre, Faustini et al. 2007). Many aspects of oocyte growth and development are believed to be 
regulated by interactions with adjacent GCs (Murray, Gosden et al. 1998, Reynaud, Cortvrindt et al. 
2000) and this is probably why most studies are performed with pre-antral follicles enclosed in ovarian 
tissue (Hovatta, Silye et al. 1997, Hovatta, Wright et al. 1999, Carlsson, Scott et al. 2006). 
Cell encapsulation is the technique whereby a pool of live cells is entrapped within a semi permeable 
membrane. Since the first publication by Chang et al in 1964 (Chang 1964), bioencapsulation has gained 
interest from researchers. The first application of cell encapsulation in reproduction was made by Nebel 
et al. who devised a technique for bovine sperm encapsulation in calcium alginate and polyamines 
(Nebel, Bame et al. 1985). Later, Pangas et al. developed an alginate beads 3D culture system designed 
for cumulus/oocyte complexes (Pangas, Saudye et al. 2003); such technology yielded good results in 
terms of structural development and meiosis resumption for murine ovary. 3D culture scaffold will slow 
the structural deterioration of the spherical follicle by giving mechanical support (Smitz and Cortvrindt 
1998).   
3.4.2. Alginate Hydrogel 
Bioactive material such as collagen and Matrigel would appear to be excellent scaffold for in vitro follicle 
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culture however, since the matrices are bioactive, some degree of cell migration from the follicle and 
enzyme activity can lead to changes in the follicle structure and follicular damage. Inert 3D matrix such 
as alginate or polyethylene glycol (PEG) has proven to be a well characterized and customizable tool for 
in vitro culture.  
Alginate is a nontoxic polysaccharide composed of repeating units of mannuronic (M) and glucuronic 
acids (G) that may be reversibly linked by exposure to divalent cations such as calcium (Ca2+)(Pangas, 
Saudye et al. 2003, Torre, Faustini et al. 2007).  It is permeable to small molecules such as glucose and 
oxygen and its permeability can be easily tailored to suit different applications. The alginate 
encapsulation procedure does not damage the ovarian cells or cellular junctions. It results in a 
surrounding alginate matrix that maintains the positions of the granulosa cells within the oocyte; hence 
preserving the granulosa cell–oocyte interactions in the presence of appropriate growth and 
differentiation factors (Pangas, Saudye et al. 2003).  Also, oocytes grown in vitro can be readily retrieved 
from the matrix for further uses by the addition of a chelating agent such as EDTA or sodium citrate. 
Further uses could include in vitro fertilisation. According to the properties described above, alginate 
hydrogel should be suitable for in vitro culture of isolated follicles. Its porous structure allows diffusion of 
hormones and other proteins that are essential for follicular development. Indeed, alginate is one of the 
most widely used biomaterials for microencapsulation because of its biocompatibility, high affinity to 
water and ability to form hydrogels under very mild conditions (Smidsrod and Skjak-Braek 1990, Draget, 
Skjak-Braek et al. 1997, Amsden and Turner 1999, West, Xu et al. 2007). 
Moreover, alginate scaffold can be functionalised for specific use. Small proteins and functional groups 
can be attached to the alginate scaffold by chemical modification. The rigidity and mechanical properties 
of the alginate can be altered by the ratio of G:M monomer and calcium concentration in the linking 
solution. The dynamic characteristics of alginate scaffold make it a suitable material for robust dynamic 
in vitro follicle culture.  
A fluid core alginate capsule can support human oocyte maturation well with 90.3% success rate after 48 
hr. Recently, another 3D alginate hydrogels system has been successfully applied to in vitro culture of 
isolated mouse (Pangas, Saudye et al. 2003, Kreeger, Fernandes et al. 2005, Kreeger, Deck et al. 2006, Xu, 
Kreeger et al. 2006, Xu, West et al. 2006, West, Xu et al. 2007) and rat (Heise, Koepsel et al. 2005) 
follicles. Mouse follicle encapsulated in alginate beads culture in 100 uL growth medium (a-MEM-0.3% 
BSA, fetuin 1 mg/mL) for 10 days grew as intact spheres of cells within the alginate bead. At this stage, 
the oocytes showed no signs of degeneration, had cortical granules around the periphery, and contained 
an intact zona pellucida with numerous microvilli projecting from the oocyte. The granulosa cells 
surrounding the oocyte were organized, spherical and had few vacuoles. No morphological evidence of 
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cellular apoptosis was noted (Pangas, Saudye et al. 2003). Follicles cultured in alginate produced 
fertilizable oocytes and live mice have been born from these (Pangas, Saudye et al. 2003, Xu, Kreeger et 
al. 2006). However, alginate exhibits minimal cellular interactions with mammalian cells, and thus likely 
provides only mechanical support.  
3.4.3. Adhesion motif RGD 
Along with the signalling molecules between cells in the follicle, the interaction between follicle cells and 
the surrounding extracellular matrix (ECM) also appear to contribute to follicle fate (Irving-Rodges et al, 
2009). Most of the inert scaffolds lack interaction with the cells. They are coated with cell surface 
adhesive proteins such as collagen, laminin and fibronectin to enhance cell attachment. However, these 
proteins are usually derived from animals so they may be contaminated with pathogen or trigger the 
immune response. Also, since they are susceptible to denaturation and degradation, they need to be 
replenished constantly.  What is more the binding of large protein molecules onto scaffold backbone 
molecules such as alginate is not easy technically. To overcome these drawbacks, immobilized peptides 
are presented as the cell recognition motifs instead. ECM usually contains several protein motives to 
interact with specific receptors. The smaller peptide motif is more stable and can be packed at higher 
density. 
RGD peptide is a cell recognition motif that consists of Arginine (R), Glycine (G), Aspartic acid (D). It is 
recognized by cell surface receptors of the integrin family. Integrins are the major receptors mediating 
adhesion to the extracellular matrix. Following ligand binding, conformational changes of integrins 
induce the recruitment of multiple signalling and scaffolding proteins that connect integrin tails to the 
actin cytoskeleton and permit activation of signalling pathways regulating cell proliferation, apoptosis, 
differentiation, and migration. In the ovary, extracellular matrix components present in the follicular 
basement membrane, around follicular cells, and in the follicular fluid and the role of integrins in the 
regulation of follicular development is strongly suggested (Monniaux, Huet-Calderwood et al. 2006). 
Smitz et al. reported that the presence of an extracellular matrix enhances follicle survival, especially 
after 10 days in mouse follicle culture and 14 days in sheep follicle culture (Smitz and Cortvrindt 1998), 
but there is no significant difference in follicle diameters with ECM culture compared to non-ECM 
culture. 
Kreeger et al showed that encapsulation and culture of follicles with RGD-modified alginate significantly 
increased growth of secondary follicles and improved meiotic competency rates of oocytes compared 
with follicles cultured in alginate alone (Kreeger, Deck et al. 2006). 
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3.4.4. Perfused system 
Follicles at different stages require different culture conditions. Consequently, well defined and well 
controlled culture environment will be the key to the success of in vitro follicle culture and this can only 
be achieved in a dynamic perfused culture system. In the conventional static culture environment all 
parameters in the culture medium change with time depending on metabolic rate and local conditions.  
Perfused technology, where culture media is pumped and flows through the culture at a pre-set manner, 
not only allows the better transportation (i.e. overcome diffusional control) and temporal regulation of 
nutrients and supplements but can also accommodate the growth of follicles by altering the calcium 
concentration in order to regulate properties of the alginate scaffold. The dynamic customizable system 
will provide an excellent tool for the in vitro culture of human follicles. 
In addition, the perfusion system will facilitate the monitoring of nutrition uptake and secretion of 
signalling molecules from the culture. On line monitoring of key biomarkers can be performed in real 
time.  This information will be crucial to understand the biological and molecular process of follicles 
tissue maturation in vitro. 
The success of the in vitro culture will be monitored by the number of follicles that survive during a 
certain period of time, the increase in sizes of the follicles and the morphology of the follicles. We will 
examine the ability of these follicles to form an antrum (the first sign that a follicle has reached the next 
stage of maturation) and secrete hormones, so to support oocyte development.  
Advances in our understanding of in vitro culturing and maturation of follicles may be applied to provide 
a fertility preservation option for women at risk of premature ovarian insufficiency as well as facilitating 
research in follicle development. 
3.4.5.  Reaggregated ovary culture 
Follicle development requires complex coordinated interactions between the oocyte and somatic cells 
with the oocyte secreting factors that influence its surrounding cells. In around half of women with 
premature ovarian failure (POF), the ovary still contains primordial follicles but ovarian function has 
ceases preventing their development; this is known as follicular POF. These cells can be obtained and 
combined with an alternate source of somatic cells that can support oocyte development; these are 
known as a reaggregated ovary (RO). ROs can be grown in vivo by transplanting the RO under the kidney 
capsule of a host mouse for 3 weeks where follicles at all stages of development can be generated (Eppig 
and Wigglesworth, 2000). The critical feature is that ROs can be generated using germ cells from one 
source and somatic cells from another.  
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Recently, the Williams Lab has established an in vitro RO culture technique using mouse germ and 
somatic cells which enables follicles to develop to the large antral stage. The aim of adapting this 
technology to grow human germ cells in vitro within an RO is to develop a treatment for follicular POF 
and also for women with ovarian cancer.  
ROs can be developed in vivo using mouse, rat and bovine cells and studies have demonstrated that 
somatic cells from one species can support oocyte development in another: rat and mouse (Eppig and 
Wigglesworth, 2000). Therefore, since we wish to adapt this technology to develop human eggs in vitro, 
initial experiments will include the use of somatic cells from alternate sources to support human oocyte 
development in an RO. One example of an alternate somatic cell are mouse somatic cells because we 
understand their function in vitro, we have demonstrated that they support oocyte development of 
mouse oocytes in vivo and in vitro and bovine oocytes in vivo, and therefore these will be a useful tool in 
our aim of establishing reliable human oocyte development in vitro.  
4. OBJECTIVES AND OUTCOME MEASURES/ENDPOINTS 
Objectives Outcome Measures/Endpoints  
Primary Objective 
To determine a successful in vitro culturing 
system of early stage human follicles.  
• Number of follicles that survive in vitro 
during a certain period of time 
Secondary Objectives 
To analyse follicular development and 
maturation using this system. 
To further identify factors involved in the in vitro 
maturation of follicles. 
 
Secondary endpoint/outcome measures –  
Proteomic, metabolomic and genomic studies to 
determine the success of the in vitro culture – 
measured by: 
• The increase in size of the follicles 
• Variations in the morphology of the 
follicles 
• Measuring numbers of follicles which 
form an antrum and time taken for 
antrum to develop 
• The concentration of hormones secreted 
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5. STUDY DESIGN 
The study design is experimental bench research, using donated human tissue samples. 
 Patient participation is limited to consenting to the study for the purposes of donating samples 
only.  
In this study donated ovarian tissue will be requested from three patient populations: 
1. Female patients having ovarian tissue cryopreservation, from age 6 years onwards, if 
clinically indicated. 
2. Adult women having planned gynaecological surgery: 
• Surgery which already involves the removal of their ovaries (Oophorectomy) or 
ovarian cysts (Cystectomy). This requires no additional interventions. 
• Surgery to provide sterilisation (i.e. family completed) – surgeons will take a 
small slice of ovarian tissue (less than 5% total ovary) at the time of surgery from 
women who agree. This will not affect the endocrine functioning of her ovaries 
since 10-20% is needed for this. 
3. Adult women having elective caesarean section with sterilisation – surgeons will take a 
small slice of ovarian tissue at the time of surgery from women who agree.  
6. PARTICIPANT IDENTIFICATION 
6.1. Study Participants 
Participants will be female patients who are able to donate ovarian tissue samples to the study. 
6.2. Inclusion Criteria 
• Participant (or parent/guardian if child unable to consent for themselves) is willing and able to give 
informed consent for participation in the study. 
• Female aged ≥6 and ≤ 43 years having clinically indicated ovarian tissue cryopreservation OR 
Female aged ≥ 18 and ≤ 43 years and having planned ovarian surgery (Oophorectomy or 
cystectomy) or sterilisation. 
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6.3. Exclusion Criteria 
• Patients donating new tissue samples (i.e. not samples ‘left over’ from Oophorectomy or 
cystectomy) with only one ovary. 
7. STUDY PROCEDURES 
See Appendix A Study Flow Chart for overview of procedures 
7.1. Recruitment 
All potential study patients (and parent/guardian as appropriate) will have a consultation with a Doctor 
at a hospital clinic prior to their gynaecological surgery or ovarian tissue preservation surgery. It is at this 
consultation that the clinic Doctor will present the Patient Information Sheet to suitable patients. 
 The patient will take the information sheet home and be able to consider the contents. Along with the 
information sheet we will include a (pre-paid) reply slip which patients will be asked to return if they are 
interested in taking part in the study. 
A research nurse will contact any patient who returns the slip to discuss the study further and, if they 
wish to take part, will arrange to obtain informed consent at the time when the patients return to the 
hospital for their surgical procedure. 
7.2. Informed Consent 
The participant (or parent/guardian if the patient is a child) must personally sign and date the latest 
approved version of the Informed Consent form before any study specific procedures are performed. 
Written and verbal versions of the Participant Information and Informed Consent will be presented to 
the participants (or parent/guardian) detailing no less than: the exact nature of the study; what it will 
involve for the participant; the implications and constraints of the protocol; the known side effects and 
any risks involved in taking part. It will be clearly stated that the participant is free to withdraw from the 
study at any time for any reason without prejudice to future care, and with no obligation to give the 
reason for withdrawal. 
The participant will be allowed as much time as wished to consider the information, and the opportunity 
to question the Investigator, their GP or other independent parties to decide whether they will 
participate in the study. Written Informed Consent will then be obtained by means of participant (or 
parent/guardian) dated signature and dated signature of the person who presented and obtained the 
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Informed Consent. The person who obtained the consent must be suitably qualified and experienced, 
and have been authorised to do so by the Chief/Principal Investigator. A copy of the signed Informed 
Consent will be given to the participant (or parent/guardian). The original signed form will be retained at 
the study site. 
7.3. Discontinuation/Withdrawal of Participants from Study 
Each participant has the right to withdraw from the study at any time.  In addition, the Investigator may 
discontinue a participant from the study at any time if the Investigator considers it necessary for any 
reason such as Ineligibility (either arising during the study or retrospectively having been overlooked at 
screening) or withdrawal of consent. 
However, in this study patient participation involves the donation of tissue samples only and so their 
involvement is for a short duration (from consent to removal of tissue). The donated tissue samples are 
anonymous to the research team (not linked to individuals) and once tissue samples have been given to 
the researchers they will continue to use the samples even if consent is withdrawn. 
7.4. Tissue samples 
Surgeons will collect the tissue samples from the study participants and place them in a study labelled 
container. This will be handed to the research team. The experimental analysis will be carried out either 
immediately in a University laboratory at OCTE or in the Nuffield Dept Obs and Gyn, or after 
cryopreservation to enable maximum use of donated tissues. No identifying details are stored. 
7.4.1. Ovarian follicles isolation 
The protocol will be based on the previously described by Dolmans et al. (Dolmans, Michaux et al. 2006) 
to isolate small pre-antral follicles. Briefly, the cortical ovarian sample will be digested using enzymes 
such as trypsin or collagenase at 37 °C with gentle agitation to release follicles. Follicles are isolated from 
the digested tissue and cultured either in isolation, in a matrix such as alginate, in groups in either static 
media or using a continual perfusion system.  
Follicles are incubated for several days and during this time follicle growth and morphology is assessed 
daily. A subsample may be analysed at various time points to determine the proportion of apoptotic cells 
in order to evaluate follicular viability after isolation.  
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7.4.2. Reaggregated ovary (RO) culture 
This protocol has been modified from Eppig et al (Eppig and Wigglesworth, 2000) and 
established in the Williams’ lab (Sheikh et al 2015). The ovarian tissue will be dissociated into 
single cells and the eggs can be isolated from the ovarian cells using differential plate adhesion. 
The cell suspension is allowed to plate down overnight, the somatic cells adhere whereas the 
germ cells do not. The following morning a second separation step is carried out. At this time, 
the floating germ cell population is removed and transferred to a new plate for a further 6-8 hrs 
to enable any remaining somatic cells to plate down and hence be removed from the germ cell 
population. The somatic cell population is also trypsinised and transferred to a new plate and 
allowed to plate down thus allowing any remaining germ cells to be separated from the 
adhesive somatic cells. After this second plating down, the two cell populations are collected, 
cells are counted and somatic cells and germ cells combined in the appropriate proportions. The 
cells are spun down to aggregate them in the presence of a binding agent (e.g the lectin LPHA). 
The RO pellet is then cultured overnight in medium supplemented with FBS.  After the overnight 
culture of ROs to promote ‘rounding up’ of the ovary, the ROs are transferred to a new well 
containing culture media. The ROs are cultured for up to 28 days in medium supplemented with 
recombinant FSH and potentially FBS, BSA, insulin-transferrin-selenium, antibiotics and ascorbic 
acid. The wells are filled with ~300ul of media, and a portion is replaced with fresh media at 
regular intervals during the culture period (current protocols are every 2 days). The cultures are 
maintained at 37°C in an incubator infused with 5% CO2 and 95% air. 
7.4.3. Follicle and oocyte analysis 
To measure follicle size  
Images of the follicles will be collected during the culture period for subsequent analysis of follicle 
diameter using ImageJ software (National Institutes of Health, USA). The oocyte diameter is visible in the 
follicle and is measured excluding the zona pellucida. 
Sectioning and staining 
To study follicle morphology  
Follicles, ovarian tissue or ROs will be fixed (e.g. 10% buffered formalin or 4% paraformaldehyde) and 
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subsequently dehydrated in increasing concentrations of ethanol (10–100%) and embedded in paraffin 
wax. Serial 3-5 µm sections are cut and stained (e.g. hematoxylin and eosin) (Grasa et al, Christensen et 
al  (Xu, Barrett et al. 2009). To determine if an atrum is present, sections can be stained with 
biotinylated-hyaluronic acid binding protein (Ploutarchou et al 2015). Follicle will be staged and counted 
to ascertain effectiveness of culture treatment. Other analyses can be carried out using 
immunohistochemistry on sections or whole follicles can be subjected to whole mount analyses and be 
imaged using confocal microscopy.  
To study follicle function 
Follicles or eggs may be subjected to various other proteomic, metabolomics or genetic analyses at 
various time points during or after culture to assess development and function. 
7.4.4. Hormone assays 
To measure the ability of follicles to secrete hormones 
Hormones secreted by follicles such as progesterone, estradiol, inhibins, and anti-Müllerian hormone 
(AMH) can be detected in the culture media using radioimmunoasssays or ELISA kits 
7.5. Definition of End of Study 
The end of the study is the date when the last sample from the last participant has been analysed, and 
any remaining tissue destroyed. 
8. SAFETY REPORTING  
We believe it very unlikely our study will be associated with any serious adverse events.  
However, the following considerations regarding safety are relevant to this study. 
Participants, including children aged 6 and older, are already having planned surgical procedures which 
require hospitalisation. Study participants are only those patients who are appropriate to donate 
samples to us and these are: 
 a) Women already having planned surgery to remove ovarian tissue (whole ovaries in oophorectomy or 
ovarian cysts in cystectomy). In both these cases the research sample can be taken from the tissue which 
is already being removed (by the surgeon doing operation) and is therefore ‘left over’ after the surgery. 
Nothing extra will happen to these women. 
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b) Women having planned surgery, including caesarean section, to provide sterilisation (i.e. family 
completed) – the same surgeon will take a small slice of ovarian tissue (less than 5% total ovary) at the 
time of surgery from women who agree. This will not affect the endocrine functioning of the ovaries 
since 10-20% is needed for this. 
 c) Women and children storing their own ovarian tissue for storage for their own fertility preservation. 
We will ask this group of patients for their consent to donate a small extra sample for the research study. 
The surgeon is already doing operation. The extra amount will not affect the procedure they are already 
having. We are including children is this study as they are most likely to be the population having this 
procedure and, potentially may be the beneficiaries of this research. 
The study interventions will increase their surgery time by 10 minutes only. There are extremely unlikely 
to be increased surgical risks above that of the planned surgical procedure. 
The surgeons are not part of the research team. 
Definitions of and reporting of any Serious Adverse Events are described below.  
8.1. Definition of Serious Adverse Events 
A serious adverse event is any untoward medical occurrence that: 
• results in death 
• is life-threatening 
• requires inpatient hospitalisation or prolongation of existing hospitalisation 
• results in persistent or significant disability/incapacity 
• consists of a congenital anomaly or birth defect. 
 
Other ‘important medical events’ may also be considered serious if they jeopardise the participant or 
require an intervention to prevent one of the above consequences. 
NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the 
participant was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe. 
8.2. Reporting Procedures for Serious Adverse Events 
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A serious adverse event (SAE) occurring to a participant should be reported to the REC that gave a 
favourable opinion of the study where in the opinion of the Chief Investigator the event was ‘related’ 
(resulted from administration of any of the research procedures) and ‘unexpected’ in relation to those 
procedures.  
Reports of related and unexpected SAEs will be submitted within 15 working days of the Chief 
Investigator becoming aware of the event, using the NRES report of serious adverse event form to the 
REC/NHS R&D and reported to the sponsor immediately (within 24 hours). 
9. STATISTICS AND ANALYSIS 
9.1. Description of Statistical Methods 
For this study, samples will be analysed using various methods. For assessment of follicle 
development, tissue will be sectioned and follicles classified and quantified. Additional analyses 
may include proteomic, metabolomic and genomic approaches and the data generated will take 
the form of experimental measurements to study the factors involved in the in vitro maturation 
of follicles obtained from human ovarian tissue samples.  Statistical analyses will be carried out 
using Graphpad Prism and a P value of >0.05 deemed to be significant. 
9.2. Number of Participants 
The number of participants is likely to small but we estimate it to be up to 50 in total.  
9.3. Analysis of Endpoints  
The samples of ovarian tissue will be collected during the patients’ surgery. Samples are put in a labeled 
container for immediate analysis. No identifying patient data e.g. name, will be retained.  
10. DATA MANAGEMENT 
10.1. Access to Data 
Direct access will be granted to authorised representatives from the Sponsor or host institution for 
monitoring and/or audit of the study to ensure compliance with regulations. 
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10.2. Data Recording and Record Keeping 
Copies of consent forms will be kept securely with other study documentation. Samples will be labelled 
with a Study ID only (anonymous). Data from experiments will be recorded by researchers in laboratory 
books which are stored securely in a locked building. Data will be transcribed onto Excel spread sheets 
for analysis. All data is kept on secure University computers and only encrypted data sticks id used. No 
personal data is available to researchers about the participants. 
11. QUALITY ASSURANCE PROCEDURES 
The study may be monitored, or audited in accordance with the current approved protocol, ICH GCP, 
relevant regulations and standard operating procedures. 
12. ETHICAL AND REGULATORY CONSIDERATIONS 
12.1. Declaration of Helsinki 
The Investigator will ensure that this study is conducted in accordance with the principles of the 
Declaration of Helsinki.  
12.2. ICH Guidelines for Good Clinical Practice 
The Investigator will ensure that this study is conducted in full conformity with relevant regulations and 
with the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996. 
12.3. Approvals 
The protocol, informed consent form, participant information sheet and any proposed advertising 
material will be submitted to an appropriate Research Ethics Committee (REC), and host institution(s) for 
written approval. 
The Investigator will submit and, where necessary, obtain approval from the above parties for all 
substantial amendments to the original approved documents. 
12.4. Reporting 
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The CI shall submit once a year throughout the study, or on request, an Annual Progress report to the 
REC Committee, host organisation and Sponsor.  In addition, an End of Study notification and final report 
will be submitted to the same parties. 
12.5. Participant Confidentiality 
The study staff will ensure that the participants’ anonymity is maintained.  The participants will be 
identified only by initials and a participants ID number on the CRF and any electronic database.  All 
documents will be stored securely and only accessible by study staff and authorised personnel. The study 
will comply with the Data Protection Act, which requires data to be anonymised as soon as it is practical 
to do so. 
12.6. Expenses and Benefits 
There is no requirement for participants to attend additional visits as part of the study, but if this is the 
case then we will reimburse reasonable travel expenses on production of receipts, or a mileage allowance 
provided as appropriate. 
 
13. FINANCE AND INSURANCE 
13.1. Funding 
Funding is being sought by SW and MF. Intermediate funds to support the consumables required for this 
project are available from SW’s discretionary account at the Department of Obstetrics and Gynaecology. 
Salary expenses for the scientists involved are covered by individual grants or DPhil student’s stipends. 
Initial funding was provided by two grants to Prof. Cui from BBSRC: Engineering human neural network, 
(BB/H008608), £3,282,711, June 10 – May 15 and Development of a high-throughput perfused three 
dimensional cell culture platform for stem cell study and drug testing, Taiwan Partnering Award,  
(BB/L003961/1), £24,991, 1 Sept 13-31 Aug 15. 
13.2. Insurance 
The University has a specialist insurance policy in place which would operate in the event of any 
participant suffering harm as a result of their involvement in the research (Newline Underwriting 
Management Ltd, at Lloyd’s of London). NHS indemnity operates in respect of the clinical treatment 
which is provided. 
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14. PUBLICATION POLICY 
The investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and 
any other publications arising from the study. Authors will acknowledge the funding for the study. 
Authorship will be determined in accordance with the ICMJE guidelines and other contributors will be 
acknowledged. 
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16. APPENDIX A:  STUDY FLOW CHART 
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ABSTRACT
This study investigated how follicle health and development in human ovarian tissue cryopre-
served for fertility preservation varied between patients before and after 6 d of in vitro culture.
Ovarian tissue from 12 patients (9–25 years) was used. In 3 patients, a 1hr neutral red (NR) incu-
bation was used to identify tissues with viable follicles. Tissues were fixed, sectioned and follicles
staged and graded for health. Inter-patient differences were observed in the non-cultured tissue
in the number of both healthy follicles (p¼ 0.005) and growing follicles (p¼ 0.005). After culture
there was significant variation in the number of transitional, primary and secondary follicles
between patients (p< 0.001). Asymmetric primary follicles with a single complete layer of granu-
losa cells plus two or more additional partial layers were 5.5 times more likely to be observed in
cultured compared to non-cultured tissue (p¼ 0.0063). Non-cultured (p¼ 0.0125) and cultured
(p< 0.001) tissue selected using NR had more healthy follicles compared to tissue not selected
using NR. Non-cultured and cultured tissue selected using NR had more healthy follicles com-
pared to tissue not selected using NR (p¼ 0.0125; p< 0.001). We demonstrate that inter-patient
variation exists in the health and development of follicles before and after culture. Culture sys-
tems need to be optimized to support cryopreserved ovarian tissue and these findings should
prompt researchers to consider patient variation when evaluating culture systems.
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Introduction
Cryopreservation of ovarian cortical tissue has been
established as a successful method for preserving fer-
tility in patients for whom traditional approaches, such
as storage of mature eggs or embryos, are not pos-
sible. This includes pre-pubertal girls and women for
whom cancer treatment cannot be delayed (Anderson,
Wallace, & Telfer, 2017). Growth of follicles from this
tissue in vitro is emerging as an alternative method to
circumvent some of the limitations associated with
transplantation (Nisolle, Casanas-Roux, Qu, Motta, &
Donnez, 2000).
The overall goal of in vitro follicle growth is to gen-
erate systems that support development and matur-
ation of a competent human egg for use by women
at risk of premature ovarian insufficiency (De Vos,
Smitz, & Woodruff, 2014; McLaughlin, Albertini,
Wallace, Anderson, & Telfer, 2018; Xiao et al., 2015).
For humans, an in vitro system capable of generating
metaphase II oocytes from fresh cortical tissue has
recently been described using a three-step culture
method prior to in vitro maturation (McLaughlin et al.,
2018). However, culture systems aiming to support the
initiation of follicle growth and early development
have predominantly used fresh tissue from healthy
women undergoing gynaecological operations whose
biology may differ from those who may benefit from
fertility preservation. To date, there is no data regard-
ing the variation in health and development of fol-
licles in vitro from tissue cryopreserved for fertility
preservation in women undergoing gonadotoxic treat-
ments, despite the high importance of this for devel-
oping techniques for fertility restoration.
Follicle distribution in the cortex of human ovaries
is extremely heterogeneous. The density of primordial
follicles between different pieces of cortex from the
same ovary can vary by greater than two orders of
magnitude (Schmidt, Byskov, Nyboe Andersen, Muller,
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& Yding Andersen, 2003). This creates challenges in
identifying cortical tissue fragments with follicles for
culture. Neutral Red (NR) is a weak cationic supravital
dye that is soluble in water and has been used in
cytotoxicity studies as a marker of cell viability (Allison
& Young, 1964; Borenfreund & Puerner, 1985). It has
been demonstrated to effectively label viable follicles
within ovine cortical tissue and has subsequently been
used to determine follicular density of fresh human
cortical tissue or medulla by incubating the tissue for
4 h before visualization (Chambers, Gosden, Yap, &
Picton, 2010; Kristensen et al., 2018). It remains to be
investigated whether this dye can be incorporated
into the workflow of human cortical strip culture with-
out the use of a 4-h incubation to allow visualization
of follicles in fresh tissue before culture.
The aims of this study were to determine: (i) how
the health and developmental stage of follicles differs
between women who have cryopreserved cortical tis-
sue for fertility preservation; (ii) whether the in vitro
developmental capacity of follicles from cryopreserved
tissue varies between them; and (iii) whether incubat-
ing cortical tissue with NR for a short period of time
to identify tissue with viable follicles could improve
the number of viable follicles after 6 d of culture.
Materials and methods
Ethical approval
The use of human tissue was approved by Health
Research Authority South Central – Oxford B Research
Ethics Committee (REC reference: 14/SC/0041).
Ovarian tissue collection
Cryopreserved ovarian tissue was obtained from
twelve patients aged 9–25 years. All were undergoing
ovarian tissue cryopreservation, as a fertility preserva-
tion measure due to malignancy or blood disorder.
None had received chemotherapy or radiation treat-
ment prior to ovarian tissue cryopreservation. As part
of the consent process, permission to use tissue in
research had been obtained.
Chemicals and consumables
Leibovitz L-15 medium, McCoy’s 5A (modified) HEPES
buffered medium, L-glutamine and ascorbic acid were
obtained from Thermo Fisher (Paisley, UK). Human
serum albumin (HSA), ITS liquid media supplement
(100), sucrose, ethylene glycol, sodium pyruvate, NR,
Bouin’s solution and Whatman Nuclepore membranes
were obtained from Sigma Aldrich (Poole, UK).
Recombinant human follicle stimulating hormone (FSH;
Gonal-F) was obtained from Merck Serono (Feltham,
UK). Corning Costar tissue culture treated 24-well plates
were obtained from Scientific Laboratory Supplies
(Nottingham, UK).
Cryoprotection and cryopreservation
Ovarian tissue cryopreservation was performed by the
Oxford Cell and Tissue Biobank. Cortical tissue cut into
cortical strips (2 1  5mm) were placed into cryo-
vials containing 1mL of cryoprotectant medium (1.5 M
ethylene glycol, 0.1 M sucrose, 10% (v/v) serum substi-
tute supplement in L-15 medium) and incubated for
1 h at 4 C before being frozen using a controlled rate
slow freezer (IceCube 15M; SY-LAB, Norcross, GA).
Following cryopreservation, the vials were stored in
vapour phase liquid nitrogen.
Tissue thawing and cortical strip culture
Cryovials were held at room temperature for approxi-
mately 1min before being immersed in a 30 C water
bath for 3min. Cortical strips were washed through
three thawing solutions containing a reversed ethyl-
ene glycol gradient (1, 0.5 and 0 M), 0.1 M sucrose
and 3mg/mL HSA in Leibovitz L-15 medium for 5min
and transferred to a petri dish containing Dissection
Medium (3mg/mL HSA, 100U/mL penicillin, 100 mg/
mL streptomycin, 2mM L-glutamine and 2mM sodium
pyruvate in L-15 medium). Tissue was mechanically
chopped using the McIlwain tissue chopper, and fur-
ther cut manually using a scalpel and forceps into
0.5 0.5 0.25mm pieces.
Tissue pieces of uniform size were distributed ran-
domly and evenly between wells of a 24-well plate
with excess remnant tissue discarded. A portion of tis-
sue fragments was fixed overnight in Bouin’s fixative
as a non-cultured control. Tissue was cultured on a
polycarbonate membrane (13mm diameter, 8 mm pore
size) floating on 1mL of culture medium in a 24-well
culture plate; culture medium contained McCoy’s 5A
supplemented with 1mg/mL HSA, 100U/mL penicillin,
100 mg/mL streptomycin, 2mM L-glutamine, 10 mg/mL
insulin, 5.5 mg/mL transferrin, 5 ng/mL selenium, 50mg/
mL ascorbic acid and 12.5 IU/L recombinant human
FSH. Cortical tissue was cultured for 6 d at 37 C under
5% CO2 in air, with half the medium being replaced
with fresh medium every other day. Following the cul-
ture period, the tissue pieces were fixed overnight in
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Bouin’s solution and stored in 70% ethanol until they
were processed.
Neutral red (NR) visualization
To identify fragments containing follicles, after proc-
essing cortical tissue with the tissue chopper,
fragments from patients E, I and L (Table 1) were incu-
bated in NR (25 lg/mL in dissection medium) at room
temperature for 1 h while the tissue was cut (as in the
standard protocol). Allocation of tissue between
groups was performed without a microscope to blind
the researcher to the degree of staining and detail of
the tissue pieces.
Histological analysis
The fixed ovarian tissue was dehydrated through a
graded series of ethanol (70, 80, 95, 3 100%), cleared
in xylene and embedded in paraffin wax at 64 C for
three hours. The wax-embedded tissue was serially
sectioned at 5mm and stained with haematoxylin
and eosin.
Follicles were staged based on criteria described by
Gougeon (1986); primordial (single layer of flattened
pre-granulosa cells), transitional (single layer with at
least one cuboidal granulosa cell), primary (complete
layer of cuboidal granulosa cells) and secondary, two
or more complete layers of cuboidal granulosa cells
(Figure 1). Where follicles had a single complete layer
of cuboidal cells, the number of any additional
partial layers of granulosa cells was recorded. Non-
growing follicles were those at the primordial stage.
Transitional, primary and secondary follicles were
classed as growing. Granulosa cell and oocyte pykno-
sis, and shrinkage of ooplasm were selected as
markers for follicle health based on the existing litera-
ture and the ease of assessing health factors in a non-
biased manner (Gougeon, 1986). Healthy follicles had
a non-pyknotic non-shrunken oocyte with non-
pyknotic granulosa cells, degenerating follicles had
one of the above factors, while follicles were classified
as atretic if they had both an oocyte with a pyknotic
nucleus and pyknotic granulosa cells (Figure 2). All tis-
sue sections were analysed for the presence of fol-
licles, and only follicles with a visible nucleolus or a
clearly defined nuclear membrane were assessed, to
avoid double-counting. A blinded researcher per-
formed follicle counts and assessment; a second
blinded researcher confirmed repeatability.
Calculation of follicle density
To determine the volume of the tissue, the area of
every 12th tissue section was measured using ImageJ
1.46r (National Institutes of Health, Bethesda, MD).
Follicle density was determined by dividing the total
number of follicles counted in a tissue sample by the
tissue volume.
Statistical analysis and modelling
All statistical analyses were performed using R statis-
tical software version 3.5.0 (R Foundation for Statistical
Computing, Vienna, Austria). Statistical analysis was
performed using Fisher’s Exact Test. Tests adjusting for
patient variation used the lme4 package in R (Bates,
M€achler, Bolker, & Walker, 2015). All logistic regres-
sions were offset for tissue volume and included
patient as a random effect. Data are presented as
mean or as odds ratio with 95% confidence intervals
where available and statistical significance was defined
Table 1. Characteristics of patients diagnosed with malignant disease or blood disorder who underwent ovarian tissue cryo-
preservation for fertility preservation.






A 9 No N/A Medulloblastoma None 3 h 16min
B 11 No N/A Sickle cell None 4 h 19min
C 16 No N/A Osteosarcoma None 5 h 20min
D 16 Yes Unknown Ewing’s sarcoma None 5 h 10min
E 17 Yes Yes Ewing’s sarcoma None 2 h 05min
F 18 Yes Unknown Sickle cell None 3 h 57min
G 19 Yes Unknown Low-grade serous adenocarcinoma None 6 h 15min
H 22 Yes Unknowna Burkitt lymphoma stage 1A None 4 h 18min
I 22 Yes Unknown Atypical teratoid None 5 h 00min
Rhabdoid tumour
(Grade IV)
J 23 Yes Yes Breast cancer, grade 3, oestrogen positive, non-metastatic None 3 h 05min
K 23 Yes Unknowna Hodgkin lymphoma None 4 h 20min
L 25 Yes Yes Cervical cancer None 3 h 32min
aPatient taking the oral contraceptive pill.
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as p< 0.05. Due to the small number of secondary fol-




Nine of the twelve patients were confirmed as having
gone through puberty, the remaining three had not.
Of the nine post-pubertal patients, information about
menstrual cycle was available for three who were
reported as having regular cycles (Table 1). Two
patients, where information about their menstrual
cycle was unavailable, were taking the oral contracep-
tive pill. The mean age (±SEM) of patients who had
gone through puberty was significantly higher than
for those who had not (20.56 ± 1.04 vs. 12± 2.08 years,
respectively; p< 0.01).
There was no difference in the time from tissue
procurement to cryopreservation between the pre-
and post-pubertal groups. The mean time from com-
pletion of surgery to start of cryopreservation was 4 h
13 ± 19min (Table 1).
Follicular density of tissue post-cryopreservation
from the 12 patients varied from 18.10 to 448.43 fol-
licles/mm3 between patient samples (Figure 3) and all
cortical strips contained follicles. Despite the small
sample of tissue and the known heterogeneity of fol-
licle distribution in the ovary, there was a significant
inverse correlation between follicular density and age
(r¼0.62, p< 0.05).
Number of growing follicles in non-cultured
cryopreserved tissue varies between patients
Follicles were observed in non-cultured tissue from 11
of the 12 patient samples. Non-growing follicles were
Figure 1. Developmental staging of human follicles from cryopreserved ovarian tissue from patients diagnosed with malignant
disease or blood disorder. Representative images of follicles in cryopreserved-thawed ovarian tissue. Tissue was fixed in Bouin’s,
embedded and stained with haematoxylin and eosin. Follicles were staged as: (A) primordial with a single layer of flattened pre-
granulosa cells; (B) transitional with a single layer of at least one cuboidal granulosa cell; (C) primary with a complete layer of
cuboidal granulosa cells; or (D) secondary with two or more complete layers of cuboidal granulosa cells. Scale bar ¼ 20 mm.
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those classified as primordial based on morphology
(Figure 1(A)), growing follicles were those classified as
transitional, primary, or secondary (Figure 1(B–D)). The
number of growing compared to non-growing follicles
in uncultured tissue varied significantly based on
patient and can be seen in Figure 4(A) (p< 0.001).
Non-growing follicles were the dominant population
in non-cultured tissue for five patient samples
(patients A, B, E, H and I), an equal percentage of
growing and non-growing were seen in two patient
samples (patients C and D), and the percentage of
growing follicles dominated in four patient samples
(patients G, J, K and L). Interestingly, only growing fol-
licles were observed in non-cultured tissue from
patient K, however, as only three follicles were seen in
this tissue (Table 2) it may be due to the small sam-
ple size.
Follicle health in non-cultured cryopreserved
tissue varies between patients
Follicles were graded as being healthy, degenerating or
atretic based on the presence or absence of pyknotic
granulosa cells, a pyknotic oocyte and shrunken
ooplasm (Figure 2). There was significant variation
between patient samples in the percentage of healthy
follicles in non-cultured tissue (Figure 4(B); p< 0.001).
In three patient samples, tissue fragments were
preferentially selected for non-culture or culture based
on visualization of follicles using the vital dye NR.
Figure 2. Classification of follicle health in human follicles from cryopreserved ovarian tissue from patients diagnosed with malig-
nant disease or blood disorder. Follicle health was assessed based on the presence or absence of pyknotic granulosa cells, a
pyknotic oocyte and a shrunken ooplasm: Images A–C show healthy follicles with healthy granulosa cells, a non-pyknotic and
non-shrunken oocyte whereas degenerating follicles had either (D) pyknotic granulosa cells (white arrowhead), (E) a pyknotic
oocyte (white arrowhead) with normal ooplasm or (F) a pyknotic oocyte (white arrowhead) with a shrunken ooplasm (black arrow-
head) and normal granulosa cells. Atretic follicles had both pyknotic granulosa cells and a pyknotic oocyte (white arrowheads),
without shrunken ooplasm (G), or with shrunken ooplasm (black arrowheads, H,I). Scale bar ¼ 20 mm.
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Tissues from these samples (patients E, I and J) showed
a similar percentage of healthy follicles in the primor-
dial and growing follicle populations. This was in con-
trast to the nine patient samples in which NR was not
used as in five of these, the percentage of healthy fol-
licles was greater in the primordial population com-
pared to the growing population (Figure 4(C,D)).
The probability of a follicle being healthy in non-
cultured tissue did not differ between pre- and post-
pubertal patients and was unaffected by the time
from surgery to cryopreservation.
Follicle health, but not development is greater in
non-cultured tissue selected by neutral
red staining
An example of a follicle with NR staining can be seen
in Figure 5(A). In non-cultured tissue where NR was
used to select tissue fragments as described above,
the odds of a follicle being healthy was over 11 times
that for follicles from tissue where NR was not used
(Figure 5(B); OR¼ 11.4, 95% CI (1.7–77.4); p¼ 0.0125).
There was a smaller percentage of growing follicles in
tissue selected using NR though this was not signifi-
cant (Figure 5(B)).
Cultured cryopreserved tissue has a dominant
population of growing follicles in all patients
Overall, culture resulted in a significant change in the
non-growing and growing follicle populations, with
the odds of observing a growing follicle in cultured
tissue being 52 times that of non-cultured tissue (OR
¼ 52.44, 95% CI (37.05–76.41), p< 0.0001).
The health and development of follicles in tissue
from each patient samples are detailed in Figure 6.
There was no difference in the percentage of follicles
growing following culture (Figure 6(A)), however, there
was variation within the growing population in the
proportion of follicles at the transitional, primary and
secondary stages (Figure 6(B)). Primary follicles were
the dominant growing follicles in all patient samples
except for patient K and patient B where 50% of fol-
licles were transitional and 50% were primary. The
number of secondary follicles observed after 6 d of
culture was low compared to transitional and primary
follicles and represented at most 9% of the total fol-
licles in cultured tissue (Figure 6(B); Patient C).
Between 8 and 80% of follicles were multi-laminar fol-
licles with more than one layer of granulosa cells
(Figure 6(C)). The percentage of growing follicles in tis-
sue after 6 d of culture was not different between
fragments that had been selected based on NR stain-
ing and those that had not been selected based on
NR (Figure 6(F)).
Neutral red selected tissue has superior follicle
health post-culture
Despite significant activation and development of fol-
licles in cultured tissue, overall follicle survival in cul-
tured tissue was low. Following 6 d of culture, all
follicles from tissue not selected using NR showed
some sign of degeneration (Figure 6(E)), however, this
is not surprising as 78.08% of follicles in this cohort
showed some sign of degeneration in non-cultured cry-
opreserved tissue (Figure 5). In tissue selected by NR
staining, 18.14% (n¼ 612; 3 patients) of follicles were
healthy after 6 d of culture (Figure 6(E)). Since 60.39%
of follicles were healthy in non-cultured tissue selected
using NR (Figure 5), this meant that follicles in these tis-
sues were over 13 times more likely to be healthy in
non-cultured compared to cultured tissue (OR¼ 13.67,
95% CI (10.04–18.91), p< 0.0001). The odds of a follicle
from NR selected tissue being healthy after 6 d in cul-
ture were 26 times that of a follicle from tissue where
NR was not used to select fragments for culture (Figure
6(E); OR ¼ 108.9, 95% CI (12.3–962.8), p< 0.001).
Follicles grown in culture have asymmetric
granulosa cell distribution
In cultured tissue, primary follicles were 3.2 times
more likely to have at least one additional partial
Figure 3. The density of follicles in relation to age in cryopre-
served ovarian cortical tissue from 12 patients diagnosed with
a malignant disease or blood disorder.
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granulosa cell layer compared to non-cultured primary
follicles (OR ¼ 3.17, 95% CI (1.83–5.80), p< 0.001;
Figure 7(A)). Asymmetric follicles, primary follicles with
two or more partial layers of granulosa cells and
only one complete layer of granulosa cells, were
observed in eight of the cultured patient samples
(Figure 7(C,D)). By contrast in non-cultured tissue,
only two asymmetric primary follicles were observed,
each in fragments of tissue from different patients
(Figure 7(A)). The odds of a primary follicle being
asymmetric in cultured tissue was 5.5 times that
of non-cultured tissue (OR ¼ 5.46, 95% CI
(1.40–46.92), p¼ 0.0063).
Figure 4. Variation between patients in the percentage of growing and healthy follicles in non-cultured cryopreserved human
ovarian tissue from patients diagnosed with malignant disease or blood disorder. Patients are listed by ascending age with the
dashed line indicating the split between those who were not post-pubertal (patients A–C) and those who were post-pubertal
(patients D–L). Significant variation in the number of growing follicles was observed in non-cultured cryopreserved ovarian cortical
tissue from all patients with follicles (A) (p< 0.001, Fisher’s Exact Test); no follicles were observed in non-cultured tissue from
patient F. The number of healthy (no morphological evidence of degeneration), degenerating (presence of either a pyknotic
oocyte, pyknotic granulosa cells or shrunken ooplasm), and atretic (presence of both pyknotic oocyte and pyknotic granulosa cells)
varied significantly between patients (B) (p< 0.001, Fisher’s Exact Test). Images (C,D) show the percentage of healthy primordial
follicles was greater than that of the growing follicle population in non-cultured tissue, with the exception of those follicles
stained with neutral red (NR; patients E, I and L) which showed a similar percentage of healthy follicles in the primordial and
growing follicle populations. NR: neutral red staining used to select tissue.
Table 2. Number of follicles observed in cultured and non-
cultured cryopreserved human ovarian tissue.
Patient Non-cultured Cultured Total
Selected using
neutral red
A 99 27 126 –
B 63a 85 148 –
C 168a 67a 235 –
D 70 58 128 –
E 1224 489a 1713 Yes
F 0 14 14 –
G 67a 68 135 –
H 13 14a 27 –
I 874 90 964 Yes
J 133a 15a 148 –
K 3a 12 15 –




This study is, to our knowledge, the first to evaluate
the patient-specific health and development of fol-
licles following in vitro culture of cortical tissue cryo-
preserved for fertility preservation. Furthermore, we
describe a protocol for human cortical strip culture uti-
lizing NR to identify fragments with viable follicles
for culture.
Our results highlight wide variation between
patients in the health and developmental stage of fol-
licles in cryopreserved ovarian cortical tissue. Early
studies looking at the viability of ovarian cortical tissue
cryopreserved in humans focused on success of xeno-
transplantation studies to demonstrate function with-
out accompanying histological assessment. Variation
and lack of clarity in morphological criteria for atresia
between studies, as well as differing methods of cryo-
protection, has made it challenging to define a base-
line for cryopreservation-derived follicle degeneration.
Here, we describe the morphological criteria assessed,
providing images of each variation of follicle health
we observed. Variation in follicle health post-thaw
may be tied to follicle health in fresh tissue as despite
finding no difference between fresh and frozen-
thawed follicles, 27% of follicles in fresh tissue showed
multiple signs of atresia; eosinophilia of the ooplasm,
contraction and clumping of the chromatin material,
and wrinkling of the nuclear membrane (Hovatta
et al., 1996).
We found the use of just 1 h of NR incubation
effective and easy to implement within the culture
workflow with follicles identified in thin cortical
fragments by their red staining. When tissue with
viable follicles was selected by NR-staining, a signifi-
cantly greater number of follicles in non-cultured tissue
had a healthy morphology (60% compared to 22%,
respectively). Our findings support those from
Kristensen et al. (2018) who used a 4h NR incubation
to demonstrate the specificity of NR for viable follicles
in cortical tissue from women undergoing fertility pres-
ervation before gonadotoxic treatment. Additionally,
our results demonstrate that a shorter NR incubation
period is adequate to identify tissue fragments with
viable follicles, enhancing the value of such a technique
in selecting tissue for culture with the aim of optimiz-
ing the proportion of healthy follicles.
In several patients, the percentage of multi-layered
follicles present after 6 d of culture was equal to or
greater than that published by McLaughlin, Kinnell,
Anderson, and Telfer (2014) indicating both methods
support equivalent follicle development. Interestingly,
a significant proportion of primary follicles in cultured
tissue were asymmetric, with two or more partial gran-
ulosa cell layers in addition to a single complete layer.
This finding is significant as current multi-step in vitro
protocols involve the excision of secondary follicles
based on size following cortical strip culture
(McLaughlin et al., 2018; Telfer, McLaughlin, Ding, &
Thong, 2008). However, based on size asymmetric fol-
licles would be indistinguishable from non-asymmetric
follicles when using a dissecting, brightfield micro-
scope. It is unclear whether the asymmetry is a result
of the physical culture environment or whether it is a
result of accelerated growth due to culture conditions.
Furthermore, it is important to ascertain the impact of
Figure 5. Use of neutral red facilitates selection of tissue fragments containing viable follicles in cryopreserved ovarian tissue
from patients diagnosed with malignant disease or blood disorder. Cortical tissue incubated in neutral red NR for 1 h revealed
viable follicles stained red shown in image (A) (white arrowhead). Thawed cryopreserved tissue fragments with follicles identified
by NR staining for 1 h (n¼ 3 patients) contained significantly more healthy follicles compared to tissue where NR was not used
(B) (n¼ 9 patients) (p< 0.02, OR ¼ 11.4, 95% CI (1.7–77.4), logistic regression adjusted for tissue volume with patient as a ran-
dom effect). There was no difference in the number of growing follicles in non-cultured tissue selected by NR staining compared
to tissue where NR was not used. Scale bar ¼ 100lm.
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asymmetry on subsequent follicle growth and devel-
opmental competence of the enclosed oocytes, par-
ticularly since current follicle selection for further
development would not differentiate between them
and non-asymmetric follicles.
Follicle health declines over the course of culture
and there is evidence to suggest that this decline is
more marked in cryopreserved tissue (Hovatta, Silye,
Abir, Krausz, & Winston, 1997). We assessed if tissue
selection using NR-staining would lead to better fol-
licle development after culture. When NR was not
used, nearly all follicles showed some sign of degener-
ation after 6 d of culture which was unsurprising given
that only 22% were healthy in the non-cultured tissue.
Figure 6. Variation between patients in percentage of growing and healthy follicles and the effect of tissue selection using neu-
tral red in cultured cryopreserved ovarian tissue from patients diagnosed with malignant disease or blood disorder. There was no
variation in the overall number of growing follicles in cultured cryopreserved ovarian cortical tissue (A) (p¼ 0.289, Fisher’s Exact
Test), however, within the growing population of follicles in cultured tissue (B), the relative number of transitional, primary and
secondary follicles varied between patients (p< 0.001, Fisher’s Exact Test), as did the percentage of multi-layered follicles, multi-
laminar follicles with more than one layer of granulosa cells (C). There was significant variation in the number of healthy, degen-
erating and atretic follicles between patients (D) (p< 0.001, Fisher’s Exact Test). Tissue selection using neutral red had a significant
impact on the proportion of healthy follicles present (E) (p< 0.001, OR ¼ 108.9, 95% CI (12.3–962.8), logistic regression adjusted
for tissue volume with patient as a random effect) but did not impact the number of growing follicles (F) (p> 0.05, Fisher’s Exact
Test). NR: neutral red staining used to select tissue.
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By contrast from 60% healthy follicles present in
NR-selected non-cultured tissue, 18% of follicles
retained a healthy morphology. These results are con-
sistent with the 2.5-to-3-fold decrease in the propor-
tion of healthy follicles reported by other groups
culturing cryopreserved tissue over a similar time-
frame, despite differences in culture systems (Asadi-
Azarbaijani et al., 2016; Azarbaijani et al., 2015;
Hovatta et al., 1997; Sanfilippo et al., 2013).
Although this analysis was based on a small volume
of tissue per patient, an inverse correlation between
age and follicle density was observed, confirming and
extending that reported by Schmidt et al. (2003) with
a sample of tissue from 21 women. The heterogeneity
in follicle distribution within the human cortex is well
described (Poirot et al., 2002; Qu, Godin, Nisolle, &
Donnez, 2000; Schmidt et al., 2003), and has been
cited as a strong reason that multiple pieces of ovar-
ian cortex should be replaced upon re-implantation. It
is possible that this heterogeneity extends to the
response of follicles within a single ovary to the
effects of cryopreservation, culture, or transplantation
and the variation between patients reported in this
study lends support to this idea.
In conclusion, in vitro development of eggs remains
an exciting option for fertility restoration, but variation
between patients may necessitate a more individual
approach to downstream treatment options. We dem-
onstrated here for the first time that there is variation
between patients both in the health of non-cultured
tissue post-cryopreservation as well as the health and
development after 6 d in culture. The culture system
described was effective in initiating follicle activation
and growth in this tissue, but optimization is required
to improve the survival of follicles across the culture
period. Given the heterogeneity of tissue and clear vari-
ation in follicle health post-thaw in these patients, dem-
onstrating that using the non-toxic viability marker NR
in the existing culture workflow as described here to
select tissue is an important advance in improving the
efficiency and effectiveness of in vitro follicle develop-
ment as an alternative method of fertility restoration.
Figure 7. Asymmetric granulosa cell layers were more common in primary follicles in cultured cryopreserved tissue from patients
diagnosed with malignant disease or blood disorder. Asymmetric primary follicles with variable numbers of partial granulosa cell
layers were observed in non-cultured and cultured tissue. Primary follicles were significantly more likely to be asymmetric (those
with a single complete layer of granulosa cells and two or more partial layers) with culture (A) (OR ¼ 1117.3, 95% CI
(250.2–4990.7), p< 0.0001, logistic regression adjusted for tissue volume with patient as a random effect). A follicle with a single
complete granulosa cell layer and one partial layer is shown in image (B). Asymmetric primary follicles with a single complete
granulosa cell layer and two or three partial layers are shown in images (C,D), respectively. Scale bar ¼ 20 mm.
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Abstract [max 200] 
In vitro follicle growth is a potential fertility preservation method for patients for whom 
current methods are contraindicated. Since many patients who may benefit from 
this treatment currently have cryopreserved ovarian tissue in storage, optimising in 
vitro follicle growth for cryopreserved-thawed tissue is critical. This study sought 
to determine the optimal culture method for cryopreserved human ovarian tissue 
by investigating the effect of culture medium (αMEM and McCoy’s 5A), medium 
volume (1 mL on a membrane and 300 µL) and dish permeability on the health and 
development of follicles after six days of culture. A total of 5797 follicles from 
three post-pubertal patients (aged 21.3 ± 2.3 years) were analysed across six 
different culture conditions and non-cultured control. Differences in follicle 
morphology were evident with follicles cultured in low volume conditions having 
significantly greater odds of being graded as healthy compared to other conditions. 
Furthermore, culture in a low volume of αMEM resulted in the highest proportion 
of healthy primary and multilayer follicles (23.8% compared to 6.3-19.9% 
depending on condition). We therefore recommend culture of cryopreserved 
human ovarian tissue in a low volume of αMEM to best support follicle health and 
development.  
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Introduction 
Advances in cancer treatment have led to increased survival rates, particularly among 
young children and adolescents. The increased number of young cancer survivors 
highlights the need for effective fertility preservation methods for these individuals. 
Current methods of female fertility preservation include cryopreservation of oocytes, 
embryos and ovarian tissue (Yasmin et al., 2018). However, pre-pubertal girls are unable 
to undergo oocyte or embryo cryopreservation and for some of these patients, 
reimplantation of ovarian tissue is contraindicated due to the risk of reintroducing 
malignant cells. There is therefore a need to develop alternative fertility preservation 
methods for these patients. 
One potential method of fertility preservation is in vitro follicle growth (IVFG) 
by culturing frozen ovarian tissue followed by in vitro maturation (IVM) of immature 
oocytes resulting in mature developmentally competent eggs. One of the limiting steps 
for IVFG is the generation of multilayer follicles from more immature follicles. Thus, 
optimisation of the initial step of ovarian tissue culture to facilitate the development of 
numerous multilayer follicles is critical for the success and subsequent clinical 
application of this method.  
McLaughlin et al recently reported successful generation of metaphase II oocytes 
from cultured human ovarian tissue using a multi-step culture system (McLaughlin et al., 
2018). The first step involves culturing small fragments of fresh cortical tissue in a low 
volume of McCoy’s 5A-based medium. In contrast, for culturing cryopreserved human 
ovarian cortical strips, many research groups use αMEM medium (Asadi-Azarbaijani et 
al., 2016; Garor et al., 2009; Huang et al., 2008; Isachenko et al., 2012; Lerer-Serfaty et 
al., 2013; Ramezani et al., 2017; Scott et al., 2004). However, there has been no reported 
comparison between the two culture media to determine which is optimal for culture of 
cryopreserved human ovarian tissue. In addition, it has been reported that increased 
oxygen availability by culturing fresh human ovarian tissue in gas-permeable culture 
plates had a positive impact on follicle health and development (Talevi et al., 2018) and 
thus this is another variable that needs to be investigated. Since many patients who will 
need IVFG have already undergone ovarian tissue cryopreservation, it is important that 
IVFG techniques are established for both fresh and cryopreserved tissue samples. 
This study aimed to determine the optimal culture method for cryopreserved 
human ovarian tissue by investigating the effect of culture medium, medium volume and 
gas permeable dishes on the health and development of follicles. We report here the effect 
each of these conditions on follicle progression and health after six days of culture, using 
statistical modelling to account for intra- and inter-patient variability. 
Materials and methods 
Ovarian tissue collection 
The use of human tissue was approved by Health Research Authority South Central – 
Oxford B Research Ethics Committee (REC reference: 14/SC/0041). Cryopreserved 
ovarian tissue was obtained from the Oxford Cell and Tissue Biobank. Patient selection 
criteria included post-pubertal patients undergoing unilateral oophorectomy and 
subsequent ovarian tissue cryopreservation due to malignancy or blood disorder. 
Exclusion criteria included ovarian cancer and prior chemotherapy or radiation treatment. 
As part of the consent process, permission to use tissue in research had been obtained. 
Cortical strips were cryopreserved by the Oxford Cell and Tissue Biobank in 1.5 M 
ethylene glycol, 0.1 M sucrose and 10% serum substitute supplement in Leibovitz L-15 
medium and stored in vapour phase liquid nitrogen. 
Chemicals and consumables 
Leibovitz L-15 medium (11415049), minimum essential medium alpha (αMEM) 
(22561021), McCoy's 5A (modified) HEPES buffered medium (22330021), L-glutamine 
(25030024) and ascorbic acid (10012011) were purchased from Thermo Fisher (Paisley, 
UK). Human serum albumin (AI653), ITS liquid media supplement (100x; I3145), 
Penicillin and streptomycin (P0781) sodium pyruvate (S8636), neutral red (N2889), 
sucrose (S7903), ethylene glycol (324558), Whatman Nucleopore membranes 
(WHA110414), Bouin's solution (HT10132), Gill no 2 haematoxylin (GHS232), Eosin Y 
solution (HT110332) and DPX mountant (06522) were purchased from Sigma Aldrich 
(Poole, UK). Recombinant human follicle stimulating hormone (FSH; Gonal-F; Z1540) 
was purchased from Merck Serono (Feltham, UK). Corning Costart tissue culture treated 
24-well plates were purchased from Scientific Laboratory Supplies (Nottingham, UK). 
Lumox® 24-well plates were generously provided by Sarstedt (Nümbrecht, Germany).  
Tissue thawing and cortical strip culture 
Cortical strips were thawed and processed for culture as described in (Walker et al., 
2019). Briefly, following thawing in a water bath (30°C for 3 minutes), cortical strips 
were washed through thawing solutions for 5 minutes each at room temperature to remove 
cryoprotectants. The thawing solutions contained a reversed ethylene glycol gradient (1.0 
M, 0.5 M and 0 M), 0.1 M sucrose and 3 mg/mL human serum albumin (HSA) in L-15 
medium. Thawed strips were transferred to dissection medium [3 mg/mL HSA, 100 U/mL 
penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine and 2 mM sodium pyruvate in 
L-15 medium] and mechanically chopped using a McIlwain tissue chopper (Campden 
Instruments Ltd, UK), after which the fragments were further cut manually using scalpels 
and forceps into approximately 0.5 x 0.5 x 0.25 mm pieces. Tissue fragments were 
incubated in 25 µg/mL neutral red for 1 hour to visualise fragments with viable follicles 
as described previously (Walker et al., 2019). 
Tissue pieces were distributed randomly and evenly between six different culture 
conditions, fragments where red staining was observed were allocated before non-stained 
fragments. A portion of tissue was fixed overnight in Bouin’s solution as a non-cultured 
control. Three different plate conditions were tested: a polycarbonate membrane (13 mm 
diameter, 8 µm pore size) floating in 1 mL of medium in a conventional 24-well culture 
plate, 300 µL of medium in a conventional 24-well plate, and 1 mL of medium in a gas-
permeable Lumox® 24-well plate (Figure 1). Two different media were compared for 
each plate condition (i.e. six experimental conditions in total): McCoy’s 5A and αMEM, 
both supplemented with 1 mg/mL HSA, 100 U/mL penicillin, 100 µg/mL streptomycin, 
2 mM L-glutamine, 10 µg/mL insulin, 5.5 µg/mL transferrin, 5 ng/mL selenium, 50 
µg/mL ascorbic acid and 12.5 IU/L recombinant human FSH. Cortical tissue pieces were 
cultured for six days at 37°C under 5% CO2 in air, with medium changes every other day 
(half the medium removed and fresh medium added). Following the culture period all 
tissue pieces (9-12 pieces per condition per patient) were fixed in Bouin's solution 
overnight before storage in 70% ethanol at 4°C. 
Histological analysis  
Fixed ovarian tissue was dehydrated in a graded series of ethanol, cleared in xylene and 
embedded in paraffin wax. The wax-embedded tissue was entirely serially sectioned at 5 
µm, mounted on glass slides and stained with haematoxylin and eosin. 
Follicles were staged as previously described (Gougeon, 1996; Walker et al., 
2019) as primordial (single layer of flattened pre-granulosa cells), transitional (single 
layer with at least one cuboidal granulosa cell), primary (complete layer of cuboidal 
granulosa cells) and multilayer (at least one complete layer of granulosa cells plus one or 
more partial or complete layers). Follicles were graded according to health based on the 
presence of pyknotic granulosa cells or oocyte and shrinkage of the ooplasm as previously 
described (Walker et al., 2019). Healthy follicles were defined as having a non-pyknotic 
non-shrunken oocyte with non-pyknotic granulosa cells, degenerating follicles had one 
of the above factors, while follicles were classified as atretic if they had both an oocyte 
with a pyknotic nucleus and pyknotic granulosa cells. Every tissue section was analysed 
and each follicle was followed through neighbouring sections to avoid double counting. 
Only follicles with a visible nucleolus or a clearly defined nuclear membrane were 
assessed. Follicles were analysed by two independent researchers with at least 10% 
overlap to ensure consistency in staging and health grading. 
The area of every 12th tissue section was measured using ImageJ 1.46r (National 
Institutes of Health, USA; Rueden et al., 2017; Schneider et al., 2012). Average area 
measurements were used to calculate the volume of each tissue piece. Follicle density 
was determined by dividing the total number of follicles counted in a tissue sample by 
the tissue volume. 
Statistical analysis and modelling 
All statistical analyses were performed using R statistical software, version 3.5.0. A 
generalised linear mixed model following a negative binomial distribution (glmmPQL; 
Venables and Ripley, 2002) was used to determine the effect of culture condition on 
follicle development, adjusted for patient and tissue volume. A proportional odds model 
(clmm2; Christensen, 2015) was used to determine whether follicle health was affected 
by culture condition, again adjusting for tissue volume and patient. Data are presented as 
mean (±SEM), combined proportions (%) from all patients or as odds ratios (OR) with 
95% confidence intervals (CI), unless otherwise stated, and statistical significance was 
defined as p < 0.05.  
Results 
Patient characteristics 
Samples from three post-pubertal patients (aged 17-25 years, mean 21.3 ± 2.3 years) were 
used in this study. Table 1 shows patient age, diagnosis and non-cultured follicle density. 
The total number of follicles analysed from all three patients across all conditions was 
5797. There was great variation in follicle density in both cultured and non-cultured tissue 
between patients, ranging from 20.4 ± 5.5 to 431.9 ± 23.8 follicles/mm3 (Table 1). This, 
coupled with our group’s previous work (Walker et al., 2019), highlighted the need for 
statistical modelling to account for this intra-patient variability. 
Follicle development was predominantly unaffected by culture condition 
Follicles were classified based on histology as primordial, transitional, primary or 
multilayer. Follicles grew during the culture period, with the majority of follicles being 
classified as primordial (70.4%) or transitional (27.2%) in non-cultured tissue, whereas 
after six days of culture 39.4-79.7% of follicles were at the primary or multilayer stages, 
depending on the culture condition (Figure 2).Tissue cultured in a low medium volume 
contained the highest proportion of multilayer follicles, 26.8% for McCoy’s (ML) and 
28.5% for αMEM (AL). Follicle development was compared across the different culture 
conditions, with all conditions being compared to culture in a high volume of McCoy’s 
5A medium on a polycarbonate membrane (MM) as this was our group’s established 
culture method based on Lopes et al., 2019 prior to this study (Walker et al., 2019; Figure 
3). There were significantly fewer transitional follicles in tissue cultured in a low volume 
of McCoy’s 5A medium (ML) compared to membrane culture (MM; 7.8 ± 6.0 
follicles/mm3 versus 28.2 ± 20.8 follicles/mm3 respectively, p<0.05, Figure 3B). There 
was no difference between the conditions for follicles at other stages. 
Culture in low volume conditions improved follicle health 
Follicles were classified as healthy, degenerating or atretic based on morphology. Non-
cultured tissue contained mostly healthy follicles at all stages, however after six days of 
culture the proportion of degenerating or atretic follicles had increased considerably for 
all culture conditions (Figure 4). A proportional odds model was used to determine 
whether a follicle was more likely to be healthy compared to degenerating or atretic after 
six days in a particular culture condition (Figure 5). Compared to MM, tissue cultured in 
low volume conditions (McCoy’s, ML or αMEM, AL) or permeable dish conditions (MP 
or AP) had greater odds of healthy multilayer follicles being observed compared to 
degenerating or atretic (Figure 5D). The most marked difference in the health of 
multilayer follicles was seen in the low volume conditions, particularly AL where the 
odds of observing a healthy follicle were 5 times greater than MM (OR=0.2; 95% CI 
0.13-0.32 p<0.001). Tissue cultured in ML had 2.6 times greater odds of multi-layered 
follicles being classified as “healthy” follicles versus “degenerating” or “atretic” 
compared to MM (OR=0.38; 95% CI 0.23-0.64; p<0.001).  
As culture in AL resulted in healthier follicles of all stages compared to MM, AL 
was set as the baseline level of comparison in the proportional odds model, to ascertain 
whether medium affected follicle health within the low volume condition. Compared to 
AL, multilayer follicles cultured in ML had 1.9 times greater odds of being classified as 
degenerating or atretic than healthy (OR=1.92; 95% CI 1.24-2.97; p<0.001) showing that 
AL yielded superior follicle health compared to the other conditions tested. When the 
proportion of healthy primary or multilayer follicles was compared between culture 
conditions, we observed that culture in AL yielded over 20% healthy primary or 
multilayer follicles, more than all other culture conditions (Figure 6). 
Discussion 
Here we report that culture medium and volume significantly impacts the health of 
follicles generated from six-day in vitro culture of cryopreserved human ovarian tissue. 
We found that culture in a low volume of αMEM resulted in healthier follicles at all stages 
of development compared to the same volume of McCoy’s 5A medium, and a higher 
volume of both base media in conventional plates with a polycarbonate membrane and in 
gas-permeable plates. We used statistical modelling to account for inter- and intra-patient 
variability. 
 Our results demonstrate that culture in a low medium volume led to improved 
follicle health compared to an approximately three-fold higher medium volume with a 
polycarbonate membrane. One possible reason is that in the low volume conditions, there 
is likely to be a greater concentrations of paracrine factors released by follicles or their 
surrounding cells which may have contributed to decreased follicle atresia. Oxygen 
availability is also a contributing factor to follicle health (Morimoto et al., 2007; Talevi 
et al., 2018). While three different plate conditions were compared in the current study 
(polycarbonate membrane, low volume and gas-permeable dish), all provided equal 
access to the air as the ovarian tissue was located close to the medium-gas interface 
(Figure 1). By culturing cryopreserved ovarian tissue in AL we observed a high level of 
follicle progression, with 26.8% multilayer follicles out of 810 follicles from three 
patients, with 34.0% healthy follicles. Talevi et al., (2018) reported that culture of fresh 
human ovarian tissue in 5 mL of αMEM medium (column height 1.4 mm) in a gas-
permeable petri dish led to improved follicle development and health, reporting that out 
of 287 follicles from six patients, 19.5% were multilayer and 41.7% healthy after six days 
of culture. This culture method is similar to that of AL described in the current study (AL 
column height 1.6 mm), however the medium volume used by Talevi et al. was 15 times 
greater. Taking into account the beneficial effects of low volume conditions, culturing 
tissue in a low volume of αMEM in gas-permeable plates may lead to even greater follicle 
health. 
 Culture in a low medium volume (ML and AL) yielded the highest proportion of 
healthy primary and multilayer follicles out of the six conditions tested, with AL resulting 
in superior follicle health at all stages. There is currently only one report of successful 
generation of mature human oocytes grown from ovarian tissue (McLaughlin et al., 2018) 
and this involved culture of fresh ovarian tissue using a four-step culture system; the first 
of which was similar to ML as described in the current study. This first culture step is the 
most limiting since it determines the number of follicles available for subsequent culture. 
McLaughlin et al. reported isolation of 87 multilayer follicles (100-150 µm diameter) 
from 160 cultured fragments and therefore improving the health and development of early 
growing follicles could therefore improve the yield of isolated follicles for IVFG. Studies 
describing culture of controlled-rate cryopreserved human ovarian tissue, as we have used 
in this study are limited, because the majority of studies use fresh ovarian tissue (Lopes 
et al., 2019; McLaughlin et al., 2018; Talevi et al., 2018; Telfer et al., 2008). Fresh and 
cryopreserved human ovarian tissue may have different requirements in vitro, as has been 
demonstrated using animal models (Castro et al., 2014), highlighting the need to optimise 
ovarian tissue culture for both fresh and cryopreserved tissue. This is indeed critical since 
there are many patients who already have tissue cryopreserved and may require IVFG to 
generate eggs. 
Follicles at all stages were more likely to be graded as healthy when cultured in a 
low volume of αMEM (AL) compared to the same volume of McCoy’s 5A medium (ML). 
αMEM contains both sodium pyruvate and a physiological concentration of glucose (5.6 
mM), whereas McCoy’s 5A contains no pyruvate and three times higher concentration of 
glucose (16.7 mM) and therefore McCoy’s 5A may provide a more suitable environment 
for follicle metabolism. Previous studies have indeed demonstrated pyruvate to be the 
main energy source during early follicle development in mice (Harris et al., 2007,  2009). 
Under normal conditions the oocyte is supplied with pyruvate by its supporting somatic 
cells however it has been demonstrated that pyruvate is taken up from the culture medium 
during in vitro follicle culture (Harris et al., 2009). Therefore, αMEM may provide a more 
suitable energy source for early follicle metabolism compared to McCoy’s, thereby better 
supporting follicle health although it is unknown at this time if cryopreservation has any 
effect on subsequent tissue requirements in culture.  
In conclusion, we report that culture in a low volume of αMEM in conventional 
24-well plates led to improved follicle health after six days of culture compared to other 
conditions tested. This highlights the need to further optimise culture systems for ovarian 
tissue culture, particularly culture of cryopreserved ovarian tissue. Improving the health 
and early development of follicles in vitro is a key aspect of developing culture systems 
capable of supporting follicle development from the earliest stages to result in mature 
fertilisable eggs. Once developed, these methods could offer a significant number of 
individuals a chance of achieving pregnancy following cancer treatment. 
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Legends 
Table 1. Patient characteristics and non-cultured follicle density.  
 
Figure 1. Overview of culture conditions. Cryopreserved human cortical strips were 
thawed and processed for culture as described in the methods section. Three plate 
conditions were tested along with two culture media, resulting in a total of six culture 
conditions. (A) Polycarbonate membrane floating in a high volume (1 mL) of McCoy’s 
5A (MM; Ai) or αMEM (AM; Aii) medium in a conventional 24-well plate. (B) Low 
volume (300 µL) of McCoy’s 5A (ML; Bi) or αMEM (AL; Bii) medium in a 
conventional 24-well plate; (C) High volume (1 mL) of McCoy’s 5A (MP; Ci) or 
αMEM (AP; Cii) medium in a gas-permeable Lumox® 24-well plate. 
Figure 2. Follicle development after six-day culture of cryopreserved human 
ovarian tissue. Follicles were staged as primordial (single layer of flattened pre-
granulosa cells), transitional (single layer with at least one cuboidal granulosa cell), 
primary (single layer of cuboidal granulosa cells) and multilayer (at least one complete 
layer of granulosa cells plus one or more partial or complete layers). Follicle 
development was observed across all culture conditions compared to non-cultured 
control (D0, separated by dashed line), with a high proportion of primary and multilayer 
follicles being observed in cultured samples. The numbers across the top of the columns 
represent the number of follicles analysed in each group, combined from three patients. 
D0: non-cultured control; MM: McCoy’s high volume with membrane, AM: αMEM 
high volume with membrane; ML: McCoy’s low volume; AL: αMEM low volume, MP: 
McCoy’s high volume, gas permeable plate; AP: αMEM high volume, gas-permeable 
plate. 
Figure 3. Follicle development is largely unaffected by culture condition. Follicles 
were classified as primordial, transitional, primary or multilayer based on histology in 
non-cultured tissue and tissue cultured for six days in different conditions. Transitional 
follicle density was significantly lower in ML compared to MM (p < 0.05). There was 
no difference in the density of primordial, primary or multilayer follicles between the 
different conditions tested and MM. Data was analysed using a generalised linear mixed 
model. * p < 0.05. D0: non-cultured control; MM: McCoy’s high volume, with 
membrane AM: αMEM high volume with membrane; ML McCoy’s low volume; AL: 
αMEM low volume, MP: McCoy’s high volume, gas permeable plate; AP: αMEM high 
volume, gas-permeable plate. 
Figure 4. Follicle health after six-day culture of cryopreserved human ovarian 
tissue. Follicles were classified as healthy (no morphological evidence of degeneration), 
degenerating (presence of either a pyknotic oocyte, pyknotic granulosa cells or 
shrunken ooplasm), and atretic (presence of both pyknotic oocyte and pyknotic 
granulosa cells). The proportion of atretic follicles was increased in cultured tissue 
compared to non-cultured control. The numbers across the top of the columns represent 
the number of follicles analysed in each group, combined from three patients. D0: non-
cultured control; MM: McCoy’s high volume with membrane, AM: αMEM high 
volume with membrane; ML McCoy’s low volume; AL: αMEM low volume, MP: 
McCoy’s high volume, gas permeable plate; AP: αMEM high volume, gas-permeable 
plate. 
Figure 5. Effect of culture condition on follicle health. A proportional odds ratio 
model was used to determine whether any of the conditions tested was more likely to 
lead to healthier follicles at each stage compared to MM. Data is represented as odds 
ratio with upper and lower confidence intervals (displayed as error bars). Odds ratio < 1 
indicates decreased odds of a follicle being degenerating or atretic compared to MM. 
Odds ratio > 1 indicates increased odds of a follicle being degenerating or atretic 
compared to MM. Those conditions where confidence intervals do not cross 1 (black 
lines) were significantly less likely to have degenerating or atretic follicles compared to 
the baseline (MM, p<0.05). MM: McCoy’s high volume with membrane, AH: αMEM 
high volume with membrane; ML McCoy’s low volume; AL: αMEM low volume, MP: 
McCoy’s high volume, gas permeable plate; AP: αMEM high volume, gas-permeable 
plate. 
 
Figure 6. Culture in low volume conditions yields healthier growing follicles. The 
proportion of healthy primary (dotted) and multilayer (checkerboard) follicles were 
compared across culture conditions. Culture in low volume conditions resulted in the 
highest proportion of healthy primary and multilayer follicles. Values represent 
combined values from three post-pubertal patients.  The numbers across the top of the 
columns represent the number of follicles analysed in each group, combined from three 
patients. D0: non-cultured control; MM: McCoy’s high volume with membrane, AM: 
αMEM high volume with membrane; ML McCoy’s low volume; AL: αMEM low 












Non-cultured follicle density 
(follicles/mm3) 
1 25 Cervical cancer 303 20.4 ± 5.5 
2 17 Ewing’s sarcoma (left pelvis) 3198 431.9 ± 23.8 
3 22 Atypical teratoid rhabdoid 
tumour 
2295 127.7 ± 77.3 
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